<SEC-DOCUMENT>0001178670-23-000011.txt : 20230504
<SEC-HEADER>0001178670-23-000011.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504082222
ACCESSION NUMBER:		0001178670-23-000011
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALNYLAM PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001178670
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770602661
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36407
		FILM NUMBER:		23886669

	BUSINESS ADDRESS:	
		STREET 1:		675 WEST KENDALL STREET
		STREET 2:		HENRI A. TERMEER SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		(617) 551-8200

	MAIL ADDRESS:	
		STREET 1:		675 WEST KENDALL STREET
		STREET 2:		HENRI A. TERMEER SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALNYLAM PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20020724
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>alny-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:b732ba76-b80e-452b-9370-f7a92071fea1,g:cc882e96-1f0e-4ac3-98d4-087e3affef76,d:90e340589f97408ea2365d8948df4c38--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:alny="http://www.alnylam.com/20230331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>alny-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80L2ZyYWc6YmE5YmQ3NTEzNWE2NDZlMDkzOWEzM2Q5ZGNhYzczOTcvdGFibGU6YzJmMDhhOGZjNTJmNGQ0Yjg0OTdlNjA0YjRkMTJhNTUvdGFibGVyYW5nZTpjMmYwOGE4ZmM1MmY0ZDRiODQ5N2U2MDRiNGQxMmE1NV8xLTEtMS0xLTExMTM2OA_ac0483f4-efa4-4e8c-8629-e8bdad4ca508">false</ix:nonNumeric><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80L2ZyYWc6YmE5YmQ3NTEzNWE2NDZlMDkzOWEzM2Q5ZGNhYzczOTcvdGFibGU6YzJmMDhhOGZjNTJmNGQ0Yjg0OTdlNjA0YjRkMTJhNTUvdGFibGVyYW5nZTpjMmYwOGE4ZmM1MmY0ZDRiODQ5N2U2MDRiNGQxMmE1NV8yLTEtMS0xLTExMTM2OA_6748eeb2-026a-4328-acf3-3cf0f00e512f">2023</ix:nonNumeric><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80L2ZyYWc6YmE5YmQ3NTEzNWE2NDZlMDkzOWEzM2Q5ZGNhYzczOTcvdGFibGU6YzJmMDhhOGZjNTJmNGQ0Yjg0OTdlNjA0YjRkMTJhNTUvdGFibGVyYW5nZTpjMmYwOGE4ZmM1MmY0ZDRiODQ5N2U2MDRiNGQxMmE1NV8zLTEtMS0xLTExMTM2OA_d5cbc29d-21fe-461e-a4f6-9a9e2707464d">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80L2ZyYWc6YmE5YmQ3NTEzNWE2NDZlMDkzOWEzM2Q5ZGNhYzczOTcvdGFibGU6YzJmMDhhOGZjNTJmNGQ0Yjg0OTdlNjA0YjRkMTJhNTUvdGFibGVyYW5nZTpjMmYwOGE4ZmM1MmY0ZDRiODQ5N2U2MDRiNGQxMmE1NV80LTEtMS0xLTExMTM2OA_ffb82ac0-a35e-4bdd-ab87-71a09bf2cf4f">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80L2ZyYWc6YmE5YmQ3NTEzNWE2NDZlMDkzOWEzM2Q5ZGNhYzczOTcvdGFibGU6YzJmMDhhOGZjNTJmNGQ0Yjg0OTdlNjA0YjRkMTJhNTUvdGFibGVyYW5nZTpjMmYwOGE4ZmM1MmY0ZDRiODQ5N2U2MDRiNGQxMmE1NV81LTEtMS0xLTExMTM2OA_d4ee3200-f610-4177-a8fe-83a8ab16678e">0001178670</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i8081d56e8ab34c85add2a725bbed1844_D20220912-20220912" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82Ny9mcmFnOjA5Njk2YWNkYzU2MjRjY2Y4ZWFjOWYwNzMyMzQxNmM5L3RleHRyZWdpb246MDk2OTZhY2RjNTYyNGNjZjhlYWM5ZjA3MzIzNDE2YzlfNDE_fc402a97-56f4-496a-b650-57c85420fcfc">0.0034941</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="alny-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90f0cfa35fa842e5b3d727a974388008_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="idf7880a1438e4b1d8934bf896e4c4569_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8195be6db017423781aa99e5f6eccbdd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32b8d81e96cb44258ca45844632dfcd5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84733ccbf66149c5b5b450843cfb6b1a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:CollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1217f0f803147f79e8c9536b829300b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:CollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bc45426006b4d8da84244a71315226f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i614f8658aaee4615b1db837d518ecf21_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i165ab1c7d45f4b59b55f6202bd02b29d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i627afa621d0246df9877bb6114adff8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib10c6162d7ee41d8b5073719840fa8ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1effbb5b358434886d5497a4dd79337_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ad08d083b134bc08112b596229b2ed4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0285951fb32549e2b7c666db15c9daf2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a77c376b2b4ba987e016002cfe1389_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c7db22afb9642d498a5f30d7ec9da76_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic503ee23109c47a485d4c943dc01c684_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50048ec3817431baf2df96733ffaa31_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id68ac710f233437aa4518ad8eb0adb93_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8d35477623a4ca9b7fc82fa82a051b8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8b5cdd9d6524a48a7c0e217c8746b86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i349f62fd0c1c46b6a699a43b81912de5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie72229676bde424e88e71e576e78694f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id64ff2050fde4c88a7a11680cbda5964_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fa61d04167f4839b28e5e693a40c913_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32343cbd739e429184dd13d72f726915_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a826bcf6ea5466cbbdc81d17d06dfc3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10b28d8521f2456da2d0123114d04efc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd6e196fd8bc401390b246f2c1842f21_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea3984c5c8334ea2b81d6e311a263566_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7c4b1ef5dd4faabe5879a7cb1a13b4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2d23f30f53a4a3b8caa38a11b48d302_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74133721fcc744889831c3b5bbd754b4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i129714144f56409c862078cd74c09670_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>alny:product</xbrli:measure></xbrli:unit><xbrli:context id="i469113cbfff1448ca7ace21682306c28_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b92d59400ad435ab232b2e3fc6af18d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d2c45ddfe4b4783b61d0c2532b261c6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e2090af379423a830396d670dd46ed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i879c1a7e15df42b1a622d6d158eedebc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id72a32ea5faa4d2aa4490f6f4d5cd32c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd786b1197ef4a61a89be31d546d3ce9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e76d8ae0a064b248bb6fc792baf7c14_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i840efee846e14303b149ccdfdf3a36a8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd036604ac7d4a5da0d65fbf272d8217_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief1d9b2c9e9b4acd9209bc90e66a8411_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71831b87aef84d13af0dc46e7eb3368e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb5e5a391b254ff999e9906a4a44fecb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2417f18ab724e43af379c82cd5c9c40_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73ca8156836b4f2da4a82227758bd9b0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i039c753c58d949c39d6d04e4fb10c8d3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i463e7ef6195945beb17fb66c0a944c2e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i933f756eaa1d499da77f10cf4ef3a9fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0754e7eb06254fb4b0be930af30fd4e8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4a7d3d13d3a4e91a7ac66295559e8bc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e770d161620415d9b7f5ffaecfd1b16_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d3be339f54740539cf50f08dd95e8e2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61661522e28049569e22780fccab15ec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfde9e56f64e49eb860585920e3307de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbc72492b6ac4d9ab9d17a76e1b3f401_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84b7e1d6726c409abc1a24d2d0d4cd0b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e09c2afc4be4d46b953611b6eedc4cd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i294c21243c484600ae87664735590a24_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9a9fb2de3341c4965ed9d0dcd38e2f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe2b83e5c274d98a554d85575908847_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50560d538c374d999be9a5694bed79c4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cd6dd169a314d9e8b10044417187c7c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33c0592038dc4276b0af9495329ef056_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ea9f42cbd234c25a0f60837c51cbcbb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb64947f4c824451ac2a67d55f9eec37_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22f96c66a004453596d01941e4ce155f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d5ea14b863b4413b7307cdb670fe0ab_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i625a2ec4ecfa4a25a2186cc5eb8e048f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700ea43392914b5bb710a1f264221b6c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic369c5ac0ae741b69d6c684ad3edcfc1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i119bb76ddc4f49b89a1e68acefe7a579_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a0b91c625484c1db6cf8d6e8200ae4b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i312ec99fcc6c43a5a131ac1f6eb87263_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8140860172b844839f38d726caf34dee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31d11f918c134929a249af868dc0a880_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f793b67069946539339f57991faca6f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ad2eeaaba1140c1b13fa6e42dba1bd4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fadae33c506406b84c2961fea62350a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba3a79574455472d858759fccd74a1f2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505a333c3b1b497290cc1a035457ef65_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c5e76a3a4cf45db98aa355177c9a5d3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i366eacf4f5df477589f244ba31e7710b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i330d2d52ecae4487a330a3ffa3b3df3e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i568cba070fdc4faab4ba5d1d1b7b45af_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f5ad1d8efc44580ac18facfdada39c1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122a5b203d314116a7be9b37a61d8bf1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3594c34bba4944ca91cc9765440d129b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a4ded065a9d42fca7d0593ecfb28c99_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ec14d6c93f549abad409a4ee60dc447_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea75117bc59d46cca891d43505fb5e06_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i989eed19cb3f4fa18bc8d14e53d5af1e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f79bfbe7bce408cafa73cf4b18f1764_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b17e6f85a474102b37c2eb6225b0f06_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>alny:target</xbrli:measure></xbrli:unit><xbrli:context id="ia2262debc8564e2ea595ab280c42f0db_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAtProgramInitiationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a62ef305c0f40a79899683564ff0247_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAtLeadCandidateIdentificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6a70a035a37440e909aac14f9fda6d9_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAnAnnualDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib324fbd9af6f4a3d8ef929b6d99bf163_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7e7e8c4e7d644c158639d2fb41e9a319_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie79a8fa8f1ce43deb7597002a348c3be_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i537f32b4a16b4543a24f40ddc6741cee_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic42228c3d8ac46a8ac291f126f2d30b6_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ae91e0688d4ae4984f1d8103dc8422_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46343ad3a9fd4ec3a826cb38ab1b6530_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10bce677b77f433a9d7d79a79b60f6a2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c437734fd146c39d505bac418fecf2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8a02cffca2849af8489d49e9b80b1b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03b27765edaa4e13a504fbffd73baf35_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i638ed215bf2a42199fc06a55c0357371_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i053739f07c5a48d4bd9b455419e9a9f3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ae2f34bc0ed44efa8a7bcadc7f60158_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ea36d76387472e84cfa6df1370b518_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida6db6b0c1dc4a37b006d8d1871fd207_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34678b9d3faf4e679a9657d9146fcacf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i567601c061914fc8a2d7fd810936ef74_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04b45c879ba940b99dd9a474d8b07978_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d582c41d901411287404a782ac66586_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f304a30d62e48ae884ec8acc207b442_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i951d48bc07e44f98a13abbaa555cc949_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78bb229c8dc8423eb6def37c2540a28f_I20300101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2030-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5af69bac6577471ab296af25cf52d953_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49f2778a30db447199954b7fd02c7ed1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie90a9b7be5ab448e86528f65d657a9ac_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i874d4cbd4e084481a20e05ffedf030e1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9816969b7f844c7b918013a5fb04632_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffe7a27d97064ac7829a670edeb037a6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4497af286544b5588685567ad285511_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacfa0b420e244ddd8c424584e49e0bbe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaa8b9115a694d4dbacbb16955919e67_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50b2a82f08e14704917d51373b47b145_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec58dda78b5f41ec9f8115e957615766_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e6a406720844217993d4483fc6e7b60_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07544a270c1b4f91be2befe47f417d06_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fbdfa377b4c45188b32b4aca0c5858c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc8655a9bfff4eb6a24a91ec23da2454_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id91db2e74566480db7790bba12bacab3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0fbbf8a866f4b1ea616c10badae83d3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4272629d98c4add80b6c45b82c2e95a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i386e3c5b4ba843509503532a3da11306_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e2b832d64eb4f1a8fdbaef5ca07646d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id76f744f31aa458e96f4d8ebe97eb886_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3272a7ba8f424ca9a1480c9d363ebc10_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cb86d593e5944cca0236d7b8f81bbf2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac8bf485b57442459c1b93f20ebfa42b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica1ebebb32214b719ee306ffc8f6cf89_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f5ba0082a2340e79246846a43e0e92b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53c118ebc744410fbbc7719c7a876694_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie823bc3a3540443788e7ed44be452ee5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i210817a6ab294c9d9aff77d7f7d56bcd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b5152586914421b5f5705f8c583545_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia372b23a3466460c91b1628f67e16648_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b1bd941ecd44d1ca58586c4a9d77e7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40eb73f6cf7b4d478059864b5fa2f8d9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b408457ee5148e38192a975210e857c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43176b0239cb476c8cf009256b574721_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i076d11b5a6224da98d27eefe80d7e72a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e9dba36ddb43e3a7cdf9a5872fb683_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6f8dc928bd848488160e1bd4f401ea3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19e64ae5cf7f45f6b977f634f04d74e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5723f8adf2d1441d932c0847136e9459_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6ceebd68e64bf0a73073a721e7d630_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i910dcea4abe947e4ab7bab94efb0b6bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i048b6a7660eb403b9a37898a77b5f141_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65b952c5bedd40b798d1a1561e6546c6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2ccbffe10394a7e94b51ab21066da05_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9706a586a2e648478e8a3e8e5b2af11f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i530c28e6901b4e84a1c2d02163b01915_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd32b8fc73844de94f0169aa6a02549_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13efc9571bfe41aa8a26035bcd11ba88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbf68c6050a641f08b05c2eb2be55064_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cd53d3ef7cf44699a9bed9051e463e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id76df98dcf234a879e9afbd45704aa86_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e8b9f7927aa4adf8ad7beaa81618725_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78e4f2d83b724aec84eb152ce5a9a38a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2d9d2300f444085a25bd1044ef04459_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0cb6ddc861e4bccabf7921700859d41_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08de5c309e4b47ce9d7bc420003d6031_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7888ab348e6b46759e5fa89592e4892c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1532ad29f7b41dfa9abd7737236a3cf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37c9e096a9ca46f28fce0d2487efa7e0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9ce486293d84aeeb0b9ecdc107a663f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50ea362dec14ed1a971c9d68f405fc1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf96df66413c488d9bfbd03f94ea7f4e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb230ab030c84a949a4708ce9359662e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e45c4599a0542b69eeec71ff8b3bf49_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie42a905d31064b9fa9efdd8b7ef9b37e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i811b7526e6a94efba6244d85ce23698b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92f68826e624d329fcbd32713162d25_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94483e1405f840b791882d67766c7723_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b2839973ded4bb9a04db596d1cd0ee7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ed1c026dd674f1d819dbc53395da662_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibebf4053fbf44fb9b675c41a096d60a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50c869678d1046f6b8952f17b26368ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i714ef67f5dd5449c8ce319985ec64bf3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0c21a9a0d854336ae2513275c632fb3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a5bbae1628a449d818c46f986a09d4c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3080c044b38407fba1e7d8658782768_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ef9a4ac510541efaaf7b5313dd58cf6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if11c68a061924916b804149e7efa13f8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i348f9d6750ba4e6d84377accaa5b9319_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ed6da55201a4d6098f35926e23ad0c5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5423daa9097405baa2e53113e5a2af9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf2fec59aefb4d9abff4b8a755874542_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia64c74b9951e43a2a4ca3afc638421c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i400fd731ed28427a98cf559b0d69a616_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5246d2e962624dce926b3bfedeadb7d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0764c7d8cbc0465a9c4b5bec84310735_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i597049e81b154f63b39f155a686eca36_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id931cec3813c4a8abbaa146d0ecf379e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32207f7e2b874ffe9f5bb035ed9216a6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i058fa58cb9ad4be2929911d5459f7ee5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if78966f3bc7e4a2c88588d499eac7518_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58d05b72c281482194642f22d74ecfe5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifca2d339be1249478491d26c1d76e094_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f8e370f342484989f74b6dadda0a7e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8575ee7bf1c64fce99658a0882ae7ee3_I20220912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027InitialAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8081d56e8ab34c85add2a725bbed1844_D20220912-20220912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-12</xbrli:startDate><xbrli:endDate>2022-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72548dd619ad4fc59ff47eaf2277707e_I20220913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027AdditionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbfa928ba64c483796841306c426679d_D20220913-20220913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-13</xbrli:startDate><xbrli:endDate>2022-09-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36aa61efaa244add8aac63cdcac4dac0_I20220913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5b391a1819e41adbce308c1b9dab192_D20220915-20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia716907dc7734c6ba46bc53ee763d5d5_D20220915-20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:DebtInstrumentConvertibleTermsOfConversionAxis">alny:DebtConversionTermsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>alny:day</xbrli:measure></xbrli:unit><xbrli:context id="i9e464817379546f69d2a4d409bf930d6_D20220915-20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alny:DebtInstrumentConvertibleTermsOfConversionAxis">alny:DebtConversionTermsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icebb5707b4014e189d610163d749eb88_I20220912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf3afa8e81834164a6949f9f03a9f2b4_D20220915-20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia532de6f95c948d98aa0f343c124b06f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9b6feac91a4baaa879c5cc27f3adcf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9534211a39af4f07af0f48f741ec3cfc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerUnit"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>alny:Unit</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i303c720c21554eb3a5e123dcdd48b762_I20220912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8025ac0fe3c444bd93fb4dffe9e6a50f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdd6f7a85c0649c687a28ff5014a352d_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:VutrisiranAndZilebesiranMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0540d1bfbba64fa980c847a4a95c9ac6_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:HELIOSBPhase3ClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i788b9050885e4755ab989256b9364634_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ALNAGTPhase2ClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d2567c90e8a458eae5bef50162e1ca4_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ALNAGTPhase3ClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifde09daab1ea4a168820da3d556f2e1f_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:VutrisiranMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if60b93a866a243d08fc76127d6370bdd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8b29740f2a6476a91d8e8b96400f6d4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i707ab3ce2b764f02a7efa7c0a56fcdd2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i728568c4126e4020bdaab60c7fd837da_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i770db94c29944af19b3195793999b048_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i920b6c081b7047af9c3d22ecd0aac5fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c75d8b324e44f0a7e6fb8cd3fed694_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19ba4c67d69f48759c03fa13464eae2a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16fefe33d0a84bbcb3bcfe4546c9b4d3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a1e6837336341aebaca13a642e99570_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e25f80d14ab4e29946dc7feeb321f9e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9057d82ed2a40ea940df490edf962c1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402e0e52c29f460db9f6c550106e1cf2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d2e5ef24f8743d687104b5084f27971_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i90e340589f97408ea2365d8948df4c38_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C.&#160;20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8xMjk_ea33a2d3-902e-40c3-a420-da5939516e05">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6YTk3MWQ3M2NmYzgzNDkxNTgwZTQ4MTkzMGYzOTEyMjAvdGFibGVyYW5nZTphOTcxZDczY2ZjODM0OTE1ODBlNDgxOTMwZjM5MTIyMF8wLTAtMS0xLTExMTM2OA_ad0da8ff-8969-4444-b6c6-db965077b9ef">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8yMDk_95432380-3284-4890-ada9-07503785f747">March&#160;31, 2023</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZTg5MmQzOTZiMmMzNGM0MGFkMDE1ZWJjMDBhMzc1MmIvdGFibGVyYW5nZTplODkyZDM5NmIyYzM0YzQwYWQwMTVlYmMwMGEzNzUyYl8wLTAtMS0xLTExMTM2OA_0d3c5e37-fcf2-450f-bbcb-2efdeb48bf58">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from ___________ to ___________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8yMTYz_e0f301d7-0b1c-4fdd-a97f-6785332d1554">001-36407</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">__________________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8yMTY0_740a106e-0591-4960-8234-98a4d733d66a">ALNYLAM PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">__________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6N2RlODU0OGE4MDg4NDYzYmE1ZDljZWNhNWRlNzY0MTEvdGFibGVyYW5nZTo3ZGU4NTQ4YTgwODg0NjNiYTVkOWNlY2E1ZGU3NjQxMV8wLTAtMS0xLTExMTM2OC90ZXh0cmVnaW9uOmRmZWI4MDkyOGM5ZDRkN2JiYzJkNDc5YjY3YjI4YmIxXzU_9feae289-0c9f-4227-b54b-4ad176dd21c9">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6N2RlODU0OGE4MDg4NDYzYmE1ZDljZWNhNWRlNzY0MTEvdGFibGVyYW5nZTo3ZGU4NTQ4YTgwODg0NjNiYTVkOWNlY2E1ZGU3NjQxMV8wLTEtMS0xLTExMTM2OC90ZXh0cmVnaW9uOmJmMTVjNjlkMmIxZTQ0MDNiNDRiY2EzNGI3NGY5NzY2XzU_23f07758-50d7-452c-9301-e8aea3d00485">77-0602661</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6YzEzYjQyMmJkOWVlNDI2N2E3MDEwMjVkYmM0YjU3MjUvdGFibGVyYW5nZTpjMTNiNDIyYmQ5ZWU0MjY3YTcwMTAyNWRiYzRiNTcyNV8wLTAtMS0xLTExMTM2OC90ZXh0cmVnaW9uOmIzZTNkOGNlYTA1NTRlYTNiZTUyNGQ4MDRjM2ZjMzdhXzU_282fd248-1e5c-4cff-b8fd-5aade8695473">675 West Kendall Street,</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6YzEzYjQyMmJkOWVlNDI2N2E3MDEwMjVkYmM0YjU3MjUvdGFibGVyYW5nZTpjMTNiNDIyYmQ5ZWU0MjY3YTcwMTAyNWRiYzRiNTcyNV8wLTAtMS0xLTExMTM2OC90ZXh0cmVnaW9uOmIzZTNkOGNlYTA1NTRlYTNiZTUyNGQ4MDRjM2ZjMzdhXzg_a46cac8d-d915-4fa2-bb82-4daf157252f9">Henri A. Termeer Square</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6YzEzYjQyMmJkOWVlNDI2N2E3MDEwMjVkYmM0YjU3MjUvdGFibGVyYW5nZTpjMTNiNDIyYmQ5ZWU0MjY3YTcwMTAyNWRiYzRiNTcyNV8wLTAtMS0xLTExMTM2OC90ZXh0cmVnaW9uOmIzZTNkOGNlYTA1NTRlYTNiZTUyNGQ4MDRjM2ZjMzdhXzEx_79145578-6cff-4a4e-9f9f-b4de57a913d3">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6YzEzYjQyMmJkOWVlNDI2N2E3MDEwMjVkYmM0YjU3MjUvdGFibGVyYW5nZTpjMTNiNDIyYmQ5ZWU0MjY3YTcwMTAyNWRiYzRiNTcyNV8wLTAtMS0xLTExMTM2OC90ZXh0cmVnaW9uOmIzZTNkOGNlYTA1NTRlYTNiZTUyNGQ4MDRjM2ZjMzdhXzE1_39eb6863-024c-4fbc-87ca-f1de943a6f70">MA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6YzEzYjQyMmJkOWVlNDI2N2E3MDEwMjVkYmM0YjU3MjUvdGFibGVyYW5nZTpjMTNiNDIyYmQ5ZWU0MjY3YTcwMTAyNWRiYzRiNTcyNV8wLTEtMS0xLTExMTM2OC90ZXh0cmVnaW9uOjY0MGVjOTJkY2QyYTRhYjJiOTRiMjYwNWU1ZGJiYzQ0XzU_02addd40-bc7a-422f-b31a-33dedfb42701">02142</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF80ODM_60cb1c6c-9194-4780-82be-3a114b52ed41">617</ix:nonNumeric>) <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF80ODc_cd2eb3fe-916f-474e-a358-f92e6af16af0">551-8200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">__________________________________________</span></div><div style="margin-top:10pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:10pt;padding-left:22.5pt;padding-right:22.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZmNkODhlZjgwM2E0NGE1M2JlNzBmYzU4YzUzMTE1OGIvdGFibGVyYW5nZTpmY2Q4OGVmODAzYTQ0YTUzYmU3MGZjNThjNTMxMTU4Yl8xLTEtMS0xLTExMTM2OA_203e5e87-74df-47d0-83fd-3ac0b34468fb">Common Stock, $0.01&#160;par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZmNkODhlZjgwM2E0NGE1M2JlNzBmYzU4YzUzMTE1OGIvdGFibGVyYW5nZTpmY2Q4OGVmODAzYTQ0YTUzYmU3MGZjNThjNTMxMTU4Yl8xLTMtMS0xLTExMTM2OA_fd2f0092-6f8d-4c3f-bed5-227dfe8222a1">ALNY</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZmNkODhlZjgwM2E0NGE1M2JlNzBmYzU4YzUzMTE1OGIvdGFibGVyYW5nZTpmY2Q4OGVmODAzYTQ0YTUzYmU3MGZjNThjNTMxMTU4Yl8xLTUtMS0xLTExMTM2OA_0eec06d1-89ce-4e26-86c4-d616bccf97df">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF85OTU_bcbeb61a-01e3-495a-9c06-257e081587f2">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;<ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8xMzIw_a666fc38-913b-4e6e-b536-3f96cec3607e">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:10pt;text-indent:45pt"><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZGMxNzVmMjIzYjg5NDZhZDhlYWY0ODVkZWMyNzI4YmUvdGFibGVyYW5nZTpkYzE3NWYyMjNiODk0NmFkOGVhZjQ4NWRlYzI3MjhiZV8wLTAtMS0xLTExMTM2OA_f71a6260-a942-4c2d-ad32-65d191e3514c">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZGMxNzVmMjIzYjg5NDZhZDhlYWY0ODVkZWMyNzI4YmUvdGFibGVyYW5nZTpkYzE3NWYyMjNiODk0NmFkOGVhZjQ4NWRlYzI3MjhiZV8xLTMtMS0xLTExMTM2OA_9507b2d9-49c5-489b-bba6-10cc05009ae0">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZGMxNzVmMjIzYjg5NDZhZDhlYWY0ODVkZWMyNzI4YmUvdGFibGVyYW5nZTpkYzE3NWYyMjNiODk0NmFkOGVhZjQ4NWRlYzI3MjhiZV8yLTEtMS0xLTExMTM2OA_d1f9d502-cb9a-4227-a755-f127678ada45">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8yMTY1_29d4c6ae-154e-4885-a231-bb58ccc45f95">x</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At April&#160;28, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="i90f0cfa35fa842e5b3d727a974388008_I20230428" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8yMDk1_5a584891-2601-438d-a00e-304b69fdffff">124,525,737</ix:nonFraction> shares of Common Stock, $0.01 par value per share, outstanding.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:9pt"><span><br/></span></div></div></div><div id="i90e340589f97408ea2365d8948df4c38_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM&#160;10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:90.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE<br/>NUMBER</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_19">PART I.&#160; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_19">ITEM 1. FINANCIAL STATEMENTS (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_19">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_19">,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_19"> 2023 AND DECEMBER 31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_25">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE MONTHS ENDED MARCH 31, 2023 AND 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_28">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; (DEFICIT) EQUITY FOR THE THREE MONTHS ENDED MARCH 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_28">, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_28">2023 AND 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_31">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2023 AND 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_34">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_34">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_82">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_82">24</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_97">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_97">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_100">ITEM 4. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_100">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_103">PART II.&#160;&#160;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_106">ITEM 1.</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_106"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_106">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_106">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_109">ITEM 1A.</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_109"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_109">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_106">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_112">ITEM 6. EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_112">72</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_115">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_115">73</a></span></div></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8220;Alnylam,&#8221; ONPATTRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, AMVUTTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, GIVLAARI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, OXLUMO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, Alnylam Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">GEMINI&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">and IKARIA&#8482; are trademarks and registered trademarks of Alnylam Pharmaceuticals, Inc. Our logo, trademarks and service marks are property of Alnylam. All other trademarks or service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective holders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i90e340589f97408ea2365d8948df4c38_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of complying with those safe harbor provisions. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.85pt">our views with respect to the potential for approved and investigational RNAi therapeutics, including ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, Leqvio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(inclisiran), fitusiran and zilebesiran;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our plans for additional global regulatory filings and the continuing product launches of ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO and our partner's plans with respect to Leqvio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our future ability to successfully expand the indications for ONPATTRO and AMVUTTRA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">risks related to the direct or indirect impact of the novel coronavirus, or COVID-19, global pandemic, emerging or future variants of COVID-19 or any future pandemic, on, among other things, our financial performance, business and operations, including manufacturing, supply chain, research and development activities and pipeline programs, and other potential impacts to our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our expectations regarding potential market size for, and the successful commercialization of, ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, Leqvio or any future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to obtain and maintain regulatory approvals and pricing and reimbursement for ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO or any future products, and our partners' ability with respect to Leqvio and fitusiran;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the progress of our research and development programs, including programs in both rare and prevalent diseases;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the potential for improved product profiles to emerge from our new technologies, including our IKARIA and GEMINI platforms and our ability to expand our product engine to include extrahepatic tissues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our current and anticipated clinical trials and expectations regarding the reporting of data from these trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any impact of the ongoing conflict in Ukraine, including disruptions to our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing of regulatory filings and interactions with, or actions or advice of, regulatory authorities, which may affect the design, initiation, timing, continuation and/or progress of clinical trials, or result in the need for additional pre-clinical and/or clinical testing or the timing or likelihood of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the status of our manufacturing operations and any delays, interruptions or failures in the manufacture and supply of ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO or any of our product candidates (or other products or product candidates being developed and commercialized by our partners), by our or their contract manufacturers or by us or our partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our progress continuing to build and leverage our global commercial infrastructure;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the possible impact of any competing products on the commercial success of ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO and Leqvio, as well as our product candidates, and, our, or with respect to Leqvio or fitusiran, our partners', ability to compete against such products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to manage our growth and operating expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our views and plans with respect to our 5-year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> strategy and our intentions to achieve the metrics associated with this strategy, including to become a top-tier biotech company by the end of 2025;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our belief that our current cash balance should enable us to achieve a self-sustainable profile without the need for future equity financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our expectations regarding the length of time our current cash, cash equivalents and marketable equity and debt securities will support our operations based on our current operating plan;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our dependence on third parties for development, manufacture and distribution of products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our expectations regarding our corporate collaborations, including potential future licensing fees and milestone and royalty payments under existing or future agreements;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to obtain, maintain and protect our intellectual property;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to attract and retain qualified key management and scientists, development, medical and commercial staff, consultants and advisors and to successfully execute on our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the outcome of litigation, including our patent infringement suits against Pfizer, Inc., BioNTech SE and Moderna, Inc., or other legal proceedings or of any current or future government investigation, including the investigation related to the subpoena received on or about April 9, 2021 pertaining to our marketing and promotion of ONPATTRO in the United States, or U.S.; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory developments in the U.S. and foreign countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the impact of laws and regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">developments relating to our competitors and our industry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to satisfy our payment obligations, and to service the interest on, or to refinance our indebtedness, including our convertible notes, or to make cash payments in connection with any conversion of our convertible notes, to the extent required; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our expectations regarding the effect of the capped call transactions and the anticipated market activities of the option counterparties and/or their respective affiliates; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">other risks and uncertainties, including those listed under the caption Part II, Item 1A, "Risk Factors" of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risks set forth above are not exhaustive. Other sections of this Quarterly Report on Form 10-Q may include additional factors that could adversely affect our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all risk factors, nor can we assess the impact of all risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events and with respect to our business and future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, "Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You are advised, however, to consult any further disclosure we make in our reports filed with the SEC.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i90e340589f97408ea2365d8948df4c38_13"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">PART I. FINANCIAL INFORMATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:none" href="#i90e340589f97408ea2365d8948df4c38_19">ITEM 1. FINANCIAL STATEMENTS (Unaudited)</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i90e340589f97408ea2365d8948df4c38_16"></div><div><span><br/></span></div><div id="i90e340589f97408ea2365d8948df4c38_19"></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:70.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMy0xLTEtMS0xMTEzNjg_ace2d9aa-3747-44b8-b0b9-9cf4d36288eb">672,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMy0zLTEtMS0xMTEzNjg_6aa62e5e-b00a-46bb-9735-58ea3fa6c381">866,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNC0xLTEtMS0xMTEzNjg_87f6206f-a724-43f0-b33c-6630716afa84">1,372,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNC0zLTEtMS0xMTEzNjg_c5e4013c-8d7b-4938-a5c4-4f9f38e81448">1,297,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNS0xLTEtMS0xMTEzNjg_41472ae2-a22d-4521-af44-f7210f3ea244">25,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNS0zLTEtMS0xMTEzNjg_fe457055-15e6-4f03-9177-831844cc98c0">28,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNi0xLTEtMS0xMTEzNjg_ad18f2aa-3e9a-4f54-a317-cf92ae7b4367">219,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNi0zLTEtMS0xMTEzNjg_d9eac035-11ca-408d-a5f8-329c0a808a00">237,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNy0xLTEtMS0xMTEzNjg_153ce335-87c8-4bca-9f56-4f3cd5bf358b">131,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNy0zLTEtMS0xMTEzNjg_033bf655-edc4-4694-b551-ab364a001b2c">128,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfOC0xLTEtMS0xMTEzNjg_c44fba7e-8872-4bf9-b9e7-05d703ee889b">119,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfOC0zLTEtMS0xMTEzNjg_131289ba-6386-497b-ab45-4b17e9876fa1">132,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTAtMS0xLTEtMTExMzY4_6d9acb01-df72-4d61-a6b2-85ec121434ce">2,541,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTAtMy0xLTEtMTExMzY4_3a9b4a60-9429-4f48-9522-4d947f36e402">2,692,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTEtMS0xLTEtMTExMzY4_0dbbcf0a-961f-4c13-a57f-46dcd663b31f">523,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTEtMy0xLTEtMTExMzY4_08f6cb27-ce5e-4d2d-b738-745502fa238f">523,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTItMS0xLTEtMTExMzY4_9a9eade8-ebf9-426c-8f05-88bb2ff131f4">215,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTItMy0xLTEtMTExMzY4_913d8c99-6d83-4707-a64e-0f74ff1d66f3">215,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:RestrictedInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTMtMS0xLTEtMTExMzY4_ac196097-71a9-4340-990c-2e07313be025">49,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:RestrictedInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTMtMy0xLTEtMTExMzY4_6dc10544-70e5-4cb2-82a1-5c8bc4e03150">49,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTQtMS0xLTEtMTExMzY4_65edb7dd-a6dd-429c-b04e-3f3aafa674d6">63,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTQtMy0xLTEtMTExMzY4_d66d9d30-f07b-48c2-b47b-f39a63c69d61">66,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTUtMS0xLTEtMTExMzY4_d793990a-182b-439f-b8d4-47012a679471">3,391,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTUtMy0xLTEtMTExMzY4_9af67621-5054-4d73-9575-fbd5a4cb2f87">3,546,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTgtMS0xLTEtMTExMzY4_50a7291e-e8f3-4c26-8341-f642f18fbfd0">62,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTgtMy0xLTEtMTExMzY4_9ca6ffbc-8d13-4017-bc1d-faec520e4ed0">98,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTktMS0xLTEtMTExMzY4_91a244cd-4019-4cce-8333-bdc9b511e98f">508,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTktMy0xLTEtMTExMzY4_5d805816-572c-462c-962b-a56a605c61db">545,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjAtMS0xLTEtMTExMzY4_131f61df-ca90-4fe1-863e-5f7f85155b3f">43,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjAtMy0xLTEtMTExMzY4_3b4ae8a1-122f-4df5-be8f-527962df969b">41,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjEtMS0xLTEtMTExMzY4_589ed23a-d39a-4ce6-a756-e7264c6dd258">35,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjEtMy0xLTEtMTExMzY4_21af395c-476d-4fe4-9444-b399468486d4">42,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="alny:RoyaltyLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjItMS0xLTEtMTExMzY4_7141a046-f9a8-485a-8f18-3f51f7366fa4">23,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="alny:RoyaltyLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjItMy0xLTEtMTExMzY4_b83057e9-ffe0-41cf-8d41-fbfe411268ff">40,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjMtMS0xLTEtMTExMzY4_57e924bb-7152-4a79-be34-40a9ee769fae">673,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjMtMy0xLTEtMTExMzY4_8ae0b9ba-6680-401b-b4a3-65d3ee636109">767,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjQtMS0xLTEtMTExMzY4_9866a7b6-04a9-43dd-825e-d4d582acf289">259,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjQtMy0xLTEtMTExMzY4_0942c417-10b8-472c-89b0-048b00893ec6">261,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjUtMS0xLTEtMTExMzY4_0c2a4f82-98de-47d2-b5ee-049d281feba5">191,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjUtMy0xLTEtMTExMzY4_76469ce9-771a-450a-ba05-21bf1b7450bd">193,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjYtMS0xLTEtMTExMzY4_e1ddf58f-7a94-4dd3-af55-01d5e1655750">1,017,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjYtMy0xLTEtMTExMzY4_ca63470d-cd5e-4cf1-97a7-f1fd43aa4117">1,016,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="alny:RoyaltyLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjgtMS0xLTEtMTExMzY4_34b02876-ac97-401f-98ab-032698dbec8e">1,285,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="alny:RoyaltyLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjgtMy0xLTEtMTExMzY4_62acd470-adb1-4527-8615-60e99c8d7d0d">1,252,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjktMS0xLTEtMTExMzY4_20ae9f8d-782a-40fb-8b11-19e8cf515a6e">224,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjktMy0xLTEtMTExMzY4_810c35c2-9b2e-4ea4-80ed-88ffd4028bb3">212,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzAtMS0xLTEtMTExMzY4_5410f92b-f1cc-4ef3-a01e-d3842df9c5a9">3,651,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzAtMy0xLTEtMTExMzY4_717af1a0-b096-46d2-b173-2a526733b3a1">3,704,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 13)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzEtMS0xLTEtMTExMzY4_e648215e-5227-44dd-a473-a8414d578b27"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzEtMy0xLTEtMTExMzY4_06136521-a925-4aef-8313-791317130a76"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; deficit:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfMjI_3ce0e910-4aaf-44d7-ad09-7b2a46501565"><ix:nonFraction unitRef="usdPerShare" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfMjI_eccc08c9-b987-4122-b1b0-41b819d51e66">0.01</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction unitRef="shares" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfNDY_79a5ca29-d290-4b03-9b1e-6ceacc57a1b3"><ix:nonFraction unitRef="shares" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfNDY_9b68ffc0-5b94-4dba-9034-42dddcea7580">5,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfNzE_3a6455ea-b51c-4216-93c5-0e13e72b33f7"><ix:nonFraction unitRef="shares" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfNzE_aa72d455-ff67-406e-b78c-14ee7652a2cc"><ix:nonFraction unitRef="shares" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfNzE_e034ea67-4fe8-466e-9cf3-c67732bc9c9f"><ix:nonFraction unitRef="shares" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfNzE_eae96671-acea-4347-8a40-f42ff6401ac3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMS0xLTEtMTExMzY4_b35f09cc-38d2-4a53-9ac3-118b5955e633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMy0xLTEtMTExMzY4_b153c680-652e-4110-80a4-2a9e57d34bd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfMTg_7f69c27a-bb06-414b-a634-4305ffb6727a"><ix:nonFraction unitRef="usdPerShare" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfMTg_d83dbb4e-a631-4e3a-a611-27e86e2aaebd">0.01</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction unitRef="shares" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfNDI_7888f226-cbd5-4a9e-a764-d3a421d0b6d5"><ix:nonFraction unitRef="shares" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfNDI_e277731f-f584-4f9f-83f1-da3f1ae3eb25">250,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfNjQ_2fb7db02-9194-44ff-9114-a6ae505585f1"><ix:nonFraction unitRef="shares" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfNjQ_e22eeb6e-90f9-419b-826a-bb8b166dc07b">124,241</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023; <ix:nonFraction unitRef="shares" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfMTA3_dad9b9b3-d785-4e72-98c1-656b1c7ad12a"><ix:nonFraction unitRef="shares" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfMTA3_e06769a9-8bc9-47b1-94dd-648f8cb26eba">123,925</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMS0xLTEtMTExMzY4_f484f8c3-7a71-4b2b-a057-cd8e2c6c21fa">1,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMy0xLTEtMTExMzY4_993ccc43-0a68-4d71-af02-24507319b848">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzUtMS0xLTEtMTExMzY4_684da35b-f9d9-46be-94c0-6d19979cd0f2">6,522,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzUtMy0xLTEtMTExMzY4_9aefbe47-6282-4856-b0e1-6dcf369a3277">6,454,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzYtMS0xLTEtMTExMzY4_e27a8dfd-aea2-4b5c-b1b7-48529499eced">39,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzYtMy0xLTEtMTExMzY4_049b013b-8f30-4013-8c83-1f71ebef071a">44,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzctMS0xLTEtMTExMzY4_73a266da-3683-4af8-839f-3e34e9b59130">6,743,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzctMy0xLTEtMTExMzY4_7f665b5e-6b99-49de-9cef-4e4f2884247f">6,569,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzgtMS0xLTEtMTExMzY4_87ad614e-9043-4688-8714-03d1fdae2107">259,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzgtMy0xLTEtMTExMzY4_d6a44096-3027-4b88-9e5b-5af85c843c56">158,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzktMS0xLTEtMTExMzY4_ab3954ea-0c49-4d73-ac4a-d9b8a6f17e1e">3,391,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzktMy0xLTEtMTExMzY4_f5dc414a-5ef0-4380-afa2-20dceebe76df">3,546,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:38.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i90e340589f97408ea2365d8948df4c38_25"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:73.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.376%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.379%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8195be6db017423781aa99e5f6eccbdd_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNC0xLTEtMS0xMTEzNjg_13cc2184-2b2e-49b5-9b54-7e957acd068d">276,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b8d81e96cb44258ca45844632dfcd5_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNC0zLTEtMS0xMTEzNjg_80e1a205-9148-4905-bda5-010990b61c05">186,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues from collaborations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84733ccbf66149c5b5b450843cfb6b1a_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNS0xLTEtMS0xMTEzNjg_ed477fd9-8696-4c4f-bada-809035633f41">36,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1217f0f803147f79e8c9536b829300b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNS0zLTEtMS0xMTEzNjg_645e79ae-6395-47be-bd1e-6326d179f09e">25,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc45426006b4d8da84244a71315226f_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNi0xLTEtMS0xMTEzNjg_34214a21-5ba4-4912-9376-ac18c8027c81">6,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i614f8658aaee4615b1db837d518ecf21_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNi0zLTEtMS0xMTEzNjg_f0e657f7-6ba0-4b6b-9033-e45ac876ac33">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNy0xLTEtMS0xMTEzNjg_63943137-3e70-44ca-8d0b-3edcb73360ee">319,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNy0zLTEtMS0xMTEzNjg_e5d9cc0c-2a20-4bdf-8c30-5442ee5fa021">213,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfOS0xLTEtMS0xMTEzNjg_51d15c0b-cc05-4c1d-ab7e-0fb11f62a82c">41,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfOS0zLTEtMS0xMTEzNjg_caffe389-9628-4cba-8f21-21c1470aab4e">23,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaborations and royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="alny:CostOfCollaborationManufacturingAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTAtMS0xLTEtMTExMzY4_2f563a1c-3218-4701-8aa5-02690d415926">13,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="alny:CostOfCollaborationManufacturingAndRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTAtMy0xLTEtMTExMzY4_bb989807-e24f-4b2f-8931-e8002b2e1983">12,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTEtMS0xLTEtMTExMzY4_f9ca65c7-2eaf-46b3-8912-d19e596d307e">230,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTEtMy0xLTEtMTExMzY4_b9e24f68-4baa-4614-8207-bf6a82cf7f32">169,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTItMS0xLTEtMTExMzY4_b9d0a522-2874-4ecf-b0de-50a328908774">183,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTItMy0xLTEtMTExMzY4_08530d73-e690-4cf4-99a4-0f7d9a696520">154,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTMtMS0xLTEtMTExMzY4_511de319-594a-4fa5-98b9-e1752c2730ca">469,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTMtMy0xLTEtMTExMzY4_0677c596-3da9-4ffc-934f-f75345f8638f">359,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTQtMS0xLTEtMTExMzY4_85462302-1bdf-441b-abf4-cdbfc072b04c">149,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTQtMy0xLTEtMTExMzY4_9f81a563-a4ef-4887-9996-ba4f751a397c">146,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTYtMS0xLTEtMTExMzY4_ac2acfa5-c8ce-40f1-9d26-70672bac52e0">28,955</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTYtMy0xLTEtMTExMzY4_effdea72-241e-4d12-aa7d-5fcaabe188f0">42,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTctMS0xLTEtMTIxMzQy_912a270f-fe53-4c17-8e94-bd17cdd9a820">18,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTctMy0xLTEtMTIxMzQy_a2d5e173-71f0-48c2-a5f5-f41fd97d9914">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTctMS0xLTEtMTExMzY4_0f7aa063-05bb-46e0-a21c-eb72af5e1784">12,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTctMy0xLTEtMTExMzY4_0b0f26da-513e-46b3-b86a-425cc4aed2ce">51,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTktMS0xLTEtMTExMzY4_c5c1debc-4df6-4e86-89df-69d4c3e59991">22,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTktMy0xLTEtMTExMzY4_829db578-df05-4769-81c5-ae756613a3a0">92,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjAtMS0xLTEtMTExMzY4_7e015151-9abf-4fa4-917e-f7a763d183e5">172,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjAtMy0xLTEtMTExMzY4_3ce5d2fd-2926-458c-beda-8b5df49bbe87">239,356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjEtMS0xLTEtMTExMzY4_b29d7c75-a838-48f9-a845-6db5ebae5c4a">1,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjEtMy0xLTEtMTExMzY4_e8690424-ecb6-40ca-b9ad-62dbb72965b7">985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjItMS0xLTEtMTExMzY4_0beda309-8cf7-4674-a044-c31fb32a4d2e">174,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjItMy0xLTEtMTExMzY4_fbba0d65-47af-4ada-8004-ede17b3f28b3">240,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjMtMS0xLTEtMTExMzY4_b1e2a57c-249c-4aa8-b8ee-4d7ed6e0f9c5"><ix:nonFraction unitRef="usdPerShare" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjMtMS0xLTEtMTExMzY4_de4630a1-4f98-4ac3-af62-a5eb070f50f3">1.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjMtMy0xLTEtMTExMzY4_5013b99e-fef2-462a-b335-83ed97ae7924"><ix:nonFraction unitRef="usdPerShare" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjMtMy0xLTEtMTExMzY4_99d450c6-166f-498a-83ea-1756748782cb">2.00</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjQtMS0xLTEtMTExMzY4_70670447-bc71-4e6b-851d-06d0a3899a4c"><ix:nonFraction unitRef="shares" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjQtMS0xLTEtMTExMzY4_c9d9a66f-97a0-413a-92f5-a54d7f49c7ad">124,111</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjQtMy0xLTEtMTExMzY4_5bc268ea-934f-412d-bbf3-eda3938e0520"><ix:nonFraction unitRef="shares" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjQtMy0xLTEtMTExMzY4_ac6085fe-e58f-4017-b2a9-0f91c0842660">120,393</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Comprehensive Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjctMS0xLTEtMTExMzY4_7737cc15-bc4d-46ef-9622-a533a5c5d3c7">174,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjctMy0xLTEtMTExMzY4_f1505d54-e9ee-4147-a5ff-4cae2f9e3efd">240,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjktMS0xLTEtMTExMzY4_500f404a-5d68-4990-9244-a5817515e6bd">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjktMy0xLTEtMTExMzY4_4e2e3292-f1a9-4342-ba74-36b510cc7e02">7,217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzAtMS0xLTEtMTExMzY4_031e4d83-af4a-4cdd-ac89-003844dfd6bf">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzAtMy0xLTEtMTExMzY4_a6beae6f-872d-48b4-844c-f4c26cc9276c">2,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzEtMS0xLTEtMTExMzY4_028278f2-59a4-4946-a1df-74720269ce97">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzEtMy0xLTEtMTExMzY4_2f412236-93f9-4845-8a3e-5defb46d8ffc">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzItMS0xLTEtMTExMzY4_2815cb0e-2d5d-4ad2-9ffb-ce6edf54a56a">5,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzItMy0xLTEtMTExMzY4_aaf36ab4-47df-4bab-9054-453404525e86">4,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzMtMS0xLTEtMTExMzY4_36375944-0b32-4270-8b60-7db752d303bc">168,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzMtMy0xLTEtMTExMzY4_20603784-17c5-4d10-bf86-41ef3bcddb5b">245,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i90e340589f97408ea2365d8948df4c38_28"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; (DEFICIT) EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.971%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Deficit</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i165ab1c7d45f4b59b55f6202bd02b29d_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMi0xLTEtMS0xMTEzNjg_edffa630-ad3c-4aa2-881e-020754ba39e8">123,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165ab1c7d45f4b59b55f6202bd02b29d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMi0zLTEtMS0xMTEzNjg_52ac93b4-b507-468c-8a47-f109041e7eba">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i627afa621d0246df9877bb6114adff8c_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMi01LTEtMS0xMTEzNjg_74eda663-b58f-47be-b05a-ebdf322388a5">6,454,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib10c6162d7ee41d8b5073719840fa8ed_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMi03LTEtMS0xMTEzNjg_d44403d9-2fea-45da-8409-45c5f9d98e96">44,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1effbb5b358434886d5497a4dd79337_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMi05LTEtMS0xMTEzNjg_a3e796fe-2a1b-4816-86c4-13492456cd7b">6,569,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMi0xMS0xLTEtMTExMzY4_05370b5a-1e25-4310-ba52-c5454d7522cd">158,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of common stock options, net of tax withholdings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ad08d083b134bc08112b596229b2ed4_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMy0xLTEtMS0xMTEzNjg_a85ddf7c-265f-4dfd-807d-f86118ff4bb2">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ad08d083b134bc08112b596229b2ed4_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMy0zLTEtMS0xMTEzNjg_8e623618-851b-4923-b549-92ff13fd04aa">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0285951fb32549e2b7c666db15c9daf2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMy01LTEtMS0xMTEzNjg_e743e17c-538b-43e6-af4d-60e5ecc4dc5a">26,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMy0xMS0xLTEtMTExMzY4_2ebb2970-cbd3-4609-ad36-b7f71338ffb3">26,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ad08d083b134bc08112b596229b2ed4_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNC0xLTEtMS0xMTEzNjg_a860c60d-84cf-4341-91c5-828ca496cc12">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNC0xMS0xLTEtMTExMzY4_7f13b28e-e342-4a8f-b617-bc05a7b6a2ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0285951fb32549e2b7c666db15c9daf2_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNS01LTEtMS0xMTEzNjg_ef99b8e3-e63e-4292-8677-b20a02795f6e">41,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNS0xMS0xLTEtMTExMzY4_df45c831-5e58-440f-a653-aae0c1bec02c">41,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a77c376b2b4ba987e016002cfe1389_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNi03LTEtMS0xMTEzNjg_b3bba7fe-74ab-4607-b047-2a7d49a8638a">5,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNi0xMS0xLTEtMTExMzY4_cf95556b-7c1c-4f2e-bf4f-764b10e17d5b">5,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c7db22afb9642d498a5f30d7ec9da76_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNy05LTEtMS0xMTEzNjg_56b85d75-823c-4c25-a180-a93b77a7e239">174,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNy0xMS0xLTEtMTExMzY4_6732c01d-e6bd-41b3-a6cb-80c530035ab3">174,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic503ee23109c47a485d4c943dc01c684_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfOC0xLTEtMS0xMTEzNjg_282b6c7b-748b-4d26-bbc9-702cf5dda3e0">124,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic503ee23109c47a485d4c943dc01c684_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfOC0zLTEtMS0xMTEzNjg_23f9ef1f-cbd8-4af5-b1dc-0002906e6ce0">1,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50048ec3817431baf2df96733ffaa31_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfOC01LTEtMS0xMTEzNjg_cadbd142-88ed-4733-8484-e245deb3a565">6,522,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id68ac710f233437aa4518ad8eb0adb93_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfOC03LTEtMS0xMTEzNjg_b2ef6cb8-4156-4cc9-810c-7636a2c7f304">39,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8d35477623a4ca9b7fc82fa82a051b8_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfOC05LTEtMS0xMTEzNjg_0fb31267-3dfa-4a2f-b9a3-2175b073fa06">6,743,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfOC0xMS0xLTEtMTExMzY4_0bbaa988-1129-46a5-a83c-721a7b51eca1">259,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.350%"><tr><td style="width:1.0%"></td><td style="width:36.045%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.930%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8b5cdd9d6524a48a7c0e217c8746b86_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMi0xLTEtMS0xMTEzNjg_23957b6c-6ba5-446a-ae75-3c353c82631b">120,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b5cdd9d6524a48a7c0e217c8746b86_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMi0zLTEtMS0xMTEzNjg_d09deee1-d66e-4193-b2d7-94b1d4c0de6b">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349f62fd0c1c46b6a699a43b81912de5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMi01LTEtMS0xMTEzNjg_879c2305-94ea-470e-a299-5498f28e8c2f">6,058,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie72229676bde424e88e71e576e78694f_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMi03LTEtMS0xMTEzNjg_05be4f1a-4cfc-456e-a294-46a985eb48e4">33,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id64ff2050fde4c88a7a11680cbda5964_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMi05LTEtMS0xMTEzNjg_6af42491-6889-4d10-a1b3-ca70c2fc4612">5,438,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa61d04167f4839b28e5e693a40c913_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMi0xMS0xLTEtMTExMzY4_fe2ed124-c1e7-4f93-9bfe-e826732225cb">588,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of common stock options, net of tax withholdings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32343cbd739e429184dd13d72f726915_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMy0xLTEtMS0xMTEzNjg_acc52b76-e630-4d37-8d4f-8c0b0a67c47e">524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32343cbd739e429184dd13d72f726915_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMy0zLTEtMS0xMTEzNjg_cbf87762-eb77-40a2-b607-4c07683b4f09">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a826bcf6ea5466cbbdc81d17d06dfc3_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMy01LTEtMS0xMTEzNjg_ec1dcdd3-cc9e-4b6a-9001-5ddb8ecf6751">28,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMy0xMS0xLTEtMTExMzY4_23ee702b-7861-4f1d-bfe6-b8b0eee138d9">28,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32343cbd739e429184dd13d72f726915_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNC0xLTEtMS0xMTEzNjg_a9e1fb84-59ac-4492-98f0-e174e4e6beb5">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a826bcf6ea5466cbbdc81d17d06dfc3_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNS01LTEtMS0xMTEzNjg_e6c4bb32-d76a-4816-aec0-5d94ce79881a">30,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNS0xMS0xLTEtMTExMzY4_cd106d7e-f01f-40a4-874b-db58b3274bfb">30,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10b28d8521f2456da2d0123114d04efc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNi03LTEtMS0xMTEzNjg_774fe636-2e36-459b-8817-33e88317cac5">4,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNi0xMS0xLTEtMTExMzY4_fd4b0af9-b93b-42f1-bef7-e88cb78cf7c4">4,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd6e196fd8bc401390b246f2c1842f21_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNy05LTEtMS0xMTEzNjg_e2505704-a46a-4091-ba3f-63ee6525cd53">240,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNy0xMS0xLTEtMTExMzY4_a61c2570-8941-4013-9b05-61ac09f8e55e">240,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea3984c5c8334ea2b81d6e311a263566_I20220331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfOC0xLTEtMS0xMTEzNjg_3e2697a9-df39-432c-8fc7-d9a70c93374d">120,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea3984c5c8334ea2b81d6e311a263566_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfOC0zLTEtMS0xMTEzNjg_9dcb68f6-d61c-41e1-b323-6354ddd26881">1,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d7c4b1ef5dd4faabe5879a7cb1a13b4_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfOC01LTEtMS0xMTEzNjg_c4a2ee19-c27b-49a1-a27b-3274c201a20b">6,116,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2d23f30f53a4a3b8caa38a11b48d302_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfOC03LTEtMS0xMTEzNjg_95d1f324-1724-4043-a3a5-a637d7f0a6f6">38,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74133721fcc744889831c3b5bbd754b4_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfOC05LTEtMS0xMTEzNjg_2ba62973-f7d4-49ea-a32a-50370c1f07e3">5,678,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129714144f56409c862078cd74c09670_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfOC0xMS0xLTEtMTExMzY4_423a0838-e987-4e23-9cb8-279e93f1575a">401,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i90e340589f97408ea2365d8948df4c38_31"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:72.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMy0xLTEtMS0xMTEzNjg_0b991dc1-0dea-4060-b179-1bb744034281">174,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMy0zLTEtMS0xMTEzNjg_ed666ef8-3aad-4fba-b48c-1f43b0744ff9">240,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNS0xLTEtMS0xMTEzNjg_6e2cbbff-cb75-40ef-8de7-60fe80b03b91">14,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNS0zLTEtMS0xMTEzNjg_fea8d7f2-d0e5-415e-b50b-3464bcc15eb0">9,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and interest accretion related to operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="alny:AmortizationAndInterestAccretionRelatedToOperatingLeases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNi0xLTEtMS0xMTEzNjg_a6c3ea51-5413-4c54-b0e6-622945135a10">12,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="alny:AmortizationAndInterestAccretionRelatedToOperatingLeases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNi0zLTEtMS0xMTEzNjg_adf1521a-e271-4f0c-a77f-e449df5ff172">10,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense on liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="alny:NonCashInterestExpenseOnSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNy0xLTEtMS0xMTEzNjg_0794d85b-0ec2-4c47-a84d-641bdf30d1c4">25,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="alny:NonCashInterestExpenseOnSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNy0zLTEtMS0xMTEzNjg_69d0b405-e4a4-4d6e-90b7-39e8be6e5b88">27,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfOC0xLTEtMS0xMTEzNjg_e4619d3b-eba6-4914-9f81-c660e5953297">39,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfOC0zLTEtMS0xMTEzNjg_27ea9954-89c6-45d0-9680-6e0401944337">29,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realized and unrealized loss on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfOS0xLTEtMS0xMTEzNjg_1ed846d4-1737-4fc7-93fb-37c8b24241e2">2,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfOS0zLTEtMS0xMTEzNjg_c2f614c9-2bdd-4e4d-a212-2ff4fceec132">31,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="alny:ChangeInFairValueOfLiabilityObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTEtMS0xLTEtMTExMzY4_4df95813-6111-430a-867f-328c1e85511d">6,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="alny:ChangeInFairValueOfLiabilityObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTEtMy0xLTEtMTExMzY4_2bc8f62f-7ab8-4174-a417-4788e519e5a1">13,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTItMS0xLTEtMTExMzY4_390a8800-f018-411e-93ef-83b44a61e3b3">6,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTItMy0xLTEtMTExMzY4_57ca7968-8666-49cd-af9e-e350c512c96e">7,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTQtMS0xLTEtMTExMzY4_7df78614-0c1e-4626-931e-dd0d3a8d3042">19,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTQtMy0xLTEtMTExMzY4_ea8545d0-94d5-4752-8993-16f30726d69e">39,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTUtMS0xLTEtMTExMzY4_d0d37871-874b-4aa3-adc8-6089f4b9a7aa">403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTUtMy0xLTEtMTExMzY4_c3145fe4-4835-4b86-b06d-48cfef93f457">1,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTYtMS0xLTEtMTExMzY4_0d5c9874-a242-4d9a-ab0b-bdd7e277aded">1,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTYtMy0xLTEtMTExMzY4_52f73976-b29c-485b-9d31-29db9979cea3">29,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTctMS0xLTEtMTExMzY4_cc9cc45c-bcc9-4eca-9315-c727a0dcd3e5">81,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTctMy0xLTEtMTExMzY4_272ce412-ba8a-4f12-b3b9-9a39dfce7174">48,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTgtMS0xLTEtMTExMzY4_ec1827a3-903f-494e-8541-0da198f9b49d">12,827</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTgtMy0xLTEtMTExMzY4_0be8883e-a6fe-4091-86e6-1f645ad07f23">10,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTktMS0xLTEtMTExMzY4_9262922a-1707-4c9c-9c78-426a078aaf96">8,850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTktMy0xLTEtMTExMzY4_c6543485-1926-443f-a76b-b800064b05a4">12,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjAtMS0xLTEtMTExMzY4_94cb2d40-97df-4530-8b34-9e328dece414">166,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjAtMy0xLTEtMTExMzY4_68fdd754-9f34-4310-aa0d-0e1767d02fe9">171,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjItMS0xLTEtMTExMzY4_35140922-0f26-45d7-a447-bf2931f24def">13,891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjItMy0xLTEtMTExMzY4_6f6dc058-15c7-442d-9316-69e8a3754625">17,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjMtMS0xLTEtMTExMzY4_8a96a9b5-0719-4213-a43a-42b8408fc7a7">435,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjMtMy0xLTEtMTExMzY4_e3a60a0a-e69b-40cb-8094-1f04c0b61261">634,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjQtMS0xLTEtMTExMzY4_5c6335fc-93f5-44b4-ab93-bd1ba12d931b">373,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjQtMy0xLTEtMTExMzY4_1cda66a1-2c18-4a1c-a73e-800ff2780563">505,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturity of restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjUtMS0xLTEtMTExMzY4_de2c0963-7a92-4d85-a754-dacf4f149c23">49,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjUtMy0xLTEtMTExMzY4_d6f90a62-7cc5-4755-920a-ee955d6c7180">9,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireRestrictedInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjYtMS0xLTEtMTExMzY4_fc26b5e5-c05b-49f2-ad8e-5314a72e7eda">49,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireRestrictedInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjYtMy0xLTEtMTExMzY4_1c61150a-62db-4cec-883a-85295a1d3b9e">9,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjctMS0xLTEtMTExMzY4_66fadf89-29ca-4e91-9605-2d2af838b4c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjctMy0xLTEtMTExMzY4_4b02d7be-8c38-42d3-9073-c4a4c1ff0b4c">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjgtMS0xLTEtMTExMzY4_a25b3eaf-9891-4350-853e-a39dc10fb594">76,217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjgtMy0xLTEtMTExMzY4_30b0c9f2-f703-4d00-bf82-5a6221ab56ba">147,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and other types of equity, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzAtMS0xLTEtMTExMzY4_0b4e2ad0-d9e8-4598-a86a-4cd39989ce78">42,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzAtMy0xLTEtMTExMzY4_b077d299-72e9-46cf-9f7f-a83275131511">27,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from development derivative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzUtMS0xLTEtMTExMzY4_deae82a9-7181-4f84-ad55-e53499f3c87b">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzUtMy0xLTEtMTExMzY4_4ab3ffde-5a20-41f7-b861-97900910ede6">7,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzgtMS0xLTEtMTExMzY4_778c2a20-523b-4d76-9d16-618f6c4e1fb4">46,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzgtMy0xLTEtMTExMzY4_db33a862-b3fc-4b52-b514-796f7e762d14">34,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzktMS0xLTEtMTExMzY4_795d4846-2bc7-449f-86ce-c65387084db2">2,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzktMy0xLTEtMTExMzY4_076b9001-7406-4fa9-a5be-492212729f40">2,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDAtMS0xLTEtMTExMzY4_e16f3677-383a-44f4-bde0-8c03f19aff73">194,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDAtMy0xLTEtMTExMzY4_34136376-5243-40b5-8cd7-48bdaa89a758">285,894</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDEtMS0xLTEtMTExMzY4_e2866084-3b27-43e9-88e4-dd32df3f419b">868,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa61d04167f4839b28e5e693a40c913_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDEtMy0xLTEtMTExMzY4_1c12ff6c-eed2-435b-8ac9-a86d01d4f6ea">822,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDItMS0xLTEtMTExMzY4_ce1dc7e7-443d-4ced-93c9-1254114241d0">674,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129714144f56409c862078cd74c09670_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDItMy0xLTEtMTExMzY4_4f99b3ca-4e87-4b34-acbb-7d56c9cf7549">536,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDQtMS0xLTEtMTExMzY4_f15e9b5e-472d-452d-8bff-97423567f483">13,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDQtMy0xLTEtMTExMzY4_50839b40-2b18-4f7f-83b0-0de4f818a6e3">14,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDctMS0xLTEtMTExMzY4_7fcca15d-d0da-4ef0-9650-329dcb1dabf3">4,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDctMy0xLTEtMTExMzY4_8a49b9c3-52f1-4015-9d23-85aae76645a9">8,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i90e340589f97408ea2365d8948df4c38_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i90e340589f97408ea2365d8948df4c38_37"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zNy9mcmFnOjRmNjA2ZTM5NzIxOTQ0Y2I4ZGY0M2QxODQxNDg4Njc5L3RleHRyZWdpb246NGY2MDZlMzk3MjE5NDRjYjhkZjQzZDE4NDE0ODg2NzlfMjA1OA_0e87c99b-330a-4105-ae59-deb9e57d82dd" continuedAt="i5ded30e3625540f08fe9a49bbd542401" escape="true">NATURE OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="i5ded30e3625540f08fe9a49bbd542401"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June&#160;14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on ribonucleic acid interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top-tier biotech company by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, while delivering exceptional financial performance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, we have <ix:nonFraction unitRef="product" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="INF" name="alny:NumberOfMarketedProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zNy9mcmFnOjRmNjA2ZTM5NzIxOTQ0Y2I4ZGY0M2QxODQxNDg4Njc5L3RleHRyZWdpb246NGY2MDZlMzk3MjE5NDRjYjhkZjQzZDE4NDE0ODg2NzlfNTQ5NzU1ODE0MTc3MQ_060d0558-2c89-40b6-a0d3-b28289abbbfa">five</ix:nonFraction> marketed products, including <ix:nonFraction unitRef="product" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="INF" name="alny:NumberOfPartneredProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zNy9mcmFnOjRmNjA2ZTM5NzIxOTQ0Y2I4ZGY0M2QxODQxNDg4Njc5L3RleHRyZWdpb246NGY2MDZlMzk3MjE5NDRjYjhkZjQzZDE4NDE0ODg2NzlfNTQ5NzU1ODE0MTc3OA_715ca6d1-1a71-4086-87b9-0d7f39b1b6cf">one</ix:nonFraction> partnered product, and multiple late-stage investigational programs advancing towards potential commercialization. We currently generate worldwide product revenues from <ix:nonFraction unitRef="product" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="INF" name="alny:NumberOfCommercializedProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zNy9mcmFnOjRmNjA2ZTM5NzIxOTQ0Y2I4ZGY0M2QxODQxNDg4Njc5L3RleHRyZWdpb246NGY2MDZlMzk3MjE5NDRjYjhkZjQzZDE4NDE0ODg2NzlfMjA2MQ_a58e107c-5c54-407a-ada6-cab2a9c9c7c2">four</ix:nonFraction> commercialized products, ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO, primarily in the United States, or U.S., Europe and Japan.</span></div></ix:continuation><div id="i90e340589f97408ea2365d8948df4c38_40"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80MC9mcmFnOjdmZDZiMmNiY2RlZTQxMDhiYjZjYzcwNTAwYjUwZTA1L3RleHRyZWdpb246N2ZkNmIyY2JjZGVlNDEwOGJiNmNjNzA1MDBiNTBlMDVfNTIwMA_38370623-486e-4112-bde0-d11dc739c2a9" continuedAt="ia55406f71343438b904cce9d47d7af8b" escape="true">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</ix:nonNumeric></span></div><ix:continuation id="ia55406f71343438b904cce9d47d7af8b"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80MC9mcmFnOjdmZDZiMmNiY2RlZTQxMDhiYjZjYzcwNTAwYjUwZTA1L3RleHRyZWdpb246N2ZkNmIyY2JjZGVlNDEwOGJiNmNjNzA1MDBiNTBlMDVfNTE5NA_6afc1c14-e519-421a-8f75-36b87a8286a8" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements of Alnylam are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2022, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 23, 2023. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80MC9mcmFnOjdmZDZiMmNiY2RlZTQxMDhiYjZjYzcwNTAwYjUwZTA1L3RleHRyZWdpb246N2ZkNmIyY2JjZGVlNDEwOGJiNmNjNzA1MDBiNTBlMDVfNTE5NQ_10f5b457-9dd1-4244-9c4f-a49545ca3ea4" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="alny:LiquidityPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80MC9mcmFnOjdmZDZiMmNiY2RlZTQxMDhiYjZjYzcwNTAwYjUwZTA1L3RleHRyZWdpb246N2ZkNmIyY2JjZGVlNDEwOGJiNmNjNzA1MDBiNTBlMDVfNTE5Ng_50007446-9b41-4882-a226-799cf7a99fa3" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of March&#160;31, 2023, together with the cash we expect to generate from product sales and under our current alliances, will be sufficient to enable us to advance our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i90e340589f97408ea2365d8948df4c38_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RleHRyZWdpb246MmI4NmQ2ZjRjZDBmNGQ3YWI2YTFlNGE0ZDcyZDFmNjVfMTc4_03ea8f08-03d1-437e-b1ce-95c402792f30" continuedAt="ia738586ba5e046cda74a8f9bdd98ab62" escape="true">NET PRODUCT REVENUES</ix:nonNumeric></span></div><ix:continuation id="ia738586ba5e046cda74a8f9bdd98ab62"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RleHRyZWdpb246MmI4NmQ2ZjRjZDBmNGQ3YWI2YTFlNGE0ZDcyZDFmNjVfMTgx_026be934-dc93-4224-99b5-a94c0a0d1d4d" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net product revenues consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.362%"><tr><td style="width:1.0%"></td><td style="width:60.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.558%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ONPATTRO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i469113cbfff1448ca7ace21682306c28_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMy0xLTEtMS0xMTEzNjg_ae42f319-411a-480c-9535-959e4441cf7b">29,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b92d59400ad435ab232b2e3fc6af18d_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMy0zLTEtMS0xMTEzNjg_4f5978ba-9f6d-435c-bc34-71c6e742d201">62,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2c45ddfe4b4783b61d0c2532b261c6_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfNC0xLTEtMS0xMTEzNjg_c2d98e43-3de1-47e3-a871-65a7f7972afe">59,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e2090af379423a830396d670dd46ed_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfNC0zLTEtMS0xMTEzNjg_437f9439-d50b-4d73-8a2c-1e02ea15651c">53,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879c1a7e15df42b1a622d6d158eedebc_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfNS0xLTEtMS0xMTEzNjg_5bf975ff-d2fb-471e-be15-ba04668d06f7">12,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72a32ea5faa4d2aa4490f6f4d5cd32c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfNS0zLTEtMS0xMTEzNjg_11383619-4c31-4d75-a492-38eaff51b2b9">21,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd786b1197ef4a61a89be31d546d3ce9_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfNi0xLTEtMS0xMTEzNjg_c537aba9-03a5-45f3-8a7e-9c70cf93fb91">102,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e76d8ae0a064b248bb6fc792baf7c14_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfNi0zLTEtMS0xMTEzNjg_1bfab180-8622-4678-9db2-ee4870779bcd">137,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMVUTTRA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840efee846e14303b149ccdfdf3a36a8_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfOS0xLTEtMS0xMTEzNjg_c2f103a7-2128-4322-9785-cb953a958908">79,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd036604ac7d4a5da0d65fbf272d8217_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfOS0zLTEtMS0xMTEzNjg_b4402514-ca6e-46d1-a184-ded53d1013d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d9b2c9e9b4acd9209bc90e66a8411_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTAtMS0xLTEtMTExMzY4_4649abd2-80c8-4320-8f0e-7f02acc615d9">6,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71831b87aef84d13af0dc46e7eb3368e_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTAtMy0xLTEtMTExMzY4_f262402a-5d3d-4caa-baca-ae032235d434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb5e5a391b254ff999e9906a4a44fecb_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTEtMS0xLTEtMTE4MDIy_c6f7d768-ccd4-4a5e-8603-864e3fc4395d">15,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2417f18ab724e43af379c82cd5c9c40_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTEtMy0xLTEtMTE4MDIy_c2974e06-1f11-446f-b435-8aad71b7af64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73ca8156836b4f2da4a82227758bd9b0_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTEtMS0xLTEtMTExMzY4_c4513951-b15d-428d-9c69-2a46429ce74e">101,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039c753c58d949c39d6d04e4fb10c8d3_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTEtMy0xLTEtMTExMzY4_b14fad40-70c3-4314-8a01-e1abf5a0cdd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GIVLAARI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463e7ef6195945beb17fb66c0a944c2e_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTQtMS0xLTEtMTExMzY4_3fd71ce0-a26e-499a-8555-fea9392ebae0">30,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i933f756eaa1d499da77f10cf4ef3a9fc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTQtMy0xLTEtMTExMzY4_df9dee3f-9029-420f-8f6b-c1c40a168fa6">23,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0754e7eb06254fb4b0be930af30fd4e8_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTUtMS0xLTEtMTExMzY4_1e55d31c-2cb9-4dc6-a56f-b877a18ba056">14,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a7d3d13d3a4e91a7ac66295559e8bc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTUtMy0xLTEtMTExMzY4_2a46f423-84c5-4f2c-9de9-8c0113f88de6">9,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e770d161620415d9b7f5ffaecfd1b16_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTYtMS0xLTEtMTExMzY4_1b76529f-7500-46a4-b44c-902686716ad7">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d3be339f54740539cf50f08dd95e8e2_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTYtMy0xLTEtMTExMzY4_8bf25597-7981-48dd-8e31-5bb5aca4006d">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61661522e28049569e22780fccab15ec_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTctMS0xLTEtMTExMzY4_c9e22ee0-2685-40d3-a86e-e2d439cc76c5">47,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfde9e56f64e49eb860585920e3307de_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTctMy0xLTEtMTExMzY4_335a6ba1-df59-455a-924a-7166b9cf0ab2">35,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OXLUMO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc72492b6ac4d9ab9d17a76e1b3f401_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjAtMS0xLTEtMTExMzY4_753fec94-4440-4922-a323-afb64fe24918">9,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b7e1d6726c409abc1a24d2d0d4cd0b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjAtMy0xLTEtMTExMzY4_a00624cf-7a76-4d8e-9189-d3880f0532eb">5,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e09c2afc4be4d46b953611b6eedc4cd_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjEtMS0xLTEtMTExMzY4_5445561a-5a44-4369-8148-fcf27f9eeca8">13,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294c21243c484600ae87664735590a24_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjEtMy0xLTEtMTExMzY4_7088d776-da29-41ef-9980-77a42230607c">8,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9a9fb2de3341c4965ed9d0dcd38e2f_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjItMS0xLTEtMTExMzY4_29c823a9-c051-4a80-b22a-57932265e9c1">1,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe2b83e5c274d98a554d85575908847_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjItMy0xLTEtMTExMzY4_7f555630-e503-483a-a07a-dc525d61b3a6">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50560d538c374d999be9a5694bed79c4_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjMtMS0xLTEtMTExMzY4_02a35be0-1b33-4172-971d-bf00e7e0c50a">24,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd6dd169a314d9e8b10044417187c7c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjMtMy0xLTEtMTExMzY4_48c6b44f-195a-4e6e-9364-c2e7d1491ee9">14,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8195be6db017423781aa99e5f6eccbdd_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjUtMS0xLTEtMTExMzY4_6f944276-df70-422f-af0e-dbda61d4fb83">276,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b8d81e96cb44258ca45844632dfcd5_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjUtMy0xLTEtMTExMzY4_1b495304-0810-4387-8565-ce03c5383fea">186,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RleHRyZWdpb246MmI4NmQ2ZjRjZDBmNGQ3YWI2YTFlNGE0ZDcyZDFmNjVfMTgz_7e2f6817-15f8-446b-9bf7-d9d04202f5d9" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the balance of our receivables related to our net product revenues: </span></div><div style="margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"><tr><td style="width:1.0%"></td><td style="width:57.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c0592038dc4276b0af9495329ef056_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjBiYzU2MjY5NTIxODRkYzZiOWUzNjVlNjg5MjVhMTdmL3RhYmxlcmFuZ2U6MGJjNTYyNjk1MjE4NGRjNmI5ZTM2NWU2ODkyNWExN2ZfMS0xLTEtMS0xMTEzNjg_c65affb8-6507-4e4b-81f2-9f4c53be011d">190,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea9f42cbd234c25a0f60837c51cbcbb_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjBiYzU2MjY5NTIxODRkYzZiOWUzNjVlNjg5MjVhMTdmL3RhYmxlcmFuZ2U6MGJjNTYyNjk1MjE4NGRjNmI5ZTM2NWU2ODkyNWExN2ZfMS0zLTEtMS0xMTEzNjg_d1d1321d-e233-4a84-a186-ae4f29f808f6">203,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i90e340589f97408ea2365d8948df4c38_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzNDA_03a6be83-fdc5-4266-b221-75455a52b162" continuedAt="i04404e818c554924933417bb0ffdd818" escape="true">NET REVENUES FROM COLLABORATIONS</ix:nonNumeric></span></div><ix:continuation id="i04404e818c554924933417bb0ffdd818" continuedAt="i7512f61097a94db7bad93851d2e57de7"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzNDE_ea7bdb04-1d42-44b4-900c-613353834ef7" continuedAt="i5d788c96f9454e82a0145ce4a02e1871" escape="true">Net revenues from collaborations consist of the following:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i5d788c96f9454e82a0145ce4a02e1871"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"><tr><td style="width:1.0%"></td><td style="width:62.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.649%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb64947f4c824451ac2a67d55f9eec37_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfMi0xLTEtMS0xMTEzNjg_66483df5-e1b5-4d85-91eb-1f1f5db983fb">19,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f96c66a004453596d01941e4ce155f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfMi0zLTEtMS0xMTEzNjg_eaea1978-2cbc-4d2b-bf59-b3e0ec7c3253">12,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ea14b863b4413b7307cdb670fe0ab_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfMy0xLTEtMS0xMTEzNjg_915e87d6-d848-44b5-b7f7-246c50b1814a">14,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625a2ec4ecfa4a25a2186cc5eb8e048f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfMy0zLTEtMS0xMTEzNjg_535d8222-4233-4d13-a29e-b77c64ffb864">13,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i700ea43392914b5bb710a1f264221b6c_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfNS0xLTEtMS0xMTEzNjg_efd8b49b-5816-450c-90fd-d51367c9ef9a">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic369c5ac0ae741b69d6c684ad3edcfc1_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfNS0zLTEtMS0xMTEzNjg_d529f50d-33bc-4d61-8b02-555cdbf0c2c0">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119bb76ddc4f49b89a1e68acefe7a579_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfNi0xLTEtMS0xMTEzNjg_f77e64e9-3157-4de4-a157-f668189bc63b">36,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0b91c625484c1db6cf8d6e8200ae4b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfNi0zLTEtMS0xMTEzNjg_4f9c3a83-c9ca-4e85-9b43-9fa90d0c3e93">25,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzMjk_cd92509e-04bf-440a-b0e8-28f432e56e52" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.502%"><tr><td style="width:1.0%"></td><td style="width:56.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312ec99fcc6c43a5a131ac1f6eb87263_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjdkNzVmODNlOGEzYjRlOWQ4ZmNkY2ZlZDRkYjJjM2Y3L3RhYmxlcmFuZ2U6N2Q3NWY4M2U4YTNiNGU5ZDhmY2RjZmVkNGRiMmMzZjdfMS0xLTEtMS0xMTEzNjg_5926a305-d5d4-4172-9419-ed03bcd419ac">22,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8140860172b844839f38d726caf34dee_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjdkNzVmODNlOGEzYjRlOWQ4ZmNkY2ZlZDRkYjJjM2Y3L3RhYmxlcmFuZ2U6N2Q3NWY4M2U4YTNiNGU5ZDhmY2RjZmVkNGRiMmMzZjdfMS0zLTEtMS0xMTEzNjg_27b7dbef-3206-4682-ab46-bae603372d23">32,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities included in &#8220;Deferred revenue&#8221;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312ec99fcc6c43a5a131ac1f6eb87263_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjdkNzVmODNlOGEzYjRlOWQ4ZmNkY2ZlZDRkYjJjM2Y3L3RhYmxlcmFuZ2U6N2Q3NWY4M2U4YTNiNGU5ZDhmY2RjZmVkNGRiMmMzZjdfMi0xLTEtMS0xMTEzNjg_3e2b8781-ae22-4fa6-b3eb-8fe77bfafd5d">226,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8140860172b844839f38d726caf34dee_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjdkNzVmODNlOGEzYjRlOWQ4ZmNkY2ZlZDRkYjJjM2Y3L3RhYmxlcmFuZ2U6N2Q3NWY4M2U4YTNiNGU5ZDhmY2RjZmVkNGRiMmMzZjdfMi0zLTEtMS0xMTEzNjg_2b267670-8efd-4bd4-a158-4302ae4bfb3b">235,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMjU3_40b3713f-4cc5-4e43-b6da-df51f4c54105">15.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMTA5OTUxMTY3MjkyOQ_b9360484-d053-431f-8ee7-858e3de7e554">9.5</ix:nonFraction> million in the three months ended March&#160;31, 2023 and 2022, respectively, that was included in the contract liability balance at the beginning of the period. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to determine revenue recognized in the period from contract liabilities, we first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability as opposed to a portion applying to the new consideration for the period.</span></div><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="alny:ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzMjI_45e0f104-4c4d-4ece-8222-e57556e94ac7" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides research and development expenses incurred by type, for which we recognize net revenue, that are directly attributable to our collaboration agreements, by collaboration partner:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Trial and Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">External Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Trial and Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">External Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31d11f918c134929a249af868dc0a880_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfMy0xLTEtMS0xMTEzNjg_0e1d514b-ec1f-4565-be08-64049747c19f">8,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f793b67069946539339f57991faca6f_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfMy0zLTEtMS0xMTEzNjg_e0f18fe7-7034-4e67-bb35-08f8793fa5ba">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ad2eeaaba1140c1b13fa6e42dba1bd4_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfMy01LTEtMS0xMTEzNjg_4207f430-22a9-4753-9238-4f0c0e046a26">9,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fadae33c506406b84c2961fea62350a_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfMy03LTEtMS0xMTEzNjg_ec371b55-565d-441e-9efd-b62a76c9c45e">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3a79574455472d858759fccd74a1f2_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfMy05LTEtMS0xMTEzNjg_f9c59cce-23f0-49e7-bbac-db7060407cc0">622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505a333c3b1b497290cc1a035457ef65_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfMy0xMS0xLTEtMTExMzY4_e4fd0a2c-f420-4b2f-8973-5960c30cfa54">9,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5e76a3a4cf45db98aa355177c9a5d3_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNS0xLTEtMS0xMTEzNjg_2cfe3f76-8c6b-47eb-97e3-955869bcba0b">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i366eacf4f5df477589f244ba31e7710b_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNS0zLTEtMS0xMTEzNjg_b843b6bb-44ae-43a6-8f49-8cd95a78bb0b">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i330d2d52ecae4487a330a3ffa3b3df3e_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNS01LTEtMS0xMTEzNjg_d18ca241-ab4c-4b57-9eaa-0ac131081091">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568cba070fdc4faab4ba5d1d1b7b45af_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNS03LTEtMS0xMTEzNjg_b7fb6026-b53f-45ac-a75b-ab8cfb8a7703">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f5ad1d8efc44580ac18facfdada39c1_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNS05LTEtMS0xMTEzNjg_b2e90f39-addc-49f8-ab74-4a38e227fd7a">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122a5b203d314116a7be9b37a61d8bf1_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNS0xMS0xLTEtMTExMzY4_eb2d79ff-d1f7-4d6a-b613-9b39a014cad8">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3594c34bba4944ca91cc9765440d129b_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNi0xLTEtMS0xMTEzNjg_434a62f9-4c0e-4863-985f-2c630067cbf4">8,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a4ded065a9d42fca7d0593ecfb28c99_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNi0zLTEtMS0xMTEzNjg_4160448f-2fcc-4982-83a3-38c51bbbce3c">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec14d6c93f549abad409a4ee60dc447_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNi01LTEtMS0xMTEzNjg_a8d2106b-04c3-4788-8d28-dc3ac7869981">9,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea75117bc59d46cca891d43505fb5e06_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNi03LTEtMS0xMTEzNjg_8bf65790-5638-48b8-a151-dac3d9513bab">1,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i989eed19cb3f4fa18bc8d14e53d5af1e_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNi05LTEtMS0xMTEzNjg_706db4dd-320e-4259-b750-b476a0d98494">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f79bfbe7bce408cafa73cf4b18f1764_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNi0xMS0xLTEtMTExMzY4_25432578-e3c2-4fa7-a705-636651106fc4">9,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The research and development expenses incurred for the agreements included in the table above consist of costs incurred for (i) clinical expenses, including manufacturing of clinical product, (ii) external services including consulting services and lab supplies and services, and (iii) other expenses, including professional services, facilities and overhead allocations, and a reasonable estimate of compensation and related costs as billed to our counterparties, for which we recognize net revenues from collaborations. For the three months ended March&#160;31, 2023 and 2022, we did not incur material selling, general and administrative expenses related to our collaboration agreements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we recognized a reduction to our research and development expenses of $<ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-5" sign="-" name="alny:IncreaseDecreaseInResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMTkyMg_15af0c24-2827-4b70-ae28-94bf479f0909">5.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-5" sign="-" name="alny:IncreaseDecreaseInResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNTQ5NzU1ODU5MDkx_b0bb51cb-b10c-43c9-8ec2-8fdaef49348a">3.9</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, from cost reimbursement due under certain of our collaboration agreements with Regeneron Pharmaceuticals, Inc., or Regeneron, accounted for under Accounting Standards Codification, or ASC, Topic 808, Collaborative Arrangements, or ASC 808. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product Alliances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Regeneron Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April&#160;2019, we entered into a global, strategic collaboration with Regeneron to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the eye and central nervous system, or CNS, in addition to a select number of targets expressed in the liver, which we refer to as the Regeneron Collaboration. The Regeneron Collaboration is governed by a Master Agreement, referred to as the Regeneron Master Agreement, which became effective on May 21, 2019. In connection with the Regeneron Master Agreement, we and Regeneron entered into (i) a binding co-co collaboration term sheet covering the continued development of cemdisiran, our C5 small </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i7512f61097a94db7bad93851d2e57de7" continuedAt="i145f04dfdc424e47a9a3c9b869ce715f"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">interfering RNA, or siRNA, currently in Phase 2 development for C5 complement-mediated diseases, as a monotherapy and (ii) a binding license term sheet to evaluate anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases including evaluating the combination of Regeneron&#8217;s pozelimab (REGN3918), currently in Phase 3 development, and cemdisiran. The C5 co-co collaboration and license agreements were executed in August 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the Regeneron Collaboration, we are working exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases for an initial research period of approximately <ix:nonNumeric contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430" name="alny:DiscoveryPeriodOfProgramsDevelopment" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzMjY_f614b5fd-6fbd-4277-9ab7-2a5f6fde0c4d">five years</ix:nonNumeric>, which we refer to as the Initial Research Term. Regeneron has an option to extend the Initial Research Term (referred to as the Research Term Extension Period, and together with the Initial Research Term, the Research Term) for up to an additional <ix:nonNumeric contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430" name="alny:ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzkyOA_a107450c-618f-4a01-83c7-e23e1cd4b205">five years</ix:nonNumeric>, for a research term extension fee of $<ix:nonFraction unitRef="usd" contextRef="i9b17e6f85a474102b37c2eb6225b0f06_D20190401-20190430" decimals="-5" name="alny:ResearchTermExtensionFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzk3NQ_c9269504-43e3-468d-acef-567593cfa453">300.0</ix:nonFraction> million. The Regeneron Collaboration also covers a select number of RNAi therapeutic programs designed to target genes expressed in the liver, including our previously announced collaboration with Regeneron to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis. We retain broad global rights to all of our other unpartnered liver-directed clinical and pre-clinical pipeline programs. The Regeneron Collaboration is governed by a joint steering committee that is comprised of an equal number of representatives from each party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regeneron leads development and commercialization for all programs targeting eye diseases (subject to limited exceptions), entitling us to certain potential milestone and royalty payments pursuant to the terms of a license agreement, the form of which has been agreed upon by the parties. We and Regeneron are alternating leadership on CNS and liver programs covered by the Regeneron Collaboration, with the lead party retaining global development and commercial responsibility. For such CNS and liver programs, both we and Regeneron have the option at lead candidate selection to enter into a&#160;co-co&#160;collaboration agreement, the form of which has been agreed upon by the parties, whereby both companies will share equally all costs of, and profits from, all development and commercialization activities under the program. If the&#160;non-lead&#160;party elects to not enter into a&#160;co-co&#160;collaboration agreement with respect to a given CNS or liver program, we and Regeneron will enter into a license agreement with respect to such program and the lead party will be the &#8220;Licensee&#8221; for the purposes of the license agreement. If the lead party for a CNS or liver program elects to not enter into the&#160;co-co&#160;collaboration agreement, then we and Regeneron will enter into a license agreement with respect to such program and leadership of the program will transfer to the other party and the former&#160;non-lead&#160;party will be the &#8220;Licensee&#8221; for the purposes of the license agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to the programs directed to C5 complement-mediated diseases, we retain control of cemdisiran monotherapy development, and Regeneron is leading combination product development. Pursuant to the C5 co-co collaboration agreement, Regeneron notified us in November 2022 of its decision to exercise its right to opt-out of the further development and commercialization of cemdisiran monotherapy. As a result, Regeneron no longer shares costs and potential future profits on any monotherapy program with us. We continue to perform our obligations under the agreement and we are solely responsible for all development and commercialization costs. Regeneron will be eligible to receive tiered double-digit royalties on net sales. Under the C5 license agreement, for cemdisiran to be used as part of a combination product, Regeneron is solely responsible for all development and commercialization costs and we will receive low double-digit royalties and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430" decimals="-5" name="alny:MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNjU3OA_1128205a-8881-4847-8b2a-de4c8a6090e6">325.0</ix:nonFraction> million on any potential combination product sales. The C5 co-co collaboration agreement, the C5 license agreement, and the Master Agreement have been combined for accounting purposes and treated as a single agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Regeneron Master Agreement, Regeneron made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430" decimals="-5" name="alny:UpfrontFeeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNjg4MA_db6030b1-764e-485f-a7ee-7feadf5ced94">400.0</ix:nonFraction> million. We are also eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430" decimals="-5" name="alny:MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNjkzNg_ecf64e01-edf5-401f-8fad-d665305801e8">200.0</ix:nonFraction> million in milestone payments upon achievement of certain criteria during early clinical development for eye and CNS programs. We and Regeneron plan to advance programs directed to up to <ix:nonFraction unitRef="target" contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430" decimals="INF" name="alny:NumberOfTargetedPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNzExOA_c4fe1766-dd8d-42ff-a4ba-59750d752333">30</ix:nonFraction> targets in the first <ix:nonNumeric contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430" name="alny:CollaborativeAgreementPeriodOfProgramDevelopment" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNzE0Mg_a45bdbe4-ab6c-4b2e-8525-3a941072c90c">five years</ix:nonNumeric> under the Regeneron Collaboration during the Initial Research Term. For each program, Regeneron will provide us with $<ix:nonFraction unitRef="usd" contextRef="ia2262debc8564e2ea595ab280c42f0db_I20190430" decimals="-5" name="alny:PotentialProceedsFromCollaborationArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNzI2Mg_3f3a2e45-c8b5-4c31-ac1f-247e90147094">2.5</ix:nonFraction> million in funding at program initiation and an additional $<ix:nonFraction unitRef="usd" contextRef="i8a62ef305c0f40a79899683564ff0247_I20190430" decimals="-5" name="alny:PotentialProceedsFromCollaborationArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNzMxNg_18109218-ab44-44df-acad-7c8425817ee8">2.5</ix:nonFraction> million at lead candidate identification, with the potential for approximately $<ix:nonFraction unitRef="usd" contextRef="if6a70a035a37440e909aac14f9fda6d9_I20190430" decimals="-5" name="alny:PotentialProceedsFromCollaborationArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNzM5MA_f7afe988-ea92-4a15-94dd-18f27df0f85d">30.0</ix:nonFraction> million in annual discovery funding to us as the Regeneron Collaboration reaches steady state.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regeneron has the right to terminate the Regeneron Master Agreement for convenience upon <ix:nonNumeric contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430" name="alny:CollaborativeAgreementTerminationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNzU2OQ_d88d47c4-2cf8-4c09-9697-bde599bde4ff">ninety days</ix:nonNumeric>&#8217; notice. The termination of the Regeneron Master Agreement does not affect the term of any license agreement or&#160;co-co&#160;collaboration agreement then in effect. In addition, either party may terminate the Regeneron Master Agreement for a material breach by, or insolvency of, the other party. Unless earlier terminated pursuant to its terms, the Regeneron Master Agreement will remain in effect with respect to each program until (a)&#160;such program becomes a terminated program or (b)&#160;the parties enter into a license agreement or&#160;co-co&#160;collaboration agreement with respect to such program.&#160;The Regeneron Master Agreement includes various representations, warranties, covenants, dispute escalation and resolution mechanisms, indemnities and other provisions customary for transactions of this nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For any license agreement subsequently entered into, the licensee will generally be responsible for its own costs and expenses incurred in connection with the development and commercialization of the collaboration products. The licensee will pay to the licensor certain development and/or commercialization milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i9b17e6f85a474102b37c2eb6225b0f06_D20190401-20190430" decimals="-5" name="alny:CollaborativeArrangementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfODcwOQ_a0a177be-21c0-44f3-8442-020ca6754eda">150.0</ix:nonFraction> million for each collaboration product. In addition, following the first commercial sale of the applicable collaboration product under a license </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i145f04dfdc424e47a9a3c9b869ce715f" continuedAt="i6210063217cd46a690e35fee077822fe"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">agreement, the licensee is required to make certain tiered royalty payments, ranging from low double-digits up to <ix:nonFraction unitRef="number" contextRef="ib324fbd9af6f4a3d8ef929b6d99bf163_I20190430" decimals="INF" name="alny:RoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfODk2Mw_9026cfa9-93b0-4c9b-8922-54387e1b0844">20</ix:nonFraction>%, to the licensor based on the aggregate annual net sales of the collaboration product, subject to customary reductions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For any co-co&#160;collaboration agreement subsequently entered into, we and Regeneron will share equally all costs of, and profits from, development and commercialization activities. Reimbursement of our share of costs will be recognized as a reduction to research and development expense in the condensed consolidated statements of operations and comprehensive loss. In the event that a party exercises its&#160;opt-out&#160;right, the lead party will be responsible for all costs and expenses incurred in connection with the development and commercialization of the collaboration products under the applicable&#160;co-co&#160;collaboration agreement, subject to continued sharing of costs through defined points. If a party exercises its&#160;opt-out&#160;right, following the first commercial sale of the applicable collaboration product under a&#160;co-co&#160;collaboration agreement, the lead party is required to make certain tiered royalty payments, ranging from low double-digits up to <ix:nonFraction unitRef="number" contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430" decimals="INF" name="alny:PercentageOfMaximumRoyaltyPayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMTAwMzc_e1b258ac-f58d-4fb6-be2c-f4c58d9e68e3">20</ix:nonFraction>%, to the other party based on the aggregate annual net sales of the collaboration product and the timing of the exercise of the&#160;opt-out&#160;right, subject to customary reductions and a reduction for&#160;opt-out&#160;transition costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any milestone or royalty payments from Regeneron under the Regeneron Master Agreement, the C5 license agreement, or any future license agreement, or under any co-co collaboration agreement in the event we exercise our opt-out right.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our obligations under the Regeneron Collaboration include: (i) a research license and research services, collectively referred to as the Research Services Obligation; (ii) a worldwide license to cemdisiran for combination therapies, and manufacturing and supply, and development service obligations, collectively referred to as the C5 License Obligation; and (iii) development, manufacturing and commercialization activities for cemdisiran monotherapies, referred to as the C5 Co-Co Obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The research license is not distinct from the research services primarily as a result of Regeneron being unable to benefit on its own or with other resources reasonably available, as the license is providing access to specialized expertise, particularly as it relates to RNAi technology that is not available in the marketplace.&#160;Similarly, the worldwide license to cemdisiran for combination therapies is not distinct from the manufacturing and supply, and development service obligations, as Regeneron cannot benefit on its own from the value of the license without receipt of supply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separately, prior to Regeneron&#8217;s decision in November 2022 to exercise its right to opt-out of the further development and commercialization of cemdisiran monotherapy, the cemdisiran monotherapy co-co collaboration agreement was under the scope of ASC 808 as we and Regeneron were both active participants in the development and manufacturing activities and were exposed to significant risks and rewards that were dependent on commercial success of the activities of the arrangement. Regeneron&#8217;s decision to exercise its right to opt-out of the arrangement caused a change in the role of Regeneron and its exposure to significant risks and rewards under the arrangement. As a result, we determined that the arrangement no longer represents a collaborative arrangement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The arrangement now represents a vendor-customer relationship under ASC 606 as we perform our obligation to provide development and manufacturing activities under the arrangement. The transaction price allocated to the C5 Co-Co obligation unit of account will be recognized over time using an input method based on cost incurred relative to the total estimated costs for the identified performance obligation by determining the proportion of effort incurred as a percentage of total effort we expect to expend.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total transaction price is comprised of the&#160;$<ix:nonFraction unitRef="usd" contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430" decimals="-5" name="alny:UpfrontFeeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMTIzMDI_25d2afdb-c224-4af8-adfd-f112bfc1da72">400.0</ix:nonFraction> million&#160;upfront payment and&#160;additional variable consideration related to research, development, manufacturing and supply activities related to the Research Services Obligation and the C5 License Obligation. We utilized the expected value method to determine the amount of reimbursement for these activities. We determined that any variable consideration related to sales-based royalties and milestones related to the worldwide license to cemdisiran for combination therapies is deemed to be constrained and therefore has been excluded from the transaction price. In addition, we are eligible to receive future milestones upon the achievement of certain criteria during early clinical development for the eye and CNS programs.&#160;We are also eligible to receive royalties on future commercial sales for certain eye, CNS or liver targets, if any; however, these amounts are excluded from variable consideration under the Regeneron Collaboration as we are only eligible to receive such amounts if, after a drug candidate is identified, the form of license agreement is subsequently executed resulting in a license that is granted to Regeneron. Any such subsequently granted license would represent a separate transaction under ASC 606. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i6210063217cd46a690e35fee077822fe" continuedAt="ia621f394259049a486123b5a425451f5"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="alny:ScheduleOfAllocatedTransactionPriceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzMzc_9bad50d9-1574-4eae-9db7-5d3a6a279d77" continuedAt="i220997d4e8cb49099eb10c6c8ee86dcb" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.713%"><tr><td style="width:1.0%"></td><td style="width:38.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.689%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Performance Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Standalone Selling Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Transaction Price Allocated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="i7e7e8c4e7d644c158639d2fb41e9a319_I20230331" decimals="-3" name="alny:StandaloneSellingPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfMS0yLTEtMS0xMTEzNjg_33dd892d-8759-46ea-96fe-317b522f63aa">130,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="ie79a8fa8f1ce43deb7597002a348c3be_D20190401-20190430" decimals="-3" name="alny:TransactionPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfMS00LTEtMS0xMTEzNjg_3dc7f537-74b4-46e9-89aa-466da45ce912">183,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="i537f32b4a16b4543a24f40ddc6741cee_I20230331" decimals="-3" name="alny:StandaloneSellingPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfMi0yLTEtMS0xMTEzNjg_d16469f6-1181-4c6c-b00b-be8b4703c763">97,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="ic42228c3d8ac46a8ac291f126f2d30b6_D20190401-20190430" decimals="-3" name="alny:TransactionPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfMi00LTEtMS0xMTEzNjg_94858bca-bfe3-44f8-9795-f19483e2813b">92,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="i24ae91e0688d4ae4984f1d8103dc8422_I20230331" decimals="-3" name="alny:StandaloneSellingPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfMy0yLTEtMS0xMTEzNjg_c96fafbd-f500-45cd-b214-3f1c08271c75">364,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="i46343ad3a9fd4ec3a826cb38ab1b6530_D20190401-20190430" decimals="-3" name="alny:TransactionPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfMy00LTEtMS0xMTEzNjg_b046bfdb-bc33-4029-ad46-710fa0a75ccb">246,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430" decimals="-3" name="alny:TransactionPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfNC00LTEtMS0xMTEzNjg_afd465e8-d227-4f8c-b17d-6c99a31744d7">521,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transaction price was allocated to the obligations based on the relative estimated standalone selling prices of each obligation, over which management has applied significant judgment. We developed the estimated standalone selling price for the licenses included in the Research Services Obligation and the C5 License Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we applied judgment in the determination of the forecasted revenues, taking into consideration the applicable market conditions and relevant entity-specific factors, the expected number of targets or indications expected to be pursued under each license, the probability of success, the time needed to develop a product candidate pursuant to the associated license and the discount rate. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the obligations, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs. The estimated standalone selling price of the C5 Co-Co Obligation was developed by estimating the present value of expected future cash flows that Regeneron is entitled to receive. In developing such estimate, we applied judgment in determining the indications that will be pursued, the forecasted revenues for such indications, the probability of success and the discount rate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the Research Services Obligation, the C5 License Obligation, and the C5 Co-Co Obligation accounted for under ASC 606, we measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for each of the identified obligations, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&#160;This ratio is applied to the transaction price allocated to each obligation. Management has applied significant judgment in the process of developing our estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. We re-evaluate the transaction price as of the end of each reporting period and as of March&#160;31, 2023, the total transaction price was determined to be $<ix:nonFraction unitRef="usd" contextRef="i10bce677b77f433a9d7d79a79b60f6a2_D20230101-20230331" decimals="-5" name="alny:TransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMTYwMzg_2d718b32-8f54-4514-a319-f5aeae7cf81a">559.6</ix:nonFraction> million. Revenue recognized under this agreement is accounted for as collaboration revenue.</span></div><ix:continuation id="i220997d4e8cb49099eb10c6c8ee86dcb"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables provide a summary of the transaction price allocated to each unit of account based on the applicable accounting guidance, in addition to revenue activity during the period, in thousands:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.561%"><tr><td style="width:1.0%"></td><td style="width:31.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.668%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Transaction Price Allocated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred Revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i84c437734fd146c39d505bac418fecf2_D20230101-20230331" decimals="-3" name="alny:TransactionPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfMi0yLTEtMS0xMTEzNjg_f60ec18f-18a7-4369-b0ed-b8fd8e1c3d3b">215,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7e7e8c4e7d644c158639d2fb41e9a319_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfMi00LTEtMS0xMTEzNjg_f075e86d-a3b6-4092-bc26-5f184ce28dcb">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie8a02cffca2849af8489d49e9b80b1b2_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfMi02LTEtMS0xMTEzNjg_3d0c8803-223a-4ad7-81e7-a610b4da5000">26,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i03b27765edaa4e13a504fbffd73baf35_D20230101-20230331" decimals="-3" name="alny:TransactionPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfMy0yLTEtMS0xMTEzNjg_a574efc4-35d5-46f1-8c28-924051e74a69">97,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i537f32b4a16b4543a24f40ddc6741cee_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfMy00LTEtMS0xMTEzNjg_26e480f2-01c7-4b1e-ad05-d7e4657c872f">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i638ed215bf2a42199fc06a55c0357371_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfMy02LTEtMS0xMTEzNjg_4a0566c1-2217-4225-a704-47659d24e5e3">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i053739f07c5a48d4bd9b455419e9a9f3_D20230101-20230331" decimals="-3" name="alny:TransactionPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfNC0yLTEtMS0xMTEzNjg_6887b043-ff7a-44e0-8f59-44055760ea2e">246,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i24ae91e0688d4ae4984f1d8103dc8422_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfNC00LTEtMS0xMTEzNjg_b398f34b-f8ed-49aa-8b7b-3922ec74acae">191,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3ae2f34bc0ed44efa8a7bcadc7f60158_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfNC02LTEtMS0xMTEzNjg_608b9848-c81e-4ed9-9f98-235bfa86c5d8">193,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i10bce677b77f433a9d7d79a79b60f6a2_D20230101-20230331" decimals="-3" name="alny:TransactionPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfNS0yLTEtMS0xMTEzNjg_c57d630e-ef96-4a27-a8bc-da585ac17d7d">559,580</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if5ea36d76387472e84cfa6df1370b518_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfNS00LTEtMS0xMTEzNjg_e41d2943-8cc0-4923-8168-0e0e0c9f92fe">220,100</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ida6db6b0c1dc4a37b006d8d1871fd207_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfNS02LTEtMS0xMTEzNjg_74252827-9ee6-4c4c-bfb1-47c82169d2a1">226,800</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:center"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="alny:ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzMzg_71bcce13-d5b0-482a-b3f4-3db471726825" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.994%"><tr><td style="width:1.0%"></td><td style="width:41.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.317%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue Recognized During</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i84c437734fd146c39d505bac418fecf2_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfMi0yLTEtMS0xMTEzNjg_fc8ffcf9-29de-4d3f-b866-4bc920c62041">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i34678b9d3faf4e679a9657d9146fcacf_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfMi00LTEtMS0xMTEzNjg_711d7b78-b886-4284-8301-90a336b37a55">7,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i03b27765edaa4e13a504fbffd73baf35_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfMy0yLTEtMS0xMTEzNjg_56841068-115c-4ef9-9f1b-c6d9611b796d">2,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i567601c061914fc8a2d7fd810936ef74_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfMy00LTEtMS0xMTEzNjg_da8dc312-0acf-412b-b23b-6e7f44c40403">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i053739f07c5a48d4bd9b455419e9a9f3_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfNC0yLTEtMS0xMTEzNjg_f9eacdea-1e07-49f7-a8e0-d3fda195993b">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i04b45c879ba940b99dd9a474d8b07978_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfNC00LTEtMS0xMTEzNjg_0f1d7af4-3f35-4060-b01e-49efe3cc063a">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i10bce677b77f433a9d7d79a79b60f6a2_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfNS0yLTEtMS0xMTEzNjg_bee4775a-4490-4312-ac0a-3a8fa48530ba">15,400</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4d582c41d901411287404a782ac66586_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfNS00LTEtMS0xMTEzNjg_6e5544ec-e7e2-40ec-8351-9ffcf9e3e1a6">10,800</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of&#160;March&#160;31, 2023, the aggregate amount of the transaction price allocated to the remaining Research Services Obligation, C5 License Obligation and C5 Co-Co Obligation that was unsatisfied was&#160;$<ix:nonFraction unitRef="usd" contextRef="if5ea36d76387472e84cfa6df1370b518_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMTY5MjM_a5eeebc0-6ce7-42a9-af56-e358ef70635b">274.4</ix:nonFraction>&#160;million, which&#160;is expected to be recognized through the term of the Regeneron Collaboration as the services are performed. Deferred revenue related to the Regeneron Collaboration is classified as either current or non-current in the condensed consolidated balance sheets based on the period the revenue is expected to be recognized.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ia621f394259049a486123b5a425451f5"><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Novartis AG</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">2013 Collaboration with The Medicines Company</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2013, we and The Medicines Company, or MDCO, entered into a license and collaboration agreement pursuant to which we granted to MDCO an exclusive, worldwide license to develop, manufacture and commercialize RNAi therapeutics targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of hypercholesterolemia and other human diseases, including inclisiran. We refer to this agreement, as amended through the date hereof, as the MDCO License Agreement. In 2020, Novartis AG, or Novartis, completed its acquisition of MDCO and assumed all rights and obligations under the MDCO License Agreement. Additional details regarding the terms, milestones earned upon the achievement of certain events and additional milestones we are entitled to receive upon the achievement of future events under the MDCO License Agreement are described in Note 4 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on February 23, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Novartis License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, we and Novartis entered into a collaboration and license agreement, or the Novartis License Agreement, pursuant to which we granted to Novartis an exclusive, worldwide license to develop, manufacture and commercialize siRNAs targeting end-stage liver disease, or ESLD, potentially leading to the development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure. Additional details regarding the terms and transaction price under the Novartis License Agreement are described in Note 4 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on February 23, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the collaboration agreements discussed above, we have various other collaboration agreements that are not individually significant to our operating results or financial condition at this time. Pursuant to the terms of those agreements, we may be required to pay, or we may receive, additional amounts contingent upon the occurrence of various future events (e.g., upon the achievement of various development and commercial milestones) which in the aggregate could be significant. We may also incur, or be reimbursed for, significant research and development costs. In addition, if any products related to these collaborations are approved for sale, we may be required to pay, or we may receive, royalties on future sales. The payment or receipt of these amounts, however, is contingent upon the occurrence of various future events.</span></div></ix:continuation><div id="i90e340589f97408ea2365d8948df4c38_49"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="alny:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMzU3Mg_f9898ce5-57e2-4305-848f-39beaba6db81" continuedAt="ia466e6132cac445bab58a13568e5ae16" escape="true">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</ix:nonNumeric></span></div><ix:continuation id="ia466e6132cac445bab58a13568e5ae16" continuedAt="i78346f846132472ba725f8cc56fc2878"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we entered into a purchase and sale agreement, or Purchase Agreement, with BX Bodyguard Royalties L.P. (an affiliate of The Blackstone Group Inc.), or Blackstone Royalties, under which Blackstone Royalties acquired <ix:nonFraction unitRef="number" contextRef="i9f304a30d62e48ae884ec8acc207b442_I20200430" decimals="INF" name="alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMjg5_a5646656-1cbb-4702-b538-ff119070f7e3">50</ix:nonFraction>% of royalties payable, or Royalty Interest, with respect to net sales by MDCO, its affiliates or sublicensees of inclisiran (or the branded drug product, Leqvio) and any other licensed products under the MDCO License Agreement, and <ix:nonFraction unitRef="number" contextRef="i9f304a30d62e48ae884ec8acc207b442_I20200430" decimals="INF" name="alny:CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfNDg1_f58ce404-52da-4a17-874f-873e7e511723">75</ix:nonFraction>% of the commercial milestone payments payable under the MDCO License Agreement, together with the Royalty Interest, the Purchased Interest. If Blackstone Royalties does not receive payments in respect of the Royalty Interest by December 31, 2029, equaling at least $<ix:nonFraction unitRef="usd" contextRef="i951d48bc07e44f98a13abbaa555cc949_D20200401-20200430" decimals="-7" name="alny:ExpectedRoyaltyInterestPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfNzUy_23e69e93-837e-4902-be12-3649feb95147">1.00</ix:nonFraction>&#160;billion, Blackstone Royalties will receive <ix:nonFraction unitRef="number" contextRef="i78bb229c8dc8423eb6def37c2540a28f_I20300101" decimals="INF" name="alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfNzkw_84b4549d-abf4-44ac-a3b6-44e2eb25c867">55</ix:nonFraction>% of the Royalty Interest beginning on January 1, 2030. In consideration for the sale of the Purchased Interest, Blackstone Royalties paid us $<ix:nonFraction unitRef="usd" contextRef="i951d48bc07e44f98a13abbaa555cc949_D20200401-20200430" decimals="-7" name="alny:CollaborativeArrangementConsiderationReceived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMjE5OTAyMzI1OTI4Ng_bbed4910-fccb-405f-b11a-45d4f045ef98">1.00</ix:nonFraction>&#160;billion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continue to own or control all inclisiran intellectual property rights and are responsible for certain ongoing manufacturing and supply obligations related to the generation of the Purchased Interest. Due to our continuing involvement, we will continue to account for any royalties and commercial milestones due to us under the MDCO License Agreement as revenue on our condensed consolidated statement of operations and comprehensive loss and record the proceeds from this transaction as a liability, net of closing costs, on our condensed consolidated balance sheet. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to determine the amortization of the liability related to the sale of future royalties, we are required to estimate the total amount of future payments to Blackstone Royalties over the life of the Purchase Agreement. The $<ix:nonFraction unitRef="usd" contextRef="i9f304a30d62e48ae884ec8acc207b442_I20200430" decimals="-7" name="alny:RoyaltyLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMTc3OA_b55772a0-80fa-4bf7-a71f-7cfe5cee94cc">1.00</ix:nonFraction>&#160;billion liability, recorded at execution of the agreement, will be accreted to the total of these royalty and commercial milestone payments as interest expense over the life of the Purchase Agreement. As of March&#160;31, 2023, our estimate of this total interest expense resulted in an effective annual interest rate of <ix:nonFraction unitRef="number" contextRef="i5af69bac6577471ab296af25cf52d953_I20230331" decimals="2" name="alny:RoyaltyLiabilityInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMjEwMQ_cd22d76f-8304-4701-a211-4c4c25da6156">8</ix:nonFraction>%. These estimates contain assumptions that impact both the amount recorded at execution and the interest expense that will be recognized in future periods. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As payments are made to Blackstone Royalties, the balance of the liability will be effectively repaid over the life of the Purchase Agreement. The exact timing and amount of repayment is likely to change each reporting period. A significant increase or decrease in Leqvio global net revenue will materially impact the liability related to the sale of future royalties, interest expense and the time period for repayment. We will periodically assess the expected payments to Blackstone Royalties </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i78346f846132472ba725f8cc56fc2878"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and to the extent the amount or timing of such payments is materially different than our initial estimates, we will prospectively adjust the amortization of the liability related to the sale of future royalties and the related interest expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the carrying value of the liability related to the sale of future royalties was $<ix:nonFraction unitRef="usd" contextRef="i5af69bac6577471ab296af25cf52d953_I20230331" decimals="-7" name="alny:RoyaltyLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMzEwNA_414549a6-82dd-4d22-a8f1-5e972b6c3082">1.31</ix:nonFraction>&#160;billion, net of closing costs of $<ix:nonFraction unitRef="usd" contextRef="i5af69bac6577471ab296af25cf52d953_I20230331" decimals="-5" name="alny:RoyaltyLiabilityClosingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMzEzMg_cd2b3dd2-1908-4ee4-8f9a-b127a785d6d8">10.6</ix:nonFraction>&#160;million. The carrying value of the liability related to the sale of future royalties approximates fair value as of March&#160;31, 2023 and is based on our current estimates of future royalties and commercial milestones expected to be paid to Blackstone Royalties over the life of the arrangement, which are considered Level 3 inputs.</span></div><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="alny:ScheduleOfRoyaltyLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMzU3MQ_d7146c7a-fd26-4279-b541-21fdfcffd1ef" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the activity with respect to the liability related to the sale of future royalties, in thousands:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.134%"><tr><td style="width:1.0%"></td><td style="width:81.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f2778a30db447199954b7fd02c7ed1_I20221231" decimals="-3" name="alny:RoyaltyLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RhYmxlOmVhOWM1OTcxYTdhYzQ3MGE5ZjAzNWY2MDdkYzE1MDk5L3RhYmxlcmFuZ2U6ZWE5YzU5NzFhN2FjNDcwYTlmMDM1ZjYwN2RjMTUwOTlfMC0yLTEtMS0xMTEzNjg_b65f24f2-cb80-4e4d-ac3a-72f481ec8a42">1,292,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90a9b7be5ab448e86528f65d657a9ac_D20230101-20230331" decimals="-3" name="alny:RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RhYmxlOmVhOWM1OTcxYTdhYzQ3MGE5ZjAzNWY2MDdkYzE1MDk5L3RhYmxlcmFuZ2U6ZWE5YzU5NzFhN2FjNDcwYTlmMDM1ZjYwN2RjMTUwOTlfMS0yLTEtMS0xMTEzNjg_39f891e6-31f1-47d2-af64-111bc3688362">25,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie90a9b7be5ab448e86528f65d657a9ac_D20230101-20230331" decimals="-3" name="alny:RoyaltyLiabilityPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RhYmxlOmVhOWM1OTcxYTdhYzQ3MGE5ZjAzNWY2MDdkYzE1MDk5L3RhYmxlcmFuZ2U6ZWE5YzU5NzFhN2FjNDcwYTlmMDM1ZjYwN2RjMTUwOTlfMi0yLTEtMS0xMTEzNjg_3a735681-0ca7-4507-a6aa-c792a712071d">8,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5af69bac6577471ab296af25cf52d953_I20230331" decimals="-3" name="alny:RoyaltyLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RhYmxlOmVhOWM1OTcxYTdhYzQ3MGE5ZjAzNWY2MDdkYzE1MDk5L3RhYmxlcmFuZ2U6ZWE5YzU5NzFhN2FjNDcwYTlmMDM1ZjYwN2RjMTUwOTlfMy0yLTEtMS0xMTEzNjg_4cb9f2da-0488-4a08-8a97-b1efb5ed992e">1,308,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i90e340589f97408ea2365d8948df4c38_52"></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RleHRyZWdpb246MWUxMTAyOTkyZmE0NDE2NzhlYzMxM2E2MzNiMjE5YzNfNTE4_61fda7a6-c616-4935-844f-f7f777c6173d" continuedAt="i1a7f492149544df4a24ce7421daf1b1a" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i1a7f492149544df4a24ce7421daf1b1a" continuedAt="i7b51d26e68034441986be05df0abacc1"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RleHRyZWdpb246MWUxMTAyOTkyZmE0NDE2NzhlYzMxM2E2MzNiMjE5YzNfNTE1_40a4cff9-bd8a-496e-82f0-aaf1a7da20d3" continuedAt="i9a25d41b4eec4977b1ef36cb36bf4e65" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables present information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874d4cbd4e084481a20e05ffedf030e1_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMy0yLTEtMS0xMTEzNjg_69906b35-5f1b-4c7b-a3ce-885a3fd3d116">214,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9816969b7f844c7b918013a5fb04632_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMy00LTEtMS0xMTEzNjg_de931cde-50f8-4f35-a765-4a0d08028ded">214,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe7a27d97064ac7829a670edeb037a6_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMy02LTEtMS0xMTEzNjg_61f2bfb1-bcbb-4ad9-a3d4-403ebd5b3c4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4497af286544b5588685567ad285511_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMy04LTEtMS0xMTEzNjg_adb4325c-2501-4f8f-b78e-d3f597766cd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacfa0b420e244ddd8c424584e49e0bbe_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS0yLTEtMS0xMTk2OTA_36f554da-284c-4a18-9d20-53d9153c61ba">2,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa8b9115a694d4dbacbb16955919e67_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS00LTEtMS0xMTk2OTA_9d2ac17f-d295-4323-b157-1c064157ae2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b2a82f08e14704917d51373b47b145_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS02LTEtMS0xMTk2OTA_d1ec5851-d746-40e2-b5a3-1b759236b443">2,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec58dda78b5f41ec9f8115e957615766_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS04LTEtMS0xMTk2OTA_97658913-b9bf-4c2e-b831-3ece8009b641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e6a406720844217993d4483fc6e7b60_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS0yLTEtMS0xMTEzNjg_cb4d6400-75bc-4751-ae89-0878d67cf96b">1,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07544a270c1b4f91be2befe47f417d06_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS00LTEtMS0xMTEzNjg_f8627b09-3743-4617-a51d-0e036f76f2e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbdfa377b4c45188b32b4aca0c5858c_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS02LTEtMS0xMTEzNjg_90a7e698-1e1f-4079-91b3-6cfa0c711bc6">1,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8655a9bfff4eb6a24a91ec23da2454_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS04LTEtMS0xMTEzNjg_7f82dd12-4e5b-43ab-8816-c476529fbb63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id91db2e74566480db7790bba12bacab3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOC0yLTEtMS0xMTEzNjg_120b2cba-6cde-44d5-828f-d8412c2ee752">742,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0fbbf8a866f4b1ea616c10badae83d3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOC00LTEtMS0xMTEzNjg_5ca24d26-9d54-48e9-badf-99792b30ad4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4272629d98c4add80b6c45b82c2e95a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOC02LTEtMS0xMTEzNjg_f5934356-3b10-4e1b-9a84-c2f844eace17">742,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386e3c5b4ba843509503532a3da11306_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOC04LTEtMS0xMTEzNjg_16970bc1-16ab-4bc7-8eb9-5a350d6e5904">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2b832d64eb4f1a8fdbaef5ca07646d_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS0yLTEtMS0xMTk3MDI_29d1e031-f98e-4894-8b0c-593375e5b132">335,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76f744f31aa458e96f4d8ebe97eb886_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS00LTEtMS0xMTk3MDI_f2e07b12-748b-492f-ab05-f29ca2b82198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3272a7ba8f424ca9a1480c9d363ebc10_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS02LTEtMS0xMTk3MDI_048e570a-74bd-4da5-a688-5e2fcbc1a429">335,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb86d593e5944cca0236d7b8f81bbf2_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS04LTEtMS0xMTk3MDI_d27f05ad-6165-4fb0-a6df-6c02c3f3c011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacfa0b420e244ddd8c424584e49e0bbe_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS0yLTEtMS0xMTEzNjg_fcd6514f-d8a0-4ef0-8d4c-9097698223e3">190,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa8b9115a694d4dbacbb16955919e67_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS00LTEtMS0xMTEzNjg_efb4eeb7-75e0-4647-af33-b54df2686748">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b2a82f08e14704917d51373b47b145_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS02LTEtMS0xMTEzNjg_4d4d6179-4925-439d-9399-07a15ae66925">190,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec58dda78b5f41ec9f8115e957615766_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS04LTEtMS0xMTEzNjg_a4e22e10-d572-4f5c-80c0-cd8949aa81ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e6a406720844217993d4483fc6e7b60_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTEtMi0xLTEtMTExMzY4_c63f9603-4ae8-42f3-8f1d-4f11454d051c">90,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07544a270c1b4f91be2befe47f417d06_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTEtNC0xLTEtMTExMzY4_9b54e7e5-a558-4298-9725-f7ec05b56c49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbdfa377b4c45188b32b4aca0c5858c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTEtNi0xLTEtMTExMzY4_f7874581-3390-45b9-9fa7-d07d7f4aa582">90,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8655a9bfff4eb6a24a91ec23da2454_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTEtOC0xLTEtMTExMzY4_9071b672-8ca1-48bc-b050-b6da5f09c841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac8bf485b57442459c1b93f20ebfa42b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTItMi0xLTEtMTExMzY4_7000bfb2-f9db-4558-988b-4a88e0ab708d">13,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1ebebb32214b719ee306ffc8f6cf89_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTItNC0xLTEtMTExMzY4_41d7b48e-ae06-4a2d-b2fa-73cd07f9d29a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f5ba0082a2340e79246846a43e0e92b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTItNi0xLTEtMTExMzY4_d998460c-c26c-49a8-8c1b-83b54dc5d967">13,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53c118ebc744410fbbc7719c7a876694_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTItOC0xLTEtMTExMzY4_dd9321f8-e309-4802-b1d4-fc36f2fb4338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie823bc3a3540443788e7ed44be452ee5_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTQtMi0xLTEtMTExMzY4_a292671e-a8d1-48e1-b983-62b87fa92722">25,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i210817a6ab294c9d9aff77d7f7d56bcd_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTQtNC0xLTEtMTExMzY4_643885e6-bf8c-405b-bf12-bd1d9b32afe7">25,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b5152586914421b5f5705f8c583545_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTQtNi0xLTEtMTExMzY4_a375c1e8-1124-483d-994e-782d82e9468e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia372b23a3466460c91b1628f67e16648_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTQtOC0xLTEtMTExMzY4_17c28e43-fa3f-4009-b65a-30343859def3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874d4cbd4e084481a20e05ffedf030e1_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTUtMi0xLTEtMTExMzY4_223326bc-5838-4ce6-899d-0677272e7703">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9816969b7f844c7b918013a5fb04632_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTUtNC0xLTEtMTExMzY4_dc326f9b-48b5-47df-a818-86ada9b2f428">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe7a27d97064ac7829a670edeb037a6_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTUtNi0xLTEtMTExMzY4_9ebebb7d-862e-49b2-afd1-116ae7757655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4497af286544b5588685567ad285511_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTUtOC0xLTEtMTExMzY4_25bfb93a-1dc4-46ef-aba7-6c9bc0cd17e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie823bc3a3540443788e7ed44be452ee5_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTYtMi0xLTEtMTExMzY4_e0169ca0-a5fd-46dd-9766-4f37db2dc589">1,618,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i210817a6ab294c9d9aff77d7f7d56bcd_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTYtNC0xLTEtMTExMzY4_3c23beb1-131b-4dd1-9b09-053e364d0ebd">241,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b5152586914421b5f5705f8c583545_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTYtNi0xLTEtMTExMzY4_837993ec-507e-44de-9484-d6b8ca91224c">1,376,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia372b23a3466460c91b1628f67e16648_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTYtOC0xLTEtMTExMzY4_bf6ee394-23b1-43bb-b89b-182cd486dca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie823bc3a3540443788e7ed44be452ee5_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTgtMi0xLTEtMTExMzY4_76c3afef-57a8-492f-9be6-ccccbd3cb8b5">219,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i210817a6ab294c9d9aff77d7f7d56bcd_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTgtNC0xLTEtMTExMzY4_f0aadf8a-3c59-46c9-8133-b4ebb7886470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b5152586914421b5f5705f8c583545_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTgtNi0xLTEtMTExMzY4_a4fc22c1-09f3-4214-a470-1b5357fb8977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia372b23a3466460c91b1628f67e16648_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTgtOC0xLTEtMTExMzY4_c488f8f3-65ef-4276-9f15-59850af29908">219,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i7b51d26e68034441986be05df0abacc1" continuedAt="i072493669eae4f1d9c415c487c0923ad"><ix:continuation id="i9a25d41b4eec4977b1ef36cb36bf4e65"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b1bd941ecd44d1ca58586c4a9d77e7a_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMy0yLTEtMS0xMTEzNjg_7f59d875-ed00-40f0-968d-fc69317fded6">270,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40eb73f6cf7b4d478059864b5fa2f8d9_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMy00LTEtMS0xMTEzNjg_80404871-8060-406d-9209-72ea9cc724e8">270,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b408457ee5148e38192a975210e857c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMy02LTEtMS0xMTEzNjg_79792c0c-070b-47d7-9463-cc9824c88f26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43176b0239cb476c8cf009256b574721_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMy04LTEtMS0xMTEzNjg_f9f6285a-237e-47fd-bbb8-c441b54c2ac6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076d11b5a6224da98d27eefe80d7e72a_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNC0yLTEtMS0xMTEzNjg_13bd3263-cc0e-4c31-a4fb-6519e2b3d050">44,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e9dba36ddb43e3a7cdf9a5872fb683_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNC00LTEtMS0xMTEzNjg_592e3291-f774-4d26-b908-72d6bcc481d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f8dc928bd848488160e1bd4f401ea3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNC02LTEtMS0xMTEzNjg_19bfd4dd-3422-4878-a967-8d5b11cbf3e7">44,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e64ae5cf7f45f6b977f634f04d74e5_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNC04LTEtMS0xMTEzNjg_fd811f07-a40e-4554-b681-7ad74c1cd57e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5723f8adf2d1441d932c0847136e9459_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNS0yLTEtMS0xMTU3NDA_ba05fe36-1245-4bbb-ade6-7218729a481f">41,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6ceebd68e64bf0a73073a721e7d630_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNS00LTEtMS0xMTU3NDA_cea3f861-e599-4d1c-a556-1ecb64319efb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i910dcea4abe947e4ab7bab94efb0b6bb_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNS02LTEtMS0xMTU3NDA_1e7fe170-5e06-48e8-8660-ff15f7fe1698">41,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048b6a7660eb403b9a37898a77b5f141_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNS04LTEtMS0xMTU3NDA_7401bfa7-0f45-413e-b6bc-5f35fe66f096">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65b952c5bedd40b798d1a1561e6546c6_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi0yLTEtMS0xMTU3NDg_3134adf5-76d5-4054-84aa-a5b23f8fdfc0">22,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ccbffe10394a7e94b51ab21066da05_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi00LTEtMS0xMTU3NDg_47cfd5d6-ce6e-40a3-b9c9-562a6a923f12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9706a586a2e648478e8a3e8e5b2af11f_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi02LTEtMS0xMTU3NDg_89f29829-5cdd-4677-ad11-0ee66c9a6541">22,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530c28e6901b4e84a1c2d02163b01915_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi04LTEtMS0xMTU3NDg_8e1ba77b-feec-4109-83f4-75e651eb136b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd32b8fc73844de94f0169aa6a02549_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy0yLTEtMS0xMTU3NTY_5dc5a209-ec54-49b9-8fac-4b5eeeddf950">3,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13efc9571bfe41aa8a26035bcd11ba88_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy00LTEtMS0xMTU3NTY_1f39d5ad-d9e2-49cb-b6bf-f0123f6cc803">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf68c6050a641f08b05c2eb2be55064_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy02LTEtMS0xMTU3NTY_53fe046a-8fa3-4355-a4c4-dde60413dc19">3,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd53d3ef7cf44699a9bed9051e463e3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy04LTEtMS0xMTU3NTY_85332341-be71-4e99-bc6f-8cae51007362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76df98dcf234a879e9afbd45704aa86_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC0yLTEtMS0xMTU3NjU_b4830969-c074-44ab-b84c-9d3b44b7f57c">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8b9f7927aa4adf8ad7beaa81618725_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC00LTEtMS0xMTU3NjU_12fd603c-c0df-4e2d-a96c-c830bac08f9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4f2d83b724aec84eb152ce5a9a38a_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC02LTEtMS0xMTU3NjU_641301be-d070-4811-beec-7b0eeafae4ba">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d9d2300f444085a25bd1044ef04459_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC04LTEtMS0xMTU3NjU_5b7f9e24-ac80-46c8-ac2c-4151cb43e236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076d11b5a6224da98d27eefe80d7e72a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi0yLTEtMS0xMTEzNjg_05849b0b-eb66-454d-9967-c81bca4b1486">820,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e9dba36ddb43e3a7cdf9a5872fb683_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi00LTEtMS0xMTEzNjg_7b3db193-94fc-4863-83c0-50e3c43c7542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f8dc928bd848488160e1bd4f401ea3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi02LTEtMS0xMTEzNjg_0ee4eda4-252d-4361-9360-b5d969a8024b">820,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e64ae5cf7f45f6b977f634f04d74e5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi04LTEtMS0xMTEzNjg_778f0148-fe4e-4cfb-b209-0c259476421b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76df98dcf234a879e9afbd45704aa86_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy0yLTEtMS0xMTEzNjg_de15ba9a-e25b-463b-8513-27000d93bdc5">208,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8b9f7927aa4adf8ad7beaa81618725_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy00LTEtMS0xMTEzNjg_941708b7-2ac1-48a7-98c4-75f4c726af77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4f2d83b724aec84eb152ce5a9a38a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy02LTEtMS0xMTEzNjg_bd656cb9-0958-4d5a-9ad2-f95c5302e8c6">208,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d9d2300f444085a25bd1044ef04459_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy04LTEtMS0xMTEzNjg_8482a990-25e8-46b6-acd2-71309e1d99c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5723f8adf2d1441d932c0847136e9459_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC0yLTEtMS0xMTEzNjg_64f3dd81-ccfc-4b1c-af8b-56db4c29a931">230,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6ceebd68e64bf0a73073a721e7d630_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC00LTEtMS0xMTEzNjg_3859a0c2-b686-491d-a707-6da25cac9778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i910dcea4abe947e4ab7bab94efb0b6bb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC02LTEtMS0xMTEzNjg_2e410499-7383-4458-93c8-4b8ed6f268e7">230,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048b6a7660eb403b9a37898a77b5f141_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC04LTEtMS0xMTEzNjg_7607eff5-851c-4269-beb0-b9e068fd09be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65b952c5bedd40b798d1a1561e6546c6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOS0yLTEtMS0xMTEzNjg_aee78fa5-6d69-4245-8732-34b42aba0af7">36,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ccbffe10394a7e94b51ab21066da05_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOS00LTEtMS0xMTEzNjg_aa0dd644-d880-4674-9727-079e9b641e11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9706a586a2e648478e8a3e8e5b2af11f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOS02LTEtMS0xMTEzNjg_87bd07b2-83a6-47a6-a5a3-7f4c6d8deb09">36,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530c28e6901b4e84a1c2d02163b01915_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOS04LTEtMS0xMTEzNjg_5c722e35-faf8-40a1-bc17-f2318ada2ad9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd32b8fc73844de94f0169aa6a02549_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTAtMi0xLTEtMTExMzY4_96c30dc8-6579-4553-81ad-9e0df37e36ac">1,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13efc9571bfe41aa8a26035bcd11ba88_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTAtNC0xLTEtMTExMzY4_ae8c2c14-c88f-4604-97cd-9797e7ff18bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf68c6050a641f08b05c2eb2be55064_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTAtNi0xLTEtMTExMzY4_a956eac4-af5e-4632-9240-53dc02e20ef5">1,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd53d3ef7cf44699a9bed9051e463e3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTAtOC0xLTEtMTExMzY4_5ae67c82-9834-4cd9-96d9-3185c8a64de5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0cb6ddc861e4bccabf7921700859d41_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTItMi0xLTEtMTExMzY4_d44ae324-e0a5-4b5c-9f29-fa2052398f7a">28,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08de5c309e4b47ce9d7bc420003d6031_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTItNC0xLTEtMTExMzY4_bb6f9034-eb56-4ff2-8ea3-6ed5802fb189">28,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7888ab348e6b46759e5fa89592e4892c_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTItNi0xLTEtMTExMzY4_0c8c2ed5-1932-444f-967b-421313cd4d00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1532ad29f7b41dfa9abd7737236a3cf_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTItOC0xLTEtMTExMzY4_77ef2abf-811f-4276-bc48-1b31178da22f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b1bd941ecd44d1ca58586c4a9d77e7a_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTMtMi0xLTEtMTExMzY4_4cf99c28-1523-47a1-9590-2700e09dcf50">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40eb73f6cf7b4d478059864b5fa2f8d9_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTMtNC0xLTEtMTExMzY4_ef160bb2-4645-4340-800f-8ba70e5ab543">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b408457ee5148e38192a975210e857c_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTMtNi0xLTEtMTExMzY4_6e294688-eae9-4788-b6c1-74cd87f2c337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43176b0239cb476c8cf009256b574721_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTMtOC0xLTEtMTExMzY4_115569b6-8942-4a6e-a9d9-1fc4051e686d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0cb6ddc861e4bccabf7921700859d41_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTQtMi0xLTEtMTExMzY4_a2dc8b88-63df-4c29-b7ac-4026f0850256">1,710,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08de5c309e4b47ce9d7bc420003d6031_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTQtNC0xLTEtMTExMzY4_d62cf7c6-9ca3-4417-a025-0d7cf041e374">299,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7888ab348e6b46759e5fa89592e4892c_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTQtNi0xLTEtMTExMzY4_d7b9d4ac-b271-4108-b19a-8f1698b11eb3">1,411,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1532ad29f7b41dfa9abd7737236a3cf_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTQtOC0xLTEtMTExMzY4_fe4db176-662b-4a4b-9415-fb2fca0383c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0cb6ddc861e4bccabf7921700859d41_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTYtMi0xLTEtMTExMzY4_c289107d-e02c-4226-a768-b5b2519d97eb">209,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08de5c309e4b47ce9d7bc420003d6031_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTYtNC0xLTEtMTExMzY4_8c22ad79-82c5-4f1d-a7e0-9fd9080246d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7888ab348e6b46759e5fa89592e4892c_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTYtNi0xLTEtMTExMzY4_16d791c4-805e-4d04-8c71-a6cfc4c1f27a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1532ad29f7b41dfa9abd7737236a3cf_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTYtOC0xLTEtMTExMzY4_432eda4f-b8ba-4cdd-a8d0-84c8d00e7bb0">209,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i072493669eae4f1d9c415c487c0923ad">The carrying amounts reflected on our condensed consolidated balance sheets for cash, accounts receivable, net, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term maturities.</ix:continuation> </span></div><div id="i90e340589f97408ea2365d8948df4c38_55"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RleHRyZWdpb246MWU3ZGZjMGE4ZGU3NDBiMzliZDk4YzIwZjQ3MTJjOGNfNjQw_e1345cc3-c4b5-4d72-b838-dc8ebb02b8ac" continuedAt="ieed835cd235d4e1ea905e1c17abfc55b" escape="true">MARKETABLE DEBT SECURITIES</ix:nonNumeric></span></div><ix:continuation id="ieed835cd235d4e1ea905e1c17abfc55b" continuedAt="i68ff3a7b5a434eafbfa29214f960c014"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We invest our excess cash balances in marketable debt securities and at each balance sheet date presented, we classify all of our investments in debt securities as available-for-sale and as current assets as they represent the investment of funds available for current operations. We did not record any impairment charges related to our marketable debt securities during the three months ended March&#160;31, 2023 or 2022.</span></div><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RleHRyZWdpb246MWU3ZGZjMGE4ZGU3NDBiMzliZDk4YzIwZjQ3MTJjOGNfNjQx_1d16d58e-c87f-48f9-858a-596be48a6349" continuedAt="i76639a21029f4f4ba841e85bbb1e25e3" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize our marketable debt securities:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c9e096a9ca46f28fce0d2487efa7e0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMi0xLTEtMS0xMTEzNjg_21ea1bbf-1bef-4374-a558-d95252fd99b3">744,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c9e096a9ca46f28fce0d2487efa7e0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMi0zLTEtMS0xMTEzNjg_6cfa58f2-2f92-40f9-b108-9404b473bf06">377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37c9e096a9ca46f28fce0d2487efa7e0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMi01LTEtMS0xMTEzNjg_43756c60-827c-4e70-a8a3-0cc7e808899e">2,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c9e096a9ca46f28fce0d2487efa7e0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMi03LTEtMS0xMTEzNjg_47fba290-b75e-4dd5-9f9b-331cf5fff95a">742,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ce486293d84aeeb0b9ecdc107a663f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy0xLTEtMS0xMTk3MTk_3f0e1ca3-668b-4cde-9d43-c1cd6233445c">337,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ce486293d84aeeb0b9ecdc107a663f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy0zLTEtMS0xMTk3MTk_a37be167-14a1-4dbb-abd1-3b8937295a51">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9ce486293d84aeeb0b9ecdc107a663f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy01LTEtMS0xMTk3MTk_47b496be-7b18-4158-bb7b-2a52af4ed2de">2,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ce486293d84aeeb0b9ecdc107a663f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy03LTEtMS0xMTk3MTk_5149ca34-10aa-467b-8bee-e9dda9ba7afa">335,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50ea362dec14ed1a971c9d68f405fc1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy0xLTEtMS0xMTEzNjg_d7e714e5-ca06-4fc9-939e-6e4b7b3a4ffa">194,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50ea362dec14ed1a971c9d68f405fc1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy0zLTEtMS0xMTEzNjg_4d85bccc-17eb-4a87-8e74-cd7cde9d572d">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if50ea362dec14ed1a971c9d68f405fc1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy01LTEtMS0xMTEzNjg_7d70d861-a3c2-440b-939d-ae8b87f86316">1,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50ea362dec14ed1a971c9d68f405fc1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy03LTEtMS0xMTEzNjg_fba99d99-aba1-43e5-8fc8-ad8b83c04034">193,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf96df66413c488d9bfbd03f94ea7f4e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNS0xLTEtMS0xMTEzNjg_77c6d151-090b-41f1-b915-7cb846ae87fe">92,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf96df66413c488d9bfbd03f94ea7f4e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNS0zLTEtMS0xMTEzNjg_ca226f8b-6568-4030-85a0-bcdbdea65dd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf96df66413c488d9bfbd03f94ea7f4e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNS01LTEtMS0xMTEzNjg_380db0d3-bcfd-4890-8197-f4d5a008ca6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf96df66413c488d9bfbd03f94ea7f4e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNS03LTEtMS0xMTEzNjg_b6f6eda9-62ff-4866-ab3d-4925e83ef4f9">92,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb230ab030c84a949a4708ce9359662e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNi0xLTEtMS0xMTEzNjg_592e1b1b-be50-4cee-a3b3-1dcfcc0c1515">13,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb230ab030c84a949a4708ce9359662e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNi0zLTEtMS0xMTEzNjg_75e8310b-3af4-4636-9a79-de2df9df1e27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb230ab030c84a949a4708ce9359662e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNi01LTEtMS0xMTEzNjg_590b50ff-7c33-495e-b861-1d27d011fdde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb230ab030c84a949a4708ce9359662e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNi03LTEtMS0xMTEzNjg_bb51d0b5-9592-4707-bcc9-cd61f1311196">13,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfOC0xLTEtMS0xMTEzNjg_a58e156d-071b-4a5f-aff7-7c4939ee3fc3">1,382,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfOC0zLTEtMS0xMTEzNjg_41243e2e-6953-4c8f-a789-1b530588975e">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfOC01LTEtMS0xMTEzNjg_5193225d-a9d1-4353-8e75-f78cab65cb57">5,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfOC03LTEtMS0xMTEzNjg_ef30e750-3e29-474b-a7ab-d2f98e15d5c2">1,376,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i68ff3a7b5a434eafbfa29214f960c014"><div style="margin-top:6pt;text-align:center"><ix:continuation id="i76639a21029f4f4ba841e85bbb1e25e3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e45c4599a0542b69eeec71ff8b3bf49_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMi0xLTEtMS0xMTEzNjg_352057d5-f882-443c-bb73-b5b4ee829099">870,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e45c4599a0542b69eeec71ff8b3bf49_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMi0zLTEtMS0xMTEzNjg_96cd58b3-2a72-41c2-a2c2-aa2d29d326e1">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e45c4599a0542b69eeec71ff8b3bf49_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMi01LTEtMS0xMTEzNjg_caf8a406-6507-413d-ba72-9474ed08ca04">4,382</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e45c4599a0542b69eeec71ff8b3bf49_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMi03LTEtMS0xMTEzNjg_5889755e-2f63-4ce8-9cc7-661767483ead">865,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie42a905d31064b9fa9efdd8b7ef9b37e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNC0xLTEtMS0xMTEzNjg_78bac39a-5f5f-43f6-a349-8c55a78caf27">275,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie42a905d31064b9fa9efdd8b7ef9b37e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNC0zLTEtMS0xMTEzNjg_9434b537-9cad-4baf-a807-3f24f460942c">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie42a905d31064b9fa9efdd8b7ef9b37e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNC01LTEtMS0xMTEzNjg_60c6b4a4-cd7f-4909-85a9-43277526ae80">3,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie42a905d31064b9fa9efdd8b7ef9b37e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNC03LTEtMS0xMTEzNjg_eaf57e9d-f8a5-4fa2-96c7-1d50075991bd">272,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i811b7526e6a94efba6244d85ce23698b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMy0xLTEtMS0xMTEzNjg_f6f81262-5f53-4fd8-b391-8501436ec581">211,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i811b7526e6a94efba6244d85ce23698b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMy0zLTEtMS0xMTEzNjg_45ada38e-fdbd-44da-a0f1-dc7ce88dd934">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i811b7526e6a94efba6244d85ce23698b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMy01LTEtMS0xMTEzNjg_0f9cc90f-8016-46c0-b4d9-dfd7aaac93ef">2,106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i811b7526e6a94efba6244d85ce23698b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMy03LTEtMS0xMTEzNjg_cf76173e-744c-4924-92cf-fa815b0b263b">209,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92f68826e624d329fcbd32713162d25_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNS0xLTEtMS0xMTEzNjg_2948ff39-622d-4c45-9c01-3602cd57361f">59,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92f68826e624d329fcbd32713162d25_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNS0zLTEtMS0xMTEzNjg_5cfb9850-e0e6-4345-b9ac-9703173d859d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92f68826e624d329fcbd32713162d25_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNS01LTEtMS0xMTEzNjg_bdd72d2e-d35d-48f8-a6b2-c124664be934">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92f68826e624d329fcbd32713162d25_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNS03LTEtMS0xMTEzNjg_4335f113-b0cc-46b2-92d7-d3661f7f847f">59,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94483e1405f840b791882d67766c7723_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNi0xLTEtMS0xMTEzNjg_ad691625-19dc-47fa-a17d-a8899bc58a86">4,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94483e1405f840b791882d67766c7723_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNi0zLTEtMS0xMTEzNjg_aba2b225-4e5c-4816-a209-4716747e3e87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94483e1405f840b791882d67766c7723_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNi01LTEtMS0xMTEzNjg_2a6a6c0c-9388-4a76-b8c0-8a2249f4ce26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94483e1405f840b791882d67766c7723_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNi03LTEtMS0xMTEzNjg_a581f361-5aa3-4fd7-9231-01ac235de5c5">4,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfOC0xLTEtMS0xMTEzNjg_991fe332-ffd3-4557-8826-0bf85263af76">1,420,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfOC0zLTEtMS0xMTEzNjg_b08b920f-38be-42b5-bc6c-0abb9f03323f">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfOC01LTEtMS0xMTEzNjg_b9214f6d-2606-4f9d-9731-107da26c60a8">9,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfOC03LTEtMS0xMTEzNjg_2a890ab6-90b5-48b3-bfe2-12c95e877c34">1,411,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RleHRyZWdpb246MWU3ZGZjMGE4ZGU3NDBiMzliZDk4YzIwZjQ3MTJjOGNfNjQz_3c124884-3ced-4dc4-9ae9-78e95f22a601" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOmFiOGEwZWMyYTZmZDQwZmJhMzdlZGIzYWQyODU2ZDU5L3RhYmxlcmFuZ2U6YWI4YTBlYzJhNmZkNDBmYmEzN2VkYjNhZDI4NTZkNTlfMS0xLTEtMS0xMTEzNjg_042b4396-4e3d-4e3a-814b-5ed9e74afef9">1,372,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOmFiOGEwZWMyYTZmZDQwZmJhMzdlZGIzYWQyODU2ZDU5L3RhYmxlcmFuZ2U6YWI4YTBlYzJhNmZkNDBmYmEzN2VkYjNhZDI4NTZkNTlfMS0zLTEtMS0xMTEzNjg_319c6632-5ae0-49ea-a2fb-bf04042359e8">1,297,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOmFiOGEwZWMyYTZmZDQwZmJhMzdlZGIzYWQyODU2ZDU5L3RhYmxlcmFuZ2U6YWI4YTBlYzJhNmZkNDBmYmEzN2VkYjNhZDI4NTZkNTlfMi0xLTEtMS0xMTEzNjg_1a11ca26-ca56-40f5-afcb-7e6ab9f2a81b">4,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOmFiOGEwZWMyYTZmZDQwZmJhMzdlZGIzYWQyODU2ZDU5L3RhYmxlcmFuZ2U6YWI4YTBlYzJhNmZkNDBmYmEzN2VkYjNhZDI4NTZkNTlfMi0zLTEtMS0xMTEzNjg_d3210be7-5967-4758-a6b1-7286f555b55f">113,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOmFiOGEwZWMyYTZmZDQwZmJhMzdlZGIzYWQyODU2ZDU5L3RhYmxlcmFuZ2U6YWI4YTBlYzJhNmZkNDBmYmEzN2VkYjNhZDI4NTZkNTlfMy0xLTEtMS0xMTEzNjg_0e2ef010-24ec-4e4e-bef8-329e99fac661">1,376,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOmFiOGEwZWMyYTZmZDQwZmJhMzdlZGIzYWQyODU2ZDU5L3RhYmxlcmFuZ2U6YWI4YTBlYzJhNmZkNDBmYmEzN2VkYjNhZDI4NTZkNTlfMy0zLTEtMS0xMTEzNjg_7acc960d-32f2-4771-9a85-da43d023eab9">1,411,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i90e340589f97408ea2365d8948df4c38_58"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">8. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTA1MA_73ace469-2837-4b6e-8f7f-d29864ecb1ed" continuedAt="i73b75d086af54894a687e9dbd8a22ef4" escape="true">OTHER BALANCE SHEET DETAILS</ix:nonNumeric></span></div><ix:continuation id="i73b75d086af54894a687e9dbd8a22ef4" continuedAt="ia173e1f1df224b8fb8c7231db3ef387e"><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inventory</span></div><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTA0NQ_ef9cbdfa-511f-459c-82e2-5d4b7eab9b0c" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of inventory are summarized as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfMS0xLTEtMS0xMTEzNjg_d5b05838-10dc-4469-b171-8c22b416fbe9">22,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfMS0zLTEtMS0xMTEzNjg_d8717f00-29c7-4b69-b5ce-1cf2cd1afdac">22,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfMi0xLTEtMS0xMTEzNjg_c4864454-4720-4ff9-b16d-8d6f16480a9a">110,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfMi0zLTEtMS0xMTEzNjg_663317e7-70cf-4b56-9133-044abbc04dd3">113,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfMy0xLTEtMS0xMTEzNjg_2009704a-0d86-46c6-8424-44895b40c587">29,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfMy0zLTEtMS0xMTEzNjg_21b6eea2-0b05-4e8d-99e8-c09160b48187">25,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="alny:InventoryCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfNC0xLTEtMS0xMTEzNjg_b2517cb4-625d-412b-9d77-d77f0bf4767f">163,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231" decimals="-3" name="alny:InventoryCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfNC0zLTEtMS0xMTEzNjg_ba18bec8-80a0-4805-8815-a35707e48274">161,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023 and December&#160;31, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="i1b2839973ded4bb9a04db596d1cd0ee7_I20230331" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTI3_2fe9a084-1b65-482a-ba1f-91111d5f7fdb">31.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3ed1c026dd674f1d819dbc53395da662_I20221231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTM0_d7fa2f5c-372b-4972-b2e1-1d5732f5dbc2">32.7</ix:nonFraction> million of long-term inventory, respectively, included within other assets in our condensed consolidated balance sheet as we anticipate it being consumed beyond our normal operating cycle.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTA0Ng_edd56854-ba30-4cc4-9027-0d9f06ec9442" escape="true"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTA0Nw_78fbe82d-31b2-4843-b2d4-d37cd294658a" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmQ3NDQ4ZGE4MGY2MjQ5MjE5YWNkYThkOGNiOGE2ODJhL3RhYmxlcmFuZ2U6ZDc0NDhkYTgwZjYyNDkyMTlhY2RhOGQ4Y2I4YTY4MmFfMi0xLTEtMS0xMTEzNjg_a7357b36-29d8-4d7c-942e-acf34451b602">672,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129714144f56409c862078cd74c09670_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmQ3NDQ4ZGE4MGY2MjQ5MjE5YWNkYThkOGNiOGE2ODJhL3RhYmxlcmFuZ2U6ZDc0NDhkYTgwZjYyNDkyMTlhY2RhOGQ4Y2I4YTY4MmFfMi0zLTEtMS0xMTEzNjg_a60605db-91ec-4e69-b485-9897c08003ec">534,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmQ3NDQ4ZGE4MGY2MjQ5MjE5YWNkYThkOGNiOGE2ODJhL3RhYmxlcmFuZ2U6ZDc0NDhkYTgwZjYyNDkyMTlhY2RhOGQ4Y2I4YTY4MmFfMy0xLTEtMS0xMTEzNjg_50f30b27-c736-465f-86e6-3837515043d2">2,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129714144f56409c862078cd74c09670_I20220331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmQ3NDQ4ZGE4MGY2MjQ5MjE5YWNkYThkOGNiOGE2ODJhL3RhYmxlcmFuZ2U6ZDc0NDhkYTgwZjYyNDkyMTlhY2RhOGQ4Y2I4YTY4MmFfMy0zLTEtMS0xMTEzNjg_516000b3-f775-47ed-947a-53868371efe6">2,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmQ3NDQ4ZGE4MGY2MjQ5MjE5YWNkYThkOGNiOGE2ODJhL3RhYmxlcmFuZ2U6ZDc0NDhkYTgwZjYyNDkyMTlhY2RhOGQ4Y2I4YTY4MmFfNC0xLTEtMS0xMTEzNjg_0567c82f-a2d6-4015-a6da-7fe2f8c6d223">674,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129714144f56409c862078cd74c09670_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmQ3NDQ4ZGE4MGY2MjQ5MjE5YWNkYThkOGNiOGE2ODJhL3RhYmxlcmFuZ2U6ZDc0NDhkYTgwZjYyNDkyMTlhY2RhOGQ4Y2I4YTY4MmFfNC0zLTEtMS0xMTEzNjg_4fc584ba-aefe-41c0-b3f2-dd9d2e736269">536,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ia173e1f1df224b8fb8c7231db3ef387e"><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accumulated Other Comprehensive (Loss) Income</span></div><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTA0OA_25a70027-4eca-4a7d-a32b-c57974b5f13f" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the changes in accumulated other comprehensive (loss) income, by component:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss on Investment in Joint Venture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized (Losses) Gains from Debt</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other<br/>Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibebf4053fbf44fb9b675c41a096d60a7_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMS0xLTEtMS0xMTEzNjg_5d7ab65e-5af6-406e-834c-933310fd6446">32,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50c869678d1046f6b8952f17b26368ed_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMS0zLTEtMS0xMTEzNjg_0fa57883-de50-43ca-8e9c-7de017ea1bc4">1,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i714ef67f5dd5449c8ce319985ec64bf3_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMS01LTEtMS0xMTEzNjg_e562914e-ac7c-4cc6-93cd-5dfc4f788cf3">9,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0c21a9a0d854336ae2513275c632fb3_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMS03LTEtMS0xMTEzNjg_bc2c6ea7-ee43-4fc9-91e0-0884ce4bed93">1,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib10c6162d7ee41d8b5073719840fa8ed_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMS05LTEtMS0xMTEzNjg_f01118d0-790a-48ef-82e0-cafe085617a2">44,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5bbae1628a449d818c46f986a09d4c_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMi0xLTEtMS0xMTEzNjg_fb47afbe-4243-4ffe-a51e-799dceb2e05d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3080c044b38407fba1e7d8658782768_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMi0zLTEtMS0xMTEzNjg_8372461c-d7eb-461c-9639-4f13ae19173c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef9a4ac510541efaaf7b5313dd58cf6_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMi01LTEtMS0xMTEzNjg_4e47d765-d1ca-49de-89ac-323a4f79ccb0">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if11c68a061924916b804149e7efa13f8_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMi03LTEtMS0xMTEzNjg_3033bc2e-5e8f-4030-a0e6-3372290701cc">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMi05LTEtMS0xMTEzNjg_5ea7a9a9-bb2b-4e37-9784-b35db7568525">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5bbae1628a449d818c46f986a09d4c_D20230101-20230331" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMy0xLTEtMS0xMTEzNjg_f70d0fc6-869a-44aa-af4e-038a26b3c88e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3080c044b38407fba1e7d8658782768_D20230101-20230331" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMy0zLTEtMS0xMTEzNjg_f3cf9154-0f03-4d70-8e18-bca01fb3f44a">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef9a4ac510541efaaf7b5313dd58cf6_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMy01LTEtMS0xMTEzNjg_9e6746cd-e04c-4424-b407-2c0ec706ad15">4,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if11c68a061924916b804149e7efa13f8_D20230101-20230331" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMy03LTEtMS0xMTEzNjg_01759530-8b81-4be9-821e-3d63f3b56d27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMy05LTEtMS0xMTEzNjg_8bd396d0-0dc7-4f91-9c77-bfa49279b249">4,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5bbae1628a449d818c46f986a09d4c_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNC0xLTEtMS0xMTEzNjg_81affeef-8470-4fba-9ea4-c0467c4bd579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3080c044b38407fba1e7d8658782768_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNC0zLTEtMS0xMTEzNjg_ef229c47-5f22-4832-97e7-e421da52621c">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef9a4ac510541efaaf7b5313dd58cf6_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNC01LTEtMS0xMTEzNjg_9f1c93cf-67f2-48f9-b09f-9c7af7b737dc">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if11c68a061924916b804149e7efa13f8_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNC03LTEtMS0xMTEzNjg_436a2d84-9d98-4157-8e1e-11635e542916">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNC05LTEtMS0xMTEzNjg_704ef917-761f-46fa-99d4-88a5f7e83139">5,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i348f9d6750ba4e6d84377accaa5b9319_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNS0xLTEtMS0xMTEzNjg_02cfd7b0-4f99-45dd-b6c3-3b0f3aa96f22">32,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ed6da55201a4d6098f35926e23ad0c5_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNS0zLTEtMS0xMTEzNjg_33d8e065-7e62-4d49-9e3b-40b774cdf4d9">1,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5423daa9097405baa2e53113e5a2af9_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNS01LTEtMS0xMTEzNjg_0919eb93-d1bc-4473-ae77-107910830516">5,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2fec59aefb4d9abff4b8a755874542_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNS03LTEtMS0xMTEzNjg_d9b35303-d816-46c3-99d4-4eeab5d561a5">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id68ac710f233437aa4518ad8eb0adb93_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNS05LTEtMS0xMTEzNjg_28b884d9-2046-4eb1-91ea-6d8d1e22f5c1">39,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss on Investment in Joint Venture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized (Losses) Gains from Debt</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other<br/>Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia64c74b9951e43a2a4ca3afc638421c2_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMS0xLTEtMS0xMTEzNjg_20ac04aa-eb7d-4c3f-9376-d72769b878ab">32,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i400fd731ed28427a98cf559b0d69a616_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMS0zLTEtMS0xMTEzNjg_d27be04f-e645-4ec2-a921-d02d4133e2fc">2,811</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5246d2e962624dce926b3bfedeadb7d3_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMS01LTEtMS0xMTEzNjg_ae0ad926-8177-4dfa-a962-471c25a2d491">1,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0764c7d8cbc0465a9c4b5bec84310735_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMS03LTEtMS0xMTEzNjg_5ad84eb1-2b81-4425-9e45-da5ba1284799">3,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie72229676bde424e88e71e576e78694f_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMS05LTEtMS0xMTEzNjg_ca5eddd2-bd1f-4889-be3c-6148fbc60fa6">33,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597049e81b154f63b39f155a686eca36_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMi0xLTEtMS0xMTEzNjg_0ace3b30-d688-4eb2-806c-f1040cf1303f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id931cec3813c4a8abbaa146d0ecf379e_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMi0zLTEtMS0xMTEzNjg_6397706a-d4a3-4cd7-854a-e3c1367c63c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32207f7e2b874ffe9f5bb035ed9216a6_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMi01LTEtMS0xMTEzNjg_8551a7d0-4e12-4066-b851-1dcc732ce527">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058fa58cb9ad4be2929911d5459f7ee5_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMi03LTEtMS0xMTEzNjg_2138439f-53ba-4a44-9534-cf0eb5f9a11a">2,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMi05LTEtMS0xMTEzNjg_927fe95c-9fd4-4898-a217-c20d51bfe36d">2,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597049e81b154f63b39f155a686eca36_D20220101-20220331" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMy0xLTEtMS0xMTEzNjg_100a12ff-54c3-4814-9170-7317752ec112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id931cec3813c4a8abbaa146d0ecf379e_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMy0zLTEtMS0xMTEzNjg_ccf1aacb-27b6-4f6c-8b87-b5113ebca296">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32207f7e2b874ffe9f5bb035ed9216a6_D20220101-20220331" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMy01LTEtMS0xMTEzNjg_da4d4bbe-84d8-46d5-9775-aed02986e8f4">7,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058fa58cb9ad4be2929911d5459f7ee5_D20220101-20220331" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMy03LTEtMS0xMTEzNjg_325f7182-2de5-4989-adf3-299066223efc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMy05LTEtMS0xMTEzNjg_3db7717d-910f-40c7-a94a-5a422da51d1c">7,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597049e81b154f63b39f155a686eca36_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNC0xLTEtMS0xMTEzNjg_45c33093-6e4c-43f4-b1e4-1bbd838e8301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id931cec3813c4a8abbaa146d0ecf379e_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNC0zLTEtMS0xMTEzNjg_611cb9df-78d2-4b40-a957-cae9d489568f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32207f7e2b874ffe9f5bb035ed9216a6_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNC01LTEtMS0xMTEzNjg_66c0fd85-aaca-4a30-83b7-fe08f358dd3e">7,217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058fa58cb9ad4be2929911d5459f7ee5_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNC03LTEtMS0xMTEzNjg_6b9d4955-a61e-4a1b-8032-1ea49d7652c8">2,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNC05LTEtMS0xMTEzNjg_7d0e23e2-6d9a-4dd1-b7b6-4bc605ddcd40">4,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if78966f3bc7e4a2c88588d499eac7518_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNS0xLTEtMS0xMTEzNjg_f519e5d0-1c30-4ec7-aaff-bd6d1751628c">32,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58d05b72c281482194642f22d74ecfe5_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNS0zLTEtMS0xMTEzNjg_d021f1b7-972f-4dd8-82bc-e90308f7ee8d">2,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca2d339be1249478491d26c1d76e094_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNS01LTEtMS0xMTEzNjg_9d067bad-8594-4844-b8f0-d2fe7f9b96d9">8,847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f8e370f342484989f74b6dadda0a7e_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNS03LTEtMS0xMTEzNjg_0c88b1aa-9f32-454e-8838-e2e76723254b">6,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2d23f30f53a4a3b8caa38a11b48d302_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNS05LTEtMS0xMTEzNjg_0cadbd12-1efe-4b98-a43d-10a7d07f78ee">38,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts reclassified out of accumulated other comprehensive loss relate to settlements of marketable equity securities and amortization of our pension obligation which are recorded as other income in the condensed consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div id="i90e340589f97408ea2365d8948df4c38_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">9. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNjA3NQ_f4d2fc3e-33b9-47c5-9ed7-d96c522fbabe" continuedAt="ib3844599e681435ca5d1f1c182818882" escape="true">CONVERTIBLE DEBT</ix:nonNumeric></span></div><ix:continuation id="ib3844599e681435ca5d1f1c182818882" continuedAt="i0c698cdcf31746abad44beffbc6bf8e1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Convertible Senior Notes Due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September&#160;12, 2022, we commenced a private offering of $<ix:nonFraction unitRef="usd" contextRef="i8575ee7bf1c64fce99658a0882ae7ee3_I20220912" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTAy_f5dcf393-f0fa-4b3a-9f7d-efeff387ed63">900.0</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i8081d56e8ab34c85add2a725bbed1844_D20220912-20220912" decimals="INF" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTM4_2d0f9cc1-61ed-4ecd-b264-a4b8eb71d3d3">1</ix:nonFraction>% Convertible Senior Notes due 2027, or the Initial Notes. On September&#160;13, 2022, the initial purchasers in such offering exercised their option to purchase an additional $<ix:nonFraction unitRef="usd" contextRef="i72548dd619ad4fc59ff47eaf2277707e_I20220913" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjk0_0af393f9-604a-4ee4-accc-1030134468bc">135.0</ix:nonFraction>&#160;million in aggregate principal amount of our <ix:nonFraction unitRef="number" contextRef="ifbfa928ba64c483796841306c426679d_D20220913-20220913" decimals="INF" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMzM0_1bda0c57-bb80-44cb-a7f9-8dae29594a5a">1</ix:nonFraction>% Convertible Senior Notes due 2027, or the Additional Notes, and together with the Initial Notes collectively referred to as the Notes, bringing the total aggregate principal amount of the Notes to $<ix:nonFraction unitRef="usd" contextRef="i36aa61efaa244add8aac63cdcac4dac0_I20220913" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTM0_bbf26035-c254-42aa-ad91-1cec31d00eeb">1.04</ix:nonFraction>&#160;billion. The Notes were issued pursuant to an indenture, dated September&#160;15, 2022, or the Indenture. The Indenture includes customary covenants and sets forth certain events of default after which the Notes may be declared immediately due and payable and sets forth certain types of bankruptcy or insolvency events of default involving the Company after which the Notes become automatically due and payable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Notes will mature on September&#160;15, 2027, unless earlier converted, redeemed or repurchased. The Notes will bear interest from September&#160;15, 2022 at a rate of <ix:nonFraction unitRef="number" contextRef="ie5b391a1819e41adbce308c1b9dab192_D20220915-20220915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTA1MQ_8e5484c1-e1c9-49a2-8098-8fa70ed94ca3">1</ix:nonFraction>% per year payable semiannually in arrears on March 15 and September 15 of each year, beginning on March&#160;15, 2023. The Notes are convertible at the option of the noteholder on or after June 15, 2027. Prior to June 15, 2027, the Notes are convertible only under the following circumstances: (1) During any calendar quarter commencing after the calendar quarter ending on December 31, 2022 (and only during such calendar quarter), if the last reported sale price of our common stock for at least <ix:nonFraction unitRef="day" contextRef="ia716907dc7734c6ba46bc53ee763d5d5_D20220915-20220915" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTUxOA_11ef9bff-f612-41b6-a011-1c944f96a0c2">20</ix:nonFraction> trading days (whether or not consecutive) during a period of <ix:nonFraction unitRef="day" contextRef="ia716907dc7734c6ba46bc53ee763d5d5_D20220915-20220915" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTU4Mg_dbd8007b-df58-40e5-a2bd-af9d5975198b">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="ia716907dc7734c6ba46bc53ee763d5d5_D20220915-20220915" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTczMQ_fd6a7043-1fa6-4e40-af57-2b53094fd36c">130</ix:nonFraction>% of the conversion price on each applicable trading day; (2) During the <ix:nonFraction unitRef="day" contextRef="i9e464817379546f69d2a4d409bf930d6_D20220915-20220915" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTgwNQ_80d95f3d-9d3b-4561-afba-8524657ebb86">five</ix:nonFraction> business day period after any <ix:nonFraction unitRef="day" contextRef="i9e464817379546f69d2a4d409bf930d6_D20220915-20220915" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTgzOA_11efa706-390f-4673-813b-fca9a2a44277">ten</ix:nonFraction> consecutive trading day period in which the trading price per $1,000 principal amount of the Notes for each trading day of that <ix:nonFraction unitRef="day" contextRef="i9e464817379546f69d2a4d409bf930d6_D20220915-20220915" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTk2OQ_9ad83127-73db-46a8-833d-18e8c0f5a0ce">ten</ix:nonFraction> consecutive trading day period was less than <ix:nonFraction unitRef="number" contextRef="i9e464817379546f69d2a4d409bf930d6_D20220915-20220915" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjAxNw_bded3c61-11a6-47cb-9bdf-91d4813d2cce">98</ix:nonFraction>% of the product of the last reported sale price of our common stock and the conversion rate of the Notes on such trading day; (3) If we call any or all of the Notes for redemption; or (4) Upon the occurrence of specific corporate events as set forth in the Indenture governing the Notes. We will settle any conversions of Notes by paying or delivering, as applicable, cash, shares of our common stock, or a combination of cash and shares of common stock, at our election.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i0c698cdcf31746abad44beffbc6bf8e1" continuedAt="i0154f4dfd9ed44bf891850ccfa886ca9"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The conversion rate for the Notes will initially be 3.4941 shares of common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="icebb5707b4014e189d610163d749eb88_I20220912" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjY3NQ_3cf1572e-3f10-42c7-a6c0-bad1c83b9c07">286.20</ix:nonFraction> per share of common stock. The initial conversion price of the Notes represents a premium of approximately <ix:nonFraction unitRef="number" contextRef="icebb5707b4014e189d610163d749eb88_I20220912" decimals="2" name="alny:ConvertibleDebtPremiumRecognizedFromConversionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjc4NQ_d3a252d7-cf0a-4971-a917-25798f521090">35</ix:nonFraction>% over the $<ix:nonFraction unitRef="usdPerShare" contextRef="icebb5707b4014e189d610163d749eb88_I20220912" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjc5Nw_f03d701d-2ca1-486e-b2e4-c466a77a69a0">212.00</ix:nonFraction> per share last reported sale price of common stock on September 12, 2022. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the Indenture.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may not redeem the Notes prior to September&#160;20, 2025. We may redeem for cash equal to 100% of the principal amount of the Notes being redeemed plus accrued and unpaid interest of all or any portion of the Notes, at our option, on or after September 20, 2025, if the last reported sales price of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="idf3afa8e81834164a6949f9f03a9f2b4_D20220915-20220915" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjE5OTAyMzI2MTkzMA_1c767079-8056-4c01-96b8-7592517f83e6">130</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonFraction unitRef="day" contextRef="idf3afa8e81834164a6949f9f03a9f2b4_D20220915-20220915" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjE5OTAyMzI2MTkzNg_ff7bb6a8-a359-483d-ab5f-3b788fafa9af">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="day" contextRef="idf3afa8e81834164a6949f9f03a9f2b4_D20220915-20220915" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjE5OTAyMzI2MTk0MA_fe3baeef-373b-49ac-b83c-b439ff6a1b45">30</ix:nonFraction> consecutive trading day period. No sinking fund is provided for the Notes and therefore we are not required to redeem or retire the Notes periodically.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we undergo a fundamental change, as defined in the indenture agreement, then subject to certain conditions, holders may require us to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased plus accrued and unpaid interest. In addition, if specific corporate events occur prior to the maturity date or if we issue a notice of redemption, we will increase the conversion rate by pre-defined amounts for holders who elect to convert their notes in connection with such corporate event. The conditions allowing holders of the Notes to convert were not met this quarter. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the Notes are classified as a long-term liability, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ia532de6f95c948d98aa0f343c124b06f_I20230331" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNDM0NA_d24e304e-d664-49f6-8519-1dd5981207e2">19.2</ix:nonFraction> million, on the condensed consolidated balance sheets. As of March&#160;31, 2023, the estimated fair value of the Notes was approximately $<ix:nonFraction unitRef="usd" contextRef="ia532de6f95c948d98aa0f343c124b06f_I20230331" decimals="-7" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTQ5NzU1ODIwMjU5_8ce8683e-a816-4313-99d3-7cbaba6d8f00">1.03</ix:nonFraction>&#160;billion. The fair value was determined based on the last actively traded price per $100 of the Notes for the three months ended March 31, 2023 (Level 2). The Notes were issued at par and costs associated with the issuance of the Notes are amortized to&#160;interest expense over the contractual term of the Notes. As of March&#160;31, 2023, the effective interest rate of the Notes is&#160;<ix:nonFraction unitRef="number" contextRef="icf9b6feac91a4baaa879c5cc27f3adcf_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNDgzMw_10152ba4-b46a-4297-9854-75aff674552d">1</ix:nonFraction>%.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Capped Call Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2022, in connection with the pricing of the Initial Notes and the initial purchasers&#8217; exercise of their option to purchase the Additional Notes, we entered into privately negotiated capped call transactions, or Capped Call Transactions. The Capped Call Transactions initially cover, subject to customary anti-dilution adjustments, the number of shares of common stock that underlie the Notes. The cap price of the Capped Call Transactions is initially $<ix:nonFraction unitRef="usdPerUnit" contextRef="i9534211a39af4f07af0f48f741ec3cfc_I20230331" decimals="2" name="us-gaap:DerivativeCapPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTMyNw_07b3069a-f1cd-4030-b2ba-277407f9f697">424.00</ix:nonFraction> per share, which represents a premium of <ix:nonFraction unitRef="number" contextRef="i303c720c21554eb3a5e123dcdd48b762_I20220912" decimals="2" name="alny:PremiumRecognizedOnCappedCallTransactions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTM3MQ_1b7e0994-fa9f-45ce-aa66-6f0bee8b47ae">100</ix:nonFraction>% over the last reported sale price of common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="i303c720c21554eb3a5e123dcdd48b762_I20220912" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTQyNw_5298c9d6-c7ee-4a92-9e6b-332c022a96d8">212.00</ix:nonFraction> per share on September 12, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. We used approximately $<ix:nonFraction unitRef="usd" contextRef="i8025ac0fe3c444bd93fb4dffe9e6a50f_D20230101-20230331" decimals="-5" name="alny:PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTU3Mg_cba88f0c-5e46-443f-8cbb-459c815386eb">118.6</ix:nonFraction>&#160;million of the proceeds from the offering of Notes to pay the cost of the Capped Call Transactions.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i0154f4dfd9ed44bf891850ccfa886ca9">We evaluated the Capped Call Transactions and determined that they should be accounted for separately from the Notes. The cost of $<ix:nonFraction unitRef="usd" contextRef="i8025ac0fe3c444bd93fb4dffe9e6a50f_D20230101-20230331" decimals="-5" name="alny:PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTc5Nw_cba88f0c-5e46-443f-8cbb-459c815386eb">118.6</ix:nonFraction>&#160;million to purchase the Capped Call Transactions was recorded as a reduction to additional paid-in capital in the condensed consolidated balance sheet as of March&#160;31, 2023 as the Capped Call Transactions are indexed to our own stock and met the criteria to be classified in stockholders' equity.</ix:continuation> </span></div><div id="i90e340589f97408ea2365d8948df4c38_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">10. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTg2Mw_8a5e81d7-2676-4285-90f4-2cc1163d9d04" continuedAt="i1f146d53dc1848b287bb58d966bc454b" escape="true">DEVELOPMENT DERIVATIVE LIABILITY</ix:nonNumeric></span></div><ix:continuation id="i1f146d53dc1848b287bb58d966bc454b" continuedAt="i83d654e2368749bf9e57f62bda4f262d"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, we entered into a co-development agreement, referred to as the Funding Agreement, with BXLS V Bodyguard &#8211; PCP L.P. and BXLS Family Investment Partnership V &#8211; ESC L.P., collectively referred to as Blackstone Life Sciences, pursuant to which Blackstone Life Sciences will provide up to $<ix:nonFraction unitRef="usd" contextRef="icdd6f7a85c0649c687a28ff5014a352d_D20200801-20200831" decimals="-5" name="alny:CollaborativeArrangementMaximumFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfMzQy_6a5997fb-7a81-42b8-a11b-3d0b0c4480c3">150.0</ix:nonFraction>&#160;million in funding for the clinical development of vutrisiran and zilebesiran, two of our cardiometabolic programs. With respect to vutrisiran, Blackstone Life Sciences has committed to provide up to $<ix:nonFraction unitRef="usd" contextRef="i0540d1bfbba64fa980c847a4a95c9ac6_D20200801-20200831" decimals="-5" name="alny:CollaborativeArrangementMaximumFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTU2_90467aac-6f87-46c7-8273-cc575820af03">70.0</ix:nonFraction>&#160;million to fund development costs related to the HELIOS-B Phase 3 clinical trial. In November 2021, Blackstone Life Sciences opted in to Phase 2 clinical trial funding of zilebesiran, committing to fund, upon meeting certain patient enrollment thresholds, up to $<ix:nonFraction unitRef="usd" contextRef="i788b9050885e4755ab989256b9364634_D20200801-20200831" decimals="-5" name="alny:CollaborativeArrangementMaximumFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfODEz_1b7a810e-d582-482a-95b4-50d3fc6b79cf">26.0</ix:nonFraction>&#160;million. Furthermore, Blackstone Life Sciences has the right, but is not obligated, to fund up to $<ix:nonFraction unitRef="usd" contextRef="i3d2567c90e8a458eae5bef50162e1ca4_D20200801-20200831" decimals="-5" name="alny:CollaborativeArrangementMaximumFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfOTA2_235ad026-e305-4b3c-97a9-ede7e964f7a6">54.0</ix:nonFraction>&#160;million for development costs related to a Phase 3 clinical trial of zilebesiran. The amount of funding ultimately provided by Blackstone Life Sciences is dependent on us achieving specified development milestones with respect to each clinical trial. We retain sole responsibility for the development and commercialization of both vutrisiran and zilebesiran.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As consideration for Blackstone Life Sciences&#8217; funding for vutrisiran clinical development costs, we have agreed to pay Blackstone Life Sciences a <ix:nonFraction unitRef="number" contextRef="ifde09daab1ea4a168820da3d556f2e1f_D20200801-20200831" decimals="2" name="alny:CollaborativeArrangementRoyaltiesPayablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfMTQwNw_08e8525c-5d91-4349-9e5b-55881b3f24c8">1</ix:nonFraction>% royalty on net sales of AMVUTTRA (vutrisiran) for a <ix:nonNumeric contextRef="ifde09daab1ea4a168820da3d556f2e1f_D20200801-20200831" name="alny:CollaborativeArrangementRoyaltiesPayableTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfMTQ2Mg_8c332dc2-9163-41b7-b5de-b91ff0f647c6">10</ix:nonNumeric>-year term beginning upon the first commercial sale following regulatory approval of vutrisiran for ATTR-cardiomyopathy, as well as fixed payments of up to <ix:nonFraction unitRef="number" contextRef="ifde09daab1ea4a168820da3d556f2e1f_D20200801-20200831" decimals="1" name="alny:CollaborativeArrangementFixedPaymentMultiplier" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfMTYyMA_30cf6009-cf48-4a38-a0c2-9483c41c0ba8">2.5</ix:nonFraction> times their investment over a <ix:nonNumeric contextRef="ifde09daab1ea4a168820da3d556f2e1f_D20200801-20200831" name="alny:CollaborativeArrangementFixedPaymentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTg2NA_1ba288ee-f6cf-4001-bc61-642e2e4c1a69">two-year</ix:nonNumeric> period upon regulatory approval of vutrisiran for ATTR-cardiomyopathy in specified countries, unless it is later withdrawn from the market following a mandatory recall. As consideration for Blackstone Life Sciences&#8217; funding for Phase 2 clinical development costs of zilebesiran, we have agreed to pay Blackstone Life Sciences fixed payments of up to <ix:nonFraction unitRef="number" contextRef="i788b9050885e4755ab989256b9364634_D20200801-20200831" decimals="2" name="alny:CollaborativeArrangementFixedPaymentMultiplier" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfMjAxMQ_61e605cc-8d65-4b65-a1ce-8d4eba141f3a">3.25</ix:nonFraction> times their Phase 2 investment over a <ix:nonNumeric contextRef="i788b9050885e4755ab989256b9364634_D20200801-20200831" name="alny:CollaborativeArrangementFixedPaymentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTg2NQ_33cf8b4d-a344-4817-b83c-6f31b57993a0">four-year</ix:nonNumeric> period upon the successful completion of the zilebesiran Phase 2 clinical trial, unless certain regulatory events affecting the continued development of zilebesiran occur. As </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i83d654e2368749bf9e57f62bda4f262d"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">consideration for Blackstone Life Sciences&#8217; funding for Phase 3 clinical development costs of zilebesiran, we have agreed to pay Blackstone Life Sciences fixed payments of up to <ix:nonFraction unitRef="number" contextRef="i3d2567c90e8a458eae5bef50162e1ca4_D20200801-20200831" decimals="1" name="alny:CollaborativeArrangementFixedPaymentMultiplier" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfMjQxMw_0b572531-a9f8-4e59-962a-f1c8b2da5098">4.5</ix:nonFraction> times their Phase 3 investment over a <ix:nonNumeric contextRef="i3d2567c90e8a458eae5bef50162e1ca4_D20200801-20200831" name="alny:CollaborativeArrangementFixedPaymentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTg2Ng_b51e99eb-ebc0-4343-96a6-dc12de2fed85">four-year</ix:nonNumeric> period upon regulatory approval of zilebesiran in specified countries, unless it is later withdrawn from the market following a mandatory recall.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our payment obligations under the Funding Agreement will be secured, subject to certain exceptions, by security interests in intellectual property owned by us relating to vutrisiran and zilebesiran, as well as in our bank account in which the funding deposits will be made.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and Blackstone Life Sciences each have the right to terminate the Funding Agreement in its entirety in the event of the other party&#8217;s bankruptcy or similar proceedings. We and Blackstone Life Sciences may each terminate the Funding Agreement in its entirety or with respect to either product in the event of an uncured material breach by the other party, or with respect to a product for certain patient health and safety reasons, or if regulatory approval in specified major market countries is not obtained for the product following the completion of clinical trials for the product. In addition, Blackstone Life Sciences has the right to terminate the Funding Agreement in its entirety upon the occurrence of certain events affecting our ability to make payments under the agreement or to develop or commercialize the products, or upon a change of control of us. Blackstone Life Sciences may also terminate the Funding Agreement with respect to a product if the joint steering committee elects to terminate the development program for that product in its entirety, if certain clinical endpoints are not achieved for that product or, with respect to vutrisiran only, if our right to develop or commercialize vutrisiran is enjoined in a specified major market as a result of an alleged patent infringement. In certain termination circumstances, we will be obligated to pay Blackstone Life Sciences an amount that is equal to, or a multiplier of, the development funding received from Blackstone Life Sciences, and we may remain obligated under certain circumstances to make the payments to Blackstone Life Sciences described above, or the royalty described above in the case of AMVUTTRA, should we obtain regulatory approval for zilebesiran or vutrisiran for ATTR-cardiomyopathy following termination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We account for the Funding Agreement under ASC Topic 815, Derivatives and Hedging, as a derivative liability, measured at fair value, within other liabilities on our condensed consolidated balance sheets. The change in fair value due to the remeasurement of the development derivative liability is recorded as other expense on our condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the derivative liability is classified as a Level 3 financial liability in the fair value hierarchy. The valuation method incorporates certain unobservable Level 3 key inputs including (i) the probability and timing of achieving stated development milestones to receive payments from Blackstone Life Sciences, (ii) the probability and timing of achieving regulatory approval and payments to Blackstone Life Sciences, (iii) an estimate of the amount and timing of the royalty payable on net sales of AMVUTTRA, assuming regulatory approval for ATTR-cardiomyopathy, (iv) our cost of borrowing (<ix:nonFraction unitRef="number" contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTY5MA_8848fa33-bbe9-4eb7-b520-0f8927736277">12</ix:nonFraction>%), and (v) Blackstone Life Sciences' cost of borrowing (<ix:nonFraction unitRef="number" contextRef="if60b93a866a243d08fc76127d6370bdd_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTc0OA_f5d8ac3b-87b1-4978-86f1-55b2f4f0af45">4</ix:nonFraction>%).</span></div><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTg2Nw_eade0fdf-7f57-43f8-96af-ad7d4962b7dd" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the activity with respect to the development derivative liability, in thousands:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"></td><td style="width:81.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b29740f2a6476a91d8e8b96400f6d4_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RhYmxlOjVhNzhhYmI3MjBhZTQ2MzQ4Y2ZjZGRiNzFhOGU3YzcwL3RhYmxlcmFuZ2U6NWE3OGFiYjcyMGFlNDYzNDhjZmNkZGI3MWE4ZTdjNzBfMC0yLTEtMS0xMTEzNjg_624b28e8-1762-4da5-b309-b2a09e489bc6">209,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount received under the Funding Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707ab3ce2b764f02a7efa7c0a56fcdd2_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RhYmxlOjVhNzhhYmI3MjBhZTQ2MzQ4Y2ZjZGRiNzFhOGU3YzcwL3RhYmxlcmFuZ2U6NWE3OGFiYjcyMGFlNDYzNDhjZmNkZGI3MWE4ZTdjNzBfMS0yLTEtMS0xMTEzNjg_ef769e29-9bef-4cbc-99ac-44188a5db2ee">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recorded from remeasurement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707ab3ce2b764f02a7efa7c0a56fcdd2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RhYmxlOjVhNzhhYmI3MjBhZTQ2MzQ4Y2ZjZGRiNzFhOGU3YzcwL3RhYmxlcmFuZ2U6NWE3OGFiYjcyMGFlNDYzNDhjZmNkZGI3MWE4ZTdjNzBfMi0yLTEtMS0xMTEzNjg_59cc8d2f-4c1a-47d4-82b8-5f4b6aea80bb">6,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i728568c4126e4020bdaab60c7fd837da_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RhYmxlOjVhNzhhYmI3MjBhZTQ2MzQ4Y2ZjZGRiNzFhOGU3YzcwL3RhYmxlcmFuZ2U6NWE3OGFiYjcyMGFlNDYzNDhjZmNkZGI3MWE4ZTdjNzBfMy0yLTEtMS0xMTEzNjg_f5482b19-c0a3-4ad9-a6ac-78a01f9da39f">219,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i90e340589f97408ea2365d8948df4c38_73"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">11. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RleHRyZWdpb246Yzk1ZDZhYTU5M2EwNGYyYzkzN2Y0ZjYxYTU3ZWNlMjlfMTQ0_f820df3f-189e-444b-a9da-5f9f38964fb7" continuedAt="i0e42bbe1c1dc413388bae5a63d19f1b2" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i0e42bbe1c1dc413388bae5a63d19f1b2"><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RleHRyZWdpb246Yzk1ZDZhYTU5M2EwNGYyYzkzN2Y0ZjYxYTU3ZWNlMjlfMTQy_872863d4-701e-4c24-a2ea-fdd54be3655f" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes stock-based compensation expenses included in operating costs and expenses:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"></td><td style="width:60.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.398%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770db94c29944af19b3195793999b048_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RhYmxlOjBmOTZkYjg4NTk0NTQ0YTA5ODhjZWMxZmQ5NWNhNjVjL3RhYmxlcmFuZ2U6MGY5NmRiODg1OTQ1NDRhMDk4OGNlYzFmZDk1Y2E2NWNfMi0xLTEtMS0xMTEzNjg_2e18e848-1f39-4828-8072-a3073db40233">16,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i920b6c081b7047af9c3d22ecd0aac5fc_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RhYmxlOjBmOTZkYjg4NTk0NTQ0YTA5ODhjZWMxZmQ5NWNhNjVjL3RhYmxlcmFuZ2U6MGY5NmRiODg1OTQ1NDRhMDk4OGNlYzFmZDk1Y2E2NWNfMi0zLTEtMS0xMTEzNjg_97174269-4f15-4bd6-90b2-f4b14cdfa938">11,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39c75d8b324e44f0a7e6fb8cd3fed694_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RhYmxlOjBmOTZkYjg4NTk0NTQ0YTA5ODhjZWMxZmQ5NWNhNjVjL3RhYmxlcmFuZ2U6MGY5NmRiODg1OTQ1NDRhMDk4OGNlYzFmZDk1Y2E2NWNfMy0xLTEtMS0xMTEzNjg_bbb5a9a4-17ac-4dcd-b2c4-6626e8ee2ba5">23,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ba4c67d69f48759c03fa13464eae2a_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RhYmxlOjBmOTZkYjg4NTk0NTQ0YTA5ODhjZWMxZmQ5NWNhNjVjL3RhYmxlcmFuZ2U6MGY5NmRiODg1OTQ1NDRhMDk4OGNlYzFmZDk1Y2E2NWNfMy0zLTEtMS0xMTEzNjg_9b55faad-bac3-4756-9c38-751f54271269">17,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RhYmxlOjBmOTZkYjg4NTk0NTQ0YTA5ODhjZWMxZmQ5NWNhNjVjL3RhYmxlcmFuZ2U6MGY5NmRiODg1OTQ1NDRhMDk4OGNlYzFmZDk1Y2E2NWNfNC0xLTEtMS0xMTEzNjg_6f10852d-27da-4f8b-ac8c-d5222f83985b">39,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RhYmxlOjBmOTZkYjg4NTk0NTQ0YTA5ODhjZWMxZmQ5NWNhNjVjL3RhYmxlcmFuZ2U6MGY5NmRiODg1OTQ1NDRhMDk4OGNlYzFmZDk1Y2E2NWNfNC0zLTEtMS0xMTEzNjg_55e3ff67-5d05-4f73-8db3-ab6c4a9a5722">29,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i90e340589f97408ea2365d8948df4c38_76"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RleHRyZWdpb246ZjdkMWY0ODJhZDAxNDAwODg5YTk0NTYyYTZmYWFmNmVfMTI5MQ_c466dd98-eaa3-409d-a508-eff8da5f09a8" continuedAt="i44809840402249dca9aca8062116fb40" escape="true">NET LOSS PER COMMON SHARE</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i44809840402249dca9aca8062116fb40" continuedAt="i6a817e9e091645639e2c861dd79dc602">We compute basic net loss per common share by dividing net loss by the weighted-average number of common shares outstanding. We compute diluted net loss per common share by dividing net loss by the weighted-average number of common </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i6a817e9e091645639e2c861dd79dc602"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">shares and dilutive potential common share equivalents then outstanding during the period. In the diluted net loss per share calculation, net loss would be adjusted for the elimination of interest expense on the Convertible debt. Potential common shares consist of shares issuable upon the vesting of restricted stock units, the exercise of stock options (the proceeds of which are then assumed to have been used to repurchase outstanding shares using the treasury stock method) and upon conversion of the convertible debt outstanding during the period (calculated using the if-converted method assuming the conversion of the convertible debt as of the earliest period reported or at the date of issuance, if later). Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share.</span></div><ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RleHRyZWdpb246ZjdkMWY0ODJhZDAxNDAwODg5YTk0NTYyYTZmYWFmNmVfMTI5Mg_f1e20df9-b9c3-4ffb-8309-8d5912f4fcf9" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the potential common shares (prior to consideration of the treasury stock or if-converted methods) excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock, inclusive of performance-based stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16fefe33d0a84bbcb3bcfe4546c9b4d3_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfMi0xLTEtMS0xMTEzNjg_bed5260c-bbeb-49a8-bde7-b57b2e939b1f">8,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a1e6837336341aebaca13a642e99570_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfMi0zLTEtMS0xMTEzNjg_c3bcf4c4-3dbd-41e8-bf4d-dc7feb493ec6">12,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units, inclusive of performance-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e25f80d14ab4e29946dc7feeb321f9e_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfMy0xLTEtMS0xMTEzNjg_614f42e1-2592-48be-8d13-ada656b2778f">2,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9057d82ed2a40ea940df490edf962c1_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfMy0zLTEtMS0xMTEzNjg_d57a090e-0d11-4745-a89e-0cd5e331d94e">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i402e0e52c29f460db9f6c550106e1cf2_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfNC0xLTEtMS0xMTEzNjg_8ca0a2c8-7242-4de3-8156-21d5231bc420">3,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d2e5ef24f8743d687104b5084f27971_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfNC0zLTEtMS0xMTEzNjg_4c0db331-560d-4b2c-b704-1a46ae590747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfNS0xLTEtMS0xMTEzNjg_8f994c00-b1ba-45c2-8089-c78ba4709679">14,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfNS0zLTEtMS0xMTEzNjg_3767e0ec-1528-4755-beaf-ad314153d860">14,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i90e340589f97408ea2365d8948df4c38_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">13. <ix:nonNumeric contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83OS9mcmFnOmI3OWIyNzBhZDYxYTQ0OWI5MTdkNDE0Mjk0NDg2MGU5L3RleHRyZWdpb246Yjc5YjI3MGFkNjFhNDQ5YjkxN2Q0MTQyOTQ0ODYwZTlfNzUyOA_bdc450b5-460b-4651-b6f9-97b2ecb3d0bd" continuedAt="i5b2cf69dcf08440bb1659188f5f7e12e" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i5b2cf69dcf08440bb1659188f5f7e12e" continuedAt="i5575d04b9867418d9148ad2c8e01e550"><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Technology License and Other Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have licensed from third parties the rights to use certain technologies and information in our research processes as well as in any other products we may develop. In accordance with the related license or technology agreements, we are required to make certain fixed payments to the licensor or a designee of the licensor over various agreement terms. Many of these agreement terms are consistent with the remaining lives of the underlying intellectual property that we have licensed. As of March 31, 2023, our commitments over the next five years to make fixed and cancellable payments under existing license agreements were not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may be a party to litigation, arbitration or other legal proceedings in the course of our business, including the matters described below. The claims and legal proceedings in which we could be involved include challenges to the scope, validity or enforceability of patents relating to our products or product candidates, and challenges by us to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents or breach our license or other agreements with such third parties. The outcome of any such legal proceedings, regardless of the merits, is inherently uncertain. In addition, litigation and related matters are costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. If we were unable to prevail in any such legal proceedings, our business, results of operations, liquidity and financial condition could be adversely affected. Our accounting policy for accrual of legal costs is to recognize such expenses as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Government Investigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have previously disclosed that, on or about April 9, 2021, we received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of Massachusetts, requiring production of documents pertaining to our marketing and promotion of ONPATTRO (patisiran) in the U.S. We are cooperating with the U.S. Attorney&#8217;s Office and producing documents in response to the subpoena. Current and former officers and employees also have received subpoenas in connection with the preservation and production of related materials. Given the ongoing nature of the investigation, it is possible that the U.S. Attorney&#8217;s Office for the District of Massachusetts or other government entities may request other information from, or issue other subpoenas, findings or similar documents to, us, our related entities and their respective directors, officers and employees. In light of the ongoing nature of the investigation, no determination has been made that a loss, if any, arising from this matter is probable or that the amount of any such loss, or range of loss, is reasonably estimable. We also previously disclosed that since learning of this federal government investigation, our nominating and corporate governance committee is directing our review of and response to the matter.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Patent Infringement Lawsuits</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022, we filed separate lawsuits in the U.S. District Court for the District of Delaware against (1) Pfizer, Inc. and its subsidiary Pharmacia &amp; Upjohn Co. LLC, collectively referred to as Pfizer, and (2) Moderna, Inc., and its subsidiaries </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i5575d04b9867418d9148ad2c8e01e550"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ModernaTX, Inc., and Moderna US, Inc., collectively referred to as Moderna. The lawsuits seek damages for infringement of U.S. Patent No. 11,246,933, or &#8216;933 Patent, in Pfizer&#8217;s and Moderna&#8217;s manufacture and sale of their messenger RNA, or mRNA, COVID-19 vaccines. The patent relates to the Company&#8217;s biodegradable cationic lipids that are foundational to the success of the mRNA COVID-19 vaccines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are seeking judgment that each of Pfizer and Moderna is infringing the &#8216;933 Patent, as well as damages adequate to compensate for the infringement, but in no event less than a reasonable royalty for the unlicensed uses made of our patented lipids by Pfizer and Moderna, together with interest and costs as may be awarded by the court. As stated in the filed complaints, we are not seeking injunctive relief in these lawsuits.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 23, 2022, Moderna filed a partial motion to dismiss, asserting an affirmative defense under Section 1498(a). We responded on May 27, 2022, opposing their motion arguing Moderna had significant non-government sales and the government contract ended in April 2022. Moderna responded on June 13, 2022, requesting a partial motion to dismiss those claims for sales under 1498(a).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 27, 2022, Pfizer filed an answer to our complaint, denying the allegations, and asserting invalidity and non-infringement defenses. In addition, Pfizer added BioNTech SE to the suit and added counter-claims seeking a declaratory judgment that our patent is invalid and a second claim alleging that our patent is invalid due to patent misuse. We believe their defenses and counter-claims have no merit and responded on June 10, 2022, with substantive arguments as to the validity of our claims and the lack of merit of their patent misuse claim.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 12, 2022, we filed a new lawsuit against each of Pfizer and Moderna seeking damages for infringing our newly granted U.S. Patent No. 11,382,979 in Pfizer&#8217;s and Moderna&#8217;s manufacture and sale of their mRNA COVID-19 vaccines. The parties agreed to combine the two patents in one lawsuit, separately against each of Moderna and Pfizer/BioNTech.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 8, 2023, we received notification from the U.S. Patent Office that a third patent would issue on February 28, 2023, as U.S. Patent No. 11,590,229, which we also believe Pfizer and Moderna&#8217;s COVID-19 vaccines infringe upon. On February 15, 2023, we filed a motion with the court to add this patent to the existing cases against Pfizer and Moderna.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 26, 2023, the court held a hearing and denied Moderna&#8217;s partial motion to dismiss those claims for sales under 1498(2), our motion to add the 11,590,229 patent to the current lawsuits as well as a motion filed by Moderna to add certain invalidity arguments made by Pfizer in our case to supplement Moderna&#8217;s invalidity arguments previously made.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The court has set a trial date of November 12, 2024, for Alnylam v. Moderna and November 18, 2024, for Alnylam v. Pfizer/BioNTech.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Indemnifications</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with license agreements we may enter with companies to obtain rights to intellectual property, we may be required to indemnify such companies for certain damages arising in connection with the intellectual property rights licensed under the agreements. Under such agreements, we may be responsible for paying the costs of any litigation relating to the license agreements or the underlying intellectual property rights, including the costs associated with certain litigation regarding the licensed intellectual property. We are also a party to a number of agreements entered into in the ordinary course of business, which contain typical provisions that obligate us to indemnify the other parties to such agreements upon the occurrence of certain events, including litigation or other legal proceedings. In addition, we have agreed to indemnify our officers and directors for expenses, judgments, fines, penalties, excise taxes, and settlement amounts paid in connection with any threatened, pending or completed litigation proceedings, including, for example, the current government investigation, in which an officer or director was, is or will be involved as a party, on account of such person&#8217;s status as an officer or director, or by reason of any action taken by the officer or director while acting in such capacity, subject to certain limitations. These indemnification costs are charged to selling, general and administrative expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our maximum potential future liability under any such indemnification provisions is uncertain. We have determined that the estimated aggregate fair value of our potential liabilities under all such indemnification provisions is minimal and had not recorded any liability related to such indemnification provisions as of March 31, 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i90e340589f97408ea2365d8948df4c38_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="i90e340589f97408ea2365d8948df4c38_85"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have developed a new class of innovative medicines, known as RNAi therapeutics. RNAi therapeutics are comprised of small interfering RNA, or siRNA, and function upstream of conventional medicines by potently silencing messenger RNA, or mRNA, that encode for proteins implicated in the cause or pathway of disease, thus preventing them from being made. We believe this is a revolutionary approach with the potential to transform the care of patients with rare and prevalent diseases. To date, our efforts to advance this revolutionary approach have yielded the approval of five first-in-class RNAi-based medicines, ONPATTRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (patisiran), AMVUTTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (vutrisiran), GIVLAARI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (givosiran), OXLUMO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (lumasiran) and Leqvio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (inclisiran).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research and development strategy is to target genetically validated genes that have been implicated in the cause or pathway of human disease. We utilize a N-acetylgalactosamine (GalNAc) conjugate approach or lipid nanoparticle (LNP) to enable hepatic delivery of siRNAs. For delivery to the central nervous system, or CNS, and the eye (ocular delivery), we are utilizing an alternative conjugate approach based on a hexadecyl (C16) moiety as a lipophilic ligand. We are also advancing approaches for heart, skeletal muscle and adipose tissue delivery of siRNAs. Our focus is on clinical indications where there is a high unmet need, a genetically validated target, early biomarkers for the assessment of clinical activity in Phase 1 clinical studies, and a definable path for drug development, regulatory approval, patient access and commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> strategy, which focuses on our planned transition to a top-tier biotech company, as measured by market capitalization, by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, while delivering exceptional financial performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have five marketed products and more than ten clinical programs, including several in late-stage development, across four Strategic Therapeutic Areas, or &#8220;STArs:&#8221; Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases.&#160;Four of our marketed products are within the Genetic Medicines STAr, ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ONPATTRO is approved by the United States Food and Drug Administration, or the FDA, for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or hATTR amyloidosis, in adults and has also been approved in the European Union, or EU, for the treatment of hATTR amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, in Japan for the treatment of transthyretin, or TTR, type familial amyloidosis with polyneuropathy, and in multiple additional countries, including Brazil. In August 2022, we reported positive results from the APOLLO-B Phase 3 study of patisiran (the non-branded name of ONPATTRO) in patients with transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy, and in December 2022, we submitted a supplemental New Drug Application, or sNDA, to the FDA for ONPATTRO as a potential treatment of the cardiomyopathy of ATTR amyloidosis. In February 2023, the FDA accepted the sNDA for filing and set an action date of October 8, 2023 under the Prescription Drug User Fee Act, or PDUFA. The FDA also indicated in the sNDA filing communication letter that it is planning to hold an advisory committee meeting to discuss the application and that it had not identified any potential review issues at such time. In March, 2023, we submitted an sNDA to the Brazilian Health Regulatory Agency (ANVISA) for ONPATTRO for the treatment of the cardiomyopathy of ATTR amyloidosis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMVUTTRA is approved in the U.S. for the treatment of the polyneuropathy of hATTR amyloidosis in adults. In September 2022, AMVUTTRA was granted marketing authorization in Europe and the United Kingdom, or UK, for the treatment of hATTR amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, and in Japan for the treatment of TTR type familial amyloidosis with polyneuropathy. In December 2022, AMVUTTRA was approved in Brazil for the treatment of hATTR amyloidosis in adults. Regulatory filings in other territories are currently under review and additional filings are pending or planned during 2023 and beyond.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GIVLAARI is approved in the U.S. for the treatment of adults with acute hepatic porphyria, or AHP, in the EU for the treatment of AHP in adults and adolescents aged 12 years and older, and in several additional countries, including Brazil, Canada, Switzerland and Japan. Regulatory filings for givosiran (the non-branded drug name for GIVLAARI) in other territories are pending or planned during 2023 and beyond. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">OXLUMO is approved in the U.S. and EU for the treatment of primary hyperoxaluria type 1, or PH1, in all age groups, and in several additional countries including Brazil and Switzerland. In October 2022, we announced that the FDA approved our sNDA for lumasiran (the non-branded drug name for OXLUMO), for the treatment of PH1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients. Regulatory filings in other territories are pending and additional filings are planned during 2023 and beyond. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our fifth product, Leqvio (inclisiran), is in the Cardio-Metabolic Diseases STAr. Leqvio is being developed and commercialized by our partner Novartis AG, or Novartis, and has received marketing authorization from the European </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commission, or EC, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia and from the FDA as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia, or HeFH, or clinical atherosclerotic cardiovascular disease, or ASCVD, who require additional lowering of LDL-C. As of the end of March 2023, Leqvio has been approved in more than 75 countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to our marketed products, we have multiple late-stage investigational programs advancing toward potential commercialization. These programs include our wholly owned programs: patisiran (the non-branded drug name for ONPATTRO) for the treatment of ATTR amyloidosis, (wild-type or hereditary) with cardiomyopathy; vutrisiran (the non-branded drug name for AMVUTTRA) for the treatment of ATTR (wild-type or hereditary) amyloidosis with cardiomyopathy; as well as fitusiran for the treatment of hemophilia, which is being advanced by our partner Genzyme Corporation, a Sanofi Company, or Sanofi; and cemdisiran for the treatment of complement-mediated diseases, where our partner Regeneron Pharmaceuticals, Inc., or Regeneron, is advancing cemdisiran in combination with pozelimab in Phase 3 studies in myasthenia gravis and paroxysmal nocturnal hemoglobinuria.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, we have multiple drivers of future growth, including the development of transformative prevalent disease medicines. In addition to Leqvio, we are advancing zilebesiran, an investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen, or AGT, in development for the treatment of hypertension. In November 2021, we reported positive interim data from the ongoing Phase 1 study of zilebesiran, and initiated the KARDIA Phase 2 clinical studies for zilebesiran. KARDIA-1 is designed to evaluate zilebesiran as a monotherapy across different doses administered quarterly and biannually. KARDIA-2 will evaluate the safety and efficacy of zilebesiran administered biannually as a concomitant therapy in patients whose blood pressure is not adequately controlled by a standard of care antihypertensive medication. Topline results from the KARDIA-1 and KARDIA-2 Phase 2 studies are anticipated in mid-2023 and at or around year-end 2023, respectively. We are also advancing ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein in development for the treatment of Alzheimer&#8217;s disease and cerebral amyloid angiopathy. In April 2023, we reported positive interim results from the ongoing single ascending dose part of the Phase 1 study of ALN-APP in patients with early-onset Alzheimer&#8217;s disease. These results establish the first human translation of our proprietary C16-siRNA conjugate platform for CNS delivery and are the first clinical demonstration of gene silencing in the human brain using an RNAi therapeutic.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In further support of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy and in view of our evolving risk profile, we remain focused on the continued evolution of our global infrastructure, including key objectives such as optimizing our global structure for execution in key markets, enhancing performance consistent with our values, and continuing to strengthen our culture. We maintain focus on our global compliance program to drive its evolution and enhancement in view of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 strategy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Building from our global Code of Business Conduct and Ethics, our compliance program is designed to empower our employees and those with whom we work to execute on our strategy consistent with our values and in compliance with applicable laws and regulations, and to mitigate risk. Comprised of components such as risk assessment and monitoring; policies, procedures, and guidance; training and communications; dedicated resources; and systems and processes supporting activities such as third party relationships and investigations and remediation; our program and related controls are built to enhance our business processes, structures, and controls across our global operations, and to empower ethical decision making.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our expertise in RNAi therapeutics and broad intellectual property estate, we have formed alliances with leading pharmaceutical and life sciences companies to support our development and commercialization efforts, including Regeneron, Novartis (which acquired our partner The Medicines Company, or MDCO, in 2020), Sanofi, Vir Biotechnology, Inc., or Vir, Dicerna Pharmaceuticals, Inc. (acquired by Novo Nordisk A/S, or Novo Nordisk, in December 2021), or Dicerna, and PeptiDream, Inc., or PeptiDream.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred significant losses since we commenced operations in 2002 and as of March&#160;31, 2023, we had an accumulated deficit of $6.74&#160;billion. Historically, we have generated losses principally from costs associated with research and development activities, acquiring, filing and expanding intellectual property rights, and selling, general and administrative costs. As a result of planned expenditures for research and development activities relating to our research platform, our drug development programs, including clinical trial and manufacturing costs, the establishment of late-stage clinical and commercial capabilities, including global commercial operations, continued management and growth of our patent portfolio, collaborations and general corporate activities, we expect to incur additional operating losses, however we expect 2019 represents our peak operating loss year as we transition towards a self-sustainable financial profile. We anticipate that our operating results will continue to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have programs focused on a number of therapeutic areas and, as of March 31, 2023, we generate worldwide product revenues from four commercialized products, ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO, primarily in the U.S., Europe and Japan. However, our ongoing development efforts may not be successful and we may not be able to commence sales of any other products and/or successfully market and sell our approved products or any other products approved in the future. A portion of our total revenues in recent years has been derived from collaboration revenues from strategic alliances with Regeneron, Vir and Novartis. In addition to revenues from the commercial sales of our approved products and potentially from sales of future products, we expect our sources of potential funding for the next several years to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">continue to be derived in part from existing and new strategic alliances. Such alliances include, or may include in the future, license and other fees, funded research and development, milestone payments and royalties on product sales by our licensors, including royalties on sales of Leqvio made by our partner Novartis, as well as proceeds from the sale of equity or debt.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2022, we issued $1.04 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2027, or Notes. The Notes will mature on September 15, 2027, unless earlier converted, redeemed or repurchased. Before June 15, 2027, noteholders will have the right to convert their Notes in certain circumstances and during specified periods. From and after June 15, 2027, the Notes will be convertible at the option of the noteholders at any time prior to the close of business on the second scheduled trading day immediately preceding the maturity date. We will settle any conversions of Notes by paying or delivering, as applicable, cash shares of our common stock, par value $0.01 per share, or Common Stock, or a combination of cash and shares of Common Stock, at our election.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the issuance of the Notes, we paid $118.6 million, including expenses, to enter into privately negotiated capped call transactions with certain initial purchasers of the Notes or their respective affiliates and certain other financial institutions, or capped call transactions. The capped call transactions are expected generally to reduce the potential dilution upon conversion of the Notes in the event that the market price per share of our common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which initially corresponds to the conversion price of the Notes, and is subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the Notes. The cap price of the capped call transactions will initially be $424.00 per share, which represents a premium of approximately 100% based on the last reported sale price of our common stock of $212.00 per share on September 12, 2022, and is subject to certain adjustments under the terms of the capped call transactions. If, however, the market price per share of our common stock, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless be dilution upon conversion of the Notes to the extent that such market price exceeds the cap price of the capped call transactions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We used approximately $762.0 million of the net proceeds from the offering of the Notes to repay borrowings, inclusive of prepayment premiums, under our credit agreement with Blackstone, and we intend to use the remainder of the net proceeds for general corporate purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since our inception, we have focused on drug discovery and development programs. Research and development expenses represent a substantial percentage of our total operating expenses, as reflected by our broad pipeline of clinical development programs, which includes multiple programs in late-stage development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Our Product Pipeline</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our broad pipeline, including five approved products and multiple late and early-stage investigational RNAi therapeutics, is focused in four STArs: Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The chart below is a summary of our commercial products and late- and early-stage development programs as of April 2023. It identifies those programs for which we have received marketing approval, the stage of our programs and our commercial rights to such programs:</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><img src="alny-20230331_g1.jpg" alt="Pipeline Chart.jpg" style="height:421px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the first quarter of 2023 and recent period, we reported the following updates from our commercially approved products and our late-stage clinical programs:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total TTR: ONPATTRO &amp; AMVUTTRA</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We achieved global net product revenues for ONPATTRO and AMVUTTRA for the first quarter of 2023 of $102.5 million and $101.8 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total Ultra-Rare: GIVLAARI &amp; OXLUMO</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We achieved global net product revenues for GIVLAARI and OXLUMO for the first quarter of 2023 of $47.9 million and $24.2 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Leqvio</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our partner, Novartis, continued the launch of Leqvio in the U.S. and in other markets, with focus on patient on-boarding, removing access hurdles and enhancing medical education. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Late-Stage Clinical Development</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We continued to advance patisiran, in development for the treatment of ATTR amyloidosis:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Submitted 18-month data from the APOLLO-B Phase 3 study to the U.S. FDA as part of the sNDA review for ONPATTRO (patisiran) for the treatment of the cardiomyopathy of ATTR amyloidosis.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our partner, Sanofi, announced results from ATLAS-INH and ATLAS-A/B Phase 3 studies of fitusiran were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Lancet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Lancet Haematology.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our partner, Regeneron, announced that it has initiated a Phase 2 study of ALN-HSD in patients with NASH.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is a risk that any drug discovery or development program may not produce revenue for a variety of reasons, including the possibility that we will not be able to adequately demonstrate the safety and effectiveness of the product candidate or obtain approval or the desired labeling for the product candidate from regulatory authorities. Moreover, there are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">uncertainties specific to any new field of drug discovery, including RNAi. The success of ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO or any other product candidate we develop is highly uncertain. Due to the numerous risks associated with developing drugs, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts necessary to complete the development of any potential product candidate or indication, or the period, if any, in which material net cash inflows will commence from any approved product or indication. Any failure to complete any stage of the development of any potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline, or at all, and the potential consequences of failing to do so, are set forth in Part&#160;II, Item&#160;1A below under the heading &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Strategic Alliances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business strategy is to develop and commercialize a broad pipeline of RNAi therapeutic products directed towards our four STArs. As part of this strategy, we have entered into, and expect to enter into additional, collaboration and licensing agreements as a means of obtaining resources, capabilities and funding to advance our investigational RNAi therapeutic programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our collaboration strategy is to form alliances that create significant value for ourselves and our collaborators in the advancement of RNAi therapeutics as a new class of innovative medicines. Specifically, with respect to our CNS/Ocular Disease pipeline, in April 2019, we entered into a global, strategic collaboration with Regeneron to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and CNS, in addition to a select number of targets expressed in the liver. In July 2020, Regeneron exercised its co-development/co-commercialization option on our first CNS-targeted development candidate, ALN-APP, an investigational RNAi therapeutic in development for the treatment of hereditary cerebral amyloid angiopathy and autosomal dominant Alzheimer&#8217;s Disease, which we are leading. We are also advancing multiple other programs with Regeneron. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to our Cardio-Metabolic pipeline, in March 2013, we entered into an exclusive, worldwide license with MDCO (acquired by Novartis AG in January 2020) pursuant to which MDCO was granted the right to develop, manufacture and commercialize RNAi therapeutics targeting proprotein convertase subtilisin/kexin type 9 for the treatment of hypercholesterolemia and other human diseases, including inclisiran. In March 2018, we entered into a discovery collaboration with Regeneron to identify RNAi therapeutics for nonalcoholic steatohepatitis, or NASH, and potentially other related diseases, and in November 2018, we and Regeneron entered into a separate, fifty-fifty collaboration to further research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts. In April 2020, we entered into a development and commercialization collaboration with Dicerna to advance investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, or alpha-1 liver disease.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to our Hepatic Infectious Disease pipeline, in October 2017, we announced an exclusive licensing agreement with Vir for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic HBV infection. In March 2020, we announced an expansion of our exclusive licensing agreement with Vir to include the development and commercialization of RNAi therapeutics targeting SARS-CoV-2, the virus that causes the disease COVID-19, which we further expanded in April 2020 to include up to three additional targets focused on host factors for SARS-CoV-2, including angiotensin converting enzyme-2, and transmembrane protease, serine 2, and potentially a third mutually selected host factor target. In July 2021, we notified Vir that we elected to discontinue ALN-COV, in development for the treatment of COVID-19, and all other COVID-19 research and development activities, based on a portfolio prioritization in view of the availability of highly effective vaccines and alternative treatment options. Following such discontinuation of COVID-19 related activities, we have no further obligations to work on the COVID-related targets and Vir has no further rights to such targets under our exclusive licensing agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to our Genetic Medicine pipeline, we formed a broad strategic alliance with Sanofi in 2014. In January 2018, we and Sanofi amended our 2014 collaboration and entered into the Exclusive License Agreement, referred to as the Exclusive TTR License, under which we have the exclusive right to pursue the further global development and commercialization of all TTR products, including ONPATTRO, AMVUTTRA and any back-up products, and the ALN-AT3 Global License Terms, referred to as the AT3 License Terms, under which Sanofi has the exclusive right to pursue the further global development and commercialization of fitusiran and any back-up products. In April 2019, we and Sanofi agreed to further amend the 2014 Sanofi collaboration to conclude the research and option phase and to amend and restate the AT3 License Terms to modify certain of the business terms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to continue to evaluate and explore partnership opportunities through collaboration and licensing arrangements, and may enter into new collaborations to advance certain products or disease areas. For example, in January 2022, we announced that we and Novartis agreed to collaborate on the discovery and development of an siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver diseases.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have entered into license agreements to obtain rights to intellectual property in the field of RNAi. In addition, because delivery of RNAi therapeutics has historically been an important objective of our research activities, we have entered </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">into various collaboration and licensing arrangements with other companies and academic institutions to gain access to delivery technologies, including various LNP delivery technologies, and we may enter into such agreements in the future to gain access to products or technologies. For example, in 2021, we entered into a license and collaboration agreement with PeptiDream to discover and develop peptide-siRNA conjugates leveraging PeptiDream's proprietary Peptide Discovery Platform System technology.</span></div><div id="i90e340589f97408ea2365d8948df4c38_88"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our critical accounting policies are described in the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of our Annual Report on Form 10-K for the year ended December&#160;31, 2022, which we filed with the SEC on February 23, 2023.&#160;There have been no significant changes to our critical accounting policies since the beginning of this fiscal year.</span></div><div id="i90e340589f97408ea2365d8948df4c38_91"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following data summarizes the results of our operations:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.251%"><tr><td style="width:1.0%"></td><td style="width:34.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.470%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs and expenses</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Discussion of Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total revenues consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.175%"><tr><td style="width:1.0%"></td><td style="width:37.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.862%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues from collaborations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,290&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Product Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net product revenues consist of the following, by product and region:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.497%"><tr><td style="width:1.0%"></td><td style="width:33.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.860%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ONPATTRO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,523)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,516)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMVUTTRA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GIVLAARI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OXLUMO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,328&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net product revenues increased during the three months ended March&#160;31, 2023, compared to the same period in 2022, primarily due to the U.S. launch of AMVUTTRA in the third quarter of 2022, partially offset by a decrease of demand for ONPATTRO due to patient switches to AMVUTTRA. Additional growth was provided by an increase in patients on GIVLAARI and OXLUMO therapies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect net product revenues to increase during 2023, as compared to 2022, as we continue to add new patients onto our commercial products, as well as launch these products into additional markets, assuming regulatory approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Revenues from Collaborations and Royalty Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net revenues from collaborations consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.988%"><tr><td style="width:1.0%"></td><td style="width:37.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.110%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,462&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,945&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net revenues from collaborations increased during the three months ended March&#160;31, 2023, as compared to the same period in 2022, primarily due to an increase in revenue recognized in connection with our collaboration agreement with Regeneron, attributed to an increase in reimbursable activities under our research services arrangement in addition to an increase in revenue recognized associated with our licensed programs within the collaboration.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Royalty revenue increased during the three months ended March&#160;31, 2023, as compared to the same period in 2022, due to increased royalties received from global net sales of Leqvio by our partner, Novartis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Recognition of our combined net revenues from collaborations and royalty revenue is dependent on a variety of factors including the level of work reimbursed by partners, achievement of milestones under our collaboration agreements, and royalties associated with sales of Leqvio. We expect variability in net revenues from collaboration and royalty revenue in 2023, as compared to 2022, due to the timing of manufacturing activities, achievement of milestones under our collaboration agreements, and royalties associated with sales of Leqvio.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Costs and Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating costs and expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.830%"><tr><td style="width:1.0%"></td><td style="width:41.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.169%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cost of goods sold as a percentage of net product revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaborations and royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of goods sold</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of goods sold as a percentage of net product revenues increased during the three months ended March&#160;31, 2023, as compared to the same period in 2022, primarily due to increased royalties due to third-parties driven by the increase in sales of AMVUTTRA partially offset by lower manufacturing costs for AMVUTTRA compared with ONPATTRO.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect cost of goods sold and cost of goods sold as a percentage of net product revenues will increase during 2023, as compared to 2022, primarily as a result of an expected increase in total net product sales as well as increased AMVUTTRA royalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of collaborations and royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of collaborations and royalties increased during the three months ended March&#160;31, 2023, as compared to the same period in 2022, primarily due to timing and demand of GalNAc material supply to our collaboration partners to support certain product manufacturing and ongoing clinical trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We anticipate variability in the cost of collaborations and royalties during 2023, as compared to 2022, due to the timing and demand of GalNAc material to be supplied to our collaboration partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"><tr><td style="width:1.0%"></td><td style="width:40.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical research and outside services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy and all other costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March&#160;31, 2023, the increase in research and development expenses, as compared to the same period in 2022, was primarily due to the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased clinical research and outside services associated with the APOLLO-B (patisiran), HELIOS-B (vutrisiran), and KARDIA-1/KARDIA-2 (zilebesiran) clinical studies, and manufacturing related expenses associated with our pre-clinical activities; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased compensation and related expenses as a result of increased headcount to support our R&amp;D pipeline and development expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2023 and 2022, in connection with advancing activities under our collaboration agreements, we incurred research and development expenses, primarily related to external development and clinical expenses, including the manufacture of clinical product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes research and development expenses incurred, for which we recognize net revenue, that are directly attributable to our collaboration agreements, by collaboration partner:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"><tr><td style="width:1.0%"></td><td style="width:48.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,917&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Selling, general and administrative</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Selling, general and administrative expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"></td><td style="width:39.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.356%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy and all other costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March&#160;31, 2023, the increase in selling, general and administrative expenses, as compared to the same period in 2022, was primarily due to increased compensation and related expenses as a result of increased headcount and other strategic investments in support of the global launch of AMVUTTRA and other expenses to support our strategic growth.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that research and development expenses combined with selling, general and administrative expenses will increase during 2023, as compared to 2022, as we continue to advance and develop our platform and pipeline, advance our product candidates, including partnered programs, into later-stage development, prepare regulatory submissions and continue to build-out our global commercial and compliance infrastructure and field team to support our commercial portfolio as well as launch our commercial products into additional markets, assuming regulatory approvals. However, we expect that certain expenses will be variable depending on the timing of manufacturing batches, clinical trial enrollment and results, regulatory review of our product candidates and programs, and stock-based compensation expenses due to our determination regarding the probability of vesting for performance-based awards.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other (Expense) Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other (expense) income consists of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:58.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.503%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,955)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized losses on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,555)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,624)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total other expense decreased during the three months ended March&#160;31, 2023, as compared to the same period in 2022, primarily due to the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Decreased realized and unrealized losses on our marketable equity securities holdings; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Decreased interest expense as a result of a more favorable interest rate under the Notes compared with the interest rate under the credit facility held with Blackstone as executed and extinguished in September 2022, respectively; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased interest income driven by higher market interest rates on our marketable debt securities.</span></div><div id="i90e340589f97408ea2365d8948df4c38_94"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes our cash flow activities:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,475)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities decreased during the three months ended March&#160;31, 2023, compared to the same period ended 2022, primarily due to decreased cash disbursements related to working capital payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Investing activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in investing activities decreased during the three months ended March&#160;31, 2023, compared to the same period ended 2022, primarily due to net activities related to our marketable debt securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financing activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by financing activities increased during the three months ended March&#160;31, 2023, compared to the same period ended 2022, primarily due to increased net proceeds from the issuance of common stock in connection with stock option exercises and other types of equity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Additional Capital Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have programs focused on a number of therapeutic areas and, as of March&#160;31, 2023, have received regulatory approval and commercially launched four products. However, our ongoing development efforts may not be successful and we may not be able to commence sales of any other products or successfully expand the indications for our approved products, including ONPATTRO and AMVUTTRA in the future. In addition, we anticipate that we will continue to generate losses as a result of planned expenditures for research and development activities relating to our research platform, our drug development programs, including clinical trial and manufacturing costs, the establishment of late-stage clinical, manufacturing, commercial and compliance capabilities, including global operations, continued management and growth of our intellectual property including our patent portfolio, collaborations and general corporate activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our expected working and other capital requirements are described in our 2022 Annual Report on Form 10-K in &#8220;Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; As of March&#160;31, 2023, other than the changes disclosed in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; and &#8220;Liquidity and Capital </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Resources&#8221; section in this Quarterly Report on Form 10-Q, there have been no other material changes to our expected working and other capital requirements as described in our 2022 Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our current operating plan, we believe that our cash, cash equivalents and marketable equity and debt securities as of March&#160;31, 2023, together with the cash we expect to generate from product sales and under our current alliances, will be sufficient to satisfy our near-term capital and operating needs for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q. However, due to numerous factors described in more detail under the caption Part II, Item 1A, "Risk Factors" of this Quarterly Report on Form 10-Q, we may require significant additional funds earlier than we currently expect in order to continue to commercialize our approved products, and to develop, conduct clinical trials for, manufacture and, if approved, commercialize additional product candidates.</span></div><div id="i90e340589f97408ea2365d8948df4c38_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial market risks related to interest rates are described in our Annual Report on Form 10-K for the year ended December&#160;31, 2022. As of March&#160;31, 2023, there have been no significant changes to the financial market risks described as of December&#160;31, 2022. We do not currently anticipate any other near-term changes in the nature of our financial market risk exposures or in management&#8217;s objectives and strategies with respect to managing such exposures.</span></div><div id="i90e340589f97408ea2365d8948df4c38_100"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management, with the participation of our Chief Executive Officer (principal executive officer) and executive vice president, Chief Financial Officer (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31, 2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&#160;31, 2023, our Chief Executive Officer and executive vice president, Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Changes in Internal Control</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no changes in our internal control over financial reporting during the quarter ended March&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i90e340589f97408ea2365d8948df4c38_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART II. OTHER INFORMATION</span></div><div id="i90e340589f97408ea2365d8948df4c38_106"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a discussion of material pending legal proceedings, please read Note 13, Commitments and Contingencies, to our condensed consolidated financial statements included in Part I, Item I, &#8220;Financial Statements (Unaudited),&#8221; of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.</span></div><div id="i90e340589f97408ea2365d8948df4c38_109"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ITEM&#160;1A. RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">We operate in an environment that involves a number of significant risks and uncertainties. We caution you to read the following risk factors, which have affected, and/or in the future could affect, our business, prospects, operating results, and financial condition. The risks described below include forward-looking statements, and actual events and our actual results may differ materially from these forward-looking statements. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also impair our business, prospects, operating results, and financial condition. Furthermore, additional risks and uncertainties are described under other captions in this report and should also be considered by our investors.</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SUMMARY OF MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is subject to numerous risks and uncertainties, discussed in more detail in the following section. These risks include, among others, the following key risks:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business Related Risks &#8211; Risks Related to Our Financial Results</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The marketing and sale of our approved products or any future products may be unsuccessful or less successful than anticipated and we may be unable to expand the indications for ONPATTRO and AMVUTTRA.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have a history of losses and may never become and remain consistently profitable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We will require substantial funds to continue our research, development and commercialization activities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The COVID-19 pandemic and its variants and the future outbreak of other highly infectious or contagious diseases, may directly or indirectly adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Although we sold a portion of the expected royalty stream and commercial milestones related to global sales of Leqvio by Novartis, we are entitled to retain the remaining portion of such future royalties and, if certain specified thresholds are met, to the remaining portion of commercial milestone payments, and any negative developments related to Leqvio could have a material adverse effect on the timing or amount of those payments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may not be able to execute our business strategy if we are unable to maintain existing or enter into new alliances with other companies that can provide business and scientific capabilities and funds for the development and commercialization of certain of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If any collaborator materially amends, terminates or fails to perform its obligations under agreements with us, the development and commercialization of certain of our product candidates could be delayed or terminated and we could suffer other economic harm.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have limited manufacturing capabilities and resources, and we must incur significant costs to develop this expertise and/or rely on third parties to manufacture our products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We rely on third parties to conduct our clinical trials, and if they fail to fulfill their obligations, our development plans may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Managing Our Operations</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to attract and retain qualified key management and scientists, development, medical and commercial staff, consultants and advisors, our ability to implement our business plan may be adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may have difficulty expanding our operations successfully as we continue our evolution from a U.S.- and Europe-based company primarily involved in discovery, pre-clinical testing and clinical development into a global company that develops and commercializes multiple drugs in multiple geographies including Asia, Latin America and the Middle East.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Industry Related Risks &#8211; Risks Related to Development, Clinical Testing and Regulatory Approval of Our Product Candidates and the Commercialization of Our Approved Products</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Any product candidates we or our partners develop may fail in development or be delayed to a point where they do not become commercially viable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We or our partners may be unable to obtain U.S. or foreign regulatory approval for our or our partnered product candidates, or if approved, may fail to obtain desired labeling for such products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Even if we or our partners obtain regulatory approvals, our marketed drugs will be subject to ongoing regulatory oversight. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Even if we receive regulatory approval to market our product candidates, and our collaborators receive regulatory approval to market product candidates discovered by us or developed with our technology, the market may not be receptive to such product candidates upon their commercial introduction, which could prevent us from becoming profitable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are a multi-product commercial company and expect to continue to invest significant financial and management resources to continue to scale our marketing, sales, market access and distribution capabilities and further establish our global commercial and compliance infrastructure, and our commercial efforts may not be successful.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may incur significant liability if enforcement authorities allege or determine that we are engaging in commercial activities or promoting our commercially approved products in a way that violates applicable regulations, including in connection with the ongoing DOJ investigation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Patents, Licenses and Trade Secrets</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are not able to obtain and enforce patent protection for our discoveries, our ability to develop and commercialize our product candidates will be harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We license patent rights from third-party owners. If such owners do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, our competitive position and business prospects may be harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Other companies or organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we become involved in intellectual property litigation or other proceedings related to a determination of rights, including our ongoing patent infringement litigation against Pfizer, Inc., or Pfizer, and Moderna, Inc., we could incur substantial costs and expenses, and in the case of such litigation or proceedings against us, substantial liability for damages or be required to stop our product development and commercialization efforts.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we fail to comply with our obligations under any licenses or related agreements, we may be required to pay damages and could lose license or other rights that are necessary for developing, commercializing and protecting our RNAi technology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Competition</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The pharmaceutical market is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable to commercialize successfully any drugs that we or our collaborators develop.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We face competition from other companies that are working to develop novel drugs and technology platforms using technology similar to ours, as well as from companies utilizing emerging technologies, including gene therapy and gene editing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Common Stock</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If our stock price fluctuates, purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may incur significant costs from class action litigation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Future sales of shares of our common stock, including by our significant stockholders, us or our directors and officers, could cause the price of our common stock to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Convertible Notes </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Servicing our debt may require a significant amount of cash. We may not have sufficient cash flow from our business to pay our indebtedness.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may not have the ability to raise the funds necessary to settle for cash conversions of the Notes or to repurchase the Notes for cash upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion of the Notes or to repurchase the Notes. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Financial Results </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The marketing and sale of our approved products or any future products may be less successful than anticipated, and we may be unable to expand the indications for ONPATTRO and AMVUTTRA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, our first commercial product, ONPATTRO, was approved by the FDA and EMA, and we have since received approval and launched ONPATTRO in several additional territories. In 2019, the FDA approved our second product, GIVLAARI, which was also approved by the EMA and has since received approval in several additional territories, and in 2020, the FDA and EMA approved our third product, OXLUMO, which received additional regulatory approvals in 2021 and 2022. In June 2022, the FDA approved AMVUTTRA, which was granted marketing authorization in Europe and the UK in September 2022 and has since received regulatory approval in Japan and Brazil. We also have multiple product candidates in late-stage clinical development. While we have commercially launched four products, we cannot predict whether we will successfully market and sell our approved products, or successfully expand the indications of certain of our approved products. For example, in August and September 2022, we reported positive safety and efficacy results from the APOLLO-B Phase 3 clinical trial of patisiran, which was designed and powered to evaluate the effects of patisiran on functional capacity and quality of life in patients with ATTR amyloidosis with cardiomyopathy. While we believe that the APOLLO-B results after 12 months validate the therapeutic hypothesis of RNAi therapeutics targeting TTR as potential treatment for patients with ATTR amyloidosis with cardiomyopathy and submitted an sNDA to the FDA that was accepted for review in February 2023, we cannot be certain that the results from the APOLLO-B clinical trial will support regulatory approval of patisiran for the treatment of patients with ATTR amyloidosis with cardiomyopathy. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To execute our business plan of building a profitable, top-tier biotech company over the next 5 years and achieving our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> strategy and the metrics associated with such strategy, in addition to successfully marketing, selling and expanding the indications of our approved products, we will need to successfully:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">execute product development activities and continue to leverage new technologies related to both RNAi and to the delivery of siRNAs to the relevant tissues and cells, including the liver, CNS, eye, lung and muscle;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">build and maintain a strong intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">gain regulatory acceptance for the development and commercialization of our product candidates and market success for our approved products, as well as any other products we commercialize;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">attract and retain customers for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and maintain successful strategic alliances; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manage our spending as costs and expenses increase due to clinical trials, regulatory approvals and commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unsuccessful in accomplishing the objectives set forth above, we may not be able to develop product candidates, successfully commercialize our approved products or any future products, raise capital, if needed, repay our indebtedness, achieve financial self-sustainability or continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have a history of losses and may never become and remain consistently profitable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have experienced significant operating losses since our inception. As of March&#160;31, 2023, we had an accumulated deficit of $6.74 billion. Although to date we have launched four products in the U.S., EU and various other countries globally, and expect to launch our commercially approved products in additional countries during 2023 and beyond, we may never attain profitability or positive cash flow from operations. For the three months ended March&#160;31, 2023, we recognized $276.3&#160;million in net product revenues from sales of ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO. While we believe 2019 was our peak operating loss year, we expect to continue to incur annual operating losses, and will require substantial resources over the next several years as we expand our efforts to discover, develop and commercialize RNAi therapeutics, and aim to achieve self-sustainability by the end of 2025. While we believe our current cash, cash equivalents and marketable equity and debt securities, as well as the revenue we expect to generate from product sales and under our current alliances, including milestones and royalties on Leqvio sales, should enable us to achieve a self-sustainable profile without the need for future equity financing, we will depend on our ability to generate revenues to achieve this goal. In addition to revenues derived from sales of our current and future, if any, commercially approved products, we anticipate that a portion of any revenues we generate over the next several years will continue to be from alliances with pharmaceutical and biotechnology companies, including Novartis and Regeneron. We cannot be certain that we will be able to maintain our existing alliances, secure and maintain new alliances, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">meet the obligations, or achieve any milestones that we may be required to meet or achieve to receive payments under our existing or new alliances. Moreover, we cannot be certain that our partners, including Novartis, will continue to successfully execute their obligations under our alliance agreements and generate additional revenues for us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that to become and remain consistently profitable, we must succeed in discovering, developing and commercializing novel drugs with significant market potential. This will require us to build upon the success we have had in a range of challenging activities, including continued platform innovation, pre-clinical testing and clinical trial stages of development, obtaining regulatory approval and reimbursement for these novel drugs and manufacturing, marketing and selling them. We may never generate revenues that are significant enough to achieve profitability and, even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we cannot become and remain consistently profitable, the market price of our common stock could decline. In addition, we may be unable to raise capital, expand our business, develop additional product candidates or continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We will require substantial funds to continue our research, development and commercialization activities and if the funds we require are greater than what we have estimated, we may need to critically limit or significantly scale back or cease certain of our activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have used substantial funds to develop our RNAi technologies and will require substantial funds to conduct further research and development, including pre-clinical testing and clinical trials of our product candidates, and to manufacture, market and sell our four approved products and any other products that are approved for commercial sale. Because the length of time or activities associated with successful development of our product candidates, including zilebesiran, may be greater than we anticipate, we are unable to estimate the actual funds we will require to develop and commercialize them.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe 2019 was our peak operating loss year, and believe that our current cash, cash equivalents and marketable equity and debt securities, as well as revenue we expect to generate from product sales and under our current alliances, including milestones and royalties on Leqvio sales, will enable us to achieve a self-sustainable financial profile without need for future equity financing. However, our future capital requirements and the period for which we expect our existing resources to support our operations may vary from what we expect. We have based our expectations on a number of factors, many of which are difficult to predict or are outside of our control, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">progress in our research and development programs, including programs in both rare and prevalent diseases as well as what may be required by regulatory bodies to advance these programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing, receipt and amount of milestone and other payments, if any, from present and future collaborators, if any, including milestone payments related to Leqvio, which is being commercialized by our partner, Novartis;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to maintain and establish additional collaborative arrangements and/or new business initiatives;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the potential for improved product profiles to emerge from our new technologies and our ability to successfully advance our delivery efforts in extrahepatic tissues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the resources, time and costs required to successfully initiate and complete our pre-clinical and clinical studies, obtain regulatory approvals, prepare for global commercialization of our product candidates and obtain and maintain licenses to third-party intellectual property;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to establish, maintain and operate our own manufacturing facilities in a timely and cost-effective manner;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to manufacture, or contract with third parties for the manufacture of, our product candidates for clinical testing and commercial sale;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the impact of COVID-19 or the ongoing conflict in Ukraine on the initiation or completion of pre-clinical studies or clinical trials and the supply of our products or product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the resources, time and cost required for the preparation, filing, prosecution, maintenance and enforcement of patent claims;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the costs associated with legal activities, including litigation and government investigations, arising in the course of our business activities and our ability to prevail or reach a satisfactory result in any such legal disputes and investigations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing, receipt and amount of sales and royalties, if any, from our approved products and our potential products, if and when approved; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the outcome of the regulatory review process and commercial success of drug products for which we are entitled to receive royalties, including Leqvio.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our estimates, predictions and financial guidance relating to these factors are incorrect, we may need to modify our operating plan and may be required to seek additional funding in the future. We may do so through either collaborative </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">arrangements, public or private equity offerings or debt financings, royalty or other monetization transactions or a combination of one or more of these funding sources. Additional funds may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The terms of any financing we may be required to pursue in the future may adversely affect the holdings or the rights of our stockholders. If we raise additional funds by issuing equity securities, further dilution to our existing stockholders will result. In addition, as a condition to providing additional funding to us, future investors may demand, and may be granted, rights superior to those of existing stockholders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to obtain additional funding on a timely basis, we may be required to significantly delay or curtail one or more of our research or development programs, or delay or curtail the further development of our global commercial infrastructure, and our ability to achieve our long-term strategic goals may be delayed or diminished. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies, product candidates or products that we would otherwise pursue on our own.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The COVID-19 pandemic and its variants, and the future outbreak of other highly infectious or contagious diseases, may directly or indirectly adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ongoing COVID-19 pandemic continues to evolve and the ultimate impact of this pandemic remains uncertain. COVID-19 has and could continue to impact our operations and those of our third-party partners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In response to the spread of COVID-19, we took, and have continued to take, both temporary and ongoing precautionary measures, intended to help minimize the risk of the virus to our employees and their families, including implementing flexible work arrangements for nearly all employees who were able to perform their duties remotely. Working arrangements for many of our employees differ from the arrangements before the COVID-19 pandemic, and we expect a number of employees will continue to work in a remote capacity or a hybrid of in-person and remote work. Changes in flexible working arrangements could impact employee retention, employees' productivity and morale, and could strain our technology resources and introduce operational risks. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our move to a hybrid working environment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the future, we may experience disruptions from COVID-19 or a future pandemic that could impact our business and operations, including our ability to successfully commercialize our approved products, and we may not be able to meet expectations with respect to commercial sales as a result. In addition, we may also experience decreased patient demand for our approved products if current or potential patients decide to delay treatment as a result of the COVID-19 or a future pandemic. Business interruptions from the current or future pandemics, including staffing shortages, raw material or other supply chain shortages, production slowdowns and disruptions in delivery systems, may also adversely impact the third parties we or our partners rely on in the U.S. and abroad to sufficiently manufacture our approved products and to produce product candidates in quantities we require, which may impair our commercialization efforts, our research and development activities and the potential commercialization of our product candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, timely completion of pre-clinical activities and initiation of planned clinical trials are dependent upon the availability of, for example, pre-clinical and clinical trial sites, researchers and investigators, patients or healthy volunteer subjects available for recruitment and enrollment, and regulatory agency personnel, which may be adversely affected by global health matters, such as the ongoing COVID-19 pandemic. We are conducting and plan to continue to conduct pre-clinical activities and clinical trials for our drug product candidates in geographies which have been and may again be affected by COVID-19, and any resurgence of the COVID-19 pandemic and its variants could have an impact on various aspects of our ongoing clinical trials and on the clinical trials and pre-clinical studies we expect to initiate during 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Health regulatory agencies globally may also experience disruptions in their operations as a result of the COVID-19 pandemic or future public health emergencies, which could impact review, inspection and approval timelines. Since March 2020, when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume pre-pandemic levels of inspection activities, including routine surveillance, bioresearch monitoring and pre-approval inspections. Should the FDA determine that an inspection is necessary for approval of a marketing application and an inspection cannot be completed during the review cycle due to restrictions on travel, and the agency does not determine a remote interactive evaluation to be adequate, the FDA has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the ultimate impact of COVID-19 on our business is uncertain, any negative impacts of COVID-19, alone or in combination with others, could exacerbate other risk factors discussed herein. The full extent to which COVID-19 will negatively affect our operations, financial performance, and stock price will depend on future developments that are highly uncertain and cannot be predicted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Although we sold a portion of the royalty stream and commercial milestones from the global sales of Leqvio by our collaborator, Novartis, we are entitled to retain the remaining portion of future royalties from the global sales of Leqvio and, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">if certain specified thresholds are met, to the remaining portion of commercial milestone payments, and any negative developments related to Leqvio could have a material adverse effect on our receipt of those payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we </span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sold to Blackstone 50% of the royalties payable to us with respect to net sales by Novartis, its affiliates or sublicensees of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leqvio</span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and 75% of the commercial milestone payments payable to us under the MDCO agreement. If Blackstone does not receive royalty payments in respect of global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leqvio</span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> equaling at least </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$1.00&#160;billion</span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> by December 31, 2029, Blackstone&#8217;s royalty interest will increase to 55% effective January 1, 2030.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our receipt of future royalty payments and a portion of commercial milestone payments may be negatively impacted if the Leqvio royalty stream and commercial milestones payments are insufficient to meet the specified thresholds. For example, in December 2020, the FDA issued a complete response letter regarding Novartis' NDA for inclisiran, stating that the agency could not approve the NDA by the PDUFA action date due to unresolved inspection-related conditions at a third party manufacturing facility, delaying the potential approval and launch of Leqvio in the U.S., as well as payment of an associated approval milestone and potential royalties. While Leqvio was granted marketing authorization by the EC in Europe in December 2020, and was approved by the FDA in December 2021, any negative impact to future royalty payments and commercial milestone payments could affect our ability to meet the specified repayment thresholds. Additional factors that may have an adverse effect on the Leqvio royalty stream and commercial milestones include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">companies working to develop new therapies or alternative formulations of products for ASCVD;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">foreign currency movement, which could have a negative impact on Novartis&#8217; sales of Leqvio, thereby reducing the royalties; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any negative developments relating to Leqvio, such as safety, efficacy, or reimbursement issues, could reduce demand for Leqvio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any disputes concerning patents, proprietary rights, or license and collaboration agreements could negatively impact our receipt of commercial milestone payments or royalties; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse regulatory or legislative developments could limit or prohibit the sale of Leqvio, such as restrictions on the use of Leqvio or safety-related label changes, including enhanced risk management programs, which may significantly reduce expected royalty revenue and commercial milestone payments and could require significant expense to address the associated legal and regulatory issues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the revenues generated by sales of Leqvio are lower than expected, our business could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Geopolitical risks associated with the ongoing military conflict between Russia and Ukraine could have an adverse impact on our business, financial condition and results of operations, including our clinical trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Russia&#8217;s invasion of Ukraine, and the global response, including the imposition of sanctions by the U.S., EU and other countries, has resulted in global business disruptions and economic volatility and may have an adverse impact on our business, including our clinical trials. The uncertain nature, magnitude, and duration of hostilities stemming from the conflict in Ukraine, including the potential effects of sanctions limitations, retaliatory cyber-attacks on the world economy and markets, have contributed to increased market volatility and uncertainty, which could continue to have an adverse impact on macroeconomic factors that might affect our business and operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the ongoing conflict in Ukraine has disrupted the ability of our contract research organizations, or CROs, to conduct clinical trials at certain sites in Ukraine. We cannot be certain what the overall impact of this conflict will be on our ability to conduct and complete our clinical trials on schedule. However, interruptions of our clinical trials could significantly delay our clinical development plans and potential authorization or approval of our product candidates, which could increase our costs and jeopardize our ability to successfully commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We expect our operating results to fluctuate in future periods, which may adversely affect our stock price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our quarterly operating results have fluctuated in the past, and may continue to do so in the future. Our operating results may fluctuate due to the level of success of our commercial efforts and resulting revenues, as well as the variable nature of our operating expenses as a result of the timing and magnitude of expenditures. For example, due to the impact of the COVID-19 pandemic, combined net product revenues in the first quarter of 2022 for our commercially approved products were negatively impacted. In addition, in one or more future periods, our results of operations may fall below the expectations of securities analysts and investors. In that event, the market price of our common stock could substantially decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If the estimates we make, or the assumptions on which we rely, in preparing our condensed consolidated financial statements and/or our projected guidance prove inaccurate, our actual results may vary from those reflected in our projections and accruals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. We base our estimates on </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our estimates, or the assumptions underlying them, will be correct.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, from time to time we issue financial guidance relating to our expectations regarding our combined product sales, collaboration and royalty revenues, and GAAP and non-GAAP combined research and development and selling, general and administrative expenses, which guidance is based on estimates and the judgment of management. If, for any reason, our revenues and/or expenses differ materially from our guidance, we may have to adjust our publicly announced financial guidance. For example, in April 2022, we decreased our 2022 guidance range for combined net product revenues, and in October 2022, we decreased our guidance range for our collaboration and royalty revenue. If we fail to meet, or if we are required to change or update any element of, our publicly disclosed financial guidance or other expectations about our business, our stock price could decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The investment of our cash, cash equivalents and marketable securities is subject to risks which may cause losses and affect the liquidity of these investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, we had $2.07 billion in cash, cash equivalents and marketable securities. We historically have invested these amounts in high&#8211;grade corporate notes, commercial paper, securities issued or sponsored by the U.S. government, certificates of deposit and money market funds meeting the criteria of our investment policy, which is focused on the preservation of our capital. Corporate notes may also include foreign bonds denominated in U.S. dollars. These investments are subject to general credit, liquidity, market and interest rate risks. We may realize losses in the fair value of these investments or a complete loss of these investments, which would have a negative effect on our condensed consolidated financial statements. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Volatility in foreign currency exchange rates could have a material adverse effect on our operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our revenue from outside of the U.S. will increase as our products, whether commercialized by us or our collaborators, gain marketing approval in such jurisdictions. Our primary foreign currency exposure relates to movements in the Japanese yen, Euro and British pound. If the U.S. dollar weakens against a specific foreign currency, our revenues will increase, having a positive impact on net income, but our overall expenses will increase, having a negative impact. Conversely, if the U.S. dollar strengthens against a specific foreign currency, our revenues will decrease, having a negative impact on net income, but our overall expenses will decrease, having a positive impact. For example, during 2022, we experienced an unfavorable impact from foreign exchange rates on our international revenues. Continued volatility in foreign exchange rates is likely to impact our operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in tax law could adversely affect our business and financial condition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is subject to numerous international, federal, state, and other governmental laws, rules, and regulations that may adversely affect our operating results, including, taxation and tax policy changes, tax rate changes, new tax laws, or revised tax law interpretations, which individually or in combination may cause our effective tax rate to increase. In the U.S., the rules dealing with federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the Organization for Economic Co-operation and Development, or OECD, the EC, and individual taxing jurisdictions where we and our affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD has released its comprehensive plan to create an agreed set of international rules for fighting base erosion and profit shifting. In addition, the OECD, the EC and individual countries are examining changes to how taxing rights should be allocated among countries considering the digital economy. As a result, the tax laws in the U.S. and other countries in which we and our affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to execute our business strategy if we are unable to maintain existing or enter into new alliances with other companies that can provide business and scientific capabilities and funds for the development and commercialization of our product candidates. If we are unsuccessful in forming or maintaining these alliances on terms favorable to us, our business may not succeed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are continuing to advance our commercial capabilities, including in marketing, sales, market access and distribution, to support our wholly-owned products. We also continue to advance our growing pipeline of RNAi therapeutic opportunities. However, we may not have adequate capacity or capabilities to advance all of our therapeutic opportunities. Accordingly, we have entered into alliances with other companies and collaborators that we believe can provide such capabilities in certain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">territories and/or for certain product candidates, and we intend to enter into additional such alliances in the future. Our collaboration strategy is to form alliances that create significant value for us and our collaborators in the advancement of RNAi therapeutics as a new class of innovative medicines. Specifically, with respect to our Genetic Medicine pipeline, as a result of our broad strategic alliance with Sanofi formed in 2014, Sanofi has the right to develop and commercialize fitusiran globally. In addition, we formed a collaboration with MDCO (which was acquired by Novartis in January 2020) to advance inclisiran. In March 2018, we entered into a discovery collaboration with Regeneron to identify RNAi therapeutics for NASH and potentially other related diseases, and in November 2018, we and Regeneron entered into a separate, fifty-fifty collaboration to further research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts. In October 2017, we announced an exclusive licensing agreement with Vir for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic HBV infection. In April 2020, we entered into a development and commercialization collaboration with Dicerna (which was acquired by Novo Nordisk in December 2021) to advance investigational RNAi therapeutics for the treatment of alpha-1 liver disease. With respect to our CNS/Ocular Disease pipeline, in April 2019, we announced a global, strategic collaboration with Regeneron to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the eye and CNS, in addition to a select number of targets expressed in the liver. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In such alliances, we expect our current, and may expect our future, collaborators to provide substantial capabilities in clinical development, regulatory affairs, and/or marketing, sales and distribution. Under certain of our alliances, we also may expect our collaborators to develop, market and/or sell certain of our product candidates. We may have limited or no control over the development, sales, marketing and distribution activities of these third parties. Our future revenues may depend heavily on the success of the efforts of these third parties. For example, we will rely entirely on (i) Regeneron for the development and commercialization of all programs targeting eye diseases (subject to limited exceptions), and potentially other CNS and liver programs, (ii) Novartis for all future development and commercialization of Leqvio worldwide, and (iii) Sanofi for the development and commercialization of fitusiran worldwide. In the case of each such collaboration referenced in clauses (i)-(iii) above, we are entitled to royalties on the sales of each of these products. If our collaborators are not successful in their development and/or commercialization efforts, our future revenues from RNAi therapeutics for these indications may be adversely affected. For example, while Leqvio was granted marketing authorization by the EC in Europe, in December 2020, Novartis received a complete response letter from the FDA stating that the agency could not approve the NDA by the PDUFA action date due to unresolved inspection-related conditions at a third party manufacturing facility. While Leqvio was approved by the FDA in December 2021, the resolution of the complete response letter resulted in a delay in the payment of an approval milestone and potential U.S. royalties. If the revenues generated by the royalties received by Blackstone from us with respect to Leqvio sales do not reach a certain level by the end of 2029, Blackstone will be entitled to a higher royalty percentage beginning in 2030, which would have an adverse impact on our revenues beginning in 2030.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may not be successful in entering into future alliances on terms favorable to us due to various factors, including our ability to demonstrate improved product profiles from our new technologies, including our IKARIA and GEMINI platforms, our ability to successfully demonstrate proof-of-concept for our technology in humans in certain tissues or disease areas, our ability to demonstrate the safety and efficacy of our specific drug candidates, our ability to manufacture or have third parties manufacture RNAi therapeutics, the strength of our intellectual property and/or concerns around challenges to our intellectual property. For example, the occurrence of a fatal thrombotic serious adverse event, or SAE, in our fitusiran study in 2017 and a subsequent pause in dosing and enrollment in fitusiran clinical studies in 2020 could contribute to further concerns about the safety of specific therapeutic candidates or therapeutic candidates for specific diseases. Even when we succeed in securing such alliances, we may not be able to maintain them if, for example, development or approval of a product candidate is delayed, challenges are raised as to the validity or scope of our intellectual property, we are unable to secure adequate reimbursement from payors or sales of an approved drug are lower than we expected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, any delay in entering into collaboration agreements would likely either delay the development and commercialization of certain of our product candidates and reduce their competitiveness even if they reach the market, or prevent the development of certain product candidates. Any such delay related to our collaborations could adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For certain product candidates, we have formed collaborations to fund all or part of the costs of drug development and commercialization, such as our collaborations with Regeneron, Novartis, Vir, Dicerna and Sanofi. We may not, however, be able to enter into additional collaborations for certain other programs, and the terms of any collaboration agreement we do secure may not be favorable to us. If we are not successful in our efforts to enter into future collaboration arrangements with respect to one or more of our product candidates, we may not have sufficient funds to develop these product candidates or other product candidates internally, or to bring our product candidates to market. If we do not have sufficient funds to develop and bring our product candidates to market, we will not be able to generate revenues from these product candidates, and this will substantially harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If any collaborator materially amends, terminates or fails to perform its obligations under agreements with us, the development and commercialization of our product candidates could be delayed or terminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our dependence on collaborators for capabilities and funding means that our business could be adversely affected if any collaborator materially amends or terminates its collaboration agreement with us or fails to perform its obligations under that agreement. Our current or future collaborations, if any, may not be scientifically or commercially successful. Disputes may arise in the future with respect to the ownership of rights to technology or products developed with collaborators, which could have an adverse effect on our ability to develop and commercialize any affected product candidate. Our current collaborations allow, and we expect that any future collaborations will allow, either party to terminate the collaboration for a material breach by the other party. In addition, our collaborators may have additional termination rights for convenience with respect to the collaboration or a particular program under the collaboration, under certain circumstances. For example, our agreement with MDCO, which was acquired by Novartis in January 2020, relating to the development and commercialization of inclisiran worldwide may be terminated by Novartis at any time upon four months&#8217; prior written notice, provided if the agreement is terminated by Novartis for convenience, Novartis must grant a license to us under certain of our technology developed in the course of MDCO's activities under the agreement, subject to a royalty to be negotiated between the parties. Moreover, any adverse actions by Novartis with respect to the MDCO agreement or disputes with Novartis regarding each party's rights and obligations under the MDCO agreement could adversely impact our ability to comply with our obligations under our agreements with Blackstone. If we were to lose a commercialization collaborator, we would have to attract a new collaborator or develop expanded sales, distribution and marketing capabilities internally, which would require us to invest significant amounts of financial and management resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we have a dispute with a collaborator over the ownership of technology or other matters, or if a collaborator terminates its collaboration with us, for breach or otherwise, or determines not to pursue the research, development and/or commercialization of RNAi therapeutics, it could delay our development of product candidates, result in the need for additional company resources to develop product candidates, require us to expend time and resources to develop expanded sales and marketing capabilities on a more expedited timeline, make it more difficult for us to attract new collaborators and could adversely affect how we are perceived in the business and financial communities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, a collaborator, or in the event of a change in control of a collaborator or the assignment of a collaboration agreement to a third party, the successor entity or assignee, as in the case of MDCO and Novartis, could determine that it is in its interests to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pursue alternative technologies or develop alternative products, either on its own or jointly with others, that may be competitive with the products on which it is collaborating with us or which could affect its commitment to the collaboration with us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pursue higher-priority programs or change the focus of its development programs, which could affect the collaborator&#8217;s commitment to us; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">if it has marketing rights, choose to devote fewer resources to the marketing of our product candidates, if any are approved for marketing, than it does for product candidates developed without us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of these occur, the development and commercialization of one or more products or product candidates could be delayed, curtailed or terminated because we may not have sufficient financial resources or capabilities to continue such development and commercialization on our own.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have limited manufacturing capabilities and resources and we must incur significant costs to develop this expertise and/or rely on third parties to manufacture our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have limited manufacturing capabilities, and in order to continue to commercialize our approved products, continue to develop our current product candidates, apply for regulatory approvals and, if approved, commercialize future products, we will need to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. Historically, our internal manufacturing capabilities were limited to small-scale production of material for use in in vitro and in vivo experiments that is not required to be produced under good manufacturing practice standards. During 2012, we developed current good manufacturing practice, or cGMP, capabilities and processes for the manufacture of patisiran formulated bulk drug product for late stage clinical trial use and commercial supply. In addition, during 2020, we completed construction and qualification of our cGMP manufacturing facility in Norton, Massachusetts where we manufacture drug substance for clinical and, eventually, will manufacture for commercial use. In December 2020, we began cGMP operations, and we believe this facility will enable us to initiate manufacturing for multiple new early-stage programs over the next few years, as well as provide us the manufacturing capabilities to support our late-stage and commercial programs in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the present time, we may manufacture limited quantities of clinical trial materials ourselves, but otherwise we continue to rely on third parties to manufacture the drug substance and finished product we will require for clinical trials that we initiate and to support the commercial supply of our approved products and any of our other product candidates. There are a limited number of manufacturers that supply synthetic siRNAs. We currently rely on a limited number of CMOs for our supply of synthetic siRNAs. There are risks inherent in pharmaceutical manufacturing that could affect the ability of our CMOs to meet </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our delivery time requirements or provide adequate amounts of material to meet our needs, and ultimately delay our clinical trials and potentially put at risk commercial supply, as well as result in additional expense to us. To fulfill our siRNA requirements, we will likely need to secure alternative suppliers of synthetic siRNAs and such alternative suppliers are limited and may not be readily available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner. As noted above, in order to ensure long-term supply capabilities for our RNAi therapeutics, we are developing our own capabilities to manufacture drug substance for clinical and commercial use.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the manufacture of the synthetic siRNAs, we may have additional manufacturing requirements related to the technology required to deliver the siRNA to the relevant cell or tissue type, such as LNPs or conjugates. In some cases, the delivery technology we utilize is highly specialized or proprietary, and for technical and/or legal reasons, we may have access to only one or a limited number of potential manufacturers for such delivery technology. In addition, the scale-up of our delivery technologies could be very difficult and/or take significant time. We also have very limited experience in such scale-up and manufacturing, requiring us to depend on a limited number of third parties, who might not be able to deliver in a timely manner, or at all. Failure by manufacturers to properly manufacture our delivery technology and/or formulate our siRNAs for delivery could result in unusable product, supply delays and shortages. Furthermore, competition for supply from our manufacturers from other companies, a breach by such manufacturers of their contractual obligations or a dispute with such manufacturers would cause delays in our discovery and development efforts, as well as additional expense to us. In response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, was enacted in March 2020, and requires that manufacturers have in place a risk management plan that identifies and evaluates the risks to the supply of approved drugs for certain serious diseases or conditions for each establishment where the drug or active pharmaceutical ingredient is manufactured. The risk management plan will be subject to FDA review during an inspection. If we experience shortages in the supply of our marketed products, as a result of COVID-19 or otherwise, our results could be materially impacted. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In developing manufacturing capabilities by building our own manufacturing facilities, we have incurred substantial expenditures, and expect to incur significant additional expenditures in the future. Also, we have had to, and will likely need to continue to, hire and train qualified employees to staff our facilities. If we are unable to manufacture sufficient quantities of material or if we encounter problems with our facilities in the future, we may also need to secure alternative suppliers, and such alternative suppliers may not be available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner. Given our dependence on a limited number of CMOs to supply our commercial products and clinical candidates, and our dependence on our own facility, any delay in supply could impact our ability to procure sufficient supplies for our approved products, and the development of our product candidates could also be delayed. Any delay or setback in the manufacture of our approved products could impede ongoing commercial supply, which could significantly impact our revenues and operating results. In addition, to the extent we or our partners rely on CMOs outside of the U.S. to supply drug substance for our product candidates, any delays or disruptions in supply could have a material adverse impact on the research and development activities and potential commercialization of our or our partners' product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The manufacturing process for our approved products and any other products that we may develop is subject to the FDA and foreign regulatory authority approval process and we will need to meet, and will need to contract with CMOs who can meet, all applicable FDA and foreign regulatory authority requirements on an ongoing basis. The failure of any CMO to meet required regulatory authority requirements could result in the delayed submission of regulatory applications, or delays in receiving regulatory approval for any of our or our current or future collaborators' product candidates. For example, in April 2022, due to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">an amendment to our existing regulatory submission to address a pending inspection classification at a third-party secondary packaging and labeling facility, the FDA extended the review timeline of the NDA for vutrisiran.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In addition, if we receive the necessary regulatory approval for any product candidate, we also expect to rely on third parties, including potentially our commercial collaborators, to produce materials required for commercial supply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we depend, and will depend in the future, on these third parties to perform their obligations in a timely manner and consistent with contractual and regulatory requirements, including those related to quality control and quality assurance. The failure of any CMO to perform its obligations as expected, or, to the extent we manufacture all or a portion of our product candidates ourselves, our failure to execute on our manufacturing requirements, could adversely affect our business in a number of ways, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we or our current or future collaborators may not be able to initiate or continue clinical trials of product candidates that are under development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we or our current or future collaborators may be delayed in submitting regulatory applications, or receiving regulatory approvals, for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we may lose the cooperation of our collaborators;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our facilities and those of our CMOs, and our products could be the subject of inspections by regulatory authorities that could have a negative outcome and result in delays in supply;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we may be required to cease distribution or recall some or all batches of our products or take action to recover clinical trial material from clinical trial sites; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">ultimately, we may not be able to meet commercial demands for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on third parties to conduct our clinical trials and source certain materials for our pre-clinical testing and studies, and if they fail to fulfill their obligations, our development plans may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on independent clinical investigators, CROs, and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our clinical trials. We have contracted, and we plan to continue to contract with, certain third parties to provide certain services, including site selection, enrollment, monitoring, auditing and data management services. These investigators and CROs are not our employees and we have limited control over the amount of time and resources they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw their time and resources away from our programs. Although we depend heavily on these parties, we control only certain aspects of their activity and therefore, we cannot be assured that these third parties will adequately perform all of their contractual obligations to us in compliance with regulatory and other legal requirements and our internal policies and procedures. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with applicable good clinical practice, or GCP, requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development, and to implement timely corrective action to any non-compliance. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites, including in connection with the review of marketing applications. If we or any of our CROs fail to comply with applicable GCP requirements, or fail to take any such corrective action, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA, the PMDA in Japan or comparable foreign regulatory authorities may require us to take additional action or perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority in the future, such regulatory authority will determine that any of our clinical trials comply with GCP regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our third-party service providers cannot adequately and timely fulfill their obligations to us for any reason, including due to disruptions caused by the COVID-19 pandemic or the ongoing conflict in Ukraine on their operations or at the sites they are overseeing, or if the quality and accuracy of our clinical trial data is compromised due to failure by such third party to adhere to our protocols or regulatory requirements or if such third parties otherwise fail to meet deadlines, our development plans and/or regulatory reviews for marketing approvals may be delayed or terminated. As a result, our stock price would likely be negatively impacted, and our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate additional revenues could be delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before conducting clinical trials to demonstrate the safety and efficacy of our product candidates in humans in support of Investigational New Drug, or IND, applications or similar applications in other jurisdictions, we must complete pre-clinical studies, which includes animal studies. In addition, we rely on third-party service providers to source certain materials for such pre-clinical studies. Our ability to complete our pre-clinical studies is contingent on, among other things, our ability to source animals and other supplies required for the conduct of such studies. If we are unable to obtain such supplies, we may be unable to complete such pre-clinical studies in a timely manner or at all. For example, some of our IND-enabling toxicology and other studies require certain non-human primates that have customarily been imported from the People&#8217;s Republic of China, or the PRC, and Cambodia. The supply of these non-human primates is currently constrained due to factors such as their limited worldwide availability, trade relations between the U.S. and the PRC, and heightened scrutiny of non-human primates originating from Cambodia following allegations in late 2022 that certain Cambodian businesses and government officials may have engaged in the smuggling of non-human primates. We may encounter delays in obtaining a sufficient supply of such non-human primates to enable the conduct of our pre-clinical studies. Our inability to obtain access to a sufficient supply of these non-human primates in a timely manner or at all may impair our ability to complete pre-clinical studies to support IND applications or similar applications in other jurisdictions or delay the submission of such applications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Managing Our Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to attract and retain qualified key management and scientists, development, medical and commercial staff, consultants and advisors, our ability to implement our business plan may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are highly dependent upon our senior management and our scientific, clinical, sales and medical staff. The loss of the service of any of the members of our senior management could significantly delay or prevent the achievement of product development and commercialization, and other business objectives, and adversely impact our stock price. Our employment arrangements with our key personnel are terminable without notice. We do not carry key person life insurance on any of our employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have grown our workforce significantly over the past several years and we face intense competition for qualified individuals from numerous pharmaceutical and biotechnology companies, universities, governmental entities and other research </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">institutions, many of which have substantially greater resources with which to attract and reward qualified individuals than we do. In addition, if we are not successful commercializing our approved products, we may be unable to attract and retain highly qualified sales and marketing professionals to support our approved products and our future products, if approved. Accordingly, we may be unable to attract and retain suitably qualified individuals in order to support our growing research, development and global commercialization efforts and initiatives, and our failure to do so could have an adverse effect on our ability to implement our future business plans.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may have difficulty expanding our operations successfully as we continue our evolution from a U.S.- and EU-based company primarily involved in discovery, pre-clinical testing and clinical development into a global company that develops and commercializes multiple drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we continue the commercial launches of our approved products, and increase the number of product candidates we are developing, we will need to continue to expand our operations in the U.S. and further develop operations in the EU and other geographies, including Asia and Latin America. To date, we have received regulatory approval for four products, which we have launched in multiple geographies globally, and we continue to expand the reach of these products with additional regulatory filings and launches. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have grown our workforce significantly over the last several years and anticipate additional employee growth globally in the future as we focus on the commercialization of our approved products, and achieving our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy. This growth has placed a strain on our administrative and operational infrastructure and, as a result, we will need to continue to develop additional and/or new infrastructure and capabilities to support our growth and obtain additional space to conduct our global operations in the U.S., the EU, Japan, Latin America and other geographies. If we are unable to develop such additional infrastructure or obtain sufficient space to accommodate our growth in a timely manner and on commercially reasonable terms, our business could be negatively impacted. As we continue the commercialization of our approved products, and as the product candidates we develop enter and advance through clinical trials, we will need to continue to expand our global development, regulatory, manufacturing, quality, compliance, and marketing and sales capabilities, or contract with other organizations to provide these capabilities for us. In addition, as our operations continue to expand, we will need to successfully manage additional relationships with various collaborators, suppliers, distributors and other organizations. Our ability to manage our operations and future growth will require us to continue to enhance our operational, financial and management controls and systems, reporting systems and infrastructure, ethics and compliance functions, and policies and procedures. We may not be able to implement enhancements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The use of social media presents risks and challenges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Social media is being used to communicate about our clinical development programs and the diseases our investigational RNAi therapeutics are being developed to treat, and we are utilizing what we believe is appropriate social media in connection with our commercialization efforts for our approved products, and we intend to do the same for our future products, if approved. Social media practices in the biopharmaceutical industry continue to evolve and regulations and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to off-label marketing or other prohibited activities. For example, for our clinical-stage candidates, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or to report an alleged adverse event, or AE. When such disclosures occur, there is a risk that study enrollment may be adversely impacted, we fail to monitor and comply with applicable AE reporting obligations or that we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our investigational products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any online platform, including a blog on the internet, or a post on a website, that can be distributed rapidly and could negatively harm our reputation. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business and operations could suffer in the event of system failures or unauthorized or inappropriate use of or access to our systems.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are increasingly dependent on our information technology systems and infrastructure for our business. We collect, store and transmit sensitive information including intellectual property, proprietary business information, including highly sensitive clinical trial data, and personal information in connection with business operations. The secure maintenance of this information is critical to our operations and business strategy. Some of this information could be an attractive target of criminal attack or unauthorized access and use by third parties with a wide range of motives and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; patient groups, disgruntled current or former employees and others. Cyber-attacks are of ever-increasing levels of sophistication, and despite our security measures, our information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The pervasiveness of cybersecurity incidents in general and the risks of cyber-crime are complex and continue to evolve. Although we are making significant efforts to maintain the security and integrity of our information systems and are exploring </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">various measures to manage the risk of a security breach or disruption, there can be no assurance that our security efforts and measures will be effective or that attempted security breaches or disruptions would not be successful or damaging. Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage or interruption from computer viruses, unauthorized or inappropriate access or use, natural disasters, pandemics (including COVID-19), terrorism, war (including the ongoing conflict in Ukraine), and telecommunication and electrical failures. Such events could cause interruption of our operations. For example, the loss of pre-clinical trial data or data from completed or ongoing clinical trials for our product candidates could result in delays in our regulatory filings and development efforts, as well as delays in the commercialization of our products, and significantly increase our costs. To the extent that any disruption, security breach or unauthorized or inappropriate use or access to our systems were to result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, including but not limited to patient, employee or vendor information, we could incur notification obligations to affected individuals and government agencies, liability, including potential lawsuits from patients, collaborators, employees, stockholders or other third parties and liability under foreign, federal and state laws that protect the privacy and security of personal information, and the development and potential commercialization of our product candidates could be delayed.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Industry</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Development, Clinical Testing and Regulatory Approval of Our Product Candidates and the Commercialization of Our Approved Products</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Any product candidates we or our partners develop may fail in development or be delayed to a point where they do not become commercially viable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before obtaining regulatory approval for the commercial distribution of our product candidates, we must conduct, at our own expense, extensive nonclinical tests and clinical trials to demonstrate the safety and/or efficacy in humans of our product candidates. Nonclinical and clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome, and the historical failure rate for product candidates is high. We currently have multiple programs in clinical development, including internal and partnered programs in Phase 3 development, as well as several earlier-stage clinical programs. However, we may not be able to further advance any of our product candidates through clinical trials and regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, several of our planned and ongoing clinical trials utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we enter into clinical trials, the results from nonclinical testing or early or late stage clinical trials of a product candidate may not predict the results that will be obtained in subsequent subjects or in subsequent human clinical trials of that product candidate or any other product candidate. For example, we are conducting the APOLLO-B and HELIOS-B Phase 3 clinical trials of patisiran and vutrisiran, respectively, which are investigating the potential of patisiran and vutrisiran to treat the cardiac manifestations of disease in patients with ATTR amyloidosis with cardiomyopathy. We announced positive topline results from the APOLLO-B study in August 2022, and patients enrolled in the study are receiving patisiran as part of an open-label extension period. While both patisiran and vutrisiran have demonstrated positive results in patients with hATTR amyloidosis with polyneuropathy, we cannot be certain that the results from HELIOS-B will be positive or that the results from APOLLO-B and/or HELIOS-B will support approval of patisiran and/or vutrisiran for the treatment of patients with ATTR amyloidosis with cardiomyopathy. There is a high failure rate for drugs proceeding through clinical studies. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development, including with respect to patisiran and/or vutrisiran, could have a material adverse effect on our business and operating results. Moreover, our approved products and our current product candidates, employ novel delivery technologies that, with the exception of inclisiran, have yet to be extensively evaluated in human clinical trials and proven safe and effective.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we, the FDA or other applicable regulatory authorities, or an institutional review board, or IRB, or similar foreign review board or committee, may delay initiation of or suspend clinical trials of a product candidate at any time for various reasons, including if we or they believe the healthy volunteer subjects or patients participating in such trials are being exposed to unacceptable health risks. Among other reasons, adverse side effects of a product candidate or related product on healthy volunteer subjects or patients in a clinical trial could result in our decision, or a decision by the FDA or foreign </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">regulatory authorities, to suspend or terminate the trial, or, in the case of regulatory agencies, a refusal to approve a particular product candidate for any or all indications of use. For example, in October 2016, we announced our decision to discontinue development of revusiran, an investigational RNAi therapeutic that was being developed for the treatment of patients with cardiomyopathy due to hATTR amyloidosis. Our decision followed the recommendation of the revusiran ENDEAVOUR Phase 3 study Data Monitoring Committee to suspend dosing and the observation of an imbalance in mortality in revusiran-treated patients as compared to those on placebo. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the age and condition of the patients, the stage and severity of disease, the availability of clinical trials for other investigational drugs for the same disease or condition, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease, and the eligibility criteria for the clinical trial. For example, we or our partners may experience difficulty enrolling our clinical trials, including, but not limited to, the ongoing clinical trials for fitusiran, due to the availability of existing approved treatments, as well as other investigational treatments in development. In addition, in November 2018 we announced that due to recruitment challenges, we had discontinued a Phase 2 study of cemdisiran in atypical hemolytic uremic syndrome and are focusing our cemdisiran clinical development efforts in a different indication. Delays or difficulties in patient enrollment, including the enrollment delays in our KARDIA-1 Phase 2 monotherapy study of zilebesiran resulting from the ongoing conflict in Ukraine, or difficulties retaining trial participants, including as a result of the availability of existing or other investigational treatments or safety concerns, including the impact of public health emergencies such as the COVID-19 pandemic, can result in increased costs, longer development times or termination of a clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although our investigational RNAi therapeutics have been generally well-tolerated in our clinical trials to date, new safety findings may emerge. For example, in September 2017, we announced that we had temporarily suspended dosing in all ongoing fitusiran studies pending further review of a fatal thrombotic serious adverse event, or SAE, that occurred in a patient with hemophilia A without inhibitors who was receiving fitusiran in our Phase 2 open label extension, or OLE, study. More recently, in October 2020, Sanofi voluntarily paused dosing in all ongoing fitusiran clinical studies to assess reports of non-fatal thrombotic events in patients participating in the ATLAS Phase 3 program. Following an assessment of available data and alignment with regulators, patients restarted on fitusiran under amended protocols in ongoing clinical studies. In October 2021, Sanofi announced that a potential filing date for fitusiran had been moved to 2024 due to the introduction of a revised dosing regimen in the ongoing phase 3 studies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As demonstrated by the discontinuation of our revusiran program in October 2016, the temporary suspension of dosing in September 2017 in our fitusiran studies, as well as Sanofi's voluntary pause of fitusiran studies in October 2020, the occurrence of SAEs and/or AEs can result in the suspension or termination of clinical trials of a product candidate by us, our partners, or the FDA or a foreign regulatory authority. The occurrence of SAEs and/or AEs could also result in refusal by the FDA or a foreign regulatory authority to approve a particular product candidate for any or all indications of use.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials also require the review, oversight and approval of IRBs, or, outside of the U.S., an independent ethics committee, which continually review clinical investigations and protect the rights and welfare of human subjects. Inability to obtain or delay in obtaining IRB or ethics committee approval can prevent or delay the initiation and completion of clinical trials, and the FDA or foreign regulatory authorities may decide not to consider any data or information derived from a clinical investigation not subject to initial and continuing IRB or ethics committee review and approval, as the case may be, in support of a marketing application.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our product candidates that we develop may encounter problems during clinical trials that will cause us, an IRB, ethics committee or regulatory authorities to delay, suspend or terminate these trials, or that will delay or confound the analysis of data from these trials. If we experience any such problems, we may not have the financial resources to continue development of the product candidate that is affected, or development of any of our other product candidates. We may also lose, or be unable to enter into, collaborative arrangements for the affected product candidate and for other product candidates we are developing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, nonclinical testing and the clinical trial process that could delay or prevent regulatory approval or our ability to commercialize our product candidates, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our nonclinical tests or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical testing or clinical trials, or we may abandon projects that we expect to be promising;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in filing IND applications or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or IRBs/ethics committees in order to commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conditions imposed on us by an IRB or ethics committee, or the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">problems in engaging IRBs or ethics committees to oversee clinical trials or problems in obtaining or maintaining IRB or ethics committee approval of trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in enrolling patients and volunteers into clinical trials, and variability in the number and types of patients and volunteers available for clinical trials, including as a result of the COVID-19 pandemic and the ongoing conflict in Ukraine;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">high drop-out rates for patients and volunteers in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inadequate supply or quality of product candidate materials or other materials necessary for the conduct of our clinical trials or disruption or delays in the clinical supply due to the COVID-19 or a future pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">greater than anticipated clinical trial costs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">poor or disappointing effectiveness of our product candidates during clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site or records of any clinical or nonclinical investigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure of our third-party contractors or investigators to comply with regulatory requirements, including GCP and cGMP, or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">interpretations of data by the FDA and similar foreign regulatory agencies that differ from ours.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if we successfully complete clinical trials of our product candidates, any given product candidate may not prove to be a safe and effective treatment for the disease for which it was being tested.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We or our partners may be unable to obtain U.S. or foreign regulatory approval for our or our partnered product candidates and, as a result, we or our partners may be unable to commercialize such product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our and our partnered product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, pricing, marketing and distribution of drugs. Rigorous nonclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that the product candidates we and our partners are developing will not obtain the regulatory approvals necessary for us or our collaborators to begin selling them, or, in the case of patisiran and vutrisiran, will not obtain regulatory approval to be sold for broader indications than are currently approved. It is also possible that the FDA or other regulatory authorities may determine that the data generated in clinical trials for a product candidate, including patisiran, while positive, is not sufficient to support the approval of an application for regulatory approval. In February 2023, the FDA accepted our sNDA for ONPATTRO for filing and set an action date of October 8, 2023, under the PDUFA. The FDA also indicated in the sNDA filing communication letter that it is planning to hold an advisory committee meeting to discuss the application and that it had not identified any potential review issues at such time. Even though the sNDA has been accepted for filing, we may receive a complete response letter rather than approval, including for reasons that may be identified during a meeting of the advisory committee.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The time required to obtain FDA and other regulatory approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from nonclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We or our partners may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because the drugs we or our partners are developing represent a new class of drug, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to these drugs. The lack of policies, practices or guidelines may hinder or slow review by the FDA of any regulatory filings that we or our partners may submit. Moreover, the FDA may respond to these submissions by defining requirements we or our partners may not have anticipated. Such responses could lead to significant delays and increased costs in the development of our or our partnered product candidates. In addition, because there may be approved treatments for some of the diseases for which we or our partners may seek approval, including patisiran and vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy, or treatments in development which are approved by the time we or they apply for approval, in order to receive regulatory approval, we or they may need to demonstrate through clinical trials that the product candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. Interruption or delays in the operations of the FDA, EMA and comparable foreign regulatory agencies may impact the review, inspection and approval timelines for our or our partnered product candidates. During the COVID-19 public health emergency, the FDA worked to ensure timely reviews of applications for medical products in line with its user fee performance goals and conducted mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. In addition, during the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA's inability to complete required inspections for their applications. In December 2020, the FDA issued a complete response letter regarding Novartis' NDA for inclisiran, stating that the agency could not approve the NDA by the PDUFA action date due to unresolved facility inspection-related conditions. In July 2021, Novartis announced that the resubmission to the FDA of the inclisiran NDA to address the complete response letter was filed, and the FDA approved Leqvio (which is the trade name under which inclisiran is marketed in the U.S.) in December 2021. The delay in the approval of Leqvio resulted in delayed milestone and royalty revenue to us. Any similar interruption or delay by the FDA, EMA or comparable foreign regulatory agency could have a material adverse effect on our efforts to obtain regulatory approval for our product candidates, which could have a material adverse effect on our financial results. For instance, the FDA may request additional clinical or other data or information in connection with the regulatory review of our or our partners&#8217; product candidates, including patisiran, including by issuing a complete response letter which may require that we or our partners&#8217; submit additional clinical or other data or impose other conditions that must be met in order to secure final approval of our or our partners&#8217; NDA applications, including potentially requiring a facility inspection. Even if such data and information are submitted, or any such inspection is completed, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any delay or failure in obtaining required approvals for our product candidates or our partnered product candidates could have a material adverse effect on our ability to generate revenues from any product candidate for which we or our partners may seek approval in the future. Furthermore, any regulatory approval to market any product, including patisiran, may be subject to limitations on the approved uses for which we or our partners may market the product or the labeling or other restrictions, which could limit each such product&#8217;s market opportunity and have a negative impact on our results of operations and our stock price. In addition, the FDA has the authority to require a Risk Evaluation and Mitigation Strategy, or REMS, plan as part of an NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. In the EU, we or our partners could be required to adopt a similar plan, known as a risk management plan, and our products could be subject to specific risk minimization measures, such as restrictions on prescription and supply, the conduct of post-marketing safety or efficacy studies, or the distribution of patient and/or prescriber educational materials. In either instance, these limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and vice versa.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Even if we or our partners obtain regulatory approvals, our marketed drugs will be subject to ongoing regulatory oversight. If we or our partners fail to comply with continuing U.S. and foreign requirements, our approvals could be limited or withdrawn, we could be subject to other penalties, and our business would be seriously harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following any initial regulatory approval of drugs we or our partners may develop, including our four approved drugs, we will also be subject to continuing regulatory oversight, including the review of adverse drug experiences and clinical results that are reported after our drug products are made commercially available. This would include results from any post-marketing tests or surveillance to monitor the safety and efficacy of our approved drugs or other drug products required as a condition of approval or agreed to by us. The regulatory approvals that we receive for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO, as well as any regulatory approvals we receive for any other product candidates may also be subject to limitations on the approved uses for which the product may be marketed, including any expanded label for ONPATTRO or AMVUTTRA. Other ongoing regulatory requirements include, among other things, submissions of safety and other post-marketing information and reports, registration and listing, as well as continued compliance with good practice quality guidelines and regulations, including cGMP requirements and GCP requirements for any clinical trials that we conduct post-approval. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">addition, we are conducting, and intend to continue to conduct, clinical trials for our product candidates, and we intend to seek approval to market our product candidates, in jurisdictions outside of the U.S., and therefore will be subject to, and must comply with, regulatory requirements in those jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA has significant post-market authority, including, for example, the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate serious safety risks related to the use of a drug and to require withdrawal of the product from the market. The FDA also has the authority to require a REMS plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. As our approved products are used commercially, we or others could identify previously unknown side effects or known side effects could be observed as being more frequent or severe than in clinical studies or earlier post-marketing periods, in which case:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">sales of our approved products may be more modest than originally anticipated;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory approvals for our approved products may be restricted or withdrawn;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we may decide, or be required, to send product warning letters or field alerts to physicians, pharmacists and hospitals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">additional nonclinical or clinical studies, changes in labeling, adoption of a REMS plan, or changes to manufacturing processes, specifications and/or facilities may be required; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">government investigations or lawsuits, including class action suits, may be brought against us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of the above occurrences could reduce or prevent sales of our approved products, increase our expenses and impair our ability to successfully commercialize one or more of these products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The CMO and manufacturing facilities we use to make our approved products and certain of our current product candidates, including our Cambridge facility, our Norton facility, as well as facilities at Agilent and other CMOs, will also be subject to periodic review and inspection by the FDA and other regulatory agencies. For example, Agilent and our Cambridge-based facility were subject to regulatory inspection by the FDA and the EMA in connection with the review of our applications for regulatory approval for ONPATTRO and GIVLAARI, and may be subject to similar inspection in connection with any subsequent applications for regulatory approval of one or more of our products filed in other territories. The discovery of any new or previously unknown problems with our facilities or our CMOs, or our or their manufacturing processes or facilities, may result in restrictions on the drug or CMO or facility, including delay in approval or, in the future, withdrawal of the drug from the market. For example, due to a routine inspection by the FDA at a CMO facility that resulted in a pending inspection classification, we amended our regulatory submission for vutrisiran, which delayed our PDUFA goal date and AMVUTTRA's FDA approval. We have developed cGMP capabilities and processes for the manufacture of patisiran formulated bulk drug product for commercial use. In addition, in 2020, we completed construction of a cGMP manufacturing facility for drug substance for clinical and, eventually, commercial use. We may not have the ability or capacity to manufacture material at a broader commercial scale in the future. We may manufacture clinical trial materials, or we may contract a third party to manufacture this material for us. Reliance on CMOs entails risks to which we would not be subject if we manufactured products ourselves, including reliance on the CMO for regulatory compliance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we or our collaborators, CMOs or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we may seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may incur significant liability if enforcement authorities allege or determine that we are engaging in commercial activities or promoting our commercially approved products in a way that violates applicable regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Physicians have the discretion to prescribe approved drug products for uses that are not described in the product&#8217;s labeling and that differ from those approved by the FDA or other applicable regulatory agencies. Off-label uses are common across medical specialties. Although the FDA and other regulatory agencies that approve drug products do not regulate a physician&#8217;s practice of medicine or choice of treatments, the FDA and other regulatory agencies regulate a manufacturer&#8217;s communications regarding off-label use and prohibit off-label promotion, as well as the dissemination of false or misleading labeling or promotional materials, including by their agents. Manufacturers and their agents may not promote drugs for off-label uses or provide off-label information in the promotion of drug products that is not consistent with the approved labeling for those products. For example, we may not promote ONPATTRO or AMVUTTRA in the U.S. for use in any indications other than the treatment of the polyneuropathy of hATTR amyloidosis in adults. The FDA and other regulatory and enforcement authorities actively enforce laws and regulations prohibiting promotion of off-label uses and the promotion of products for which marketing approval has not been obtained. In April 2021, we received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of Massachusetts, requiring production of documents pertaining to our marketing and promotion of ONPATTRO (patisiran) in the U.S. We are cooperating with the U.S. Attorney&#8217;s Office and producing documents in response to the subpoena. Current and former officers and employees also have received subpoenas in connection with the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">preservation and production of related materials. Given the ongoing nature of the investigation, it is possible that the U.S. Attorney&#8217;s Office for the District of Massachusetts or other government entities may request other information from, or issue other subpoenas, findings or similar documents to, us, our related entities and their respective directors, officers and employees. If we are found to have improperly marketed or promoted ONPATTRO in connection with such subpoenas, we may be subject to a broad range of civil, administrative and criminal penalties, including injunctive relief related to ONPATTRO promotional activities, substantial fines or penalties, and other legal or equitable sanctions. Any adverse decision, finding, allegation, or exercise of enforcement or regulatory discretion could harm our business, prospects, operating results, and financial condition. Other internal or government investigations or legal or regulatory proceedings, including lawsuits brought by private litigants, may also follow as a consequence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notwithstanding regulations related to product promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading and non-promotional scientific exchange concerning their products, and we intend to engage in medical education activities and communicate with healthcare providers in compliance with all applicable laws and regulatory guidance. Nonetheless, the FDA, other applicable regulatory authorities, competitors, and other third parties may take the position that we are not in compliance with such regulations, and if such non-compliance is proven, it could harm our reputation, financial condition or divert financial and management resources from our core business, and would have a material adverse effect on our business, financial condition and results of operations. Moreover, any threatened or actual government enforcement actions or lawsuits by third parties could also generate adverse publicity, which could decrease demand for our products and require that we devote substantial resources that could be used productively on other aspects of our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to our medical education efforts, we also offer patient support services to assist patients receiving treatment with our commercially approved products. Manufacturers have increasingly become the focus of government investigation of patient support programs based on allegations that through such services illegal inducements are provided to physicians and/or patients, leading to improper utilization of government resources through Medicare, Medicaid and other government programs. Companies that are found to have violated laws such as the federal Anti-Kickback Statute and/or the federal False Claims Act, or FCA, face significant liability, including civil and administrative penalties, criminal sanctions, and potential exclusion from participation in government programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As described above, we remain focused on our global compliance program, which is designed to support the execution of these programs and activities in compliance with applicable laws.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Even if we receive regulatory approval to market our product candidates, the market may not be receptive to our product candidates upon their commercial introduction, which could prevent us from becoming profitable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The product candidates that we are developing are based upon new technologies or therapeutic approaches. Key participants in pharmaceutical marketplaces, such as physicians, third-party payors and consumers, may not accept a product intended to improve therapeutic results based on RNAi technology. As a result, it may be more difficult for us to convince the medical community and third-party payors to accept and use our product, or to provide favorable reimbursement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other factors that we believe will materially affect market acceptance of our product candidates include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing of our receipt of any marketing approvals, the terms of any approvals and the countries in which approvals are obtained;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the safety and efficacy of our product candidates, as demonstrated in clinical trials and as compared with alternative treatments, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">relative convenience and ease of administration of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the willingness of patients to accept potentially new routes of administration or new or different therapeutic approaches and mechanisms of action;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the success of our physician education programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the availability of adequate government and third-party payor reimbursement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the pricing of our products, particularly as compared to alternative treatments, and the market perception of such prices and any price increase that we may implement in the future; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">availability of alternative effective treatments for the diseases that product candidates we develop are intended to treat and the relative risks, benefits and costs of those treatments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For example, one of our two commercially approved therapeutics for the treatment of the polyneuropathy of hATTR amyloidosis in adults, ONPATTRO, utilizes an intravenous mode of administration with pre-medication that physicians and/or patients may not readily adopt, or which may not compete favorably with other available options, including inotersen, marketed by Ionis in several countries, which is administered subcutaneously, or tafamidis, marketed by Pfizer in several countries, which is in pill form. In addition, fitusiran represents a new approach to treating hemophilia which may not be readily accepted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">by patients and their caregivers. Patisiran, if approved for the treatment of ATTR amyloidosis with cardiomyopathy, could face similar challenges in market acceptance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are a multi-product commercial company and expect to continue to invest significant financial and management resources to continue to build our marketing, sales, market access and distribution capabilities and further establish our global infrastructure. Even if we successfully scale our commercial capabilities, the market may not be receptive to our commercial products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Having received our first product approval in August 2018, we have established our capabilities for marketing, sales, market access and distribution over the last several years. We currently expect to rely on third parties to launch and market certain of our product candidates in certain geographies, if approved. However, we are commercializing ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO, and intend to commercialize several of our late-stage product candidates, if approved, on our own globally in major markets. Accordingly, we have developed internal marketing, sales, market access and distribution capabilities as part of our core product strategy initially in the U.S., Europe and Japan, with expansion ongoing globally, which has, and will continue to, require significant financial and management resources. For those products for which we will perform marketing, sales, market access and distribution functions ourselves, including ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO, and for future products we successfully develop where we may retain certain product development and commercialization rights, we could face a number of additional risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">scaling and retaining our global sales, marketing and administrative infrastructure and capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">hiring, training, managing and supervising our personnel worldwide;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the cost of further developing, or leveraging an established, marketing or sales force, which may not be justifiable in light of the revenues generated by any particular product and/or in any specific geographic region; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our direct sales and marketing efforts may not be successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to continue to develop and scale our own global marketing, sales, market access and distribution capabilities for our current and any future products, we will not be able to successfully commercialize our products without reliance on third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The patient populations suffering from hATTR amyloidosis, AHP and PH1 are small and have not been established with precision. If the actual number of patients is smaller than we estimate, or if we cannot raise awareness of these diseases and diagnosis is not improved, our revenue and ability to achieve profitability from these products may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our estimates regarding the potential market size for ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO or any future products at the time we commence commercialization, may be materially different from the actual market size, including as a result of the indication approved by regulatory authorities, which could result in significant changes in our business plan and may have a material adverse effect on our results of operations and financial condition. For example, the initial indication approved by the FDA for ONPATTRO is for the treatment of the polyneuropathy of hATTR amyloidosis and not for the treatment of cardiomyopathy or other manifestations of the disease. In addition, the U.S. label does not include cardiac data included in our APOLLO-B Phase 3 study results. This had an adverse impact on the market opportunity for ONPATTRO in the U.S. While data from the APOLLO-B study of patisiran in ATTR amyloidosis patients with cardiomyopathy was positive, the FDA may determine that the data is not supportive of a label expansion of ONPATTRO for the treatment of cardiomyopathy, which would further impact ONPATTRO's market opportunity. In addition, our efforts to raise disease awareness and improve diagnosis of our relevant disease states have been and may in the future be impacted by the COVID-19 pandemic. For example, in 2020 and 2021, we saw a reduction in peer to peer educational opportunities, reduced physician attendance at congresses and symposia and overall opportunities for physician engagement. As is the case with most orphan diseases, if we cannot successfully raise awareness of these diseases and improve diagnosis, it will be more difficult or impossible to achieve profitability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. We are actively monitoring these regulations as we market and sell our approved products and as several of our other programs move through late stages of development. However, a number of our programs are currently in the earlier stages of development, and we will not be able to assess the impact of price regulations for such programs for a number of years. We might obtain regulatory approval for a product, including one or more of our approved products, in a particular country, but then be subject to price regulations that delay our commercial launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that country and potentially in other countries due to reference pricing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to commercialize our approved products or any future products successfully also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. One or more of our approved products and other products for which we are able to obtain marketing approval may not be considered cost-effective, and the amount reimbursed may be insufficient to allow us to sell such product(s) or any future products on a competitive basis. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for drug products. In the U.S., we have entered into over 40 value-based agreements, or VBAs, and are negotiating additional VBAs with commercial health insurers. The goal of these agreements is to ensure that we are paid based on the ability of our commercially approved products to deliver results in the real world setting comparable to those demonstrated in clinical trials, and the agreements are structured to link the performance of our approved products in real-world use to financial terms. Partnering with payers on these agreements is also intended to provide more certainty to them for their investment and help accelerate coverage decisions for patients. If the payment we receive for our products, or the reimbursement provided for such products, is inadequate in light of our development and other costs, or if reimbursement is denied, our return on investment could be adversely affected. In addition, we have stated publicly that we intend to grow through continued scientific innovation rather than arbitrary price increases. Specifically, we have stated that we will not raise the price of any product for which we receive marketing approval over the rate of inflation, as determined by the consumer price index for urban consumers (approximately 5.0% currently) absent a significant value driver. Our patient access philosophy could also negatively impact the revenues we are able to generate from the sale of one or more of our products in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of the drugs we market need to be administered under the supervision of a physician or other healthcare professional on an outpatient basis, including ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO. Under currently applicable U.S. law, certain drugs that are not usually self-administered (including injectable drugs) may be eligible for coverage under the Medicare Part B program if:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">they are incident to a physician&#8217;s services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">they are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to accepted standards of medical practice; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">they have been approved by the FDA and meet other requirements of the statute.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There may be significant delays in obtaining coverage for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or foreign regulatory authorities. Moreover, eligibility for coverage does not imply that any drug will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution or that covers a particular provider&#8217;s cost of acquiring the drug. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement may be based on payments allowed for lower-cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President Biden signed an Executive Order on July 9, 2021 affirming the administration&#8217;s policy to (i) support legislative reforms that would lower the prices of prescription drugs, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs the U.S. Department of Health and Human Services, or HHS, to provide a report on actions to combat excessive pricing of prescription drugs, continue to clarify and improve the approval framework for generic drugs and identify and address any efforts to impede generic drug competition, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price gouging in the industry; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#8217;s implementing regulations. The FDA released such implementing regulations on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. In response, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. If implemented, importation of drugs from Canada and the Most Favored Nation, or MFN, Model may materially and adversely affect the price we receive for any of our commercially approved products. Further, on November 20, 2020, the Centers for Medicare and Medicaid Services, or CMS, issued an Interim Final Rule implementing the MFN Model under which Medicare Part B reimbursement rates will be calculated for certain drugs based on the lowest price drug manufacturers receive in OECD countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and would have applied to all U.S. states and territories for a seven-year period beginning January 1, 2021, and ending December 31, 2027. However, on December 29, 2021, CMS rescinded the proposed MFN rule. Additionally, on December 2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors have been delayed until January 1, 2023, requiring manufacturers to ensure the full value of co-pay assistance is passed on to the patient or these dollars will count toward the Average Manufacturer Price and Best Price calculation of the drug. On May 17, 2022, the U.S. District Court for the District of Columbia granted the Pharmaceutical Research and Manufacturers of America&#8217;s motion for summary judgement invalidating the accumulator adjustment rule. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the current U.S. presidential administration may reverse or otherwise change these measures, both the current U.S. presidential administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the efforts of governments and third-party payors to contain or reduce the cost of healthcare and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical companies. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A number of other legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare markets have been proposed or enacted in recent months and years, and such efforts have expanded substantially in recent years. These developments could, directly or indirectly, affect our ability to sell ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO or future products, if approved, at a favorable price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In particular, in March 2010, the Patient Protection and Affordable Care Act, also referred to as the Affordable Care Act, or the ACA, was signed into law. This legislation changed the system of healthcare insurance and benefits intended to broaden coverage and control costs. The law also contains provisions that affect companies in the pharmaceutical industry and other healthcare related industries by imposing additional costs and changes to business practices. Among the provisions affecting pharmaceutical companies are the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Mandatory rebates for drugs sold into the Medicaid program were increased, and the rebate requirement was extended to drugs used in risk-based Medicaid managed care plans.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The 340B Drug Pricing Program under the Public Health Service Act was extended to require mandatory discounts for drug products sold to certain critical access hospitals, cancer hospitals and other covered entities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Pharmaceutical companies are required to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly referred to as the &#8220;donut hole.&#8221;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Pharmaceutical companies are required to pay an annual non-tax deductible fee to the federal government based on each company&#8217;s market share of prior year total sales of branded products to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs and Department of Defense. Since we expect our branded pharmaceutical sales to constitute a small portion of the total federal healthcare program pharmaceutical market, we do not expect this annual assessment to have a material impact on our financial condition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law provides that approval of an application for a follow-on biologic product may not become effective until 12 years after the date on which the reference innovator biologic product was first licensed by the FDA, with a possible six-month extension for pediatric products. After this exclusivity ends, it will be easier for generic manufacturers to enter the market, which is likely to reduce the pricing for such products and could affect our profitability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law creates a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law expands eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law expands the entities eligible for discounts under the Public Health Service Act pharmaceutical pricing program.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law expands healthcare fraud and abuse laws, including the civil FCA and the federal Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law establishes new requirements to report financial arrangements with physicians and teaching hospitals and to annually report drug samples that manufacturers and distributors provide to physicians.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law establishes a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery methods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Following the suspension, a 1% payment reduction began April 1, 2022, lasting through June 30, 2022. The 2% payment reduction resumed on July 1, 2022. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for our approved products or any of our product candidates for which we may obtain regulatory approval, or the frequency with which our products or any future product is prescribed or used.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, there have been several changes to the 340B Drug Pricing Program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain healthcare facilities. On December 27, 2018, the District Court for the District of Columbia invalidated a reimbursement formula change under the 340B Drug Pricing Program, and CMS subsequently altered the fiscal years 2019 and 2018 reimbursement formula on specified covered outpatient drugs. The court ruled this change was not an &#8220;adjustment&#8221; which was within the Secretary&#8217;s discretion to make but was instead a fundamental change in the reimbursement calculation. However, most recently, on July 31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#8217;s decision and found that the changes were within the Secretary&#8217;s authority. On September 14, 2020, the plaintiffs-appellees filed a Petition for Rehearing En Banc (i.e., before the full court), and the court denied this petition on October 16, 2020. Plaintiffs-appellees filed a petition for a writ of certiorari at the Supreme Court on February 10, 2021. On July 2, 2021, the Supreme Court granted the petition. On June 15, 2022, the Supreme Court unanimously reversed the Court of Appeals&#8217; decision, holding that HHS&#8217;s 2018 and 2019 reimbursement rates for 340B hospitals were contrary to the statute and unlawful. It is unclear how these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Inflation Reduction Act of 2022, or IRA, which among other things, allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. Further, the legislation caps Medicare beneficiaries&#8217; annual out-of-pocket drug expenses at $2,000. Under the IRA, a second FDA approval for vutrisiran for Stargardt Disease would cause us to lose the single-orphan exemption for AMVUTTRA from Medicare price negotiation. As a result, in October 2022, we announced we would not pursue a Phase 3 clinical trial to study vutrisiran in Stargardt Disease. The effect of the IRA on our business and the healthcare industry in general is developing and may have an additional adverse impact on our industry.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full effects of the U.S. healthcare reform legislation cannot be known until the law is fully implemented through regulations or guidance issued by CMS and other federal and state healthcare agencies. The financial impact of the U.S. healthcare reform legislation over the next few years will depend on a number of factors, including, but not limited, to the policies reflected in implementing regulations and guidance, and changes in sales volumes for products affected by the new system of rebates, discounts and fees. This legislation may also have a positive impact on our future net sales, if any, by increasing the aggregate number of persons with healthcare coverage in the U.S.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court's decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for the purpose of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing. Some of these measures include price or patient reimbursement constraints, discounts, restrictions on certain product access, marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal and state legislative and regulatory developments are likely, and we expect ongoing initiatives in the U.S. to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from one or more of our approved products or other product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop drug candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Failure to comply with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control, the Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. From time to time, we may engage third parties to conduct clinical trials outside of the U.S., to sell our products abroad, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We remain focused on these laws and the activities they regulate and, as detailed above, maintain a global compliance program designed to empower our business to operate in compliance with their requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Governments outside the U.S. may impose strict price controls, which may adversely affect our revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The pricing of prescription pharmaceuticals is also subject to governmental control outside the U.S. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of regulatory approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In some countries, including Member States of the EU, or Japan, the pricing of prescription drugs is subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In such countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Moreover, political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between low-priced and high-priced countries, can further reduce prices. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of a product candidate to other available therapies in order to obtain or maintain reimbursement or pricing approval, which is time-consuming and costly. We cannot be sure that such prices and reimbursement will be acceptable to us or our strategic partners. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the potential profitability of our approved products or any future products in those countries would be negatively affected. Another impact from the tightening pricing control could be felt from greater competition from less expensive generic or biosimilar products once the exclusivity expires; the governments have adopted policies to switch prescribed products to generic versions in order to cut the medical cost.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we or our collaborators, CMOs or service providers fail to comply with healthcare laws and regulations, or legal obligations related to privacy, data protection and information security, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a manufacturer of pharmaceuticals, we are subject to federal, state, and comparable foreign healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights, in addition to legal obligations related to privacy, data protection and information security. These laws and regulations include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchase, lease, order, arrangement, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal FCA or federal civil money penalties.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The U.S. federal false claims laws, including the FCA, which prohibit, among other things, individuals or entities from knowingly presenting or causing to be presented, claims for payment by government-funded programs such as Medicare or Medicaid that are false or fraudulent, making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, which imposes requirements relating to the privacy, security, and transmission of individually identifiable health information; and requires notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Federal &#8220;sunshine&#8221; requirements imposed by the ACA on drug, device, biological and medical supply manufacturers when payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to HHS under the Open Payments Program, information regarding any payment or other &#8220;transfer of value&#8221; made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician providers such as physician assistants and nurse practitioners, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in civil monetary penalties for all payments, transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Federal statutory and regulatory requirements applicable to pricing and sales of product to Federal Government Agencies.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">State and foreign laws comparable to each of the above federal laws, including in the EU laws prohibiting giving healthcare professionals any gift or benefit in kind as an inducement to prescribe our products, national transparency laws requiring the public disclosure of payments made to healthcare professionals and institutions, and data privacy laws, in addition to anti-kickback and false claims laws applicable to commercial insurers and other non-federal payors, requirements for mandatory corporate regulatory compliance programs, and laws relating to government reimbursement programs, patient data privacy and security.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">European privacy laws including Regulation 2016/679, known as the General Data Protection Regulation, or the EU GDPR, and the EU GDPR as transposed into the laws of the UK, the UK GDPR, collectively referred to as the GDPR, and the e-Privacy Directive (2002/58/EC), and the national laws implementing each of them, as well as the Public and Electronic Communications Regulations 2003 in the UK and the privacy laws of Japan and other territories. Failure to comply with our obligations under the privacy regime could expose us to significant fines and/or adverse publicity, which could have material adverse effects on our reputation and business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The California Consumer Privacy Act of 2018, or CCPA, effective as of January 1, 2020, that gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Additionally, a new California ballot initiative, the California Privacy Rights Act of 2020, or CPRA, was passed in November 2020. Effective as of January 1, 2023, the CPRA imposes additional obligations on companies covered by the legislation and will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. Furthermore, similar laws were enacted in four other states and proposed in numerous others. The effects of the CCPA and the CPRA are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply and increase our potential exposure to regulatory enforcement and/or litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some state laws also require pharmaceutical manufacturers to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, in addition to requiring manufacturers to report information related to payments to physicians and other healthcare provides or marketing expenditures and pricing information. State and foreign laws also govern the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our operations are found to be in violation of any of the aforementioned requirements, we may be subject to penalties, including civil or criminal penalties (including individual imprisonment), criminal prosecution, monetary damages, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, or the imposition of a corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services, any of which could adversely affect our financial results. We remain focused on enhancing our global compliance infrastructure following the commercial launch of our four products over the last four years in the U.S., EU and multiple other geographies, and as we prepare for the launch of our products in additional countries, assuming regulatory approvals. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. For additional information, see the Risk Factor captioned &#8220;We may incur significant liability if enforcement authorities allege or determine that we are engaging in commercial activities or promoting our commercially approved products in a way that violates applicable regulations.&#8221; Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we or our collaborators, CMOs or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our approved products, or any other future products, successfully and could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, among others:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse regulatory inspection findings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">untitled letters or warning letters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">voluntary or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">restrictions on, or prohibitions against, marketing our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">restrictions on, or prohibitions against, importation or exportation of our products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">suspension of review or refusal to approve pending applications or supplements to approved applications;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">exclusion from participation in government-funded healthcare programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">exclusion from eligibility for the award of government contracts for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">suspension or withdrawal of product approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">product seizures;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">injunctions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">civil and criminal penalties, up to and including criminal prosecution resulting in fines, exclusion from healthcare reimbursement programs and imprisonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, federal, state or foreign laws or regulations are subject to change, and while we, our collaborators, CMOs and/or service providers currently may be compliant, that could change due to changes in interpretation, prevailing industry standards or the legal structure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third party patient assistance programs that receive financial support from companies have become the subject of enhanced government and regulatory scrutiny. The OIG has established guidelines that suggest that it is lawful for pharmaceutical manufacturers to make donations to charitable organizations who provide co-pay assistance to Medicare patients, provided that such organizations, among other things, are bona fide charities, are entirely independent of and not controlled by the manufacturer, provide aid to applicants on a first-come basis according to consistent financial criteria and do not link aid to use of a donor's product. However, donations to patient assistance programs have received some negative publicity and have been the subject of multiple government enforcement actions, related to allegations regarding their use to promote branded pharmaceutical products over other less costly alternatives. Specifically, in recent years, there have been multiple settlements resulting out of government claims challenging the legality of their patient assistance programs under a variety of federal and state laws. It is possible that we may make grants to independent charitable foundations that help financially needy patients with their premium, co-pay, and co-insurance obligations. If we choose to do so, and if we or our vendors or donation recipients are deemed to fail to comply with relevant laws, regulations or evolving government guidance in the operation of these programs, we could be subject to damages, fines, penalties, or other criminal, civil, or administrative sanctions or enforcement actions. We cannot ensure that our compliance controls, policies, and procedures will be sufficient to protect against acts of our employees, business partners, or vendors that may violate the laws or regulations of the jurisdictions in which we operate. Regardless of whether we have complied with the law, a government investigation could impact our business practices, harm our reputation, divert the attention of management, increase our expenses, and reduce the availability of foundation support for our patients who need assistance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to governmental regulation and other legal obligations, particularly related to privacy, data protection and information security, and we are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our actual or perceived failure to comply with such obligations could harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;special category data,&#8221; which includes health, biometric and genetic information of data subjects located in the EEA and UK. Further, GDPR provides a broad right for EEA Member States to create supplemental national laws, such as laws relating to the processing of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase, and harm our business and financial condition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EEA Member States and the UK, which may deviate slightly from the GDPR, may result in fines of up to 4% of total global annual revenue, or &#8364;20.0 million (&#8356;17.5 million under the UK GDPR), whichever is greater, and in addition to such fines, we may be the subject of litigation and/or adverse publicity, which could have a material adverse effect on our reputation and business. As a result of the implementation of the GDPR, we are required to put in place a number of measures to ensure compliance with the data protection regime. The GDPR requires us to inform data subjects of how we process their personal data and how they can exercise their rights, ensure we have a valid legal basis to process personal data (if this is consent, the requirements for obtaining consent carries a higher threshold), appoint a data protection officer where sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification requirements throughout the EEA and UK, requires us to maintain records of our processing activities and to document data protection impact assessments where there is high risk processing, imposes additional obligations on us when we are contracting with service providers, requires appropriate technical and organisational measures to be put in place to safeguard personal data and requires us to adopt appropriate privacy governance including policies, procedures, training and data audit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significantly, the GDPR imposes strict rules on the transfer of personal data out of the EEA and UK to the U.S. or other regions that have not been deemed to offer &#8220;adequate&#8221; privacy protections. In the past, companies in the U.S. were able to rely upon the EU-U.S., UK-U.S. and the Swiss-U.S. Privacy Shield frameworks to legitimize data transfers from the EU and the UK to the U.S. In July 2020, the Court of Justice of the European Union, or CJEU, in Case C-311/18 (Data Protection </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commissioner v Facebook Ireland and Maximillian Schrems, or Schrems II) invalidated the EU-U.S. Privacy Shield on the grounds that the Privacy Shield failed to offer adequate protections to EU personal data transferred to the U.S. The CJEU, in the same decision, deemed that the Standard Contractual Clauses, or SCCs, published by the EC are valid. However, the CJEU ruled that transfers made pursuant to the SCCs need to be assessed on a case-by-case basis to ensure the law in the recipient country provides &#8220;essentially equivalent&#8221; protections to safeguard the transferred personal data as the EU, and required businesses to adopt supplementary measures if such standard is not met. Subsequent guidance published by the European Data Protection Board, or EDPB, in June 2021 described what such supplementary measures must be, and stated that businesses should avoid or cease transfers of personal data if, in the absence of supplementary measures, equivalent protections cannot be afforded. On June 4, 2021, the EC published new versions of the SCCs, which seek to address the issues identified by the CJEU&#8217;s Schrems II decision and provide further details regarding the transfer assessments that the parties are required to conduct when implementing the New SCCs. However, there continue to be concerns about whether the SCCs and other mechanisms will face additional challenges. Similarly, the Swiss data protection authority determined the Swiss-U.S. Privacy Shield framework was no longer a valid mechanism for Swiss-U.S. data transfers and also raised questions about the validity of the SCCs as a mechanism for transferring personal data from Switzerland. While SCCs provide an alternative to our Privacy Shield certification for EU-U.S. data flows, the decision (and certain regulatory guidance issued in its wake) casts doubt on the legality of EU-U.S. data flows in general. Any inability to transfer personal data from the EU to the U.S. in compliance with data protection laws may impede our ability to conduct trials and may adversely affect our business and financial position. The UK is not subject to the EC&#8217;s new SCCs but has published its own transfer mechanism, the International Data Transfer Agreement or International Data Transfer Addendum, which enables transfers from the UK. On March 25, 2022, the EC and the U.S. announced to have reached a political agreement on a new &#8220;Trans-Atlantic Data Privacy Framework&#8221; to replace the invalidated Privacy Shield, but this has faced scrutiny from other EU authorities, such as the EDPB which casts doubt on whether the new framework will come into force.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EEA Member States have adopted implementing national laws to implement the GDPR which may partially deviate from the GDPR and the competent authorities in the EEA Member States may interpret GDPR obligations slightly differently from country to country, so that we do not expect to operate in a uniform legal landscape in the EU. In addition, the UK Government has now introduced a Data Protection and Digital Information Bill, or the UK Bill, into the UK legislative process. The aim of the UK Bill is to reform UK&#8217;s data protection regime following Brexit. If passed, the final version of the UK Bill may have the effect of further altering the similarities between the UK and EEA data protection regime.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the supervision of local data protection authorities in those jurisdictions where we are monitoring the behavior of individuals in the EEA or UK (i.e., undertaking clinical trials). We depend on a number of third parties in relation to the provision of our services, a number of which process personal data of EU and/or UK individuals on our behalf. With each such provider we enter or intend to enter into contractual arrangements under which they are contractually obligated to only process personal data according to our instructions, and conduct or intend to conduct diligence to ensure that they have sufficient technical and organizational security measures in place.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to evolving European privacy laws on electronic marketing and cookies. The EU is in the process of replacing the e-Privacy Directive (2002/58/EC) with a new set of rules taking the form of a regulation, which will be directly implemented in the laws of each European member state, without the need for further enactment. While the e-Privacy Regulation was originally intended to be adopted on May 25, 2018 (alongside the GDPR), it is still going through the European legislative process. Draft regulations were rejected by the Permanent Representatives Committee of the Council of EU on November 22, 2019; it is not clear when new regulations will be adopted.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending and services, and any inability on our part to effectively adapt to such changes could substantially affect our financial position, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Budget Control Act of 2011, the failure of Congress to enact deficit reduction measures of at least $1.2 trillion for the years 2013 through 2021 triggered automatic cuts to most federal programs. These cuts included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, starting in 2013. Certain of these automatic cuts have been implemented resulting in reductions in Medicare payments to physicians, hospitals, and other healthcare providers, among other things. Due to legislation amending the statute, including the Bipartisan Budget Act of 2018, these reductions will stay in effect through 2030 unless additional Congressional action is taken. Pursuant to the CARES Act, as well as subsequent legislation, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">these reductions were suspended from May 1, 2020 through December 31, 2021 due to the COVID-19 pandemic. The full impact on our business of these automatic cuts is uncertain.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If other federal spending is reduced, any budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health to continue to function. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve drug research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell our approved products and any other products we may develop. Further, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">There is a substantial risk of product liability claims in our business. If we are unable to obtain sufficient insurance, a product liability claim against us could adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business exposes us to significant potential product liability risks that are inherent in the development, testing, manufacturing and marketing of human therapeutic products. Product liability claims could delay or prevent completion of our clinical development programs. Following the decision to discontinue clinical development of revusiran, we conducted a comprehensive evaluation of available revusiran data. We reported the results of this evaluation in August 2017, however, our investigation did not result in a conclusive explanation regarding the cause of the mortality imbalance observed in the ENDEAVOUR Phase 3 study. In addition, in September 2017, we announced that we had temporarily suspended dosing in all ongoing fitusiran studies pending further review of a fatal thrombotic SAE and agreement with regulatory authorities on a risk mitigation strategy. Notwithstanding the risks undertaken by all persons who participate in clinical trials, and the information on risks provided to study investigators and patients participating in our clinical trials, including the revusiran and fitusiran studies, it is possible that product liability claims will be asserted against us relating to the worsening of a patient&#8217;s condition, injury or death alleged to have been caused by one of our product candidates, including revusiran or fitusiran. Such claims might not be fully covered by product liability insurance. In addition, product liability claims could result in an FDA investigation of the safety and effectiveness of our approved products, our manufacturing processes and facilities or our marketing programs, and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used, or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development, including the marketing and sale of our approved products. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements or insider trading violations, which could significantly harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with governmental regulations, comply with healthcare fraud and abuse and anti-kickback laws and regulations in the U.S. and abroad, or failure to report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including improper trading based upon, information obtained in the course of clinical studies, which could result in regulatory sanctions and serious harm to our reputation. We maintain a global compliance program and remain focused on its evolution and enhancement. Our program includes efforts such as risk assessment and monitoring, fostering a speak up culture encouraging employees and third parties to raise good faith questions or concerns, and defined processes and systems for reviewing and remediating allegations and identified potential concerns. It is not always possible, however, to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research, development and manufacturing involve the use of hazardous materials, chemicals and various radioactive compounds. We maintain quantities of various flammable and toxic chemicals in our facilities in Cambridge and Norton that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Cambridge and Norton facilities comply with the relevant guidelines of the City of Cambridge, the town of Norton, the Commonwealth of Massachusetts and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Patents, Licenses and Trade Secrets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are not able to obtain and enforce patent protection for our discoveries, our ability to develop and commercialize our product candidates will be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends, in part, on our ability to protect proprietary compositions, methods and technologies that we develop under the patent and other intellectual property laws of the U.S. and other countries, so that we can prevent others from unlawfully using our inventions and proprietary information. However, we may not hold proprietary rights to some patents required for us to manufacture and commercialize our proposed products. Because certain U.S. patent applications are confidential until the patents issue, such as applications filed prior to November 29, 2000, or applications filed after such date which will not be filed in foreign countries, third parties may have filed patent applications for subject matter covered by our pending patent applications without our being aware of those applications, and our patent applications may not have priority over those applications. For this and other reasons, we may be unable to secure desired patent rights, thereby losing desired exclusivity. Further, we or our licensees may be required to obtain licenses under third-party patents to market one or more of our or our partner's approved products, or further develop and commercialize future products, or continue to develop candidates in our pipeline being developed by us or our licensees. If licenses are not available to us or not available on reasonable terms, we or our licensees may not be able to market the affected products or conduct the desired activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our strategy depends on our ability to rapidly identify and seek patent protection for our discoveries. In addition, we may rely on third-party collaborators to file patent applications relating to proprietary technology that we develop jointly during certain collaborations. The process of obtaining patent protection is expensive and time-consuming. If our present or future collaborators fail to file and prosecute all necessary and desirable patent applications at a reasonable cost and in a timely manner, our business may be adversely affected. Despite our efforts and the efforts of our collaborators to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. While issued patents are presumed valid, this does not guarantee that the patent will survive a validity challenge or be held enforceable. Any patents we have obtained, or obtain in the future, may be challenged, invalidated, adjudged unenforceable or circumvented by parties attempting to design around our intellectual property. Moreover, third parties or the United States Patent and Trademark Office, or USPTO, may commence interference proceedings involving our patents or patent applications. Any challenge to, finding of unenforceability or invalidation or circumvention of, our patents or patent applications, would be costly, would require significant time and attention of our management, could reduce or eliminate royalty payments to us from third party licensors and could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our pending patent applications may not result in issued patents. The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the U.S. and foreign countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts and lawmakers. Moreover, there are periodic discussions in the Congress of the United States and in international jurisdictions about modifying various aspects of patent law. For example, the America Invents Act, or AIA, included a number of changes to the patent laws of the U.S. If any of the enacted changes do not provide adequate protection for discoveries, including our ability to pursue infringers of our patents for substantial damages, our business could be adversely affected. One major </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">provision of the AIA, which took effect in March 2013, changed U.S. patent practice from a first-to-invent to a first-to-file system. If we fail to file an invention before a competitor files on the same invention, we no longer have the ability to provide proof that we were in possession of the invention prior to the competitor&#8217;s filing date, and thus would not be able to obtain patent protection for our invention. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued to us or to others. We also rely to a certain extent on trade secrets, know-how and technology, which are not protected by patents, to maintain our competitive position. If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to obtain and maintain all available regulatory exclusivities, broad patent scope and to maximize patent term restoration or extension on patents covering our products may lead to loss of exclusivity and early generic entry resulting in a loss of market share and/or revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We license patent rights from third-party owners. If such owners do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, our competitive position and business prospects may be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a party to a number of licenses that give us rights to third-party intellectual property that is necessary or useful for our business. In particular, we have obtained licenses from, among others, Ionis, Arbutus Biopharma Corp., or Arbutus, and Dicerna. We also intend to enter into additional licenses to third-party intellectual property in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, in particular, those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we sublicense our rights under various third-party licenses to our collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our collaboration agreements or result in termination of an agreement by one or more of our collaborators.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other companies or organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RNAi is a relatively new scientific field, the commercial exploitation of which has resulted in many different patents and patent applications from organizations and individuals seeking to obtain patent protection in the field. We have obtained grants and issuances of RNAi patents and have licensed many of these patents from third parties on an exclusive basis. The issued patents and pending patent applications in the U.S. and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of RNAi therapeutics.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Specifically, we have a portfolio of patents, patent applications and other intellectual property covering: fundamental aspects of the structure and uses of siRNAs, including their use as therapeutics, and RNAi-related mechanisms; chemical modifications to siRNAs that improve their suitability for therapeutic and other uses; siRNAs directed to specific targets as treatments for particular diseases; delivery technologies, such as in the fields of carbohydrate conjugates and cationic liposomes; and all aspects of our specific development candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the field of RNAi therapeutics is maturing, patent applications are being fully processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. It is likely that there will be significant litigation and other proceedings, such as interference, re-examination and opposition proceedings, as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and post-grant review proceedings introduced by provisions of the AIA, which became available to third party challengers on September 16, 2012, in various patent offices relating to patent rights in the RNAi field. In addition, third parties may challenge the validity of our patents. For example, a third party has filed an opposition in the European Patent Office, or EPO, against our owned patent EP 2723758, with claims directed to compositions and methods of ANGPTL3, arguing that the granted claims are invalid. An oral hearing was held at the EPO in February 2021, where the patent was revoked. A notice of appeal of the EPO's decision was filed in June 2021. In addition, in February 2023, a third party filed an opposition with the EPO against our owned patent EP 3366775, titled &#8220;Modified RNA Agents&#8221; seeking to revoke the patent. An oral hearing is anticipated at a time to be determined by the EPO. We expect that additional oppositions will be filed in the EPO and elsewhere, and other challenges will be raised relating to other patents and patent applications in our portfolio. In many cases, the possibility of appeal exists for either us or our opponents, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. Even if our rights are not directly challenged, disputes could lead to the weakening of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material adverse effect on our business and our ability to successfully compete in the field of RNAi.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are many issued and pending patents that claim aspects of oligonucleotide chemistry and modifications that we may need for our siRNA products marketed by us or our licensees, our late-stage therapeutic candidates being developed by us or our licensees, including zilebesiran and fitusiran, as well as our other pipeline products. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for siRNA drugs we wish to develop. In addition, there may be issued and pending patent applications that may be asserted against us in a court proceeding or otherwise based upon the asserting party&#8217;s belief that we may need such patents for our siRNA therapeutic candidates or marketed products, or to further develop and commercialize future products, or to continue to develop candidates in our pipeline that are being developed by us or our licensees. Thus, it is possible that one or more organizations will hold patent rights to which we may need a license, or hold patent rights which could be asserted against us. If those organizations refuse to grant us a license to such patent rights on reasonable terms and/or a court rules that we need such patent rights that have been asserted against us and we are not able to obtain a license on reasonable terms, we may be unable to market products, including ONPATTRO, AMVUTTRA, GIVLAARI or OXLUMO, or perform research and development or other activities covered by such patents. For example, during 2017 and 2018, Silence Therapeutics, plc, or Silence, filed claims in several jurisdictions, including the High Court of England and Wales, and named us and our wholly owned subsidiary Alnylam UK Ltd. as co-defendants. Silence alleged various claims, including that ONPATTRO infringed one or more Silence patents. There were also a number of related actions brought by us or Silence in connection with this intellectual property dispute. In December 2018, we entered into a Settlement and License Agreement with Silence, resolving all ongoing claims, administrative proceedings, and regulatory proceedings worldwide between us regarding, among other issues, patent infringement, patent invalidity and breach of contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we become involved in intellectual property litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, and in the case of such litigation or proceedings against us, substantial liability for damages or be required to stop our product development and commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third parties may sue us for infringing their patent rights. For example, in October 2017 Silence sued us in the UK alleging that ONPATTRO and other investigational RNAi therapeutics we or MDCO are developing infringed one or more Silence patents. In December 2018 we and Silence settled all ongoing litigation between us. A third party may also claim that we have improperly obtained or used its confidential or proprietary information. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, third parties may challenge the inventorship of our patents or licensed patents. For example, in March 2011, The University of Utah, or Utah, filed a complaint against us, Max Planck Gesellschaft Zur Foerderung Der Wissenschaften e.V. and Max Planck Innovation, together, Max Planck, Whitehead, MIT and the University of Massachusetts, claiming that a professor of Utah was the sole inventor, or in the alternative, a joint inventor of certain of our in-licensed patents. Utah was seeking correction of inventorship of the Tuschl patents, unspecified damages and other relief. After several years of court proceedings and discovery, the court granted our motions for summary judgment, and dismissed Utah&#8217;s state law damages claims as well. During the pendency of this litigation, as well as the Dicerna litigation described above, we incurred significant costs, and in each case, the litigation diverted the attention of our management and other resources that would otherwise have been engaged in other activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may need to resort to litigation to enforce a patent issued or licensed to us or to determine the scope and validity of proprietary rights of others or protect our proprietary information and trade secrets. For example, during the second quarter of 2015, we filed a trade secret misappropriation lawsuit against Dicerna to protect our rights in the RNAi assets we purchased from Merck Sharp &amp; Dohme Corp., or Merck. We and Dicerna settled the ongoing litigation between us in April 2018. In March 2022, we announced that we separately filed suit in United States District Court for the District of Delaware against Pfizer and Moderna, Inc., seeking damages for infringement of U.S. Patent No. 11,246,933 in the parties&#8217; manufacture and sale of their messenger RNA, or mRNA, COVID-19 vaccines. Pfizer joined BioNTech SE, or BioNTech, to the suit and filed counterclaims. In July 2022, we filed a new lawsuit in United States District Court for the District of Delaware against each of Pfizer/BioNTech and Moderna seeking damages for infringing our newly granted U.S. Patent No. 11,382,979. The Court combined the two patents in a single suit for each of Pfizer/BioNTech and Moderna with trial dates set for each in November 2024. The aforementioned patents relate to our biodegradable cationic lipids that are foundational to the success of the mRNA COVID-19 vaccines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In protecting our intellectual patent rights through litigation or other means, a third party may claim that we have improperly asserted our rights against them. For example, in August 2017, Dicerna successfully added counterclaims against us in the above-referenced trade secret lawsuit alleging that our lawsuit represented abuse of process and claiming tortious interference with its business. In addition, in August 2017, Dicerna filed a lawsuit against us in the United States District Court of Massachusetts alleging attempted monopolization by us under the Sherman Antitrust Act. As noted above, in April 2018, we and Dicerna settled the ongoing litigation between us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, in connection with certain license and collaboration agreements, we have agreed to indemnify certain third parties for certain costs incurred in connection with litigation relating to intellectual property rights or the subject matter of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">agreements. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of any litigation or legal proceeding could delay our research, development and commercialization efforts and limit our ability to continue our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any parties successfully claim that our creation or use of proprietary technologies infringes upon or otherwise violates their intellectual property rights, we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed on such parties&#8217; patent rights. In addition to any damages we might have to pay, a court could issue an injunction requiring us to stop the infringing activity or obtain a license. Any license required under any patent may not be made available on commercially reasonable terms, if at all. In addition, such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and products, which could limit our ability to generate revenues or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Moreover, we expect that a number of our collaborations will provide that royalties payable to us for licenses to our intellectual property may be offset by amounts paid by our collaborators to third parties who have competing or superior intellectual property positions in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with our obligations under any licenses or related agreements, we may be required to pay damages and could lose license or other rights that are necessary for developing, commercializing and protecting our RNAi technology, as well as our approved products and any other product candidates that we develop, or we could lose certain rights to grant sublicenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license or render the license non-exclusive, which could result in us being unable to develop, manufacture, market and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, we could incur significant costs and/or disruption to our business and distraction of our management defending against any breach of such licenses alleged by the licensor. For example, in June 2018, Ionis sent us a notice claiming that it was owed payments under our second amended and restated strategic collaboration and license agreement as a result of the January 2018 amendment of our collaboration agreement with Sanofi and the related Exclusive TTR License and AT3 License Terms. Ionis claimed it was owed technology access fees, or TAFs, based on rights granted and amounts paid to us in connection with the Sanofi restructuring. Ionis later filed a Demand for Arbitration with the Boston office of the American Arbitration Association against us, asserting, among other things, breach of contract. Upon completion of the arbitration process in the second quarter of 2020, in October 2020, a partial award was issued by the arbitration panel that sought additional information from us. The arbitration panel issued its final award in December 2020, which ruled in favor of Ionis&#8217;s request for a TAF on certain rights the panel determined we received in the Sanofi restructuring (but rejecting the TAF amount sought by Ionis), and in favor of us in denying Ionis&#8217;s request for a TAF on a milestone payment received by us in the same restructuring. The panel&#8217;s final award also denied Ionis&#8217;s request for pre-judgement interest and attorney&#8217;s fees. Pursuant to the panel's final award, we paid $41.2 million to Ionis in January 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we will be required to pay on sales of each of our approved products or future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in such products. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, CMOs, outside scientific collaborators and sponsored researchers, and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover trade secrets and proprietary information, and in such cases we could not assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Competition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The pharmaceutical market is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable to commercialize successfully any drugs that we develop.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The pharmaceutical market is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to target. Many of our competitors have:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">more extensive experience in pre-clinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and selling drug products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">product candidates that are based on previously tested or accepted technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">products that have been approved or are in late stages of development; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collaborative arrangements in our target markets with leading companies and research institutions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will face intense competition from drugs that have already been approved and accepted by the medical community for the treatment of the conditions for which we may develop drugs. For example, if approved by the FDA, patisiran, our RNAi therapeutic in development for ATTR amyloidosis patients with cardiomyopathy, would compete with tafamidis, marketed by Pfizer, which is currently approved to treat this disease. We also expect to face competition from new drugs that enter the market. There are a number of drugs currently under development, which may become commercially available in the future, for the treatment of conditions for which we may try to develop drugs. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively, than any products we develop and commercialize. For example, we developed ONPATTRO for the treatment of hATTR amyloidosis. In August 2018, the FDA approved ONPATTRO lipid complex injection for the treatment of the polyneuropathy of hATTR amyloidosis in adults, and the EC granted marketing authorization for ONPATTRO for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. We are aware of other approved products used to treat this disease, including tafamidis, and inotersen, developed and marketed by Ionis, as well as product candidates in various stages of clinical development, including eplontersen, an additional investigational drug developed by Ionis in partnership with AstraZeneca, which met co-primary and secondary endpoints in an interim analysis of a Phase 3 study for the polyneuropathy of hATTR amyloidosis, and is currently under regulatory review by the FDA with a PDUFA action date of December 22, 2023. Finally, we are aware that BridgeBio Pharma, Inc., or BridgeBio, announced topline results from Part A of its Phase 3 clinical trial of acoramidis, a TTR stabilizer, in ATTR-CM in December 2021, which did not meet the primary endpoint of the study at month 12. BridgeBio initiated enrollment in Part B of its Phase 3 clinical trial of acoramidis in ATTR-PN patients in the fourth quarter of 2020, and anticipates topline results in mid-2023. While we believe that ONPATTRO and AMVUTTRA have and will continue to have a competitive product profile for the treatment of patients with hATTR amyloidosis with polyneuropathy, it is possible that ONPATTRO and/or AMVUTTRA may not compete favorably with these products and product candidates, or others, and, as a result, may not achieve commercial success. Moreover, positive or negative data and/or the commercial success or failure of competitive products could negatively impact our stock price. For example, our stock price was negatively impacted by the results of Part A of BridgeBio's Phase 3 clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we continue to successfully develop product candidates, and obtain approval for them, we will face competition based on many different factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the safety and effectiveness of our products relative to alternative therapies, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing and scope of regulatory approvals for these products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the availability and cost of manufacturing, marketing and sales capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the price of our products relative to alternative approved therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reimbursement coverage; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">patent position.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are aware of product candidates in various stages of clinical development for the treatment of PH1 which would compete with OXLUMO, our RNAi therapeutic approved in the U.S. and EU for the treatment of this disease, including Oxabact&#174;, a bacteria-based investigational therapy in development by OxThera AB, reloxaliase an investigational enzyme therapy in Phase 3 development for primary or severe secondary hyperoxaluria by Allena Pharmaceuticals, Inc., and nedosiran, an investigational RNAi therapeutic in development by Dicerna for the treatment of primary hyperoxaluria. In July 2019, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA granted a Breakthrough Therapy Designation to nedosiran for the treatment of patients with primary hyperoxaluria, and in August 2021, Dicerna reported positive topline results from its PHYOX2 pivotal clinical trial of nedosiran for the treatment of primary hyperoxaluria. Based on the results of the trial, Novo Nordisk submitted an NDA to the FDA in September 2022 for the treatment of PH1 in patients aged six years and older. In April 2020, we and Dicerna granted each other a non-exclusive cross-license to our respective intellectual property related to lumasiran, and Dicerna&#8217;s nedosiran product candidate. Our competitors may develop or commercialize products with significant advantages over any products we develop based on any of the factors listed above or on other factors. In addition, our competitors may develop strategic alliances with or receive funding from larger pharmaceutical or biotechnology companies, providing them with an advantage over us. Our competitors may therefore be more successful in commercializing their products than we are, which could adversely affect our competitive position and business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and the ability to execute on our business plan. Furthermore, we also face competition from existing and new treatment methods that reduce or eliminate the need for drugs, such as the use of advanced medical devices. The development of new medical devices or other treatment methods for the diseases we are targeting could make our product candidates noncompetitive, obsolete or uneconomical.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We face competition from other companies that are working to develop novel drugs and technology platforms using technology similar to ours. If these companies develop drugs more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability to successfully commercialize drugs may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the competition we face from competing drugs in general, we also face competition from other companies working to develop novel drugs using technology that competes more directly with our own. We are aware of several other companies that are working to develop RNAi therapeutic products. Some of these companies are seeking, as we are, to develop chemically synthesized siRNAs as drugs. Others are following a gene therapy approach, with the goal of treating patients not with synthetic siRNAs but with synthetic, exogenously-introduced genes designed to produce siRNA-like molecules within cells. Companies working on chemically synthesized siRNAs include, but are not limited to, Takeda Pharmaceutical Company Ltd., or Takeda, Marina Biotech, Inc., Arrowhead Pharmaceuticals Inc, Inc., or Arrowhead, Quark Pharmaceuticals, Inc., or Quark, Silence, Arbutus, Sylentis, S.A.U, or Sylentis, Dicerna and its collaborators, WAVE Life Sciences Ltd., Arcturus Therapeutics Inc., and Genevant Sciences, launched by Arbutus and Roivant Sciences. In addition, we granted licenses or options for licenses to Ionis, Benitec Biopharma Ltd., or Benitec, Arrowhead, Arbutus, Quark, Sylentis and others under which these companies may independently develop RNAi therapeutics against a limited number of targets. Any one of these companies may develop its RNAi technology more rapidly and more effectively than us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as a result of agreements that we have entered into, Takeda has obtained a non-exclusive license, and Arrowhead, as the assignee of Novartis, has obtained specific exclusive licenses for 30 gene targets, that include access to certain aspects of our technology. We also compete with companies working to develop antisense-based drugs. Like RNAi therapeutics, antisense drugs target mRNAs in order to suppress the activity of specific genes. Akcea Therapeutics, Inc. (acquired by Ionis in October 2020), has received marketing approval for an antisense drug, inotersen that was developed by Ionis, for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis. Several antisense drugs developed by Ionis have been approved and are currently marketed, and Ionis has multiple antisense product candidates in clinical trials. Ionis is also developing antisense drugs using ligand-conjugated GalNAc technology licensed from us, and these drugs have been shown to have increased potency at lower doses in clinical and pre-clinical studies, compared with antisense drugs that do not use such licensed GalNAc technology. The development of antisense drugs and antisense technology may become the preferred technology for drugs that target mRNAs to silence specific genes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to competition with respect to RNAi and with respect to specific products, we face substantial competition to discover and develop safe and effective means to deliver siRNAs to the relevant cell and tissue types. Safe and effective means to deliver siRNAs to the relevant cell and tissue types may be developed by our competitors, and our ability to successfully commercialize a competitive product would be adversely affected. In addition, substantial resources are being expended by third parties in the effort to discover and develop a safe and effective means of delivering siRNAs into the relevant cell and tissue types, both in academic laboratories and in the corporate sector. Some of our competitors have substantially greater resources than we do, and if our competitors are able to negotiate exclusive access to those delivery solutions developed by third parties, we may be unable to successfully commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our stock price fluctuates, purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The market price of our common stock has fluctuated significantly and may continue to fluctuate significantly in response to factors that are beyond our control. The stock market in general has from time to time experienced extreme price and volume fluctuations, and the biotechnology sector in particular has experienced extreme price and volume fluctuations. The market prices of securities of pharmaceutical and biotechnology companies have been extremely volatile, and have experienced fluctuations that often have been unrelated or disproportionate to the clinical development progress or operating performance of these companies, including as a result of adverse development events reported by other companies, and more recently as a result </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of disruptions to the U.S. banking system caused by the failure of Silicon Valley Bank. For example, the trading price for our common stock and the common stock of other biopharmaceutical companies was highly volatile during the initial stages of the COVID-19 pandemic. These broad market and sector fluctuations have resulted and could in the future result in extreme fluctuations in the price of our common stock, which could cause purchasers of our common stock to incur substantial losses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may incur significant costs from class action litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of our development and commercialization efforts or the development and commercialization efforts of our collaborators and/or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of pharmaceutical and biotechnology companies. When the market price of a stock has been volatile as our stock price has been, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For example, on September 12, 2019, the Chester County Employees Retirement Fund, individually and on behalf of all others similarly situated, filed a purported securities class action complaint alleging violation of federal securities laws against us, certain of our current and former directors and officers, and the underwriters of our November 14, 2017 public stock offering, in the Supreme Court of the State of New York, New York County. While we believe the allegations in the New York State Securities Litigation were without merit, in August 2021, the parties reached an agreement in principle to resolve the matter. At a hearing on April 12, 2022, the Supreme Court of the State of New York granted final approval to the settlement. Proceedings in the First Department were adjourned until April 2022, pending final approval of any settlement, and were withdrawn as a result of final approval on April 18, 2022. Future litigation could result in substantial costs and divert our management&#8217;s attention and resources, which could cause serious harm to our business, operating results and financial condition. We maintain liability insurance; however, if any costs or expenses associated with litigation exceed our insurance coverage, we may be forced to bear some or all of these costs and expenses directly, which could be substantial. In addition, we have obligations to indemnify third parties in connection with certain litigation, and such obligations are not covered by insurance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future sales of shares of our common stock, including by our significant stockholders, us or our directors and officers, could cause the price of our common stock to decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A small number of our stockholders beneficially own a substantial amount of our common stock. As of March 31, 2023, our six largest stockholders beneficially owned in excess of 50% of our outstanding shares of common stock. If our significant stockholders, or we or our officers and directors, sell substantial amounts of our common stock in the public market, or there is a perception that such sales may occur, the market price of our common stock could be adversely affected. Sales of common stock by our significant stockholders might make it more difficult for us to raise funds by selling equity or equity-related securities in the future at a time and price that we deem appropriate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Regeneron&#8217;s ownership of our common stock could delay or prevent a change in corporate control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of May 21, 2019, the closing date of the stock purchase in connection with the 2019 Regeneron collaboration, Regeneron held approximately 4% of our outstanding common stock and has the right to increase its ownership up to 30%. This concentration of ownership could harm the market price of our common stock in the future by:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delaying, deferring or preventing a change in control of our company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">impeding a merger, consolidation, takeover or other business combination involving our company; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Provisions in our certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a classified board of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a prohibition on actions by our stockholders by written consent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">limitations on the removal of directors; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders.</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Servicing our debt may require a significant amount of cash. We may not have sufficient cash flow from our business to pay our indebtedness.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 12, 2022, we commenced a private offering of $900.0 million in aggregate principal amount of the Initial Notes. On September 13, 2022, the initial purchasers in such offering exercised their option to purchase an additional $135.0 million in aggregate principal amount of the Additional Notes, bringing the total aggregate principal amount of the Notes to $1.04 billion. The interest rate for the Notes is fixed at 1.00% per annum and is payable semi-annually in arrears on May 15 and September 15 of each year, beginning on March 15, 2023. Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including the Notes, or to make cash payments in connection with any conversions of Notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional debt financing or equity capital on terms that may be onerous or highly dilutive. Our ability to refinance any future indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. In addition, any of our future debt agreements may contain restrictive covenants that may prohibit us from adopting any of these alternatives. Our failure to comply with these covenants could result in an event of default which, if not cured or waived, could result in the acceleration of our debt.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not have the ability to raise the funds necessary to settle for cash conversions of the Notes or to repurchase the Notes for cash upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion of the Notes or to repurchase the Notes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of the Notes have the right to require us to repurchase their Notes upon the occurrence of a fundamental change (as defined in the indenture governing the Notes) at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any. Upon conversion of the Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to make cash payments in respect of the Notes being converted. We may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Notes surrendered or Notes being converted.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our ability to repurchase the Notes or to pay cash upon conversions of the Notes may be limited by law, by regulatory authority or by agreements governing our future indebtedness. Our failure to repurchase Notes at a time when the repurchase is required by the indenture governing such notes or to pay any cash payable on future conversions of the Notes as required by such indenture would constitute a default under such indenture. A default under the indenture governing the Notes or the fundamental change itself could also lead to a default under agreements governing our future indebtedness. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes or make cash payments upon conversions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our indebtedness, combined with our other financial obligations and contractual commitments, could have other important consequences. For example, it could:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">make us more vulnerable to adverse changes in general U.S. and worldwide economic, industry and competitive conditions and adverse changes in government regulation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">limit our flexibility in planning for, or reacting to, changes in our business and our industry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">place us at a disadvantage compared to our competitors who have less debt;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">limit our ability to borrow additional amounts to fund acquisitions, for working capital and for other general corporate purposes; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">make an acquisition of our company less attractive or more difficult.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these factors could harm our business, results of operations and financial condition. In addition, if we incur additional indebtedness, the risks related to our business and our ability to service or repay our indebtedness would increase. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event the conditional conversion feature of the Notes is triggered, holders of the Notes will be entitled to convert the Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current liability, rather than long-term liability, which would result in a material reduction of our net working capital.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Transactions relating to our Notes may affect the value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The conversion of some or all of the Notes would dilute the ownership interests of existing stockholders to the extent we satisfy our conversion obligation by delivering shares of our common stock upon any conversion of such Notes. Our Notes may become in the future convertible at the option of their holders under certain circumstances. If holders of our Notes elect to convert their notes, we may settle our conversion obligation by delivering to them a significant number of shares of our common stock, which would cause dilution to our existing stockholders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, in connection with the issuance of the Notes, we entered into the Capped Calls with certain financial institutions, or the Option Counterparties. The Capped Calls are generally expected to reduce potential dilution to our common stock upon any conversion or settlement of the Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, with such reduction and/or offset subject to a cap.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with establishing their initial hedges of the Capped Calls, the Option Counterparties or their respective affiliates entered into various derivative transactions with respect to our common stock and/or purchased shares of our common stock concurrently with or shortly after the pricing of the Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Option Counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivative transactions with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions prior to the maturity of the Notes (and are likely to do so following any conversion of the Notes, any repurchase of the Notes by us on any fundamental change repurchase date, any redemption date, or any other date on which the Notes are retired by us, in each case, if we exercise our option to terminate the relevant portion of the Capped Calls). This activity could cause a decrease and/or increased volatility in the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not make any representation or prediction as to the direction or magnitude of any potential effect that the transactions described above may have on the price of the Notes or our common stock. In addition, we do not make any representation that the Option Counterparties will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to counterparty risk with respect to the Capped Calls.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Option Counterparties are financial institutions, and we will be subject to the risk that any or all of them might default under the Capped Calls. Our exposure to the credit risk of the Option Counterparties will not be secured by any collateral. Past global economic conditions have resulted in the actual or perceived failure or financial difficulties of many financial institutions. If an Option Counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings with a claim equal to our exposure at that time under the Capped Calls with such Option Counterparty. Our exposure will depend on many factors but, generally, an increase in our exposure will be correlated to an increase in the market price and in the volatility of our common stock. In addition, upon a default by an Option Counterparty, we may suffer adverse tax consequences and more dilution than we currently anticipate with respect to our common stock. We can provide no assurances as to the financial stability or viability of the Option Counterparties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The accounting method for convertible debt securities that may be settled in cash, such as the Notes, could have a material effect on our reported financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accounting method for reflecting the Notes on our condensed consolidated balance sheet, accruing interest expense for the Notes and reflecting the underlying shares of our common stock in our reported diluted earnings per share may adversely affect our reported earnings and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the Financial Accounting Standards Board published an Accounting Standards Update, which we refer to as ASU 2020-06, which simplified certain of the accounting standards that apply to convertible notes. ASU 2020-06 became effective for us beginning January 1, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with ASU 2020-06, the Notes will be reflected as a liability on our condensed consolidated balance sheets, with the initial carrying amount equal to the principal amount of the Notes, net of issuance costs. The issuance costs will be treated as a debt discount for accounting purposes, which will be amortized into interest expense over the term of the Notes. As </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a result of this amortization, the interest expense that we expect to recognize for the Notes for accounting purposes will be greater than the cash interest payments we will pay on the Notes, which will result in lower reported net income or higher reported net loss, as the case may be.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we expect that the shares of common stock underlying the Notes will be reflected in our diluted earnings per share using the &#8220;if converted&#8221; method, in accordance with ASU 2020-06. Under that method, diluted earnings per share would generally be calculated assuming that all the Notes were converted solely into shares of common stock at the beginning of the reporting period, unless the result would be anti-dilutive. The application of the if-converted method may reduce our reported diluted earnings per share to the extent we are profitable in the future, and accounting standards may change in the future in a manner that may adversely affect our diluted earnings per share.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, if any of the conditions to the convertibility of the Notes is satisfied, then we may be required under applicable accounting standards to reclassify the liability carrying value of the Notes as a current, rather than a long-term, liability. This reclassification could be required even if no holders convert their notes and could materially reduce our reported working capital.</span></div><div id="i90e340589f97408ea2365d8948df4c38_112"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ITEM 6. EXHIBITS</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1#*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="alny2023q1exhibit101.htm">Form of Performance Stock Unit Award Agreement for Executive Officers under 2018 Stock Incentive Plan, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2#*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="alny2023q1exhibit102.htm">Form of Restricted Stock Unit Award Agreement for Executive Officers under 2018 Stock Incentive Plan, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="alny2023q110-qex311.htm">Certification of principal executive officer pursuant to Rule&#160;13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="alny2023q110-qex312.htm">Certification of principal financial officer pursuant to Rule&#160;13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1#+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="alny2023q110-qex321.htm">Certification of principal executive officer pursuant to Rule&#160;13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and Section&#160;1350 of Chapter&#160;63 of Title 18 of the United States Code</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2#+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="alny2023q110-qex322.htm">Certification of principal financial officer pursuant to Rule&#160;13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and Section&#160;1350 of Chapter&#160;63 of Title 18 of the United States Code</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contracts or compensatory plans or arrangements.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i90e340589f97408ea2365d8948df4c38_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90e340589f97408ea2365d8948df4c38_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALNYLAM PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 4, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Yvonne L. Greenstreet, MBChB, MBA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yvonne L. Greenstreet, MBChB, MBA<br/>Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 4, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey V. Poulton</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey V. Poulton<br/>Executive Vice President, Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>alny2023q1exhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i56d8cc080c39400aa4b65e00314a168d_38"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="margin-bottom:18pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ALNYLAM PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance Stock Unit Award Agreement<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Granted Under 2018 Stock Incentive Plan</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Name of Grantee&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No. of Performance Stock Units&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">Pursuant to the Alnylam Pharmaceuticals, Inc. 2018 Stock Incentive Plan, as amended through the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;), Alnylam Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;) hereby grants an award of the number of Performance Stock Units listed above (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;) to the Grantee named above on the Grant Date. Each Performance Stock Unit shall relate to one share of common stock, par value $0.01 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;) of the Company. Unless earlier terminated, this Award shall have a term of ten (10) years from the Grant Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Restrictions on Transfer of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i)&#160;the Performance Stock Units have vested as provided in Section 2 of this Agreement and (ii)&#160;shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Vesting of Performance Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">. So long as the Grantee remains an Eligible Participant, the restrictions and conditions of Section&#160;1 of this Agreement shall lapse with respect to all or a portion of the Award on the date (in each case, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;) that is the later of&#58; (i) the one-year anniversary of the Grant Date and (ii) the date on which the Board or Committee determines that the Performance Measures specified in the vesting schedule attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%"> to this agreement, in relation to all or a portion of the Award, have been achieved (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Determination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;). The number of Performance Stock Units that actually vest pursuant to the Award is variable based on the specifications in the vesting schedule attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">, and if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%"> allocates the Award to multiple different Performance Measures, then the restrictions in Section 1 shall lapse only with respect to the number of Performance Stock Units allocated to the achievement of the particular Performance Measure on the applicable Vesting Date as determined by the Committee. The Committee has authority to terminate the portion of the Award allocated to a Performance Measure based upon its determination, in its sole discretion, that such Performance Measure cannot be attained, or could not reasonably be expected to be attained, during the term of the Award.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">Notwithstanding the foregoing, the Award will become fully vested in the event the Grantee dies while they are an Eligible Participant prior to the Vesting Date(s) (and, in such case, the date of death shall be deemed a Vesting Date for purposes of Section 4 of this Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">The Committee may at any time accelerate the vesting schedule specified in this Section 2. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Termination of Relationship with the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">. The Grantee shall remain an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Eligible Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221; so long as the Grantee remains an employee or officer of, or consultant or advisor to, the Company or a subsidiary. If the Grantee ceases to be an Eligible Participant for any reason other than death prior to the Vesting Date(s) set forth in Section 2 above, any Performance Stock Units that have </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;March 2023</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">not vested as of such Vesting Date(s) shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of their successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Performance Stock Units. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Issuance of Shares of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">. As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Performance Stock Units that have vested pursuant to Section 2 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%"> of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Incorporation of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Committee set forth in Section&#160;3 of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">. As a condition to this Award, the Grantee hereby agrees that any required tax withholding obligation shall be satisfied through a mandatory, non-discretionary &#8220;sell-to-cover&#8221; arrangement with a broker designated by the Company and hereby authorizes the Company to make such arrangement&#59; provided, however, that in the event that the Grantee has engaged in any opposite way transactions within the previous six (6) months that were not exempt from Section 16(b) of the Exchange Act of 1934, as amended, any required tax withholding obligation associated with this Award shall be satisfied by the Company withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. Unless the withholding tax obligations of the Company and&#47;or any subsidiary thereof are satisfied by the Grantee in accordance with this provision, the Company shall have no obligation to issue any shares of Stock on the Grantee&#8217;s behalf pursuant to the vesting of this Award.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;text-decoration:underline">Section&#160;409A of the Code.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%"> This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section&#160;409A of the Code as &#8220;short-term deferrals&#8221; as described in Section&#160;409A of the Code. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;text-decoration:underline">No Obligation to Continue Service Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">. Neither the Company nor any subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment or other service relationship and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any subsidiary to terminate the employment or other service relationship of the Grantee at any time. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;padding-left:22.7pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. The Company collects, processes and transfers personal data about the Grantee, in electronic or other form, including but not limited to, the Grantee&#8217;s name, home address, email address and telephone number, date of birth, social insurance or social security number, passport number or other national identification number, salary, nationality, job title, any shares of Common Stock or directorships held in the Company, details of all options, stock units or any other </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">entitlement to shares of Common Stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor, which the Company and its subsidiaries receive from the Grantee (&#8220;Data&#8221;) for the purposes of implementing, administering and managing the Plan. The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent, compliance with relevant laws or regulations to which the Company is subject to or the pursuit by the Company of its respective legitimate interests not outweighed by the Grantee&#8217;s interests, rights or freedoms as needed to provide the requested services to the Grantee in accordance with the Plan. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;padding-left:22.02pt;text-decoration:underline">Stock Plan Administration Vendors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. The Company may transfer Data to a designated third-party external broker or such other independent stock plan vendors, as may be selected by the Company in the future, which shall assist the Company with the implementation, administration and management of the Plan. Such vendor(s) may open an account for the Grantee to receive and trade shares of Common Stock underlying this Award. The Grantee may be asked to acknowledge, or agree to, separate terms and data processing practices with the vendor(s) with such agreement being a condition of participation in the Plan.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">An updated list with the details of all recipients of the Grantee&#8217;s Data can be made available upon a relevant request to privacy&#64;alnylam.com.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;padding-left:22.7pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws. In the latter case, the Grantee understands and acknowledges that the Company&#8217;s legal basis for the processing of the Data would be compliance with the relevant laws or regulations and the pursuit by the Company of respective legitimate interests not outweighed by the Grantee&#8217;s interests, rights or freedoms. When the Company no longer needs the Data for any of the above purposes, the Grantee understands the Company will isolate it from active systems, remove it from its systems, or anonymize it to be used for statistical purposes as the case may be.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;padding-left:22.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">.  The Grantee understands that the Grantee may have a number of rights under data privacy and data protection laws and regulations in the Grantee&#8217;s jurisdiction. Depending on where the Grantee is based and the applicable data privacy and data protection laws and regulations, such rights may include the right to (i) request access or copies of Data the Company processes, (ii) rectify or supplement Data that is incorrect, incomplete or out-of-date in light of the purposes underlying the processing, (iii) anonymize or delete Data, (iv) restrict or object to the processing of Data, (v) portability of Data, (vi) lodge complaints with competent authorities in the Grantee&#8217;s jurisdiction, (vii) receive a list with the names and addresses of any potential recipients of the Grantee&#8217;s Data, and&#47;or (viii) receive information about the possibility of not giving consent to process Data and the consequences of not giving consent. To receive clarification regarding these rights or to exercise these rights, the Grantee can contact privacy&#64;alnylam.com. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Participation in the Plan is voluntary, and the Grantee is providing the consents herein on a free and purely voluntary basis. If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Company will not be affected&#59; the only adverse consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Grantee&#8217;s ability to participate to the Plan may be affected, as the Company would not (or no longer) be able to grant this Award or other equity awards to the Grantee or administer or maintain such awards. Please note that withdrawal of consent does not affect any processing of Data carried out prior to and up to the date of such withdrawal.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 3 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting this Award and indicating consent via the Company&#8217;s acceptance procedure, the Grantee is declaring that the Grantee agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of such Data to the recipients mentioned above, including recipients located in countries which do not ensure an adequate level of protection from applicable data privacy and data protection law and regulation perspective, for the purposes described above.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, the Grantee understands that the Company as the Data Controller of the Data may rely on a different legal basis for the processing or transfer of Data in the future and&#47;or request that the Grantee provide supplementary consents or provide the Grantee with additional privacy related information as the case may be.  If applicable and upon request of the Company, the Grantee agrees to provide an executed acknowledgement or any data privacy consent to the Company (or any other acknowledgements, agreements or consents as may be required by the Company) that the Company may deem necessary to obtain under the data privacy laws in the Grantee&#8217;s jurisdiction, either now or in the future. The Grantee understands that the Grantee will not be able to participate in the Plan if the Grantee fails to execute any such acknowledgement, agreement or consent requested by the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="padding-left:260.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.851%"><tr><td style="width:1.0%"></td><td style="width:10.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ALNYLAM PHARMACEUTICALS, INC</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Grantee (including through an online acceptance process) is acceptable. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 4 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GRANTEE&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADDRESS&#58;</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 5 -</font></div></div></div><div id="i56d8cc080c39400aa4b65e00314a168d_41"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%;text-decoration:underline">Appendix A to</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%;text-decoration:underline">Performance Restricted Stock Unit Agreement (the &#8220;Agreement&#8221;)</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">VESTING SCHEDULE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#93;</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>alny2023q1exhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i303f65ee782c432884233cebed0ee86a_38"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div></div><div style="margin-bottom:18pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ALNYLAM PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Restricted Stock Unit Award Agreement<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Granted Under 2018 Stock Incentive Plan</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of Grantee&#58;&#160;&#160;&#160;&#160;&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No. of Restricted Stock Units&#58;&#160;&#160;&#160;&#160;&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;&#160;&#160;&#160;&#160;&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">Pursuant to the Alnylam Pharmaceuticals, Inc. 2018 Stock Incentive Plan, as amended through the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">&#8221;), Alnylam Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">&#8221;) hereby grants an award of the number of Restricted Stock Units listed above (this &#8220;Award&#8221;) to the Grantee named above on the Grant Date. Each Restricted Stock Unit shall relate to one share of common stock, par value $0.01 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">&#8221;) of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Restrictions on Transfer of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i)&#160;the Restricted Stock Units have vested as provided in Section 2 of this Agreement and (ii)&#160;shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Vesting of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. The restrictions and conditions of Section&#160;1 of this Agreement shall lapse on the date or dates (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">&#8221;) specified in the following schedule so long as the Grantee remains an employee or officer of, or consultant or advisor to, the Company or a subsidiary (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Eligible Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">&#8221;) on such Vesting Date(s). If a series of Vesting Dates is specified, then the restrictions and conditions in Section&#160;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date. </font></div><div style="margin-bottom:12pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">VESTING SCHEDULE&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">Notwithstanding the foregoing, this Award will become fully vested in the event the Grantee dies while he or she is an Eligible Participant prior to the Vesting Date(s) (and, in such case, the date of death shall be deemed a Vesting Date for purposes of Section 4 of this Agreement).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">The Committee may at any time accelerate the vesting schedule specified in this Section 2. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Termination of Relationship with the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. If the Grantee ceases to be an Eligible Participant for any reason other than death prior to the Vesting Date(s) set forth in Section 2 above, any Restricted Stock Units that have not vested as of such Vesting Date(s) shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;March 2023</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Issuance of Shares of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Section 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Incorporation of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Committee set forth in Section&#160;3 of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. As a condition to this Award, the Grantee hereby agrees that any required tax withholding obligation shall be satisfied through a mandatory, non-discretionary &#8220;sell-to-cover&#8221; arrangement with a broker designated by the Company and hereby authorizes the Company to make such arrangement&#59; provided, however, that in the event that the Grantee has engaged in any opposite way transactions within the previous six (6) months that were not exempt from Section 16(b) of the Exchange Act of 1934, as amended, any required tax withholding obligation associated with this Award shall be satisfied by the Company withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. Unless the withholding tax obligations of the Company and&#47;or any subsidiary thereof are satisfied by the Grantee in accordance with this provision, the Company shall have no obligation to issue any shares of Stock on the Grantee&#8217;s behalf pursuant to the vesting of this Award.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Section&#160;409A of the Code.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%"> This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section&#160;409A of the Code as &#8220;short-term deferrals&#8221; as described in Section&#160;409A of the Code. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">No Obligation to Continue Service Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. Neither the Company nor any subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment or other service relationship and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any subsidiary to terminate the employment or other service relationship of the Grantee at any time. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;padding-left:22.7pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. The Company collects, processes and transfers personal data about the Grantee, in electronic or other form, including but not limited to, the Grantee&#8217;s name, home address, email address and telephone number, date of birth, social insurance or social security number, passport number or other national identification number, salary, nationality, job title, any shares of Common Stock or directorships held in the Company, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">details of all options, stock units or any other entitlement to shares of Common Stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor, which the Company and its subsidiaries receive from the Grantee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">&#8221;) for the purposes of implementing, administering and managing the Plan. The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent, compliance with relevant laws or regulations to which the Company is subject to or the pursuit by the Company of its respective legitimate interests not outweighed by the Grantee&#8217;s interests, rights or freedoms as needed to provide the requested services to the Grantee in accordance with the Plan. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;padding-left:22.02pt;text-decoration:underline">Stock Plan Administration Vendors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. The Company may transfer Data to a designated third-party external broker or such other independent stock plan vendors, as may be selected by the Company in the future, which shall assist the Company with the implementation, administration and management of the Plan. Such vendor(s) may open an account for the Grantee to receive and trade shares of Common Stock underlying this Award. The Grantee may be asked to acknowledge, or agree to, separate terms and data processing practices with the vendor(s) with such agreement being a condition of participation in the Plan.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">An updated list with the details of all recipients of the Grantee&#8217;s Data can be made available upon a relevant request to privacy&#64;alnylam.com.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;padding-left:22.7pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws. In the latter case, the Grantee understands and acknowledges that the Company&#8217;s legal basis for the processing of the Data would be compliance with the relevant laws or regulations and the pursuit by the Company of respective legitimate interests not outweighed by the Grantee&#8217;s interests, rights or freedoms. When the Company no longer needs the Data for any of the above purposes, the Grantee understands the Company will isolate it from active systems, remove it from its systems, or anonymize it to be used for statistical purposes as the case may be.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;padding-left:22.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">.  The Grantee understands that the Grantee may have a number of rights under data privacy and data protection laws and regulations in the Grantee&#8217;s jurisdiction. Depending on where the Grantee is based and the applicable data privacy and data protection laws and regulations, such rights may include the right to (i) request access or copies of Data the Company processes, (ii) rectify or supplement Data that is incorrect, incomplete or out-of-date in light of the purposes underlying the processing, (iii) anonymize or delete Data, (iv) restrict or object to the processing of Data, (v) portability of Data, (vi) lodge complaints with competent authorities in the Grantee&#8217;s jurisdiction, (vii) receive a list with the names and addresses of any potential recipients of the Grantee&#8217;s Data, and&#47;or (viii) receive information about the possibility of not giving consent to process Data and the consequences of not giving consent. To receive clarification regarding these rights or to exercise these rights, the Grantee can contact privacy&#64;alnylam.com. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;padding-left:22.7pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. Participation in the Plan is voluntary, and the Grantee is providing the consents herein on a free and purely voluntary basis. If the Grantee does not consent, or if the Grantee later seeks to revoke the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 3 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Company will not be affected&#59; the only adverse consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Grantee&#8217;s ability to participate to the Plan may be affected, as the Company would not (or no longer) be able to grant this Award or other equity awards to the Grantee or administer or maintain such awards. Please note that withdrawal of consent does not affect any processing of Data carried out prior to and up to the date of such withdrawal.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">By accepting this Award and indicating consent via the Company&#8217;s acceptance procedure, the Grantee is declaring that the Grantee agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of such Data to the recipients mentioned above, including recipients located in countries which do not ensure an adequate level of protection from applicable data privacy and data protection law and regulation perspective, for the purposes described above.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">Finally, the Grantee understands that the Company as the Data Controller of the Data may rely on a different legal basis for the processing or transfer of Data in the future and&#47;or request that the Grantee provide supplementary consents or provide the Grantee with additional privacy related information as the case may be.  If applicable and upon request of the Company, the Grantee agrees to provide an executed acknowledgement or any data privacy consent to the Company (or any other acknowledgements, agreements or consents as may be required by the Company) that the Company may deem necessary to obtain under the data privacy laws in the Grantee&#8217;s jurisdiction, either now or in the future. The Grantee understands that the Grantee will not be able to participate in the Plan if the Grantee fails to execute any such acknowledgement, agreement or consent requested by the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </font></div><div style="padding-left:238.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.198%"><tr><td style="width:1.0%"></td><td style="width:10.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ALNYLAM PHARMACEUTICALS, INC</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Grantee (including through an online acceptance process) is acceptable. </font></div><div style="margin-top:9pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GRANTEE&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADDRESS&#58;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 4 -</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>alny2023q110-qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i15a793fea76e4288ba3c29b48b4ddf35_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Yvonne L. Greenstreet, MBChB, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Yvonne L. Greenstreet, MBChB, MBA</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yvonne L. Greenstreet, MBChB, MBA<br>Chief Executive Officer&#160;</font></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>alny2023q110-qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibe3769a5c7be40e3b723f65784bac137_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I,&#160;Jeffrey V. Poulton, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey V. Poulton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey V. Poulton<br>Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>alny2023q110-qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3a9dfcf1533b4f739b81e88ae2fb37bd_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 32.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the quarter ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Yvonne L. Greenstreet, MBChB, Chief Executive Officer of the Company, hereby certifies, pursuant to Section&#160;1350 of Chapter 63 of Title 18, United States Code, that to his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:76.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:76.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Yvonne L. Greenstreet, MBChB, MBA</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yvonne L. Greenstreet, MBChB, MBA<br>Chief Executive Officer&#160;</font></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>alny2023q110-qex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i07dd4ef0832a41e785a917e11897c938_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 32.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the quarter ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned,&#160;Jeffrey V. Poulton, Executive Vice President, Chief Financial Officer, hereby certifies, pursuant to Section&#160;1350 of Chapter&#160;63 of Title 18, United States Code, that to his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:76.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:76.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey V. Poulton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey V. Poulton<br>Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>alny-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b732ba76-b80e-452b-9370-f7a92071fea1,g:cc882e96-1f0e-4ac3-98d4-087e3affef76-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:alny="http://www.alnylam.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.alnylam.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alny-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alny-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alny-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alny-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.alnylam.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESS" roleURI="http://www.alnylam.com/role/NATUREOFBUSINESS">
        <link:definition>0000007 - Disclosure - NATURE OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION">
        <link:definition>0000008 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETPRODUCTREVENUES" roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUES">
        <link:definition>0000009 - Disclosure - NET PRODUCT REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONS" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS">
        <link:definition>0000010 - Disclosure - NET REVENUES FROM COLLABORATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES" roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES">
        <link:definition>0000011 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000012 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLEDEBTSECURITIES" roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES">
        <link:definition>0000013 - Disclosure - MARKETABLE DEBT SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERBALANCESHEETDETAILS" roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS">
        <link:definition>0000014 - Disclosure - OTHER BALANCE SHEET DETAILS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLEDEBT" roleURI="http://www.alnylam.com/role/CONVERTIBLEDEBT">
        <link:definition>0000015 - Disclosure - CONVERTIBLE DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEVELOPMENTDERIVATIVELIABILITY" roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY">
        <link:definition>0000016 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>0000017 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERCOMMONSHARE" roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE">
        <link:definition>0000018 - Disclosure - NET LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000019 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies">
        <link:definition>0000020 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETPRODUCTREVENUESTables" roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESTables">
        <link:definition>0000021 - Disclosure - NET PRODUCT REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSTables" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables">
        <link:definition>0000022 - Disclosure - NET REVENUES FROM COLLABORATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables" roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables">
        <link:definition>0000023 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>0000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLEDEBTSECURITIESTables" roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables">
        <link:definition>0000025 - Disclosure - MARKETABLE DEBT SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERBALANCESHEETDETAILSTables" roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables">
        <link:definition>0000026 - Disclosure - OTHER BALANCE SHEET DETAILS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEVELOPMENTDERIVATIVELIABILITYTables" roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables">
        <link:definition>0000027 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>0000028 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERCOMMONSHARETables" roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables">
        <link:definition>0000029 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESSDetails" roleURI="http://www.alnylam.com/role/NATUREOFBUSINESSDetails">
        <link:definition>0000030 - Disclosure - NATURE OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail" roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail">
        <link:definition>0000031 - Disclosure - NET PRODUCT REVENUES - Summary of Net Product Revenues (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETPRODUCTREVENUESReceivablesDetail" roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail">
        <link:definition>0000032 - Disclosure - NET PRODUCT REVENUES - Receivables (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail">
        <link:definition>0000033 - Disclosure - NET REVENUES FROM COLLABORATIONS - Revenue from Collaborators (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail">
        <link:definition>0000034 - Disclosure - NET REVENUES FROM COLLABORATIONS - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail">
        <link:definition>0000035 - Disclosure - NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail">
        <link:definition>0000036 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails">
        <link:definition>0000037 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails">
        <link:definition>0000038 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails">
        <link:definition>0000039 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails" roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails">
        <link:definition>0000040 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails" roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails">
        <link:definition>0000041 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES - Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail">
        <link:definition>0000042 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Assets Measured on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail">
        <link:definition>0000043 - Disclosure - MARKETABLE DEBT SECURITIES - Summary of Marketable Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail" roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail">
        <link:definition>0000044 - Disclosure - MARKETABLE DEBT SECURITIES - Summary of Fair Value of Marketable Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail">
        <link:definition>0000045 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Inventory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail">
        <link:definition>0000046 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>0000047 - Disclosure - OTHER BALANCE SHEET DETAILS - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLEDEBTDetails" roleURI="http://www.alnylam.com/role/CONVERTIBLEDEBTDetails">
        <link:definition>0000048 - Disclosure - CONVERTIBLE DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails" roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails">
        <link:definition>0000049 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails" roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails">
        <link:definition>0000050 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY - Development Derivative Liability Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail">
        <link:definition>0000051 - Disclosure - STOCK-BASED COMPENSATION - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail">
        <link:definition>0000052 - Disclosure - NET LOSS PER COMMON SHARE - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" abstract="false" name="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" abstract="false" name="CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alny_UpfrontFeeReceived" abstract="false" name="UpfrontFeeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" abstract="false" name="RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_VutrisiranMember" abstract="true" name="VutrisiranMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_InventoryCurrentAndNoncurrent" abstract="false" name="InventoryCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_RoyaltyLiabilityCurrent" abstract="false" name="RoyaltyLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_NumberOfTargetedPrograms" abstract="false" name="NumberOfTargetedPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alny_FundingAtProgramInitiationMember" abstract="true" name="FundingAtProgramInitiationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_CollaborativeArrangementFixedPaymentTerm" abstract="false" name="CollaborativeArrangementFixedPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_CollaborationsMember" abstract="true" name="CollaborationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alny_CostOfCollaborationManufacturingAndRoyalties" abstract="false" name="CostOfCollaborationManufacturingAndRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ConvertibleSeniorNotesDue2027InitialAmountMember" abstract="true" name="ConvertibleSeniorNotesDue2027InitialAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_ALNAGTPhase3ClinicalTrialMember" abstract="true" name="ALNAGTPhase3ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_PremiumRecognizedOnCappedCallTransactions" abstract="false" name="PremiumRecognizedOnCappedCallTransactions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="alny_HELIOSBPhase3ClinicalTrialMember" abstract="true" name="HELIOSBPhase3ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alny_VutrisiranAndZilebesiranMember" abstract="true" name="VutrisiranAndZilebesiranMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_ALNAGTPhase2ClinicalTrialMember" abstract="true" name="ALNAGTPhase2ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_CollaborativeArrangementMaximumFunding" abstract="false" name="CollaborativeArrangementMaximumFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_CollaborativeArrangementMilestonePayments" abstract="false" name="CollaborativeArrangementMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_NumberOfMarketedProducts" abstract="false" name="NumberOfMarketedProducts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alny_CollaborativeArrangementRoyaltiesPayablePercent" abstract="false" name="CollaborativeArrangementRoyaltiesPayablePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alny_PotentialProceedsFromCollaborationArrangement" abstract="false" name="PotentialProceedsFromCollaborationArrangement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_AccumulatedLossOnInvestmentInJointVentureMember" abstract="true" name="AccumulatedLossOnInvestmentInJointVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_ResearchServicesObligationMember" abstract="true" name="ResearchServicesObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_TransactionPrice" abstract="false" name="TransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_CollaborativeArrangementConsiderationReceived" abstract="false" name="CollaborativeArrangementConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ScheduleOfRoyaltyLiabilityTableTextBlock" abstract="false" name="ScheduleOfRoyaltyLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="alny_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" abstract="false" name="ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" abstract="false" name="ScheduleOfAllocatedTransactionPriceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="alny_ONPATTROMember" abstract="true" name="ONPATTROMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_ConvertibleSeniorNotesDue2025Member" abstract="true" name="ConvertibleSeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" abstract="false" name="AmortizationAndInterestAccretionRelatedToOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ClinicalTrialAndManufacturingMember" abstract="true" name="ClinicalTrialAndManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember" abstract="true" name="ConvertibleSeniorNotesDue2027AdditionalAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" abstract="false" name="NonCashInterestExpenseOnSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_CollaborativeArrangementRoyaltiesPayableTerm" abstract="false" name="CollaborativeArrangementRoyaltiesPayableTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_PercentageOfMaximumRoyaltyPayments" abstract="false" name="PercentageOfMaximumRoyaltyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alny_GIVLAARIMember" abstract="true" name="GIVLAARIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" abstract="false" name="ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" abstract="false" name="MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_NumberOfPartneredProducts" abstract="false" name="NumberOfPartneredProducts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alny_ConvertibleDebtPremiumRecognizedFromConversionRate" abstract="false" name="ConvertibleDebtPremiumRecognizedFromConversionRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="alny_C5CoCoObligationMember" abstract="true" name="C5CoCoObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_RoyaltyLiabilityInterestRate" abstract="false" name="RoyaltyLiabilityInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alny_FundingAtLeadCandidateIdentificationMember" abstract="true" name="FundingAtLeadCandidateIdentificationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_RoyaltyLiabilityNoncurrent" abstract="false" name="RoyaltyLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_BlackstoneGroupIncMember" abstract="true" name="BlackstoneGroupIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_CollaborativeAgreementTerminationPeriod" abstract="false" name="CollaborativeAgreementTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_OXLUMOMember" abstract="true" name="OXLUMOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_C5LicenseObligationMember" abstract="true" name="C5LicenseObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_CollaborativeArrangementFixedPaymentMultiplier" abstract="false" name="CollaborativeArrangementFixedPaymentMultiplier" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="alny_OtherCollaborationsMember" abstract="true" name="OtherCollaborationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_LiquidityPolicyPolicyTextBlock" abstract="false" name="LiquidityPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="alny_StandaloneSellingPrice" abstract="false" name="StandaloneSellingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ExternalServicesMember" abstract="true" name="ExternalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_FundingAnAnnualDiscoveryMember" abstract="true" name="FundingAnAnnualDiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" abstract="false" name="InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="alny_RoyaltyLiabilityPayments" abstract="false" name="RoyaltyLiabilityPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_CollaborativeAgreementPeriodOfProgramDevelopment" abstract="false" name="CollaborativeAgreementPeriodOfProgramDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alny_RoyaltyLiabilityClosingCosts" abstract="false" name="RoyaltyLiabilityClosingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_RoyaltyRate" abstract="false" name="RoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alny_NonUSOrEuropeMember" abstract="true" name="NonUSOrEuropeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_ConvertibleSeniorNotesDue2027Member" abstract="true" name="ConvertibleSeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alny_DiscoveryPeriodOfProgramsDevelopment" abstract="false" name="DiscoveryPeriodOfProgramsDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_DebtConversionTermsTwoMember" abstract="true" name="DebtConversionTermsTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="alny_DebtConversionTermsOneMember" abstract="true" name="DebtConversionTermsOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_RegeneronPharmaceuticalsIncorporationMember" abstract="true" name="RegeneronPharmaceuticalsIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_AmvuttraMember" abstract="true" name="AmvuttraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_NumberOfCommercializedProducts" abstract="false" name="NumberOfCommercializedProducts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alny_ChangeInFairValueOfLiabilityObligation" abstract="false" name="ChangeInFairValueOfLiabilityObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ResearchTermExtensionFee" abstract="false" name="ResearchTermExtensionFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_BlackstoneLifeSciencesMember" abstract="true" name="BlackstoneLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_GlobalStrategicCollaborationMember" abstract="true" name="GlobalStrategicCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" abstract="false" name="MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes" abstract="false" name="PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ExpectedRoyaltyInterestPayments" abstract="false" name="ExpectedRoyaltyInterestPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_DebtInstrumentConvertibleTermsOfConversionDomain" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="alny_IncreaseDecreaseInResearchAndDevelopmentExpense" abstract="false" name="IncreaseDecreaseInResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" abstract="false" name="CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" abstract="false" name="ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="alny_DebtInstrumentConvertibleTermsOfConversionAxis" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>alny-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b732ba76-b80e-452b-9370-f7a92071fea1,g:cc882e96-1f0e-4ac3-98d4-087e3affef76-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="alny-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6ea36b38-4795-4e0b-ad4e-36b75a474e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b11f9964-2e56-47de-877c-3370a5223e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea36b38-4795-4e0b-ad4e-36b75a474e17" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b11f9964-2e56-47de-877c-3370a5223e98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9a58fc85-5218-4fd7-8b3d-42412408ad4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea36b38-4795-4e0b-ad4e-36b75a474e17" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9a58fc85-5218-4fd7-8b3d-42412408ad4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_97e5f7bf-763d-49ca-84e8-cf04dbb8d892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea36b38-4795-4e0b-ad4e-36b75a474e17" xlink:to="loc_us-gaap_LiabilitiesCurrent_97e5f7bf-763d-49ca-84e8-cf04dbb8d892" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2fd1cbf2-62d8-4184-a1c4-c30991fe5851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea36b38-4795-4e0b-ad4e-36b75a474e17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2fd1cbf2-62d8-4184-a1c4-c30991fe5851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent_fbd175fc-a6ca-4a97-ac29-4a9c68c5c1d8" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea36b38-4795-4e0b-ad4e-36b75a474e17" xlink:to="loc_alny_RoyaltyLiabilityNoncurrent_fbd175fc-a6ca-4a97-ac29-4a9c68c5c1d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_055b9e8f-ddba-40aa-8d9e-4c721c8d69dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea36b38-4795-4e0b-ad4e-36b75a474e17" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_055b9e8f-ddba-40aa-8d9e-4c721c8d69dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3e87ab7-c9f4-46f5-9d28-fe76f6f6fbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_12cea26b-8490-49f4-a4e0-c6c124a7691d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3e87ab7-c9f4-46f5-9d28-fe76f6f6fbcc" xlink:to="loc_us-gaap_Liabilities_12cea26b-8490-49f4-a4e0-c6c124a7691d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4e3b2b4f-04a8-4a6d-8466-663e7682cd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3e87ab7-c9f4-46f5-9d28-fe76f6f6fbcc" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4e3b2b4f-04a8-4a6d-8466-663e7682cd8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0af67963-f9a0-4608-b260-0a571e415549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3e87ab7-c9f4-46f5-9d28-fe76f6f6fbcc" xlink:to="loc_us-gaap_StockholdersEquity_0af67963-f9a0-4608-b260-0a571e415549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1547f956-5afd-409a-8319-b357d91a64cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d0dbcb7c-3e12-4cc0-b281-919a2f8832f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1547f956-5afd-409a-8319-b357d91a64cd" xlink:to="loc_us-gaap_AssetsCurrent_d0dbcb7c-3e12-4cc0-b281-919a2f8832f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a769c4ed-c9f6-4257-b179-946f674eb01f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1547f956-5afd-409a-8319-b357d91a64cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a769c4ed-c9f6-4257-b179-946f674eb01f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fe968108-9638-409d-8597-ec4aa0df23b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1547f956-5afd-409a-8319-b357d91a64cd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fe968108-9638-409d-8597-ec4aa0df23b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_3528173c-407e-4556-922c-2b8b35a842e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1547f956-5afd-409a-8319-b357d91a64cd" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_3528173c-407e-4556-922c-2b8b35a842e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f9ea5602-cd63-4d8a-b0f4-f2a29bc59a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1547f956-5afd-409a-8319-b357d91a64cd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f9ea5602-cd63-4d8a-b0f4-f2a29bc59a5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c1cb3a74-e995-4eab-93ae-57d940cef1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0079ac3c-a82b-4b9b-85c4-384950b8342f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c1cb3a74-e995-4eab-93ae-57d940cef1e3" xlink:to="loc_us-gaap_AccountsPayableCurrent_0079ac3c-a82b-4b9b-85c4-384950b8342f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0beb126c-22f6-4266-9905-48748481dcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c1cb3a74-e995-4eab-93ae-57d940cef1e3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0beb126c-22f6-4266-9905-48748481dcd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_edf2feb1-48ca-43a6-8470-a9f3434e7114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c1cb3a74-e995-4eab-93ae-57d940cef1e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_edf2feb1-48ca-43a6-8470-a9f3434e7114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b0dfa188-172a-4722-a6f0-ee9f27967e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c1cb3a74-e995-4eab-93ae-57d940cef1e3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b0dfa188-172a-4722-a6f0-ee9f27967e47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityCurrent_98becbe6-acfe-40ce-aade-576f74bb0562" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c1cb3a74-e995-4eab-93ae-57d940cef1e3" xlink:to="loc_alny_RoyaltyLiabilityCurrent_98becbe6-acfe-40ce-aade-576f74bb0562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d78c7e8d-df73-47bf-aaba-2e34a97c57ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_65b08484-fd41-4048-950c-ede632a58453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d78c7e8d-df73-47bf-aaba-2e34a97c57ed" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_65b08484-fd41-4048-950c-ede632a58453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5525290c-16b9-4b3c-b8fd-27d227a5a496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d78c7e8d-df73-47bf-aaba-2e34a97c57ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5525290c-16b9-4b3c-b8fd-27d227a5a496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fdd47228-f301-402c-9d47-1c3821c89edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d78c7e8d-df73-47bf-aaba-2e34a97c57ed" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fdd47228-f301-402c-9d47-1c3821c89edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ed329a23-9dba-4b33-98a1-f52e63e4706a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d78c7e8d-df73-47bf-aaba-2e34a97c57ed" xlink:to="loc_us-gaap_InventoryNet_ed329a23-9dba-4b33-98a1-f52e63e4706a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7f68e563-438e-4743-a17c-63eb8db4f48d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d78c7e8d-df73-47bf-aaba-2e34a97c57ed" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7f68e563-438e-4743-a17c-63eb8db4f48d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0c0c0951-c180-463b-81a0-58cf22501a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d78c7e8d-df73-47bf-aaba-2e34a97c57ed" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0c0c0951-c180-463b-81a0-58cf22501a65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e9251085-a02a-4d8f-b2b7-72828801cf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_af676456-cdcb-4f20-81d2-f5027ad8b777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9251085-a02a-4d8f-b2b7-72828801cf2d" xlink:to="loc_us-gaap_PreferredStockValue_af676456-cdcb-4f20-81d2-f5027ad8b777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6b507715-3485-40b6-b9a3-381c16756fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9251085-a02a-4d8f-b2b7-72828801cf2d" xlink:to="loc_us-gaap_CommonStockValue_6b507715-3485-40b6-b9a3-381c16756fce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_32c9f560-ea0f-48a4-a034-b616f2394a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9251085-a02a-4d8f-b2b7-72828801cf2d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_32c9f560-ea0f-48a4-a034-b616f2394a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_06400e7d-a66f-4776-9700-f9a486d046e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9251085-a02a-4d8f-b2b7-72828801cf2d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_06400e7d-a66f-4776-9700-f9a486d046e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c0e93110-680e-454e-b90a-d55019705972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9251085-a02a-4d8f-b2b7-72828801cf2d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c0e93110-680e-454e-b90a-d55019705972" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="alny-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_434a976c-5a8a-4bb9-acce-04f32df015ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CostOfCollaborationManufacturingAndRoyalties_3b5d00f6-b165-4489-a05d-fc5badb10ff9" xlink:href="alny-20230331.xsd#alny_CostOfCollaborationManufacturingAndRoyalties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_434a976c-5a8a-4bb9-acce-04f32df015ef" xlink:to="loc_alny_CostOfCollaborationManufacturingAndRoyalties_3b5d00f6-b165-4489-a05d-fc5badb10ff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ad95b2d4-0233-46d9-b623-9f9005bcc329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_434a976c-5a8a-4bb9-acce-04f32df015ef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ad95b2d4-0233-46d9-b623-9f9005bcc329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ab1cebd1-9746-449f-9a97-ce26315a108e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_434a976c-5a8a-4bb9-acce-04f32df015ef" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ab1cebd1-9746-449f-9a97-ce26315a108e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_48f709ba-53c9-4bf8-9db3-fb6544ce4089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_434a976c-5a8a-4bb9-acce-04f32df015ef" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_48f709ba-53c9-4bf8-9db3-fb6544ce4089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3560e8d0-ce70-46cc-b21a-063feabd525d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8544a888-3ba8-40a7-a2af-20e715839b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3560e8d0-ce70-46cc-b21a-063feabd525d" xlink:to="loc_us-gaap_CostsAndExpenses_8544a888-3ba8-40a7-a2af-20e715839b6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5910806c-06d7-4b40-b2d4-aa41f3bcc3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3560e8d0-ce70-46cc-b21a-063feabd525d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5910806c-06d7-4b40-b2d4-aa41f3bcc3f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ba893d6e-2a1e-408b-ab3b-868ec6040df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7c05758f-7de3-47fb-948d-8342b5389968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ba893d6e-2a1e-408b-ab3b-868ec6040df7" xlink:to="loc_us-gaap_OperatingIncomeLoss_7c05758f-7de3-47fb-948d-8342b5389968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_865c94ed-250b-49b8-8186-bb82bea88f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ba893d6e-2a1e-408b-ab3b-868ec6040df7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_865c94ed-250b-49b8-8186-bb82bea88f35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2459a5c3-1bc3-4e84-8f00-c2c5486a9f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_66784dfe-77b7-4e7d-8408-d3637defdcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2459a5c3-1bc3-4e84-8f00-c2c5486a9f06" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_66784dfe-77b7-4e7d-8408-d3637defdcd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_293cd096-dab1-408d-9cc5-d6998b73b691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2459a5c3-1bc3-4e84-8f00-c2c5486a9f06" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_293cd096-dab1-408d-9cc5-d6998b73b691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d669ff82-0f0b-430a-a721-35e6ca99f4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_178b1975-a390-4eb0-b738-2c66a0b7674f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d669ff82-0f0b-430a-a721-35e6ca99f4b0" xlink:to="loc_us-gaap_NetIncomeLoss_178b1975-a390-4eb0-b738-2c66a0b7674f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_24c4a2f8-8694-425f-8b08-8bbb7008644a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d669ff82-0f0b-430a-a721-35e6ca99f4b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_24c4a2f8-8694-425f-8b08-8bbb7008644a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ba3e3606-38cd-46d6-b6da-6c8f2bdd5ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_a435bf7c-7c2b-4eb1-a260-6b3bc1e48484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ba3e3606-38cd-46d6-b6da-6c8f2bdd5ec4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_a435bf7c-7c2b-4eb1-a260-6b3bc1e48484" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_0984841d-e3b5-422f-9fed-1236609b04cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ba3e3606-38cd-46d6-b6da-6c8f2bdd5ec4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_0984841d-e3b5-422f-9fed-1236609b04cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_65db2c67-58d7-47f0-881b-499dc533da0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ba3e3606-38cd-46d6-b6da-6c8f2bdd5ec4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_65db2c67-58d7-47f0-881b-499dc533da0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f1ccd00d-7cec-4715-901f-1d56c981318b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_99a032cc-1ef5-4a67-bafe-50ec2f4f4146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f1ccd00d-7cec-4715-901f-1d56c981318b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_99a032cc-1ef5-4a67-bafe-50ec2f4f4146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0f48bc41-9d2e-4b78-bd1c-3516eb9c48b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f1ccd00d-7cec-4715-901f-1d56c981318b" xlink:to="loc_us-gaap_InterestExpense_0f48bc41-9d2e-4b78-bd1c-3516eb9c48b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c7311c74-bb7b-45fb-8d3d-6100cca0b60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f1ccd00d-7cec-4715-901f-1d56c981318b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c7311c74-bb7b-45fb-8d3d-6100cca0b60d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="alny-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a4901d4-0b3a-49d3-9b2d-5db37695f99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7b755462-e12c-4d31-936c-ad29947a70fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a4901d4-0b3a-49d3-9b2d-5db37695f99c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7b755462-e12c-4d31-936c-ad29947a70fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_f54622e6-4b5c-401d-8954-5184a9a541e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a4901d4-0b3a-49d3-9b2d-5db37695f99c" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_f54622e6-4b5c-401d-8954-5184a9a541e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0245a8e8-e5ca-455d-9e32-f5f4ed480719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5b025193-6adf-4ea1-803f-054bd262c6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0245a8e8-e5ca-455d-9e32-f5f4ed480719" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5b025193-6adf-4ea1-803f-054bd262c6ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_74e49fbb-feb2-4b2f-b873-c0ce5990321d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0245a8e8-e5ca-455d-9e32-f5f4ed480719" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_74e49fbb-feb2-4b2f-b873-c0ce5990321d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_6e55dc7d-83b3-400b-b77e-4a3eeb25bcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0245a8e8-e5ca-455d-9e32-f5f4ed480719" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_6e55dc7d-83b3-400b-b77e-4a3eeb25bcd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_57607108-7af3-4a55-9fa1-a0e14a9386ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0245a8e8-e5ca-455d-9e32-f5f4ed480719" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_57607108-7af3-4a55-9fa1-a0e14a9386ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7e53f564-90bc-429b-a23a-c1c4248b01cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0245a8e8-e5ca-455d-9e32-f5f4ed480719" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7e53f564-90bc-429b-a23a-c1c4248b01cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_04646b34-5b0c-4ea5-b586-76793a577c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0245a8e8-e5ca-455d-9e32-f5f4ed480719" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_04646b34-5b0c-4ea5-b586-76793a577c25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6a5c2da8-9f87-48d8-8c12-5488d414d2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6a5c2da8-9f87-48d8-8c12-5488d414d2f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e2d53f39-abb2-4071-b7ae-eeed12281924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e2d53f39-abb2-4071-b7ae-eeed12281924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13d3d40c-d2ec-43ce-851e-5b6d18c78b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13d3d40c-d2ec-43ce-851e-5b6d18c78b1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_4b40b28a-9ef1-4d83-bf90-24b85d0fa368" xlink:href="alny-20230331.xsd#alny_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_4b40b28a-9ef1-4d83-bf90-24b85d0fa368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c2c35d78-bd5c-4660-9eb9-6d1329197e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c2c35d78-bd5c-4660-9eb9-6d1329197e27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_cb5573f7-cd5c-44e5-8479-7632ece6d165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_cb5573f7-cd5c-44e5-8479-7632ece6d165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a9d66608-a114-460a-b70d-d43a91431dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a9d66608-a114-460a-b70d-d43a91431dfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c458b2c7-e507-4339-8efc-3913a12881be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_us-gaap_NetIncomeLoss_c458b2c7-e507-4339-8efc-3913a12881be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_16f2315f-761a-4120-bd42-cca7eb515247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_16f2315f-761a-4120-bd42-cca7eb515247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_48a80074-a37f-4caa-860b-5b854cdcb83e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_48a80074-a37f-4caa-860b-5b854cdcb83e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_c0913fb5-c606-4db8-a0e4-b80ff297eb56" xlink:href="alny-20230331.xsd#alny_NonCashInterestExpenseOnSaleOfFutureRoyalties"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_c0913fb5-c606-4db8-a0e4-b80ff297eb56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c8efb924-ce75-4fad-a2f5-2ddad0f5d5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c8efb924-ce75-4fad-a2f5-2ddad0f5d5f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3e8e6985-d869-4150-ab93-f19bb094caa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_us-gaap_ShareBasedCompensation_3e8e6985-d869-4150-ab93-f19bb094caa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ChangeInFairValueOfLiabilityObligation_c40751d8-2d51-4beb-bb20-ea3ae2cbe045" xlink:href="alny-20230331.xsd#alny_ChangeInFairValueOfLiabilityObligation"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b314e975-ebe0-4e1f-ba83-5d616bcefe79" xlink:to="loc_alny_ChangeInFairValueOfLiabilityObligation_c40751d8-2d51-4beb-bb20-ea3ae2cbe045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffa067d5-ce8e-4588-b0c8-6b96c7632143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a6b1ab68-5ab0-4bf8-b2f3-d344b6e0ce81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffa067d5-ce8e-4588-b0c8-6b96c7632143" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a6b1ab68-5ab0-4bf8-b2f3-d344b6e0ce81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0778fb85-5bfc-48af-ac01-c3c38113ef04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffa067d5-ce8e-4588-b0c8-6b96c7632143" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0778fb85-5bfc-48af-ac01-c3c38113ef04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a0d71e5-ecf1-4eb9-be7d-69cf9666bec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffa067d5-ce8e-4588-b0c8-6b96c7632143" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a0d71e5-ecf1-4eb9-be7d-69cf9666bec7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89bf79a2-9180-45b6-bb20-4fb3c270c8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ffa067d5-ce8e-4588-b0c8-6b96c7632143" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89bf79a2-9180-45b6-bb20-4fb3c270c8a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1ce14601-3d66-4922-80d9-9352c7564006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9717b9b7-2ce2-48c8-928e-1cb565e28f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1ce14601-3d66-4922-80d9-9352c7564006" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9717b9b7-2ce2-48c8-928e-1cb565e28f29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bd1e8aa3-35dc-42ec-b0d1-2a223d359c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1ce14601-3d66-4922-80d9-9352c7564006" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bd1e8aa3-35dc-42ec-b0d1-2a223d359c72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6779fa59-6da9-4275-9a4d-e69cb212e059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1ce14601-3d66-4922-80d9-9352c7564006" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6779fa59-6da9-4275-9a4d-e69cb212e059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_33ed19b5-77da-430e-a1bc-6834fcfa1156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1ce14601-3d66-4922-80d9-9352c7564006" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_33ed19b5-77da-430e-a1bc-6834fcfa1156" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_38f932bb-8bb5-4b0b-8964-5e02788c1cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c45031b9-b295-4ea0-aa68-9f304a2fd20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_38f932bb-8bb5-4b0b-8964-5e02788c1cf2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c45031b9-b295-4ea0-aa68-9f304a2fd20a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5c674d0d-f667-4471-b119-58821e14a5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_38f932bb-8bb5-4b0b-8964-5e02788c1cf2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5c674d0d-f667-4471-b119-58821e14a5dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_45ca4aeb-14b0-4306-9a17-d723d17e4ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_38f932bb-8bb5-4b0b-8964-5e02788c1cf2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_45ca4aeb-14b0-4306-9a17-d723d17e4ad7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_35627435-2c2d-412f-a099-52dead89ffc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b35c3c32-ff8a-48ef-a33d-e483182a7b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_35627435-2c2d-412f-a099-52dead89ffc3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b35c3c32-ff8a-48ef-a33d-e483182a7b70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c0d26048-1885-4032-aa90-f9477899207a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_35627435-2c2d-412f-a099-52dead89ffc3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c0d26048-1885-4032-aa90-f9477899207a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alny_InventoryCurrentAndNoncurrent_1cb3fb5c-1940-4595-a662-290bbb99a299" xlink:href="alny-20230331.xsd#alny_InventoryCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_d6f1a900-7b40-430f-9bf2-55277e6b7309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alny_InventoryCurrentAndNoncurrent_1cb3fb5c-1940-4595-a662-290bbb99a299" xlink:to="loc_us-gaap_InventoryRawMaterials_d6f1a900-7b40-430f-9bf2-55277e6b7309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_91b0d251-eaa7-40b4-a76f-74bea178b35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alny_InventoryCurrentAndNoncurrent_1cb3fb5c-1940-4595-a662-290bbb99a299" xlink:to="loc_us-gaap_InventoryWorkInProcess_91b0d251-eaa7-40b4-a76f-74bea178b35b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_2e695a69-fe61-45dc-88b8-87d091ddd4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alny_InventoryCurrentAndNoncurrent_1cb3fb5c-1940-4595-a662-290bbb99a299" xlink:to="loc_us-gaap_InventoryFinishedGoods_2e695a69-fe61-45dc-88b8-87d091ddd4cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_be79c6f1-0206-4fcc-98dc-6a01a10bba0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_13cb22fd-5a49-490d-9287-37bd50397ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_be79c6f1-0206-4fcc-98dc-6a01a10bba0f" xlink:to="loc_us-gaap_RestrictedCash_13cb22fd-5a49-490d-9287-37bd50397ce7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b395700d-cfaa-4d4f-b897-874dabe336ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_be79c6f1-0206-4fcc-98dc-6a01a10bba0f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b395700d-cfaa-4d4f-b897-874dabe336ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f5433387-b36b-49d9-afd1-62fbf98a0658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6ee75cfe-c030-4b7c-87a3-1caa76450d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f5433387-b36b-49d9-afd1-62fbf98a0658" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6ee75cfe-c030-4b7c-87a3-1caa76450d2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7686b7b8-91bd-41a0-bbdf-236770661c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f5433387-b36b-49d9-afd1-62fbf98a0658" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7686b7b8-91bd-41a0-bbdf-236770661c28" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>alny-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b732ba76-b80e-452b-9370-f7a92071fea1,g:cc882e96-1f0e-4ac3-98d4-087e3affef76-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="alny-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="i681beeaf4a9e4c128731ee6cb90dfbec_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8641417a-3c6c-41e7-b9ce-f8ef67b3583f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_RevenuesAbstract_8641417a-3c6c-41e7-b9ce-f8ef67b3583f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84a54221-5cc4-4daa-96e7-5712537b85fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_8641417a-3c6c-41e7-b9ce-f8ef67b3583f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84a54221-5cc4-4daa-96e7-5712537b85fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_03bbe88c-b6be-431f-93ae-caef455aca35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_03bbe88c-b6be-431f-93ae-caef455aca35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CostOfCollaborationManufacturingAndRoyalties_79f6549a-2903-495c-81aa-f40ed65b27fe" xlink:href="alny-20230331.xsd#alny_CostOfCollaborationManufacturingAndRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:to="loc_alny_CostOfCollaborationManufacturingAndRoyalties_79f6549a-2903-495c-81aa-f40ed65b27fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_94d7a7a9-975d-45bd-bce7-2bd4dfa79d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_94d7a7a9-975d-45bd-bce7-2bd4dfa79d78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_68d0e782-2ed4-41e1-82c8-dc873a513010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_68d0e782-2ed4-41e1-82c8-dc873a513010" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c37797d9-9290-4e3f-9476-943483d65c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:to="loc_us-gaap_CostsAndExpenses_c37797d9-9290-4e3f-9476-943483d65c6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bf24c50d-1f9a-40ed-857a-bbbf7008d836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_OperatingIncomeLoss_bf24c50d-1f9a-40ed-857a-bbbf7008d836" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c4bd782-655f-4ecf-adad-64d3806702dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c4bd782-655f-4ecf-adad-64d3806702dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2bd30b25-e2ed-4b16-b649-92f5bc4921e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c4bd782-655f-4ecf-adad-64d3806702dc" xlink:to="loc_us-gaap_InterestExpense_2bd30b25-e2ed-4b16-b649-92f5bc4921e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_868d2ad6-a626-4393-85a8-c9f9b24a25bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c4bd782-655f-4ecf-adad-64d3806702dc" xlink:to="loc_us-gaap_InvestmentIncomeInterest_868d2ad6-a626-4393-85a8-c9f9b24a25bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7bd87020-0f3b-462f-80a0-ffd4b2787a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c4bd782-655f-4ecf-adad-64d3806702dc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7bd87020-0f3b-462f-80a0-ffd4b2787a6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_46d98225-1cbb-486d-84c7-545b3f3de7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c4bd782-655f-4ecf-adad-64d3806702dc" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_46d98225-1cbb-486d-84c7-545b3f3de7d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33d054a1-b39d-4ac4-aa8a-d0e817bab59f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33d054a1-b39d-4ac4-aa8a-d0e817bab59f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6149e559-068a-432d-92ca-5c4b047e83db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6149e559-068a-432d-92ca-5c4b047e83db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1726f44e-e0bf-4b05-ae96-27a6a6c710e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_NetIncomeLoss_1726f44e-e0bf-4b05-ae96-27a6a6c710e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4be553a7-b807-4abf-8559-65ee00543a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_EarningsPerShareBasic_4be553a7-b807-4abf-8559-65ee00543a04" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d56da973-bd7f-4ba7-ba58-33279d204f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d56da973-bd7f-4ba7-ba58-33279d204f3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f76baec9-eae5-4a77-942b-666a98e35c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f76baec9-eae5-4a77-942b-666a98e35c27" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12b7264a-439f-47fa-9170-9d13071ab534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12b7264a-439f-47fa-9170-9d13071ab534" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_50d60f54-37ba-4646-a057-01e8df04b4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_50d60f54-37ba-4646-a057-01e8df04b4c0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3992dd3a-2f52-4355-af51-b5ad3b8b6624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_72c4edf0-a724-4fda-a26a-33685f5ffe10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_50d60f54-37ba-4646-a057-01e8df04b4c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_72c4edf0-a724-4fda-a26a-33685f5ffe10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_133a3701-8c40-4c20-8ec8-60ed9e6c4229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_72c4edf0-a724-4fda-a26a-33685f5ffe10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_133a3701-8c40-4c20-8ec8-60ed9e6c4229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_8479c3a9-d360-46e6-8a3e-ffa587dfb0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_72c4edf0-a724-4fda-a26a-33685f5ffe10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_8479c3a9-d360-46e6-8a3e-ffa587dfb0f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_29e5fae9-cefa-4942-9cd8-7f1063a5cf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_72c4edf0-a724-4fda-a26a-33685f5ffe10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_29e5fae9-cefa-4942-9cd8-7f1063a5cf13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cd5d2041-8de7-4e20-b4bd-cb166c260fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_72c4edf0-a724-4fda-a26a-33685f5ffe10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cd5d2041-8de7-4e20-b4bd-cb166c260fca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e7398273-1d41-445b-9297-c3d97a24dc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_50d60f54-37ba-4646-a057-01e8df04b4c0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e7398273-1d41-445b-9297-c3d97a24dc73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dd241cf5-565b-41ac-82a4-25b34835d626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_StatementTable_dd241cf5-565b-41ac-82a4-25b34835d626" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_da36d319-9e10-4174-8c1d-8f805969b689" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_dd241cf5-565b-41ac-82a4-25b34835d626" xlink:to="loc_srt_ProductOrServiceAxis_da36d319-9e10-4174-8c1d-8f805969b689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_da36d319-9e10-4174-8c1d-8f805969b689_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_da36d319-9e10-4174-8c1d-8f805969b689" xlink:to="loc_srt_ProductsAndServicesDomain_da36d319-9e10-4174-8c1d-8f805969b689_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_edc5ad7c-6b66-4cc1-981b-1cc8b46e1101" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_da36d319-9e10-4174-8c1d-8f805969b689" xlink:to="loc_srt_ProductsAndServicesDomain_edc5ad7c-6b66-4cc1-981b-1cc8b46e1101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_853eacb9-1862-400b-bcbb-821dc05e0140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edc5ad7c-6b66-4cc1-981b-1cc8b46e1101" xlink:to="loc_us-gaap_ProductMember_853eacb9-1862-400b-bcbb-821dc05e0140" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborationsMember_ff60bbd0-7075-4e1d-87ac-97529dfa2d70" xlink:href="alny-20230331.xsd#alny_CollaborationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edc5ad7c-6b66-4cc1-981b-1cc8b46e1101" xlink:to="loc_alny_CollaborationsMember_ff60bbd0-7075-4e1d-87ac-97529dfa2d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_a2a7f91a-a141-493e-b232-f1843fb45521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edc5ad7c-6b66-4cc1-981b-1cc8b46e1101" xlink:to="loc_us-gaap_RoyaltyMember_a2a7f91a-a141-493e-b232-f1843fb45521" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="alny-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i705e403a1fe94bedbeb2e0191fab45ab_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b24bf5ac-990e-44fe-91f8-445c55525f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b24bf5ac-990e-44fe-91f8-445c55525f6c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_80d3e868-6a85-4a68-9cad-e233d42c052c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_80d3e868-6a85-4a68-9cad-e233d42c052c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d8bcd896-5cdd-45a4-9fad-0fca8dfa3943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_StockholdersEquity_d8bcd896-5cdd-45a4-9fad-0fca8dfa3943" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a30727eb-0e33-4275-b52a-80634f426c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a30727eb-0e33-4275-b52a-80634f426c24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6487b7bf-5531-4fe2-8f8d-7e7ba3b55ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6487b7bf-5531-4fe2-8f8d-7e7ba3b55ae1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_a6f2ece3-7cd5-40b1-b4e1-d00e7f00465a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_a6f2ece3-7cd5-40b1-b4e1-d00e7f00465a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_37ec402e-0174-4d46-8e80-f5d6c6ca29e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_37ec402e-0174-4d46-8e80-f5d6c6ca29e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5fa8d41-31cd-4b13-abc1-82280cd4e747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5fa8d41-31cd-4b13-abc1-82280cd4e747" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6dce8ca3-9d83-48ae-be1d-31cf678819a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6dce8ca3-9d83-48ae-be1d-31cf678819a5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b5c21c4b-f7f7-48e3-bc9c-9183b8aa9504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_NetIncomeLoss_b5c21c4b-f7f7-48e3-bc9c-9183b8aa9504" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a5b87d9c-5ba0-421d-abd7-4a6f4ad6fcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_14560414-e7ff-4a39-beb3-d6e62b4200ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c4060277-8cee-4b7f-8cd1-e242dcd4a6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b24bf5ac-990e-44fe-91f8-445c55525f6c" xlink:to="loc_us-gaap_StatementTable_c4060277-8cee-4b7f-8cd1-e242dcd4a6df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_03e06590-fe2d-4dc5-96ec-827a2cc9d9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c4060277-8cee-4b7f-8cd1-e242dcd4a6df" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_03e06590-fe2d-4dc5-96ec-827a2cc9d9d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_03e06590-fe2d-4dc5-96ec-827a2cc9d9d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_03e06590-fe2d-4dc5-96ec-827a2cc9d9d5" xlink:to="loc_us-gaap_EquityComponentDomain_03e06590-fe2d-4dc5-96ec-827a2cc9d9d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_96b28feb-1277-4003-8baf-164cd556ead6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_03e06590-fe2d-4dc5-96ec-827a2cc9d9d5" xlink:to="loc_us-gaap_EquityComponentDomain_96b28feb-1277-4003-8baf-164cd556ead6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_06be5658-71e1-453b-857d-aa59e5fcde5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96b28feb-1277-4003-8baf-164cd556ead6" xlink:to="loc_us-gaap_CommonStockMember_06be5658-71e1-453b-857d-aa59e5fcde5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_efe06e72-a7ed-408d-b637-fc5fe607cef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96b28feb-1277-4003-8baf-164cd556ead6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_efe06e72-a7ed-408d-b637-fc5fe607cef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3483d57b-71bd-476f-a9e5-b26b53580fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96b28feb-1277-4003-8baf-164cd556ead6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3483d57b-71bd-476f-a9e5-b26b53580fbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ece079ac-f354-4e94-a9d9-ce373415d4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96b28feb-1277-4003-8baf-164cd556ead6" xlink:to="loc_us-gaap_RetainedEarningsMember_ece079ac-f354-4e94-a9d9-ce373415d4d5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail" xlink:type="extended" id="i8691df7072da4483b84ab6a99126f63a_NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fb0cc011-8ca7-4f95-8b5f-86451096c416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_250bbf14-83ab-4836-a4ab-17cea562b1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fb0cc011-8ca7-4f95-8b5f-86451096c416" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_250bbf14-83ab-4836-a4ab-17cea562b1b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_17c75d00-9280-4921-a1bf-0d62e164b82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fb0cc011-8ca7-4f95-8b5f-86451096c416" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_17c75d00-9280-4921-a1bf-0d62e164b82c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_18485b04-b367-49cf-bb2a-df6af16cd65f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_17c75d00-9280-4921-a1bf-0d62e164b82c" xlink:to="loc_srt_StatementGeographicalAxis_18485b04-b367-49cf-bb2a-df6af16cd65f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_18485b04-b367-49cf-bb2a-df6af16cd65f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_18485b04-b367-49cf-bb2a-df6af16cd65f" xlink:to="loc_srt_SegmentGeographicalDomain_18485b04-b367-49cf-bb2a-df6af16cd65f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ef090490-ce16-4168-a97f-76adc080e196" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_18485b04-b367-49cf-bb2a-df6af16cd65f" xlink:to="loc_srt_SegmentGeographicalDomain_ef090490-ce16-4168-a97f-76adc080e196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_581cdb55-22df-4135-b476-48ec4400e254" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ef090490-ce16-4168-a97f-76adc080e196" xlink:to="loc_country_US_581cdb55-22df-4135-b476-48ec4400e254" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_dc01ae5b-01d5-4b81-b175-2f67a97b1a08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ef090490-ce16-4168-a97f-76adc080e196" xlink:to="loc_srt_EuropeMember_dc01ae5b-01d5-4b81-b175-2f67a97b1a08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonUSOrEuropeMember_02ccf420-c19e-4f10-87db-133bcbad2071" xlink:href="alny-20230331.xsd#alny_NonUSOrEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ef090490-ce16-4168-a97f-76adc080e196" xlink:to="loc_alny_NonUSOrEuropeMember_02ccf420-c19e-4f10-87db-133bcbad2071" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9a6fd5dd-f21a-4863-bd28-2ec969975938" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_17c75d00-9280-4921-a1bf-0d62e164b82c" xlink:to="loc_srt_ProductOrServiceAxis_9a6fd5dd-f21a-4863-bd28-2ec969975938" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9a6fd5dd-f21a-4863-bd28-2ec969975938_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9a6fd5dd-f21a-4863-bd28-2ec969975938" xlink:to="loc_srt_ProductsAndServicesDomain_9a6fd5dd-f21a-4863-bd28-2ec969975938_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a9c76037-0014-4388-96d9-9f3f0f27d900" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9a6fd5dd-f21a-4863-bd28-2ec969975938" xlink:to="loc_srt_ProductsAndServicesDomain_a9c76037-0014-4388-96d9-9f3f0f27d900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f4d8590c-eaf3-4aa8-9395-31a6413b0cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a9c76037-0014-4388-96d9-9f3f0f27d900" xlink:to="loc_us-gaap_ProductMember_f4d8590c-eaf3-4aa8-9395-31a6413b0cd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ONPATTROMember_c07fb97d-a673-4fe9-9055-63bf3394c7b6" xlink:href="alny-20230331.xsd#alny_ONPATTROMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_f4d8590c-eaf3-4aa8-9395-31a6413b0cd8" xlink:to="loc_alny_ONPATTROMember_c07fb97d-a673-4fe9-9055-63bf3394c7b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AmvuttraMember_b2490b2c-99f3-40aa-9ecd-9969be6688f2" xlink:href="alny-20230331.xsd#alny_AmvuttraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_f4d8590c-eaf3-4aa8-9395-31a6413b0cd8" xlink:to="loc_alny_AmvuttraMember_b2490b2c-99f3-40aa-9ecd-9969be6688f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GIVLAARIMember_873eef84-2c0c-41eb-ae4a-a594222eac26" xlink:href="alny-20230331.xsd#alny_GIVLAARIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_f4d8590c-eaf3-4aa8-9395-31a6413b0cd8" xlink:to="loc_alny_GIVLAARIMember_873eef84-2c0c-41eb-ae4a-a594222eac26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OXLUMOMember_72278e3a-33ef-4ead-ac5f-07ebad24d6d3" xlink:href="alny-20230331.xsd#alny_OXLUMOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_f4d8590c-eaf3-4aa8-9395-31a6413b0cd8" xlink:to="loc_alny_OXLUMOMember_72278e3a-33ef-4ead-ac5f-07ebad24d6d3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETPRODUCTREVENUESReceivablesDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail" xlink:type="extended" id="i67401a640cd34841a576078c61443f65_NETPRODUCTREVENUESReceivablesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b3dde8bc-dbac-42aa-927a-c429db58db8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_81fdb33e-b818-4432-a6b2-7174cb8e73d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b3dde8bc-dbac-42aa-927a-c429db58db8c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_81fdb33e-b818-4432-a6b2-7174cb8e73d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cc4907e6-8d01-4e7b-a477-76606e0e4c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b3dde8bc-dbac-42aa-927a-c429db58db8c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cc4907e6-8d01-4e7b-a477-76606e0e4c82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2b881b24-2fee-4a71-bd8a-19ec7e4e07cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cc4907e6-8d01-4e7b-a477-76606e0e4c82" xlink:to="loc_srt_ProductOrServiceAxis_2b881b24-2fee-4a71-bd8a-19ec7e4e07cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b881b24-2fee-4a71-bd8a-19ec7e4e07cf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2b881b24-2fee-4a71-bd8a-19ec7e4e07cf" xlink:to="loc_srt_ProductsAndServicesDomain_2b881b24-2fee-4a71-bd8a-19ec7e4e07cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_be5cced8-d8ab-4353-8f6d-55a5f5a3fdb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2b881b24-2fee-4a71-bd8a-19ec7e4e07cf" xlink:to="loc_srt_ProductsAndServicesDomain_be5cced8-d8ab-4353-8f6d-55a5f5a3fdb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ffbd55f3-33c9-4891-bb67-6143e1f790a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_be5cced8-d8ab-4353-8f6d-55a5f5a3fdb0" xlink:to="loc_us-gaap_ProductMember_ffbd55f3-33c9-4891-bb67-6143e1f790a3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail" xlink:type="extended" id="id4c48d7bce014beaa4b57db71da9e2e5_NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa105aa7-2ef9-473e-bcfe-c828f066bcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_339a09bd-847b-4fb0-bbba-85c78a0711c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa105aa7-2ef9-473e-bcfe-c828f066bcfe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_339a09bd-847b-4fb0-bbba-85c78a0711c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc6d7145-5e97-457d-9794-e464c71d02df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa105aa7-2ef9-473e-bcfe-c828f066bcfe" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc6d7145-5e97-457d-9794-e464c71d02df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_42b446c8-fc04-488e-b2d7-eeb4ddfb1346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc6d7145-5e97-457d-9794-e464c71d02df" xlink:to="loc_us-gaap_TypeOfArrangementAxis_42b446c8-fc04-488e-b2d7-eeb4ddfb1346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_42b446c8-fc04-488e-b2d7-eeb4ddfb1346_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_42b446c8-fc04-488e-b2d7-eeb4ddfb1346" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_42b446c8-fc04-488e-b2d7-eeb4ddfb1346_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1e12b35-3170-4184-af6f-25d56843b801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_42b446c8-fc04-488e-b2d7-eeb4ddfb1346" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1e12b35-3170-4184-af6f-25d56843b801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_25468cc1-0a41-4981-873f-f9d43cb16a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1e12b35-3170-4184-af6f-25d56843b801" xlink:to="loc_us-gaap_CollaborativeArrangementMember_25468cc1-0a41-4981-873f-f9d43cb16a13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9e005d36-fa65-4070-ba80-bfa9c4bc8c25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc6d7145-5e97-457d-9794-e464c71d02df" xlink:to="loc_srt_CounterpartyNameAxis_9e005d36-fa65-4070-ba80-bfa9c4bc8c25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e005d36-fa65-4070-ba80-bfa9c4bc8c25_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9e005d36-fa65-4070-ba80-bfa9c4bc8c25" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e005d36-fa65-4070-ba80-bfa9c4bc8c25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed1cfb6a-ff49-4ad8-8331-9390b919324c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9e005d36-fa65-4070-ba80-bfa9c4bc8c25" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed1cfb6a-ff49-4ad8-8331-9390b919324c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_e7d04eea-e11c-4eee-8b3a-a4b3dafb7aaa" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed1cfb6a-ff49-4ad8-8331-9390b919324c" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_e7d04eea-e11c-4eee-8b3a-a4b3dafb7aaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NovartisMember_ae5521d4-9d73-4df9-9bb7-10495605d228" xlink:href="alny-20230331.xsd#alny_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed1cfb6a-ff49-4ad8-8331-9390b919324c" xlink:to="loc_alny_NovartisMember_ae5521d4-9d73-4df9-9bb7-10495605d228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherCollaborationsMember_6bdb7e0b-b8df-484c-ade6-d8f93cf74cb2" xlink:href="alny-20230331.xsd#alny_OtherCollaborationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed1cfb6a-ff49-4ad8-8331-9390b919324c" xlink:to="loc_alny_OtherCollaborationsMember_6bdb7e0b-b8df-484c-ade6-d8f93cf74cb2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="extended" id="id1fa82b275ed4760b1e22f5f37d0dbf8_NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82c76b78-3334-43b5-a2ca-152852b03683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4200e462-4e13-47ab-a09c-407d8d0be731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82c76b78-3334-43b5-a2ca-152852b03683" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4200e462-4e13-47ab-a09c-407d8d0be731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e74e4682-1e3c-4777-8bad-0e5936484ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82c76b78-3334-43b5-a2ca-152852b03683" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e74e4682-1e3c-4777-8bad-0e5936484ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a0522b48-4d0d-4377-b604-cdad4b23f455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82c76b78-3334-43b5-a2ca-152852b03683" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a0522b48-4d0d-4377-b604-cdad4b23f455" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4d495b62-bbee-459d-9e32-100d93a70627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a0522b48-4d0d-4377-b604-cdad4b23f455" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4d495b62-bbee-459d-9e32-100d93a70627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d495b62-bbee-459d-9e32-100d93a70627_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4d495b62-bbee-459d-9e32-100d93a70627" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d495b62-bbee-459d-9e32-100d93a70627_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e11ba183-23b0-4e67-8310-a47c48d71a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4d495b62-bbee-459d-9e32-100d93a70627" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e11ba183-23b0-4e67-8310-a47c48d71a6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_611f0d15-1313-4b14-9c2f-6a7e88fc8696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e11ba183-23b0-4e67-8310-a47c48d71a6b" xlink:to="loc_us-gaap_CollaborativeArrangementMember_611f0d15-1313-4b14-9c2f-6a7e88fc8696" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail" xlink:type="extended" id="i74ab227d700546608c9f3743dfe41cab_NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8b0e2513-1b75-463d-a7d0-a3380213d8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8b0e2513-1b75-463d-a7d0-a3380213d8d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_IncreaseDecreaseInResearchAndDevelopmentExpense_d4e9fb52-ae69-4194-9440-eba1d3fae6a2" xlink:href="alny-20230331.xsd#alny_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_IncreaseDecreaseInResearchAndDevelopmentExpense_d4e9fb52-ae69-4194-9440-eba1d3fae6a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DiscoveryPeriodOfProgramsDevelopment_2aa6ce05-a60b-43c8-b004-56e347b646d3" xlink:href="alny-20230331.xsd#alny_DiscoveryPeriodOfProgramsDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_DiscoveryPeriodOfProgramsDevelopment_2aa6ce05-a60b-43c8-b004-56e347b646d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_657b33a9-67eb-4c78-9504-d0c69c4ea185" xlink:href="alny-20230331.xsd#alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_657b33a9-67eb-4c78-9504-d0c69c4ea185" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchTermExtensionFee_999fdba0-8591-47a9-95b1-f673c242b1d9" xlink:href="alny-20230331.xsd#alny_ResearchTermExtensionFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_ResearchTermExtensionFee_999fdba0-8591-47a9-95b1-f673c242b1d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_e1b5fb0b-4ac6-4a26-a064-a0fff610a652" xlink:href="alny-20230331.xsd#alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_e1b5fb0b-4ac6-4a26-a064-a0fff610a652" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_UpfrontFeeReceived_8d39a8eb-d078-43a3-b755-7bc979b6641c" xlink:href="alny-20230331.xsd#alny_UpfrontFeeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_UpfrontFeeReceived_8d39a8eb-d078-43a3-b755-7bc979b6641c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_756f5a91-c857-400f-8652-91b2a176cf58" xlink:href="alny-20230331.xsd#alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_756f5a91-c857-400f-8652-91b2a176cf58" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfTargetedPrograms_6e67b05c-9562-4cea-b78f-1c1b366d0902" xlink:href="alny-20230331.xsd#alny_NumberOfTargetedPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_NumberOfTargetedPrograms_6e67b05c-9562-4cea-b78f-1c1b366d0902" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeAgreementPeriodOfProgramDevelopment_b69dd9cf-7efa-4f24-9c61-4145be15b534" xlink:href="alny-20230331.xsd#alny_CollaborativeAgreementPeriodOfProgramDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_CollaborativeAgreementPeriodOfProgramDevelopment_b69dd9cf-7efa-4f24-9c61-4145be15b534" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PotentialProceedsFromCollaborationArrangement_867ce891-8270-4427-a96b-ed12b643c351" xlink:href="alny-20230331.xsd#alny_PotentialProceedsFromCollaborationArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_PotentialProceedsFromCollaborationArrangement_867ce891-8270-4427-a96b-ed12b643c351" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeAgreementTerminationPeriod_f8db59a9-1e00-4d02-95b2-82469a8c26ed" xlink:href="alny-20230331.xsd#alny_CollaborativeAgreementTerminationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_CollaborativeAgreementTerminationPeriod_f8db59a9-1e00-4d02-95b2-82469a8c26ed" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMilestonePayments_6c524b5f-c360-4c74-86b9-b3972d2a6d35" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_CollaborativeArrangementMilestonePayments_6c524b5f-c360-4c74-86b9-b3972d2a6d35" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyRate_cf8a22b4-b12c-405f-a239-ab77f553dcaf" xlink:href="alny-20230331.xsd#alny_RoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_RoyaltyRate_cf8a22b4-b12c-405f-a239-ab77f553dcaf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PercentageOfMaximumRoyaltyPayments_aba14580-577e-4c5f-a4f3-45daa081cfc3" xlink:href="alny-20230331.xsd#alny_PercentageOfMaximumRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_PercentageOfMaximumRoyaltyPayments_aba14580-577e-4c5f-a4f3-45daa081cfc3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_eded559b-760f-4a0b-b92d-49054411887e" xlink:href="alny-20230331.xsd#alny_TransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_TransactionPrice_eded559b-760f-4a0b-b92d-49054411887e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_47611de1-9d05-4f55-9d25-7c07304eab14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_47611de1-9d05-4f55-9d25-7c07304eab14" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_893f2be0-87d0-4d33-8b04-6f316cd587c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:to="loc_us-gaap_TypeOfArrangementAxis_893f2be0-87d0-4d33-8b04-6f316cd587c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893f2be0-87d0-4d33-8b04-6f316cd587c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_893f2be0-87d0-4d33-8b04-6f316cd587c5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893f2be0-87d0-4d33-8b04-6f316cd587c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39881dd1-72b3-4a4b-966f-d49268abb17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_893f2be0-87d0-4d33-8b04-6f316cd587c5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39881dd1-72b3-4a4b-966f-d49268abb17e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_f754d7ca-c484-4bb7-8297-f11cc7338297" xlink:href="alny-20230331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39881dd1-72b3-4a4b-966f-d49268abb17e" xlink:to="loc_alny_GlobalStrategicCollaborationMember_f754d7ca-c484-4bb7-8297-f11cc7338297" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6fe3b3a-f48e-4333-aa77-98fdcf3f946a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6fe3b3a-f48e-4333-aa77-98fdcf3f946a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a6fe3b3a-f48e-4333-aa77-98fdcf3f946a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6fe3b3a-f48e-4333-aa77-98fdcf3f946a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a6fe3b3a-f48e-4333-aa77-98fdcf3f946a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7aaa4d92-d275-4d7f-b8db-32905e75fe03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6fe3b3a-f48e-4333-aa77-98fdcf3f946a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7aaa4d92-d275-4d7f-b8db-32905e75fe03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtProgramInitiationMember_d9e1f136-ec0f-4a83-a701-5ec73a769d91" xlink:href="alny-20230331.xsd#alny_FundingAtProgramInitiationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7aaa4d92-d275-4d7f-b8db-32905e75fe03" xlink:to="loc_alny_FundingAtProgramInitiationMember_d9e1f136-ec0f-4a83-a701-5ec73a769d91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtLeadCandidateIdentificationMember_69703612-c3a5-4c39-8322-9d93d37ebd0a" xlink:href="alny-20230331.xsd#alny_FundingAtLeadCandidateIdentificationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7aaa4d92-d275-4d7f-b8db-32905e75fe03" xlink:to="loc_alny_FundingAtLeadCandidateIdentificationMember_69703612-c3a5-4c39-8322-9d93d37ebd0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAnAnnualDiscoveryMember_144688ee-f577-421c-b701-486ad36a6355" xlink:href="alny-20230331.xsd#alny_FundingAnAnnualDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7aaa4d92-d275-4d7f-b8db-32905e75fe03" xlink:to="loc_alny_FundingAnAnnualDiscoveryMember_144688ee-f577-421c-b701-486ad36a6355" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_66cc64d8-90d1-434f-ab0f-8757d1d97b9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:to="loc_srt_CounterpartyNameAxis_66cc64d8-90d1-434f-ab0f-8757d1d97b9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_66cc64d8-90d1-434f-ab0f-8757d1d97b9f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_66cc64d8-90d1-434f-ab0f-8757d1d97b9f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_66cc64d8-90d1-434f-ab0f-8757d1d97b9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f5dba5d-e37c-415a-9621-513bd6bbf385" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_66cc64d8-90d1-434f-ab0f-8757d1d97b9f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f5dba5d-e37c-415a-9621-513bd6bbf385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_fce66c92-f3c6-4c9b-9c89-8044bf15236e" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f5dba5d-e37c-415a-9621-513bd6bbf385" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_fce66c92-f3c6-4c9b-9c89-8044bf15236e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c41ba0a5-05ec-474e-9e02-f36882ad51b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:to="loc_srt_RangeAxis_c41ba0a5-05ec-474e-9e02-f36882ad51b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c41ba0a5-05ec-474e-9e02-f36882ad51b7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c41ba0a5-05ec-474e-9e02-f36882ad51b7" xlink:to="loc_srt_RangeMember_c41ba0a5-05ec-474e-9e02-f36882ad51b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f2edf54-0717-4543-aaae-baad42ec50d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c41ba0a5-05ec-474e-9e02-f36882ad51b7" xlink:to="loc_srt_RangeMember_6f2edf54-0717-4543-aaae-baad42ec50d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0f759c1c-912c-4aa4-be39-fba7e08fc883" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6f2edf54-0717-4543-aaae-baad42ec50d1" xlink:to="loc_srt_MaximumMember_0f759c1c-912c-4aa4-be39-fba7e08fc883" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="extended" id="i347c0295fbd14f318d80b4174e5447e3_NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34c4ee4e-c86e-44fa-8275-3f274a8c6c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9e97a8c0-c07c-4cd1-ad0c-a5007fe047b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34c4ee4e-c86e-44fa-8275-3f274a8c6c19" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9e97a8c0-c07c-4cd1-ad0c-a5007fe047b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3b1b205-1742-463a-93df-6af0d98e2cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34c4ee4e-c86e-44fa-8275-3f274a8c6c19" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3b1b205-1742-463a-93df-6af0d98e2cc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_40763e42-56bd-4de6-a60c-97ab13081f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3b1b205-1742-463a-93df-6af0d98e2cc6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_40763e42-56bd-4de6-a60c-97ab13081f93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40763e42-56bd-4de6-a60c-97ab13081f93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40763e42-56bd-4de6-a60c-97ab13081f93" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40763e42-56bd-4de6-a60c-97ab13081f93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db047ce6-82c1-45ce-bea9-97ba7e690a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40763e42-56bd-4de6-a60c-97ab13081f93" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db047ce6-82c1-45ce-bea9-97ba7e690a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ClinicalTrialAndManufacturingMember_ae0d6a50-a1d0-4e12-9ecb-b01ba7c5f9df" xlink:href="alny-20230331.xsd#alny_ClinicalTrialAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db047ce6-82c1-45ce-bea9-97ba7e690a38" xlink:to="loc_alny_ClinicalTrialAndManufacturingMember_ae0d6a50-a1d0-4e12-9ecb-b01ba7c5f9df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExternalServicesMember_9c1565c5-1cc2-461c-ba88-cba402185df3" xlink:href="alny-20230331.xsd#alny_ExternalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db047ce6-82c1-45ce-bea9-97ba7e690a38" xlink:to="loc_alny_ExternalServicesMember_9c1565c5-1cc2-461c-ba88-cba402185df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherMember_8a6d0441-4041-4e90-aa61-1c2ab5e7394d" xlink:href="alny-20230331.xsd#alny_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db047ce6-82c1-45ce-bea9-97ba7e690a38" xlink:to="loc_alny_OtherMember_8a6d0441-4041-4e90-aa61-1c2ab5e7394d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d8f0f395-58d1-4359-b8ff-339c6dd573d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3b1b205-1742-463a-93df-6af0d98e2cc6" xlink:to="loc_srt_CounterpartyNameAxis_d8f0f395-58d1-4359-b8ff-339c6dd573d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8f0f395-58d1-4359-b8ff-339c6dd573d2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d8f0f395-58d1-4359-b8ff-339c6dd573d2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8f0f395-58d1-4359-b8ff-339c6dd573d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8000e237-dedf-4f5e-be1b-15aedb5409b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d8f0f395-58d1-4359-b8ff-339c6dd573d2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8000e237-dedf-4f5e-be1b-15aedb5409b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_d859d855-434b-496f-8caf-c89ffda24eda" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8000e237-dedf-4f5e-be1b-15aedb5409b7" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_d859d855-434b-496f-8caf-c89ffda24eda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherCollaborationsMember_77d540b4-ef4f-429f-b314-746658b5fc11" xlink:href="alny-20230331.xsd#alny_OtherCollaborationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8000e237-dedf-4f5e-be1b-15aedb5409b7" xlink:to="loc_alny_OtherCollaborationsMember_77d540b4-ef4f-429f-b314-746658b5fc11" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails" xlink:type="extended" id="i7836d9fc7d3d4b9ab1777225e07d46a7_NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba8e40a2-0313-417b-86e5-ee54831cfbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_StandaloneSellingPrice_7c656ecc-ba0a-459f-b6f2-bcea8c876274" xlink:href="alny-20230331.xsd#alny_StandaloneSellingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba8e40a2-0313-417b-86e5-ee54831cfbd5" xlink:to="loc_alny_StandaloneSellingPrice_7c656ecc-ba0a-459f-b6f2-bcea8c876274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_9b812d9f-2da5-4c0f-8ee2-97d447be8e8e" xlink:href="alny-20230331.xsd#alny_TransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba8e40a2-0313-417b-86e5-ee54831cfbd5" xlink:to="loc_alny_TransactionPrice_9b812d9f-2da5-4c0f-8ee2-97d447be8e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4722c87-5be8-4523-980c-e76b6c52c108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba8e40a2-0313-417b-86e5-ee54831cfbd5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4722c87-5be8-4523-980c-e76b6c52c108" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dbdf706c-7747-4042-b453-31d0e529f0f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4722c87-5be8-4523-980c-e76b6c52c108" xlink:to="loc_srt_ProductOrServiceAxis_dbdf706c-7747-4042-b453-31d0e529f0f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dbdf706c-7747-4042-b453-31d0e529f0f0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dbdf706c-7747-4042-b453-31d0e529f0f0" xlink:to="loc_srt_ProductsAndServicesDomain_dbdf706c-7747-4042-b453-31d0e529f0f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_97ab1bd1-5696-4d06-944e-e6cbe07aeb86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dbdf706c-7747-4042-b453-31d0e529f0f0" xlink:to="loc_srt_ProductsAndServicesDomain_97ab1bd1-5696-4d06-944e-e6cbe07aeb86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_9cba4b61-c924-44cb-896e-5466f995f98c" xlink:href="alny-20230331.xsd#alny_ResearchServicesObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97ab1bd1-5696-4d06-944e-e6cbe07aeb86" xlink:to="loc_alny_ResearchServicesObligationMember_9cba4b61-c924-44cb-896e-5466f995f98c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_4aff2800-5a34-417c-b7fb-692d8be3af05" xlink:href="alny-20230331.xsd#alny_C5LicenseObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97ab1bd1-5696-4d06-944e-e6cbe07aeb86" xlink:to="loc_alny_C5LicenseObligationMember_4aff2800-5a34-417c-b7fb-692d8be3af05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_2b467c6c-c4d0-4b61-851e-2fc4bd0cd554" xlink:href="alny-20230331.xsd#alny_C5CoCoObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97ab1bd1-5696-4d06-944e-e6cbe07aeb86" xlink:to="loc_alny_C5CoCoObligationMember_2b467c6c-c4d0-4b61-851e-2fc4bd0cd554" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3a1fd335-8e38-4e44-a815-bb2329aaad9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4722c87-5be8-4523-980c-e76b6c52c108" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3a1fd335-8e38-4e44-a815-bb2329aaad9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a1fd335-8e38-4e44-a815-bb2329aaad9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3a1fd335-8e38-4e44-a815-bb2329aaad9e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a1fd335-8e38-4e44-a815-bb2329aaad9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca54487d-0c5d-4111-8f0e-4400a40bd0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3a1fd335-8e38-4e44-a815-bb2329aaad9e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca54487d-0c5d-4111-8f0e-4400a40bd0d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_2cc499dc-7c88-451a-ae7b-e1abb951f391" xlink:href="alny-20230331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca54487d-0c5d-4111-8f0e-4400a40bd0d8" xlink:to="loc_alny_GlobalStrategicCollaborationMember_2cc499dc-7c88-451a-ae7b-e1abb951f391" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_30f46c67-4167-4904-a4c3-9a7e433e69f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4722c87-5be8-4523-980c-e76b6c52c108" xlink:to="loc_srt_CounterpartyNameAxis_30f46c67-4167-4904-a4c3-9a7e433e69f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_30f46c67-4167-4904-a4c3-9a7e433e69f2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_30f46c67-4167-4904-a4c3-9a7e433e69f2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_30f46c67-4167-4904-a4c3-9a7e433e69f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9fad44d-9d8c-4a43-8a73-055debc2b1fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_30f46c67-4167-4904-a4c3-9a7e433e69f2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9fad44d-9d8c-4a43-8a73-055debc2b1fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_96b82cff-7b92-4573-b6ee-51d971bc15a0" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9fad44d-9d8c-4a43-8a73-055debc2b1fc" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_96b82cff-7b92-4573-b6ee-51d971bc15a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails" xlink:type="extended" id="i25887155514e4b3ab95f47bcdc0c2130_NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a513b867-90ae-4593-a165-ca6d06794f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_25544d3a-ef89-4864-b68a-5f65626da608" xlink:href="alny-20230331.xsd#alny_TransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a513b867-90ae-4593-a165-ca6d06794f14" xlink:to="loc_alny_TransactionPrice_25544d3a-ef89-4864-b68a-5f65626da608" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d2c36bd6-3a15-4cb8-a768-097cc06f0f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a513b867-90ae-4593-a165-ca6d06794f14" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d2c36bd6-3a15-4cb8-a768-097cc06f0f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00649093-cc6d-41bc-a17f-ae468e635b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a513b867-90ae-4593-a165-ca6d06794f14" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00649093-cc6d-41bc-a17f-ae468e635b22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8b140194-aebb-41cd-9c13-6855dcc5d8ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00649093-cc6d-41bc-a17f-ae468e635b22" xlink:to="loc_srt_ProductOrServiceAxis_8b140194-aebb-41cd-9c13-6855dcc5d8ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b140194-aebb-41cd-9c13-6855dcc5d8ad_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8b140194-aebb-41cd-9c13-6855dcc5d8ad" xlink:to="loc_srt_ProductsAndServicesDomain_8b140194-aebb-41cd-9c13-6855dcc5d8ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ee1b7b8-38cc-4c75-825c-ab2883d226ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8b140194-aebb-41cd-9c13-6855dcc5d8ad" xlink:to="loc_srt_ProductsAndServicesDomain_7ee1b7b8-38cc-4c75-825c-ab2883d226ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_2b7bb709-ca0f-4923-a064-9022c29d2b9c" xlink:href="alny-20230331.xsd#alny_ResearchServicesObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7ee1b7b8-38cc-4c75-825c-ab2883d226ff" xlink:to="loc_alny_ResearchServicesObligationMember_2b7bb709-ca0f-4923-a064-9022c29d2b9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_30cd14ec-7cf8-4972-9962-b221c5bc363a" xlink:href="alny-20230331.xsd#alny_C5LicenseObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7ee1b7b8-38cc-4c75-825c-ab2883d226ff" xlink:to="loc_alny_C5LicenseObligationMember_30cd14ec-7cf8-4972-9962-b221c5bc363a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_db6f742f-c593-4a1a-ab87-17e055c89cfd" xlink:href="alny-20230331.xsd#alny_C5CoCoObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7ee1b7b8-38cc-4c75-825c-ab2883d226ff" xlink:to="loc_alny_C5CoCoObligationMember_db6f742f-c593-4a1a-ab87-17e055c89cfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bc97d60a-8af2-4b7d-b95f-b29ff3befb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00649093-cc6d-41bc-a17f-ae468e635b22" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bc97d60a-8af2-4b7d-b95f-b29ff3befb9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bc97d60a-8af2-4b7d-b95f-b29ff3befb9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bc97d60a-8af2-4b7d-b95f-b29ff3befb9e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bc97d60a-8af2-4b7d-b95f-b29ff3befb9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0122ba46-30b2-4f29-83c7-ce0fc707f379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bc97d60a-8af2-4b7d-b95f-b29ff3befb9e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0122ba46-30b2-4f29-83c7-ce0fc707f379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_1e0f651e-9bab-4654-bc08-33c05489e43c" xlink:href="alny-20230331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0122ba46-30b2-4f29-83c7-ce0fc707f379" xlink:to="loc_alny_GlobalStrategicCollaborationMember_1e0f651e-9bab-4654-bc08-33c05489e43c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_763b048b-a681-495b-a712-d930abdb18ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00649093-cc6d-41bc-a17f-ae468e635b22" xlink:to="loc_srt_CounterpartyNameAxis_763b048b-a681-495b-a712-d930abdb18ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_763b048b-a681-495b-a712-d930abdb18ed_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_763b048b-a681-495b-a712-d930abdb18ed" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_763b048b-a681-495b-a712-d930abdb18ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3a4373c-a31f-4f09-91a2-aadc05bd5c3c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_763b048b-a681-495b-a712-d930abdb18ed" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3a4373c-a31f-4f09-91a2-aadc05bd5c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_50ac1183-380e-4534-b02a-47f5699f37e0" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3a4373c-a31f-4f09-91a2-aadc05bd5c3c" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_50ac1183-380e-4534-b02a-47f5699f37e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="extended" id="i9aaaeaeaf1734feca6548ad3e6663ec3_NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1e41cff0-aacc-415b-9e76-997cf595d48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e0b34fd7-59ef-4643-982b-3048c70735aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1e41cff0-aacc-415b-9e76-997cf595d48b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e0b34fd7-59ef-4643-982b-3048c70735aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ba6ff7-5240-47a4-a6ed-061374cbd127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1e41cff0-aacc-415b-9e76-997cf595d48b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ba6ff7-5240-47a4-a6ed-061374cbd127" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_467a0df1-dce9-4824-91df-462698ecd9ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ba6ff7-5240-47a4-a6ed-061374cbd127" xlink:to="loc_srt_CounterpartyNameAxis_467a0df1-dce9-4824-91df-462698ecd9ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467a0df1-dce9-4824-91df-462698ecd9ff_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_467a0df1-dce9-4824-91df-462698ecd9ff" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467a0df1-dce9-4824-91df-462698ecd9ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_46390a75-cffb-4d41-a67f-5d0285926557" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_467a0df1-dce9-4824-91df-462698ecd9ff" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_46390a75-cffb-4d41-a67f-5d0285926557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_698cbc74-c050-4a8e-b695-9f274637a1ff" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_46390a75-cffb-4d41-a67f-5d0285926557" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_698cbc74-c050-4a8e-b695-9f274637a1ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2d550d74-de8c-43e2-82c0-265288a6358b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ba6ff7-5240-47a4-a6ed-061374cbd127" xlink:to="loc_srt_ProductOrServiceAxis_2d550d74-de8c-43e2-82c0-265288a6358b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2d550d74-de8c-43e2-82c0-265288a6358b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2d550d74-de8c-43e2-82c0-265288a6358b" xlink:to="loc_srt_ProductsAndServicesDomain_2d550d74-de8c-43e2-82c0-265288a6358b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_84464677-8801-41bf-a4d2-7708b128aefa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2d550d74-de8c-43e2-82c0-265288a6358b" xlink:to="loc_srt_ProductsAndServicesDomain_84464677-8801-41bf-a4d2-7708b128aefa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_48f047c4-e965-4552-8bdf-6266378acf28" xlink:href="alny-20230331.xsd#alny_ResearchServicesObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_84464677-8801-41bf-a4d2-7708b128aefa" xlink:to="loc_alny_ResearchServicesObligationMember_48f047c4-e965-4552-8bdf-6266378acf28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_0fe6ed9b-fbdd-449a-b6a9-9d475ccb9b92" xlink:href="alny-20230331.xsd#alny_C5LicenseObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_84464677-8801-41bf-a4d2-7708b128aefa" xlink:to="loc_alny_C5LicenseObligationMember_0fe6ed9b-fbdd-449a-b6a9-9d475ccb9b92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_438b10c8-82da-41b1-a139-2c7bb9fc16bc" xlink:href="alny-20230331.xsd#alny_C5CoCoObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_84464677-8801-41bf-a4d2-7708b128aefa" xlink:to="loc_alny_C5CoCoObligationMember_438b10c8-82da-41b1-a139-2c7bb9fc16bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3f951810-ae57-422f-8147-985dbdfb0748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ba6ff7-5240-47a4-a6ed-061374cbd127" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3f951810-ae57-422f-8147-985dbdfb0748" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3f951810-ae57-422f-8147-985dbdfb0748_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3f951810-ae57-422f-8147-985dbdfb0748" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3f951810-ae57-422f-8147-985dbdfb0748_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73d528d5-588a-422b-b52c-46cc9676c732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3f951810-ae57-422f-8147-985dbdfb0748" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73d528d5-588a-422b-b52c-46cc9676c732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_d1326a10-8890-4a30-ae3e-30c2bd369e3f" xlink:href="alny-20230331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73d528d5-588a-422b-b52c-46cc9676c732" xlink:to="loc_alny_GlobalStrategicCollaborationMember_d1326a10-8890-4a30-ae3e-30c2bd369e3f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails" xlink:type="extended" id="i9f21aa82dd404da0b46ac2f6b6f1c68a_LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_42411f5e-8792-46c0-ae4d-a155a99694b2" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_42411f5e-8792-46c0-ae4d-a155a99694b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_b5a97a35-255d-4de6-9bbd-2f937a92dedc" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_b5a97a35-255d-4de6-9bbd-2f937a92dedc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExpectedRoyaltyInterestPayments_79f53ff9-e894-4e25-904f-fdea63a87540" xlink:href="alny-20230331.xsd#alny_ExpectedRoyaltyInterestPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_ExpectedRoyaltyInterestPayments_79f53ff9-e894-4e25-904f-fdea63a87540" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementConsiderationReceived_2c8999e2-57d9-4ebc-97c4-e4baf2a0192e" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_CollaborativeArrangementConsiderationReceived_2c8999e2-57d9-4ebc-97c4-e4baf2a0192e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent_563ab384-4ef6-4de0-b362-2a2d0bbc1e61" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_RoyaltyLiabilityNoncurrent_563ab384-4ef6-4de0-b362-2a2d0bbc1e61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityInterestRate_63e4e12b-01e8-4240-9f62-fd3b08e71b81" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_RoyaltyLiabilityInterestRate_63e4e12b-01e8-4240-9f62-fd3b08e71b81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityClosingCosts_bb06ecde-12da-47b6-8f1e-cb78802e3634" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityClosingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_RoyaltyLiabilityClosingCosts_bb06ecde-12da-47b6-8f1e-cb78802e3634" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_3e611658-9675-455d-b4be-bd09e0afc00d" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_3e611658-9675-455d-b4be-bd09e0afc00d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_490aed5f-bd80-4d89-a769-c1bc56cf61c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_3e611658-9675-455d-b4be-bd09e0afc00d" xlink:to="loc_srt_StatementScenarioAxis_490aed5f-bd80-4d89-a769-c1bc56cf61c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_490aed5f-bd80-4d89-a769-c1bc56cf61c3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_490aed5f-bd80-4d89-a769-c1bc56cf61c3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_490aed5f-bd80-4d89-a769-c1bc56cf61c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8659c69c-0a1a-4742-a172-87129bd689f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_490aed5f-bd80-4d89-a769-c1bc56cf61c3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8659c69c-0a1a-4742-a172-87129bd689f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c4804a63-2ff2-40aa-8111-3898aab7cfcf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8659c69c-0a1a-4742-a172-87129bd689f6" xlink:to="loc_srt_ScenarioForecastMember_c4804a63-2ff2-40aa-8111-3898aab7cfcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_75a9a228-88f9-48ef-bb7b-485fc1153d94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_3e611658-9675-455d-b4be-bd09e0afc00d" xlink:to="loc_srt_CounterpartyNameAxis_75a9a228-88f9-48ef-bb7b-485fc1153d94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_75a9a228-88f9-48ef-bb7b-485fc1153d94_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_75a9a228-88f9-48ef-bb7b-485fc1153d94" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_75a9a228-88f9-48ef-bb7b-485fc1153d94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b3d33ff-6ddd-416f-a546-cb254f725344" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_75a9a228-88f9-48ef-bb7b-485fc1153d94" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b3d33ff-6ddd-416f-a546-cb254f725344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneGroupIncMember_babdac3f-ee75-4a36-b4b5-b99c5865dd25" xlink:href="alny-20230331.xsd#alny_BlackstoneGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b3d33ff-6ddd-416f-a546-cb254f725344" xlink:to="loc_alny_BlackstoneGroupIncMember_babdac3f-ee75-4a36-b4b5-b99c5865dd25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3c7f624b-2692-4d05-829b-9ba0546a8842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_3e611658-9675-455d-b4be-bd09e0afc00d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3c7f624b-2692-4d05-829b-9ba0546a8842" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c7f624b-2692-4d05-829b-9ba0546a8842_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3c7f624b-2692-4d05-829b-9ba0546a8842" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c7f624b-2692-4d05-829b-9ba0546a8842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_63d6e8a6-9d3a-405a-9d6a-1745e28f2957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3c7f624b-2692-4d05-829b-9ba0546a8842" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_63d6e8a6-9d3a-405a-9d6a-1745e28f2957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_98347cf8-d5f2-497e-b9d5-d9125258dcce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_63d6e8a6-9d3a-405a-9d6a-1745e28f2957" xlink:to="loc_us-gaap_CollaborativeArrangementMember_98347cf8-d5f2-497e-b9d5-d9125258dcce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails" xlink:type="extended" id="i534ce9bbeeeb432799a9ec62988ddc12_LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems_3b6fa66d-61b5-4585-bedc-aa1030edc6d1" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_c53585d5-d72c-4b8d-8da9-0c0a1c404ce5" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems_3b6fa66d-61b5-4585-bedc-aa1030edc6d1" xlink:to="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_c53585d5-d72c-4b8d-8da9-0c0a1c404ce5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent_1b163620-f88d-436b-ad40-ac944e6e3f6b" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_c53585d5-d72c-4b8d-8da9-0c0a1c404ce5" xlink:to="loc_alny_RoyaltyLiabilityNoncurrent_1b163620-f88d-436b-ad40-ac944e6e3f6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_21fc9ecf-b99c-4c65-9a6d-45819157b951" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_c53585d5-d72c-4b8d-8da9-0c0a1c404ce5" xlink:to="loc_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_21fc9ecf-b99c-4c65-9a6d-45819157b951" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityPayments_cb48abff-7876-4dab-90c3-5628bac2042c" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_c53585d5-d72c-4b8d-8da9-0c0a1c404ce5" xlink:to="loc_alny_RoyaltyLiabilityPayments_cb48abff-7876-4dab-90c3-5628bac2042c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent_f43484e9-dcf7-480b-8566-bc49f329a752" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_c11c9c35-d81f-4826-8529-3d02679407dc" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems_3b6fa66d-61b5-4585-bedc-aa1030edc6d1" xlink:to="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_c11c9c35-d81f-4826-8529-3d02679407dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_968368d3-d995-49d1-8d0d-b22cad469f76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_c11c9c35-d81f-4826-8529-3d02679407dc" xlink:to="loc_srt_CounterpartyNameAxis_968368d3-d995-49d1-8d0d-b22cad469f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_968368d3-d995-49d1-8d0d-b22cad469f76_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_968368d3-d995-49d1-8d0d-b22cad469f76" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_968368d3-d995-49d1-8d0d-b22cad469f76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cfa917da-e00a-44f2-b7f2-6aa0285e82f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_968368d3-d995-49d1-8d0d-b22cad469f76" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cfa917da-e00a-44f2-b7f2-6aa0285e82f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneGroupIncMember_992abfd9-2eed-4f9a-baca-133bd04055dc" xlink:href="alny-20230331.xsd#alny_BlackstoneGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cfa917da-e00a-44f2-b7f2-6aa0285e82f8" xlink:to="loc_alny_BlackstoneGroupIncMember_992abfd9-2eed-4f9a-baca-133bd04055dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_09e01b56-9707-4a34-b9ed-4ded1308f168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_c11c9c35-d81f-4826-8529-3d02679407dc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_09e01b56-9707-4a34-b9ed-4ded1308f168" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09e01b56-9707-4a34-b9ed-4ded1308f168_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_09e01b56-9707-4a34-b9ed-4ded1308f168" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09e01b56-9707-4a34-b9ed-4ded1308f168_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1bea5f50-05d2-49c9-adac-78ad77f01b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_09e01b56-9707-4a34-b9ed-4ded1308f168" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1bea5f50-05d2-49c9-adac-78ad77f01b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_1eecd1ea-7fb9-4935-899f-6befa30dae81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1bea5f50-05d2-49c9-adac-78ad77f01b46" xlink:to="loc_us-gaap_CollaborativeArrangementMember_1eecd1ea-7fb9-4935-899f-6befa30dae81" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="extended" id="i937b1e6c24d344e08cc2a0b2e8210a7a_FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cb0b0335-20a1-4f58-8ac6-976f0ba0d5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cb0b0335-20a1-4f58-8ac6-976f0ba0d5e7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3e393956-b4ed-4180-bac0-4d7e6973fae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3e393956-b4ed-4180-bac0-4d7e6973fae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d38b24f0-9011-4518-aaeb-5fe04000cdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d38b24f0-9011-4518-aaeb-5fe04000cdc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_11785e24-dd37-4238-ba42-9ad4bfb09955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_11785e24-dd37-4238-ba42-9ad4bfb09955" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_f61ae31e-6a9c-4c52-9094-a0835bb10f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_f61ae31e-6a9c-4c52-9094-a0835bb10f09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_26553efe-8f12-475f-85a7-83763ab87ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_26553efe-8f12-475f-85a7-83763ab87ba6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_745d7790-9ca4-49c6-9966-1ea79306debb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cb0b0335-20a1-4f58-8ac6-976f0ba0d5e7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_745d7790-9ca4-49c6-9966-1ea79306debb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_9c1f83d0-1b00-482c-98ca-88c3a2ef8819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_745d7790-9ca4-49c6-9966-1ea79306debb" xlink:to="loc_us-gaap_DerivativeLiabilities_9c1f83d0-1b00-482c-98ca-88c3a2ef8819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad97fe65-4633-4e42-b3ed-47ace91df0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cb0b0335-20a1-4f58-8ac6-976f0ba0d5e7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad97fe65-4633-4e42-b3ed-47ace91df0c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_45fd2ed7-984e-4d0b-99fd-71fc65d195a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad97fe65-4633-4e42-b3ed-47ace91df0c8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_45fd2ed7-984e-4d0b-99fd-71fc65d195a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_45fd2ed7-984e-4d0b-99fd-71fc65d195a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_45fd2ed7-984e-4d0b-99fd-71fc65d195a9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_45fd2ed7-984e-4d0b-99fd-71fc65d195a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_55219081-4909-4798-a34b-25853692932d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_45fd2ed7-984e-4d0b-99fd-71fc65d195a9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_55219081-4909-4798-a34b-25853692932d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e30bf417-fedc-4d9e-a115-3fb91b068d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_55219081-4909-4798-a34b-25853692932d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e30bf417-fedc-4d9e-a115-3fb91b068d3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_9a14405b-d043-488b-bee1-5390ccff41a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad97fe65-4633-4e42-b3ed-47ace91df0c8" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_9a14405b-d043-488b-bee1-5390ccff41a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9a14405b-d043-488b-bee1-5390ccff41a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9a14405b-d043-488b-bee1-5390ccff41a9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9a14405b-d043-488b-bee1-5390ccff41a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9a14405b-d043-488b-bee1-5390ccff41a9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ea184ee5-dee9-4e17-bab7-6963bd9f306c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ea184ee5-dee9-4e17-bab7-6963bd9f306c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_dc9aa9e9-113b-4fa2-a675-dfe00965623e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_dc9aa9e9-113b-4fa2-a675-dfe00965623e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3a6b4368-e816-4f80-8bf4-7efe3fe035c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:to="loc_us-gaap_CommercialPaperMember_3a6b4368-e816-4f80-8bf4-7efe3fe035c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_e7a4ebbb-e3f3-4e40-8b84-0fa332a62220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_e7a4ebbb-e3f3-4e40-8b84-0fa332a62220" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2d4dfdee-20cb-4e1e-9df5-f1d1c1c7519d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2d4dfdee-20cb-4e1e-9df5-f1d1c1c7519d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d74d33f2-a397-46a1-baa5-7efde60bc181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d74d33f2-a397-46a1-baa5-7efde60bc181" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5f1020d5-d601-49c6-83da-1e74d1cd0fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad97fe65-4633-4e42-b3ed-47ace91df0c8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5f1020d5-d601-49c6-83da-1e74d1cd0fbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f1020d5-d601-49c6-83da-1e74d1cd0fbf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5f1020d5-d601-49c6-83da-1e74d1cd0fbf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f1020d5-d601-49c6-83da-1e74d1cd0fbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_616cf9ce-5813-451c-ae58-60df5dab3469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5f1020d5-d601-49c6-83da-1e74d1cd0fbf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_616cf9ce-5813-451c-ae58-60df5dab3469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8e93efe8-dfd9-48cf-a64e-1bfd43491d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_616cf9ce-5813-451c-ae58-60df5dab3469" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8e93efe8-dfd9-48cf-a64e-1bfd43491d44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_75adfa96-d477-43a7-b8cc-5eceee26099e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_616cf9ce-5813-451c-ae58-60df5dab3469" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_75adfa96-d477-43a7-b8cc-5eceee26099e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c64f26f8-73dc-4d09-b5c5-84db8e69c247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_616cf9ce-5813-451c-ae58-60df5dab3469" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c64f26f8-73dc-4d09-b5c5-84db8e69c247" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" xlink:type="extended" id="i62ada864a18b4b2d8f1fbf4dc49ff689_MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42aed7a2-c998-437f-ac79-a577fa176829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0e644f26-213b-40e9-a771-7b76cda8f362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42aed7a2-c998-437f-ac79-a577fa176829" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0e644f26-213b-40e9-a771-7b76cda8f362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5689ec94-805d-4d8a-a532-d4a3f83207fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42aed7a2-c998-437f-ac79-a577fa176829" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5689ec94-805d-4d8a-a532-d4a3f83207fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37104c8e-6b29-4ed2-9e30-2868bdcf2e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42aed7a2-c998-437f-ac79-a577fa176829" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37104c8e-6b29-4ed2-9e30-2868bdcf2e90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_da5027f2-4410-40a0-a41d-1dc1089664b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42aed7a2-c998-437f-ac79-a577fa176829" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_da5027f2-4410-40a0-a41d-1dc1089664b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_96a1b92b-8115-4e0b-9f04-e6634233e22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42aed7a2-c998-437f-ac79-a577fa176829" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_96a1b92b-8115-4e0b-9f04-e6634233e22f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8d6be577-163e-4e6f-99fa-996926075575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_96a1b92b-8115-4e0b-9f04-e6634233e22f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8d6be577-163e-4e6f-99fa-996926075575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d6be577-163e-4e6f-99fa-996926075575_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8d6be577-163e-4e6f-99fa-996926075575" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d6be577-163e-4e6f-99fa-996926075575_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8d6be577-163e-4e6f-99fa-996926075575" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d2c377a4-12e0-4e33-a148-e772f0358350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d2c377a4-12e0-4e33-a148-e772f0358350" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_49e12f2b-3222-421b-8bca-284b51749c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_49e12f2b-3222-421b-8bca-284b51749c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6701d85f-5baa-4b1f-829d-2bfa7e527e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6701d85f-5baa-4b1f-829d-2bfa7e527e1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_93989c8c-6e8a-4023-9a3a-934a3ee74bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:to="loc_us-gaap_CommercialPaperMember_93989c8c-6e8a-4023-9a3a-934a3ee74bb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b960fcc2-dac1-4a45-91de-539605799270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b960fcc2-dac1-4a45-91de-539605799270" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" xlink:type="extended" id="i00034282496146b2acc4ca316d5a1704_OTHERBALANCESHEETDETAILSScheduleofInventoryDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_ac8bf49e-c322-4759-a621-4454d0046508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:to="loc_us-gaap_InventoryRawMaterials_ac8bf49e-c322-4759-a621-4454d0046508" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_2aaec66f-b0c0-473d-9dc3-7a4cedcc2aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:to="loc_us-gaap_InventoryWorkInProcess_2aaec66f-b0c0-473d-9dc3-7a4cedcc2aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_84081e07-1609-4c23-8c07-5ac426b9c34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:to="loc_us-gaap_InventoryFinishedGoods_84081e07-1609-4c23-8c07-5ac426b9c34e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InventoryCurrentAndNoncurrent_3068dd96-c43d-43b2-b908-1c6f8d17ad17" xlink:href="alny-20230331.xsd#alny_InventoryCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:to="loc_alny_InventoryCurrentAndNoncurrent_3068dd96-c43d-43b2-b908-1c6f8d17ad17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_f3317112-573e-40e4-a85e-f71cedfeb62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:to="loc_us-gaap_InventoryNoncurrent_f3317112-573e-40e4-a85e-f71cedfeb62b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_51097125-7a30-458a-a6aa-e4d8b3bcaa30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:to="loc_us-gaap_InventoryCurrentTable_51097125-7a30-458a-a6aa-e4d8b3bcaa30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e67814f5-eafd-4f78-bf0c-110e4a1a3be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_51097125-7a30-458a-a6aa-e4d8b3bcaa30" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e67814f5-eafd-4f78-bf0c-110e4a1a3be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e67814f5-eafd-4f78-bf0c-110e4a1a3be0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e67814f5-eafd-4f78-bf0c-110e4a1a3be0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e67814f5-eafd-4f78-bf0c-110e4a1a3be0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0a5704d1-7385-4917-9e87-81802ec495d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e67814f5-eafd-4f78-bf0c-110e4a1a3be0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0a5704d1-7385-4917-9e87-81802ec495d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_e3b93f07-be15-4598-8145-357e43a20296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0a5704d1-7385-4917-9e87-81802ec495d5" xlink:to="loc_us-gaap_OtherAssetsMember_e3b93f07-be15-4598-8145-357e43a20296" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i9106b26473954dd3874944b964e28949_OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_aebe8c4b-1f6c-4fed-8739-db0d6e5c919f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_aebe8c4b-1f6c-4fed-8739-db0d6e5c919f" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_581e0d39-8cf6-4831-93a1-7d4c45d69c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:to="loc_us-gaap_StockholdersEquity_581e0d39-8cf6-4831-93a1-7d4c45d69c00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e3a2f8e3-da88-4c52-af34-37ae8b624bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e3a2f8e3-da88-4c52-af34-37ae8b624bcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6ea77358-9ff5-4bdf-a851-8405c136cebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6ea77358-9ff5-4bdf-a851-8405c136cebd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5d2e9a3d-5fe8-4322-8183-d39addb34fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5d2e9a3d-5fe8-4322-8183-d39addb34fe3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e439b6e-db98-471c-8daa-3e55ea438f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c19854d-7924-4e61-a288-264f5bc291c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_aebe8c4b-1f6c-4fed-8739-db0d6e5c919f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c19854d-7924-4e61-a288-264f5bc291c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_418e7030-bf1a-47e8-9e25-684f01147834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c19854d-7924-4e61-a288-264f5bc291c9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_418e7030-bf1a-47e8-9e25-684f01147834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_418e7030-bf1a-47e8-9e25-684f01147834_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_418e7030-bf1a-47e8-9e25-684f01147834" xlink:to="loc_us-gaap_EquityComponentDomain_418e7030-bf1a-47e8-9e25-684f01147834_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_418e7030-bf1a-47e8-9e25-684f01147834" xlink:to="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember_69f4ab84-9603-49b9-94c4-76abe276c7d0" xlink:href="alny-20230331.xsd#alny_AccumulatedLossOnInvestmentInJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:to="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember_69f4ab84-9603-49b9-94c4-76abe276c7d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2cff8203-dbef-447a-840b-f7587f5f8fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2cff8203-dbef-447a-840b-f7587f5f8fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f52af01e-5884-4a99-b782-ac11ab13960f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f52af01e-5884-4a99-b782-ac11ab13960f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_b60dab43-e48f-4df7-8264-6824979c326b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_b60dab43-e48f-4df7-8264-6824979c326b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_27334c3e-e8ea-412f-ae09-9e19f0f6b2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_27334c3e-e8ea-412f-ae09-9e19f0f6b2c6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONVERTIBLEDEBTDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#CONVERTIBLEDEBTDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONVERTIBLEDEBTDetails" xlink:type="extended" id="i00535c9b2918435199814257f1ca43e7_CONVERTIBLEDEBTDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e1ad9d8b-1707-41bd-9e41-53c0aa385716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e1ad9d8b-1707-41bd-9e41-53c0aa385716" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_24228789-3e82-4cea-ab3a-f0b51705d802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_24228789-3e82-4cea-ab3a-f0b51705d802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5a90c473-16a1-4fa1-9dc0-3d73c90aed94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5a90c473-16a1-4fa1-9dc0-3d73c90aed94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_41cf938b-afd5-4537-8ca3-0cd6730f2d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_41cf938b-afd5-4537-8ca3-0cd6730f2d87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cc4cebe8-14d2-4986-8d2f-b7496695671c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cc4cebe8-14d2-4986-8d2f-b7496695671c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_de65ea93-b09c-475c-9b4f-f23fe0f2272a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_de65ea93-b09c-475c-9b4f-f23fe0f2272a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c6705ced-315a-42c8-b7e9-791a17e7f0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c6705ced-315a-42c8-b7e9-791a17e7f0f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleDebtPremiumRecognizedFromConversionRate_1584f8b5-e2d9-4800-ac09-6aaa06f2185d" xlink:href="alny-20230331.xsd#alny_ConvertibleDebtPremiumRecognizedFromConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_alny_ConvertibleDebtPremiumRecognizedFromConversionRate_1584f8b5-e2d9-4800-ac09-6aaa06f2185d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e52ea6a9-5db2-464b-a047-7a06112f4e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e52ea6a9-5db2-464b-a047-7a06112f4e8c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_e7aeacdf-d39a-4b4d-b75c-b051ba0f4262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_e7aeacdf-d39a-4b4d-b75c-b051ba0f4262" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_700dd600-8e0d-4940-8945-a14d0613e56f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_LongTermDebtFairValue_700dd600-8e0d-4940-8945-a14d0613e56f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCapPrice_4d6954e7-2aa5-49a9-8701-b871b52eb688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCapPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DerivativeCapPrice_4d6954e7-2aa5-49a9-8701-b871b52eb688" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PremiumRecognizedOnCappedCallTransactions_beeec44c-9c32-4136-b750-de50bb869efb" xlink:href="alny-20230331.xsd#alny_PremiumRecognizedOnCappedCallTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_alny_PremiumRecognizedOnCappedCallTransactions_beeec44c-9c32-4136-b750-de50bb869efb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes_38ea5ff1-dccd-44f0-b8eb-76e74cdbb78e" xlink:href="alny-20230331.xsd#alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes_38ea5ff1-dccd-44f0-b8eb-76e74cdbb78e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_d58d1848-1c36-4091-a3b4-ec207d39f9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_d58d1848-1c36-4091-a3b4-ec207d39f9c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_90e22068-315b-4b24-aedd-d3534d66a3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d58d1848-1c36-4091-a3b4-ec207d39f9c0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_90e22068-315b-4b24-aedd-d3534d66a3fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_90e22068-315b-4b24-aedd-d3534d66a3fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_90e22068-315b-4b24-aedd-d3534d66a3fc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_90e22068-315b-4b24-aedd-d3534d66a3fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7f2b9d40-72aa-4bda-8e20-1f68fe16776a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_90e22068-315b-4b24-aedd-d3534d66a3fc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7f2b9d40-72aa-4bda-8e20-1f68fe16776a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_2c229640-3763-46c1-9fba-211bb54da8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7f2b9d40-72aa-4bda-8e20-1f68fe16776a" xlink:to="loc_us-gaap_ConvertibleDebtMember_2c229640-3763-46c1-9fba-211bb54da8e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_63e4838e-d992-4820-b30c-8528ae243eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d58d1848-1c36-4091-a3b4-ec207d39f9c0" xlink:to="loc_us-gaap_DebtInstrumentAxis_63e4838e-d992-4820-b30c-8528ae243eea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_63e4838e-d992-4820-b30c-8528ae243eea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_63e4838e-d992-4820-b30c-8528ae243eea" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_63e4838e-d992-4820-b30c-8528ae243eea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_268140be-cc01-4bbb-8b66-c0cffb6e8ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_63e4838e-d992-4820-b30c-8528ae243eea" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_268140be-cc01-4bbb-8b66-c0cffb6e8ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleSeniorNotesDue2027Member_049b2c87-76e1-45ec-8668-0c2d8dc25bed" xlink:href="alny-20230331.xsd#alny_ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_268140be-cc01-4bbb-8b66-c0cffb6e8ca6" xlink:to="loc_alny_ConvertibleSeniorNotesDue2027Member_049b2c87-76e1-45ec-8668-0c2d8dc25bed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleSeniorNotesDue2027InitialAmountMember_f62b99a0-eacc-42b1-afd8-c7df3058e296" xlink:href="alny-20230331.xsd#alny_ConvertibleSeniorNotesDue2027InitialAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_ConvertibleSeniorNotesDue2027Member_049b2c87-76e1-45ec-8668-0c2d8dc25bed" xlink:to="loc_alny_ConvertibleSeniorNotesDue2027InitialAmountMember_f62b99a0-eacc-42b1-afd8-c7df3058e296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember_31331d15-804f-4084-aa02-861a8f5c4cc5" xlink:href="alny-20230331.xsd#alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_ConvertibleSeniorNotesDue2027Member_049b2c87-76e1-45ec-8668-0c2d8dc25bed" xlink:to="loc_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember_31331d15-804f-4084-aa02-861a8f5c4cc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleSeniorNotesDue2025Member_bf23bb27-24c3-49b1-ae10-99160776b914" xlink:href="alny-20230331.xsd#alny_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_268140be-cc01-4bbb-8b66-c0cffb6e8ca6" xlink:to="loc_alny_ConvertibleSeniorNotesDue2025Member_bf23bb27-24c3-49b1-ae10-99160776b914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_ac09717e-1111-450f-8dc1-1df15a30900a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CallOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_268140be-cc01-4bbb-8b66-c0cffb6e8ca6" xlink:to="loc_us-gaap_CallOptionMember_ac09717e-1111-450f-8dc1-1df15a30900a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentConvertibleTermsOfConversionAxis_5fd0e6b2-3c76-414c-a8fd-6533d22c995d" xlink:href="alny-20230331.xsd#alny_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d58d1848-1c36-4091-a3b4-ec207d39f9c0" xlink:to="loc_alny_DebtInstrumentConvertibleTermsOfConversionAxis_5fd0e6b2-3c76-414c-a8fd-6533d22c995d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentConvertibleTermsOfConversionDomain_5fd0e6b2-3c76-414c-a8fd-6533d22c995d_default" xlink:href="alny-20230331.xsd#alny_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alny_DebtInstrumentConvertibleTermsOfConversionAxis_5fd0e6b2-3c76-414c-a8fd-6533d22c995d" xlink:to="loc_alny_DebtInstrumentConvertibleTermsOfConversionDomain_5fd0e6b2-3c76-414c-a8fd-6533d22c995d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentConvertibleTermsOfConversionDomain_6e82c469-e72e-431f-8409-83006532e9ae" xlink:href="alny-20230331.xsd#alny_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alny_DebtInstrumentConvertibleTermsOfConversionAxis_5fd0e6b2-3c76-414c-a8fd-6533d22c995d" xlink:to="loc_alny_DebtInstrumentConvertibleTermsOfConversionDomain_6e82c469-e72e-431f-8409-83006532e9ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtConversionTermsOneMember_ec7dd500-f0d9-49fc-864e-863d6f1963d0" xlink:href="alny-20230331.xsd#alny_DebtConversionTermsOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_DebtInstrumentConvertibleTermsOfConversionDomain_6e82c469-e72e-431f-8409-83006532e9ae" xlink:to="loc_alny_DebtConversionTermsOneMember_ec7dd500-f0d9-49fc-864e-863d6f1963d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtConversionTermsTwoMember_fbfc13c7-8cd8-4ab4-863e-7949af851e34" xlink:href="alny-20230331.xsd#alny_DebtConversionTermsTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_DebtInstrumentConvertibleTermsOfConversionDomain_6e82c469-e72e-431f-8409-83006532e9ae" xlink:to="loc_alny_DebtConversionTermsTwoMember_fbfc13c7-8cd8-4ab4-863e-7949af851e34" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails" xlink:type="extended" id="id42098cee16348fbbbdd17a0266c347b_DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMaximumFunding_80dcba27-4da6-4088-9ab1-bf0c711732af" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementMaximumFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_alny_CollaborativeArrangementMaximumFunding_80dcba27-4da6-4088-9ab1-bf0c711732af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesPayablePercent_a7f4d749-8813-42aa-87b6-28d938fa858a" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementRoyaltiesPayablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_alny_CollaborativeArrangementRoyaltiesPayablePercent_a7f4d749-8813-42aa-87b6-28d938fa858a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesPayableTerm_a4ed8d17-3cff-43b0-9329-c14c3e45e0ac" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementRoyaltiesPayableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_alny_CollaborativeArrangementRoyaltiesPayableTerm_a4ed8d17-3cff-43b0-9329-c14c3e45e0ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementFixedPaymentMultiplier_4925c83c-c70b-434b-ae20-80f11cc951ab" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementFixedPaymentMultiplier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_alny_CollaborativeArrangementFixedPaymentMultiplier_4925c83c-c70b-434b-ae20-80f11cc951ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementFixedPaymentTerm_fb89cba7-76fe-4547-9dc4-f8e15ebb5a93" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementFixedPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_alny_CollaborativeArrangementFixedPaymentTerm_fb89cba7-76fe-4547-9dc4-f8e15ebb5a93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_288b81b0-821d-4841-bbd2-6a348c1c5f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_288b81b0-821d-4841-bbd2-6a348c1c5f88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cd3bb24f-65b8-4a41-89b4-e5dcb05747e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cd3bb24f-65b8-4a41-89b4-e5dcb05747e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cd3bb24f-65b8-4a41-89b4-e5dcb05747e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cd3bb24f-65b8-4a41-89b4-e5dcb05747e0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cd3bb24f-65b8-4a41-89b4-e5dcb05747e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0eba9151-df78-4766-bdfe-7fff8d79b691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cd3bb24f-65b8-4a41-89b4-e5dcb05747e0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0eba9151-df78-4766-bdfe-7fff8d79b691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b804534a-6787-4d75-a2ae-8fef8bf0f44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0eba9151-df78-4766-bdfe-7fff8d79b691" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b804534a-6787-4d75-a2ae-8fef8bf0f44f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3d2eeb8b-7dcf-49a1-9e90-eebedb698366" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:to="loc_srt_CounterpartyNameAxis_3d2eeb8b-7dcf-49a1-9e90-eebedb698366" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2eeb8b-7dcf-49a1-9e90-eebedb698366_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3d2eeb8b-7dcf-49a1-9e90-eebedb698366" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2eeb8b-7dcf-49a1-9e90-eebedb698366_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c5c0828-b896-4f90-a0cc-eac162a33f6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3d2eeb8b-7dcf-49a1-9e90-eebedb698366" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c5c0828-b896-4f90-a0cc-eac162a33f6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneLifeSciencesMember_4d9e060f-25cd-43bc-9977-eb022cc62df6" xlink:href="alny-20230331.xsd#alny_BlackstoneLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c5c0828-b896-4f90-a0cc-eac162a33f6a" xlink:to="loc_alny_BlackstoneLifeSciencesMember_4d9e060f-25cd-43bc-9977-eb022cc62df6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f603bca3-9d0e-43c4-9715-bf1132698914" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:to="loc_srt_ProductOrServiceAxis_f603bca3-9d0e-43c4-9715-bf1132698914" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f603bca3-9d0e-43c4-9715-bf1132698914_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f603bca3-9d0e-43c4-9715-bf1132698914" xlink:to="loc_srt_ProductsAndServicesDomain_f603bca3-9d0e-43c4-9715-bf1132698914_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f603bca3-9d0e-43c4-9715-bf1132698914" xlink:to="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VutrisiranAndZilebesiranMember_9290b230-81cb-4a49-a5d8-30d70751b3de" xlink:href="alny-20230331.xsd#alny_VutrisiranAndZilebesiranMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:to="loc_alny_VutrisiranAndZilebesiranMember_9290b230-81cb-4a49-a5d8-30d70751b3de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_HELIOSBPhase3ClinicalTrialMember_eb534aff-9075-422c-8795-4041115709fc" xlink:href="alny-20230331.xsd#alny_HELIOSBPhase3ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:to="loc_alny_HELIOSBPhase3ClinicalTrialMember_eb534aff-9075-422c-8795-4041115709fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ALNAGTPhase2ClinicalTrialMember_925cde54-0010-4005-8c84-39dbf2abea4b" xlink:href="alny-20230331.xsd#alny_ALNAGTPhase2ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:to="loc_alny_ALNAGTPhase2ClinicalTrialMember_925cde54-0010-4005-8c84-39dbf2abea4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ALNAGTPhase3ClinicalTrialMember_fc59693d-271d-45fd-b018-4c7173196c2d" xlink:href="alny-20230331.xsd#alny_ALNAGTPhase3ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:to="loc_alny_ALNAGTPhase3ClinicalTrialMember_fc59693d-271d-45fd-b018-4c7173196c2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VutrisiranMember_1976771a-84c6-45b8-a296-f6c04eb77248" xlink:href="alny-20230331.xsd#alny_VutrisiranMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:to="loc_alny_VutrisiranMember_1976771a-84c6-45b8-a296-f6c04eb77248" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_97eb5bb6-1869-46a3-b615-b2ae2bdb56d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:to="loc_dei_LegalEntityAxis_97eb5bb6-1869-46a3-b615-b2ae2bdb56d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_97eb5bb6-1869-46a3-b615-b2ae2bdb56d1_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_97eb5bb6-1869-46a3-b615-b2ae2bdb56d1" xlink:to="loc_dei_EntityDomain_97eb5bb6-1869-46a3-b615-b2ae2bdb56d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0fc91169-f773-4457-8584-e3bbc175c160" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_97eb5bb6-1869-46a3-b615-b2ae2bdb56d1" xlink:to="loc_dei_EntityDomain_0fc91169-f773-4457-8584-e3bbc175c160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneLifeSciencesMember_0a1df650-041f-494e-b0b7-0ceb22918f45" xlink:href="alny-20230331.xsd#alny_BlackstoneLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0fc91169-f773-4457-8584-e3bbc175c160" xlink:to="loc_alny_BlackstoneLifeSciencesMember_0a1df650-041f-494e-b0b7-0ceb22918f45" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails" xlink:type="extended" id="i1c16bdb5d1b8482baf51df09b990beff_DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_489c6f75-b86f-4c69-aa3b-b8876a09f00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20a886ec-61e4-4e93-afa2-59114f927c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_489c6f75-b86f-4c69-aa3b-b8876a09f00c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20a886ec-61e4-4e93-afa2-59114f927c5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ca7db111-c9bf-4ab1-90df-7643b57b2a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20a886ec-61e4-4e93-afa2-59114f927c5c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ca7db111-c9bf-4ab1-90df-7643b57b2a0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b38f8fea-3119-475f-a9b8-8d484e46a345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20a886ec-61e4-4e93-afa2-59114f927c5c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b38f8fea-3119-475f-a9b8-8d484e46a345" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89148e4c-eef9-4404-93de-d5d40488a593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20a886ec-61e4-4e93-afa2-59114f927c5c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89148e4c-eef9-4404-93de-d5d40488a593" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5d596259-5e97-4860-b7a1-f3f51edc8140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_62e962b0-c268-4612-8b83-afa8e56f0634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_489c6f75-b86f-4c69-aa3b-b8876a09f00c" xlink:to="loc_us-gaap_DerivativeTable_62e962b0-c268-4612-8b83-afa8e56f0634" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6ae96406-a342-4aa4-a8ba-103d3032afa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_62e962b0-c268-4612-8b83-afa8e56f0634" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6ae96406-a342-4aa4-a8ba-103d3032afa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ae96406-a342-4aa4-a8ba-103d3032afa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6ae96406-a342-4aa4-a8ba-103d3032afa5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ae96406-a342-4aa4-a8ba-103d3032afa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f7f10d6-2925-4431-838b-7341f2f4c71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6ae96406-a342-4aa4-a8ba-103d3032afa5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f7f10d6-2925-4431-838b-7341f2f4c71f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember_7446b793-088b-4d32-8576-ae1a35992119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f7f10d6-2925-4431-838b-7341f2f4c71f" xlink:to="loc_us-gaap_DerivativeMember_7446b793-088b-4d32-8576-ae1a35992119" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="extended" id="ice15fff531244a8da6f1dd4486cf318f_STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4cea4bd-41e0-4bee-a1f0-357da5fdb1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7a13c800-0f02-41b4-94b7-5d61f55b9095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4cea4bd-41e0-4bee-a1f0-357da5fdb1e2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7a13c800-0f02-41b4-94b7-5d61f55b9095" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9099a4b-6dc5-47ba-98a7-7b7cc5abc4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4cea4bd-41e0-4bee-a1f0-357da5fdb1e2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9099a4b-6dc5-47ba-98a7-7b7cc5abc4dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d3b3ac8a-a6f3-4e72-a971-a5a3e4282889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9099a4b-6dc5-47ba-98a7-7b7cc5abc4dd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d3b3ac8a-a6f3-4e72-a971-a5a3e4282889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d3b3ac8a-a6f3-4e72-a971-a5a3e4282889_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d3b3ac8a-a6f3-4e72-a971-a5a3e4282889" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d3b3ac8a-a6f3-4e72-a971-a5a3e4282889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f40be050-1f9e-4afe-a868-4910a197809e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d3b3ac8a-a6f3-4e72-a971-a5a3e4282889" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f40be050-1f9e-4afe-a868-4910a197809e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8fdddeba-7244-4a61-b160-bd2bde212dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f40be050-1f9e-4afe-a868-4910a197809e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8fdddeba-7244-4a61-b160-bd2bde212dcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2d6e8e33-91d2-4ccf-b44a-e08f696f3662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f40be050-1f9e-4afe-a868-4910a197809e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2d6e8e33-91d2-4ccf-b44a-e08f696f3662" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="extended" id="i9201e8647a4c4644888bbedf98fe7117_NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8726a6bb-572b-4bc8-b394-c7c657c6b1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_39880395-0b8a-40c7-9f04-382190d1c983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8726a6bb-572b-4bc8-b394-c7c657c6b1a7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_39880395-0b8a-40c7-9f04-382190d1c983" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b459a36e-d982-4c44-9cd6-8c994e8ef9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8726a6bb-572b-4bc8-b394-c7c657c6b1a7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b459a36e-d982-4c44-9cd6-8c994e8ef9cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d3bed91-c022-4329-96cd-b61c82b7d599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b459a36e-d982-4c44-9cd6-8c994e8ef9cc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d3bed91-c022-4329-96cd-b61c82b7d599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7d3bed91-c022-4329-96cd-b61c82b7d599_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d3bed91-c022-4329-96cd-b61c82b7d599" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7d3bed91-c022-4329-96cd-b61c82b7d599_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c14beb13-8299-4719-8c85-8ce978cea9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d3bed91-c022-4329-96cd-b61c82b7d599" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c14beb13-8299-4719-8c85-8ce978cea9b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f03ddc04-9a7c-4b47-83c3-634471f2e20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c14beb13-8299-4719-8c85-8ce978cea9b8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f03ddc04-9a7c-4b47-83c3-634471f2e20e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_59c4017d-69c4-4d94-9ca9-67ac780ab12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c14beb13-8299-4719-8c85-8ce978cea9b8" xlink:to="loc_us-gaap_RestrictedStockMember_59c4017d-69c4-4d94-9ca9-67ac780ab12c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_417a3ddb-e6a8-41dc-b689-ec0868272082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c14beb13-8299-4719-8c85-8ce978cea9b8" xlink:to="loc_us-gaap_ConvertibleDebtMember_417a3ddb-e6a8-41dc-b689-ec0868272082" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>alny-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b732ba76-b80e-452b-9370-f7a92071fea1,g:cc882e96-1f0e-4ac3-98d4-087e3affef76-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_62a9f501-e622-4b91-a5b5-54b1556bb489_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bc4f070-7356-4554-942d-8e6d641d1e07_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NumberOfTargetedPrograms_2e4d862e-4e35-4976-bcf4-b39ed4e1b853_terseLabel_en-US" xlink:label="lab_alny_NumberOfTargetedPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targeted programs</link:label>
    <link:label id="lab_alny_NumberOfTargetedPrograms_label_en-US" xlink:label="lab_alny_NumberOfTargetedPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Targeted Programs</link:label>
    <link:label id="lab_alny_NumberOfTargetedPrograms_documentation_en-US" xlink:label="lab_alny_NumberOfTargetedPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targeted programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfTargetedPrograms" xlink:href="alny-20230331.xsd#alny_NumberOfTargetedPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NumberOfTargetedPrograms" xlink:to="lab_alny_NumberOfTargetedPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_22c0e430-cae2-4c52-932e-14150df0a252_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f9fbf6af-4744-4de5-9bf5-48d1b3e6f96b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c06dd78a-b698-4ae9-b8bc-4d3bab836887_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading days threshold</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_c8b67ef1-2f98-4540-9cb3-7f1e1af87c39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_82822f05-2ebf-4be5-9633-2c0e551b2f57_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from development derivative</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_OtherMember_4e83d515-5a44-4349-a797-06a9e2bb4308_terseLabel_en-US" xlink:label="lab_alny_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_alny_OtherMember_label_en-US" xlink:label="lab_alny_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_alny_OtherMember_documentation_en-US" xlink:label="lab_alny_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherMember" xlink:href="alny-20230331.xsd#alny_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_OtherMember" xlink:to="lab_alny_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_ecdbf9e7-2f53-41cf-ae8a-b01f999844fd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NumberOfPartneredProducts_2c650296-4ae2-4afe-8076-820f0fe570af_terseLabel_en-US" xlink:label="lab_alny_NumberOfPartneredProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of partnered products</link:label>
    <link:label id="lab_alny_NumberOfPartneredProducts_label_en-US" xlink:label="lab_alny_NumberOfPartneredProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Partnered Products</link:label>
    <link:label id="lab_alny_NumberOfPartneredProducts_documentation_en-US" xlink:label="lab_alny_NumberOfPartneredProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Partnered Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfPartneredProducts" xlink:href="alny-20230331.xsd#alny_NumberOfPartneredProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NumberOfPartneredProducts" xlink:to="lab_alny_NumberOfPartneredProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_HELIOSBPhase3ClinicalTrialMember_2693a661-1144-44e5-ad1c-2fd0189f3c71_terseLabel_en-US" xlink:label="lab_alny_HELIOSBPhase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HELIOS-B Phase 3 Clinical Trial</link:label>
    <link:label id="lab_alny_HELIOSBPhase3ClinicalTrialMember_label_en-US" xlink:label="lab_alny_HELIOSBPhase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HELIOS-B Phase 3 Clinical Trial [Member]</link:label>
    <link:label id="lab_alny_HELIOSBPhase3ClinicalTrialMember_documentation_en-US" xlink:label="lab_alny_HELIOSBPhase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HELIOS-B Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_HELIOSBPhase3ClinicalTrialMember" xlink:href="alny-20230331.xsd#alny_HELIOSBPhase3ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_HELIOSBPhase3ClinicalTrialMember" xlink:to="lab_alny_HELIOSBPhase3ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b1d501ab-6c44-48c0-8120-8f4992a39336_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_2603c145-3f95-418c-b63e-d8d69e8038d0_terseLabel_en-US" xlink:label="lab_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_label_en-US" xlink:label="lab_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_documentation_en-US" xlink:label="lab_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:to="lab_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock_1dffe047-a4b6-4cc1-9e3a-7cfb6b133481_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents And Restricted Cash</link:label>
    <link:label id="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Table Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of reconciliation of cash, cash equivalents and restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" xlink:href="alny-20230331.xsd#alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" xlink:to="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a1cac8aa-fed8-414e-8263-df9f07f15ad4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ConvertibleSeniorNotesDue2027Member_d3980a54-d787-4609-af0b-b53c5e0677ef_terseLabel_en-US" xlink:label="lab_alny_ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027</link:label>
    <link:label id="lab_alny_ConvertibleSeniorNotesDue2027Member_label_en-US" xlink:label="lab_alny_ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027 [Member]</link:label>
    <link:label id="lab_alny_ConvertibleSeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_alny_ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleSeniorNotesDue2027Member" xlink:href="alny-20230331.xsd#alny_ConvertibleSeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ConvertibleSeniorNotesDue2027Member" xlink:to="lab_alny_ConvertibleSeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b4ed154f-11e8-429a-a59e-e0e47c3e5305_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_906c813e-54d8-4a71-8903-0f6e54be7a6d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options, net of tax withholdings (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9119eb5c-344c-4308-8873-eb09118ba3d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of borrowing</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_90638d29-1218-4f31-8871-f955e65a7d8e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d111944e-438f-40d1-a417-c817d0b04f44_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ONPATTROMember_bfde901a-d0b2-4652-bca4-5d2c6212423d_terseLabel_en-US" xlink:label="lab_alny_ONPATTROMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ONPATTRO</link:label>
    <link:label id="lab_alny_ONPATTROMember_label_en-US" xlink:label="lab_alny_ONPATTROMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ONPATTRO [Member]</link:label>
    <link:label id="lab_alny_ONPATTROMember_documentation_en-US" xlink:label="lab_alny_ONPATTROMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ONPATTRO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ONPATTROMember" xlink:href="alny-20230331.xsd#alny_ONPATTROMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ONPATTROMember" xlink:to="lab_alny_ONPATTROMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_61c87ebf-5db6-4eab-8d51-b2406b629e5c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DebtConversionTermsOneMember_e502c75a-1d4f-4b5f-bce4-be637d40c1d1_terseLabel_en-US" xlink:label="lab_alny_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:label id="lab_alny_DebtConversionTermsOneMember_label_en-US" xlink:label="lab_alny_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms One [Member]</link:label>
    <link:label id="lab_alny_DebtConversionTermsOneMember_documentation_en-US" xlink:label="lab_alny_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtConversionTermsOneMember" xlink:href="alny-20230331.xsd#alny_DebtConversionTermsOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DebtConversionTermsOneMember" xlink:to="lab_alny_DebtConversionTermsOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyLiabilityClosingCosts_2c9ee63c-fb97-440c-a5fe-0edbcfee90dd_terseLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityClosingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing costs</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityClosingCosts_label_en-US" xlink:label="lab_alny_RoyaltyLiabilityClosingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Closing Costs</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityClosingCosts_documentation_en-US" xlink:label="lab_alny_RoyaltyLiabilityClosingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Closing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityClosingCosts" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityClosingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyLiabilityClosingCosts" xlink:to="lab_alny_RoyaltyLiabilityClosingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f15f48f8-6770-424e-9abf-7b98b87bf5d4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e9c8e9e6-5799-4f03-85df-6d6046af7928_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_da580a8b-3ead-4362-a09c-f9320b9e6c8c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_799069dd-79ad-4423-8535-304b2a4c6431_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c58828c6-b435-4449-85ad-4aa079e2651f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NovartisMember_30600aae-3b55-4a05-b114-c2691f6f8f63_verboseLabel_en-US" xlink:label="lab_alny_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis AG</link:label>
    <link:label id="lab_alny_NovartisMember_label_en-US" xlink:label="lab_alny_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_alny_NovartisMember_documentation_en-US" xlink:label="lab_alny_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Medicines Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NovartisMember" xlink:href="alny-20230331.xsd#alny_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NovartisMember" xlink:to="lab_alny_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes_dfe08e85-0552-4c37-a175-230cc0755e47_terseLabel_en-US" xlink:label="lab_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of capped calls related to convertible debt</link:label>
    <link:label id="lab_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes_label_en-US" xlink:label="lab_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases Of Capped Calls Related To Convertible Senior Notes</link:label>
    <link:label id="lab_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes_documentation_en-US" xlink:label="lab_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases Of Capped Calls Related To Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes" xlink:href="alny-20230331.xsd#alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes" xlink:to="lab_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_67582aed-a2af-4ec5-9ece-b5b3994fdd5a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_759df617-3a9b-4ad3-94a7-7a912d7fa617_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_76899729-d608-42b1-aa15-1fe9c1f07a53_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_073abdfa-6df2-4e38-a68e-986594c8621e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of restricted investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a186c0cf-6b13-463b-bdf5-69322b4f6969_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d85352cd-129c-4141-9955-246cfa40f722_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10896fb0-0071-4180-a18f-11e1abd05029_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d7fb9dd2-5861-4768-8ae4-5f5e4c11b568_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flows:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_4d468362-2807-43c5-80d6-e57838582a73_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_78f24ba2-f698-40c2-a340-2603c448b185_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_16fdb87c-006d-4a03-9386-b9b6cb172a37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_IncreaseDecreaseInResearchAndDevelopmentExpense_b7f647bb-e0f0-4581-a26e-addd2d355c3c_negatedLabel_en-US" xlink:label="lab_alny_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in research and development expense</link:label>
    <link:label id="lab_alny_IncreaseDecreaseInResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_alny_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Research And Development Expense</link:label>
    <link:label id="lab_alny_IncreaseDecreaseInResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_alny_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:href="alny-20230331.xsd#alny_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="lab_alny_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7b8ca11b-d347-481e-af20-a2515e533d67_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_FundingAnAnnualDiscoveryMember_36f732ef-c6f6-42c3-9711-e9e040f8795f_terseLabel_en-US" xlink:label="lab_alny_FundingAnAnnualDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Steady State</link:label>
    <link:label id="lab_alny_FundingAnAnnualDiscoveryMember_label_en-US" xlink:label="lab_alny_FundingAnAnnualDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding An Annual Discovery [Member]</link:label>
    <link:label id="lab_alny_FundingAnAnnualDiscoveryMember_documentation_en-US" xlink:label="lab_alny_FundingAnAnnualDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding an annual discovery.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAnAnnualDiscoveryMember" xlink:href="alny-20230331.xsd#alny_FundingAnAnnualDiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_FundingAnAnnualDiscoveryMember" xlink:to="lab_alny_FundingAnAnnualDiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_64be3c15-0c43-4029-88f5-0c3e1fbdc190_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_54c4288f-69e8-4a84-a7ee-a72d650e7587_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06eef8df-e95f-4586-acfd-619780997980_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_cff2c8ec-2206-4d11-80bd-da0a8327ea9e_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_44bdb507-0058-484a-8c29-0274ef8a292b_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent_758c4c05-69c3-40ed-bb2b-e712662c8e21_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties payable, percent</link:label>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent_label_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Payable, Percent</link:label>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Payable, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesPayablePercent" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementRoyaltiesPayablePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementRoyaltiesPayablePercent" xlink:to="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_d516b7b4-0704-4e15-8d82-8b8a20bd6d7d_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock_3bbc1d28-9de1-4381-9419-d27aca096e82_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements</link:label>
    <link:label id="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Research And Development Expenses Incurred For Collaboration Agreements Table [Table Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of research and development expenses incurred for collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" xlink:href="alny-20230331.xsd#alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" xlink:to="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_97354b78-1be4-48b4-8237-72a7ee5980e9_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_542e08d0-3818-4061-af3b-2e6704812b05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_9d02d4c8-331b-429f-8938-4ecd1fb6314a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0b0d3105-bdac-4fdd-8882-0f1349039358_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b179ea1f-ab92-440f-8ed1-4f5ef37b2c52_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1b54ad6e-5ca2-409c-8ff5-4748ed800042_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_5ad5a791-3c32-4eb8-aa39-6ddbb34e1189_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Collaborators</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f08b3205-411e-4213-81a8-c889ef9c3772_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5877b08a-dbd5-4132-96ae-aace7f5ed7e1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f06ba381-64ff-43ef-b810-a309904698a5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (Losses) Gains from Debt Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_ede9367c-765c-4c4b-b2d5-1a994d1296cf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_13ff78b4-145e-46c6-a081-b43aebb5dc63_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyRate_c86ab746-c31d-4d72-aadd-3a05494c14af_terseLabel_en-US" xlink:label="lab_alny_RoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate</link:label>
    <link:label id="lab_alny_RoyaltyRate_label_en-US" xlink:label="lab_alny_RoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate</link:label>
    <link:label id="lab_alny_RoyaltyRate_documentation_en-US" xlink:label="lab_alny_RoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential maximum royalty percentage that will received for sales completed by collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyRate" xlink:href="alny-20230331.xsd#alny_RoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyRate" xlink:to="lab_alny_RoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_08a63c2e-6092-4999-8229-80555db6d206_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_089ac2b7-d894-4fa3-b58a-55ac55a6473a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONVERTIBLE DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_6b5a4b6f-5eb9-4a55-9b07-8ac212b181bb_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_836e2547-a34f-4af4-b19b-1be912d4a4ed_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_OtherCollaborationsMember_ceca9ccc-45b4-47eb-aca9-a979f7e6f1b1_terseLabel_en-US" xlink:label="lab_alny_OtherCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_alny_OtherCollaborationsMember_label_en-US" xlink:label="lab_alny_OtherCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaborations [Member]</link:label>
    <link:label id="lab_alny_OtherCollaborationsMember_documentation_en-US" xlink:label="lab_alny_OtherCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherCollaborationsMember" xlink:href="alny-20230331.xsd#alny_OtherCollaborationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_OtherCollaborationsMember" xlink:to="lab_alny_OtherCollaborationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_VutrisiranAndZilebesiranMember_ab1882d9-3d6c-4b2a-8e3e-23cd2d262390_terseLabel_en-US" xlink:label="lab_alny_VutrisiranAndZilebesiranMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vutrisiran and ALN-AGT</link:label>
    <link:label id="lab_alny_VutrisiranAndZilebesiranMember_label_en-US" xlink:label="lab_alny_VutrisiranAndZilebesiranMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vutrisiran and Zilebesiran [Member]</link:label>
    <link:label id="lab_alny_VutrisiranAndZilebesiranMember_documentation_en-US" xlink:label="lab_alny_VutrisiranAndZilebesiranMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vutrisiran and Zilebesiran</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VutrisiranAndZilebesiranMember" xlink:href="alny-20230331.xsd#alny_VutrisiranAndZilebesiranMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_VutrisiranAndZilebesiranMember" xlink:to="lab_alny_VutrisiranAndZilebesiranMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_OXLUMOMember_cabeb581-8ba1-4851-8518-054f71e1f2a1_terseLabel_en-US" xlink:label="lab_alny_OXLUMOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OXLUMO</link:label>
    <link:label id="lab_alny_OXLUMOMember_label_en-US" xlink:label="lab_alny_OXLUMOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OXLUMO [Member]</link:label>
    <link:label id="lab_alny_OXLUMOMember_documentation_en-US" xlink:label="lab_alny_OXLUMOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OXLUMO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OXLUMOMember" xlink:href="alny-20230331.xsd#alny_OXLUMOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_OXLUMOMember" xlink:to="lab_alny_OXLUMOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5ec2ead2-7398-4ee6-ab86-4d2f58d6a125_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_0287ef74-6257-4cbe-b285-8df10fc38b86_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance and Change in Receivables and Contract Liabilities Related to Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_05113197-e7a7-4723-afed-a8484d613d85_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_FundingAtProgramInitiationMember_079b960c-169b-4df8-8838-9ba220c9ecb0_terseLabel_en-US" xlink:label="lab_alny_FundingAtProgramInitiationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Program Initiation</link:label>
    <link:label id="lab_alny_FundingAtProgramInitiationMember_label_en-US" xlink:label="lab_alny_FundingAtProgramInitiationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Program Initiation [Member]</link:label>
    <link:label id="lab_alny_FundingAtProgramInitiationMember_documentation_en-US" xlink:label="lab_alny_FundingAtProgramInitiationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding at program initiation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtProgramInitiationMember" xlink:href="alny-20230331.xsd#alny_FundingAtProgramInitiationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_FundingAtProgramInitiationMember" xlink:to="lab_alny_FundingAtProgramInitiationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d40fd41e-ec88-4476-8cc2-33b7359337f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_34f89f81-2c8e-4d8c-94fc-e079d69cfc97_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_80b09c8e-d947-4d51-a868-8fbba667ddd9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d0fbc078-2ce0-469a-a32d-6f8d8993ad94_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_09fb2f25-f2b9-4930-956e-5f4dac278e31_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_ce69a496-b57c-4d10-af1b-a6863007ee18_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_642a4120-7a02-4aac-b76a-6152e68a9c87_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_6db8ed30-faea-4946-8e48-5b4dfc681429_terseLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense recognized</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_label_en-US" xlink:label="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Interest Expense Including Amortization Of Closing Costs</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_documentation_en-US" xlink:label="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Interest Expense Including Amortization Of Closing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" xlink:to="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4162a087-1870-4c8c-8838-fdbf68ab02be_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_dfab419c-b713-4120-b959-72dbdd443efb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DebtInstrumentConvertibleTermsOfConversionAxis_9328344c-c8c4-45db-8855-d6b52ddc099a_terseLabel_en-US" xlink:label="lab_alny_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms of Conversion [Axis]</link:label>
    <link:label id="lab_alny_DebtInstrumentConvertibleTermsOfConversionAxis_label_en-US" xlink:label="lab_alny_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms of Conversion [Axis]</link:label>
    <link:label id="lab_alny_DebtInstrumentConvertibleTermsOfConversionAxis_documentation_en-US" xlink:label="lab_alny_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms of Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:href="alny-20230331.xsd#alny_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:to="lab_alny_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_9443a43a-4080-4df9-b200-6cb127a6eb24_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a01a35c8-e1da-4b1c-bf75-a4ec88cff589_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6b1c49f4-3086-4ebe-a9e1-b681930e315d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_80089612-8e99-403f-a3ed-656a338100b3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_000420ce-3c63-4a4e-9e5a-9bab6f93ed9d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c3ba1161-517c-4556-90f8-eb35c7f340ec_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_4bee8d30-7bee-422f-b88a-9c42085ec11a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER BALANCE SHEET DETAILS</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_455d9a04-bc2a-424c-b7f1-0ec0163ce965_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_0244cb5f-abec-455b-9e5d-c122e0198088_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Recognized Based on Accounting Guidance</link:label>
    <link:label id="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Recognized Based on Accounting Guidance [Table Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Recognized Based on Accounting Guidance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:href="alny-20230331.xsd#alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:to="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_ae86bc30-2519-406c-8a2b-bbe02b0ec49b_terseLabel_en-US" xlink:label="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended additional discovery period of programs development</link:label>
    <link:label id="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_label_en-US" xlink:label="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Additional Discovery Period Of Programs Development</link:label>
    <link:label id="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_documentation_en-US" xlink:label="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended additional discovery period of programs development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:href="alny-20230331.xsd#alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:to="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_305b2cbc-a0ed-4c75-9df0-66a547d36f6b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0379d286-9a15-4e3a-887b-5f4bfc701680_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value of Marketable Debt Securities</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementFixedPaymentMultiplier_d6d2f73a-a57e-4430-9ee8-6cd972260a73_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementFixedPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed payment multiplier</link:label>
    <link:label id="lab_alny_CollaborativeArrangementFixedPaymentMultiplier_label_en-US" xlink:label="lab_alny_CollaborativeArrangementFixedPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed Payment Multiplier</link:label>
    <link:label id="lab_alny_CollaborativeArrangementFixedPaymentMultiplier_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementFixedPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed Payment Multiplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementFixedPaymentMultiplier" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementFixedPaymentMultiplier"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementFixedPaymentMultiplier" xlink:to="lab_alny_CollaborativeArrangementFixedPaymentMultiplier" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_9c81394d-86da-4e1b-9142-d32282560106_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborationsMember_aef6af0c-0474-45db-8c20-8c83d6730b2e_terseLabel_en-US" xlink:label="lab_alny_CollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues from collaborations</link:label>
    <link:label id="lab_alny_CollaborationsMember_label_en-US" xlink:label="lab_alny_CollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations [Member]</link:label>
    <link:label id="lab_alny_CollaborationsMember_documentation_en-US" xlink:label="lab_alny_CollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborationsMember" xlink:href="alny-20230331.xsd#alny_CollaborationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborationsMember" xlink:to="lab_alny_CollaborationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9d4411d6-7609-4c5e-ac8b-9af3aa47aaec_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementConsiderationReceived_30667d21-4c9f-4943-843f-43e7f19cffc3_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_alny_CollaborativeArrangementConsiderationReceived_label_en-US" xlink:label="lab_alny_CollaborativeArrangementConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Consideration Received</link:label>
    <link:label id="lab_alny_CollaborativeArrangementConsiderationReceived_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Consideration Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementConsiderationReceived" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementConsiderationReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementConsiderationReceived" xlink:to="lab_alny_CollaborativeArrangementConsiderationReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_b3d1a223-2adf-416c-b74f-7bd11b65e218_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_25583394-b491-432d-828f-bff935f13873_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_34666282-3693-4222-b0f5-bd4820ae24cc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_GlobalStrategicCollaborationMember_12ab3c12-3b83-429d-8b32-61032b693058_terseLabel_en-US" xlink:label="lab_alny_GlobalStrategicCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Strategic Collaboration</link:label>
    <link:label id="lab_alny_GlobalStrategicCollaborationMember_label_en-US" xlink:label="lab_alny_GlobalStrategicCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Strategic Collaboration [Member]</link:label>
    <link:label id="lab_alny_GlobalStrategicCollaborationMember_documentation_en-US" xlink:label="lab_alny_GlobalStrategicCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global strategic collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember" xlink:href="alny-20230331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_GlobalStrategicCollaborationMember" xlink:to="lab_alny_GlobalStrategicCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember_7220680a-2e2b-48f4-89fc-1d45be83c908_terseLabel_en-US" xlink:label="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Investment in Joint Venture</link:label>
    <link:label id="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember_label_en-US" xlink:label="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Loss On Investment In Joint Venture [Member]</link:label>
    <link:label id="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember_documentation_en-US" xlink:label="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated loss on investment in joint venture.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:href="alny-20230331.xsd#alny_AccumulatedLossOnInvestmentInJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:to="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_fd8dbc67-82a1-4170-ad0b-abbead69b77b_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f8572f53-c7e9-40f5-a575-980f4290efc2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyLiabilityCurrent_e48c96a5-d7ec-4cfb-87b1-15cbbae5a805_terseLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityCurrent_label_en-US" xlink:label="lab_alny_RoyaltyLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Current</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityCurrent_documentation_en-US" xlink:label="lab_alny_RoyaltyLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityCurrent" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyLiabilityCurrent" xlink:to="lab_alny_RoyaltyLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_ddb1bd61-c7fe-4d61-8d5f-e3715d45b370_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_d0cf312f-5f73-43c0-b115-d764b11a5fd8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_094d7f72-63ea-4f07-b1a5-2ed785f9c216_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_725670c1-9eca-46ef-b274-972f8b27774e_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ac17e8a5-2e28-41d8-bc22-3a5c4bc41206_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9c6bbc2d-b3ab-4393-bfc7-1183d79870c4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, previously reported value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeAgreementPeriodOfProgramDevelopment_8a6d900d-a48d-4e39-9223-260fbafa3c90_terseLabel_en-US" xlink:label="lab_alny_CollaborativeAgreementPeriodOfProgramDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direction period of programs development</link:label>
    <link:label id="lab_alny_CollaborativeAgreementPeriodOfProgramDevelopment_label_en-US" xlink:label="lab_alny_CollaborativeAgreementPeriodOfProgramDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period Of Program Development</link:label>
    <link:label id="lab_alny_CollaborativeAgreementPeriodOfProgramDevelopment_documentation_en-US" xlink:label="lab_alny_CollaborativeAgreementPeriodOfProgramDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period Of Program Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeAgreementPeriodOfProgramDevelopment" xlink:href="alny-20230331.xsd#alny_CollaborativeAgreementPeriodOfProgramDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeAgreementPeriodOfProgramDevelopment" xlink:to="lab_alny_CollaborativeAgreementPeriodOfProgramDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_79c4e5bc-6594-4be1-bb15-d6920d0a24b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_483f7b87-dc37-48ee-b8fe-8e8b765cec4f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b7151346-4d15-48eb-a452-bce9a0579ccf_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8042e980-90f0-4bc0-bd96-eaaf75394510_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_39f1a02b-4059-48a2-baa2-fb7f8fd015cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_f0608381-1f25-4c80-a25d-1bfe041c8835_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_59cd22f4-4917-49cd-9319-08f4f5df8ed6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_95d7e022-db90-459c-91ed-7d616f37df96_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_17c38880-24ac-43c1-ad5f-223539568fc2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash (money market funds)</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ExpectedRoyaltyInterestPayments_8bd15b99-6e26-4b74-b1f9-3855a61e6d8a_terseLabel_en-US" xlink:label="lab_alny_ExpectedRoyaltyInterestPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected royalty interest payments</link:label>
    <link:label id="lab_alny_ExpectedRoyaltyInterestPayments_label_en-US" xlink:label="lab_alny_ExpectedRoyaltyInterestPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Royalty Interest Payments</link:label>
    <link:label id="lab_alny_ExpectedRoyaltyInterestPayments_documentation_en-US" xlink:label="lab_alny_ExpectedRoyaltyInterestPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Royalty Interest Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExpectedRoyaltyInterestPayments" xlink:href="alny-20230331.xsd#alny_ExpectedRoyaltyInterestPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ExpectedRoyaltyInterestPayments" xlink:to="lab_alny_ExpectedRoyaltyInterestPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_VutrisiranMember_90c1d789-a70b-4c7c-98da-b18a3e732d8f_terseLabel_en-US" xlink:label="lab_alny_VutrisiranMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vutrisiran</link:label>
    <link:label id="lab_alny_VutrisiranMember_label_en-US" xlink:label="lab_alny_VutrisiranMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vutrisiran [Member]</link:label>
    <link:label id="lab_alny_VutrisiranMember_documentation_en-US" xlink:label="lab_alny_VutrisiranMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vutrisiran</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VutrisiranMember" xlink:href="alny-20230331.xsd#alny_VutrisiranMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_VutrisiranMember" xlink:to="lab_alny_VutrisiranMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_5cfd5169-8c5c-47ab-8663-844a736be9c9_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember_02f2d7e0-4154-4b4e-9acc-4ad6ac444524_terseLabel_en-US" xlink:label="lab_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027, Additional Amount</link:label>
    <link:label id="lab_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember_label_en-US" xlink:label="lab_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027, Additional Amount [Member]</link:label>
    <link:label id="lab_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember_documentation_en-US" xlink:label="lab_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027, Additional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember" xlink:href="alny-20230331.xsd#alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember" xlink:to="lab_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a0c1c9c2-6687-4cb5-9c5c-39f1a36c55b9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19bb5dd1-77a6-4bdc-87be-3545cd64aabe_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_79a88bed-6bd4-4bf8-b9ae-52ddb9e57c12_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1922e918-40c7-4c8e-83e0-2dbb1f80f04d_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6344f9ee-9957-4fa8-8988-ca2d83ea84f3_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ConvertibleDebtPremiumRecognizedFromConversionRate_fd214ddc-bd3c-4f01-86d7-6930cae0fe52_terseLabel_en-US" xlink:label="lab_alny_ConvertibleDebtPremiumRecognizedFromConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium from conversion</link:label>
    <link:label id="lab_alny_ConvertibleDebtPremiumRecognizedFromConversionRate_label_en-US" xlink:label="lab_alny_ConvertibleDebtPremiumRecognizedFromConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Premium Recognized From Conversion Rate</link:label>
    <link:label id="lab_alny_ConvertibleDebtPremiumRecognizedFromConversionRate_documentation_en-US" xlink:label="lab_alny_ConvertibleDebtPremiumRecognizedFromConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Premium Recognized From Conversion Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleDebtPremiumRecognizedFromConversionRate" xlink:href="alny-20230331.xsd#alny_ConvertibleDebtPremiumRecognizedFromConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ConvertibleDebtPremiumRecognizedFromConversionRate" xlink:to="lab_alny_ConvertibleDebtPremiumRecognizedFromConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b8806519-e3b1-49ba-adc0-170b724081e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeAgreementTerminationPeriod_6b32ad2b-1f73-459b-be3e-d3a46334e00c_terseLabel_en-US" xlink:label="lab_alny_CollaborativeAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination period</link:label>
    <link:label id="lab_alny_CollaborativeAgreementTerminationPeriod_label_en-US" xlink:label="lab_alny_CollaborativeAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Termination Period</link:label>
    <link:label id="lab_alny_CollaborativeAgreementTerminationPeriod_documentation_en-US" xlink:label="lab_alny_CollaborativeAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement termination period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeAgreementTerminationPeriod" xlink:href="alny-20230331.xsd#alny_CollaborativeAgreementTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeAgreementTerminationPeriod" xlink:to="lab_alny_CollaborativeAgreementTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementFixedPaymentTerm_48e5e19a-e865-4102-8add-5d14c29d7497_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementFixedPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed payment, term (in years)</link:label>
    <link:label id="lab_alny_CollaborativeArrangementFixedPaymentTerm_label_en-US" xlink:label="lab_alny_CollaborativeArrangementFixedPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed Payment, Term</link:label>
    <link:label id="lab_alny_CollaborativeArrangementFixedPaymentTerm_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementFixedPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed Payment, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementFixedPaymentTerm" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementFixedPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementFixedPaymentTerm" xlink:to="lab_alny_CollaborativeArrangementFixedPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_bce3b177-58fc-48e2-ba06-9b876d55be6c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c8d3392d-ee09-404f-b641-ee3aca2dc5d6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_17246ae9-d8c1-4e0d-ae47-0c1cdf1a562b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f13ab35b-5182-4d52-8e38-32c4adc8de1a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e77853e2-5eb1-4339-9e06-db1d77ab93ff_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6479478c-d0a0-4412-8b74-251a68cd7a0e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2ed835c7-95c2-401d-a637-eedb6e1b594d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0ef1cefa-a1bd-4c37-ad03-1e2d30e4c837_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_8f61255d-5102-4af2-a5be-2cf375474a02_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f272e64c-e1f9-4e1e-962c-b56f70ee9e8c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEVELOPMENT DERIVATIVE LIABILITY</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_8d8239cb-98bb-4bd6-8197-fb21f6499503_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9bcb9121-e533-456a-a5f7-425ec7089a9a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CostOfCollaborationManufacturingAndRoyalties_b4d8ca13-ba30-4380-9dfc-4ddcb976b5b7_terseLabel_en-US" xlink:label="lab_alny_CostOfCollaborationManufacturingAndRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of collaborations and royalties</link:label>
    <link:label id="lab_alny_CostOfCollaborationManufacturingAndRoyalties_label_en-US" xlink:label="lab_alny_CostOfCollaborationManufacturingAndRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Collaboration Manufacturing And Royalties</link:label>
    <link:label id="lab_alny_CostOfCollaborationManufacturingAndRoyalties_documentation_en-US" xlink:label="lab_alny_CostOfCollaborationManufacturingAndRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Collaboration Manufacturing And Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CostOfCollaborationManufacturingAndRoyalties" xlink:href="alny-20230331.xsd#alny_CostOfCollaborationManufacturingAndRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CostOfCollaborationManufacturingAndRoyalties" xlink:to="lab_alny_CostOfCollaborationManufacturingAndRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c3575ac3-9a47-4155-8b57-abbd92a68e74_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored enterprise securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a10700ce-70ef-45fa-888e-65a00bd68439_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_0f83024d-4b0f-4943-a81f-16da8a5eb4ae_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_3162abba-d4bb-44e8-87a6-77997a85c5eb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fea09a83-86a2-43c1-8154-ea2477fc6a70_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a8cc14c5-179e-485d-8dce-fc0311738a57_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_ce8ced89-137e-4c05-a750-4a3ca321a476_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7e346507-947d-438e-bd1d-82ccd577d829_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_PremiumRecognizedOnCappedCallTransactions_459c465b-2e05-42e5-b786-7c8d3d94fe38_terseLabel_en-US" xlink:label="lab_alny_PremiumRecognizedOnCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on capped call transactions</link:label>
    <link:label id="lab_alny_PremiumRecognizedOnCappedCallTransactions_label_en-US" xlink:label="lab_alny_PremiumRecognizedOnCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Recognized On Capped Call Transactions</link:label>
    <link:label id="lab_alny_PremiumRecognizedOnCappedCallTransactions_documentation_en-US" xlink:label="lab_alny_PremiumRecognizedOnCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Recognized On Capped Call Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PremiumRecognizedOnCappedCallTransactions" xlink:href="alny-20230331.xsd#alny_PremiumRecognizedOnCappedCallTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_PremiumRecognizedOnCappedCallTransactions" xlink:to="lab_alny_PremiumRecognizedOnCappedCallTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_143ed8db-c765-4e89-827c-012a65f7612c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_AmvuttraMember_0f88c494-3141-4f3a-aed1-4e6ad5d3d0b7_terseLabel_en-US" xlink:label="lab_alny_AmvuttraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMVUTTRA</link:label>
    <link:label id="lab_alny_AmvuttraMember_label_en-US" xlink:label="lab_alny_AmvuttraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amvuttra [Member]</link:label>
    <link:label id="lab_alny_AmvuttraMember_documentation_en-US" xlink:label="lab_alny_AmvuttraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amvuttra</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AmvuttraMember" xlink:href="alny-20230331.xsd#alny_AmvuttraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_AmvuttraMember" xlink:to="lab_alny_AmvuttraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0062b1c3-78e5-4ac1-8f21-c4a3e6d0a1bc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_5f6400aa-bcc9-41cb-8a43-0ef81b560a01_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_dfa3c3b2-b385-4f90-adca-c838a3dedb15_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_e9e09c98-bbc2-4204-92fd-a753bc5c6122_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_873a81a7-77c8-4200-8c06-d62460d096a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_be394673-7e54-47b9-88ee-f59ce276b417_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables included in &#8220;Accounts receivable, net&#8221;</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a4c72e03-3b5e-4e3d-bdc3-a66023c8109e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_a389becb-d1ae-47ab-ad87-2bc4a02a7235_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2cbcb0d1-9508-48b6-abc8-2e9cc54d0fb3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d75ae4a6-5bf2-4a30-af52-2bff67d8b74e_verboseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9d2bf94e-31e2-4549-9bec-361e242b41cf_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_6a8cb552-f670-43c6-961d-4721dcf2f4e5_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Transaction Price Based on Accounting Guidance</link:label>
    <link:label id="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Transaction Price [Table Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:href="alny-20230331.xsd#alny_ScheduleOfAllocatedTransactionPriceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:to="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_2d299b37-e31a-4a83-ac11-9eba0ed98373_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_UpfrontFeeReceived_e66de6f8-3148-4982-a07d-f52d07c1b371_terseLabel_en-US" xlink:label="lab_alny_UpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fee received</link:label>
    <link:label id="lab_alny_UpfrontFeeReceived_label_en-US" xlink:label="lab_alny_UpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Fee Received</link:label>
    <link:label id="lab_alny_UpfrontFeeReceived_documentation_en-US" xlink:label="lab_alny_UpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of upfront fees received under the terms of collaborative and licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_UpfrontFeeReceived" xlink:href="alny-20230331.xsd#alny_UpfrontFeeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_UpfrontFeeReceived" xlink:to="lab_alny_UpfrontFeeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_7bf5b024-e7cc-468c-9e34-21b9ceb41005_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_00640bc8-33a7-4438-9f20-f8f2b9baf7db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ce8fc15e-0ce5-4e6d-9c80-e6702d9a7645_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_26d7d171-cfb0-4214-b006-d9f6e19399ce_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_e6aa5de6-0740-4e1e-8509-c5ac0c404258_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_167df501-9948-4de7-8c29-ef231db6eff9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e4a5999d-fbc2-4573-983b-6f86485aec31_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_PercentageOfMaximumRoyaltyPayments_adafe8ef-ff10-4391-a983-2c9c6e6c6fd0_terseLabel_en-US" xlink:label="lab_alny_PercentageOfMaximumRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of royalty payments</link:label>
    <link:label id="lab_alny_PercentageOfMaximumRoyaltyPayments_label_en-US" xlink:label="lab_alny_PercentageOfMaximumRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Maximum Royalty Payments</link:label>
    <link:label id="lab_alny_PercentageOfMaximumRoyaltyPayments_documentation_en-US" xlink:label="lab_alny_PercentageOfMaximumRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of maximum royalty payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PercentageOfMaximumRoyaltyPayments" xlink:href="alny-20230331.xsd#alny_PercentageOfMaximumRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_PercentageOfMaximumRoyaltyPayments" xlink:to="lab_alny_PercentageOfMaximumRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0f33efcc-a1de-4121-a7f3-23392d65f85c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_454456a2-b4f8-4c24-a4f3-c4180bb95e0b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3ab3bd2f-d3ed-4f33-b181-e34d4a741a85_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_cd1e56fe-3e9e-4ad4-8545-e61187b27538_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2b1eb650-4169-438a-b96d-a3b230eb53d4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_11b34b90-b7c6-4084-8b60-8914bd5add4f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1ce48ebb-5654-4306-ac46-53a87f239b85_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ce63582d-0940-419b-a22b-fe9aeb9b4f91_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_474abb49-c6fe-4b58-bd58-a929d00f1164_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cd7e4ffa-93c0-4258-881e-3f3e78127f2a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_16b32805-99db-4ed9-99ac-fb448d16ddb9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e97e9acf-e43a-4ec1-bc65-d1af04da5988_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_028feb49-733b-4363-b0d5-5eae67a37b9c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_364fd631-4beb-43a6-a5b2-203206b75886_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_90bbd1af-32cd-4ac3-96c4-27dd10c0130b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_976ddbce-eb66-4385-aa6c-60648f0594c7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ef938262-6d08-44f6-85ef-07e48a964d40_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_dee27e12-f16a-4461-b198-ab877703056f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_50f6fcc2-775f-424f-bd7c-dda9b85ed67a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_217abaa4-45f6-409a-95bf-dc4993903b1b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_db7782f1-2244-4794-a661-6f2ac2327ee3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute diluted net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_64177b75-0fbb-479c-a521-343d4e7427ba_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2df115e9-0da5-43d1-91ac-20b7dfd8ce29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1402162-4755-4870-8760-ed9757b4606b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_f62e08f3-9210-4d0b-a3de-7f2436538eaf_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues from collaborations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_a2361ff1-9f59-4812-8359-e908f139e12f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues from collaborations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_e16d701d-48a7-48e4-82dc-572f8ea06358_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_78cc53b4-3ba2-4d87-81c5-138a3be84f4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_75d2db52-174d-454a-a45a-fbcf1befb7ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Marketable Debt Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_714835c8-3416-42b8-8cf5-c92c62f10a01_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RegeneronPharmaceuticalsIncorporationMember_e19d5585-f2d7-4f85-9884-987faedde3db_terseLabel_en-US" xlink:label="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals</link:label>
    <link:label id="lab_alny_RegeneronPharmaceuticalsIncorporationMember_label_en-US" xlink:label="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals Incorporation [Member]</link:label>
    <link:label id="lab_alny_RegeneronPharmaceuticalsIncorporationMember_documentation_en-US" xlink:label="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:to="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock_4dc2c7d3-1c57-4684-b3e4-1bb7c94c4dc2_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Royalty Liability</link:label>
    <link:label id="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Royalty Liability [Table Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Royalty Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfRoyaltyLiabilityTableTextBlock" xlink:href="alny-20230331.xsd#alny_ScheduleOfRoyaltyLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfRoyaltyLiabilityTableTextBlock" xlink:to="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9b9b0e3d-8aeb-44d9-a967-fb97334e8d48_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value per share, 250,000 shares authorized; 124,241 shares issued and outstanding as of March&#160;31, 2023; 123,925 shares issued and outstanding as of December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e09b22b2-2a83-48bb-b15c-9fa0dcd5b856_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_e2974aba-00e5-4c63-8e49-e59a98d3f9e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7436136d-b933-407d-9ecf-cc0e29571166_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Share Equivalents Excluded from the Calculation of Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_851cd62b-abe4-41e7-962e-bd940201dd94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_59f512ed-7564-4110-876a-b6fc5a1b90c8_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCapPrice_f4a714d9-2439-448b-b84f-7e7a247e84af_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCapPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DerivativeCapPrice_label_en-US" xlink:label="lab_us-gaap_DerivativeCapPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Cap Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCapPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCapPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCapPrice" xlink:to="lab_us-gaap_DerivativeCapPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ac3e1aae-ed46-437d-8aa9-7da491c0d818_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_2a6693fd-0a91-4a3d-a6c7-5ff2212a2961_terseLabel_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties Line Items [Line Items]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_label_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties Line Items [Line Items]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_documentation_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties Line Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" xlink:to="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_494be48e-d7fd-4970-925b-8105f4b4749e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99b1697b-823f-4755-87e9-326a84cc2293_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9c956372-93a3-4a02-8853-9cc63787873e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6be90f2f-3f62-4f82-8254-0e7b860d3016_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_b4ac3c8e-a102-424e-8535-2af766731542_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturity of restricted investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8bfd5146-cf87-4d23-980a-3663a643f9f9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7ff5b951-be68-40bd-80eb-d29c5eae341f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_197bd685-a53d-4730-b595-0ec3e6f25099_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities included in &#8220;Deferred revenue&#8221;</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1807b2fe-ccac-40d3-aa7e-afb28f55b038_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_a0b090c5-128e-4993-a039-9c575a48cb09_terseLabel_en-US" xlink:label="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and interest accretion related to operating leases</link:label>
    <link:label id="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_label_en-US" xlink:label="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Interest Accretion Related to Operating Leases</link:label>
    <link:label id="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_documentation_en-US" xlink:label="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Interest Accretion Related to Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:href="alny-20230331.xsd#alny_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:to="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c28c799c-7975-4b32-a607-c0b9c40ccc18_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5dbd5adc-157b-4efa-8561-e5aca8a007a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_992f35ae-b9d3-4f72-b4a0-4615a246e5e4_terseLabel_en-US" xlink:label="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to the sale of future royalties</link:label>
    <link:label id="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_label_en-US" xlink:label="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense On Sale Of Future Royalties</link:label>
    <link:label id="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense On Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" xlink:href="alny-20230331.xsd#alny_NonCashInterestExpenseOnSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" xlink:to="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1649062f-527c-42f5-985a-0dce87a25380_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_11ba2fae-efb8-42b0-bbfb-c3d7a1cf70a4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_51d0e69a-86b0-4277-a5bb-753b327f44be_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a4d56cf0-82dd-4eb5-8d36-8dbd534a7d33_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_905d4bbd-875f-474b-b87a-806a9c3f7dca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5b0dfed4-7226-49c5-9e08-bb94a4dc3bf9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_77aebeaa-90e8-4ddd-b93d-b5a3a172a433_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and other types of equity, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b134b34f-be01-4a51-af31-09d0875a27a3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_93a07c8e-1983-41e7-a831-840e9e534162_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_4bfab514-5123-4fc7-9b94-88ad5abd4eab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_1ede38b0-d299-468b-92b9-488204163ca6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_FundingAtLeadCandidateIdentificationMember_07cd0a8f-1719-483c-8319-f0afd63a0fe6_terseLabel_en-US" xlink:label="lab_alny_FundingAtLeadCandidateIdentificationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Lead Candidate Identification</link:label>
    <link:label id="lab_alny_FundingAtLeadCandidateIdentificationMember_label_en-US" xlink:label="lab_alny_FundingAtLeadCandidateIdentificationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Lead Candidate Identification [Member]</link:label>
    <link:label id="lab_alny_FundingAtLeadCandidateIdentificationMember_documentation_en-US" xlink:label="lab_alny_FundingAtLeadCandidateIdentificationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding at lead candidate identification.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtLeadCandidateIdentificationMember" xlink:href="alny-20230331.xsd#alny_FundingAtLeadCandidateIdentificationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_FundingAtLeadCandidateIdentificationMember" xlink:to="lab_alny_FundingAtLeadCandidateIdentificationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementMaximumFunding_ef3f3a78-7c2e-402e-8dc2-80fd25c9d36b_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementMaximumFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum funding</link:label>
    <link:label id="lab_alny_CollaborativeArrangementMaximumFunding_label_en-US" xlink:label="lab_alny_CollaborativeArrangementMaximumFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Funding</link:label>
    <link:label id="lab_alny_CollaborativeArrangementMaximumFunding_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementMaximumFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMaximumFunding" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementMaximumFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementMaximumFunding" xlink:to="lab_alny_CollaborativeArrangementMaximumFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d9df1363-8b02-4e62-8d9c-50f54417dbcf_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_79de60aa-c8d3-4f96-8be8-03024848a345_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3ce7e8c9-efcb-4349-aa9c-102ccd009bf2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_7c310e9e-df95-4f7a-ae44-fc6168e5386a_terseLabel_en-US" xlink:label="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum royalties and commercial milestone payments upon potential product sale</link:label>
    <link:label id="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_label_en-US" xlink:label="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Royalties And Commercial Milestone Payments Upon Potential Product Sale</link:label>
    <link:label id="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_documentation_en-US" xlink:label="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum royalties and commercial milestone payments upon potential product sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:href="alny-20230331.xsd#alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:to="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b95d86b3-9645-4cc2-ad61-a10e751c4b27_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7280590c-60f5-4b4f-9993-7dc4b6783e5f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5081ba3f-42e6-4982-a4fa-4955bcf6d40a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5a4aefef-a107-4616-9a93-6c4a913e819e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_bd02734a-f1e3-41fa-9e48-cecdee50fb2d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b0b5c5b7-81d2-4a21-91e0-98653efaf1be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recorded from remeasurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cba85df1-0b7b-4d1a-86b2-b418dd724c11_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock, inclusive of performance-based stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ResearchTermExtensionFee_f915f74e-51a9-4590-a181-1fd1007ef49a_terseLabel_en-US" xlink:label="lab_alny_ResearchTermExtensionFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research term extension fee</link:label>
    <link:label id="lab_alny_ResearchTermExtensionFee_label_en-US" xlink:label="lab_alny_ResearchTermExtensionFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Term Extension Fee</link:label>
    <link:label id="lab_alny_ResearchTermExtensionFee_documentation_en-US" xlink:label="lab_alny_ResearchTermExtensionFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research term extension fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchTermExtensionFee" xlink:href="alny-20230331.xsd#alny_ResearchTermExtensionFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ResearchTermExtensionFee" xlink:to="lab_alny_ResearchTermExtensionFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_0066b3d3-b278-4cff-859f-8b5171d14808_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_a024f930-3810-4b7b-9942-ab9629ebede0_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit pension plans, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8bb06399-6dce-46db-b4ac-4245c14846b4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options, net of tax withholdings</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0f81120b-8fea-44b6-9a1d-39abf40f311e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ALNAGTPhase2ClinicalTrialMember_0cffa8d5-b8dc-49de-955e-2b1580d41734_terseLabel_en-US" xlink:label="lab_alny_ALNAGTPhase2ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALN-AGT Phase 2 Clinical Trial</link:label>
    <link:label id="lab_alny_ALNAGTPhase2ClinicalTrialMember_label_en-US" xlink:label="lab_alny_ALNAGTPhase2ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALN-AGT Phase 2 Clinical Trial [Member]</link:label>
    <link:label id="lab_alny_ALNAGTPhase2ClinicalTrialMember_documentation_en-US" xlink:label="lab_alny_ALNAGTPhase2ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALN-AGT Phase 2 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ALNAGTPhase2ClinicalTrialMember" xlink:href="alny-20230331.xsd#alny_ALNAGTPhase2ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ALNAGTPhase2ClinicalTrialMember" xlink:to="lab_alny_ALNAGTPhase2ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_c6e2a090-6ec2-4d3f-8064-008bfe854e04_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DebtConversionTermsTwoMember_a596796f-644a-47be-8e24-3be59631702b_terseLabel_en-US" xlink:label="lab_alny_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:label id="lab_alny_DebtConversionTermsTwoMember_label_en-US" xlink:label="lab_alny_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Two [Member]</link:label>
    <link:label id="lab_alny_DebtConversionTermsTwoMember_documentation_en-US" xlink:label="lab_alny_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtConversionTermsTwoMember" xlink:href="alny-20230331.xsd#alny_DebtConversionTermsTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DebtConversionTermsTwoMember" xlink:to="lab_alny_DebtConversionTermsTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1f865992-785e-4d3c-8925-20ac10bdaf06_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d8cd66dc-0482-4091-acfb-9a455594e2e2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0b6c5ccd-0f78-4843-8668-5815ee70111b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_e96628a2-ccdc-49ea-a66b-d1661bab308c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1bb3671c-a31d-44d6-865c-c8663b4739e2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_aaa26ac6-29f6-483d-974f-a0541e444abd_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_9d43878e-1cb5-4a08-81ee-bd69e17ca4ae_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_aff8b4b8-2499-4f52-bbc0-cfaab4799ff3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_6ddd1a8a-de56-4455-836b-25c613749a78_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized and unrealized loss on marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_622494fc-2f94-4f6e-810f-cac4ac4466fb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_PotentialProceedsFromCollaborationArrangement_04344bc5-c2c8-46f5-95d9-b681328a2a76_terseLabel_en-US" xlink:label="lab_alny_PotentialProceedsFromCollaborationArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from collaboration arrangement</link:label>
    <link:label id="lab_alny_PotentialProceedsFromCollaborationArrangement_label_en-US" xlink:label="lab_alny_PotentialProceedsFromCollaborationArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Proceeds From Collaboration Arrangement</link:label>
    <link:label id="lab_alny_PotentialProceedsFromCollaborationArrangement_documentation_en-US" xlink:label="lab_alny_PotentialProceedsFromCollaborationArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from collaboration arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PotentialProceedsFromCollaborationArrangement" xlink:href="alny-20230331.xsd#alny_PotentialProceedsFromCollaborationArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_PotentialProceedsFromCollaborationArrangement" xlink:to="lab_alny_PotentialProceedsFromCollaborationArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6615f5d7-20dc-4629-8b2e-ea6d25579cb8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer liability revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_595a0ed2-d966-452c-a8dd-002e05754783_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9b814c92-9ceb-42e6-8d99-ffab72781990_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_951d2bb2-a7bb-4828-b712-ddc3e054f416_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_24061b69-489a-4858-932a-2d9211fba838_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_523d23d3-bcef-4452-9406-2b5d908ea3cc_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_80f26bbb-38c2-4174-8eef-746762154ee6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restricted cash included in other assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_52ea4319-c840-4428-a510-f5ee9b28d390_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_BlackstoneLifeSciencesMember_7933dc39-c1ab-465a-9871-31a8f04c640f_terseLabel_en-US" xlink:label="lab_alny_BlackstoneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Life Sciences</link:label>
    <link:label id="lab_alny_BlackstoneLifeSciencesMember_label_en-US" xlink:label="lab_alny_BlackstoneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Life Sciences [Member]</link:label>
    <link:label id="lab_alny_BlackstoneLifeSciencesMember_documentation_en-US" xlink:label="lab_alny_BlackstoneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Life Sciences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneLifeSciencesMember" xlink:href="alny-20230331.xsd#alny_BlackstoneLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_BlackstoneLifeSciencesMember" xlink:to="lab_alny_BlackstoneLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_9f878d1c-f461-4a1d-8e28-0b316986aea4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading days threshold</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_78017af1-9dfc-4fb1-9ee8-2d17117942eb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_dc86d00c-a542-4f49-bda1-dd45bfe79236_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyLiabilityPayments_6bf61613-0315-44eb-b8e2-5a097c83aedb_negatedTerseLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityPayments_label_en-US" xlink:label="lab_alny_RoyaltyLiabilityPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Payments</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityPayments_documentation_en-US" xlink:label="lab_alny_RoyaltyLiabilityPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityPayments" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyLiabilityPayments" xlink:to="lab_alny_RoyaltyLiabilityPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_ffef9772-0a87-4811-b288-787be5fe1f97_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_InventoryCurrentAndNoncurrent_15b5049c-705c-40c5-ba4e-b73a1da07c49_totalLabel_en-US" xlink:label="lab_alny_InventoryCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_alny_InventoryCurrentAndNoncurrent_label_en-US" xlink:label="lab_alny_InventoryCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current And Noncurrent</link:label>
    <link:label id="lab_alny_InventoryCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_alny_InventoryCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current And Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InventoryCurrentAndNoncurrent" xlink:href="alny-20230331.xsd#alny_InventoryCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_InventoryCurrentAndNoncurrent" xlink:to="lab_alny_InventoryCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_275faea4-19e6-4d1c-846b-bdbd8203cbfd_terseLabel_en-US" xlink:label="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional milestone payments to be receive upon achievement of certain criteria</link:label>
    <link:label id="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_label_en-US" xlink:label="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Additional Milestone Payments To Be Receive Upon Achievement Of Certain Criteria</link:label>
    <link:label id="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_documentation_en-US" xlink:label="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional milestone payments to be receive upon achievement of certain criteria.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:href="alny-20230331.xsd#alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:to="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5df631d6-1f09-499b-886a-4aaff25ee417_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bc9cdb9b-1608-4952-a3de-21cbb824c20b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ExternalServicesMember_acf31e36-899d-4512-b576-e8259f7cfd92_terseLabel_en-US" xlink:label="lab_alny_ExternalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Services</link:label>
    <link:label id="lab_alny_ExternalServicesMember_label_en-US" xlink:label="lab_alny_ExternalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Services [Member]</link:label>
    <link:label id="lab_alny_ExternalServicesMember_documentation_en-US" xlink:label="lab_alny_ExternalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExternalServicesMember" xlink:href="alny-20230331.xsd#alny_ExternalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ExternalServicesMember" xlink:to="lab_alny_ExternalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05f43026-07a4-48ed-a149-e927787374e0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_74660ed5-b19c-4b41-b5e0-9ab18aca903b_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_16dcdbb8-3102-408c-834b-a2ae86d96b15_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_681209f8-edfc-4fca-bc85-c9f597d3f0e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_c05ee1c7-c095-44ae-8aa9-48d89fb01865_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, royalties and commercial milestones acquired by collaborator, percent</link:label>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_label_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties And Commercial Milestones Acquired By Collaborator, Percent</link:label>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Acquired By Collaborator, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" xlink:to="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_05b004ea-c8cf-4a51-81ce-58c453869d12_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_BlackstoneGroupIncMember_eec63570-0cf4-47ad-a76d-1d09723a6cb5_terseLabel_en-US" xlink:label="lab_alny_BlackstoneGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Group Inc.</link:label>
    <link:label id="lab_alny_BlackstoneGroupIncMember_label_en-US" xlink:label="lab_alny_BlackstoneGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Group Inc. [Member]</link:label>
    <link:label id="lab_alny_BlackstoneGroupIncMember_documentation_en-US" xlink:label="lab_alny_BlackstoneGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Group Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneGroupIncMember" xlink:href="alny-20230331.xsd#alny_BlackstoneGroupIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_BlackstoneGroupIncMember" xlink:to="lab_alny_BlackstoneGroupIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f6c99a97-8374-4818-a553-1a09582739be_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ClinicalTrialAndManufacturingMember_be2e4465-ad19-44a3-8e82-37347ef6fe82_terseLabel_en-US" xlink:label="lab_alny_ClinicalTrialAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial and Manufacturing</link:label>
    <link:label id="lab_alny_ClinicalTrialAndManufacturingMember_label_en-US" xlink:label="lab_alny_ClinicalTrialAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial And Manufacturing [Member]</link:label>
    <link:label id="lab_alny_ClinicalTrialAndManufacturingMember_documentation_en-US" xlink:label="lab_alny_ClinicalTrialAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and manufacturing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ClinicalTrialAndManufacturingMember" xlink:href="alny-20230331.xsd#alny_ClinicalTrialAndManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ClinicalTrialAndManufacturingMember" xlink:to="lab_alny_ClinicalTrialAndManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d91884ff-9fa4-488f-b7b7-7b4545065803_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ConvertibleSeniorNotesDue2027InitialAmountMember_368fcf0e-bbc5-4cea-871a-7e8c2b2aae21_terseLabel_en-US" xlink:label="lab_alny_ConvertibleSeniorNotesDue2027InitialAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027, Initial Amount</link:label>
    <link:label id="lab_alny_ConvertibleSeniorNotesDue2027InitialAmountMember_label_en-US" xlink:label="lab_alny_ConvertibleSeniorNotesDue2027InitialAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027, Initial Amount [Member]</link:label>
    <link:label id="lab_alny_ConvertibleSeniorNotesDue2027InitialAmountMember_documentation_en-US" xlink:label="lab_alny_ConvertibleSeniorNotesDue2027InitialAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027, Initial Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleSeniorNotesDue2027InitialAmountMember" xlink:href="alny-20230331.xsd#alny_ConvertibleSeniorNotesDue2027InitialAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ConvertibleSeniorNotesDue2027InitialAmountMember" xlink:to="lab_alny_ConvertibleSeniorNotesDue2027InitialAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4cf079ab-216c-48a1-88fb-967b575d6717_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_81e0f120-0304-45dd-9395-42bc76d97b29_terseLabel_en-US" xlink:label="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARKETABLE DEBT SECURITIES</link:label>
    <link:label id="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_label_en-US" xlink:label="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Marketable Debt Securities Disclosure [Text Block]</link:label>
    <link:label id="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_documentation_en-US" xlink:label="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable debt securities disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:href="alny-20230331.xsd#alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:to="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_2f7bd5ad-2252-462a-87ba-cc2b9d59b8e3_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c507b85d-d74e-4f7c-a9af-164b1c565dcb_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4bc9cd37-c8f8-48ce-b0bc-547c823eb0d2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute basic net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_9b81dfdc-02c0-4673-b198-cd66e66f4418_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyLiabilityNoncurrent_c36e80da-58b9-496d-9ba0-c646d78cfcb0_terseLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties, net of current portion</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityNoncurrent_50b0a816-5cb6-4b36-ad7a-d26c39a392fd_periodStartLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityNoncurrent_7ca88af3-9816-49c2-aa0d-80a82fbe94eb_periodEndLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityNoncurrent_label_en-US" xlink:label="lab_alny_RoyaltyLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Noncurrent</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityNoncurrent_documentation_en-US" xlink:label="lab_alny_RoyaltyLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyLiabilityNoncurrent" xlink:to="lab_alny_RoyaltyLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_6e15ebc5-d630-4bf4-a43e-3cdb675453be_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_bed94b26-d5d9-46c7-ac71-be60c8b46d95_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_StandaloneSellingPrice_4b859732-20bc-4966-9e40-37bc51a92633_terseLabel_en-US" xlink:label="lab_alny_StandaloneSellingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standalone Selling Price</link:label>
    <link:label id="lab_alny_StandaloneSellingPrice_label_en-US" xlink:label="lab_alny_StandaloneSellingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standalone Selling Price</link:label>
    <link:label id="lab_alny_StandaloneSellingPrice_documentation_en-US" xlink:label="lab_alny_StandaloneSellingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standalone Selling Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_StandaloneSellingPrice" xlink:href="alny-20230331.xsd#alny_StandaloneSellingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_StandaloneSellingPrice" xlink:to="lab_alny_StandaloneSellingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_77b52599-c3b4-4910-8d15-001f5d706950_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_16c95510-a1ff-4507-a489-49812421db14_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c8399d6d-cbcd-4659-a849-06cc8b464844_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NonUSOrEuropeMember_0cfdd6e3-11e7-4a11-90fa-19c0d680dae4_terseLabel_en-US" xlink:label="lab_alny_NonUSOrEuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_alny_NonUSOrEuropeMember_label_en-US" xlink:label="lab_alny_NonUSOrEuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US Or Europe [Member]</link:label>
    <link:label id="lab_alny_NonUSOrEuropeMember_documentation_en-US" xlink:label="lab_alny_NonUSOrEuropeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US Or Europe</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonUSOrEuropeMember" xlink:href="alny-20230331.xsd#alny_NonUSOrEuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NonUSOrEuropeMember" xlink:to="lab_alny_NonUSOrEuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ALNAGTPhase3ClinicalTrialMember_c0779470-d904-4543-9748-3ab0a790159e_terseLabel_en-US" xlink:label="lab_alny_ALNAGTPhase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALN-AGT Phase 3 Clinical Trial</link:label>
    <link:label id="lab_alny_ALNAGTPhase3ClinicalTrialMember_label_en-US" xlink:label="lab_alny_ALNAGTPhase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALN-AGT Phase 3 Clinical Trial [Member]</link:label>
    <link:label id="lab_alny_ALNAGTPhase3ClinicalTrialMember_documentation_en-US" xlink:label="lab_alny_ALNAGTPhase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALN-AGT Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ALNAGTPhase3ClinicalTrialMember" xlink:href="alny-20230331.xsd#alny_ALNAGTPhase3ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ALNAGTPhase3ClinicalTrialMember" xlink:to="lab_alny_ALNAGTPhase3ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e999ee9c-ceef-45a2-8b50-1e8bc84421f4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_c1748471-8755-4283-bdb3-c8cfb81e9415_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units, inclusive of performance-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08be4958-e7e6-4fa9-bf59-e89db834deea_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c9e6b8d8-fc32-40aa-9007-5d36ea2808e6_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized under ASC 606</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_bfc010c8-5e13-4b17-9416-e0ab34669e79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_13d212bd-a60e-4cfa-8aad-5f0d4113ec11_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeMember_5e5803ee-549b-4dc4-b1f5-f8d59536b5e2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeMember_label_en-US" xlink:label="lab_us-gaap_DerivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeMember" xlink:to="lab_us-gaap_DerivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_93774b42-5256-481d-9319-ce0a58722520_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm_f1363ed0-44fc-476d-a0e4-e26f495a14c6_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties payable, term (in years)</link:label>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm_label_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Payable, Term</link:label>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Payable, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesPayableTerm" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementRoyaltiesPayableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementRoyaltiesPayableTerm" xlink:to="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_a425f4cb-428d-4daa-9a75-77c4c6ce1e88_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET PRODUCT REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CallOptionMember_074bafdf-8086-4f3f-a2d1-f1a1c6d4bd84_terseLabel_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call Transactions</link:label>
    <link:label id="lab_us-gaap_CallOptionMember_label_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CallOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CallOptionMember" xlink:to="lab_us-gaap_CallOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_TransactionPrice_c65e5a8b-117c-405c-b7fc-bfde9c62b18b_verboseLabel_en-US" xlink:label="lab_alny_TransactionPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_alny_TransactionPrice_741412ca-ed38-4d78-a501-84626d818a0a_terseLabel_en-US" xlink:label="lab_alny_TransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Price Allocated</link:label>
    <link:label id="lab_alny_TransactionPrice_label_en-US" xlink:label="lab_alny_TransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Price</link:label>
    <link:label id="lab_alny_TransactionPrice_documentation_en-US" xlink:label="lab_alny_TransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice" xlink:href="alny-20230331.xsd#alny_TransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_TransactionPrice" xlink:to="lab_alny_TransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_d6be71b9-bcd6-437e-98cc-87b5945acdfc_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyLiabilityInterestRate_be725d67-6475-47ad-957b-55c482474063_terseLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityInterestRate_label_en-US" xlink:label="lab_alny_RoyaltyLiabilityInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Interest Rate</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityInterestRate_documentation_en-US" xlink:label="lab_alny_RoyaltyLiabilityInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityInterestRate" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyLiabilityInterestRate" xlink:to="lab_alny_RoyaltyLiabilityInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f8a21344-d5c7-4826-bd08-349ac0dab59d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_f1f44fcf-12d4-4395-ab05-2f146f822cf9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ff19d51f-c263-4784-bbbc-ded5aa2bb40d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d548670f-0816-4a7f-8450-5413d07b91eb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_d14b7081-6f27-4732-b28b-8242e8e3b4c9_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ChangeInFairValueOfLiabilityObligation_5a96ebdd-f693-49fd-afb2-a2db5a382d2d_negatedTerseLabel_en-US" xlink:label="lab_alny_ChangeInFairValueOfLiabilityObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_alny_ChangeInFairValueOfLiabilityObligation_label_en-US" xlink:label="lab_alny_ChangeInFairValueOfLiabilityObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Liability Obligation</link:label>
    <link:label id="lab_alny_ChangeInFairValueOfLiabilityObligation_documentation_en-US" xlink:label="lab_alny_ChangeInFairValueOfLiabilityObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of liability obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ChangeInFairValueOfLiabilityObligation" xlink:href="alny-20230331.xsd#alny_ChangeInFairValueOfLiabilityObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ChangeInFairValueOfLiabilityObligation" xlink:to="lab_alny_ChangeInFairValueOfLiabilityObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_f8f4e0b3-c14d-4511-980e-aa6629809fb2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount received under the Funding Agreement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_333edb49-4e50-42de-810a-5f58afac8ec6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_24a5b1ca-e9f6-475d-9028-2180236532ea_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0431d65d-4b43-4281-b8ba-c7293c0cecd8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_d8daa622-d6cd-46ad-9ed8-34ee5a6e44d8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_e443710b-c6b0-408f-8e77-847e4cc2b5b5_terseLabel_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITY RELATED TO SALE OF FUTURE ROYALTIES</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Text Block]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:to="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5e33b79e-3b62-4b38-97d5-afacf7ce99d9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_30dad7a3-e5de-434d-9ff3-a575c6abf41a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_de7c611c-f0e5-477e-b982-06cd5969e9e2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_35d986f8-56ef-4707-abfe-2a687cd39879_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Receivables Related to Net Product Revenues</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LiquidityPolicyPolicyTextBlock_1cc282d8-87ab-453e-b0cd-ca5604fd4344_terseLabel_en-US" xlink:label="lab_alny_LiquidityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_alny_LiquidityPolicyPolicyTextBlock_label_en-US" xlink:label="lab_alny_LiquidityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity Policy [Policy Text Block]</link:label>
    <link:label id="lab_alny_LiquidityPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_alny_LiquidityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiquidityPolicyPolicyTextBlock" xlink:href="alny-20230331.xsd#alny_LiquidityPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LiquidityPolicyPolicyTextBlock" xlink:to="lab_alny_LiquidityPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2cacf5e3-95de-4224-bf56-b7f621a7987f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NumberOfMarketedProducts_209dfb02-bd79-4055-b450-ba8bda851772_terseLabel_en-US" xlink:label="lab_alny_NumberOfMarketedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of marketed products</link:label>
    <link:label id="lab_alny_NumberOfMarketedProducts_label_en-US" xlink:label="lab_alny_NumberOfMarketedProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Marketed Products</link:label>
    <link:label id="lab_alny_NumberOfMarketedProducts_documentation_en-US" xlink:label="lab_alny_NumberOfMarketedProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Marketed Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfMarketedProducts" xlink:href="alny-20230331.xsd#alny_NumberOfMarketedProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NumberOfMarketedProducts" xlink:to="lab_alny_NumberOfMarketedProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_24687703-d6c0-4b9b-ad4f-37fba367adfe_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transactional price remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ba20b5a6-fe80-4f43-9886-5799e05686f8_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_5d3feb97-154b-4fc5-b4e3-fea61bbcf708_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ResearchServicesObligationMember_2614bfc4-4b95-4f89-a169-202917c50dbd_terseLabel_en-US" xlink:label="lab_alny_ResearchServicesObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services Obligation</link:label>
    <link:label id="lab_alny_ResearchServicesObligationMember_label_en-US" xlink:label="lab_alny_ResearchServicesObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services Obligation [Member]</link:label>
    <link:label id="lab_alny_ResearchServicesObligationMember_documentation_en-US" xlink:label="lab_alny_ResearchServicesObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember" xlink:href="alny-20230331.xsd#alny_ResearchServicesObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ResearchServicesObligationMember" xlink:to="lab_alny_ResearchServicesObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_89bee42b-81e1-41db-ae0b-67e4812709ab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a1fdd40f-7b6d-48b2-92f2-e69849d53504_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems_0442fd00-010b-4a72-9761-1d37a0235725_terseLabel_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Line Items]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems_label_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Line Items]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems_documentation_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems" xlink:to="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NumberOfCommercializedProducts_b9811429-c38b-4b91-864b-a03c4499a6c3_terseLabel_en-US" xlink:label="lab_alny_NumberOfCommercializedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of commercialized products</link:label>
    <link:label id="lab_alny_NumberOfCommercializedProducts_label_en-US" xlink:label="lab_alny_NumberOfCommercializedProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Commercialized Products</link:label>
    <link:label id="lab_alny_NumberOfCommercializedProducts_documentation_en-US" xlink:label="lab_alny_NumberOfCommercializedProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Commercialized Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfCommercializedProducts" xlink:href="alny-20230331.xsd#alny_NumberOfCommercializedProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NumberOfCommercializedProducts" xlink:to="lab_alny_NumberOfCommercializedProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_fc5815de-d181-4c65-8d82-7ba6a2d6706b_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_a7c071d6-8d89-4ef1-999f-d3e963fcf631_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9d4528fe-5590-4a09-8e3e-cfb22d92c1fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_735be8e5-54a6-4f3e-b59f-ae198fe7e009_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1b9a9194-57eb-421b-9182-1009a31ec4d9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_364f1304-c130-4fd0-ad8e-146ca4bbc737_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DebtInstrumentConvertibleTermsOfConversionDomain_5241f1de-4f79-4e13-a4ee-abb9b55ec284_terseLabel_en-US" xlink:label="lab_alny_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms of Conversion [Domain]</link:label>
    <link:label id="lab_alny_DebtInstrumentConvertibleTermsOfConversionDomain_label_en-US" xlink:label="lab_alny_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms of Conversion [Domain]</link:label>
    <link:label id="lab_alny_DebtInstrumentConvertibleTermsOfConversionDomain_documentation_en-US" xlink:label="lab_alny_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms of Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:href="alny-20230331.xsd#alny_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:to="lab_alny_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementMilestonePayments_6a216d95-0f28-44aa-90d8-6f62d71420f0_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement milestone payments</link:label>
    <link:label id="lab_alny_CollaborativeArrangementMilestonePayments_label_en-US" xlink:label="lab_alny_CollaborativeArrangementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Milestone Payments</link:label>
    <link:label id="lab_alny_CollaborativeArrangementMilestonePayments_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMilestonePayments" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementMilestonePayments" xlink:to="lab_alny_CollaborativeArrangementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_dedfa2cc-99f9-4cc9-aca1-0395b7efae5a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_3cca8d50-c928-4cc2-bbc4-dc30afd3f0f7_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestones acquired by collaborator, percent</link:label>
    <link:label id="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_label_en-US" xlink:label="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent</link:label>
    <link:label id="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" xlink:to="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_50ffc738-7a48-4761-936f-6e1f9f6e1540_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Product Revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DiscoveryPeriodOfProgramsDevelopment_1c816b6d-afb2-41d8-b0eb-6ea26838f8db_terseLabel_en-US" xlink:label="lab_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery period of programs development</link:label>
    <link:label id="lab_alny_DiscoveryPeriodOfProgramsDevelopment_label_en-US" xlink:label="lab_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery Period Of Programs Development</link:label>
    <link:label id="lab_alny_DiscoveryPeriodOfProgramsDevelopment_documentation_en-US" xlink:label="lab_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery period of programs development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:href="alny-20230331.xsd#alny_DiscoveryPeriodOfProgramsDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:to="lab_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_6d31ea64-93ae-46ef-90a3-75fc81a0d80f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_0d42fe80-9f13-48d1-81da-12bd8edc1eff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_00b9f664-adfa-4b86-991f-5a27ca9f5c58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_89acc6af-8888-4a13-8fd0-ca24714795ad_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_591715c6-e2eb-4323-94c0-6705e2663ae6_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_479d424f-a1dd-43eb-bec7-3657418a9367_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b2ec3f3d-eca0-468c-84ae-d23224b530ae_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_C5CoCoObligationMember_c3b69084-b577-414d-92c0-492df8e95f74_terseLabel_en-US" xlink:label="lab_alny_C5CoCoObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 Co-Co Obligation</link:label>
    <link:label id="lab_alny_C5CoCoObligationMember_label_en-US" xlink:label="lab_alny_C5CoCoObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 Co Co Obligation [Member]</link:label>
    <link:label id="lab_alny_C5CoCoObligationMember_documentation_en-US" xlink:label="lab_alny_C5CoCoObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 Co-Co obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember" xlink:href="alny-20230331.xsd#alny_C5CoCoObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_C5CoCoObligationMember" xlink:to="lab_alny_C5CoCoObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_a09c5c93-1852-4a65-a5d5-859e4b12598c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_89d63f7c-5ca1-4631-a189-9ef47251b20e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dabfe7ef-8b3d-4667-aa9a-323e23a537a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_48250777-9119-45d5-b42e-b7763f867e01_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET REVENUES FROM COLLABORATIONS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_dca427b7-c95b-47dc-ab5b-1e9ec53ab237_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_GIVLAARIMember_661392f0-d26f-4a8d-917a-2bab85812a6b_terseLabel_en-US" xlink:label="lab_alny_GIVLAARIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GIVLAARI</link:label>
    <link:label id="lab_alny_GIVLAARIMember_label_en-US" xlink:label="lab_alny_GIVLAARIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GIVLAARI [Member]</link:label>
    <link:label id="lab_alny_GIVLAARIMember_documentation_en-US" xlink:label="lab_alny_GIVLAARIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GIVLAARI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GIVLAARIMember" xlink:href="alny-20230331.xsd#alny_GIVLAARIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_GIVLAARIMember" xlink:to="lab_alny_GIVLAARIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9be9d518-c0e5-4eb0-a6b4-c3bd260f0a03_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b0c9e5f3-68d8-4bde-8c49-ed98110f2fcd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_03df648c-23dc-43ee-89db-73f0c56768ef_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a80d1c1d-19d6-409a-ab64-70241b71f7a6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_863c7b94-87f5-4168-95ea-3e73df9c6456_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ConvertibleSeniorNotesDue2025Member_8cf54672-c67d-42cd-85a4-bc202d0b039c_terseLabel_en-US" xlink:label="lab_alny_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025</link:label>
    <link:label id="lab_alny_ConvertibleSeniorNotesDue2025Member_label_en-US" xlink:label="lab_alny_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025 [Member]</link:label>
    <link:label id="lab_alny_ConvertibleSeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_alny_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleSeniorNotesDue2025Member" xlink:href="alny-20230331.xsd#alny_ConvertibleSeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ConvertibleSeniorNotesDue2025Member" xlink:to="lab_alny_ConvertibleSeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_47b4bbb0-2ddc-48b1-9261-77352a96c925_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6d11de9a-a619-4706-938c-0c3131102ba4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7c0f3bd9-e747-4662-b0de-89da37d4f22e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_74dafd0f-4397-4a4b-bd0e-0ba344513f59_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7da38328-b00f-4b8d-931e-4c79148f2ed4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_1f0ffd0b-6af7-4ab1-b828-667693dc1d08_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_4ae840b4-469f-4d30-a426-a5716df38ad1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_C5LicenseObligationMember_14661476-15f0-43f0-95d9-babd8708d3e5_terseLabel_en-US" xlink:label="lab_alny_C5LicenseObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 License Obligation</link:label>
    <link:label id="lab_alny_C5LicenseObligationMember_label_en-US" xlink:label="lab_alny_C5LicenseObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 License Obligation [Member]</link:label>
    <link:label id="lab_alny_C5LicenseObligationMember_documentation_en-US" xlink:label="lab_alny_C5LicenseObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 license obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember" xlink:href="alny-20230331.xsd#alny_C5LicenseObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_C5LicenseObligationMember" xlink:to="lab_alny_C5LicenseObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_8a11b1a6-3bc6-4665-93ca-9c6d4692eaf3_terseLabel_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_label_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_documentation_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" xlink:to="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>alny-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b732ba76-b80e-452b-9370-f7a92071fea1,g:cc882e96-1f0e-4ac3-98d4-087e3affef76-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.alnylam.com/role/CoverPage" xlink:type="simple" xlink:href="alny-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b09e4e80-22b8-4d22-8306-036cd62ef1d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_DocumentType_b09e4e80-22b8-4d22-8306-036cd62ef1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_fcb04215-0112-401b-8153-6e8c88b13a81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_DocumentQuarterlyReport_fcb04215-0112-401b-8153-6e8c88b13a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5158bf87-0a58-41d8-be36-a08234af96a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_DocumentPeriodEndDate_5158bf87-0a58-41d8-be36-a08234af96a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_90b4aabb-c488-4ab5-b6fb-afe97122bc77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_DocumentTransitionReport_90b4aabb-c488-4ab5-b6fb-afe97122bc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_065e4dfb-1a42-40f1-aa24-f112f8b3c4bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityFileNumber_065e4dfb-1a42-40f1-aa24-f112f8b3c4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9fb0116e-a024-40e6-92d3-a0c085641be2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityRegistrantName_9fb0116e-a024-40e6-92d3-a0c085641be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_573f79a5-1ad7-471c-a09f-6c48da7140a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityIncorporationStateCountryCode_573f79a5-1ad7-471c-a09f-6c48da7140a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6e9899f0-4d5c-4b79-8495-11692d707d46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityTaxIdentificationNumber_6e9899f0-4d5c-4b79-8495-11692d707d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ab4acb43-9e0e-4a9a-85a3-16d9a064edcd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityAddressAddressLine1_ab4acb43-9e0e-4a9a-85a3-16d9a064edcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_392e02d4-074e-4872-8e1b-71765269d570" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityAddressAddressLine2_392e02d4-074e-4872-8e1b-71765269d570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7293fc2a-3566-48f9-a0f0-412f1e26b08e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityAddressCityOrTown_7293fc2a-3566-48f9-a0f0-412f1e26b08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_90751a4e-01d1-48b1-be83-d8bccd6ff9bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityAddressStateOrProvince_90751a4e-01d1-48b1-be83-d8bccd6ff9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3297b1b9-4204-4fb6-823b-a07dc47cc471" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityAddressPostalZipCode_3297b1b9-4204-4fb6-823b-a07dc47cc471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0cf4a92b-4b9e-4def-aee5-1844bf977656" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_CityAreaCode_0cf4a92b-4b9e-4def-aee5-1844bf977656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1c947d4b-5d7f-4519-9fd0-5261b39eaab4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_LocalPhoneNumber_1c947d4b-5d7f-4519-9fd0-5261b39eaab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2968cfff-68f3-4d06-ac0d-6a82bbd8879b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_Security12bTitle_2968cfff-68f3-4d06-ac0d-6a82bbd8879b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_aa2891f4-8774-459c-81e8-6a69cf36cb4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_TradingSymbol_aa2891f4-8774-459c-81e8-6a69cf36cb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_aaaeae07-f6ed-4c23-bd74-47e58fce18c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_SecurityExchangeName_aaaeae07-f6ed-4c23-bd74-47e58fce18c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b0f72cc3-2266-4ba4-a0bc-7a91d5cbec86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityCurrentReportingStatus_b0f72cc3-2266-4ba4-a0bc-7a91d5cbec86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_035114db-c70f-4183-9a03-0ecc13a137e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityInteractiveDataCurrent_035114db-c70f-4183-9a03-0ecc13a137e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_cd82740a-cf37-43aa-bd38-bb2165864ff7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityFilerCategory_cd82740a-cf37-43aa-bd38-bb2165864ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_07d97068-ef54-43dd-8643-73190c2088dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntitySmallBusiness_07d97068-ef54-43dd-8643-73190c2088dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cbb9c09c-c1ee-43f2-a7cc-d7632a2de164" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityEmergingGrowthCompany_cbb9c09c-c1ee-43f2-a7cc-d7632a2de164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_cbe508ac-825e-42a0-8cc0-3435e272f2c4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityShellCompany_cbe508ac-825e-42a0-8cc0-3435e272f2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_577e339f-2fa3-42b7-9a70-c7861e18351c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_577e339f-2fa3-42b7-9a70-c7861e18351c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_38c952c6-c211-4945-a888-be4b194acfda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_AmendmentFlag_38c952c6-c211-4945-a888-be4b194acfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_05f583ee-f3e3-4893-a6bb-2b3e6422ab19" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_DocumentFiscalYearFocus_05f583ee-f3e3-4893-a6bb-2b3e6422ab19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_30127e36-ad24-4f7b-9fe0-ecbe9dfa6a9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_CurrentFiscalYearEndDate_30127e36-ad24-4f7b-9fe0-ecbe9dfa6a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_05a1a169-7d62-46ee-a776-7ec42ff4d73c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_DocumentFiscalPeriodFocus_05a1a169-7d62-46ee-a776-7ec42ff4d73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4d1e6590-696b-4326-8807-3a55b1805068" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_baf334f0-d424-40c6-9537-f4003d378862" xlink:to="loc_dei_EntityCentralIndexKey_4d1e6590-696b-4326-8807-3a55b1805068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="alny-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_711bb045-bf2b-48f3-afb1-ea5ed65c0d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_756d87d1-628b-4461-b4d0-4e9da8abf665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_711bb045-bf2b-48f3-afb1-ea5ed65c0d5f" xlink:to="loc_us-gaap_AssetsAbstract_756d87d1-628b-4461-b4d0-4e9da8abf665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_90b3e91d-fa4f-4432-91be-1f8619ebe9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_756d87d1-628b-4461-b4d0-4e9da8abf665" xlink:to="loc_us-gaap_AssetsCurrentAbstract_90b3e91d-fa4f-4432-91be-1f8619ebe9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc572624-ed4f-4515-929d-ee130442f06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b3e91d-fa4f-4432-91be-1f8619ebe9ae" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc572624-ed4f-4515-929d-ee130442f06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fa419ed2-1106-4ede-b0ed-f0dac30ed45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b3e91d-fa4f-4432-91be-1f8619ebe9ae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fa419ed2-1106-4ede-b0ed-f0dac30ed45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_15dc9ac0-507f-4063-b6bd-64bb8f7e40ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b3e91d-fa4f-4432-91be-1f8619ebe9ae" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_15dc9ac0-507f-4063-b6bd-64bb8f7e40ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f7cef7b6-9ad0-45c6-9e03-24923ac20eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b3e91d-fa4f-4432-91be-1f8619ebe9ae" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f7cef7b6-9ad0-45c6-9e03-24923ac20eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_737754a5-c4fa-4b10-83da-a731f040dd10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b3e91d-fa4f-4432-91be-1f8619ebe9ae" xlink:to="loc_us-gaap_InventoryNet_737754a5-c4fa-4b10-83da-a731f040dd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5e2e097e-db88-43de-b5ff-77419f3f7efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b3e91d-fa4f-4432-91be-1f8619ebe9ae" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5e2e097e-db88-43de-b5ff-77419f3f7efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4ffb15eb-cb7e-48f1-b4af-2405ed9a5c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b3e91d-fa4f-4432-91be-1f8619ebe9ae" xlink:to="loc_us-gaap_AssetsCurrent_4ffb15eb-cb7e-48f1-b4af-2405ed9a5c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_99a37d31-2b6c-4b6c-8172-022766179d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_756d87d1-628b-4461-b4d0-4e9da8abf665" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_99a37d31-2b6c-4b6c-8172-022766179d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a525850c-90d8-467c-aaeb-6b023ea1fde4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_756d87d1-628b-4461-b4d0-4e9da8abf665" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a525850c-90d8-467c-aaeb-6b023ea1fde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_852cd376-78fd-4f2e-9381-913dbe5605bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_756d87d1-628b-4461-b4d0-4e9da8abf665" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_852cd376-78fd-4f2e-9381-913dbe5605bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8dc11e9b-238c-491f-83b7-c5af93f0364b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_756d87d1-628b-4461-b4d0-4e9da8abf665" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8dc11e9b-238c-491f-83b7-c5af93f0364b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_edd8014b-408e-4f60-a339-775e6441bd74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_756d87d1-628b-4461-b4d0-4e9da8abf665" xlink:to="loc_us-gaap_Assets_edd8014b-408e-4f60-a339-775e6441bd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70a4aa9e-0fbd-490f-b147-cd0898579bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_711bb045-bf2b-48f3-afb1-ea5ed65c0d5f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70a4aa9e-0fbd-490f-b147-cd0898579bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_308ad6eb-1e85-4648-9952-e4b8b19fa791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70a4aa9e-0fbd-490f-b147-cd0898579bf0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_308ad6eb-1e85-4648-9952-e4b8b19fa791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a19a1504-10bf-4bb2-89ba-a157f601ae04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_308ad6eb-1e85-4648-9952-e4b8b19fa791" xlink:to="loc_us-gaap_AccountsPayableCurrent_a19a1504-10bf-4bb2-89ba-a157f601ae04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_486efa79-893b-4d1d-a6b2-61d8f5e2a51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_308ad6eb-1e85-4648-9952-e4b8b19fa791" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_486efa79-893b-4d1d-a6b2-61d8f5e2a51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7885f4ab-5d78-4f95-8c2c-4b829e47dd67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_308ad6eb-1e85-4648-9952-e4b8b19fa791" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7885f4ab-5d78-4f95-8c2c-4b829e47dd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5d8a252c-3307-4b75-baf0-ed6a52ce8dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_308ad6eb-1e85-4648-9952-e4b8b19fa791" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5d8a252c-3307-4b75-baf0-ed6a52ce8dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityCurrent_180afdd6-e786-47dd-940a-fc1d84ceae60" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_308ad6eb-1e85-4648-9952-e4b8b19fa791" xlink:to="loc_alny_RoyaltyLiabilityCurrent_180afdd6-e786-47dd-940a-fc1d84ceae60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_be2cf468-4ef3-4156-8697-ec2788867eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_308ad6eb-1e85-4648-9952-e4b8b19fa791" xlink:to="loc_us-gaap_LiabilitiesCurrent_be2cf468-4ef3-4156-8697-ec2788867eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9d43a509-65d9-4755-af38-f90114e33068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70a4aa9e-0fbd-490f-b147-cd0898579bf0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9d43a509-65d9-4755-af38-f90114e33068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_20597fd0-0534-4067-bfa3-ddcc4705de5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70a4aa9e-0fbd-490f-b147-cd0898579bf0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_20597fd0-0534-4067-bfa3-ddcc4705de5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_f7d6837c-d17c-4953-a732-15488ed10025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70a4aa9e-0fbd-490f-b147-cd0898579bf0" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_f7d6837c-d17c-4953-a732-15488ed10025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent_6dfd1d3f-2ea6-413f-9c9b-d8ecb26f7f58" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70a4aa9e-0fbd-490f-b147-cd0898579bf0" xlink:to="loc_alny_RoyaltyLiabilityNoncurrent_6dfd1d3f-2ea6-413f-9c9b-d8ecb26f7f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ad0c6289-eddf-45f2-8ab4-985400c1c2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70a4aa9e-0fbd-490f-b147-cd0898579bf0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ad0c6289-eddf-45f2-8ab4-985400c1c2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8b6a3fef-26b2-4636-87bc-81ad117f2f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70a4aa9e-0fbd-490f-b147-cd0898579bf0" xlink:to="loc_us-gaap_Liabilities_8b6a3fef-26b2-4636-87bc-81ad117f2f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3ac32f29-243e-49c1-b3da-aff819b783b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70a4aa9e-0fbd-490f-b147-cd0898579bf0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3ac32f29-243e-49c1-b3da-aff819b783b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d8233740-a0c9-402c-9a9b-20658799131f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70a4aa9e-0fbd-490f-b147-cd0898579bf0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d8233740-a0c9-402c-9a9b-20658799131f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_df82718a-4c95-4be8-818e-24febb4d39a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d8233740-a0c9-402c-9a9b-20658799131f" xlink:to="loc_us-gaap_PreferredStockValue_df82718a-4c95-4be8-818e-24febb4d39a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0fd5d525-f88e-4c78-8040-d25ee7c964a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d8233740-a0c9-402c-9a9b-20658799131f" xlink:to="loc_us-gaap_CommonStockValue_0fd5d525-f88e-4c78-8040-d25ee7c964a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3a8b9dc4-a142-42a8-b4b8-b686c291542b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d8233740-a0c9-402c-9a9b-20658799131f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3a8b9dc4-a142-42a8-b4b8-b686c291542b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f88b6cdd-4778-4871-ac0f-074b87ab86f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d8233740-a0c9-402c-9a9b-20658799131f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f88b6cdd-4778-4871-ac0f-074b87ab86f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_78a0b1f6-9824-48e2-b685-591a0400f46c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d8233740-a0c9-402c-9a9b-20658799131f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_78a0b1f6-9824-48e2-b685-591a0400f46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_494f44b2-d542-4e30-978e-2642aab5e3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d8233740-a0c9-402c-9a9b-20658799131f" xlink:to="loc_us-gaap_StockholdersEquity_494f44b2-d542-4e30-978e-2642aab5e3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_eca67add-d644-4a5f-89ab-95b7eb2fe424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70a4aa9e-0fbd-490f-b147-cd0898579bf0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_eca67add-d644-4a5f-89ab-95b7eb2fe424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="alny-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_254d874e-855b-4230-a1f7-299e425c7314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fe60868a-1d43-4db9-b347-0cb71fac45d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_254d874e-855b-4230-a1f7-299e425c7314" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fe60868a-1d43-4db9-b347-0cb71fac45d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_dd95f20d-c803-4813-8955-26f6ab6447cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_254d874e-855b-4230-a1f7-299e425c7314" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_dd95f20d-c803-4813-8955-26f6ab6447cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4caded19-9e74-4dc6-abbf-d25af3301e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_254d874e-855b-4230-a1f7-299e425c7314" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4caded19-9e74-4dc6-abbf-d25af3301e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e3237224-4054-4bd3-af0b-bd3239735f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_254d874e-855b-4230-a1f7-299e425c7314" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e3237224-4054-4bd3-af0b-bd3239735f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e4cd0fc8-7661-4893-88f9-096c27e7fd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_254d874e-855b-4230-a1f7-299e425c7314" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e4cd0fc8-7661-4893-88f9-096c27e7fd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_57bbb363-37c1-4b51-86bb-4c32a9de295b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_254d874e-855b-4230-a1f7-299e425c7314" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_57bbb363-37c1-4b51-86bb-4c32a9de295b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_731a1005-5518-4ba1-8846-8c0a40a72787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_254d874e-855b-4230-a1f7-299e425c7314" xlink:to="loc_us-gaap_CommonStockSharesIssued_731a1005-5518-4ba1-8846-8c0a40a72787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dafc1dc5-a8b3-400d-bc54-84f980939e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_254d874e-855b-4230-a1f7-299e425c7314" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dafc1dc5-a8b3-400d-bc54-84f980939e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="alny-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_30e2b0b1-c1d2-4a50-9002-821ae0fe08d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dd241cf5-565b-41ac-82a4-25b34835d626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_30e2b0b1-c1d2-4a50-9002-821ae0fe08d4" xlink:to="loc_us-gaap_StatementTable_dd241cf5-565b-41ac-82a4-25b34835d626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_da36d319-9e10-4174-8c1d-8f805969b689" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dd241cf5-565b-41ac-82a4-25b34835d626" xlink:to="loc_srt_ProductOrServiceAxis_da36d319-9e10-4174-8c1d-8f805969b689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_edc5ad7c-6b66-4cc1-981b-1cc8b46e1101" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_da36d319-9e10-4174-8c1d-8f805969b689" xlink:to="loc_srt_ProductsAndServicesDomain_edc5ad7c-6b66-4cc1-981b-1cc8b46e1101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_853eacb9-1862-400b-bcbb-821dc05e0140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edc5ad7c-6b66-4cc1-981b-1cc8b46e1101" xlink:to="loc_us-gaap_ProductMember_853eacb9-1862-400b-bcbb-821dc05e0140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborationsMember_ff60bbd0-7075-4e1d-87ac-97529dfa2d70" xlink:href="alny-20230331.xsd#alny_CollaborationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edc5ad7c-6b66-4cc1-981b-1cc8b46e1101" xlink:to="loc_alny_CollaborationsMember_ff60bbd0-7075-4e1d-87ac-97529dfa2d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_a2a7f91a-a141-493e-b232-f1843fb45521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edc5ad7c-6b66-4cc1-981b-1cc8b46e1101" xlink:to="loc_us-gaap_RoyaltyMember_a2a7f91a-a141-493e-b232-f1843fb45521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dd241cf5-565b-41ac-82a4-25b34835d626" xlink:to="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8641417a-3c6c-41e7-b9ce-f8ef67b3583f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_RevenuesAbstract_8641417a-3c6c-41e7-b9ce-f8ef67b3583f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84a54221-5cc4-4daa-96e7-5712537b85fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8641417a-3c6c-41e7-b9ce-f8ef67b3583f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84a54221-5cc4-4daa-96e7-5712537b85fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_03bbe88c-b6be-431f-93ae-caef455aca35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_03bbe88c-b6be-431f-93ae-caef455aca35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CostOfCollaborationManufacturingAndRoyalties_79f6549a-2903-495c-81aa-f40ed65b27fe" xlink:href="alny-20230331.xsd#alny_CostOfCollaborationManufacturingAndRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:to="loc_alny_CostOfCollaborationManufacturingAndRoyalties_79f6549a-2903-495c-81aa-f40ed65b27fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_94d7a7a9-975d-45bd-bce7-2bd4dfa79d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_94d7a7a9-975d-45bd-bce7-2bd4dfa79d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_68d0e782-2ed4-41e1-82c8-dc873a513010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_68d0e782-2ed4-41e1-82c8-dc873a513010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c37797d9-9290-4e3f-9476-943483d65c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_43fc3ba5-fb01-44f4-976c-d3cca9abe971" xlink:to="loc_us-gaap_CostsAndExpenses_c37797d9-9290-4e3f-9476-943483d65c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bf24c50d-1f9a-40ed-857a-bbbf7008d836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_OperatingIncomeLoss_bf24c50d-1f9a-40ed-857a-bbbf7008d836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c4bd782-655f-4ecf-adad-64d3806702dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c4bd782-655f-4ecf-adad-64d3806702dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2bd30b25-e2ed-4b16-b649-92f5bc4921e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c4bd782-655f-4ecf-adad-64d3806702dc" xlink:to="loc_us-gaap_InterestExpense_2bd30b25-e2ed-4b16-b649-92f5bc4921e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_868d2ad6-a626-4393-85a8-c9f9b24a25bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c4bd782-655f-4ecf-adad-64d3806702dc" xlink:to="loc_us-gaap_InvestmentIncomeInterest_868d2ad6-a626-4393-85a8-c9f9b24a25bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7bd87020-0f3b-462f-80a0-ffd4b2787a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c4bd782-655f-4ecf-adad-64d3806702dc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7bd87020-0f3b-462f-80a0-ffd4b2787a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_46d98225-1cbb-486d-84c7-545b3f3de7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c4bd782-655f-4ecf-adad-64d3806702dc" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_46d98225-1cbb-486d-84c7-545b3f3de7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33d054a1-b39d-4ac4-aa8a-d0e817bab59f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33d054a1-b39d-4ac4-aa8a-d0e817bab59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6149e559-068a-432d-92ca-5c4b047e83db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6149e559-068a-432d-92ca-5c4b047e83db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1726f44e-e0bf-4b05-ae96-27a6a6c710e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_NetIncomeLoss_1726f44e-e0bf-4b05-ae96-27a6a6c710e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4be553a7-b807-4abf-8559-65ee00543a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_EarningsPerShareBasic_4be553a7-b807-4abf-8559-65ee00543a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d56da973-bd7f-4ba7-ba58-33279d204f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d56da973-bd7f-4ba7-ba58-33279d204f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f76baec9-eae5-4a77-942b-666a98e35c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f76baec9-eae5-4a77-942b-666a98e35c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12b7264a-439f-47fa-9170-9d13071ab534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12b7264a-439f-47fa-9170-9d13071ab534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_50d60f54-37ba-4646-a057-01e8df04b4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4888eef-9992-4df3-a8af-2ae4f013c8c9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_50d60f54-37ba-4646-a057-01e8df04b4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3992dd3a-2f52-4355-af51-b5ad3b8b6624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_50d60f54-37ba-4646-a057-01e8df04b4c0" xlink:to="loc_us-gaap_NetIncomeLoss_3992dd3a-2f52-4355-af51-b5ad3b8b6624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_72c4edf0-a724-4fda-a26a-33685f5ffe10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_50d60f54-37ba-4646-a057-01e8df04b4c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_72c4edf0-a724-4fda-a26a-33685f5ffe10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_133a3701-8c40-4c20-8ec8-60ed9e6c4229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_72c4edf0-a724-4fda-a26a-33685f5ffe10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_133a3701-8c40-4c20-8ec8-60ed9e6c4229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_8479c3a9-d360-46e6-8a3e-ffa587dfb0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_72c4edf0-a724-4fda-a26a-33685f5ffe10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_8479c3a9-d360-46e6-8a3e-ffa587dfb0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_29e5fae9-cefa-4942-9cd8-7f1063a5cf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_72c4edf0-a724-4fda-a26a-33685f5ffe10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_29e5fae9-cefa-4942-9cd8-7f1063a5cf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cd5d2041-8de7-4e20-b4bd-cb166c260fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_72c4edf0-a724-4fda-a26a-33685f5ffe10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cd5d2041-8de7-4e20-b4bd-cb166c260fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e7398273-1d41-445b-9297-c3d97a24dc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_50d60f54-37ba-4646-a057-01e8df04b4c0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e7398273-1d41-445b-9297-c3d97a24dc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="alny-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a3673ac0-602b-4ce6-81bb-65e2abeec7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c4060277-8cee-4b7f-8cd1-e242dcd4a6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a3673ac0-602b-4ce6-81bb-65e2abeec7d7" xlink:to="loc_us-gaap_StatementTable_c4060277-8cee-4b7f-8cd1-e242dcd4a6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_03e06590-fe2d-4dc5-96ec-827a2cc9d9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c4060277-8cee-4b7f-8cd1-e242dcd4a6df" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_03e06590-fe2d-4dc5-96ec-827a2cc9d9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_96b28feb-1277-4003-8baf-164cd556ead6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_03e06590-fe2d-4dc5-96ec-827a2cc9d9d5" xlink:to="loc_us-gaap_EquityComponentDomain_96b28feb-1277-4003-8baf-164cd556ead6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_06be5658-71e1-453b-857d-aa59e5fcde5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96b28feb-1277-4003-8baf-164cd556ead6" xlink:to="loc_us-gaap_CommonStockMember_06be5658-71e1-453b-857d-aa59e5fcde5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_efe06e72-a7ed-408d-b637-fc5fe607cef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96b28feb-1277-4003-8baf-164cd556ead6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_efe06e72-a7ed-408d-b637-fc5fe607cef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3483d57b-71bd-476f-a9e5-b26b53580fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96b28feb-1277-4003-8baf-164cd556ead6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3483d57b-71bd-476f-a9e5-b26b53580fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ece079ac-f354-4e94-a9d9-ce373415d4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96b28feb-1277-4003-8baf-164cd556ead6" xlink:to="loc_us-gaap_RetainedEarningsMember_ece079ac-f354-4e94-a9d9-ce373415d4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b24bf5ac-990e-44fe-91f8-445c55525f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c4060277-8cee-4b7f-8cd1-e242dcd4a6df" xlink:to="loc_us-gaap_StatementLineItems_b24bf5ac-990e-44fe-91f8-445c55525f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b24bf5ac-990e-44fe-91f8-445c55525f6c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_80d3e868-6a85-4a68-9cad-e233d42c052c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_80d3e868-6a85-4a68-9cad-e233d42c052c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d8bcd896-5cdd-45a4-9fad-0fca8dfa3943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_StockholdersEquity_d8bcd896-5cdd-45a4-9fad-0fca8dfa3943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a30727eb-0e33-4275-b52a-80634f426c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a30727eb-0e33-4275-b52a-80634f426c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6487b7bf-5531-4fe2-8f8d-7e7ba3b55ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6487b7bf-5531-4fe2-8f8d-7e7ba3b55ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_a6f2ece3-7cd5-40b1-b4e1-d00e7f00465a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_a6f2ece3-7cd5-40b1-b4e1-d00e7f00465a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_37ec402e-0174-4d46-8e80-f5d6c6ca29e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_37ec402e-0174-4d46-8e80-f5d6c6ca29e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5fa8d41-31cd-4b13-abc1-82280cd4e747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5fa8d41-31cd-4b13-abc1-82280cd4e747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6dce8ca3-9d83-48ae-be1d-31cf678819a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6dce8ca3-9d83-48ae-be1d-31cf678819a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b5c21c4b-f7f7-48e3-bc9c-9183b8aa9504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_NetIncomeLoss_b5c21c4b-f7f7-48e3-bc9c-9183b8aa9504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a5b87d9c-5ba0-421d-abd7-4a6f4ad6fcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a5b87d9c-5ba0-421d-abd7-4a6f4ad6fcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_14560414-e7ff-4a39-beb3-d6e62b4200ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af7143c6-c897-4a98-a9eb-5b5aba57b757" xlink:to="loc_us-gaap_StockholdersEquity_14560414-e7ff-4a39-beb3-d6e62b4200ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="alny-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6b1012a8-54b2-4e72-b5c8-99d20f2169b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f6f4d38a-7eb3-47a6-9af9-525b97556143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b1012a8-54b2-4e72-b5c8-99d20f2169b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f6f4d38a-7eb3-47a6-9af9-525b97556143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_936febb4-ab72-4a20-b818-03d51925bd45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f6f4d38a-7eb3-47a6-9af9-525b97556143" xlink:to="loc_us-gaap_NetIncomeLoss_936febb4-ab72-4a20-b818-03d51925bd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e2327d9-d989-4e28-baad-3a7c8efda851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f6f4d38a-7eb3-47a6-9af9-525b97556143" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e2327d9-d989-4e28-baad-3a7c8efda851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_bff2e53a-31a3-4c82-8465-369b65376314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e2327d9-d989-4e28-baad-3a7c8efda851" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_bff2e53a-31a3-4c82-8465-369b65376314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_8812985b-7400-433a-8787-db41366587dc" xlink:href="alny-20230331.xsd#alny_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e2327d9-d989-4e28-baad-3a7c8efda851" xlink:to="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_8812985b-7400-433a-8787-db41366587dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_88196585-565a-415c-b2d1-dba45092015e" xlink:href="alny-20230331.xsd#alny_NonCashInterestExpenseOnSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e2327d9-d989-4e28-baad-3a7c8efda851" xlink:to="loc_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_88196585-565a-415c-b2d1-dba45092015e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_980142f1-5e05-4f84-8b15-49e026f569fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e2327d9-d989-4e28-baad-3a7c8efda851" xlink:to="loc_us-gaap_ShareBasedCompensation_980142f1-5e05-4f84-8b15-49e026f569fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_fe9abef6-7909-4e01-a4e2-11f5bead1a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e2327d9-d989-4e28-baad-3a7c8efda851" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_fe9abef6-7909-4e01-a4e2-11f5bead1a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ChangeInFairValueOfLiabilityObligation_e7eede25-6287-4510-9792-c2c1e35ea1f0" xlink:href="alny-20230331.xsd#alny_ChangeInFairValueOfLiabilityObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e2327d9-d989-4e28-baad-3a7c8efda851" xlink:to="loc_alny_ChangeInFairValueOfLiabilityObligation_e7eede25-6287-4510-9792-c2c1e35ea1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_1db70c9d-9362-4bcc-9e8d-d20042009c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e2327d9-d989-4e28-baad-3a7c8efda851" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_1db70c9d-9362-4bcc-9e8d-d20042009c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb8de6a4-bb6f-42ce-aed0-f8ed84fba7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e2327d9-d989-4e28-baad-3a7c8efda851" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb8de6a4-bb6f-42ce-aed0-f8ed84fba7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_90305070-4df5-47b3-9494-4ed2e92e9c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb8de6a4-bb6f-42ce-aed0-f8ed84fba7cc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_90305070-4df5-47b3-9494-4ed2e92e9c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4c2cfee7-2704-4cb4-a1c5-92a09583085d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb8de6a4-bb6f-42ce-aed0-f8ed84fba7cc" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4c2cfee7-2704-4cb4-a1c5-92a09583085d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8dc44acd-930d-4d00-9d18-2996addc4e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb8de6a4-bb6f-42ce-aed0-f8ed84fba7cc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8dc44acd-930d-4d00-9d18-2996addc4e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c75caddc-7688-47ef-9ac9-dcf91be5a9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb8de6a4-bb6f-42ce-aed0-f8ed84fba7cc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c75caddc-7688-47ef-9ac9-dcf91be5a9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_22f7199c-2fc0-4b87-920f-92dd3cec1895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb8de6a4-bb6f-42ce-aed0-f8ed84fba7cc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_22f7199c-2fc0-4b87-920f-92dd3cec1895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0bf7e3fc-6524-4038-8c9e-7075fbae6804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb8de6a4-bb6f-42ce-aed0-f8ed84fba7cc" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0bf7e3fc-6524-4038-8c9e-7075fbae6804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5f2f7761-7b7a-4e82-bba1-59dcf3654c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f6f4d38a-7eb3-47a6-9af9-525b97556143" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5f2f7761-7b7a-4e82-bba1-59dcf3654c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ac72db52-ac3b-4e5a-910e-70b6bb8b1d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b1012a8-54b2-4e72-b5c8-99d20f2169b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ac72db52-ac3b-4e5a-910e-70b6bb8b1d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1cc5c4db-51cc-484e-933d-eaeae16e0c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ac72db52-ac3b-4e5a-910e-70b6bb8b1d21" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1cc5c4db-51cc-484e-933d-eaeae16e0c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2c948352-dc78-4c78-9a93-394e800895fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ac72db52-ac3b-4e5a-910e-70b6bb8b1d21" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2c948352-dc78-4c78-9a93-394e800895fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_86cd7ae2-e79e-4a92-aa9e-42bfbe99da0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ac72db52-ac3b-4e5a-910e-70b6bb8b1d21" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_86cd7ae2-e79e-4a92-aa9e-42bfbe99da0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_34678f93-282a-4b48-afbe-9bbd5d03d1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ac72db52-ac3b-4e5a-910e-70b6bb8b1d21" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_34678f93-282a-4b48-afbe-9bbd5d03d1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_2897d1ee-8986-49be-9e1e-917271b38662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ac72db52-ac3b-4e5a-910e-70b6bb8b1d21" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_2897d1ee-8986-49be-9e1e-917271b38662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_524bc69c-d8c8-447e-a5c9-295e8e9d0670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ac72db52-ac3b-4e5a-910e-70b6bb8b1d21" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_524bc69c-d8c8-447e-a5c9-295e8e9d0670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae21b40e-ba6b-45a7-8916-58096429b98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ac72db52-ac3b-4e5a-910e-70b6bb8b1d21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae21b40e-ba6b-45a7-8916-58096429b98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6cacea2c-076d-48f6-8641-f63e680bc73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b1012a8-54b2-4e72-b5c8-99d20f2169b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6cacea2c-076d-48f6-8641-f63e680bc73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f3ddf016-174c-4ab1-8001-87a594f53ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6cacea2c-076d-48f6-8641-f63e680bc73c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f3ddf016-174c-4ab1-8001-87a594f53ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_20e162cb-ac74-40ba-943f-1b85c36deb10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6cacea2c-076d-48f6-8641-f63e680bc73c" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_20e162cb-ac74-40ba-943f-1b85c36deb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b38aa37-27b2-4fd1-8ae2-34a09afc1515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6cacea2c-076d-48f6-8641-f63e680bc73c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b38aa37-27b2-4fd1-8ae2-34a09afc1515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68d299f5-9f01-4737-9fe6-9f314b98d7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b1012a8-54b2-4e72-b5c8-99d20f2169b1" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68d299f5-9f01-4737-9fe6-9f314b98d7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1176c44b-ec37-4cb3-b64b-70d3d050bf0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b1012a8-54b2-4e72-b5c8-99d20f2169b1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1176c44b-ec37-4cb3-b64b-70d3d050bf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a4dfa27-287f-47f2-9bca-fdd372dd9792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b1012a8-54b2-4e72-b5c8-99d20f2169b1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a4dfa27-287f-47f2-9bca-fdd372dd9792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2cb239e8-db60-4070-937f-3d6a5a7bf224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b1012a8-54b2-4e72-b5c8-99d20f2169b1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2cb239e8-db60-4070-937f-3d6a5a7bf224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_988ee3d3-1ad2-466a-9484-acb24c0b80f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b1012a8-54b2-4e72-b5c8-99d20f2169b1" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_988ee3d3-1ad2-466a-9484-acb24c0b80f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_160c2696-511a-412a-bad0-1561b1e8610d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_988ee3d3-1ad2-466a-9484-acb24c0b80f5" xlink:to="loc_us-gaap_InterestPaidNet_160c2696-511a-412a-bad0-1561b1e8610d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f2d8601c-935d-4ba1-afbb-97aadb212835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b1012a8-54b2-4e72-b5c8-99d20f2169b1" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f2d8601c-935d-4ba1-afbb-97aadb212835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7d3f78b9-7720-4ff4-aafc-f970e230b8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f2d8601c-935d-4ba1-afbb-97aadb212835" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7d3f78b9-7720-4ff4-aafc-f970e230b8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="simple" xlink:href="alny-20230331.xsd#NATUREOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87552303-672e-4779-9df9-a791d3e84559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_29ba309b-c312-4b2b-b797-af90e1a0495a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87552303-672e-4779-9df9-a791d3e84559" xlink:to="loc_us-gaap_NatureOfOperations_29ba309b-c312-4b2b-b797-af90e1a0495a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="simple" xlink:href="alny-20230331.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_020f0260-733a-4504-b574-7b2333b07e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_65955312-9495-4e3e-b2c4-6b761806cafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_020f0260-733a-4504-b574-7b2333b07e70" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_65955312-9495-4e3e-b2c4-6b761806cafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUES" xlink:type="simple" xlink:href="alny-20230331.xsd#NETPRODUCTREVENUES"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5243fba5-a1cf-4bf1-acc4-a6746280b403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1aa1f710-8bf1-489b-a09f-37c541733f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5243fba5-a1cf-4bf1-acc4-a6746280b403" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1aa1f710-8bf1-489b-a09f-37c541733f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9ae7aed-6e66-4a3f-97c0-2694011f83dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_239e763d-e848-44ea-aa9c-053988f388f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9ae7aed-6e66-4a3f-97c0-2694011f83dc" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_239e763d-e848-44ea-aa9c-053988f388f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES" xlink:type="simple" xlink:href="alny-20230331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_02a7499e-1c43-4422-b430-447be08ebc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_3563dd2d-3f5b-4f2e-8bae-718f1e3b6e98" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_02a7499e-1c43-4422-b430-447be08ebc9a" xlink:to="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_3563dd2d-3f5b-4f2e-8bae-718f1e3b6e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="alny-20230331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a9645cb1-8b55-468f-9c29-1de69031b49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e62d4a44-c1ee-4f5a-9836-2e6f98e441bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a9645cb1-8b55-468f-9c29-1de69031b49c" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e62d4a44-c1ee-4f5a-9836-2e6f98e441bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="simple" xlink:href="alny-20230331.xsd#MARKETABLEDEBTSECURITIES"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ad848795-eb01-4675-8de4-dfa58aaf7dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_b207f51d-4942-4a7b-a095-c1f8995ae354" xlink:href="alny-20230331.xsd#alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ad848795-eb01-4675-8de4-dfa58aaf7dba" xlink:to="loc_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_b207f51d-4942-4a7b-a095-c1f8995ae354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS" xlink:type="simple" xlink:href="alny-20230331.xsd#OTHERBALANCESHEETDETAILS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0eddc32e-2509-4805-85ce-7a4d9a5d9003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_fcbdd43e-c6a2-40af-a2c8-c0d0fa9aaa24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0eddc32e-2509-4805-85ce-7a4d9a5d9003" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_fcbdd43e-c6a2-40af-a2c8-c0d0fa9aaa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONVERTIBLEDEBT" xlink:type="simple" xlink:href="alny-20230331.xsd#CONVERTIBLEDEBT"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONVERTIBLEDEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_de1b1cd9-57e3-4958-9abc-dbcd512d7e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_31f0bbb1-5799-493e-aacf-5ae95005e2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_de1b1cd9-57e3-4958-9abc-dbcd512d7e7f" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_31f0bbb1-5799-493e-aacf-5ae95005e2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY" xlink:type="simple" xlink:href="alny-20230331.xsd#DEVELOPMENTDERIVATIVELIABILITY"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f439b3ef-1a46-4c71-9073-32604f12d060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_dbd43aee-ed7e-468e-8f08-ae8d8cd1820f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f439b3ef-1a46-4c71-9073-32604f12d060" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_dbd43aee-ed7e-468e-8f08-ae8d8cd1820f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="alny-20230331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63902a58-9962-403b-b76f-166ee58a27ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0358fc75-bdc9-4b39-81dd-c888ee44cc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63902a58-9962-403b-b76f-166ee58a27ec" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0358fc75-bdc9-4b39-81dd-c888ee44cc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="simple" xlink:href="alny-20230331.xsd#NETLOSSPERCOMMONSHARE"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f36ab4d7-c560-471c-9ff3-c246a9654c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e52c00ca-1bb8-4901-8413-1ad2254c4699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f36ab4d7-c560-471c-9ff3-c246a9654c70" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e52c00ca-1bb8-4901-8413-1ad2254c4699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="alny-20230331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24d47920-04c1-4eff-b35d-7b6cb8ffd171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e220ff0c-1a85-4664-8419-a0790478cb54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24d47920-04c1-4eff-b35d-7b6cb8ffd171" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e220ff0c-1a85-4664-8419-a0790478cb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="simple" xlink:href="alny-20230331.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_20d55b8d-8707-4fe6-9785-9c98c356ecda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e12a8542-5ab9-4bee-838c-9cec1a2e96c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20d55b8d-8707-4fe6-9785-9c98c356ecda" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e12a8542-5ab9-4bee-838c-9cec1a2e96c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_4df6c4c9-806a-4fcd-a20d-9be11de8c653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20d55b8d-8707-4fe6-9785-9c98c356ecda" xlink:to="loc_us-gaap_UseOfEstimates_4df6c4c9-806a-4fcd-a20d-9be11de8c653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiquidityPolicyPolicyTextBlock_56a7a495-27ac-46fd-b4b6-ca76ff6ff6d3" xlink:href="alny-20230331.xsd#alny_LiquidityPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20d55b8d-8707-4fe6-9785-9c98c356ecda" xlink:to="loc_alny_LiquidityPolicyPolicyTextBlock_56a7a495-27ac-46fd-b4b6-ca76ff6ff6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESTables" xlink:type="simple" xlink:href="alny-20230331.xsd#NETPRODUCTREVENUESTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8c387ee1-67f1-4404-9be3-f1adece69cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_caa4fa36-3103-4500-912a-413760351109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8c387ee1-67f1-4404-9be3-f1adece69cf2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_caa4fa36-3103-4500-912a-413760351109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_7425b48e-05eb-4430-bbe1-c1a88260d6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8c387ee1-67f1-4404-9be3-f1adece69cf2" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_7425b48e-05eb-4430-bbe1-c1a88260d6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6520b075-2a40-40dd-bb73-1c36fc61106c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_ebc4be67-3dda-45e3-ab66-16b202e05687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6520b075-2a40-40dd-bb73-1c36fc61106c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_ebc4be67-3dda-45e3-ab66-16b202e05687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_02d2db99-8049-4c83-a905-c046ff991e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6520b075-2a40-40dd-bb73-1c36fc61106c" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_02d2db99-8049-4c83-a905-c046ff991e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock_26a470c2-0018-440e-95fc-ea49633898f9" xlink:href="alny-20230331.xsd#alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6520b075-2a40-40dd-bb73-1c36fc61106c" xlink:to="loc_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock_26a470c2-0018-440e-95fc-ea49633898f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_154be0e9-0309-412c-98c0-80a6efd0af04" xlink:href="alny-20230331.xsd#alny_ScheduleOfAllocatedTransactionPriceTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6520b075-2a40-40dd-bb73-1c36fc61106c" xlink:to="loc_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_154be0e9-0309-412c-98c0-80a6efd0af04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_4a50b6ae-85a9-4250-b04e-6471dac81023" xlink:href="alny-20230331.xsd#alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6520b075-2a40-40dd-bb73-1c36fc61106c" xlink:to="loc_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_4a50b6ae-85a9-4250-b04e-6471dac81023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables" xlink:type="simple" xlink:href="alny-20230331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5e09194f-14a1-42c8-9310-cc106425432d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfRoyaltyLiabilityTableTextBlock_00fc6450-3a24-44aa-aa60-2008008630af" xlink:href="alny-20230331.xsd#alny_ScheduleOfRoyaltyLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5e09194f-14a1-42c8-9310-cc106425432d" xlink:to="loc_alny_ScheduleOfRoyaltyLiabilityTableTextBlock_00fc6450-3a24-44aa-aa60-2008008630af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="alny-20230331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_37fc2383-5621-4b64-b4b7-d09e3de639ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_897d2f0b-df7b-4439-9445-e618414f22bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_37fc2383-5621-4b64-b4b7-d09e3de639ad" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_897d2f0b-df7b-4439-9445-e618414f22bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="simple" xlink:href="alny-20230331.xsd#MARKETABLEDEBTSECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2a7ee73d-84d9-4807-ace9-aebb5ac9ef1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1d082de4-aaab-4fc5-b98f-1c634cf57439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2a7ee73d-84d9-4807-ace9-aebb5ac9ef1b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1d082de4-aaab-4fc5-b98f-1c634cf57439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0ba995d0-bdf7-44d0-9fcf-b3a4b26ac929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2a7ee73d-84d9-4807-ace9-aebb5ac9ef1b" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0ba995d0-bdf7-44d0-9fcf-b3a4b26ac929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables" xlink:type="simple" xlink:href="alny-20230331.xsd#OTHERBALANCESHEETDETAILSTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_002a3513-d3e8-4653-8cce-06e1efbd9ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b9e4cac4-408e-4ae2-bbbd-d535a133090d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_002a3513-d3e8-4653-8cce-06e1efbd9ca5" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b9e4cac4-408e-4ae2-bbbd-d535a133090d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock_48e7c007-ed3f-4ece-9475-75f27ce7f96c" xlink:href="alny-20230331.xsd#alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_002a3513-d3e8-4653-8cce-06e1efbd9ca5" xlink:to="loc_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock_48e7c007-ed3f-4ece-9475-75f27ce7f96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f0ae4c2c-db36-4ec0-8e07-54114a4444b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_002a3513-d3e8-4653-8cce-06e1efbd9ca5" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f0ae4c2c-db36-4ec0-8e07-54114a4444b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables" xlink:type="simple" xlink:href="alny-20230331.xsd#DEVELOPMENTDERIVATIVELIABILITYTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dd25d506-72d2-4525-be4a-2286a5c339e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_e65ac3fa-0d95-48cc-a94e-6fb3727a5ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dd25d506-72d2-4525-be4a-2286a5c339e6" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_e65ac3fa-0d95-48cc-a94e-6fb3727a5ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="alny-20230331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df0839b6-b298-40cc-ab53-bb389bd5c93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_44fdfd33-7987-437b-9800-bebac89c81c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df0839b6-b298-40cc-ab53-bb389bd5c93f" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_44fdfd33-7987-437b-9800-bebac89c81c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="simple" xlink:href="alny-20230331.xsd#NETLOSSPERCOMMONSHARETables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_75b65cb1-3ba4-4948-9834-62770c6462db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a629a4c7-d316-4ee9-ae6d-00b6d2d73117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_75b65cb1-3ba4-4948-9834-62770c6462db" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a629a4c7-d316-4ee9-ae6d-00b6d2d73117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NATUREOFBUSINESSDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#NATUREOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NATUREOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9380545e-222d-4282-b1c0-8bc1dde463c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfMarketedProducts_7a239797-3052-4b88-8f5e-a6923b2c697d" xlink:href="alny-20230331.xsd#alny_NumberOfMarketedProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9380545e-222d-4282-b1c0-8bc1dde463c9" xlink:to="loc_alny_NumberOfMarketedProducts_7a239797-3052-4b88-8f5e-a6923b2c697d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfPartneredProducts_5747af4c-d074-4a4e-b705-806c12738e68" xlink:href="alny-20230331.xsd#alny_NumberOfPartneredProducts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9380545e-222d-4282-b1c0-8bc1dde463c9" xlink:to="loc_alny_NumberOfPartneredProducts_5747af4c-d074-4a4e-b705-806c12738e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfCommercializedProducts_fde2529f-3007-4179-bf78-6eb15bd0c578" xlink:href="alny-20230331.xsd#alny_NumberOfCommercializedProducts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9380545e-222d-4282-b1c0-8bc1dde463c9" xlink:to="loc_alny_NumberOfCommercializedProducts_fde2529f-3007-4179-bf78-6eb15bd0c578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5d9a4fb6-ec2f-4e0d-aae1-875a58c935bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_17c75d00-9280-4921-a1bf-0d62e164b82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5d9a4fb6-ec2f-4e0d-aae1-875a58c935bc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_17c75d00-9280-4921-a1bf-0d62e164b82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_18485b04-b367-49cf-bb2a-df6af16cd65f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_17c75d00-9280-4921-a1bf-0d62e164b82c" xlink:to="loc_srt_StatementGeographicalAxis_18485b04-b367-49cf-bb2a-df6af16cd65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ef090490-ce16-4168-a97f-76adc080e196" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_18485b04-b367-49cf-bb2a-df6af16cd65f" xlink:to="loc_srt_SegmentGeographicalDomain_ef090490-ce16-4168-a97f-76adc080e196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_581cdb55-22df-4135-b476-48ec4400e254" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ef090490-ce16-4168-a97f-76adc080e196" xlink:to="loc_country_US_581cdb55-22df-4135-b476-48ec4400e254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_dc01ae5b-01d5-4b81-b175-2f67a97b1a08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ef090490-ce16-4168-a97f-76adc080e196" xlink:to="loc_srt_EuropeMember_dc01ae5b-01d5-4b81-b175-2f67a97b1a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonUSOrEuropeMember_02ccf420-c19e-4f10-87db-133bcbad2071" xlink:href="alny-20230331.xsd#alny_NonUSOrEuropeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ef090490-ce16-4168-a97f-76adc080e196" xlink:to="loc_alny_NonUSOrEuropeMember_02ccf420-c19e-4f10-87db-133bcbad2071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9a6fd5dd-f21a-4863-bd28-2ec969975938" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_17c75d00-9280-4921-a1bf-0d62e164b82c" xlink:to="loc_srt_ProductOrServiceAxis_9a6fd5dd-f21a-4863-bd28-2ec969975938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a9c76037-0014-4388-96d9-9f3f0f27d900" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9a6fd5dd-f21a-4863-bd28-2ec969975938" xlink:to="loc_srt_ProductsAndServicesDomain_a9c76037-0014-4388-96d9-9f3f0f27d900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f4d8590c-eaf3-4aa8-9395-31a6413b0cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a9c76037-0014-4388-96d9-9f3f0f27d900" xlink:to="loc_us-gaap_ProductMember_f4d8590c-eaf3-4aa8-9395-31a6413b0cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ONPATTROMember_c07fb97d-a673-4fe9-9055-63bf3394c7b6" xlink:href="alny-20230331.xsd#alny_ONPATTROMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_f4d8590c-eaf3-4aa8-9395-31a6413b0cd8" xlink:to="loc_alny_ONPATTROMember_c07fb97d-a673-4fe9-9055-63bf3394c7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AmvuttraMember_b2490b2c-99f3-40aa-9ecd-9969be6688f2" xlink:href="alny-20230331.xsd#alny_AmvuttraMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_f4d8590c-eaf3-4aa8-9395-31a6413b0cd8" xlink:to="loc_alny_AmvuttraMember_b2490b2c-99f3-40aa-9ecd-9969be6688f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GIVLAARIMember_873eef84-2c0c-41eb-ae4a-a594222eac26" xlink:href="alny-20230331.xsd#alny_GIVLAARIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_f4d8590c-eaf3-4aa8-9395-31a6413b0cd8" xlink:to="loc_alny_GIVLAARIMember_873eef84-2c0c-41eb-ae4a-a594222eac26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OXLUMOMember_72278e3a-33ef-4ead-ac5f-07ebad24d6d3" xlink:href="alny-20230331.xsd#alny_OXLUMOMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_f4d8590c-eaf3-4aa8-9395-31a6413b0cd8" xlink:to="loc_alny_OXLUMOMember_72278e3a-33ef-4ead-ac5f-07ebad24d6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fb0cc011-8ca7-4f95-8b5f-86451096c416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_17c75d00-9280-4921-a1bf-0d62e164b82c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_fb0cc011-8ca7-4f95-8b5f-86451096c416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_250bbf14-83ab-4836-a4ab-17cea562b1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fb0cc011-8ca7-4f95-8b5f-86451096c416" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_250bbf14-83ab-4836-a4ab-17cea562b1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETPRODUCTREVENUESReceivablesDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0a8c3e01-5696-4a2e-9925-5375e9fce8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cc4907e6-8d01-4e7b-a477-76606e0e4c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0a8c3e01-5696-4a2e-9925-5375e9fce8a4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cc4907e6-8d01-4e7b-a477-76606e0e4c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2b881b24-2fee-4a71-bd8a-19ec7e4e07cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cc4907e6-8d01-4e7b-a477-76606e0e4c82" xlink:to="loc_srt_ProductOrServiceAxis_2b881b24-2fee-4a71-bd8a-19ec7e4e07cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_be5cced8-d8ab-4353-8f6d-55a5f5a3fdb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2b881b24-2fee-4a71-bd8a-19ec7e4e07cf" xlink:to="loc_srt_ProductsAndServicesDomain_be5cced8-d8ab-4353-8f6d-55a5f5a3fdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ffbd55f3-33c9-4891-bb67-6143e1f790a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_be5cced8-d8ab-4353-8f6d-55a5f5a3fdb0" xlink:to="loc_us-gaap_ProductMember_ffbd55f3-33c9-4891-bb67-6143e1f790a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b3dde8bc-dbac-42aa-927a-c429db58db8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cc4907e6-8d01-4e7b-a477-76606e0e4c82" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b3dde8bc-dbac-42aa-927a-c429db58db8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_81fdb33e-b818-4432-a6b2-7174cb8e73d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b3dde8bc-dbac-42aa-927a-c429db58db8c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_81fdb33e-b818-4432-a6b2-7174cb8e73d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9d06c559-47b6-4a95-a557-0738caeffdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc6d7145-5e97-457d-9794-e464c71d02df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9d06c559-47b6-4a95-a557-0738caeffdec" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc6d7145-5e97-457d-9794-e464c71d02df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_42b446c8-fc04-488e-b2d7-eeb4ddfb1346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc6d7145-5e97-457d-9794-e464c71d02df" xlink:to="loc_us-gaap_TypeOfArrangementAxis_42b446c8-fc04-488e-b2d7-eeb4ddfb1346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1e12b35-3170-4184-af6f-25d56843b801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_42b446c8-fc04-488e-b2d7-eeb4ddfb1346" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1e12b35-3170-4184-af6f-25d56843b801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_25468cc1-0a41-4981-873f-f9d43cb16a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1e12b35-3170-4184-af6f-25d56843b801" xlink:to="loc_us-gaap_CollaborativeArrangementMember_25468cc1-0a41-4981-873f-f9d43cb16a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9e005d36-fa65-4070-ba80-bfa9c4bc8c25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc6d7145-5e97-457d-9794-e464c71d02df" xlink:to="loc_srt_CounterpartyNameAxis_9e005d36-fa65-4070-ba80-bfa9c4bc8c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed1cfb6a-ff49-4ad8-8331-9390b919324c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9e005d36-fa65-4070-ba80-bfa9c4bc8c25" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed1cfb6a-ff49-4ad8-8331-9390b919324c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_e7d04eea-e11c-4eee-8b3a-a4b3dafb7aaa" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed1cfb6a-ff49-4ad8-8331-9390b919324c" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_e7d04eea-e11c-4eee-8b3a-a4b3dafb7aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NovartisMember_ae5521d4-9d73-4df9-9bb7-10495605d228" xlink:href="alny-20230331.xsd#alny_NovartisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed1cfb6a-ff49-4ad8-8331-9390b919324c" xlink:to="loc_alny_NovartisMember_ae5521d4-9d73-4df9-9bb7-10495605d228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherCollaborationsMember_6bdb7e0b-b8df-484c-ade6-d8f93cf74cb2" xlink:href="alny-20230331.xsd#alny_OtherCollaborationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed1cfb6a-ff49-4ad8-8331-9390b919324c" xlink:to="loc_alny_OtherCollaborationsMember_6bdb7e0b-b8df-484c-ade6-d8f93cf74cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa105aa7-2ef9-473e-bcfe-c828f066bcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc6d7145-5e97-457d-9794-e464c71d02df" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa105aa7-2ef9-473e-bcfe-c828f066bcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_339a09bd-847b-4fb0-bbba-85c78a0711c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa105aa7-2ef9-473e-bcfe-c828f066bcfe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_339a09bd-847b-4fb0-bbba-85c78a0711c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22efd7ff-86c0-4ea0-9d93-b654f7dc18f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a0522b48-4d0d-4377-b604-cdad4b23f455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22efd7ff-86c0-4ea0-9d93-b654f7dc18f8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a0522b48-4d0d-4377-b604-cdad4b23f455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4d495b62-bbee-459d-9e32-100d93a70627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a0522b48-4d0d-4377-b604-cdad4b23f455" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4d495b62-bbee-459d-9e32-100d93a70627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e11ba183-23b0-4e67-8310-a47c48d71a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4d495b62-bbee-459d-9e32-100d93a70627" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e11ba183-23b0-4e67-8310-a47c48d71a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_611f0d15-1313-4b14-9c2f-6a7e88fc8696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e11ba183-23b0-4e67-8310-a47c48d71a6b" xlink:to="loc_us-gaap_CollaborativeArrangementMember_611f0d15-1313-4b14-9c2f-6a7e88fc8696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82c76b78-3334-43b5-a2ca-152852b03683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a0522b48-4d0d-4377-b604-cdad4b23f455" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82c76b78-3334-43b5-a2ca-152852b03683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4200e462-4e13-47ab-a09c-407d8d0be731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82c76b78-3334-43b5-a2ca-152852b03683" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4200e462-4e13-47ab-a09c-407d8d0be731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e74e4682-1e3c-4777-8bad-0e5936484ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82c76b78-3334-43b5-a2ca-152852b03683" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e74e4682-1e3c-4777-8bad-0e5936484ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_baf4e039-c86f-418d-b1a6-962d6ead0735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_baf4e039-c86f-418d-b1a6-962d6ead0735" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_893f2be0-87d0-4d33-8b04-6f316cd587c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:to="loc_us-gaap_TypeOfArrangementAxis_893f2be0-87d0-4d33-8b04-6f316cd587c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39881dd1-72b3-4a4b-966f-d49268abb17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_893f2be0-87d0-4d33-8b04-6f316cd587c5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39881dd1-72b3-4a4b-966f-d49268abb17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_f754d7ca-c484-4bb7-8297-f11cc7338297" xlink:href="alny-20230331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39881dd1-72b3-4a4b-966f-d49268abb17e" xlink:to="loc_alny_GlobalStrategicCollaborationMember_f754d7ca-c484-4bb7-8297-f11cc7338297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6fe3b3a-f48e-4333-aa77-98fdcf3f946a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6fe3b3a-f48e-4333-aa77-98fdcf3f946a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7aaa4d92-d275-4d7f-b8db-32905e75fe03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6fe3b3a-f48e-4333-aa77-98fdcf3f946a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7aaa4d92-d275-4d7f-b8db-32905e75fe03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtProgramInitiationMember_d9e1f136-ec0f-4a83-a701-5ec73a769d91" xlink:href="alny-20230331.xsd#alny_FundingAtProgramInitiationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7aaa4d92-d275-4d7f-b8db-32905e75fe03" xlink:to="loc_alny_FundingAtProgramInitiationMember_d9e1f136-ec0f-4a83-a701-5ec73a769d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtLeadCandidateIdentificationMember_69703612-c3a5-4c39-8322-9d93d37ebd0a" xlink:href="alny-20230331.xsd#alny_FundingAtLeadCandidateIdentificationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7aaa4d92-d275-4d7f-b8db-32905e75fe03" xlink:to="loc_alny_FundingAtLeadCandidateIdentificationMember_69703612-c3a5-4c39-8322-9d93d37ebd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAnAnnualDiscoveryMember_144688ee-f577-421c-b701-486ad36a6355" xlink:href="alny-20230331.xsd#alny_FundingAnAnnualDiscoveryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7aaa4d92-d275-4d7f-b8db-32905e75fe03" xlink:to="loc_alny_FundingAnAnnualDiscoveryMember_144688ee-f577-421c-b701-486ad36a6355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_66cc64d8-90d1-434f-ab0f-8757d1d97b9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:to="loc_srt_CounterpartyNameAxis_66cc64d8-90d1-434f-ab0f-8757d1d97b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f5dba5d-e37c-415a-9621-513bd6bbf385" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_66cc64d8-90d1-434f-ab0f-8757d1d97b9f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f5dba5d-e37c-415a-9621-513bd6bbf385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_fce66c92-f3c6-4c9b-9c89-8044bf15236e" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f5dba5d-e37c-415a-9621-513bd6bbf385" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_fce66c92-f3c6-4c9b-9c89-8044bf15236e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c41ba0a5-05ec-474e-9e02-f36882ad51b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:to="loc_srt_RangeAxis_c41ba0a5-05ec-474e-9e02-f36882ad51b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f2edf54-0717-4543-aaae-baad42ec50d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c41ba0a5-05ec-474e-9e02-f36882ad51b7" xlink:to="loc_srt_RangeMember_6f2edf54-0717-4543-aaae-baad42ec50d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0f759c1c-912c-4aa4-be39-fba7e08fc883" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6f2edf54-0717-4543-aaae-baad42ec50d1" xlink:to="loc_srt_MaximumMember_0f759c1c-912c-4aa4-be39-fba7e08fc883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69e97150-6369-4c2a-b70c-be5e33aba791" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8b0e2513-1b75-463d-a7d0-a3380213d8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8b0e2513-1b75-463d-a7d0-a3380213d8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_IncreaseDecreaseInResearchAndDevelopmentExpense_d4e9fb52-ae69-4194-9440-eba1d3fae6a2" xlink:href="alny-20230331.xsd#alny_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_IncreaseDecreaseInResearchAndDevelopmentExpense_d4e9fb52-ae69-4194-9440-eba1d3fae6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DiscoveryPeriodOfProgramsDevelopment_2aa6ce05-a60b-43c8-b004-56e347b646d3" xlink:href="alny-20230331.xsd#alny_DiscoveryPeriodOfProgramsDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_DiscoveryPeriodOfProgramsDevelopment_2aa6ce05-a60b-43c8-b004-56e347b646d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_657b33a9-67eb-4c78-9504-d0c69c4ea185" xlink:href="alny-20230331.xsd#alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_657b33a9-67eb-4c78-9504-d0c69c4ea185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchTermExtensionFee_999fdba0-8591-47a9-95b1-f673c242b1d9" xlink:href="alny-20230331.xsd#alny_ResearchTermExtensionFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_ResearchTermExtensionFee_999fdba0-8591-47a9-95b1-f673c242b1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_e1b5fb0b-4ac6-4a26-a064-a0fff610a652" xlink:href="alny-20230331.xsd#alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_e1b5fb0b-4ac6-4a26-a064-a0fff610a652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_UpfrontFeeReceived_8d39a8eb-d078-43a3-b755-7bc979b6641c" xlink:href="alny-20230331.xsd#alny_UpfrontFeeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_UpfrontFeeReceived_8d39a8eb-d078-43a3-b755-7bc979b6641c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_756f5a91-c857-400f-8652-91b2a176cf58" xlink:href="alny-20230331.xsd#alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_756f5a91-c857-400f-8652-91b2a176cf58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfTargetedPrograms_6e67b05c-9562-4cea-b78f-1c1b366d0902" xlink:href="alny-20230331.xsd#alny_NumberOfTargetedPrograms"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_NumberOfTargetedPrograms_6e67b05c-9562-4cea-b78f-1c1b366d0902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeAgreementPeriodOfProgramDevelopment_b69dd9cf-7efa-4f24-9c61-4145be15b534" xlink:href="alny-20230331.xsd#alny_CollaborativeAgreementPeriodOfProgramDevelopment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_CollaborativeAgreementPeriodOfProgramDevelopment_b69dd9cf-7efa-4f24-9c61-4145be15b534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PotentialProceedsFromCollaborationArrangement_867ce891-8270-4427-a96b-ed12b643c351" xlink:href="alny-20230331.xsd#alny_PotentialProceedsFromCollaborationArrangement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_PotentialProceedsFromCollaborationArrangement_867ce891-8270-4427-a96b-ed12b643c351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeAgreementTerminationPeriod_f8db59a9-1e00-4d02-95b2-82469a8c26ed" xlink:href="alny-20230331.xsd#alny_CollaborativeAgreementTerminationPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_CollaborativeAgreementTerminationPeriod_f8db59a9-1e00-4d02-95b2-82469a8c26ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMilestonePayments_6c524b5f-c360-4c74-86b9-b3972d2a6d35" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementMilestonePayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_CollaborativeArrangementMilestonePayments_6c524b5f-c360-4c74-86b9-b3972d2a6d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyRate_cf8a22b4-b12c-405f-a239-ab77f553dcaf" xlink:href="alny-20230331.xsd#alny_RoyaltyRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_RoyaltyRate_cf8a22b4-b12c-405f-a239-ab77f553dcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PercentageOfMaximumRoyaltyPayments_aba14580-577e-4c5f-a4f3-45daa081cfc3" xlink:href="alny-20230331.xsd#alny_PercentageOfMaximumRoyaltyPayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_PercentageOfMaximumRoyaltyPayments_aba14580-577e-4c5f-a4f3-45daa081cfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_eded559b-760f-4a0b-b92d-49054411887e" xlink:href="alny-20230331.xsd#alny_TransactionPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_alny_TransactionPrice_eded559b-760f-4a0b-b92d-49054411887e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_47611de1-9d05-4f55-9d25-7c07304eab14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab9432c6-18ce-46d9-b4c8-151cb644f9fa" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_47611de1-9d05-4f55-9d25-7c07304eab14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7c2b9866-bc70-487a-b71a-c16f9183aeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3b1b205-1742-463a-93df-6af0d98e2cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7c2b9866-bc70-487a-b71a-c16f9183aeb3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3b1b205-1742-463a-93df-6af0d98e2cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_40763e42-56bd-4de6-a60c-97ab13081f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3b1b205-1742-463a-93df-6af0d98e2cc6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_40763e42-56bd-4de6-a60c-97ab13081f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db047ce6-82c1-45ce-bea9-97ba7e690a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40763e42-56bd-4de6-a60c-97ab13081f93" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db047ce6-82c1-45ce-bea9-97ba7e690a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ClinicalTrialAndManufacturingMember_ae0d6a50-a1d0-4e12-9ecb-b01ba7c5f9df" xlink:href="alny-20230331.xsd#alny_ClinicalTrialAndManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db047ce6-82c1-45ce-bea9-97ba7e690a38" xlink:to="loc_alny_ClinicalTrialAndManufacturingMember_ae0d6a50-a1d0-4e12-9ecb-b01ba7c5f9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExternalServicesMember_9c1565c5-1cc2-461c-ba88-cba402185df3" xlink:href="alny-20230331.xsd#alny_ExternalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db047ce6-82c1-45ce-bea9-97ba7e690a38" xlink:to="loc_alny_ExternalServicesMember_9c1565c5-1cc2-461c-ba88-cba402185df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherMember_8a6d0441-4041-4e90-aa61-1c2ab5e7394d" xlink:href="alny-20230331.xsd#alny_OtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db047ce6-82c1-45ce-bea9-97ba7e690a38" xlink:to="loc_alny_OtherMember_8a6d0441-4041-4e90-aa61-1c2ab5e7394d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d8f0f395-58d1-4359-b8ff-339c6dd573d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3b1b205-1742-463a-93df-6af0d98e2cc6" xlink:to="loc_srt_CounterpartyNameAxis_d8f0f395-58d1-4359-b8ff-339c6dd573d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8000e237-dedf-4f5e-be1b-15aedb5409b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d8f0f395-58d1-4359-b8ff-339c6dd573d2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8000e237-dedf-4f5e-be1b-15aedb5409b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_d859d855-434b-496f-8caf-c89ffda24eda" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8000e237-dedf-4f5e-be1b-15aedb5409b7" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_d859d855-434b-496f-8caf-c89ffda24eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherCollaborationsMember_77d540b4-ef4f-429f-b314-746658b5fc11" xlink:href="alny-20230331.xsd#alny_OtherCollaborationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8000e237-dedf-4f5e-be1b-15aedb5409b7" xlink:to="loc_alny_OtherCollaborationsMember_77d540b4-ef4f-429f-b314-746658b5fc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34c4ee4e-c86e-44fa-8275-3f274a8c6c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3b1b205-1742-463a-93df-6af0d98e2cc6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34c4ee4e-c86e-44fa-8275-3f274a8c6c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9e97a8c0-c07c-4cd1-ad0c-a5007fe047b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34c4ee4e-c86e-44fa-8275-3f274a8c6c19" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9e97a8c0-c07c-4cd1-ad0c-a5007fe047b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cc95a348-c92e-40fa-b4c6-b12e4823e75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4722c87-5be8-4523-980c-e76b6c52c108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cc95a348-c92e-40fa-b4c6-b12e4823e75c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4722c87-5be8-4523-980c-e76b6c52c108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dbdf706c-7747-4042-b453-31d0e529f0f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4722c87-5be8-4523-980c-e76b6c52c108" xlink:to="loc_srt_ProductOrServiceAxis_dbdf706c-7747-4042-b453-31d0e529f0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_97ab1bd1-5696-4d06-944e-e6cbe07aeb86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dbdf706c-7747-4042-b453-31d0e529f0f0" xlink:to="loc_srt_ProductsAndServicesDomain_97ab1bd1-5696-4d06-944e-e6cbe07aeb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_9cba4b61-c924-44cb-896e-5466f995f98c" xlink:href="alny-20230331.xsd#alny_ResearchServicesObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97ab1bd1-5696-4d06-944e-e6cbe07aeb86" xlink:to="loc_alny_ResearchServicesObligationMember_9cba4b61-c924-44cb-896e-5466f995f98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_4aff2800-5a34-417c-b7fb-692d8be3af05" xlink:href="alny-20230331.xsd#alny_C5LicenseObligationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97ab1bd1-5696-4d06-944e-e6cbe07aeb86" xlink:to="loc_alny_C5LicenseObligationMember_4aff2800-5a34-417c-b7fb-692d8be3af05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_2b467c6c-c4d0-4b61-851e-2fc4bd0cd554" xlink:href="alny-20230331.xsd#alny_C5CoCoObligationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97ab1bd1-5696-4d06-944e-e6cbe07aeb86" xlink:to="loc_alny_C5CoCoObligationMember_2b467c6c-c4d0-4b61-851e-2fc4bd0cd554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3a1fd335-8e38-4e44-a815-bb2329aaad9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4722c87-5be8-4523-980c-e76b6c52c108" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3a1fd335-8e38-4e44-a815-bb2329aaad9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca54487d-0c5d-4111-8f0e-4400a40bd0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3a1fd335-8e38-4e44-a815-bb2329aaad9e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca54487d-0c5d-4111-8f0e-4400a40bd0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_2cc499dc-7c88-451a-ae7b-e1abb951f391" xlink:href="alny-20230331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca54487d-0c5d-4111-8f0e-4400a40bd0d8" xlink:to="loc_alny_GlobalStrategicCollaborationMember_2cc499dc-7c88-451a-ae7b-e1abb951f391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_30f46c67-4167-4904-a4c3-9a7e433e69f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4722c87-5be8-4523-980c-e76b6c52c108" xlink:to="loc_srt_CounterpartyNameAxis_30f46c67-4167-4904-a4c3-9a7e433e69f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9fad44d-9d8c-4a43-8a73-055debc2b1fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_30f46c67-4167-4904-a4c3-9a7e433e69f2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9fad44d-9d8c-4a43-8a73-055debc2b1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_96b82cff-7b92-4573-b6ee-51d971bc15a0" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9fad44d-9d8c-4a43-8a73-055debc2b1fc" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_96b82cff-7b92-4573-b6ee-51d971bc15a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba8e40a2-0313-417b-86e5-ee54831cfbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4722c87-5be8-4523-980c-e76b6c52c108" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba8e40a2-0313-417b-86e5-ee54831cfbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_StandaloneSellingPrice_7c656ecc-ba0a-459f-b6f2-bcea8c876274" xlink:href="alny-20230331.xsd#alny_StandaloneSellingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba8e40a2-0313-417b-86e5-ee54831cfbd5" xlink:to="loc_alny_StandaloneSellingPrice_7c656ecc-ba0a-459f-b6f2-bcea8c876274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_9b812d9f-2da5-4c0f-8ee2-97d447be8e8e" xlink:href="alny-20230331.xsd#alny_TransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba8e40a2-0313-417b-86e5-ee54831cfbd5" xlink:to="loc_alny_TransactionPrice_9b812d9f-2da5-4c0f-8ee2-97d447be8e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4ce117b6-040f-4b2d-a3d7-86bd0f3d8ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00649093-cc6d-41bc-a17f-ae468e635b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4ce117b6-040f-4b2d-a3d7-86bd0f3d8ae2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00649093-cc6d-41bc-a17f-ae468e635b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8b140194-aebb-41cd-9c13-6855dcc5d8ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00649093-cc6d-41bc-a17f-ae468e635b22" xlink:to="loc_srt_ProductOrServiceAxis_8b140194-aebb-41cd-9c13-6855dcc5d8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ee1b7b8-38cc-4c75-825c-ab2883d226ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8b140194-aebb-41cd-9c13-6855dcc5d8ad" xlink:to="loc_srt_ProductsAndServicesDomain_7ee1b7b8-38cc-4c75-825c-ab2883d226ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_2b7bb709-ca0f-4923-a064-9022c29d2b9c" xlink:href="alny-20230331.xsd#alny_ResearchServicesObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7ee1b7b8-38cc-4c75-825c-ab2883d226ff" xlink:to="loc_alny_ResearchServicesObligationMember_2b7bb709-ca0f-4923-a064-9022c29d2b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_30cd14ec-7cf8-4972-9962-b221c5bc363a" xlink:href="alny-20230331.xsd#alny_C5LicenseObligationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7ee1b7b8-38cc-4c75-825c-ab2883d226ff" xlink:to="loc_alny_C5LicenseObligationMember_30cd14ec-7cf8-4972-9962-b221c5bc363a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_db6f742f-c593-4a1a-ab87-17e055c89cfd" xlink:href="alny-20230331.xsd#alny_C5CoCoObligationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7ee1b7b8-38cc-4c75-825c-ab2883d226ff" xlink:to="loc_alny_C5CoCoObligationMember_db6f742f-c593-4a1a-ab87-17e055c89cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bc97d60a-8af2-4b7d-b95f-b29ff3befb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00649093-cc6d-41bc-a17f-ae468e635b22" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bc97d60a-8af2-4b7d-b95f-b29ff3befb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0122ba46-30b2-4f29-83c7-ce0fc707f379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bc97d60a-8af2-4b7d-b95f-b29ff3befb9e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0122ba46-30b2-4f29-83c7-ce0fc707f379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_1e0f651e-9bab-4654-bc08-33c05489e43c" xlink:href="alny-20230331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0122ba46-30b2-4f29-83c7-ce0fc707f379" xlink:to="loc_alny_GlobalStrategicCollaborationMember_1e0f651e-9bab-4654-bc08-33c05489e43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_763b048b-a681-495b-a712-d930abdb18ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00649093-cc6d-41bc-a17f-ae468e635b22" xlink:to="loc_srt_CounterpartyNameAxis_763b048b-a681-495b-a712-d930abdb18ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3a4373c-a31f-4f09-91a2-aadc05bd5c3c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_763b048b-a681-495b-a712-d930abdb18ed" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3a4373c-a31f-4f09-91a2-aadc05bd5c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_50ac1183-380e-4534-b02a-47f5699f37e0" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3a4373c-a31f-4f09-91a2-aadc05bd5c3c" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_50ac1183-380e-4534-b02a-47f5699f37e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a513b867-90ae-4593-a165-ca6d06794f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00649093-cc6d-41bc-a17f-ae468e635b22" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a513b867-90ae-4593-a165-ca6d06794f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_25544d3a-ef89-4864-b68a-5f65626da608" xlink:href="alny-20230331.xsd#alny_TransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a513b867-90ae-4593-a165-ca6d06794f14" xlink:to="loc_alny_TransactionPrice_25544d3a-ef89-4864-b68a-5f65626da608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d2c36bd6-3a15-4cb8-a768-097cc06f0f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a513b867-90ae-4593-a165-ca6d06794f14" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d2c36bd6-3a15-4cb8-a768-097cc06f0f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_690ee6db-7dad-491a-87d8-9b74a311d58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ba6ff7-5240-47a4-a6ed-061374cbd127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_690ee6db-7dad-491a-87d8-9b74a311d58f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ba6ff7-5240-47a4-a6ed-061374cbd127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_467a0df1-dce9-4824-91df-462698ecd9ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ba6ff7-5240-47a4-a6ed-061374cbd127" xlink:to="loc_srt_CounterpartyNameAxis_467a0df1-dce9-4824-91df-462698ecd9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_46390a75-cffb-4d41-a67f-5d0285926557" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_467a0df1-dce9-4824-91df-462698ecd9ff" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_46390a75-cffb-4d41-a67f-5d0285926557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_698cbc74-c050-4a8e-b695-9f274637a1ff" xlink:href="alny-20230331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_46390a75-cffb-4d41-a67f-5d0285926557" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_698cbc74-c050-4a8e-b695-9f274637a1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2d550d74-de8c-43e2-82c0-265288a6358b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ba6ff7-5240-47a4-a6ed-061374cbd127" xlink:to="loc_srt_ProductOrServiceAxis_2d550d74-de8c-43e2-82c0-265288a6358b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_84464677-8801-41bf-a4d2-7708b128aefa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2d550d74-de8c-43e2-82c0-265288a6358b" xlink:to="loc_srt_ProductsAndServicesDomain_84464677-8801-41bf-a4d2-7708b128aefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_48f047c4-e965-4552-8bdf-6266378acf28" xlink:href="alny-20230331.xsd#alny_ResearchServicesObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_84464677-8801-41bf-a4d2-7708b128aefa" xlink:to="loc_alny_ResearchServicesObligationMember_48f047c4-e965-4552-8bdf-6266378acf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_0fe6ed9b-fbdd-449a-b6a9-9d475ccb9b92" xlink:href="alny-20230331.xsd#alny_C5LicenseObligationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_84464677-8801-41bf-a4d2-7708b128aefa" xlink:to="loc_alny_C5LicenseObligationMember_0fe6ed9b-fbdd-449a-b6a9-9d475ccb9b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_438b10c8-82da-41b1-a139-2c7bb9fc16bc" xlink:href="alny-20230331.xsd#alny_C5CoCoObligationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_84464677-8801-41bf-a4d2-7708b128aefa" xlink:to="loc_alny_C5CoCoObligationMember_438b10c8-82da-41b1-a139-2c7bb9fc16bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3f951810-ae57-422f-8147-985dbdfb0748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ba6ff7-5240-47a4-a6ed-061374cbd127" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3f951810-ae57-422f-8147-985dbdfb0748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73d528d5-588a-422b-b52c-46cc9676c732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3f951810-ae57-422f-8147-985dbdfb0748" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73d528d5-588a-422b-b52c-46cc9676c732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_d1326a10-8890-4a30-ae3e-30c2bd369e3f" xlink:href="alny-20230331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73d528d5-588a-422b-b52c-46cc9676c732" xlink:to="loc_alny_GlobalStrategicCollaborationMember_d1326a10-8890-4a30-ae3e-30c2bd369e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1e41cff0-aacc-415b-9e76-997cf595d48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ba6ff7-5240-47a4-a6ed-061374cbd127" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1e41cff0-aacc-415b-9e76-997cf595d48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e0b34fd7-59ef-4643-982b-3048c70735aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1e41cff0-aacc-415b-9e76-997cf595d48b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e0b34fd7-59ef-4643-982b-3048c70735aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ab87a3ce-e474-4de3-9e4f-9ba18f281e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_3e611658-9675-455d-b4be-bd09e0afc00d" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ab87a3ce-e474-4de3-9e4f-9ba18f281e3b" xlink:to="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_3e611658-9675-455d-b4be-bd09e0afc00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_490aed5f-bd80-4d89-a769-c1bc56cf61c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_3e611658-9675-455d-b4be-bd09e0afc00d" xlink:to="loc_srt_StatementScenarioAxis_490aed5f-bd80-4d89-a769-c1bc56cf61c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8659c69c-0a1a-4742-a172-87129bd689f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_490aed5f-bd80-4d89-a769-c1bc56cf61c3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8659c69c-0a1a-4742-a172-87129bd689f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c4804a63-2ff2-40aa-8111-3898aab7cfcf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8659c69c-0a1a-4742-a172-87129bd689f6" xlink:to="loc_srt_ScenarioForecastMember_c4804a63-2ff2-40aa-8111-3898aab7cfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_75a9a228-88f9-48ef-bb7b-485fc1153d94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_3e611658-9675-455d-b4be-bd09e0afc00d" xlink:to="loc_srt_CounterpartyNameAxis_75a9a228-88f9-48ef-bb7b-485fc1153d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b3d33ff-6ddd-416f-a546-cb254f725344" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_75a9a228-88f9-48ef-bb7b-485fc1153d94" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b3d33ff-6ddd-416f-a546-cb254f725344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneGroupIncMember_babdac3f-ee75-4a36-b4b5-b99c5865dd25" xlink:href="alny-20230331.xsd#alny_BlackstoneGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b3d33ff-6ddd-416f-a546-cb254f725344" xlink:to="loc_alny_BlackstoneGroupIncMember_babdac3f-ee75-4a36-b4b5-b99c5865dd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3c7f624b-2692-4d05-829b-9ba0546a8842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_3e611658-9675-455d-b4be-bd09e0afc00d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3c7f624b-2692-4d05-829b-9ba0546a8842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_63d6e8a6-9d3a-405a-9d6a-1745e28f2957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3c7f624b-2692-4d05-829b-9ba0546a8842" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_63d6e8a6-9d3a-405a-9d6a-1745e28f2957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_98347cf8-d5f2-497e-b9d5-d9125258dcce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_63d6e8a6-9d3a-405a-9d6a-1745e28f2957" xlink:to="loc_us-gaap_CollaborativeArrangementMember_98347cf8-d5f2-497e-b9d5-d9125258dcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_3e611658-9675-455d-b4be-bd09e0afc00d" xlink:to="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_42411f5e-8792-46c0-ae4d-a155a99694b2" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_42411f5e-8792-46c0-ae4d-a155a99694b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_b5a97a35-255d-4de6-9bbd-2f937a92dedc" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_b5a97a35-255d-4de6-9bbd-2f937a92dedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExpectedRoyaltyInterestPayments_79f53ff9-e894-4e25-904f-fdea63a87540" xlink:href="alny-20230331.xsd#alny_ExpectedRoyaltyInterestPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_ExpectedRoyaltyInterestPayments_79f53ff9-e894-4e25-904f-fdea63a87540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementConsiderationReceived_2c8999e2-57d9-4ebc-97c4-e4baf2a0192e" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementConsiderationReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_CollaborativeArrangementConsiderationReceived_2c8999e2-57d9-4ebc-97c4-e4baf2a0192e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent_563ab384-4ef6-4de0-b362-2a2d0bbc1e61" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_RoyaltyLiabilityNoncurrent_563ab384-4ef6-4de0-b362-2a2d0bbc1e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityInterestRate_63e4e12b-01e8-4240-9f62-fd3b08e71b81" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityInterestRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_RoyaltyLiabilityInterestRate_63e4e12b-01e8-4240-9f62-fd3b08e71b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityClosingCosts_bb06ecde-12da-47b6-8f1e-cb78802e3634" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityClosingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_5ab6e0d6-3317-4cbe-bc68-78d064ec77f3" xlink:to="loc_alny_RoyaltyLiabilityClosingCosts_bb06ecde-12da-47b6-8f1e-cb78802e3634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6744594e-a6c8-4fa1-aba9-b2c2638af2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_c11c9c35-d81f-4826-8529-3d02679407dc" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6744594e-a6c8-4fa1-aba9-b2c2638af2fd" xlink:to="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_c11c9c35-d81f-4826-8529-3d02679407dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_968368d3-d995-49d1-8d0d-b22cad469f76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_c11c9c35-d81f-4826-8529-3d02679407dc" xlink:to="loc_srt_CounterpartyNameAxis_968368d3-d995-49d1-8d0d-b22cad469f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cfa917da-e00a-44f2-b7f2-6aa0285e82f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_968368d3-d995-49d1-8d0d-b22cad469f76" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cfa917da-e00a-44f2-b7f2-6aa0285e82f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneGroupIncMember_992abfd9-2eed-4f9a-baca-133bd04055dc" xlink:href="alny-20230331.xsd#alny_BlackstoneGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cfa917da-e00a-44f2-b7f2-6aa0285e82f8" xlink:to="loc_alny_BlackstoneGroupIncMember_992abfd9-2eed-4f9a-baca-133bd04055dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_09e01b56-9707-4a34-b9ed-4ded1308f168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_c11c9c35-d81f-4826-8529-3d02679407dc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_09e01b56-9707-4a34-b9ed-4ded1308f168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1bea5f50-05d2-49c9-adac-78ad77f01b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_09e01b56-9707-4a34-b9ed-4ded1308f168" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1bea5f50-05d2-49c9-adac-78ad77f01b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_1eecd1ea-7fb9-4935-899f-6befa30dae81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1bea5f50-05d2-49c9-adac-78ad77f01b46" xlink:to="loc_us-gaap_CollaborativeArrangementMember_1eecd1ea-7fb9-4935-899f-6befa30dae81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems_3b6fa66d-61b5-4585-bedc-aa1030edc6d1" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_c11c9c35-d81f-4826-8529-3d02679407dc" xlink:to="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems_3b6fa66d-61b5-4585-bedc-aa1030edc6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_c53585d5-d72c-4b8d-8da9-0c0a1c404ce5" xlink:href="alny-20230331.xsd#alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems_3b6fa66d-61b5-4585-bedc-aa1030edc6d1" xlink:to="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_c53585d5-d72c-4b8d-8da9-0c0a1c404ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent_1b163620-f88d-436b-ad40-ac944e6e3f6b" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_c53585d5-d72c-4b8d-8da9-0c0a1c404ce5" xlink:to="loc_alny_RoyaltyLiabilityNoncurrent_1b163620-f88d-436b-ad40-ac944e6e3f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_21fc9ecf-b99c-4c65-9a6d-45819157b951" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_c53585d5-d72c-4b8d-8da9-0c0a1c404ce5" xlink:to="loc_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_21fc9ecf-b99c-4c65-9a6d-45819157b951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityPayments_cb48abff-7876-4dab-90c3-5628bac2042c" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_c53585d5-d72c-4b8d-8da9-0c0a1c404ce5" xlink:to="loc_alny_RoyaltyLiabilityPayments_cb48abff-7876-4dab-90c3-5628bac2042c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent_f43484e9-dcf7-480b-8566-bc49f329a752" xlink:href="alny-20230331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_c53585d5-d72c-4b8d-8da9-0c0a1c404ce5" xlink:to="loc_alny_RoyaltyLiabilityNoncurrent_f43484e9-dcf7-480b-8566-bc49f329a752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_99e85662-e21e-461f-88e2-b3a6307fda8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad97fe65-4633-4e42-b3ed-47ace91df0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_99e85662-e21e-461f-88e2-b3a6307fda8d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad97fe65-4633-4e42-b3ed-47ace91df0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_45fd2ed7-984e-4d0b-99fd-71fc65d195a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad97fe65-4633-4e42-b3ed-47ace91df0c8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_45fd2ed7-984e-4d0b-99fd-71fc65d195a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_55219081-4909-4798-a34b-25853692932d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_45fd2ed7-984e-4d0b-99fd-71fc65d195a9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_55219081-4909-4798-a34b-25853692932d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e30bf417-fedc-4d9e-a115-3fb91b068d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_55219081-4909-4798-a34b-25853692932d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e30bf417-fedc-4d9e-a115-3fb91b068d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_9a14405b-d043-488b-bee1-5390ccff41a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad97fe65-4633-4e42-b3ed-47ace91df0c8" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_9a14405b-d043-488b-bee1-5390ccff41a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9a14405b-d043-488b-bee1-5390ccff41a9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ea184ee5-dee9-4e17-bab7-6963bd9f306c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ea184ee5-dee9-4e17-bab7-6963bd9f306c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_dc9aa9e9-113b-4fa2-a675-dfe00965623e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_dc9aa9e9-113b-4fa2-a675-dfe00965623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3a6b4368-e816-4f80-8bf4-7efe3fe035c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:to="loc_us-gaap_CommercialPaperMember_3a6b4368-e816-4f80-8bf4-7efe3fe035c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_e7a4ebbb-e3f3-4e40-8b84-0fa332a62220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_e7a4ebbb-e3f3-4e40-8b84-0fa332a62220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2d4dfdee-20cb-4e1e-9df5-f1d1c1c7519d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2d4dfdee-20cb-4e1e-9df5-f1d1c1c7519d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d74d33f2-a397-46a1-baa5-7efde60bc181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8969874-691e-4f9a-904e-49989f1c3398" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d74d33f2-a397-46a1-baa5-7efde60bc181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5f1020d5-d601-49c6-83da-1e74d1cd0fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad97fe65-4633-4e42-b3ed-47ace91df0c8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5f1020d5-d601-49c6-83da-1e74d1cd0fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_616cf9ce-5813-451c-ae58-60df5dab3469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5f1020d5-d601-49c6-83da-1e74d1cd0fbf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_616cf9ce-5813-451c-ae58-60df5dab3469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8e93efe8-dfd9-48cf-a64e-1bfd43491d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_616cf9ce-5813-451c-ae58-60df5dab3469" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8e93efe8-dfd9-48cf-a64e-1bfd43491d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_75adfa96-d477-43a7-b8cc-5eceee26099e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_616cf9ce-5813-451c-ae58-60df5dab3469" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_75adfa96-d477-43a7-b8cc-5eceee26099e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c64f26f8-73dc-4d09-b5c5-84db8e69c247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_616cf9ce-5813-451c-ae58-60df5dab3469" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c64f26f8-73dc-4d09-b5c5-84db8e69c247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cb0b0335-20a1-4f58-8ac6-976f0ba0d5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad97fe65-4633-4e42-b3ed-47ace91df0c8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cb0b0335-20a1-4f58-8ac6-976f0ba0d5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cb0b0335-20a1-4f58-8ac6-976f0ba0d5e7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3e393956-b4ed-4180-bac0-4d7e6973fae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3e393956-b4ed-4180-bac0-4d7e6973fae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d38b24f0-9011-4518-aaeb-5fe04000cdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d38b24f0-9011-4518-aaeb-5fe04000cdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_11785e24-dd37-4238-ba42-9ad4bfb09955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_11785e24-dd37-4238-ba42-9ad4bfb09955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_f61ae31e-6a9c-4c52-9094-a0835bb10f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_f61ae31e-6a9c-4c52-9094-a0835bb10f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_26553efe-8f12-475f-85a7-83763ab87ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_21c8adc3-3e14-448d-b4de-1d7bab7aef70" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_26553efe-8f12-475f-85a7-83763ab87ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_745d7790-9ca4-49c6-9966-1ea79306debb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cb0b0335-20a1-4f58-8ac6-976f0ba0d5e7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_745d7790-9ca4-49c6-9966-1ea79306debb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_9c1f83d0-1b00-482c-98ca-88c3a2ef8819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_745d7790-9ca4-49c6-9966-1ea79306debb" xlink:to="loc_us-gaap_DerivativeLiabilities_9c1f83d0-1b00-482c-98ca-88c3a2ef8819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_51c92e15-268d-45ea-bb74-4b16fa3b298d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_96a1b92b-8115-4e0b-9f04-e6634233e22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_51c92e15-268d-45ea-bb74-4b16fa3b298d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_96a1b92b-8115-4e0b-9f04-e6634233e22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8d6be577-163e-4e6f-99fa-996926075575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_96a1b92b-8115-4e0b-9f04-e6634233e22f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8d6be577-163e-4e6f-99fa-996926075575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8d6be577-163e-4e6f-99fa-996926075575" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d2c377a4-12e0-4e33-a148-e772f0358350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d2c377a4-12e0-4e33-a148-e772f0358350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_49e12f2b-3222-421b-8bca-284b51749c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_49e12f2b-3222-421b-8bca-284b51749c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6701d85f-5baa-4b1f-829d-2bfa7e527e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6701d85f-5baa-4b1f-829d-2bfa7e527e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_93989c8c-6e8a-4023-9a3a-934a3ee74bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:to="loc_us-gaap_CommercialPaperMember_93989c8c-6e8a-4023-9a3a-934a3ee74bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b960fcc2-dac1-4a45-91de-539605799270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497ea869-43ff-43b0-ac80-c4227a80ce6e" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b960fcc2-dac1-4a45-91de-539605799270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42aed7a2-c998-437f-ac79-a577fa176829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_96a1b92b-8115-4e0b-9f04-e6634233e22f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42aed7a2-c998-437f-ac79-a577fa176829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0e644f26-213b-40e9-a771-7b76cda8f362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42aed7a2-c998-437f-ac79-a577fa176829" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0e644f26-213b-40e9-a771-7b76cda8f362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5689ec94-805d-4d8a-a532-d4a3f83207fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42aed7a2-c998-437f-ac79-a577fa176829" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5689ec94-805d-4d8a-a532-d4a3f83207fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37104c8e-6b29-4ed2-9e30-2868bdcf2e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42aed7a2-c998-437f-ac79-a577fa176829" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37104c8e-6b29-4ed2-9e30-2868bdcf2e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_da5027f2-4410-40a0-a41d-1dc1089664b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42aed7a2-c998-437f-ac79-a577fa176829" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_da5027f2-4410-40a0-a41d-1dc1089664b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_addef93e-a659-475b-a3ed-7dad0d03573f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e631b367-eb7e-4b95-9b22-b35366aa9215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_addef93e-a659-475b-a3ed-7dad0d03573f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e631b367-eb7e-4b95-9b22-b35366aa9215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f9d892bd-a008-4fc1-89f0-cb9d6631a94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_addef93e-a659-475b-a3ed-7dad0d03573f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f9d892bd-a008-4fc1-89f0-cb9d6631a94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_524f27f4-1bfd-42ab-b82e-219292899deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_addef93e-a659-475b-a3ed-7dad0d03573f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_524f27f4-1bfd-42ab-b82e-219292899deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1afae897-6c5c-496a-a3e3-9fbee244a5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_51097125-7a30-458a-a6aa-e4d8b3bcaa30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1afae897-6c5c-496a-a3e3-9fbee244a5ed" xlink:to="loc_us-gaap_InventoryCurrentTable_51097125-7a30-458a-a6aa-e4d8b3bcaa30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e67814f5-eafd-4f78-bf0c-110e4a1a3be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_51097125-7a30-458a-a6aa-e4d8b3bcaa30" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e67814f5-eafd-4f78-bf0c-110e4a1a3be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0a5704d1-7385-4917-9e87-81802ec495d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e67814f5-eafd-4f78-bf0c-110e4a1a3be0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0a5704d1-7385-4917-9e87-81802ec495d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_e3b93f07-be15-4598-8145-357e43a20296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0a5704d1-7385-4917-9e87-81802ec495d5" xlink:to="loc_us-gaap_OtherAssetsMember_e3b93f07-be15-4598-8145-357e43a20296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_51097125-7a30-458a-a6aa-e4d8b3bcaa30" xlink:to="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_ac8bf49e-c322-4759-a621-4454d0046508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:to="loc_us-gaap_InventoryRawMaterials_ac8bf49e-c322-4759-a621-4454d0046508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_2aaec66f-b0c0-473d-9dc3-7a4cedcc2aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:to="loc_us-gaap_InventoryWorkInProcess_2aaec66f-b0c0-473d-9dc3-7a4cedcc2aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_84081e07-1609-4c23-8c07-5ac426b9c34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:to="loc_us-gaap_InventoryFinishedGoods_84081e07-1609-4c23-8c07-5ac426b9c34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InventoryCurrentAndNoncurrent_3068dd96-c43d-43b2-b908-1c6f8d17ad17" xlink:href="alny-20230331.xsd#alny_InventoryCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:to="loc_alny_InventoryCurrentAndNoncurrent_3068dd96-c43d-43b2-b908-1c6f8d17ad17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_f3317112-573e-40e4-a85e-f71cedfeb62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_92c85e4c-0a03-456f-be85-4f3c69325976" xlink:to="loc_us-gaap_InventoryNoncurrent_f3317112-573e-40e4-a85e-f71cedfeb62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f9ff9c0-cdfc-4044-a268-cbc3e543d918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9302cf6d-71e8-46b3-98f8-742296819122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f9ff9c0-cdfc-4044-a268-cbc3e543d918" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9302cf6d-71e8-46b3-98f8-742296819122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_973fb5fc-9b9d-487a-bef3-19f96dd15625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f9ff9c0-cdfc-4044-a268-cbc3e543d918" xlink:to="loc_us-gaap_RestrictedCash_973fb5fc-9b9d-487a-bef3-19f96dd15625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e543f68b-6b53-4bcd-a1ec-7b75b6ee386c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f9ff9c0-cdfc-4044-a268-cbc3e543d918" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e543f68b-6b53-4bcd-a1ec-7b75b6ee386c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ebd8a02-b3fc-4150-9119-0fa7ed612151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c19854d-7924-4e61-a288-264f5bc291c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ebd8a02-b3fc-4150-9119-0fa7ed612151" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c19854d-7924-4e61-a288-264f5bc291c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_418e7030-bf1a-47e8-9e25-684f01147834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c19854d-7924-4e61-a288-264f5bc291c9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_418e7030-bf1a-47e8-9e25-684f01147834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_418e7030-bf1a-47e8-9e25-684f01147834" xlink:to="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember_69f4ab84-9603-49b9-94c4-76abe276c7d0" xlink:href="alny-20230331.xsd#alny_AccumulatedLossOnInvestmentInJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:to="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember_69f4ab84-9603-49b9-94c4-76abe276c7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2cff8203-dbef-447a-840b-f7587f5f8fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2cff8203-dbef-447a-840b-f7587f5f8fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f52af01e-5884-4a99-b782-ac11ab13960f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f52af01e-5884-4a99-b782-ac11ab13960f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_b60dab43-e48f-4df7-8264-6824979c326b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_b60dab43-e48f-4df7-8264-6824979c326b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_27334c3e-e8ea-412f-ae09-9e19f0f6b2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0a4dd9ec-4d46-4170-9a07-06a968f07ea3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_27334c3e-e8ea-412f-ae09-9e19f0f6b2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_aebe8c4b-1f6c-4fed-8739-db0d6e5c919f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c19854d-7924-4e61-a288-264f5bc291c9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_aebe8c4b-1f6c-4fed-8739-db0d6e5c919f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_aebe8c4b-1f6c-4fed-8739-db0d6e5c919f" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_581e0d39-8cf6-4831-93a1-7d4c45d69c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:to="loc_us-gaap_StockholdersEquity_581e0d39-8cf6-4831-93a1-7d4c45d69c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e3a2f8e3-da88-4c52-af34-37ae8b624bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e3a2f8e3-da88-4c52-af34-37ae8b624bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6ea77358-9ff5-4bdf-a851-8405c136cebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6ea77358-9ff5-4bdf-a851-8405c136cebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5d2e9a3d-5fe8-4322-8183-d39addb34fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5d2e9a3d-5fe8-4322-8183-d39addb34fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e439b6e-db98-471c-8daa-3e55ea438f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_102b49c4-9080-48a8-bc29-071101b6649a" xlink:to="loc_us-gaap_StockholdersEquity_9e439b6e-db98-471c-8daa-3e55ea438f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONVERTIBLEDEBTDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#CONVERTIBLEDEBTDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONVERTIBLEDEBTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3bd4a2bb-a4e9-4d19-ae27-1ccaf507362b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_d58d1848-1c36-4091-a3b4-ec207d39f9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3bd4a2bb-a4e9-4d19-ae27-1ccaf507362b" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_d58d1848-1c36-4091-a3b4-ec207d39f9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_90e22068-315b-4b24-aedd-d3534d66a3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d58d1848-1c36-4091-a3b4-ec207d39f9c0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_90e22068-315b-4b24-aedd-d3534d66a3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7f2b9d40-72aa-4bda-8e20-1f68fe16776a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_90e22068-315b-4b24-aedd-d3534d66a3fc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7f2b9d40-72aa-4bda-8e20-1f68fe16776a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_2c229640-3763-46c1-9fba-211bb54da8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7f2b9d40-72aa-4bda-8e20-1f68fe16776a" xlink:to="loc_us-gaap_ConvertibleDebtMember_2c229640-3763-46c1-9fba-211bb54da8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_63e4838e-d992-4820-b30c-8528ae243eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d58d1848-1c36-4091-a3b4-ec207d39f9c0" xlink:to="loc_us-gaap_DebtInstrumentAxis_63e4838e-d992-4820-b30c-8528ae243eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_268140be-cc01-4bbb-8b66-c0cffb6e8ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_63e4838e-d992-4820-b30c-8528ae243eea" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_268140be-cc01-4bbb-8b66-c0cffb6e8ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleSeniorNotesDue2027Member_049b2c87-76e1-45ec-8668-0c2d8dc25bed" xlink:href="alny-20230331.xsd#alny_ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_268140be-cc01-4bbb-8b66-c0cffb6e8ca6" xlink:to="loc_alny_ConvertibleSeniorNotesDue2027Member_049b2c87-76e1-45ec-8668-0c2d8dc25bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleSeniorNotesDue2027InitialAmountMember_f62b99a0-eacc-42b1-afd8-c7df3058e296" xlink:href="alny-20230331.xsd#alny_ConvertibleSeniorNotesDue2027InitialAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_ConvertibleSeniorNotesDue2027Member_049b2c87-76e1-45ec-8668-0c2d8dc25bed" xlink:to="loc_alny_ConvertibleSeniorNotesDue2027InitialAmountMember_f62b99a0-eacc-42b1-afd8-c7df3058e296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember_31331d15-804f-4084-aa02-861a8f5c4cc5" xlink:href="alny-20230331.xsd#alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_ConvertibleSeniorNotesDue2027Member_049b2c87-76e1-45ec-8668-0c2d8dc25bed" xlink:to="loc_alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember_31331d15-804f-4084-aa02-861a8f5c4cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleSeniorNotesDue2025Member_bf23bb27-24c3-49b1-ae10-99160776b914" xlink:href="alny-20230331.xsd#alny_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_268140be-cc01-4bbb-8b66-c0cffb6e8ca6" xlink:to="loc_alny_ConvertibleSeniorNotesDue2025Member_bf23bb27-24c3-49b1-ae10-99160776b914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_ac09717e-1111-450f-8dc1-1df15a30900a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CallOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_268140be-cc01-4bbb-8b66-c0cffb6e8ca6" xlink:to="loc_us-gaap_CallOptionMember_ac09717e-1111-450f-8dc1-1df15a30900a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentConvertibleTermsOfConversionAxis_5fd0e6b2-3c76-414c-a8fd-6533d22c995d" xlink:href="alny-20230331.xsd#alny_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d58d1848-1c36-4091-a3b4-ec207d39f9c0" xlink:to="loc_alny_DebtInstrumentConvertibleTermsOfConversionAxis_5fd0e6b2-3c76-414c-a8fd-6533d22c995d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentConvertibleTermsOfConversionDomain_6e82c469-e72e-431f-8409-83006532e9ae" xlink:href="alny-20230331.xsd#alny_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_DebtInstrumentConvertibleTermsOfConversionAxis_5fd0e6b2-3c76-414c-a8fd-6533d22c995d" xlink:to="loc_alny_DebtInstrumentConvertibleTermsOfConversionDomain_6e82c469-e72e-431f-8409-83006532e9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtConversionTermsOneMember_ec7dd500-f0d9-49fc-864e-863d6f1963d0" xlink:href="alny-20230331.xsd#alny_DebtConversionTermsOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_DebtInstrumentConvertibleTermsOfConversionDomain_6e82c469-e72e-431f-8409-83006532e9ae" xlink:to="loc_alny_DebtConversionTermsOneMember_ec7dd500-f0d9-49fc-864e-863d6f1963d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtConversionTermsTwoMember_fbfc13c7-8cd8-4ab4-863e-7949af851e34" xlink:href="alny-20230331.xsd#alny_DebtConversionTermsTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_DebtInstrumentConvertibleTermsOfConversionDomain_6e82c469-e72e-431f-8409-83006532e9ae" xlink:to="loc_alny_DebtConversionTermsTwoMember_fbfc13c7-8cd8-4ab4-863e-7949af851e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d58d1848-1c36-4091-a3b4-ec207d39f9c0" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e1ad9d8b-1707-41bd-9e41-53c0aa385716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e1ad9d8b-1707-41bd-9e41-53c0aa385716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_24228789-3e82-4cea-ab3a-f0b51705d802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_24228789-3e82-4cea-ab3a-f0b51705d802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5a90c473-16a1-4fa1-9dc0-3d73c90aed94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5a90c473-16a1-4fa1-9dc0-3d73c90aed94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_41cf938b-afd5-4537-8ca3-0cd6730f2d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_41cf938b-afd5-4537-8ca3-0cd6730f2d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cc4cebe8-14d2-4986-8d2f-b7496695671c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cc4cebe8-14d2-4986-8d2f-b7496695671c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_de65ea93-b09c-475c-9b4f-f23fe0f2272a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_de65ea93-b09c-475c-9b4f-f23fe0f2272a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c6705ced-315a-42c8-b7e9-791a17e7f0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c6705ced-315a-42c8-b7e9-791a17e7f0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ConvertibleDebtPremiumRecognizedFromConversionRate_1584f8b5-e2d9-4800-ac09-6aaa06f2185d" xlink:href="alny-20230331.xsd#alny_ConvertibleDebtPremiumRecognizedFromConversionRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_alny_ConvertibleDebtPremiumRecognizedFromConversionRate_1584f8b5-e2d9-4800-ac09-6aaa06f2185d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e52ea6a9-5db2-464b-a047-7a06112f4e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e52ea6a9-5db2-464b-a047-7a06112f4e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_e7aeacdf-d39a-4b4d-b75c-b051ba0f4262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_e7aeacdf-d39a-4b4d-b75c-b051ba0f4262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_700dd600-8e0d-4940-8945-a14d0613e56f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_LongTermDebtFairValue_700dd600-8e0d-4940-8945-a14d0613e56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCapPrice_4d6954e7-2aa5-49a9-8701-b871b52eb688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCapPrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_us-gaap_DerivativeCapPrice_4d6954e7-2aa5-49a9-8701-b871b52eb688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PremiumRecognizedOnCappedCallTransactions_beeec44c-9c32-4136-b750-de50bb869efb" xlink:href="alny-20230331.xsd#alny_PremiumRecognizedOnCappedCallTransactions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_alny_PremiumRecognizedOnCappedCallTransactions_beeec44c-9c32-4136-b750-de50bb869efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes_38ea5ff1-dccd-44f0-b8eb-76e74cdbb78e" xlink:href="alny-20230331.xsd#alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8b74d797-bb0c-47dc-beee-01dcc9eccbcf" xlink:to="loc_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes_38ea5ff1-dccd-44f0-b8eb-76e74cdbb78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_99ef943c-7526-4148-a4f6-e3153ea44eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_99ef943c-7526-4148-a4f6-e3153ea44eba" xlink:to="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cd3bb24f-65b8-4a41-89b4-e5dcb05747e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cd3bb24f-65b8-4a41-89b4-e5dcb05747e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0eba9151-df78-4766-bdfe-7fff8d79b691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cd3bb24f-65b8-4a41-89b4-e5dcb05747e0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0eba9151-df78-4766-bdfe-7fff8d79b691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b804534a-6787-4d75-a2ae-8fef8bf0f44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0eba9151-df78-4766-bdfe-7fff8d79b691" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b804534a-6787-4d75-a2ae-8fef8bf0f44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3d2eeb8b-7dcf-49a1-9e90-eebedb698366" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:to="loc_srt_CounterpartyNameAxis_3d2eeb8b-7dcf-49a1-9e90-eebedb698366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c5c0828-b896-4f90-a0cc-eac162a33f6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3d2eeb8b-7dcf-49a1-9e90-eebedb698366" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c5c0828-b896-4f90-a0cc-eac162a33f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneLifeSciencesMember_4d9e060f-25cd-43bc-9977-eb022cc62df6" xlink:href="alny-20230331.xsd#alny_BlackstoneLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c5c0828-b896-4f90-a0cc-eac162a33f6a" xlink:to="loc_alny_BlackstoneLifeSciencesMember_4d9e060f-25cd-43bc-9977-eb022cc62df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f603bca3-9d0e-43c4-9715-bf1132698914" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:to="loc_srt_ProductOrServiceAxis_f603bca3-9d0e-43c4-9715-bf1132698914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f603bca3-9d0e-43c4-9715-bf1132698914" xlink:to="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VutrisiranAndZilebesiranMember_9290b230-81cb-4a49-a5d8-30d70751b3de" xlink:href="alny-20230331.xsd#alny_VutrisiranAndZilebesiranMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:to="loc_alny_VutrisiranAndZilebesiranMember_9290b230-81cb-4a49-a5d8-30d70751b3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_HELIOSBPhase3ClinicalTrialMember_eb534aff-9075-422c-8795-4041115709fc" xlink:href="alny-20230331.xsd#alny_HELIOSBPhase3ClinicalTrialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:to="loc_alny_HELIOSBPhase3ClinicalTrialMember_eb534aff-9075-422c-8795-4041115709fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ALNAGTPhase2ClinicalTrialMember_925cde54-0010-4005-8c84-39dbf2abea4b" xlink:href="alny-20230331.xsd#alny_ALNAGTPhase2ClinicalTrialMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:to="loc_alny_ALNAGTPhase2ClinicalTrialMember_925cde54-0010-4005-8c84-39dbf2abea4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ALNAGTPhase3ClinicalTrialMember_fc59693d-271d-45fd-b018-4c7173196c2d" xlink:href="alny-20230331.xsd#alny_ALNAGTPhase3ClinicalTrialMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:to="loc_alny_ALNAGTPhase3ClinicalTrialMember_fc59693d-271d-45fd-b018-4c7173196c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VutrisiranMember_1976771a-84c6-45b8-a296-f6c04eb77248" xlink:href="alny-20230331.xsd#alny_VutrisiranMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_215d2f9d-c77d-400a-9a9c-8ab06549e832" xlink:to="loc_alny_VutrisiranMember_1976771a-84c6-45b8-a296-f6c04eb77248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_97eb5bb6-1869-46a3-b615-b2ae2bdb56d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:to="loc_dei_LegalEntityAxis_97eb5bb6-1869-46a3-b615-b2ae2bdb56d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0fc91169-f773-4457-8584-e3bbc175c160" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_97eb5bb6-1869-46a3-b615-b2ae2bdb56d1" xlink:to="loc_dei_EntityDomain_0fc91169-f773-4457-8584-e3bbc175c160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneLifeSciencesMember_0a1df650-041f-494e-b0b7-0ceb22918f45" xlink:href="alny-20230331.xsd#alny_BlackstoneLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0fc91169-f773-4457-8584-e3bbc175c160" xlink:to="loc_alny_BlackstoneLifeSciencesMember_0a1df650-041f-494e-b0b7-0ceb22918f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9efddc89-35a5-4cef-8bda-5b7471918be9" xlink:to="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMaximumFunding_80dcba27-4da6-4088-9ab1-bf0c711732af" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementMaximumFunding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_alny_CollaborativeArrangementMaximumFunding_80dcba27-4da6-4088-9ab1-bf0c711732af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesPayablePercent_a7f4d749-8813-42aa-87b6-28d938fa858a" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementRoyaltiesPayablePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_alny_CollaborativeArrangementRoyaltiesPayablePercent_a7f4d749-8813-42aa-87b6-28d938fa858a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesPayableTerm_a4ed8d17-3cff-43b0-9329-c14c3e45e0ac" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementRoyaltiesPayableTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_alny_CollaborativeArrangementRoyaltiesPayableTerm_a4ed8d17-3cff-43b0-9329-c14c3e45e0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementFixedPaymentMultiplier_4925c83c-c70b-434b-ae20-80f11cc951ab" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementFixedPaymentMultiplier"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_alny_CollaborativeArrangementFixedPaymentMultiplier_4925c83c-c70b-434b-ae20-80f11cc951ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementFixedPaymentTerm_fb89cba7-76fe-4547-9dc4-f8e15ebb5a93" xlink:href="alny-20230331.xsd#alny_CollaborativeArrangementFixedPaymentTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_alny_CollaborativeArrangementFixedPaymentTerm_fb89cba7-76fe-4547-9dc4-f8e15ebb5a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_288b81b0-821d-4841-bbd2-6a348c1c5f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5fa83e2a-f0e2-4a02-83d0-9826d7bf8833" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_288b81b0-821d-4841-bbd2-6a348c1c5f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails" xlink:type="simple" xlink:href="alny-20230331.xsd#DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_db699a5c-7087-4d5e-a886-0bed93149898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_62e962b0-c268-4612-8b83-afa8e56f0634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_db699a5c-7087-4d5e-a886-0bed93149898" xlink:to="loc_us-gaap_DerivativeTable_62e962b0-c268-4612-8b83-afa8e56f0634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6ae96406-a342-4aa4-a8ba-103d3032afa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_62e962b0-c268-4612-8b83-afa8e56f0634" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6ae96406-a342-4aa4-a8ba-103d3032afa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f7f10d6-2925-4431-838b-7341f2f4c71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6ae96406-a342-4aa4-a8ba-103d3032afa5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f7f10d6-2925-4431-838b-7341f2f4c71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember_7446b793-088b-4d32-8576-ae1a35992119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f7f10d6-2925-4431-838b-7341f2f4c71f" xlink:to="loc_us-gaap_DerivativeMember_7446b793-088b-4d32-8576-ae1a35992119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_489c6f75-b86f-4c69-aa3b-b8876a09f00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_62e962b0-c268-4612-8b83-afa8e56f0634" xlink:to="loc_us-gaap_DerivativeLineItems_489c6f75-b86f-4c69-aa3b-b8876a09f00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20a886ec-61e4-4e93-afa2-59114f927c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_489c6f75-b86f-4c69-aa3b-b8876a09f00c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20a886ec-61e4-4e93-afa2-59114f927c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ca7db111-c9bf-4ab1-90df-7643b57b2a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20a886ec-61e4-4e93-afa2-59114f927c5c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ca7db111-c9bf-4ab1-90df-7643b57b2a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b38f8fea-3119-475f-a9b8-8d484e46a345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20a886ec-61e4-4e93-afa2-59114f927c5c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b38f8fea-3119-475f-a9b8-8d484e46a345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89148e4c-eef9-4404-93de-d5d40488a593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20a886ec-61e4-4e93-afa2-59114f927c5c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_89148e4c-eef9-4404-93de-d5d40488a593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5d596259-5e97-4860-b7a1-f3f51edc8140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_20a886ec-61e4-4e93-afa2-59114f927c5c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5d596259-5e97-4860-b7a1-f3f51edc8140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea4359d0-1b2d-4d15-8aa9-396e3f8dd1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9099a4b-6dc5-47ba-98a7-7b7cc5abc4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea4359d0-1b2d-4d15-8aa9-396e3f8dd1fc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9099a4b-6dc5-47ba-98a7-7b7cc5abc4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d3b3ac8a-a6f3-4e72-a971-a5a3e4282889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9099a4b-6dc5-47ba-98a7-7b7cc5abc4dd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d3b3ac8a-a6f3-4e72-a971-a5a3e4282889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f40be050-1f9e-4afe-a868-4910a197809e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d3b3ac8a-a6f3-4e72-a971-a5a3e4282889" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f40be050-1f9e-4afe-a868-4910a197809e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8fdddeba-7244-4a61-b160-bd2bde212dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f40be050-1f9e-4afe-a868-4910a197809e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8fdddeba-7244-4a61-b160-bd2bde212dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2d6e8e33-91d2-4ccf-b44a-e08f696f3662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f40be050-1f9e-4afe-a868-4910a197809e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2d6e8e33-91d2-4ccf-b44a-e08f696f3662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4cea4bd-41e0-4bee-a1f0-357da5fdb1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9099a4b-6dc5-47ba-98a7-7b7cc5abc4dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4cea4bd-41e0-4bee-a1f0-357da5fdb1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7a13c800-0f02-41b4-94b7-5d61f55b9095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4cea4bd-41e0-4bee-a1f0-357da5fdb1e2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7a13c800-0f02-41b4-94b7-5d61f55b9095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="simple" xlink:href="alny-20230331.xsd#NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_92bc19f5-b8fa-4050-bb27-9fc17b7650dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b459a36e-d982-4c44-9cd6-8c994e8ef9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92bc19f5-b8fa-4050-bb27-9fc17b7650dd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b459a36e-d982-4c44-9cd6-8c994e8ef9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d3bed91-c022-4329-96cd-b61c82b7d599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b459a36e-d982-4c44-9cd6-8c994e8ef9cc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d3bed91-c022-4329-96cd-b61c82b7d599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c14beb13-8299-4719-8c85-8ce978cea9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d3bed91-c022-4329-96cd-b61c82b7d599" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c14beb13-8299-4719-8c85-8ce978cea9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f03ddc04-9a7c-4b47-83c3-634471f2e20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c14beb13-8299-4719-8c85-8ce978cea9b8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f03ddc04-9a7c-4b47-83c3-634471f2e20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_59c4017d-69c4-4d94-9ca9-67ac780ab12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c14beb13-8299-4719-8c85-8ce978cea9b8" xlink:to="loc_us-gaap_RestrictedStockMember_59c4017d-69c4-4d94-9ca9-67ac780ab12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_417a3ddb-e6a8-41dc-b689-ec0868272082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c14beb13-8299-4719-8c85-8ce978cea9b8" xlink:to="loc_us-gaap_ConvertibleDebtMember_417a3ddb-e6a8-41dc-b689-ec0868272082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8726a6bb-572b-4bc8-b394-c7c657c6b1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b459a36e-d982-4c44-9cd6-8c994e8ef9cc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8726a6bb-572b-4bc8-b394-c7c657c6b1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_39880395-0b8a-40c7-9f04-382190d1c983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8726a6bb-572b-4bc8-b394-c7c657c6b1a7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_39880395-0b8a-40c7-9f04-382190d1c983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>alny-20230331_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 alny-20230331_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0!P17AI9@  34T *@    @ !@$Q  (
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M.QC7KPHJ+G]I\J\W_P "^I^A]%%?)?\ P6__ &FO''[('_!-[QOX^^'>M_\
M".^+-'N-/2TOOL=O=^4);V&*0>7.CQG*.PY4XSD8/-8Q7-.,%]II?-M)?BS;
MHWV3?W*_Z'UI17\_?[+O[5W_  5?_;0^$MOXZ^&FO?\ "2>%;NXEM8K[[#X/
ML]\D3;9%\NXCCD&#QDK@]LUN_#'_ (+U?M8_\$\?VH]/\!_M=>'UU72[R9)+
M]Y]*M+/4;2UD(07%I-8A;:XC0JYP%?<=Z[P0,>[_ *O5O:>QC4@Y_P O-J_D
MTCQ8YY2</:NG/D_FY=%TW3?70_>>BOC_ /X*VZG^U)K/P'\'7G[(<J3^)KO5
M1-J<B'1RLFG-;N58'4OW6#(8S\GS?AFO>/V0/^%A?\,N^ _^%L?\E+_L6W_X
M27_CV_X_M@\[_CV_<?>S_JOD].*\GZN_8NJVM)<O+?WMKWMVZ7[Z'IK$)U%3
M2;35[_9WM:_?K;L>D4445SFX4444 %%8OQ'U:XT'X>:]?6DGDW5EIUQ/"^T-
ML=8F93@Y!P0.",5^67_!M9_P4S^-W[?WCWXKV7Q<\;?\)9:^&K#3I]-3^Q["
MP^S/+).LAS:P1%LA%X;(&.,<UU87"3KQJSA;]VDW?LVTK?=Y'-BL5"@Z:G?]
MXVE;NK;_ 'KN?K/17Y_I_P -V_\ #WD[O^34?[6X_P"1>_X\_L/_ (,/^/K_
M (%_P&OT J*E'DIPJ<R?.KV3U7E)='Y%TZW-4G3Y6N5VNUH_-/JO,****P-@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JOJNJ6^B:7<WMU*D%K9Q---(YPL:*"68GT !-6*^%_\
M@XC_ &NE_93_ ."9WBZ"SO3:^(OB&5\+:6$)$A$X)N6!'3;;K+SV++ZT<LY-
M0I_%)I+U;LOE=ZE1<5[U3X5=OT6K_ _/7_@C]'=_\%2?^"]GQ ^/6JPF;0/!
MCW.L661^[BW#[%IL1!SR(0TG^]"37(^(+N;_ ((^?\'*)N8V;3?!7C37%DE'
M"Q/I6L,-_7HD-RQ/&/\ CV%8/_!./_@B5^V1X]_9RT?XD_"#XQ:7\)]"^(4
MO!9Q>,-9T6\O(HWD2*2=+.W9&!&YDR[?+)GC)%<#_P %:/\ @DI^U#^RM\,]
M,^*WQQ^)>F_%.VCO(M"2^3Q+JFM7VFAQ))&&:]@0I"6# ;6/SN./FS7WT5AJ
M&-ITO:+DA'V+B]VGH_+F;T]/,^)E+$8C"5JOLWS5)>U4ELK*ZMUY5&[['[U?
M\%ACG_@EK\>O^Q+U#_T4:^(O^#0'_DR[XG?]CH/_ $AMZ]%?]JUOVR_^#9_Q
M=XTNKIKS6A\.+_2=9D<YD:^M(V@E=O=R@D^D@KSK_@T!_P"3+OB=_P!CH/\
MTAMZ\6CAI8?#X^A/>/(O6T]_GN>I4Q"Q%;!5H_:YWZ>YM\MC\Y?V5O WQB^,
MO_!7WXO_  ]^"WBY_ >O>/M<\0:7JVOQLZ2:7I:ZBUQ<2(Z?O$<^2B@H58E@
MNY Q8;O_  4J_P""?WQ<_P""$7QH\$_$#PK\:M:\0:AXRFN)AXAM()=+O&NH
M7CDDBN8S/,)XWWJQ\QV5\,&7'7VK_@@Z@;_@X1^,I(!*GQ41D=/^)FE>W?\
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MOY)MGXN?\&>7PLTS5?%_QL\<75O#<:UIMOIND6EPZ[I((IVN)9L'_;:&'/\
MN"OV]\;>#-+^(_@[5/#^N6,&IZ+K=I+8WUI,,QW,$BE'1O8J2/QK^>3_ ((<
M?M?67_!&G]O#XF?"7XZ0S>$+/Q(\&E7NHSQ,8M,O;5Y#;RR8&?LTJ3N1* 0
MT;<(68?JW^W-_P %R_@'^S)^SGK_ (A\,_%+P'XZ\7-9R1Z#H_A[6;?5IKB\
M92(O-$#.(HU8AF:3:,*0,M@'WN)J<Z^(5:C%SA.,>6RNGHKI>KN_G?J>1P[+
MV%.5&M+EJ1D^:[M;7?Y+2_D?0W[-7[%WPI_8ZTB\LOAAX"\-^"XM26);Q].M
M0L]Z(@1'YTIS))MW-C>QY9CU8D_B9#_RMY-_V-9_],E?H1_P0._X*/\ Q@_X
M*0_ OQ)X@^)WA/0]-L= NXM/TWQ#IR26R:]+M8S*8&+ &,>7ET8*3)@*"IK\
M]X?^5O)O^QK/_IDJLKP]>CF\Z>(=Y*E/6]]^1K7T,LRKT:V51G05H^TCI:VR
MF@_X+L_\K#?P;_[E7_TYR5]'_P#!X#_R9G\+?^QT/_I#<5\X?\%V?^5AOX-_
M]RK_ .G.2OH__@\!_P"3,_A;_P!CH?\ TAN*B'^ZX#_KY+_TN)I/_><;_@C_
M .D2/G/]GS_@BO\ M ?\%7/V$?"'COQI\<FT+1K/0X;7P-X,EL);FP%G9Q&W
MMWD"S1QV[R>63YBQRN5<,QYV#NO^#5#]LKXBZO\ '/Q]\#?%NO:QKGA_1=#;
M5=+M]0N6N/[$EMKB&VDAA9R66)EE7]V#L4QY !9B?TR_X)!($_X);? @* H_
MX0O3SP/^F(K\CO\ @V7_ .4QGQF_[%[6?_3O:5Z/UJ5;%8W"32Y(QFTK+1Q;
MUONVW9MOJO-G"L-&GA,)BHM\[E33=WM):JVR2V273>X[_@NS_P K#?P;_P"Y
M5_\ 3G)7T3_P<I_\%._B%\%O%W@_]G_X1ZI?Z'XD\;6J7FKZAITC0ZAY4TQ@
MMK6"52#&9'5RS+AL; " 6S\[?\%V?^5AOX-_]RK_ .G.2I?^#GGPGK7P!_X*
M@?"3XRR6,EUH,FGZ?);.!\CW.G7CRR0DD$ E)(R,YR&/H:Y\#1I5J>74J_PN
M=6Z>SMKK\U?Y'1BZM6E/'U*'Q*%.WET;7R;]-]+7*?QP_P"#:3X]_LQ_!:3X
MP>#?BUJWBSXP6'EWM]H_AZRNX=3:65@LQM;]9S-<2+O)):*,LH8^Q_6#_@F+
MXW_:*\6?L++'\;/"HT+XO:*MS86<VKW$*Q:X$3_1KF?[,TACRQV2'8&.PN%(
M85P/[5__  7I^!?PI_8GU;XC^ OB1X!\7>+;G3%E\/\ AK^T5FOY;N4 1I<V
M:.MQ$B$YDWA" I&02*X_]GO_ (+&_$3]I+_@DE\8/V@_^%9V?A+4_!EK?)X?
M1+R2]M]5>&%2USL:-#Y44CX.&8,8I!QM->?CJ^.KX2JL1#W8/>W*X[*T=OUW
MN]DUV8.C@Z6)HNA/WIWTNVI=;RW_  MM8^0=7_X-WOVFOVZ?B+XL\5?M-_'*
MQ\--8S?:-/N4W>(+20.H:7R83/;I9P(%1<8&=OW< ,?-_P#@BG\>/B%^P]_P
M6)@_9QA^)2^./AS=:E?^'YXK6]:ZTB5HK>:>*YM4+.L$GF* X0XRSJQ;:",G
M_@FQH'P1_P""F>E>+O&W[:'[2FOR>(=#U=I++PUX@\91:387%N\&?/B64Y;#
MLZK%:F/9Y:@@JX6N)_X)DM\,)O\ @XI\'K\)K>6V^%\7B/4(_#BRR3NSP)IU
MRJ/NF8RD.X+#><X8 @=!]%A:=6-6>"KV<53D^6,+03LK-2WYM796M>^S5CQ<
M5.E.DL91^+G5I.3YOM77*M+72OKV6S/9_P#@NS_RL-_!O_N5?_3G)7] -?S_
M '_!=G_E8;^#?_<J_P#ISDK^@&OFL9_R*\+ZU/\ TI'N87_D98GTI_\ I+/G
M_P#X*M?\HT?CQ_V(VK?^DLE?G_\ \&>__)K/Q<_[&JW_ /21:_0#_@JU_P H
MT?CQ_P!B-JW_ *2R5^7_ /P:L?M9?"O]GC]FWXH6/Q ^)?P_\#7VH>)8)[6W
M\0>(;33);F,6JJ719Y%+*#QD C/%/*XN6"QD8[VI_P#I89I)+%8-O;FJ?^D(
M^_?^"^'PSTOXF_\ !)OXP1ZG;QS-HFEIK-E(R!FM[BWE1U9?0D;E)]':OA[_
M (-P/VP8_P!F_P#X)%?';Q3KWG7VC_"W6+G5[>V#G,F^RB<0(>=N^5/3@R$\
MUZ)_P<#?\%@_@W<_L(>*/AG\//B%X9\>>+OB L6GD>'-1BU*WL+02I)/)+/"
M6C7<B^6$W;B7/&%)'!_\$]?^"=7C#1/^#<+XO:7)IMY'XN^+EE>>)M/TUXBL
M[0111?9H]O7=*MN748R1,M&'A.CE.*E5]V,G%*^FJ:;:_P"W5O\ W6BJTHU<
MSPD(6DUS-I:VBU97MYO;SOU/FO\ 9+_8?^.7_!R5XD\;_$SXB?&&?POX5T35
M?L=C;O:2:G:VUR4$GV>TLO/B2&..*1,R;MS%^=[%R/6/^";'[2?QF_X)+?\
M!5JQ_90^*GC"X\9>!/$5Q#IFF27-S)/#9-/$#8W%IYA9X4<A(G@R$4L2.5RW
MR1_P2&_8W_9'_:V\+^)[#X__ !<\1?"OQII-Z&L VOZ;HVF7]DT:])+RWD!F
M602!EWK\K)A3\QK[G_8]_P""5_\ P3UF_:R\,CX<_M)>+O$GC[PCXAMKS3--
M;Q-IC0ZE=VS)<HD1%@@NHSM&3;R$'# ,&4X^EQ'L:%=X:5_8\MN10NK67O*6
M]T_N>FZN?.TG6KTOK"M[;F^)SLTTW[KCM:W3JMM-#SG_ (+T^!]4_P"";O\
MP6!^&/[2WA>">'3_ !-<6^IWAC VRW=IM@O(.F!YUHR YY)=S]/NK_@O[^W7
M8?!K_@DYJ6J>%]2MKFX^,D$&AZ+<Q2;EFM+R(RS3(5/3[*' (XS(M=%_P<+?
ML<C]KO\ X)K>+FL;5;CQ)\/?^*JTH\[L6ZM]I08ZEK<R@#H6"_6OQ!\'?%3Q
M%_P5:G_9 _9LADO9E\&B?1]08-M"PO=N[S#/!\G3H4Q_NL!7AY;AUF.%HX:6
M]&=G_P!>VG+7^ZN7D\M6>YF&(> Q-3&1VJ4W:W_/R-HJWG[RF][_ ('Z%?\
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MV#_V]-2_X*'_ /!%KQ=XU\0?9V\7:7X<UK0M?:!55)[J"S<^<%'"^9$\3E0
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MX+F5E[UXQW>^B?*M=O,^=H45_9$\7=\]-WCK\/O*]EMJVV]+WZV.5_X*S?\
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M#" ,E0N #K?\%VT$G_!PQ\&U8!E8>%001P?^)G)7ZG?\%U_^42?QO_[ 2_\
MI1#7C_7JN%RW"SHVNY3ULGISJZ5]KWUMKMKH>M3P=/%9G7I5K\MH:)M:N.[M
MO:VE]-]&?%_[#6E^,/\ @N/_ ,$$O$'@3QUXZO;'Q!X;\0_V:WB6\LO[3N;R
M&Q^SWL7FKYL1D<I((C(S[CM#-O.<_FU_P1;_ ."4_P#P\^^,WBC3_P#A//\
MA!_^$ AM-5\S^Q/[3^W[IROEX^T0^7]S.<MUZ5^I/_!J+:_;O^"7_P 1(0=O
MG>--03.,XSIUD.E?(/\ P:Z_M'_#S]F#]I#XR_\ "PO''A?P3#?:-!%9S:[J
M,6GQW;Q73[TC:5@&DPP.P$L>< X->W3JU,-C\;#"Z-1A.*23]]QU=K=;+3;R
MW/'J8>&(R_"SQ&MY2@VW]GF=E^,M=_/8_H<B3RXE7KM %?"/_!RG_P H??B3
M_P!?>D_^G&WK[NCD66-64AE89!'<5\(_\'*?_*'WXD_]?>D_^G&WKX.C_'I?
MXX?^EQ/M=/9SMMRR_P#26?(?_!!C_@LA^S?^Q?\ \$\-%\"_$OXC?\(WXJM-
M8U"ZEL?[ U2\V1RR[HV\RWMI(SD<X#9'?%?*_P#P77_;T\,_\%@/VN/AGX4^
M!VEZOXF318I-(L+LV+V\VMW=W+&=L44@#K&FQ?FD"G+.2 !D_5'_  08_P""
M-_[-_P"VA_P3PT7QU\2_AS_PDGBJ[UC4+66^_M_5+/?'%+MC7R[>YCC&!QD+
MD]\U^FO[*_\ P3'^ G[%&HK??#+X8^'?#6J+&\(U,B6]U%4<Y9!=7#R3;2>V
M_& !T %?68[$8'#YD\3.,I5(N]M%&[C;UV9\M@*.,KY?["#BH25KZ\VDK^FZ
M^X_-S_@Z2\#S?#'_ ()E_L_^&[B19;CP_K5IILCKT=H=*EC)'U*U[3XM_P"5
M6&/_ +)%;?\ HJ.O/O\ @\!_Y,S^%O\ V.A_](;BO0?%O_*K#'_V2*V_]%1U
MY=:I*IE%2I+=UDW\X,]##T8TLTI4H;1I67HII'YI?\$>O^"?/QJ_X*F_L[^(
M_ .F_%>Z^&/P3\*ZI)/>K!;/=#6=2N8DW1O;I-")E2*-"3(^U-XVJQ9L=1\/
M_&WQF_X-P?\ @I#X:^'6O>-I?$_PKUZ2VN+FU65TTW4-,N)FC>Z2WD9A;7,3
MB1CM/)3!9E;->K_\&M'_  4@^%G[.GPU^('PO^(WB_0? MUJ&KKXATO4-<O8
M[&QO%:".&6+SY"L:2+Y,;!68;@YQG::\N_X+F?'KP[_P5/\ ^"K'PO\  7P>
MU*W\80Z?#:>&EU333]HM;JZGNFDE:)UR)(8D92TBY7Y9#D@9KZF4JTLZAA91
M_<3MS::-<NLF][J7N[Z;6N?/TJ=!91/$<[56%^775/GV2\XWEYN[O:Z/J3_@
MXK_X*4?$JP^//@G]F'X,:Q?>']<\8+9OJVI6%V;2ZNGO)O)M;))P08D/WI&4
M@L'49"[@WSO^U3_P0?\ C=_P2C^!%Y^T%X#^.UYJ/BGPUY5]XBBTJVGTN>&-
MI$,CK.9W^UH)""Z2QH&4$E3RM8G_  <N_ RU\"?\%6_!_B3QO'K,?PY\::5I
M:W=[I@47(M[9_(O$@9U9//2,*X#!AF1,@@UZ1K?_  2C_P""8WA_P9I^O7'[
M5_B=[+4I(8HHK;QAH]U>H92 OFVL6GM/$ 3\S2(JH,EBH!->1E]J. HU:$N5
MRE+F:CSN5I6Y7V716U?35'J8YRJXV=*O&ZC&+2<N5*\;N2WN[ZW=TM+JUDOT
M;_X)B?MY7O\ P42_X);2>.M;6VC\5V>GZAHNOBW7;&]Y!"<RA< +YD;1R;1P
MID(' K\[/^#.;_DJ/QT_[!6D_P#HZZK]$?\ @F]^R7\%_P!DS]@OQM9_ ?QY
MJ?Q$\$>)FU#5CJEYJMKJ.+G[(L#QJ]O#$JA1"N59=P).3T _.[_@SF_Y*C\=
M/^P5I/\ Z.NJBC[%U,P=!6BX0=K6M=RNK=$G>WD%9551P*K.\N>>J=[KW+:]
M=+7\SG8?^5O)O^QK/_IDKF_^#CWQ9XD\"?\ !;OP/K7@X ^+=*T70;K108Q)
MF]2\G:#Y6X;]X%X/!KI(?^5O)O\ L:S_ .F2D_X+MH)/^#ACX-JP#*P\*@@C
M@_\ $SDKJRQ7J96G_P ^U_Z0<^82:AF+7\__ +>9/_!2_P#X(9_'']GS]F^^
M_:2\:?'V^\??$+PU]FOM8MS%<K/I?F3*";2^:<LPBDE!"B&$ 9*A< ']$?\
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MEO&L2LYRS!0 "3Z\5-7Y]*U]#[2-W%<VX4444B@HHHH **** "BBB@ HHHH
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MU_X@6/BSPK_9_P!DM-+OK2+3I/L4YGB\Q)+:20Y9B&Q(,CIM/-=M_P %(/\
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M$8JMB(*G6DY)=&[_ ->NYU8?#TJ%3VM&*C+NE_7W;'RO_P $TO\ @D1\-O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L/XF_$
MG1?@Y\/-:\5^)+W^S= \.V<NH:A=>3)-]G@C4L[[(U9VP 3A5)/8&MRO#?\
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M8U"CIQM##2LE&;4=N:R?=<L9I^2<9+_AKM84I-Q7-\5KM=O><6O_  *-M/\
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M?^CA/@?_ .%WI?\ \?H^KU?Y7]S#ZQ2_F7WH]PHKP_\ X>;_ +-O_1PGP/\
M_"[TO_X_1_P\W_9M_P"CA/@?_P"%WI?_ ,?H^KU?Y7]S#ZQ2_F7WH]PHKP__
M (>;_LV_]'"? _\ \+O2_P#X_1_P\W_9M_Z.$^!__A=Z7_\ 'Z/J]7^5_<P^
ML4OYE]Z/<**\/_X>;_LV_P#1PGP/_P#"[TO_ ./T?\/-_P!FW_HX3X'_ /A=
MZ7_\?H^KU?Y7]S#ZQ2_F7WH]PHKP_P#X>;_LV_\ 1PGP/_\ "[TO_P"/T?\
M#S?]FW_HX3X'_P#A=Z7_ /'Z/J]7^5_<P^L4OYE]Z/<**\/_ .'F_P"S;_T<
M)\#_ /PN]+_^/T?\/-_V;?\ HX3X'_\ A=Z7_P#'Z/J]7^5_<P^L4OYE]Z/<
M**\/_P"'F_[-O_1PGP/_ /"[TO\ ^/T?\/-_V;?^CA/@?_X7>E__ !^CZO5_
ME?W,/K%+^9?>CW"BO#_^'F_[-O\ T<)\#_\ PN]+_P#C]'_#S?\ 9M_Z.$^!
M_P#X7>E__'Z/J]7^5_<P^L4OYE]Z/<**\/\ ^'F_[-O_ $<)\#__  N]+_\
MC]'_  \W_9M_Z.$^!_\ X7>E_P#Q^CZO5_E?W,/K%+^9?>CW"BO#_P#AYO\
MLV_]'"? _P#\+O2__C]'_#S?]FW_ *.$^!__ (7>E_\ Q^CZO5_E?W,/K%+^
M9?>CW"BO#_\ AYO^S;_T<)\#_P#PN]+_ /C]'_#S?]FW_HX3X'_^%WI?_P ?
MH^KU?Y7]S#ZQ2_F7WH]PHKP__AYO^S;_ -'"? __ ,+O2_\ X_1_P\W_ &;?
M^CA/@?\ ^%WI?_Q^CZO5_E?W,/K%+^9?>CW"BO#_ /AYO^S;_P!'"? __P +
MO2__ (_1_P /-_V;?^CA/@?_ .%WI?\ \?H^KU?Y7]S#ZQ2_F7WH]PHKP_\
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M?>CW"BO#_P#AYO\ LV_]'"? _P#\+O2__C]'_#S?]FW_ *.$^!__ (7>E_\
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M'_\ A=Z7_P#'Z/J]7^5_<P^L4OYE]Z/<**\/_P"'F_[-O_1PGP/_ /"[TO\
M^/T?\/-_V;?^CA/@?_X7>E__ !^CZO5_E?W,/K%+^9?>CW"BO#_^'F_[-O\
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M+O2__C]'_#S?]FW_ *.$^!__ (7>E_\ Q^CZO5_E?W,/K%+^9?>CW"BO#_\
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M<UK/FA4FGOK=][-1?KK+\WW,XVY(JVFB2]5S6^Z*=O*/D;6F_P#!-3X%Z/\
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MKIOIO\BZ^65:3FFTU&,973NFI6M9VUWU]&?'M%%%>@><%%%% !1110 4444
M%?<'_!N#_P IGO@U_P!QO_TQZA7P_7W!_P &X/\ RF>^#7_<;_\ 3'J%<>9?
M[I5_PR_)G7E_^]4_\2_-']4%%%%?DY^FA1110 4444 ?'/\ P68_9GUCXW_
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M** "BBB@ HHHH **** "OYS_ /@[N_Y22^"?^R:6'_ITU6OZ,*_G/_X.[O\
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MNURI:[?<M#LIYK6IRYZ*47>+NKM^[>R]YO34_3L_\%9]*_8^_P"";GP/\%?
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M7]L[XK_$BU^!OP1\?:7X\O+1=-A^)/A0:Y=:3:6D/V>$1$3((FD0!Y%!8;@
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M#QKXHTC4=&TK[#<R?;(()+=I7\Y8S"FT(W#NI.. >*[7]F7_ (*/>#_V9?\
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M?M9?$;X@-))-'XM\0WFHV[.NUA \K&$$8&,1[!C':O6/VH?^"7.O?LF?L2^
M?BYXD\4:-<:GXZU?^S_^$<L MRVDQ/9K=Q//<K(5$S1LA,(3Y5="7R2H^6ZZ
M,#@\+"M.IAWM*2MTBY*%TM-K1C;5I'/C,=B:E"G2K+3EC9]6HNI9O7=N<KZ*
M^C\V4445ZQY(4444 %%%% !1110 4444 %%%% !1110!]X?L;_M4_!?XW?\
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MCBM3X0?LG> _@1X@DU3PSH]Y:7C6IL(#<ZM>7\>G6I<.;:TCN)9$M8-P4^5
M(T^1?E^5<73<5NOU^Q%?C).3ZZZ6UO'+.V^NGE]N3?\ Y*U%>FO2WB,/PR;X
MP_%+]H;4M0\;?$;1+[PCKD-OHD^G>,M3L[+1T71;&X!%DDXM)%$LCNRRPNK;
MF# @XKSKX6_MV_%7Q1\,9O$6G^'5:XOI]#?6]3AT35/$L>BQW/A^TNVF&E07
M:RE'GDV8M=@16\QTD;<Q^G_&/[#WPY\>^,=>UO4]/\1R7'BB9)]9LX?%>K6V
MEZLZ11PC[18QW*VLH,44:%7B(95 8&K7B[]C;X=>-+^]O+K1+RSU"^O8M1>]
MTO6;[2[N&>*U6T5H9K::.2 ?9T6,K$RJRCY@<G,1NJ?+UY8+R3C;F?\ V]U[
MV5[].J4HN=_\7KK:WW6=M[7TZW^;?$'_  4T\;:M>[?!^CZ7XG.@^&].UF_@
MT+P?XA\0IXDN[CS#)9VMQ;1*NG;1"P5[R-F+MM:-0CM72:Y^WIXQTCX\^&])
ML9/ WB;2?%6OWN@PZ+I>FZC]LTUXK6XFB^T:J["T6X,D!C>U,*LC%P)'\IS7
MKVL?L%_"C6[73K>3PO);6NG6":4;>RU:]LH-0M$<NMO>1PS*M[%N9VV7(E!,
MCD@[VRU/V!/A.GBZ#6O^$9N&NK/4YM8M;=]:OWL+*ZF$@GD@M#.;>$2^;)YB
MQQJLFX[PU5*S>G=_<VO7IY673N91TCKO;Y7Y?O\ BU[M;Z:'SF__  4U^('A
M?0H]+\0Z?HMCX[US4-/L+71I? ^O0:AH+S_:#</)8JTSZK!"L&$GL9E69FP5
MA&&.YXB_;L^,%G\/;/4%\&SZ/;6-]J-IJGB:_P#ASK\EC.L"0R6LHTO?'J%K
M;SK*X:=A.L+6[C$F0U>VZ?\ L ?"C3M%O+%?#NH3174<$,4MSX@U*YN=,C@<
MO#'93R7#2V21L=R+;-$$., 8%2ZA^P=\+]2T*SL6T76(6LY+F7[?;>)-3MM4
MNC<A!<"XOH[A;FX641Q[UFE</Y:9!VKA7W?7IVZ6\]+/J[W][FT#[2OMU[];
M^6MUTTM[MM3TCX>^+8?'O@+1=<MKG3[RWUBP@O8Y["8S6LRR1JX:)R%+1G.5
M8J"1@X'2MBJ/AKPWI_@[P[8Z1I5G;Z?I>EV\=I:6L"!(K>)%"HBJ. JJ  /0
M5>JJCBY-PVOIZ$T^912EOU"BBBH*"BBB@ HHHH *^,O^"G7CB^D\<:#X;$C+
MIT%@-29 W$LKR21@D?[*Q\?[YK[-KQ/]LO\ 9<F_: T"SOM(DAA\0:.&6)93
MM2[B;DQEOX6!&5)XY8'KD:T9)3NSX'Q,RG'9CP]7PN7W<WROE6\DFFTOSMUM
M;J?GW7VE_P $R/'-]K?@CQ%H=Q(\EKH<\$MKN.?+6?S-R#VW1EOJQKY]L_V,
M_B9>:O\ 8_\ A%+V.3(!DDEC6%???NVG\"?Y5]J?LL?L^1_L\_#LZ?+-'=ZM
M?R_:+^>,?(6QA43/.U1W/))8\9P.G$5(N-D?AO@]POG5#/HXVK1G2I0C)2<H
MN/-=-**O:_O6EY<NO0X'4/#5U^TG^U5\0_#>O>)O%^C:'X%L-+&E:;X>UZ[T
M1Y9+J*:1[Z:6UDCDF^93$D;,8AY+$HQ.1X?XT^.7CKX-?M6:7K^C_$2\^)G@
M7X?_  ]M9_%]O!*DL6L6_P#:=Y;7>H1QPMY(O;;R59]B[G6&6/@X%?7'Q;_9
M:\$_&W7X-6UW3]4CU:"U:Q^WZ3K=]HUU/;$EC;RRV<T3RPY)/E2%DR2<9-7?
M!_[.G@GX?>((M3T3P[8Z9<PZ%#X9C2W++;QZ=%(\D=N(<^4%#2.<A=QW8)(X
MK@IWBXM=+NW1^[):^K:OUML_=B?UE*S4HOJDK[-6E!NW;1.S[[K5GQIX \9^
M+?CYI=I?Z?KGB?XD>&(-7\47,_A[POX^?0O$<L)UV:*RO8I1<V[36<<"21I$
MUQ'&"% #D +%\2/VK_%+?!'PE-X3\=:Y?7W@_1=6U;6=6U*T^Q75JXOAH]O%
MJ%NCM'));--<R/O+1R2:=YF,'CZ>T[_@GS\)= \):-HNC^&;SP[9^'I+M]-E
MT/7M1TF\LUNI3-<1)=6T\<XA>0[C#O\ +R%PHVKCI_!'[+'P^^'5GJ%KI/A>
MPAM=6TJ+1+VWE9[B&ZLXWG<1.DC,I#/<SLY(W2-*Q<L>:O11Y5M^>DK7:\VM
M;-Z6V20IMRJ.?=W\DFU=6]+Z7M=ZIMMGCOQ,\/S_ +&OC/X;ZSH?C+QWKL?B
MC7O[%UW3M>\07>M)K$36=U<-<0Q3NXMIHVA#XMEBC*;E*8V[<GP'^US\8=2^
M'_PJ\;:M8_#B7PK\6M8T:&T@L;>\6^T6VOC*S0REI6CFD6/R<3@QC>74P$8:
MO;/AI^R#\/\ X2^)H=8T?2=0DO[.%[:Q;4];O]6328GX>*SCNII4M$8?*5@5
M%*@+C  '/VW_  3K^#]EI][:P^%;B..\,7E,NN:@)-*6*?[1&E@_G[K!%F_>
M!+4Q*& (' HC*TDY:KFB_P#MU/6-NSMH]+:I::.)1O!I:/E:^>MI7[J^VM[)
MMIGCOBO]KWQ-/^T3-/\ VKX?TG3_  D?&>G1Q7NHSV&C7/V)-),$M\R^9ED:
M>4%E0E0Q"J"3G)T?]O\ ^*6O?%AOA[IMY\/=3UB7Q!HVFP>(F\):KI]A]GOK
M/4II"ME/=B28Q/8<2I<>7('*X1E)'T!:?\$__A'::%<:;_PB9FM+H:CYPN-5
MO;AYFO\ R/M;L[S%S)(;>%MY.Y63<I5BQ,WA#]A/X8>!_&\/B:RT/4YO$$-U
M;7IU&_\ $.I:A=3SVT=Q%!)+)<7#M*R1W4Z R%OE8#HB!2GRJ,(SULHI^;3O
M)_/Y/4TE+W96W]^WE=OE^Y/S7KN<W^U7HEYXN^*GP-\+ZEKGB*SLM=U>_BU?
M_A'M:O\ 0#?F+2KB51OM9TF6,2HK!#*V, $MU/EMW\6?$GP/^/\ =?#O2;S6
M/&&DZ3XSTN+2AJVNWLU[ +S1M1N6L9+HSA[@"2V1E%V9E"W R&*1LGT]\9/V
M>_"_QZ_L9O$46M"X\/7+W>G76E:]?Z-=6DKQM$Y6:SFBD^:-V4@M@@GBLO2?
MV0_AWH^A6&GIX?-Q!I^K-KJR7E_=7EQ=7S0/;-<7$TLC2W+F&1T)G9\C']U<
M9N^K6FJVZZQ?HG9.SL^VS9,;+?71KT;4DOE=J^OXI'RV_P#P4U^('A?0H]+\
M0Z?HMCX[US4-/L+71I? ^O0:AH+S_:#</)8JTSZK!"L&$GL9E69FP5A&&/8?
M\-N?$#4/AU;^?-X6\&^((+[4;8SZ_P""=?6Y\1PVT<+Q7&G:&QBO3')YZHY:
M5O*==JB;<"/6=/\ V /A1IVBWEBOAW4)HKJ."&*6Y\0:E<W.F1P.7ACLIY+A
MI;)(V.Y%MFB"'& ,"I;K]@OX6W=EI\+:%JB2Z>]S)]LB\1:E%?7WVGR_M"W=
MTMP)[Q)?*BWI</(KB-00<"JEK&2ZN]O+:W?:SW;O?WN;2PM))].OGO?IUNMK
M6MI;5/P;X9_\%&?B#XUN_AWKFNZ'H/@KP;XOL](F6YO]"U*ZLM5>[51.L>J0
M.T-C*DC;(X+N#]Z5 \U=P(3X3_\ !1CXH?%6UCUC0_A]>>)K'Q)IVJ76C:9:
M^#];TU=,EMXI)+-;C5[E/L-TMSY>S,/EA'D109 2P]R\.?\ !/CX1^$9]';3
M?"]U9V^ABU%O9)KFH?8)C:G-LUQ;>?Y-RT)"^6TZ2,@1 I 10+UI^PU\++35
M=0NCX7^U1ZE%=PO87>HW=UIMLMTI6Y^SV<DK6UL90S!S!&A;<<DY-5-IN5O[
MUO*^W_#].FF@1TM?^[?Y;_IU5^IB_L4_M'ZY\<[?Q)8^*+S1V\0>'Y;8S647
MAK4O#>H6231E@+FQOGD91N5PDT4TD<H4D;2I%>Z5Q'P<_9U\)_ 8ZB_ARSU)
M;K5O*6[O-3UB\U>\G2)2L49N+N667RXPS;8PVQ=S8 R<]O3J23?N^7Y:_P!?
M>3!-*S_K^OD@HHHJ"@HHHH **** "BBB@ HHHH **** "OYS_P#@[N_Y22^"
M?^R:6'_ITU6OZ,*_G/\ ^#N[_E)+X)_[)I8?^G35:^@X:_WU>C/#X@_W-^J/
MROHHHK]$/@PHHHH ^C_^":/P5\-_$3XH^+_&/C338]<\&_!WPG>^-M1TF1BL
M>LR6Y2.ULWQSY<ES+$']4#CO7Z%?"#X/_!?PS=:7J7Q0^'/@%["'X;>&]/\
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MKMJ*Z14>MR<PQ5.LH\F_X[**3[NT>9OK*4M$%%%%>D>:%%%% !1110 4444
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MN=M?@37I/Q+_ &R_C!\:/"(\/^,?BM\2?%F@J5(TW6?$U[?V8*XVGRI9&3C
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MD$*7*@C@[<UW5=%&;G3C*2LVD[=O(:/RH_X2'_@JK_SV_P#'/"'^%'_"0_\
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M-_T2#_RZM-_^3*_HWHH_M+%_\_9?^!/_ ##ZAA?^?<?N7^1_.1_Q#Q?M#?\
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M#ZAA?^?<?N7^1_.1_P 0\7[0W_1(/_+JTW_Y,H_XAXOVAO\ HD'_ )=6F_\
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M_+JTW_Y,K^C>BC^TL7_S]E_X$_\ ,/J&%_Y]Q^Y?Y'\Y'_$/%^T-_P!$@_\
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MR/YR/^(>+]H;_HD'_EU:;_\ )E'_ !#Q?M#?]$@_\NK3?_DROZ-Z*/[2Q?\
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MC>*ZABE57 5@&.V1P%;*G=R.!CT:>:M55.2=E'EWULG=:]^[^8K'QA^U _\
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M=O*[=A1BDW;^DDDK^=DK]V%%%%24%%%% !1110 4444 %%%% !1110 4444
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M!Y-_PF/QT_Z)S\)O_#C:A_\ *2C_ (3'XZ?]$Y^$W_AQM0_^4E>LT4 >3?\
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M2C_A,?CI_P!$Y^$W_AQM0_\ E)7K-% 'DW_"8_'3_HG/PF_\.-J'_P I*/\
MA,?CI_T3GX3?^'&U#_Y25ZS10!Y-_P )C\=/^B<_";_PXVH?_*2C_A,?CI_T
M3GX3?^'&U#_Y25ZS10!Y-_PF/QT_Z)S\)O\ PXVH?_*2C_A,?CI_T3GX3?\
MAQM0_P#E)7K-% 'DW_"8_'3_ *)S\)O_  XVH?\ RDH_X3'XZ?\ 1.?A-_X<
M;4/_ )25ZS10!Y-_PF/QT_Z)S\)O_#C:A_\ *2C_ (3'XZ?]$Y^$W_AQM0_^
M4E>LT4 >3?\ "8_'3_HG/PF_\.-J'_RDH_X3'XZ?]$Y^$W_AQM0_^4E>LT4
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MVH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:X3]G[]I#5/VHOVJ_@CX@UJRL[/5-/MO&NBW)M;:>UAN6M9;*+SE@N/WT&\
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M]>UNW\-:'>:E>/Y=II\#W,[XSM1%+,?P - 'F/\ PT9XP_Z('\6?_!AX8_\
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M_P!$#^+/_@P\,?\ RWH_X:,\8?\ 1 _BS_X,/#'_ ,MZ]9HH \F_X:,\8?\
M1 _BS_X,/#'_ ,MZ/^&C/&'_ $0/XL_^##PQ_P#+>O6:* /)O^&C/&'_ $0/
MXL_^##PQ_P#+>C_AHSQA_P!$#^+/_@P\,?\ RWKUFB@#R;_AHSQA_P!$#^+/
M_@P\,?\ RWH_X:,\8?\ 1 _BS_X,/#'_ ,MZ]9HH \F_X:,\8?\ 1 _BS_X,
M/#'_ ,MZ/^&C/&'_ $0/XL_^##PQ_P#+>O6:* /)O^&C/&'_ $0/XL_^##PQ
M_P#+>C_AHSQA_P!$#^+/_@P\,?\ RWKUFB@#R;_AHSQA_P!$#^+/_@P\,?\
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M_P!$#^+/_@P\,?\ RWKUFB@#R;_AHSQA_P!$#^+/_@P\,?\ RWH_X:,\8?\
M1 _BS_X,/#'_ ,MZ]9HH \F_X:,\8?\ 1 _BS_X,/#'_ ,MZ/^&C/&'_ $0/
MXL_^##PQ_P#+>O6:* /)O^&C/&'_ $0/XL_^##PQ_P#+>C_AHSQA_P!$#^+/
M_@P\,?\ RWKUFB@#R;_AHSQA_P!$#^+/_@P\,?\ RWH_X:,\8?\ 1 _BS_X,
M/#'_ ,MZ]9HH \F_X:,\8?\ 1 _BS_X,/#'_ ,MZ/^&C/&'_ $0/XL_^##PQ
M_P#+>O6:* /)O^&C/&'_ $0/XL_^##PQ_P#+>C_AHSQA_P!$#^+/_@P\,?\
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M_P!$#^+/_@P\,?\ RWH_X:,\8?\ 1 _BS_X,/#'_ ,MZ]9HH \F_X:,\8?\
M1 _BS_X,/#'_ ,MZ/^&C/&'_ $0/XL_^##PQ_P#+>O6:* /)O^&C/&'_ $0/
MXL_^##PQ_P#+>C_AHSQA_P!$#^+/_@P\,?\ RWKUFB@#R;_AHSQA_P!$#^+/
M_@P\,?\ RWH_X:,\8?\ 1 _BS_X,/#'_ ,MZ]9HH \F_X:,\8?\ 1 _BS_X,
M/#'_ ,MZ/^&C/&'_ $0/XL_^##PQ_P#+>O6:* /)O^&C/&'_ $0/XL_^##PQ
M_P#+>C_AHSQA_P!$#^+/_@P\,?\ RWKUFB@#R;_AHSQA_P!$#^+/_@P\,?\
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M_%G_ ,&'AC_Y;UZS10!Y-_PT9XP_Z('\6?\ P8>&/_EO1_PT9XP_Z('\6?\
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M,0^:O2)/@EX7F\,>*M'?2U?3_&SW$FN(T\I?4&GC$4FY]V\9C 0!2 BJH7:
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MN[:\C:]:"-];U![2S^VI*ET(+9IS# )1-(6$2*"S;L;@"'4U3Y.S:\F];/\
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MSM)'(_"I***@<;I684444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;1-Q4U5H?S:?X;MV?FM.][;ZM'NU%%%24%%%% !1110 4444 %%%% !1110
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M_P"@/\6?_#6^)_\ Y7UZS10!Y-_PVCX/_P"@/\6?_#6^)_\ Y7T?\-H^#_\
MH#_%G_PUOB?_ .5]>LT4 >3?\-H^#_\ H#_%G_PUOB?_ .5]'_#:/@__ * _
MQ9_\-;XG_P#E?7K-% 'DW_#:/@__ * _Q9_\-;XG_P#E?1_PVCX/_P"@/\6?
M_#6^)_\ Y7UZS10!Y-_PVCX/_P"@/\6?_#6^)_\ Y7T?\-H^#_\ H#_%G_PU
MOB?_ .5]>LT4 >3?\-H^#_\ H#_%G_PUOB?_ .5]'_#:/@__ * _Q9_\-;XG
M_P#E?7K-% 'DW_#:/@__ * _Q9_\-;XG_P#E?1_PVCX/_P"@/\6?_#6^)_\
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MI_\ M9_LL>*/C'^SS\*O$GPSDL]0\<?"_6H/$VF6E]*(X-1(;=-;;FPJG>%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVVK>'K3[7<:=*"',#J2 N&W+AF7<JQL,X*CK?^";GP<\5?';]KSXQ?M >-?
M<_@KPS\0K:WTW2- UBUQ-=)'Y!^T21.HQQ;1MN*X9Y7*Y R?OS.: <TJF:N5
M-Q4$I.*BY7>J5K:;)Z*[_()9FW3<5%*3BHMZ[*UM-D]%J &T<<4445Y)Y844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A_BO]MSPA\-/VG/$'@O
MQ?XQ\!^$=+T?0K"_BDUG6(+&ZN[JXEN0R)YLJAD2.&,G"YS*.>@K"^$W_!0/
M2]?^&]_J_B*QNTO(=,B\0V,>G6R^7JUC>ZA=6NFQ6^Z8F2YE$,0(;8I>9<$
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M'-?5]K*WO$OA?+ORRMZ\LK=NO+;;O=WT]3U#]OSPKIUU?7C>'_&3>"]+U?\
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M=W;3+9[KE'AV%H'C@PR8$F"35U;*514]=N6_7XK+IH]+O3ILG=3'6,'+SO\
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M$'258) "B\'<0.NNOV.M4?X.76BQ_"?]FJ.#4=:6^N_"EOI<UIILENL>Q/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2E%.:YM/=;]'9KE?1ZO1K>U^MB*CLO=U]ZWRN]?+1*Z>U['W-1114E!1110
M4444 %%%% !1110 4444 %7?#W_(8A_X%_Z":I5=\/?\AB'_ (%_Z": .GHH
MHH **** .8\0_P#(8F_X#_Z"*I5Q/Q:_9&^%'Q/^(.H:YXF^&/P]\1:W?>7]
MIU#4_#EG=W5QLC1%WRR1EFVHJJ,DX"@= *YS_A@CX%_]$7^$W_A(:?\ _&J
M/6:*\F_X8(^!?_1%_A-_X2&G_P#QJC_A@CX%_P#1%_A-_P"$AI__ ,:H ]9H
MKR;_ (8(^!?_ $1?X3?^$AI__P :H_X8(^!?_1%_A-_X2&G_ /QJ@#UFBO)O
M^&"/@7_T1?X3?^$AI_\ \:H_X8(^!?\ T1?X3?\ A(:?_P#&J /6:*\F_P"&
M"/@7_P!$7^$W_A(:?_\ &J/^&"/@7_T1?X3?^$AI_P#\:H ]9HKR;_A@CX%_
M]$7^$W_A(:?_ /&J/^&"/@7_ -$7^$W_ (2&G_\ QJ@#UFBO)O\ A@CX%_\
M1%_A-_X2&G__ !JC_A@CX%_]$7^$W_A(:?\ _&J /6:*\F_X8(^!?_1%_A-_
MX2&G_P#QJC_A@CX%_P#1%_A-_P"$AI__ ,:H ]9HKR;_ (8(^!?_ $1?X3?^
M$AI__P :H_X8(^!?_1%_A-_X2&G_ /QJ@#UFBO)O^&"/@7_T1?X3?^$AI_\
M\:H_X8(^!?\ T1?X3?\ A(:?_P#&J /6:*\F_P"&"/@7_P!$7^$W_A(:?_\
M&J/^&"/@7_T1?X3?^$AI_P#\:H ]9HKR;_A@CX%_]$7^$W_A(:?_ /&J/^&"
M/@7_ -$7^$W_ (2&G_\ QJ@#UFBO)O\ A@CX%_\ 1%_A-_X2&G__ !JC_A@C
MX%_]$7^$W_A(:?\ _&J /6:*\F_X8(^!?_1%_A-_X2&G_P#QJC_A@CX%_P#1
M%_A-_P"$AI__ ,:H ]9HKR;_ (8(^!?_ $1?X3?^$AI__P :H_X8(^!?_1%_
MA-_X2&G_ /QJ@#UFBO)O^&"/@7_T1?X3?^$AI_\ \:H_X8(^!?\ T1?X3?\
MA(:?_P#&J /6:*\F_P"&"/@7_P!$7^$W_A(:?_\ &J/^&"/@7_T1?X3?^$AI
M_P#\:H ]9HKR;_A@CX%_]$7^$W_A(:?_ /&J/^&"/@7_ -$7^$W_ (2&G_\
MQJ@#UFBO)O\ A@CX%_\ 1%_A-_X2&G__ !JC_A@CX%_]$7^$W_A(:?\ _&J
M/6:*\F_X8(^!?_1%_A-_X2&G_P#QJC_A@CX%_P#1%_A-_P"$AI__ ,:H ]9H
MKR;_ (8(^!?_ $1?X3?^$AI__P :H_X8(^!?_1%_A-_X2&G_ /QJ@#UFBO)O
M^&"/@7_T1?X3?^$AI_\ \:H_X8(^!?\ T1?X3?\ A(:?_P#&J /6:*\F_P"&
M"/@7_P!$7^$W_A(:?_\ &J/^&"/@7_T1?X3?^$AI_P#\:H ]9HKR;_A@CX%_
M]$7^$W_A(:?_ /&J/^&"/@7_ -$7^$W_ (2&G_\ QJ@#UFBO)O\ A@CX%_\
M1%_A-_X2&G__ !JC_A@CX%_]$7^$W_A(:?\ _&J /6:*\F_X8(^!?_1%_A-_
MX2&G_P#QJC_A@CX%_P#1%_A-_P"$AI__ ,:H ]9HKR;_ (8(^!?_ $1?X3?^
M$AI__P :H_X8(^!?_1%_A-_X2&G_ /QJ@#UFBO)O^&"/@7_T1?X3?^$AI_\
M\:H_X8(^!?\ T1?X3?\ A(:?_P#&J /6:*\F_P"&"/@7_P!$7^$W_A(:?_\
M&J/^&"/@7_T1?X3?^$AI_P#\:H ]9HKR;_A@CX%_]$7^$W_A(:?_ /&J/^&"
M/@7_ -$7^$W_ (2&G_\ QJ@#UFBO)O\ A@CX%_\ 1%_A-_X2&G__ !JC_A@C
MX%_]$7^$W_A(:?\ _&J /6:*\F_X8(^!?_1%_A-_X2&G_P#QJC_A@CX%_P#1
M%_A-_P"$AI__ ,:H ]9HKR;_ (8(^!?_ $1?X3?^$AI__P :H_X8(^!?_1%_
MA-_X2&G_ /QJ@#UFBO)O^&"/@7_T1?X3?^$AI_\ \:H_X8(^!?\ T1?X3?\
MA(:?_P#&J /6:*\F_P"&"/@7_P!$7^$W_A(:?_\ &J/^&"/@7_T1?X3?^$AI
M_P#\:H ]9HKR;_A@CX%_]$7^$W_A(:?_ /&J/^&"/@7_ -$7^$W_ (2&G_\
MQJ@#UFBO)O\ A@CX%_\ 1%_A-_X2&G__ !JC_A@CX%_]$7^$W_A(:?\ _&J
M/6:*\F_X8(^!?_1%_A-_X2&G_P#QJC_A@CX%_P#1%_A-_P"$AI__ ,:H ]9H
MKR;_ (8(^!?_ $1?X3?^$AI__P :H_X8(^!?_1%_A-_X2&G_ /QJ@#UFBO)O
M^&"/@7_T1?X3?^$AI_\ \:H_X8(^!?\ T1?X3?\ A(:?_P#&J /6:*\F_P"&
M"/@7_P!$7^$W_A(:?_\ &J/^&"/@7_T1?X3?^$AI_P#\:H ]9HKR;_A@CX%_
M]$7^$W_A(:?_ /&J/^&"/@7_ -$7^$W_ (2&G_\ QJ@#UFBO)O\ A@CX%_\
M1%_A-_X2&G__ !JC_A@CX%_]$7^$W_A(:?\ _&J /6:*\F_X8(^!?_1%_A-_
MX2&G_P#QJC_A@CX%_P#1%_A-_P"$AI__ ,:H ]9HKR;_ (8(^!?_ $1?X3?^
M$AI__P :H_X8(^!?_1%_A-_X2&G_ /QJ@#UFBO)O^&"/@7_T1?X3?^$AI_\
M\:H_X8(^!?\ T1?X3?\ A(:?_P#&J /6:*\F_P"&"/@7_P!$7^$W_A(:?_\
M&J/^&"/@7_T1?X3?^$AI_P#\:H ]9HKR;_A@CX%_]$7^$W_A(:?_ /&J/^&"
M/@7_ -$7^$W_ (2&G_\ QJ@#UFBO)O\ A@CX%_\ 1%_A-_X2&G__ !JC_A@C
MX%_]$7^$W_A(:?\ _&J /6:*\F_X8(^!?_1%_A-_X2&G_P#QJC_A@CX%_P#1
M%_A-_P"$AI__ ,:H ]9HKR;_ (8(^!?_ $1?X3?^$AI__P :H_X8(^!?_1%_
MA-_X2&G_ /QJ@#UFBO)O^&"/@7_T1?X3?^$AI_\ \:H_X8(^!?\ T1?X3?\
MA(:?_P#&J /6:*\F_P"&"/@7_P!$7^$W_A(:?_\ &J/^&"/@7_T1?X3?^$AI
M_P#\:H ]9HKR;_A@CX%_]$7^$W_A(:?_ /&J/^&"/@7_ -$7^$W_ (2&G_\
MQJ@#UFBO)O\ A@CX%_\ 1%_A-_X2&G__ !JC_A@CX%_]$7^$W_A(:?\ _&J
M/6:*\F_X8(^!?_1%_A-_X2&G_P#QJC_A@CX%_P#1%_A-_P"$AI__ ,:H ]9H
MKR;_ (8(^!?_ $1?X3?^$AI__P :H_X8(^!?_1%_A-_X2&G_ /QJ@#UFBO)O
M^&"/@7_T1?X3?^$AI_\ \:H_X8(^!?\ T1?X3?\ A(:?_P#&J /6:*\F_P"&
M"/@7_P!$7^$W_A(:?_\ &J/^&"/@7_T1?X3?^$AI_P#\:H ]9HKR;_A@CX%_
M]$7^$W_A(:?_ /&J/^&"/@7_ -$7^$W_ (2&G_\ QJ@#UFBO)O\ A@CX%_\
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M /XU1_PP1\"_^B+_  F_\)#3_P#XU0!ZS17DW_#!'P+_ .B+_";_ ,)#3_\
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M1+S[-<217T, !EP4C.UUW!?+?#EOE"EN*]$^"/QS\)_M'?#BQ\7>"=:M]?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#RPH ]9HKR;_AB[P?_ -!CXL_^'2\3_P#RPH_X8N\'_P#08^+/_ATO$_\
M\L* /6:*\F_X8N\'_P#08^+/_ATO$_\ \L*/^&+O!_\ T&/BS_X=+Q/_ /+"
M@#UFBO)O^&+O!_\ T&/BS_X=+Q/_ /+"C_AB[P?_ -!CXL_^'2\3_P#RPH ]
M9HKR;_AB[P?_ -!CXL_^'2\3_P#RPH_X8N\'_P#08^+/_ATO$_\ \L* /6:*
M\F_X8N\'_P#08^+/_ATO$_\ \L*/^&+O!_\ T&/BS_X=+Q/_ /+"@#UFBO)O
M^&+O!_\ T&/BS_X=+Q/_ /+"C_AB[P?_ -!CXL_^'2\3_P#RPH ]9HKR;_AB
M[P?_ -!CXL_^'2\3_P#RPH_X8N\'_P#08^+/_ATO$_\ \L* /6:*\F_X8N\'
M_P#08^+/_ATO$_\ \L*/^&+O!_\ T&/BS_X=+Q/_ /+"@#UFBO)O^&+O!_\
MT&/BS_X=+Q/_ /+"C_AB[P?_ -!CXL_^'2\3_P#RPH ]9HKR;_AB[P?_ -!C
MXL_^'2\3_P#RPH_X8N\'_P#08^+/_ATO$_\ \L* /6:*\F_X8N\'_P#08^+/
M_ATO$_\ \L*/^&+O!_\ T&/BS_X=+Q/_ /+"@#UFBO)O^&+O!_\ T&/BS_X=
M+Q/_ /+"C_AB[P?_ -!CXL_^'2\3_P#RPH ]9HKR;_AB[P?_ -!CXL_^'2\3
M_P#RPH_X8N\'_P#08^+/_ATO$_\ \L* /6:*\F_X8N\'_P#08^+/_ATO$_\
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MPH ]9HKR;_AB[P?_ -!CXL_^'2\3_P#RPH_X8N\'_P#08^+/_ATO$_\ \L*
M/6:*\F_X8N\'_P#08^+/_ATO$_\ \L*/^&+O!_\ T&/BS_X=+Q/_ /+"@#UF
MBO)O^&+O!_\ T&/BS_X=+Q/_ /+"C_AB[P?_ -!CXL_^'2\3_P#RPH ]9HKR
M;_AB[P?_ -!CXL_^'2\3_P#RPH_X8N\'_P#08^+/_ATO$_\ \L* /6:*\F_X
M8N\'_P#08^+/_ATO$_\ \L*/^&+O!_\ T&/BS_X=+Q/_ /+"@#UFBO)O^&+O
M!_\ T&/BS_X=+Q/_ /+"C_AB[P?_ -!CXL_^'2\3_P#RPH ]9HKR;_AB[P?_
M -!CXL_^'2\3_P#RPH_X8N\'_P#08^+/_ATO$_\ \L* /6:*\F_X8N\'_P#0
M8^+/_ATO$_\ \L*/^&+O!_\ T&/BS_X=+Q/_ /+"@#UFBO)O^&+O!_\ T&/B
MS_X=+Q/_ /+"C_AB[P?_ -!CXL_^'2\3_P#RPH ]9HKR;_AB[P?_ -!CXL_^
M'2\3_P#RPH_X8N\'_P#08^+/_ATO$_\ \L* /6:*\F_X8N\'_P#08^+/_ATO
M$_\ \L*/^&+O!_\ T&/BS_X=+Q/_ /+"@#UFBO)O^&+O!_\ T&/BS_X=+Q/_
M /+"C_AB[P?_ -!CXL_^'2\3_P#RPH ]9HKR;_AB[P?_ -!CXL_^'2\3_P#R
MPH_X8N\'_P#08^+/_ATO$_\ \L* /6:*\F_X8N\'_P#08^+/_ATO$_\ \L*/
M^&+O!_\ T&/BS_X=+Q/_ /+"@#UFBO)O^&+O!_\ T&/BS_X=+Q/_ /+"C_AB
M[P?_ -!CXL_^'2\3_P#RPH ]9HKR;_AB[P?_ -!CXL_^'2\3_P#RPH_X8N\'
M_P#08^+/_ATO$_\ \L* /6:*\F_X8N\'_P#08^+/_ATO$_\ \L*/^&+O!_\
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M_L,_#+]GC7CJWAOPZBZM@JE[=SO=30@@@^67)"9!()4 D'!)%/\ ^&+O!_\
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M=+U#QQ=7$T#VS)K/C/6-:@"G#$K#>74L:OE1APH8 L 0&8$ ]>HHHH ****
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MRA 2!G-=/X-\9:5\0O"NGZYH>H6NJ:1JD*W%I=VSAXIXV&0RD?Y%>#'Q;=?
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MKY.SOMRIRVL?I3XT\8Z;\//!^J:]K-TMCI&BVDM]>W#*S""&)"[OA06.%!.
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MQUX.\76MOX^N8?%'AVXE"W$_V6.&\LU)'SH8U57"\DJRDGH&'%?*7B[PK?\
M@;Q1J&C:I;R6NHZ7</;7$3C!1T)!'Z=>XJE:VLE]<QPPQR333,$CC12S.Q.
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ME9^:Y5=]%?337]0JYGQ-\7="\(_$CPSX3OKJ2/7?%ZW;Z9 L+,LJVT:R3,7
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M36=6N];U"\OG1[F\NKF4R2.Y157C(10%&$11SC)YC_AG/QA_T7SXL_\ @O\
M#'_RHH_X9S\8?]%\^+/_ (+_  Q_\J*-G=>GRW_-+[D&ZL_7YZK\F_O/6:*\
MF_X9S\8?]%\^+/\ X+_#'_RHH_X9S\8?]%\^+/\ X+_#'_RHH ]9HKR;_AG/
MQA_T7SXL_P#@O\,?_*BC_AG/QA_T7SXL_P#@O\,?_*B@#UFBO)O^&<_&'_1?
M/BS_ ."_PQ_\J*/^&<_&'_1?/BS_ ."_PQ_\J* /6:*\F_X9S\8?]%\^+/\
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M^&/_ )44 >LT5Y-_PSGXP_Z+Y\6?_!?X8_\ E11_PSGXP_Z+Y\6?_!?X8_\
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M/BS_ ."_PQ_\J*/^&<_&'_1?/BS_ ."_PQ_\J* /6:*\F_X9S\8?]%\^+/\
MX+_#'_RHH_X9S\8?]%\^+/\ X+_#'_RHH ]9HKR;_AG/QA_T7SXL_P#@O\,?
M_*BC_AG/QA_T7SXL_P#@O\,?_*B@#UFBO)O^&<_&'_1?/BS_ ."_PQ_\J*/^
M&<_&'_1?/BS_ ."_PQ_\J* /6:*\F_X9S\8?]%\^+/\ X+_#'_RHH_X9S\8?
M]%\^+/\ X+_#'_RHH ]9HKR;_AG/QA_T7SXL_P#@O\,?_*BC_AG/QA_T7SXL
M_P#@O\,?_*B@#UFBO)O^&<_&'_1?/BS_ ."_PQ_\J*/^&<_&'_1?/BS_ ."_
MPQ_\J* /6:*\F_X9S\8?]%\^+/\ X+_#'_RHH_X9S\8?]%\^+/\ X+_#'_RH
MH ]9HKR;_AG/QA_T7SXL_P#@O\,?_*BC_AG/QA_T7SXL_P#@O\,?_*B@#UFB
MO)O^&<_&'_1?/BS_ ."_PQ_\J*/^&<_&'_1?/BS_ ."_PQ_\J* /6:*\F_X9
MS\8?]%\^+/\ X+_#'_RHH_X9S\8?]%\^+/\ X+_#'_RHH ]9HKR;_AG/QA_T
M7SXL_P#@O\,?_*BC_AG/QA_T7SXL_P#@O\,?_*B@#UFBO)O^&<_&'_1?/BS_
M ."_PQ_\J*/^&<_&'_1?/BS_ ."_PQ_\J* /6:*\F_X9S\8?]%\^+/\ X+_#
M'_RHH_X9S\8?]%\^+/\ X+_#'_RHH ]9HKR;_AG/QA_T7SXL_P#@O\,?_*BC
M_AG/QA_T7SXL_P#@O\,?_*B@#UFBO)O^&<_&'_1?/BS_ ."_PQ_\J*/^&<_&
M'_1?/BS_ ."_PQ_\J* /6:*\F_X9S\8?]%\^+/\ X+_#'_RHH_X9S\8?]%\^
M+/\ X+_#'_RHH ]9HKR;_AG/QA_T7SXL_P#@O\,?_*BC_AG/QA_T7SXL_P#@
MO\,?_*B@#N_#GPZT_P ,^,_$6O0M<2:CXF>W:Z>5PPC2"(1QQH !A!\[8.3N
MD<YP0!O5Y-_PSGXP_P"B^?%G_P %_AC_ .5%'_#.?C#_ *+Y\6?_  7^&/\
MY44 >LT5Y-_PSGXP_P"B^?%G_P %_AC_ .5%'_#.?C#_ *+Y\6?_  7^&/\
MY44 >LT5Y-_PSGXP_P"B^?%G_P %_AC_ .5%'_#.?C#_ *+Y\6?_  7^&/\
MY44 >LT5Y-_PSGXP_P"B^?%G_P %_AC_ .5%'_#.?C#_ *+Y\6?_  7^&/\
MY44 >LT5Y-_PSGXP_P"B^?%G_P %_AC_ .5%'_#.?C#_ *+Y\6?_  7^&/\
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MQX?^'_CJUUS6K> W+6<EA=V,KQCJR"XBC\S'?9D@<G KV^OSM\,^#O%OP_\
MV^+'1_V@OB-KGBO6XO"VI-\-?$NGZ):Z?;S>="$O8UMK:'S#?1H-R)ODW C
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M<T*M*\CA5)("%VV !0<**]"JZD>6;CV9G"7-%2"BBBH*"BBB@ HHHH ****
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MR;_A#OCI_P!%&^$W_AN=0_\ EW1_PAWQT_Z*-\)O_#<ZA_\ +N@#UFBO)O\
MA#OCI_T4;X3?^&YU#_Y=T?\ "'?'3_HHWPF_\-SJ'_R[H ]9HKR;_A#OCI_T
M4;X3?^&YU#_Y=T?\(=\=/^BC?";_ ,-SJ'_R[H ]9HKR;_A#OCI_T4;X3?\
MAN=0_P#EW1_PAWQT_P"BC?";_P -SJ'_ ,NZ /6:*\F_X0[XZ?\ 11OA-_X;
MG4/_ )=T?\(=\=/^BC?";_PW.H?_ "[H ]9HKR;_ (0[XZ?]%&^$W_AN=0_^
M7='_  AWQT_Z*-\)O_#<ZA_\NZ /6:*\F_X0[XZ?]%&^$W_AN=0_^7='_"'?
M'3_HHWPF_P##<ZA_\NZ /6:*\F_X0[XZ?]%&^$W_ (;G4/\ Y=T?\(=\=/\
MHHWPF_\ #<ZA_P#+N@#UFBO)O^$.^.G_ $4;X3?^&YU#_P"7='_"'?'3_HHW
MPF_\-SJ'_P NZ /6:*\F_P"$.^.G_11OA-_X;G4/_EW1_P (=\=/^BC?";_P
MW.H?_+N@#UFBO)O^$.^.G_11OA-_X;G4/_EW1_PAWQT_Z*-\)O\ PW.H?_+N
M@#UFBO)O^$.^.G_11OA-_P"&YU#_ .7='_"'?'3_ **-\)O_  W.H?\ R[H
M]9HKR;_A#OCI_P!%&^$W_AN=0_\ EW1_PAWQT_Z*-\)O_#<ZA_\ +N@#UFBO
M)O\ A#OCI_T4;X3?^&YU#_Y=T?\ "'?'3_HHWPF_\-SJ'_R[H ]9HKR;_A#O
MCI_T4;X3?^&YU#_Y=T?\(=\=/^BC?";_ ,-SJ'_R[H ]9HKR;_A#OCI_T4;X
M3?\ AN=0_P#EW1_PAWQT_P"BC?";_P -SJ'_ ,NZ /6:*\F_X0[XZ?\ 11OA
M-_X;G4/_ )=T?\(=\=/^BC?";_PW.H?_ "[H ]9HKR;_ (0[XZ?]%&^$W_AN
M=0_^7='_  AWQT_Z*-\)O_#<ZA_\NZ /6:*\F_X0[XZ?]%&^$W_AN=0_^7='
M_"'?'3_HHWPF_P##<ZA_\NZ /6:*\F_X0[XZ?]%&^$W_ (;G4/\ Y=T?\(=\
M=/\ HHWPF_\ #<ZA_P#+N@#UFBO)O^$.^.G_ $4;X3?^&YU#_P"7='_"'?'3
M_HHWPF_\-SJ'_P NZ /6:*\F_P"$.^.G_11OA-_X;G4/_EW1_P (=\=/^BC?
M";_PW.H?_+N@#UFBO)O^$.^.G_11OA-_X;G4/_EW1_PAWQT_Z*-\)O\ PW.H
M?_+N@#UFBO)O^$.^.G_11OA-_P"&YU#_ .7='_"'?'3_ **-\)O_  W.H?\
MR[H ]9HKR;_A#OCI_P!%&^$W_AN=0_\ EW1_PAWQT_Z*-\)O_#<ZA_\ +N@#
MUFBO)O\ A#OCI_T4;X3?^&YU#_Y=T?\ "'?'3_HHWPF_\-SJ'_R[H ]9HKR;
M_A#OCI_T4;X3?^&YU#_Y=T?\(=\=/^BC?";_ ,-SJ'_R[H ]9HKR;_A#OCI_
MT4;X3?\ AN=0_P#EW1_PAWQT_P"BC?";_P -SJ'_ ,NZ /6:*\F_X0[XZ?\
M11OA-_X;G4/_ )=T?\(=\=/^BC?";_PW.H?_ "[H ]9HKR;_ (0[XZ?]%&^$
MW_AN=0_^7='_  AWQT_Z*-\)O_#<ZA_\NZ /6:*\F_X0[XZ?]%&^$W_AN=0_
M^7='_"'?'3_HHWPF_P##<ZA_\NZ /6:*\F_X0[XZ?]%&^$W_ (;G4/\ Y=T?
M\(=\=/\ HHWPF_\ #<ZA_P#+N@#U:YMH[RWDAFC2:&52CHZ[E=3P00>"#Z5R
M7P^_9Y\ ?"76+S4/"O@;P?X9U#4.+JYTG1K:RFN>2?G>-%+<DGDGJ:Y;_A#O
MCI_T4;X3?^&YU#_Y=T?\(=\=/^BC?";_ ,-SJ'_R[H\PZ6.GU_\ 9T^'OBOP
M7:^&]4\">#=2\.V,S7%MI=UHMM-96\C,S,Z0LA16+,Q) !)8GN:=XP_9[\ _
M$/2K&P\0>!_!^N6.F0-:V=OJ&C6UU%:1,4+1QJZ$(A,<9*J "47T%<M_PAWQ
MT_Z*-\)O_#<ZA_\ +NC_ (0[XZ?]%&^$W_AN=0_^7= [N]SI_%'[.OP^\<>&
M-)T36O O@W6-%T'']F6%[HMM<6NG8&T>3&Z%8\#CY0.*M>&O@CX+\&:K#?:/
MX1\+Z3?6\EQ-%<6>E002Q/<;?/96500TNQ-Y!R^Q<YP*X[_A#OCI_P!%&^$W
M_AN=0_\ EW1_PAWQT_Z*-\)O_#<ZA_\ +NG=WN+I8]9HKR;_ (0[XZ?]%&^$
MW_AN=0_^7='_  AWQT_Z*-\)O_#<ZA_\NZ0'K-%>3?\ "'?'3_HHWPF_\-SJ
M'_R[H_X0[XZ?]%&^$W_AN=0_^7= 'K-%>3?\(=\=/^BC?";_ ,-SJ'_R[H_X
M0[XZ?]%&^$W_ (;G4/\ Y=T >LT5Y-_PAWQT_P"BC?";_P -SJ'_ ,NZ/^$.
M^.G_ $4;X3?^&YU#_P"7= 'K-%>3?\(=\=/^BC?";_PW.H?_ "[H_P"$.^.G
M_11OA-_X;G4/_EW0!ZS17DW_  AWQT_Z*-\)O_#<ZA_\NZ/^$.^.G_11OA-_
MX;G4/_EW0!ZS5WP]_P AB'_@7_H)KQG_ (0[XZ?]%&^$W_AN=0_^7==?\$]
M^).E>-?,\8>+/ ^O:8T#K%;Z-X3NM)G2;C#M++J-RK(%#@H(P264[AM(8 ]>
MHHHH **** .8\0_\AB;_ (#_ .@BN!^)W[1/P_\ @G>6MOXS\=>#O"-Q?(TE
MM%K6M6U@]PJG!9!*ZE@"0"1G&:[[Q#_R&)O^ _\ H(K\WO\ @K#_ ,GS_"G_
M )(7_P BKJG_ "5K_D7?]?#U_P"F_P#<_P"!5G*34XQ[M_A%O]"E'W92[6_%
MI?J??W@CQ]H7Q,\-V^L^&]:TGQ!H]UGR;[3;R.[MIL'!VR1DJV#QP:=XK\<:
M+X#L[>XUS6-+T6WO+J.RMY;ZZCMTGN)#MCA4N0&D=N%4<D\ &OR)T_\ :"\4
M? _]C/XA:?X)?P_IUQJGQ9M]/UO6?A_KT.G>'(K:[M%D*Z3>RIY5@G[N.(RR
M!A&7W$\@+V7AWXF>.OB!^QUX?M_&&I+K=CH_QE\.0:)?2^-]-\7WWV=IXV:&
MYOK$[))$<D@NJ.5D48P 3T0ASS26UZ:_\#Y+V[VYU;O9WMI?.4N6-WO:;_\
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M5UIEA#X3^(^G:QH*K(9##%<Z&8?/LE1%13)$[A71LLH.'YWPKXR\??'+P_\
MLZ^&9OBG\2O#_P#PFOC7QCINJZGI6O31W\]M!++Y4?F.6!V*NU-RMY><J 0*
M*=YJ+C]K\'=:?*Z_K>I14923^S^*49N__DC_ *O;]3**_*W]L+]H]? GQJDN
MO ?QH^)\?BCX?^*=(\*3>'M<\9P06>IA3$DSII:6YFNU8,?,N)V4%BY!;:BF
MG\9_&'Q.T[PE^TE\5+'XQ?$K3G^$_P 3!::'H-OJY.EO&UQ;I)%-&ZDO#LE
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MXGNNSO)-/Y<NV^O2QGS)OW-N_?2-K?/FWZ6ZW+]%%%24%%%% !1110 4444
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M%% !1110 4444 %<[\5OBIH?P4\ ZCXF\17BV.DZ9'OED(W,Y)PJ(O5F9B
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .4E 'K-%>3?\)C\=/\ HG/PF_\ #C:A_P#*2C_A,?CI_P!$Y^$W_AQM0_\
ME)0!ZS17DW_"8_'3_HG/PF_\.-J'_P I*/\ A,?CI_T3GX3?^'&U#_Y24 >L
MT5Y-_P )C\=/^B<_";_PXVH?_*2C_A,?CI_T3GX3?^'&U#_Y24 >LT5Y-_PF
M/QT_Z)S\)O\ PXVH?_*2C_A,?CI_T3GX3?\ AQM0_P#E)0!ZS17DW_"8_'3_
M *)S\)O_  XVH?\ RDH_X3'XZ?\ 1.?A-_X<;4/_ )24 >LT5Y-_PF/QT_Z)
MS\)O_#C:A_\ *2C_ (3'XZ?]$Y^$W_AQM0_^4E 'K-%>3?\ "8_'3_HG/PF_
M\.-J'_RDH_X3'XZ?]$Y^$W_AQM0_^4E 'K-%>3?\)C\=/^B<_";_ ,.-J'_R
MDH_X3'XZ?]$Y^$W_ (<;4/\ Y24 >LT5Y-_PF/QT_P"B<_";_P .-J'_ ,I*
M/^$Q^.G_ $3GX3?^'&U#_P"4E 'K-<[\6/A5H?QL^'^I>&?$5FMYI6J1[)4S
MAD(.5=#_  LI (/8BN(_X3'XZ?\ 1.?A-_X<;4/_ )24?\)C\=/^B<_";_PX
MVH?_ "DK2C6G2FJM-M2B[IK=-;-&5>A3K4Y4:T5*,DTTU=-/1IKJF?)'BC_@
MB'K"Z^_]B^.=-?2V?*&]LW6XC7/0A"58@=_ESZ"OJ7]C;]B'P[^Q_P"'KD6=
MQ)K'B'4U"WVJ2QB,NHY$<:9.R,'G&22>23@ :7_"8_'3_HG/PF_\.-J'_P I
M*/\ A,?CI_T3GX3?^'&U#_Y25]1FW&^<YCAOJF+K7AU225[=[)7]-KGQ60^&
MO#F3XSZ_E^'4:FMFY2ERWWY5)M+M=:VTV/6:*\F_X3'XZ?\ 1.?A-_X<;4/_
M )24?\)C\=/^B<_";_PXVH?_ "DKY,^Z/6:*\F_X3'XZ?]$Y^$W_ (<;4/\
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M;C9YA& !][H*Y#_A,?CI_P!$Y^$W_AQM0_\ E)1_PF/QT_Z)S\)O_#C:A_\
M*2G=WN'?S.JT3]GWP%X:^(-QXMTWP/X0T_Q5>;OM&LVVC6\6H3[L;MTZH)&S
M@9RW.*U?!?PU\.?#=-07P[X?T705U:[>_OAIUC%:B\N'QOFD\M1OD; R[98X
M&37 ?\)C\=/^B<_";_PXVH?_ "DH_P"$Q^.G_1.?A-_X<;4/_E)26BLO3Y=@
MW/2/#OA#2?!Z7BZ3I>G:6NH7<E_="TMD@%S<2',DS[0-TCGEG.2>Y-,_X0;1
M?[<U#4_['TO^TM7MDL[Z[^R1^?>P)NV12OC<Z+O?"L2!O; Y->=?\)C\=/\
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M7#PP\ITM'%7WW_KR/M,TX;PE/"RJ4;J45?>][=[_ *6/WQHHHKX\_/PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P_B%
M\3?#?PD\.-K'BOQ!H?AG2$D6)K[5K^*RME=N%4R2,JY/89R:Q=)_:6^'.O>
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M.9=[?C:R[WU=^B5]5=KZDHHHJ1A1110 5=\/?\AB'_@7_H)JE5WP]_R&(?\
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M?_*2@#UFBO)O^$Q^.G_1.?A-_P"'&U#_ .4E'_"8_'3_ *)S\)O_  XVH?\
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M_P##C:A_\I* /6:*\F_X3'XZ?]$Y^$W_ (<;4/\ Y24?\)C\=/\ HG/PF_\
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M_P"$Q^.G_1.?A-_X<;4/_E)1_P )C\=/^B<_";_PXVH?_*2C^OR_R7W(+O\
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M/"?@?0=,6!VBN-&\676K3O-QA&BETZV54*ER7$A(*J-IW$J >O4444 %%%%
M',>(?^0Q-_P'_P!!%4JN^(?^0Q-_P'_T$5\'_P#!7K]FOP'^T-J/A?P_%X0B
M\3_&WQA&=&\-3OJ%W#%H=DC^9<ZA/'%*L?E0AR075MSNBX8<5,F[I15VW;^O
MUNTDKMNR*BDTW)VLK_\ #_\  3;=DEJ?<=%?#]A\#])_8B^//[+OPM\*6^G2
M:0UIXE:^O+S3+:XOKNX%BCO.D\B-+;EW)W"%T!7:ARJ@5\N_"[]LOXG?"C]E
MSX(_#GX:KXRT^XU/2-8UZ[OO"_@R'Q9J4X35;B)(%M9I(T2(8)DD!+#<F!US
MI+E7PN^MEYZSN_DH-]VNE] C&7)S2TV?W[?.]EVUWLKG[!45^8D?C#XM?M*?
MMJ_"?4+?6$^"'Q*USX37:ZE+K'ASSY[1XM1<2"*RN'7:9/*#CS-VV-F.#@&J
M'B__ (*E?&;QM\&/A1H^AC7K3QAXE;64U;6_!G@Z+Q->7W]G7'D!K:QFDCCV
M2?>D?=\O\( XJ6K:=;O3R4I1;3[>[?H^B3)\^FFO9RBI)-=];:76EVT?J517
MY\^.OVAOVIOB-\"_AKXBT_3/&GPUMY+.\'BZZTWP';:MK,5S#/Y<3OI=Y-&Z
M6\D(,N8?,<-\H# KF[XF_:KU#Q'\5?#OB?PWX@T'7C-\#=<UZV\00^&+>TN)
MKR"50)$$RR3P()%.ZW,IC++RK8!HJ/D3;Z<W_DL92OZ-0=KVOOL53BYM16[M
M][E&-ODY*]KGWS17P+\/?BW\9-:_9*^'VI:Y^T)#I_C[XS?9+KP[#9?#RSOK
MJ"-+8RS6\,?F1Q.S#$DDTP"+RJ*NY37"^!/VW?C]\7O#WP2\.Z7XTT_1/%'B
M?QCXA\*:OJ]UH-C<)?162(4N7@C=HUD0%SM@E5&=1RR<FY4Y*HZ7VD[?DGKM
MHVD_OVU,XR3@JG1IOY)2?XJ+MZ6T9^FE%?$O[.^C>-/V\_@+XN\'^/\ QS<G
MQ)\+_B%=Z)+X@TRR%F=7%B\4T$CVT;K"#YWE,<HV%0A2CGS1]GZ#I7]A:'9V
M0DFF^R0I#YDLLDSOM &6>1F=B<=79F/<D\TN6ROWLUYII-/\=BM4[-:IM/R:
M;37X%NBBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKYQUK
MX_>)O#?[6'Q#EL?"'CGQIX7\+Z+ING/%H]_I<-GI]X5GN[AY$O+ZW_>&&:U^
M9%;Y5P2. ?-_@]^V7XT\*>%]#T"\2UU3Q3\1?#MEXD\*0ZE)--</>:G?WCR1
M3$RG=:V=N8'*1[2D43@'E=I'WK6W?Z\S7WJ+:Z#DN6[>RL[^7NW?R<DG]Y]K
M45\;ZI^W]X^^%O@G1_''BG3_  CK7A7Q+;Z]<Z=INBV5S!J2P6*S36EPTCSR
M*ZSQQQHRB(;'F0AF!V!T'[<7Q83PIJ40\+6=UK]_-HUOH=S>^#==\/:;%=7M
M\MO+92B^"27#0QGS//A*AADF)=N&<8MR45N[*WFVTE^'Z/5I$RDDG)[*_P!R
MM=_C]UWLFU]C45\+VO[6WQ6^'GQ%\20ZGJVE>)+GQ-XMF\-:2^F^"]8OK/18
M--M$>\O%L+6XN)YE,TOE>6K*2X+M*J@(FYJ'[=_Q0OO!.N7]OHOAWPU/X%\'
MWWB3Q"VOZ!J,$ER\=Y/#9B"TEE@FA2[BM)W F):/S(_OX(91UBI+9I/Y./-^
M7S;T5WH7RN_+YV^?-R_^E:=EN[)J_P!F45\NWO[9/C.T^-%C'=1^"])\"W4D
M=K')<)-<O>W$=I)-?VXOX)7BM[RV>.5?LL]NOF")B)@3M7A_"_[;'Q$M?@'K
M/C/3=/\ "MKI'@&PL-0\06.JO?WU[K%Y?QPWTEG:3R7.;81PW<2H9//!=@BI
M&B"JC%MM+I:_E?9OR]/3<SYM%YJZ\_\ @KKV/MJBOF/X:?M;>//&?Q/\(-<6
M7A?_ (1'QQXJUO0]-M+>TG&IK96"7)6_DF:<Q@&2WV&,1'(F1@ZGY3].4K.R
M;Z_U_7W;W'S*[2_K5K]/UV:"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCXE\2Z?X-\/WFK:
MM?6FF:7IL+7%U=W4JQ0V\:C+.[L0%4 9)-7J^#?^#@CQ_JWAC]DWP_H]A<26
M]CXC\0)#J.S_ );QQPR2K$?]DR*C?6,=LUI2I\\U#N>UP[E#S3,J.7J7+[25
MK]ENWZV6GF7_ !O_ ,%_/@KX6\426.GZ;XV\16<+;3J%C80QPR<\E%FEC<_\
M"5:^H?V;/VIO!'[6G@'_ (2+P/K":I91R>3<Q.ABN;*3KLEC;E3W!Z,.02.:
M_G!K['_X(7?$35_"7[>FDZ-8_:)--\5:;>VFI1JS>4J10/<1RLO3(DB5 3C'
MFD _-@^GB,!"--RANC]SXM\)<KPF45<7@)252E%R?,TU)15W?16=EI:VNEC]
MN:***\@_G(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HKP7]N_7M0FL_AIX.M=0OM'T[XB
M>,[71-7O;.X:WG%F(9[B2!9$(9#-Y B+*00KM@UPWQ#\#?#C]E[XY>!I]%^%
M?B[P"MQX@M-&@\1^$DT>STO7Y;I&1;:_B%S]IGB#,Q9Y+?>KIN5^<LHN_P#X
M%RKUM'\^9+OOIM<G[J?E'F^5VO\ VU^7GO;ZSHKX3_8.^-7C+4OA9X!^%_@%
MO#.FZH-)U?Q+JFKZ[8SW\%M;_P!LW5O##';PS0,\DD@<EC* BI]UBP%1CXT>
M.OVD?VK?@]>:!#X4\/\ C#P\/&?A[69KV&?4=-MGM)[.&6:&))89)5?"%4,B
M%?,.6.SYK4;R45UYONC=-^G,N7\=MR6E[]&E\WJEZN.J^[<^\**^4=/_ &V/
M%6O:#'IMUKWPM\$^)M)\0ZGX:U>?4;>]U,7US9!&#Z?IT4D4LD;QNKN6N 8<
MA<2YS7"_"G]I#5/VHOCI^SKX@UJRL[/5-/\ $/B_1;DVMM/:PW+6MFT7G+!<
M?OH-X /E2$NAR"211"/,_=VM?Y-:/YW6CL];VL*3Y5[W=KYJ]U_Y*]5=>9]T
M4445(PHHHH **** "BBB@ HHHH **** "KOA[_D,0_\  O\ T$U2J[X>_P"0
MQ#_P+_T$T =/1110 4444 <QXA_Y#$W_  '_ -!%?/W[1G_!-;X*_M:>/H_$
M_P 0O!TGB+6XK5+)+AM:U"V6.%"Q5%CAG1!RS'A<DGG-=]\6OC3XD\)?$'4-
M/T_X1_$/Q1:6_E^7J>F7FA1VMSNC1CL6YU&&8;22IWQKRIQE<,><_P"&C/&'
M_1 _BS_X,/#'_P MZ3BGJQJ36B*'PC_X)[?!_P"!,WAN3PKX1_LMO"%Q?7>D
MG^U;V?[)+>1)#<M^\F;?OCC08?<%QE<$DUG^,_\ @F3\"_B%\)_#_@C6/A_9
M7WASPJ\TFDPM?W:SV1FD,DH6X643[6=BQ4N5)QQP,;__  T9XP_Z('\6?_!A
MX8_^6]'_  T9XP_Z('\6?_!AX8_^6]5*3EOY?AM]UW84?=^'^OZN_O,#XG?\
M$R?@3\8K72(/$7P[TR]M] TA="TV*.ZN;:.QLUD\P)&L4JA6W9/F#YSN8;L$
M@ZGQ*_X)\?!GXN_"+0/ >O\ @'1[OPKX5&W2+.)YK5M/'\7ES1.LHW$9;Y_G
M/+9-6_\ AHSQA_T0/XL_^##PQ_\ +>C_ (:,\8?]$#^+/_@P\,?_ "WI/56?
M>_SNW?UNV[]VP6C3716^5K6]+)*W9&!\3/\ @F+\!_B_X*\-^'M>^'&CW&D^
M$8#;:3';3W%E):1$EBGFP2)(ZEF9B'9@68L>2374-^QC\,?,LFC\*6MJNG>&
MKCPA;1VUQ/;Q0Z5/@RVX1'"_,1G?C>#T89-5O^&C/&'_ $0/XL_^##PQ_P#+
M>C_AHSQA_P!$#^+/_@P\,?\ RWHEK=/K=OS;33^]-I]TWW".EFNEK>5FFK>C
M2:\TNQ!\1/V!_A%\6?@[X8\ ^(O!EIJGA3P:L::+9RW=R'L5C78H699!*1M
M!#.0P W9IW@G]@WX2_#?5?#MYH/@^#2Y/"6JWFM:.EO?72P:==7<8CN&CB\S
MRPK*H CV[%_A534O_#1GC#_H@?Q9_P#!AX8_^6]'_#1GC#_H@?Q9_P#!AX8_
M^6]5S/F<NK=V^[TU]=%]R%964>B5EZ:JWI9M?-]SK/A5\#/"OP2E\1R>&-+_
M +,;Q9K$^OZJ?M,TWVJ]FV^9+^\=MF[:/E3:HQP!76UY-_PT9XP_Z('\6?\
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M?_+>@#UFBO)O^&C/&'_1 _BS_P"##PQ_\MZ/^&C/&'_1 _BS_P"##PQ_\MZ
M/6:*\F_X:,\8?]$#^+/_ (,/#'_RWH_X:,\8?]$#^+/_ (,/#'_RWH ]9HKR
M;_AHSQA_T0/XL_\ @P\,?_+>C_AHSQA_T0/XL_\ @P\,?_+>@#UFBO)O^&C/
M&'_1 _BS_P"##PQ_\MZ/^&C/&'_1 _BS_P"##PQ_\MZ /6:*\F_X:,\8?]$#
M^+/_ (,/#'_RWH_X:,\8?]$#^+/_ (,/#'_RWH ]9HKR;_AHSQA_T0/XL_\
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MQA_T0/XL_P#@P\,?_+>@#UFBO)O^&C/&'_1 _BS_ .##PQ_\MZ/^&C/&'_1
M_BS_ .##PQ_\MZ /6:*\F_X:,\8?]$#^+/\ X,/#'_RWH_X:,\8?]$#^+/\
MX,/#'_RWH ]9HKR;_AHSQA_T0/XL_P#@P\,?_+>C_AHSQA_T0/XL_P#@P\,?
M_+>@#UFBO)O^&C/&'_1 _BS_ .##PQ_\MZ/^&C/&'_1 _BS_ .##PQ_\MZ /
M6:*\F_X:,\8?]$#^+/\ X,/#'_RWH_X:,\8?]$#^+/\ X,/#'_RWH ]9HKR;
M_AHSQA_T0/XL_P#@P\,?_+>C_AHSQA_T0/XL_P#@P\,?_+>@#UFBO)O^&C/&
M'_1 _BS_ .##PQ_\MZ/^&C/&'_1 _BS_ .##PQ_\MZ /6:*\F_X:,\8?]$#^
M+/\ X,/#'_RWH_X:,\8?]$#^+/\ X,/#'_RWH ]9HKR;_AHSQA_T0/XL_P#@
MP\,?_+>C_AHSQA_T0/XL_P#@P\,?_+>@#UFBO)O^&C/&'_1 _BS_ .##PQ_\
MMZ/^&C/&'_1 _BS_ .##PQ_\MZ /6:*\F_X:,\8?]$#^+/\ X,/#'_RWH_X:
M,\8?]$#^+/\ X,/#'_RWH ]9HKR;_AHSQA_T0/XL_P#@P\,?_+>C_AHSQA_T
M0/XL_P#@P\,?_+>@#UFBO)O^&C/&'_1 _BS_ .##PQ_\MZ/^&C/&'_1 _BS_
M .##PQ_\MZ /6:*\F_X:,\8?]$#^+/\ X,/#'_RWH_X:,\8?]$#^+/\ X,/#
M'_RWH ]9HKR;_AHSQA_T0/XL_P#@P\,?_+>C_AHSQA_T0/XL_P#@P\,?_+>@
M#UFBO)O^&C/&'_1 _BS_ .##PQ_\MZ/^&C/&'_1 _BS_ .##PQ_\MZ /6:*\
MF_X:,\8?]$#^+/\ X,/#'_RWH_X:,\8?]$#^+/\ X,/#'_RWH ]9HKR;_AHS
MQA_T0/XL_P#@P\,?_+>C_AHSQA_T0/XL_P#@P\,?_+>@#UFBO)O^&C/&'_1
M_BS_ .##PQ_\MZ/^&C/&'_1 _BS_ .##PQ_\MZ /6:*\F_X:,\8?]$#^+/\
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M6]'_  T9XP_Z('\6?_!AX8_^6] 'K-%>3?\ #1GC#_H@?Q9_\&'AC_Y;T?\
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M "BBB@#F/$/_ "&)O^ _^@BJ57?$/_(8F_X#_P"@BOCS_@JQ\=O^$3T/X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)*ME21P>:]+_ .&T?!__ $!_BS_X:WQ/_P#*^C_AM'P?_P! ?XL_^&M\3_\
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M09)974E?,; 4*I.U=V22V%^I?^&T?!__ $!_BS_X:WQ/_P#*^C_AM'P?_P!
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M_H#_ !9_\-;XG_\ E?0!ZS17DW_#:/@__H#_ !9_\-;XG_\ E?1_PVCX/_Z
M_P 6?_#6^)__ )7T >LT5Y-_PVCX/_Z _P 6?_#6^)__ )7T?\-H^#_^@/\
M%G_PUOB?_P"5] 'K-%>3?\-H^#_^@/\ %G_PUOB?_P"5]'_#:/@__H#_ !9_
M\-;XG_\ E?0!ZS17DW_#:/@__H#_ !9_\-;XG_\ E?1_PVCX/_Z _P 6?_#6
M^)__ )7T >LT5Y-_PVCX/_Z _P 6?_#6^)__ )7T?\-H^#_^@/\ %G_PUOB?
M_P"5] 'K-%>3?\-H^#_^@/\ %G_PUOB?_P"5]'_#:/@__H#_ !9_\-;XG_\
ME?0!ZS17DW_#:/@__H#_ !9_\-;XG_\ E?1_PVCX/_Z _P 6?_#6^)__ )7T
M >LT5Y-_PVCX/_Z _P 6?_#6^)__ )7T?\-H^#_^@/\ %G_PUOB?_P"5] 'K
M-%>3?\-H^#_^@/\ %G_PUOB?_P"5]'_#:/@__H#_ !9_\-;XG_\ E?0!ZS17
MDW_#:/@__H#_ !9_\-;XG_\ E?1_PVCX/_Z _P 6?_#6^)__ )7T >LT5Y-_
MPVCX/_Z _P 6?_#6^)__ )7T?\-H^#_^@/\ %G_PUOB?_P"5] 'K-%>3?\-H
M^#_^@/\ %G_PUOB?_P"5]'_#:/@__H#_ !9_\-;XG_\ E?0!ZS17DW_#:/@_
M_H#_ !9_\-;XG_\ E?1_PVCX/_Z _P 6?_#6^)__ )7T >LT5Y-_PVCX/_Z
M_P 6?_#6^)__ )7T?\-H^#_^@/\ %G_PUOB?_P"5] 'K-%>3?\-H^#_^@/\
M%G_PUOB?_P"5]'_#:/@__H#_ !9_\-;XG_\ E?0!ZS17DW_#:/@__H#_ !9_
M\-;XG_\ E?1_PVCX/_Z _P 6?_#6^)__ )7T >LT5Y-_PVCX/_Z _P 6?_#6
M^)__ )7T?\-H^#_^@/\ %G_PUOB?_P"5] 'K-%>3?\-H^#_^@/\ %G_PUOB?
M_P"5]'_#:/@__H#_ !9_\-;XG_\ E?0!ZS17DW_#:/@__H#_ !9_\-;XG_\
ME?1_PVCX/_Z _P 6?_#6^)__ )7T >LT5Y-_PVCX/_Z _P 6?_#6^)__ )7T
M?\-H^#_^@/\ %G_PUOB?_P"5] 'K-%>3?\-H^#_^@/\ %G_PUOB?_P"5]'_#
M:/@__H#_ !9_\-;XG_\ E?0!ZS17DW_#:/@__H#_ !9_\-;XG_\ E?1_PVCX
M/_Z _P 6?_#6^)__ )7T =+\.O@9H_PS\9^.-<L9M0N+KX@:E'JFHQW+HT44
MB6T5L%B"H"$*1*2&+')/., >:Z!_P3N\*^"M"TVT\.^)?&WAZX\-ZO>:KX<O
M;.[M6G\-I=G-Q96ZRV[QM:.>?*G27!P000N.E_X;1\'_ /0'^+/_ (:WQ/\
M_*^C_AM'P?\ ] ?XL_\ AK?$_P#\KZ-K6Z)+Y*UONM_5V'^;?S=[_FSS']J'
M]BQ;O]D3Q-\-_"6A:WXNUWXA:DMY?Z_J.I6T<UK?EXV_M6ZD9HS^[\I-L=M$
M?N*BHBY([R;]A_0[&Q\!MX>\2>*/!6K?#[0CX;L=1T-K3S+BQ98@\,J74$\;
M!FA1]P0.&&0PR:TO^&T?!_\ T!_BS_X:WQ/_ /*^C_AM'P?_ - ?XL_^&M\3
M_P#ROHCIMY?@N5+T2;7H[/2R0]7=^?XM-OU;2?JKK6[?,?"W_@G#X'^%&J:?
M<VNJ>+=473GUQDBU*]BG64:OY1NED;RA(^#$"I+;@7;<6XQYY\?O^"?/_"P?
M!_P<^%=K9^(O$'A7P)K-OJ$GB;5[NP3^SM,@1HVTP)"(I9C)&$CYA(V_,\K,
MNT^U?\-H^#_^@/\ %G_PUOB?_P"5]'_#:/@__H#_ !9_\-;XG_\ E?3C)Q<6
MOL\O_DK;C]S;^]K9M,>J:[\W_DRL_O7Z/=(]950BA5& . !VHKR;_AM'P?\
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M\7^-M+\2:M-8:;86MU-X63R;X6%S]HAEU:&2>0:C*Y&R1MT(9&<*J%B:]&^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BL?XA:[<>&/ 6N:E9V=UJ%WI]A/<P6MM$TLURZ1LRHB*"S,Q   !))
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MK]/_ /CM$M8.#V>GR3DU_P"E2^^VR5ERKFY^O^:BG_Z2ON[MW?\ L3_LQ?\
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MA-_X5^G_ /QVC_AO?X%_]%H^$W_A7Z?_ /': /6:*\F_X;W^!?\ T6CX3?\
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M ,*_3_\ X[4E'K-%>3?\-[_ O_HM'PF_\*_3_P#X[1_PWO\  O\ Z+1\)O\
MPK]/_P#CM 'K-%>3?\-[_ O_ *+1\)O_  K]/_\ CM'_  WO\"_^BT?";_PK
M]/\ _CM 'K-%>3?\-[_ O_HM'PF_\*_3_P#X[1_PWO\  O\ Z+1\)O\ PK]/
M_P#CM 'K-%>3?\-[_ O_ *+1\)O_  K]/_\ CM'_  WO\"_^BT?";_PK]/\
M_CM 'K-%>3?\-[_ O_HM'PF_\*_3_P#X[1_PWO\  O\ Z+1\)O\ PK]/_P#C
MM 'K-%>3?\-[_ O_ *+1\)O_  K]/_\ CM'_  WO\"_^BT?";_PK]/\ _CM
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M_P =H ]9HKR;_AO?X%_]%H^$W_A7Z?\ _':/^&]_@7_T6CX3?^%?I_\ \=H
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M_P =H ]9HKR;_AO?X%_]%H^$W_A7Z?\ _':/^&]_@7_T6CX3?^%?I_\ \=H
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M'0Z;<_"5=!^$VJ:;>F]>/2-$2/2=8S$\1CO[.W>W^TH%<LF9%9'4%6'(,_\
MPWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT_P#^.UI*3D[MZ_B]
M;ZOK\R%%+;_ANFG;Y''ZM^PE>ZA'_P )%%XR@M_B>WBN'Q>^OC1B;!KF.T^Q
M"W^Q>>'^RFU+)L-P7RQ;S":[_P#9[^ EY\(M2\7:YKNO0^)O%GCG4DU'5;ZW
MT_\ L^U41P)!#!! 9)62-(XP/FE=B68EN<"A_P -[_ O_HM'PF_\*_3_ /X[
M1_PWO\"_^BT?";_PK]/_ /CM*,FM%VM\K)?+X5MV&]=7_6K?YM_>>LT5Y-_P
MWO\  O\ Z+1\)O\ PK]/_P#CM'_#>_P+_P"BT?";_P *_3__ ([2 ]9HKR;_
M (;W^!?_ $6CX3?^%?I__P =H_X;W^!?_1:/A-_X5^G_ /QV@#UFBO)O^&]_
M@7_T6CX3?^%?I_\ \=H_X;W^!?\ T6CX3?\ A7Z?_P#': /6:*\F_P"&]_@7
M_P!%H^$W_A7Z?_\ ':/^&]_@7_T6CX3?^%?I_P#\=H ]9HKR;_AO?X%_]%H^
M$W_A7Z?_ /':/^&]_@7_ -%H^$W_ (5^G_\ QV@#UFBO)O\ AO?X%_\ 1:/A
M-_X5^G__ !VC_AO?X%_]%H^$W_A7Z?\ _': /6:N^'O^0Q#_ ,"_]!->,_\
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MPOA^"?P<\+^$8+IKZ/PWID&G_:F38UTT:!6E*Y."[ L1DX+=3755Y-_PWO\
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MA-_X5^G_ /QVC_AO?X%_]%H^$W_A7Z?_ /': /6:*\F_X;W^!?\ T6CX3?\
MA7Z?_P#':/\ AO?X%_\ 1:/A-_X5^G__ !V@#UFBO)O^&]_@7_T6CX3?^%?I
M_P#\=H_X;W^!?_1:/A-_X5^G_P#QV@#UFBO)O^&]_@7_ -%H^$W_ (5^G_\
MQVC_ (;W^!?_ $6CX3?^%?I__P =H ]9HKR;_AO?X%_]%H^$W_A7Z?\ _':/
M^&]_@7_T6CX3?^%?I_\ \=H ]9HKR;_AO?X%_P#1:/A-_P"%?I__ ,=H_P"&
M]_@7_P!%H^$W_A7Z?_\ ': /6:*\F_X;W^!?_1:/A-_X5^G_ /QVC_AO?X%_
M]%H^$W_A7Z?_ /': /6:*\F_X;W^!?\ T6CX3?\ A7Z?_P#':/\ AO?X%_\
M1:/A-_X5^G__ !V@#UFBO)O^&]_@7_T6CX3?^%?I_P#\=H_X;W^!?_1:/A-_
MX5^G_P#QV@#UFBO)O^&]_@7_ -%H^$W_ (5^G_\ QVC_ (;W^!?_ $6CX3?^
M%?I__P =H ]9HKR;_AO?X%_]%H^$W_A7Z?\ _':/^&]_@7_T6CX3?^%?I_\
M\=H ]9HKR;_AO?X%_P#1:/A-_P"%?I__ ,=H_P"&]_@7_P!%H^$W_A7Z?_\
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MICR1_1C+D?A5[_AO?X%_]%H^$W_A7Z?_ /':[JV82G#D2L?JG$GC!B,SRZ6
MH4%3<U:4N;FT>Z2LK7VUOH[;ZGK-%>3?\-[_  +_ .BT?";_ ,*_3_\ X[1_
MPWO\"_\ HM'PF_\ "OT__P".UYY^-GK-%>3?\-[_  +_ .BT?";_ ,*_3_\
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M^BT?";_PK]/_ /CM 'K-%>3?\-[_  +_ .BT?";_ ,*_3_\ X[1_PWO\"_\
MHM'PF_\ "OT__P".T >LT5Y-_P -[_ O_HM'PF_\*_3_ /X[1_PWO\"_^BT?
M";_PK]/_ /CM 'K-%>3?\-[_  +_ .BT?";_ ,*_3_\ X[1_PWO\"_\ HM'P
MF_\ "OT__P".T >LT5Y-_P -[_ O_HM'PF_\*_3_ /X[1_PWO\"_^BT?";_P
MK]/_ /CM 'K-%>3?\-[_  +_ .BT?";_ ,*_3_\ X[1_PWO\"_\ HM'PF_\
M"OT__P".T >LT5Y-_P -[_ O_HM'PF_\*_3_ /X[1_PWO\"_^BT?";_PK]/_
M /CM 'K-%>3?\-[_  +_ .BT?";_ ,*_3_\ X[1_PWO\"_\ HM'PF_\ "OT_
M_P".T >LT5Y-_P -[_ O_HM'PF_\*_3_ /X[1_PWO\"_^BT?";_PK]/_ /CM
M 'K-%>3?\-[_  +_ .BT?";_ ,*_3_\ X[1_PWO\"_\ HM'PF_\ "OT__P".
MT >LT5Y-_P -[_ O_HM'PF_\*_3_ /X[1_PWO\"_^BT?";_PK]/_ /CM 'K-
M%>3?\-[_  +_ .BT?";_ ,*_3_\ X[1_PWO\"_\ HM'PF_\ "OT__P".T >L
MT5Y-_P -[_ O_HM'PF_\*_3_ /X[1_PWO\"_^BT?";_PK]/_ /CM 'K-%>3?
M\-[_  +_ .BT?";_ ,*_3_\ X[1_PWO\"_\ HM'PF_\ "OT__P".T >LT5Y-
M_P -[_ O_HM'PF_\*_3_ /X[1_PWO\"_^BT?";_PK]/_ /CM 'K-%>3?\-[_
M  +_ .BT?";_ ,*_3_\ X[1_PWO\"_\ HM'PF_\ "OT__P".T >LT5Y-_P -
M[_ O_HM'PF_\*_3_ /X[1_PWO\"_^BT?";_PK]/_ /CM 'K-%>3?\-[_  +_
M .BT?";_ ,*_3_\ X[1_PWO\"_\ HM'PF_\ "OT__P".T >LT5Y-_P -[_ O
M_HM'PF_\*_3_ /X[1_PWO\"_^BT?";_PK]/_ /CM 'K-%>3?\-[_  +_ .BT
M?";_ ,*_3_\ X[1_PWO\"_\ HM'PF_\ "OT__P".T >LT5Y-_P -[_ O_HM'
MPF_\*_3_ /X[1_PWO\"_^BT?";_PK]/_ /CM 'K-%>3?\-[_  +_ .BT?";_
M ,*_3_\ X[1_PWO\"_\ HM'PF_\ "OT__P".T >LT5Y-_P -[_ O_HM'PF_\
M*_3_ /X[1_PWO\"_^BT?";_PK]/_ /CM 'K-%>3?\-[_  +_ .BT?";_ ,*_
M3_\ X[1_PWO\"_\ HM'PF_\ "OT__P".T >LT5Y-_P -[_ O_HM'PF_\*_3_
M /X[1_PWO\"_^BT?";_PK]/_ /CM 'K-%>3?\-[_  +_ .BT?";_ ,*_3_\
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M^BT?";_PK]/_ /CM 'K-%>3?\-[_  +_ .BT?";_ ,*_3_\ X[1_PWO\"_\
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M%:*M_P"2Q^Y]W>I:N[_K5O\ .3_I*WK-%>3?\-[_  +_ .BT?";_ ,*_3_\
MX[1_PWO\"_\ HM'PF_\ "OT__P".U('K-%>3?\-[_ O_ *+1\)O_  K]/_\
MCM'_  WO\"_^BT?";_PK]/\ _CM 'K-%>3?\-[_ O_HM'PF_\*_3_P#X[1_P
MWO\  O\ Z+1\)O\ PK]/_P#CM 'K-%>3?\-[_ O_ *+1\)O_  K]/_\ CM'_
M  WO\"_^BT?";_PK]/\ _CM 'K-%>3?\-[_ O_HM'PF_\*_3_P#X[1_PWO\
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MNT\I/LV\2(R;9)LA@&V,0#-X\_:"\;0_%OQ'X;\$^!M!\46_A'3;2^U2ZO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW^!?_1:/A-_X5^G_ /QV@#UFBO)O^&]_@7_T6CX3?^%?I_\ \=H_X;W^!?\
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MUEX=U+7&\)Z?J7P_M-.TWP_HVDZYJ-G:7D%M*LLKRWT,4=S:O*8X2@B23R#
MIW2[CCW']FWX&:A\#/ASKS?9--'BKQ%=R:G<H=>U35HGG\I(H4EO;YY;B7:D
M4:&0)&,+Q$N,%/\ AO?X%_\ 1:/A-_X5^G__ !VC_AO?X%_]%H^$W_A7Z?\
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M #^2LEHDEZS17DW_  WO\"_^BT?";_PK]/\ _CM'_#>_P+_Z+1\)O_"OT_\
M^.U)1ZS17DW_  WO\"_^BT?";_PK]/\ _CM'_#>_P+_Z+1\)O_"OT_\ ^.T
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M  WO\"_^BT?";_PK]/\ _CM'_#>_P+_Z+1\)O_"OT_\ ^.T >LT5Y-_PWO\
M O\ Z+1\)O\ PK]/_P#CM'_#>_P+_P"BT?";_P *_3__ ([0!ZS17DW_  WO
M\"_^BT?";_PK]/\ _CM'_#>_P+_Z+1\)O_"OT_\ ^.T >LT5Y-_PWO\  O\
MZ+1\)O\ PK]/_P#CM'_#>_P+_P"BT?";_P *_3__ ([0!ZS17DW_  WO\"_^
MBT?";_PK]/\ _CM'_#>_P+_Z+1\)O_"OT_\ ^.T >LT5Y-_PWO\  O\ Z+1\
M)O\ PK]/_P#CM'_#>_P+_P"BT?";_P *_3__ ([0!ZS17DW_  WO\"_^BT?"
M;_PK]/\ _CM'_#>_P+_Z+1\)O_"OT_\ ^.T >LU\B_\ !9W]E;7OVG?V4XF\
M+VTNH:YX/U%=72QB7=+?0>6\<J1CNX#!P.21&5 )8"O8?^&]_@7_ -%H^$W_
M (5^G_\ QVC_ (;W^!?_ $6CX3?^%?I__P =JZ=1PDI+H>ED^:5LMQM+'T+<
MU-IJ^S[I^36A_.U-"]O,T<BM')&2K*PPRD=017Z!?\$&?V2=;\5?'H?%B_L;
MBU\-^%[:X@TVZD!1;^\FC:!A'_?5(GE#'D!F4=<X^Y/&GQ+_ &//B/XH_MOQ
M!XE_9PUK6"=S7M]JFC3SR$=-SLY+8[;LXKN=/_;G^ >DV,-K:_&+X06MM;H(
MXHHO%FG)'&HX"JHEP /05WULP<X<L5:Y^O<3>,+S'+)X'"T'3E47+)N5[)[I
M62O=:7=M.AZ_17DW_#>_P+_Z+1\)O_"OT_\ ^.T?\-[_  +_ .BT?";_ ,*_
M3_\ X[7FGX>>LT5Y-_PWO\"_^BT?";_PK]/_ /CM'_#>_P "_P#HM'PF_P#"
MOT__ ..T >LT5Y-_PWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT
M_P#^.T >LT5Y-_PWO\"_^BT?";_PK]/_ /CM'_#>_P "_P#HM'PF_P#"OT__
M ..T >LT5Y-_PWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT_P#^
M.T >LT5Y-_PWO\"_^BT?";_PK]/_ /CM'_#>_P "_P#HM'PF_P#"OT__ ..T
M >LT5Y-_PWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT_P#^.T >
MLT5Y-_PWO\"_^BT?";_PK]/_ /CM'_#>_P "_P#HM'PF_P#"OT__ ..T >LT
M5Y-_PWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT_P#^.T >LT5Y
M-_PWO\"_^BT?";_PK]/_ /CM'_#>_P "_P#HM'PF_P#"OT__ ..T >LT5Y-_
MPWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT_P#^.T >LT5Y-_PW
MO\"_^BT?";_PK]/_ /CM'_#>_P "_P#HM'PF_P#"OT__ ..T >LT5Y-_PWO\
M"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT_P#^.T >LT5Y-_PWO\"_
M^BT?";_PK]/_ /CM'_#>_P "_P#HM'PF_P#"OT__ ..T >LT5Y-_PWO\"_\
MHM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT_P#^.T >LT5Y-_PWO\"_^BT?
M";_PK]/_ /CM'_#>_P "_P#HM'PF_P#"OT__ ..T >LT5Y-_PWO\"_\ HM'P
MF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT_P#^.T >LT5Y-_PWO\"_^BT?";_P
MK]/_ /CM'_#>_P "_P#HM'PF_P#"OT__ ..T >LT5Y-_PWO\"_\ HM'PF_\
M"OT__P".T?\ #>_P+_Z+1\)O_"OT_P#^.T >LT5Y-_PWO\"_^BT?";_PK]/_
M /CM'_#>_P "_P#HM'PF_P#"OT__ ..T >LT5Y-_PWO\"_\ HM'PF_\ "OT_
M_P".T?\ #>_P+_Z+1\)O_"OT_P#^.T >LT5Y-_PWO\"_^BT?";_PK]/_ /CM
M'_#>_P "_P#HM'PF_P#"OT__ ..T >LT5Y-_PWO\"_\ HM'PF_\ "OT__P".
MT?\ #>_P+_Z+1\)O_"OT_P#^.T >LT5Y-_PWO\"_^BT?";_PK]/_ /CM'_#>
M_P "_P#HM'PF_P#"OT__ ..T >LT5Y-_PWO\"_\ HM'PF_\ "OT__P".T?\
M#>_P+_Z+1\)O_"OT_P#^.T >LT5Y-_PWO\"_^BT?";_PK]/_ /CM'_#>_P "
M_P#HM'PF_P#"OT__ ..T >LT5Y-_PWO\"_\ HM'PF_\ "OT__P".T?\ #>_P
M+_Z+1\)O_"OT_P#^.T >LT5Y-_PWO\"_^BT?";_PK]/_ /CM'_#>_P "_P#H
MM'PF_P#"OT__ ..T >LT5Y-_PWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+
M1\)O_"OT_P#^.T >LT5Y-_PWO\"_^BT?";_PK]/_ /CM'_#>_P "_P#HM'PF
M_P#"OT__ ..T >LT5Y-_PWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O
M_"OT_P#^.T >LT5Y-_PWO\"_^BT?";_PK]/_ /CM'_#>_P "_P#HM'PF_P#"
MOT__ ..T >LT5Y-_PWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT
M_P#^.T >LT5Y-_PWO\"_^BT?";_PK]/_ /CM'_#>_P "_P#HM'PF_P#"OT__
M ..T >LT5Y-_PWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT_P#^
M.T >LT5Y-_PWO\"_^BT?";_PK]/_ /CM'_#>_P "_P#HM'PF_P#"OT__ ..T
M >LT5Y-_PWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT_P#^.T >
MLT5Y-_PWO\"_^BT?";_PK]/_ /CM'_#>_P "_P#HM'PF_P#"OT__ ..T >LT
M5Y-_PWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+1\)O_"OT_P#^.T /_:M^
M"FL?%72O">L^&9+%?%7P_P!?A\1:7!>NT=KJ!6.2&6VD=03&)(9I ' .UMI(
M(!!\?^*7[/\ JO[37QM\$^((_@AIGP_UCPWXDL-=UGQ=K4FDR:E?PVN[%K;O
M923S2AL(,SM" H7Y21M'KO\ PWO\"_\ HM'PF_\ "OT__P".T?\ #>_P+_Z+
M1\)O_"OT_P#^.T15FGV?-\]-?_)5IMIMJ[DO>33ZKE^3OI^+UWU\E;Y\_9C_
M &<OB9^RQ?\ @GQ=-X'OO%-Q;^'-4\-ZKH=AJE@M_IIDU>:^@N(6GGCMW217
M"R 3!AB,X8J0&_#[]G/XI? GXM> _&W_  @?_"6-]O\ %VKZYIFEZK9+-HO]
MK75O+!!;M<RP1RR*L9W$%4_UOS<KN^A?^&]_@7_T6CX3?^%?I_\ \=H_X;W^
M!?\ T6CX3?\ A7Z?_P#':J,FFFNG,EZ2;;7S;OW[.V@2]YN_5IOU2LG\EIV[
MZZG@GAOX+_&SX=:M'JATOQ,_A[QIKVM^)=<\.>$M8TVWU/2[JZ:(6<<MS=21
MQO$D:.9!;R ^:X(\Q1DYO[)'[(OQ*^'7C?X7WGB#PQ-IL/AOQEXNU747EUR'
M4FAMK^$BUD,S2M+.79MI9AYF06<+G)^C?^&]_@7_ -%H^$W_ (5^G_\ QVC_
M (;W^!?_ $6CX3?^%?I__P =HIRY+<O1<J]-+>;LDDKWT%47/OU;E\VI7^_F
M;TZGK-%>3?\ #>_P+_Z+1\)O_"OT_P#^.T?\-[_ O_HM'PF_\*_3_P#X[4C/
M6:*\F_X;W^!?_1:/A-_X5^G_ /QVC_AO?X%_]%H^$W_A7Z?_ /': /6:*\F_
MX;W^!?\ T6CX3?\ A7Z?_P#':/\ AO?X%_\ 1:/A-_X5^G__ !V@#UFBO)O^
M&]_@7_T6CX3?^%?I_P#\=H_X;W^!?_1:/A-_X5^G_P#QV@#UFBO)O^&]_@7_
M -%H^$W_ (5^G_\ QVC_ (;W^!?_ $6CX3?^%?I__P =H ]9HKR;_AO?X%_]
M%H^$W_A7Z?\ _':/^&]_@7_T6CX3?^%?I_\ \=H ]9J[X>_Y#$/_  +_ -!-
M>,_\-[_ O_HM'PF_\*_3_P#X[71_"7]KGX4?$_X@Z?H?AGXG?#WQ%K=]YGV;
M3],\1V=W=7&R-W;9%'(6;:BLQP#@*3T!H ]JHHHH *\I_:Z_:GM?V4OAL^N2
M:#JGB2\9D\JSM%,<:H9HHFEEG*E(D4S)URS$X56.<>K5Y#^W?\+]=^,W[*_B
M?PWX;L?[2UK4&LS;V_G1P^9Y=Y!(_P TC*HPB,>2,XP.<"CJO5?=<'LSC?CU
M_P $D/V>_P!I[XL:KXY\<?#_ /MSQ3KGD_;;W^W=2MO.\J%((_W<-PD:XCC1
M?E49VY.223X3\ _^"6G[%_[1>O>/M/T3X.ZQ:S?#OQ%-X9U)K[Q#JD:SW,2J
MS/#LOG+1D.,%@K=?E%?H,.E?ECXH\<Z[\-_V._V[M:\-:QJF@:Y8_%&X:TO]
M.NWM;FW8RV2DI(A#+D$@X(X)'>IC+WI)ZVBW\^>$?RDS6G3YU%+=SC'Y.,W^
M:1]'_P##A7]D_P#Z)3_Y<VL?_)='_#A7]D__ *)3_P"7-K'_ ,EUY]XS^'?Q
M&_8I^*'P,\=77QN^)WCBX^(OBW3_  OXKT/6[Z*;19/MD#_/9VJHJVWER("-
MI)(_B/.YWA'P-\2?^"D?CKXO^*K#XT_$+X9V_P /?%E]X4\':/X<O5L]/6:R
M5,W&HIL8W:22D$QDX"Y'0XK3E>MM>7FO;IR\M[=_CC;O?I8PC*Z3>G-RV\^;
MFM?M\$K^GG8DOO\ @DU^QKI_[2>G_"U_@_JA\0:EX?G\217"^(M5^QK;Q3QP
M,C-]NW^86D4@!"N ?F!X/=_\.%?V3_\ HE/_ )<VL?\ R77+:L/'&B?MK>&!
MXRN]-E\?V?P%U@:E=Z'))]FEO$O;?,L!*1NNY@& VKM)P.@K"F^-OBZ#_@WL
MC\;2>+O$:>,&\))/_;S:I,-2,QNP@?[3N\S>0=N=V><5+LJ7/O:][;.]2K%6
M^4/Q-(Q<JT:2TYK6OT]VFW?YS_ ]&_X<*_LG_P#1*?\ RYM8_P#DNO/O@E_P
M2E_8S^//B;QYI6C_  ?U:VN/AWK[^'=2:\\1:HB3W"11REH2M\Q:/;(HRP4Y
M!^7N>BU/0O&7[=O[4WB?P-_PM3XB?#7PC\*-!T29AX0OAI^HZUJ-];M.9I[A
MD<O"B*%\O&&8DGD5\\Z7^T'X]_8W^ W[0<=OJNJZ]XZU[XUQ>$QK>D:.EWJ#
M^=:P!KF"TRL;W;0QG;'E4,S@#C IVM-QEV=EW;J0A%^CYON:?=*8^_!2CW5_
M)<DIO\$OFFNU_J7_ (<*_LG_ /1*?_+FUC_Y+H_X<*_LG_\ 1*?_ "YM8_\
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M454.!\QKIQ48TIU%TAS-]THN":\W[WS]#&C><:;ZSY;>;ESV?EI#Y+S/;O\
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MFJ#CZ-NKUTUUV*J>[)*6G?RLZO,_1*G?37RU/6O^'"O[)_\ T2G_ ,N;6/\
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MG1]L]M+^5U>S[-=4^NU]2JBY:OL_7YV=M.Z?1KIO;2_S!_PX5_9/_P"B4_\
MES:Q_P#)=>?^(?\ @E)^QGX;_:2\.?"V?X/ZLWB#Q/H]WK=K<1^(M4-G'#;/
M&CJ[&^#AR9%P A! .2.]3X(?";XG?M]?!&^^/'_"_/B=X%US5KG4;CPIH.A7
M<5OX?TBVM[B6*"*\M"C"\8^5EV9AG=CG%<+H/C#Q=_P4*^/W[,^M1^*M2^'>
ML>,/AGK7]NZGH(1+Y4CNH8I_L;N&$#R/&"'VL8U8X^8 U48R<U%K7JNUX3DM
M?)P][TTO<*EHJ6ODGZ3C%Z>:E[O?K8]R\:_\$1_V._AUX.U7Q!K7PTCL-'T.
MTEO[ZY?Q+K3+;P1(7=R%NB3A5)P 3Q47P\_X(H_L>?%+P%HOB;1OA>]QI'B"
MQAU&RE?Q%K4;20RH)$8JUT"I*L#@C(KRSXY^#O%W@CX>?M&_ #Q!\5/B)XLT
M'0_AXOCSP]KMU?XUV*(&X2;3KR["?Z1#(\(# J"T;NO Z:ECI>G_  "_X)K_
M  1TG6/VA/B=X*TOQ98V][.NGPOJ_BK6?.L8W73=,FC1GM((2<KMA<HH1=Z#
MDJ-G"4^GN6_[><TT_G%K3JG:]T.46I1CU]Z_RC&2M\I+?NKVLSTGQ-_P0P_9
M/\,^&]0U+_A3M]J']GVTES]ELO$.L2W-SL4MY<2?:QN=L85<C)(%4/AC_P $
M3OV3_B;\/-%\0_\ "D==\/\ ]LV<=W_9FM:YK%IJ-CO4'RIXOMA\N1<X9<G!
M[UXS^R-^T=XAT/XS_&;P!H?C;XZ>(O!5O\,+KQ1H]]\3$EBURVO$)C:6VF=(
MY3!EL!B% >)L#Y=QF\%:A\3OVD/%G[)WA&U^+GQ"\*V7C+X4W.I>*-0TW56-
M_?[! 3*'EWK]I9F51.RLZ!F(.351BV[+K:W2VE6]_P#P6_PMO8F4DE=]+WZW
M_AVM_P"#%\[W?4]]_P"'"O[)_P#T2G_RYM8_^2Z/^'"O[)__ $2G_P N;6/_
M )+KR"]_:2\>?\$[_#'[47A63QIXI^)T?PPT?1]9\)ZCXIF_M'4K9M1+Q%+B
M4!3,J2[7&<#:,?*#7F?PT_: ^*_PV\>>%_$OAW2_V]/%FO7VIVB>)+'QSX-5
MO"M]:2.JW+00PEFLBJL70Q[N5 /!)HII3FHQV=M?-]/D_B[=+A4O3@Y2Z7T\
MDD_Q4E9?)V/JH_\ !!;]D\#_ ))3_P"7-K'_ ,EUP'[,W_!*3]C/]JKX6KXN
M\/?!_5K/36U"\TX1ZCXBU2.?S+6X>"0XCOG7:6C)4[LD$9 /%;_A+P'X^_;Y
M^-OQ2\3)\9/B+\-]+^&?BVX\*^%]&\-3QVMFTMI'$TEQJ$4D;?;%DD?_ %;8
M4(, \UU7_!$N.\B_8*TU=1D@EU!?$6NBZ>%2L;R_VE<;RH/(4MG /:II>\N9
M_P JDEY2LT_N>JZ70ZGNZ+I+E?JE*Z^^.C\GY7K?\.%?V3_^B4_^7-K'_P E
MUPGQO_X)-?L:_ .\\%PZQ\']4N6\=>([;PQ8&S\1:JXAN9UD9'EW7RXC C;)
M7<W(PI[=!;^"O&_[?G[3WQ7DC^,7Q"^&OACX2Z]#X=T#3?"-W'9BZO([:*>:
MYOM\;BYC,DH40MA"J8[DGQ/X9^,O%OC/X)_!]_&WB34/%6O:;^TU+ITM_=32
M2;A"]V@6,.S&.(8.R,'" @#I3H^_.FGIS<C]8RG!?>U._EIUO8K>Y";[*:])
M1A.7X.%O/7I9OZ'_ .'"O[)__1*?_+FUC_Y+KSWXG?\ !*C]C+X4?&?X=^!=
M1^#^K3:M\3)[VWTN:V\1:HUO UK!Y\AF9KY64%>%V*^3UP.:T?AK\+/'G_!2
M+Q%\0?'5U\;OBE\-M-\,^+=1\.>$]$\(7\=A9VR6,@B\^^38WVMI)%W%&8 +
ME0<-@>/ZG\2O'_[8WB+]DR&_\4?\(WX\M_$GB_PQJ7B/3K5#([6=NUO-=01L
M-B2R1(Q7*[4=MVW "TJ=Y<G>23M_=DKIW\KJ_:^E];5*RYK[+G5_[T5)V\_A
M=O3I=7^D?^'"O[)__1*?_+FUC_Y+H_X<*_LG_P#1*?\ RYM8_P#DNLKX61^,
MOV+OVK+_ .%-]\6O$WC+P;XH\#W_ (GTG6O',PU34/#-W:2HDK33CRO.MBLH
M?:S)C9M!7J?D'XW?M/R_!_PI:_$CX>_'[]J+XG>,+'4K%[V]O=(GM?A_J$3S
M)',WV:2!(8(7SL3:[_.R[=V[>*II3G",?M6^]R<-O*2=WVU5];3).,9-[K_Y
M%2W\TUIWT=M+_3'@[_@DU^QKXW^/7C/X=VOP?U2/6O UGI][?SR^(M5%K,EX
MLK1")A?%BP$3;MRJ!D8)YQW?_#A7]D__ *)3_P"7-K'_ ,EUO?LZ2^?_ ,%/
MOVA'Z;_#WA5L>F8KRN8_X*6ZEXRUK]IS]G/P1X6\=^)_ =IX\U+6=.U:ZT6[
M,,LEN+-&8A3E#*J[_+=U;RW8.!D"IU]Q+>6GSU*T<I/HE?Y<BD_U.<'_  1L
M_9//QO/@G_A0OBSC1O[9_M_^UM8_L,_OO*^R_:?MO_'U_'Y>W[G.>U=9_P .
M%?V3_P#HE/\ Y<VL?_)=>??$7XK>(/V&OVH/%&EP^,O''C+0_AY\ [K7H(?$
MNM2WS:E?QZC)LN+C[J/,1A#($#;!C.!7 ?M3_!OXO?!/_@GY=?&>/]HKXJWW
MB[Q%::1>Z[8-J0BTB);FYMLII\<2H]F4,@&Y'Q(@<,OS\53BI<MMF[7]:DX1
MT_[==^RMU8I1:GRO=VLO^W(2?_I:]7Y([_PA_P $I?V,_&O[1'C'X9VOP?U:
M/7O!-A8ZC?3R^(M4%I+'=B0QB)A?%RP\MMP9% R,$]M;XT?\$@?V*?V?? <O
MB3Q9\.?[-TF*XM[/S1XAUN5GFGE6&*-52Z)):1U'3 SDD $C'U/]GO6_VDO^
M"HGQMT:T^)7CCX=:.OA3PW+J,WA*YCL=5OGV3>4JW3([1(I#E@@!?(!( (/B
M/[1]OXH^.?\ P3BUK2_%WQ#\<:AJ_P '_C!_PABZE;WXMGUZ!=1MHHIKL!3Y
MLL22AD<X*R(&.X]9IWGR+JVOFG44&_)^\K??Y$5)**E/HE]S]E[1>J=G^"]/
MK'_APM^R?_T2G_RYM8_^2Z/^'"O[)_\ T2G_ ,N;6/\ Y+KQO]O/2O'?P6^)
MOA/0?$WBW]J:/X(:'X:M;2U\3_#J^2XUB74UD99KC6;@)YK+Y6TY"X8\J"V0
M/K/_ ()W?%33_B]^R[H^IZ=\4O\ A<,$4TUN/$4FE_V;=N%<E8;F'.1/&C*K
M,0I?A]OS9-02G&4HO9O\VKOM?=7Z-:] DW&48RZI?E?3O;9VZ]+:G@MG_P $
M@OV*=0^--Y\/8?ASYGBS3M)CURZLAXAUO]Q:22M%&Y?[5LRSJP"@EL+D@ C/
M5_\ #A7]D_\ Z)3_ .7-K'_R77COC;P"/@C_ ,%7_C/\2F\9_$B\'@?X;#QM
M_97]M_Z'?<W2_P!GR1[!NLTV;XXLC:YW;CTI^H_"/XP>'OV*?^&FA^T)\1[C
MXB1^&T\:3:#)<1'P<\!B%RUB-.V84>5^[\T/NS\W!-9PDO8JK/1)7D^UY32\
MWI!WMVNMTC247[5TH:W:4?/W8-^GQ*WJET;/7_\ APK^R?\ ]$I_\N;6/_DN
MN=^+O_!&']C_ ."_PJ\2>,-4^$=Y<:;X7TRXU6ZBM?$FK-/)%!&TCA UXJEB
MJG + 9ZD=:^M_AQ\35\>?!+0O&36KVZ:QHD&L&W4[VB$D"R[ >Y&<>]?GAK7
MPN^)?[3G_!.WQK^T)J7QI\>6>N>*/"NL:A'X1AN(_P#A$X-+V3J+-K,QY,OD
MJ1]HW!PY!YQS.*YZ2J+9P3N^SUMZ[/;HGULG6#Y*SIO=3:LNK6E_S7S:\VO6
MOA-_P1=_9!^,?PN\.>+M+^$EW!IOB?3+?5;6.Z\2:LL\<4\:R('"WC*&"L,@
M,1GH3UKH/^'"O[)__1*?_+FUC_Y+KY@^)G[4OB>;PS\#_A#IJ_M V_ABT^$^
MC>(=5?X/:2MUXBO)98TBB4SL0;>W3RR2R EV<*<"NS^#WQ$^-_Q%_9G^,7AW
M2[?]H;29/ $=AXE\!ZU\0]*DT;7]4$#>;/IES-&1'=JWDE"6;+K<$.N *ZL1
M&$:E2VD8N6_:,G%OY6;\TN]D^>@Y2A"^LI*/WR2:^^Z3[7[)V]L_X<*_LG_]
M$I_\N;6/_DNC_APK^R?_ -$I_P#+FUC_ .2Z9\0?VJY_CE\</A#)X0U;5H/"
MVC^#;KXK>(HM/NI(3?6QM_*L+.7RR-ZO,\KF-L@FW'!Q7Q7X<_:O^+GQ9\$1
M?%+3U_;DN_B1J,+ZAI-KH'@^.;X<G+,T-N+4,3<6^"$,Y_>$?-C( K'52<9:
M6O?Y-Q_]*C)?*_57TC:45*/6UNFZ3^6CB_\ MY=G;Z<A_P""37[&L_[2]Q\*
MU^#^J?\ "0V_AQ/$[7!\1:K]C-L]RUN$#?;M_F;U)QLVX_BSQ7=_\.%?V3_^
MB4_^7-K'_P EUQTWQ_OO#'[8^O?$[5M!O=,U/3_V<H?$=YHUS"\,]K,EY-.]
MNZ/M965@4(;!&.:Y'4?A'\8/#W[%/_#30_:$^(]Q\1(_#:>-)M!DN(CX.> Q
M"Y:Q&G;,*/*_=^:'W9^;@FF_<AS5-%&_,]TO?J16V^D'>W;JVD$;SJ<L/M<O
M*O\ MRG)W[:S7W]DV>O_ /#A7]D__HE/_ES:Q_\ )='_  X5_9/_ .B4_P#E
MS:Q_\EUYI86WCK]O']MS7]'MOBQ\1?AKX%O_ (<^'?$=SI_AG53;WB37(E=5
MMYF#);\_ZQT3?($520,U[A_P3L\;^+M.U[XK_"GQEXHU#QQ>_"77H+#3_$%_
M'B\O["YM([B!;AQQ)-&&96?JW!/6J5-W<9:-7=O\,^1_C;Y&?M(M*4=4[?\
MDT>=?A^-OES7_#A7]D__ *)3_P"7-K'_ ,ET?\.%?V3_ /HE/_ES:Q_\EU]?
MGI7Y7>%?"_Q:\?\ [$?Q4^,LOQ[^*.FZI\-==\1WGAK2K+5?] DCL[J5O+OQ
M(CR72'846,N(XT50%Y:L742;YMDG)OLDTGZ[F\8.5DMVU%>K3:_(^DO^'"O[
M)_\ T2G_ ,N;6/\ Y+H_X<*_LG_]$I_\N;6/_DNO/=>TGXG?!KQ_^SW\6;OX
MQ>-O$&H?%CQ-INC>(_#5Q.B>%X;:_MI)MEG8JO[DQ;%"R,[R'&2QR0> _:_^
M*&EZO\3?B!<0_M%?M+>(?&7AN[NTT[1/A7HUQ;:!H<D2!X[&Y6..2*ZD3 \U
MWG&?F#"/D5=7]W?F^RY)^3CRMV[Z26NVZO>UXI?O+..S46GY2<DF^VL7Y[:;
MV^@?^'"O[)__ $2G_P N;6/_ )+H_P"'"O[)_P#T2G_RYM8_^2Z\$T_XN?%;
M]KVX_8QL;;XF>*_!=U\2/"^M2^*;_0[E8)+U;>*+=*(R/)\YMIVN8SY1E9E
MQ70:YK'CW]E./]J+X41?%#XB>-K+P]\,/^$P\,ZQKVIFYUS2)72ZCD47:!)&
M(=%92,;=HQCG+KKV2ES=.>WGR.5_32+:OVMVN46JO+R_:Y/ESV2^=VKKMJ>M
M_P##A7]D_P#Z)3_Y<VL?_)=>)?$+]@']BWP/^U!I/PEL?@!\0/%WB:]6VEU&
MX\/WNL7FG^&X;ARL4U_.;Y1"AVLV0&(52<<@'TC]IGXO^*/#O_!(SX4^)+/Q
M1KUCXDU1?!XN-4AU*6*^NS/-:>?OF#!W,BL^_).X%LYR:YGX$?LQ-H/_  5[
M^-VN+\4/B9"WAO2M-UP1WVN^;I]T;N.[/V>\BVKYMG;9S#%N7RP/O'K5U(>S
MK.$]HRFGY\D5+Y7O^!G"IST>>.[C&2\N:7+^%OQ\CTO_ (<*_LG_ /1*?_+F
MUC_Y+H_X<*_LG_\ 1*?_ "YM8_\ DNOBS]HS]I9_AW\.]4^)'@']HO\ :>^)
M7C[1IX[EKZUT:>U^'MR!.L4I-JT(MX[< E PDD!<J06)S7UAXZN?&7[?G[:7
MB3X:6_Q*\=?"WP5\.O"^EZI>_P#"&WRZ=JFK:A?J95)NMKLL$<:@; !N).?4
M1&+:3CO=I_)7OYKHO/33<TE:-[[6_51M]\E\ON*_Q+_X)!?L4_"+5?"]CKWP
MY^QWGC+5H]#T>$>(=;D:\NW1G"?+=$* B.Q9L*,=<D ]7_PX5_9/_P"B4_\
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M']'N-*U6Y%WX:^R:@4@1GL\!YKA/,1WG>4N[!SD9&'#W[<NS<4O64I02_P#
MH/RMJ*2<4^;=<S^48QG?_P !DO.^GF?0O_#A7]D__HE/_ES:Q_\ )='_  X5
M_9/_ .B4_P#ES:Q_\EUA>"/!GC;]DK]O32O",GQ<^(GQ$\/_ !$\&:QK-]#X
MJOTNFL;^TDAQ):"-$6VC(F($:#:!ZX7'SEX-A^,NA_\ !+;PS^TDWQX^)%YX
MQ\-[+C3]$N-3,V@WMJ=2%NT=_$RF6[D968EWD^7*JNW:#1#WDI+;3[W*4?SB
M_EKOH&O-R+>]DN_NQDO322]']Y]5?\.%?V3_ /HE/_ES:Q_\ET?\.%?V3_\
MHE/_ )<VL?\ R77+ZEX5^('['O[:?PAU"\^,'Q \?6'Q6.K6_B?2=;N$DTR&
M6WT]KJ-].M8T"VBAD(V@L2, EN2?E+0_VNOBA^T-X:F^*%M_PW)'XTOVN;GP
M_;^"O"<5QX ME61U@A: L?MD8 VO*^&)SQE12NO\_+5JWG>S:\O.R;M=776U
MO-.^OE:UG\NFWVK_ ,.%?V3_ /HE/_ES:Q_\ET?\.%?V3_\ HE/_ )<VL?\
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M7VD?%:-IK2ZBU/59(M"C$32A]0=+]E@5MNQ2"X+D#WKUO_APK^R?_P!$I_\
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MWGR2<7^3:\D_*_.JB<>:/]UORYE%K_TI)V[^MH/^'"O[)_\ T2G_ ,N;6/\
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M?7OBPWBVU^">L7=WHJOX8BL7:PEL1:16+-'-C,7S/YS!F?=@@8!KU/\ 9O\
MV2?^&?/A]\0M!_X2#^U_^$\\3:OXB\_[#]G^P_;VSY.WS&\SR_[V5W?W5KV2
MBBH^=24]>9-/S3Y;_-\JN][J]]7<C[O+;[+37E;FM]W-+3;7R5OSC_:H^#/A
M3]@KX#? O2]6^(7C[P)XB^&]G>6&D_%;1?"8U+2]/$A7S+;4+(22L8Y]R;$(
M8%HS\XY!U/\ @DOX1U3X@?M8_$WXN+XX\6?%#P[KGA_3M*C\8:WH!T./7;Q7
M>27[#:E5\NUB01J!MQO=L$\FOT(HJHU&INI+5OF_\FO?3SN]K*^KNR94XN"I
MQT2M_P"2M-?DM[^5CP?]L;]C35OVC/%'@WQ=X-^(6H?#'XA> VNDTG6X=*@U
M:$072HEQ%):S$(^Y47!R-ISUZ5X+XL_X)R>(O@7:_%[XP>)OC%K_ ,2/$FM?
M"_5]"U<:II,-M'*WDF5'MA$X6VA7RSB$*PR['<.<_4_[7?[5'A[]B[X"ZQ\1
M/%5GK%]H>B/ D\.EPQRW3&:9(5VK))&IPS@G+#@'&3Q6Y8_''P_K7P+'Q&TR
MY;5?#,FBG7H)K4!GN+80F;Y02!N*C&"1@\'%<]2*]C4:=DE)-[\O-%W]+IMV
M5KZO?4Z:,FJU.ZN[II;7Y9)K[G;?;;8^)/V1?^"=7B+XY?LE?"2U\2?&KQ=?
M_!N^\.Z1JUSX .G6P%Q,(XIS ^H?Z]K,N/\ CW(P!@!@ N''X">,_BW_ ,%/
MOVBI?AW\4M6^$WB+2=+\,1)>VVE6^K6=S!):2;XYK2?$;$;%*."&0[L'#$'[
M<^!7QBTS]H/X->&?'&BP7UKI/BO3H=3M(KU$2XCBE4,HD5&90P!Y 8CW-=97
M;B)/V\FU;66G5-VO=[O16UW6FVAR4+*CRK6ZBK]-&GHME>W3KKNCYAM/^"9N
ME:+\$O#GA2Q\6:K-JFG^/++X@:YK^J6XO+WQ'?PW FD\W:R!/,VJ@(R$55^5
MCG-SQ!_P3;\/_$"#X\V/BC6KC4](^.&H6FHO#;6WV6?0I+:WCCB:.7>XD=9(
MED#%5 (P589S])45AT:[_P#VBT[6Y(6M:W+I;4T6C4NJU^?O/7OK.5[[WUZ'
MR?\ #7_@FQXEO/B+H^N?&+XU>(OC%:^$8;F#PUIL^C6VCP:=Y\+6[S3F$EKJ
M<1,5$KD$$L<9/'G>O_\ !&[QWXF^"-Y\*+K]IGQ@OPF@M&M-&\/V_AFQ@FLT
M!S"ES=H1)=PHV"T9\L. !E< U]Z5R-Q\<?#-O\:5^'O]H&3Q>VB/XA^P)"Y*
MV2S"'S"^-G,AVA<Y.TG&!FIE:6CZK;O:[NUU:5W?=:NXXWCJNGX7:5EV3=E9
M:-VT/%]:_8*\0I\5O@YXT\/_ !-?P_KWPST&'PQK!_X1Z&Z@\4:<K0M-%LDD
MS:M(8C\Z%V4-P3C)R$_X)9Z;<? K4/"LWC;6;/7HO'5]X_T#Q+I-L+.\T"]N
M)GD555GD6155V1@Q D4GA3C'T'\%/BG_ ,+I^&FG>)/^$;\5>$_[1\S_ (E7
MB33_ +!J=MLD:/\ >P[FV[MNY>3E64]ZZJM*CE=\V]V_FY*;LUM[R4E;9WM:
M[O$8Q226RLONBX*_?W6UKNM[V1\Q_ __ ()^>(M"^*\?Q ^+7Q:U?XP^-M)T
MZXTK0;J;1+;1;#0H;A=LSQVD!*F9Q\K2%LE>,< UH>%/V ?^$8_X)N77[/?_
M  EGG_:-!O-$_M_^R]NW[0\C>;]F\X_=\S&WS><=1FOHRBIG:4'3>S5FMN[_
M #E)ONW=E1]V:J+=.Z_#_):;:&'\//!8\"?#70_#K7+70T;3(-.-PJF%IO*B
M6/> "2N=N< G&>O>OE'Q5_P3"^(WCRQOO!NO_M->.M>^#>I2%;OPSJ&B6=UJ
MUS;E]YMWUAR;AEW<;BN=OR^]>X_$G]KO2_A/HWQ2U36O"?CNUTGX4Z?%J5WJ
M#:6B6FNQO"9F&GRO(JSM&!M?)0*Y SWJ_P"$_P!J3P_XR^.=O\/[6SUB/6;K
MPG;^,EFEBC%J+.:8PK&6$A;S@PR1MVX_B)XJG)U*G.]6]?)W3EJMMDWMI9DQ
MBJ5/D6B6W=:Q6CW6LHK1]4>6?&7_ ()[^(-;^/D?C_X6_%S7/A'?:AI-IH.O
MVMGHUIJL.JV5L6\D1BXX@F56*B7#X&,+UW<,W_!&^U7X#W7@&/XD:U#9W7Q/
M'Q%&I+9M_:,:C ^S";S]WG<;OM/7<<^7VKZ4^.O[26A_L^:OX%LM:M=6NI?B
M!XC@\,:<;**-UAN9DD=7EWNNV,"-LE=S9(^4]O0JF-TN9=[7\TXSM?UY9?\
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MC?&;1?B!\8/C%K/QE\2>$89X/#2RZ';:)I^C><@22;[/ 6$LY7*^:S9VGID
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MY.,^B:T\U)S\T]9-ZJZN^5HJK)R37VFM_)I0_**6C2=O>3/)OAQ^R]_PK_\
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MM]++!!/X:M=.TR2UEB>.2*.V@<"&5MRYFRY(0 J>"/5_@3^QE_PI3]F3Q?\
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M$/P1^)/A&[\::E;W?C;Q_/\ $+3-7T^R6WN/#MZTL4L*JK.XE\MH\%ODW!B
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MOXS_ ,%?]'UCQ"_[/=CX?U9=!UF\^*FG0VFHM +C["[6UT/-$;?*S+G(!X)
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MV1FW7<SNN]XG"A58*.&-??7PE_8[F^&G[5.L?%"X\3+J<^L>$-.\+26"Z;Y
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MJ < J<9)+2$K;VE;TO1:6RM\,]-EKW5ZI2M6IRELG%OY>TN^[WCKN].S./\
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MCI%IFG EWBD( ",D<GEJK80#)'/_ +#_ ,>-1\*?M\:/X"\-^.?VAO&7P_\
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M.=_G;EZI-==+'QSXTN?$W[<7[$W[*?BSQAX^^(>G^(+KXGQ^%+B?3-073I)
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M#6/AMXUC\*?8?^$ABM/[1AQ \M[YDL86/RXYF;ROF+>7@-EN/%O$/P"\/_\
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M.^R^?"DOE[]J[MN[&[:,XS@=*ZNO*?V%/^3)?A'_ -B;I/\ Z1Q5\(_L>?\
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M%P\SPPPR0^7]V21542>8,-(HVXR:ZK]AC]F[Q%^R_P#"?5M!\2>*)_%%Y?\
MB/5=7BE80;(8KJ]FG3!BMX/WCK('D!4J)&<(1&%4>#_M,? [P_\ M)?\%4CX
M)\46OVK1?$'P5O+>8#B2%O[6C*2QM_#(CA75NS*#1)_OH**NG=M+K:G*5DWU
MNM'WWNKFD8ITZK;MKH^UZBBG;JK/;MYZGT5^T?\ M._\,^^.?A9HO]A_VO\
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M+Q6O1.^ZL]VN5I3Z_/2UV^^BOINVE;1W7Z3_ +57[4'_  S+)\.U_L/^V_\
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ML9^!_P!C+_@IW^S/I'P]_M32/#FI0>)9O[ GU2XOK:SF6P&^XA\^1W0R;@'
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M7>O-IO[5EM;?VC=2"2XO=EY;KYDC#AG;&6/<Y-&'CS5(QG]I1:7E*I2BF_\
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M?_P"5EULKM7N=%.FG547K9QO_P!O.*5N_P 4;]KNUVK'U_\ L-?M4>,/VN_
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MVK?C!>:Q^SOX@^.FF^!?%4OA[0]OQ6B\*6OAA+=$V&&T!5FFDW>:9V+!MZ@
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M:[QA,3&3]YO0*0_(QQ6A^V%^T/\ \,G_ +-/B[XB?V/_ &__ ,(K9_:_[/\
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M:A-^V+=_%R/P[\=-%T2U\*RZ(^I_%Z^$WB?Q#>2W*-EH=Q,,$$<6U20N[>I
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M?S^=^;\]?)W[L\'^$_\ P3R\%_!W4?A%<Z9JGBB>3X+Z7?Z3H@NKF!ENHKP
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M>H .,CBIC[R<ET=OG:_ST:O;:ZONBI:-)]5?Y7M\M4[7WL[;&Y1110 4444
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M%_"NI:CHR[Q_K;@:-*L+MQ]]BLIS_>8^M=5\42;K_@KS\)X[4_OK3X?:]-?
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M.0:\WTG_ ()]-^T'^V_^T7KFMZA\5OANUUJFCKHWB/POJ4^AS:M:_P!G(MQ
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M$'B*/Q?\6?"NG^,9S=>(_#?ASQ3)IVAZ_,R[7DN(%4L6=0 VUU!QTR3F5?\
M@DY\.;+]E;3_ (1Z?K?CW1]!T'Q$WB;0]1L=62'5M N_->1?LUQY7RJF]PI=
M7<!B2Q;##GP]H1CS*]G!V\XR7-;IJG))N[:TD^_15?-=)[\ROY.,E'STERMI
M62:ND[*WS3^TWX_U3]ECXM_M;:AX%,VEWF@^ /".F:;/$S.^EQ.TEMYX9LG,
M4;EPS'JF2>];'[4'[$O@O_@G/\&M ^,WPKU3Q1I_Q&TW7-(34=3N?$%U>?\
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M77WK=+7Y;:=-I7Y;):6M>15.T9-_X;];VYK]K[QMS;ZWVB?#^G_!#PS^V/\
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MG_!1C1?A]H?P?\6_!7X?_$CP/J\6K^&M;\3'54ULKA3<& SS&$J $#,V6!;
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MRM7TTDKI]]%:]D]-4V7-*,Y1Z1YKV[Q3OY6=FDVT[[I'ZD45\0?LC_ [P_\
ML2_\%-_$WPK^'L>I:3\/_$'P\@\4_P!BS:E<7EO97R7[6[21><[L-Z'YOFY(
M'8 #1_X+*_$;QGHW@OX7^"O"&DZQK@^(WBM=+U'3],U^/0+K5H8X))A9+?2
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M=:^/?"&FZU917\-GJMLEU#'>V<MG<*C@$"2&55DC;!Y5E!'<5S?C;]F[P/\
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M2>CZR482E)[6LY123MMS;V3*KR]FYM;Q6JZ+FG&,4^MTI-R5^BVNT>Y?#_\
MX*O>#]8_90^('Q*\5Z%K/@_4?A3>R:3XJ\-2NEU>6-^K*BV\3C:DHDD8*C_*
M"<YV@$UROPJ_X*UZY>_$KX?:7\4/@KKWPK\-_%R58?!NO3Z[;ZE'J+N%,2W$
M,:*]JTBO'A7+'+^@+5R7_!.?Q-8^$?VY_P!MSQ/?7UKI_A'3/$-H]U>RGR[:
M!X([HW#,V<#9U8X_&O/OAOXI\4?\%K?V[/"WC>RTV\T+]G?X(ZO]NTNXNH]D
MOB/4HV5E8 ^K*A*\B.,8)#R8%T+3J4VUI*,)272,7%.3[W;?N:[V5GJTJZY(
MU%_+*<4^LFG[J[:?:^;NNON7[1/_  5GUKX5?$KQ_IO@_P""?BCQ[X9^$:QR
M>-?$!U:#2HM,1EWEK:&5&>[VJ')VE?N$_=(>OJ'X$?&K0OVC/@[X=\<^&9I+
MC0O$UDE]:-*FR15;JKKV96!4C)P5/)KY\_X*3^&K_P#;#_90\?>'?AA\7?#N
MCR>%X;H>*[&S6#4FOHXX79M-N723?9EBOS$#>0"",$YZ/_@DQ\7]"^-O_!/W
MX=ZOX<\-KX2TNULGTQ-+21I8[=[:1H7*.Q+.K,A;<Q+$L<DG)J*'O4YI[QY7
M?NI*5WVLVER]=[MW3;K:3C);2YE\U:R[WM=OIM;9H^C:*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\B_:S_8T\/\ [7FG^&_[
M4U_QEX3U;PAJ!U+2-:\+ZF-/U*RD:,QN%E*.-KH2K#;DCN***.J?9I_-:H+_
M *KY/1FO\$_V9=#^!&L^/;[2;[6+RX^(FMOK^I_;98W$5P\,<1$6R-=J;8P<
M-N.2><<#SA_^"7GPUF_9=\,?"N2Z\6?8?!=W-J&@:]#J0M==TBZEEED,T-S"
MB!6!E8 ;"I 7(8C-%%%M.7_"O_ ?A^[H--K[V_OO?[[N_J;O[+_[!'A7]F#Q
M5?>)$\0>/O'_ (RU"U_L]_$?C777UC4X[3=O^S1N0JQQ[@"0J@D@9)P*[']I
M7]F?PG^UA\,)O"?B^UNIK%IX[RUN;.X:VO--NHSNBN;>9?FCE0\@CCD@@@D$
MHHE[R2?3;RZZ=M=?77<4?==U_73\M/338\H^#O\ P2U\$_!_XMZ-X\;Q=\3O
M%OC'2=.O=+DU?Q/KXU2[U&"Y4+MF=X\XB4$1K'L5=S$JQ8FNT^%O[#7@;X7_
M +'X^!Y35-?\#-976GS)JEPINKB*XDDD<-)"L8!#2':552,#N,T442]Z+@]G
MI;RNW^<G]X1]V7,M[W^=DOR27R/+_"'_  1W^'GAG4?"=Y>>,OBUXHOO VO6
MFN:%/K_B3^T3I:VV2EC"LD6R.U)VEE15D;8@\S"@5\?_ +=?Q$^&?@K]LCQ9
MX9\7>#_CUX-\7>-+TQII'P_\;6L'AWXCQ.HC@GU!7>)H&D&$=0N0"Q+.>:**
MF*]IB:5"3TFVG\TKOU]U;W3W:;LUII&C4J+>,4U\GHO3WGM9KHTKI_H%_P $
MW/V>=4_97_8D\ >!]<6./6-)L7DO88Y1*MM+/-).T(<<-L,NS<,@[<C(-==\
M./V:]#^&'QS^(7Q T^ZU:;6?B4; ZG#<2QM:P?8X##%Y*J@9<J26W,V3TP.*
M**VJU'.I*H]W?\7?]$<]&-J:CZ?YGEVO_P#!+3X>>(/A%<>$_P"U_'&GR?\
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MXHQZW_;VHP_%C5;/6M24WHA;3KNTC2."6S>)4DB9?+5LLSG=G^$E:SOV?O\
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M;5_MT=A"MN@D%M&!BWA:5G"Q<G";C]X >I445.R2[)+[E8KJWW;?WNX4444
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MGX+_ &A/B9_PF5OXE^(WPX\37-I'I^I:AX(U]M'DUJUCX2"Z 5ED51P" &P
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M)2)&:!!$'5V$*$EG89S@#-%%9\JLUWO_ .3)*7WI)/T-.9_E^#NON;;.%/\
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MDDEF)+$DDDDFBBIC[L.2.W^6WW7=NW0<O>ESRW_X:_WV5^]CHJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773123756112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALNYLAM PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0602661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">675 West Kendall Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Henri A. Termeer Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">551-8200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01&#160;par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALNY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,525,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773122891072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 672,245<span></span>
</td>
<td class="nump">$ 866,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable debt securities</a></td>
<td class="nump">1,372,574<span></span>
</td>
<td class="nump">1,297,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">25,856<span></span>
</td>
<td class="nump">28,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">219,434<span></span>
</td>
<td class="nump">237,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">131,879<span></span>
</td>
<td class="nump">128,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">119,030<span></span>
</td>
<td class="nump">132,916<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,541,018<span></span>
</td>
<td class="nump">2,692,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">523,032<span></span>
</td>
<td class="nump">523,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">215,049<span></span>
</td>
<td class="nump">215,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="nump">49,388<span></span>
</td>
<td class="nump">49,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">63,453<span></span>
</td>
<td class="nump">66,092<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,391,940<span></span>
</td>
<td class="nump">3,546,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">62,237<span></span>
</td>
<td class="nump">98,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">508,599<span></span>
</td>
<td class="nump">545,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">43,055<span></span>
</td>
<td class="nump">41,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">35,794<span></span>
</td>
<td class="nump">42,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyLiabilityCurrent', window );">Liability related to the sale of future royalties</a></td>
<td class="nump">23,706<span></span>
</td>
<td class="nump">40,289<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">673,391<span></span>
</td>
<td class="nump">767,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">259,399<span></span>
</td>
<td class="nump">261,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">191,257<span></span>
</td>
<td class="nump">193,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt</a></td>
<td class="nump">1,017,887<span></span>
</td>
<td class="nump">1,016,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyLiabilityNoncurrent', window );">Liability related to the sale of future royalties, net of current portion</a></td>
<td class="nump">1,285,200<span></span>
</td>
<td class="nump">1,252,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">224,046<span></span>
</td>
<td class="nump">212,580<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,651,180<span></span>
</td>
<td class="nump">3,704,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value per share, 250,000 shares authorized; 124,241 shares issued and outstanding as of March&#160;31, 2023; 123,925 shares issued and outstanding as of December&#160;31, 2022</a></td>
<td class="nump">1,243<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">6,522,091<span></span>
</td>
<td class="nump">6,454,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(39,124)<span></span>
</td>
<td class="num">(44,654)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(6,743,450)<span></span>
</td>
<td class="num">(6,569,349)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(259,240)<span></span>
</td>
<td class="num">(158,223)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 3,391,940<span></span>
</td>
<td class="nump">$ 3,546,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773122488736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">124,241<span></span>
</td>
<td class="nump">123,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">124,241<span></span>
</td>
<td class="nump">123,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773122933552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 319,290<span></span>
</td>
<td class="nump">$ 213,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">41,432<span></span>
</td>
<td class="nump">23,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CostOfCollaborationManufacturingAndRoyalties', window );">Cost of collaborations and royalties</a></td>
<td class="nump">13,437<span></span>
</td>
<td class="nump">12,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">230,569<span></span>
</td>
<td class="nump">169,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">183,659<span></span>
</td>
<td class="nump">154,471<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">469,097<span></span>
</td>
<td class="nump">359,991<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(149,807)<span></span>
</td>
<td class="num">(146,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(28,955)<span></span>
</td>
<td class="num">(42,362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">18,655<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(12,255)<span></span>
</td>
<td class="num">(51,274)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(22,555)<span></span>
</td>
<td class="num">(92,624)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(172,362)<span></span>
</td>
<td class="num">(239,356)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(1,739)<span></span>
</td>
<td class="num">(985)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (174,101)<span></span>
</td>
<td class="num">$ (240,341)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (1.40)<span></span>
</td>
<td class="num">$ (2.00)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.40)<span></span>
</td>
<td class="num">$ (2.00)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used to compute basic net loss per common share (in shares)</a></td>
<td class="nump">124,111<span></span>
</td>
<td class="nump">120,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares used to compute diluted net loss per common share (in shares)</a></td>
<td class="nump">124,111<span></span>
</td>
<td class="nump">120,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (174,101)<span></span>
</td>
<td class="num">$ (240,341)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">4,125<span></span>
</td>
<td class="num">(7,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="nump">1,410<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Defined benefit pension plans, net of tax</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">5,530<span></span>
</td>
<td class="num">(4,806)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(168,571)<span></span>
</td>
<td class="num">(245,147)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">276,328<span></span>
</td>
<td class="nump">186,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_CollaborationsMember', window );">Net revenues from collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36,462<span></span>
</td>
<td class="nump">25,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">$ 442<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CostOfCollaborationManufacturingAndRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost Of Collaboration Manufacturing And Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CostOfCollaborationManufacturingAndRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_CollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_CollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773120684176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 588,203<span></span>
</td>
<td class="nump">$ 1,202<span></span>
</td>
<td class="nump">$ 6,058,453<span></span>
</td>
<td class="num">$ (33,259)<span></span>
</td>
<td class="num">$ (5,438,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings</a></td>
<td class="nump">28,059<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">28,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">30,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(4,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(240,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(240,341)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 401,166<span></span>
</td>
<td class="nump">$ 1,207<span></span>
</td>
<td class="nump">6,116,558<span></span>
</td>
<td class="num">(38,065)<span></span>
</td>
<td class="num">(5,678,534)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">123,925<span></span>
</td>
<td class="nump">123,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">$ (158,223)<span></span>
</td>
<td class="nump">$ 1,240<span></span>
</td>
<td class="nump">6,454,540<span></span>
</td>
<td class="num">(44,654)<span></span>
</td>
<td class="num">(6,569,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings</a></td>
<td class="nump">26,418<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">26,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock under equity plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">41,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">5,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (174,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174,101)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">124,241<span></span>
</td>
<td class="nump">124,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="num">$ (259,240)<span></span>
</td>
<td class="nump">$ 1,243<span></span>
</td>
<td class="nump">$ 6,522,091<span></span>
</td>
<td class="num">$ (39,124)<span></span>
</td>
<td class="num">$ (6,743,450)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773123872320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (174,101)<span></span>
</td>
<td class="num">$ (240,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Non-cash adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">14,065<span></span>
</td>
<td class="nump">9,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases', window );">Amortization and interest accretion related to operating leases</a></td>
<td class="nump">12,014<span></span>
</td>
<td class="nump">10,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="nump">25,275<span></span>
</td>
<td class="nump">27,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">39,947<span></span>
</td>
<td class="nump">29,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Realized and unrealized loss on marketable equity securities</a></td>
<td class="nump">2,267<span></span>
</td>
<td class="nump">31,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_ChangeInFairValueOfLiabilityObligation', window );">Change in fair value of development derivative liability</a></td>
<td class="nump">6,471<span></span>
</td>
<td class="nump">13,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(6,276)<span></span>
</td>
<td class="nump">7,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">19,153<span></span>
</td>
<td class="nump">39,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(403)<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,235)<span></span>
</td>
<td class="num">(29,852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="num">(81,975)<span></span>
</td>
<td class="num">(48,736)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(12,827)<span></span>
</td>
<td class="num">(10,672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(8,850)<span></span>
</td>
<td class="num">(12,325)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(166,475)<span></span>
</td>
<td class="num">(171,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(13,891)<span></span>
</td>
<td class="num">(17,859)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(435,746)<span></span>
</td>
<td class="num">(634,705)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and maturities of marketable securities</a></td>
<td class="nump">373,420<span></span>
</td>
<td class="nump">505,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from maturity of restricted investments</a></td>
<td class="nump">49,225<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases of restricted investments</a></td>
<td class="num">(49,225)<span></span>
</td>
<td class="num">(9,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(76,217)<span></span>
</td>
<td class="num">(147,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and other types of equity, net</a></td>
<td class="nump">42,371<span></span>
</td>
<td class="nump">27,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities', window );">Proceeds from development derivative</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">7,833<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">46,371<span></span>
</td>
<td class="nump">34,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,176<span></span>
</td>
<td class="num">(2,238)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(194,145)<span></span>
</td>
<td class="num">(285,894)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">868,556<span></span>
</td>
<td class="nump">822,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">674,411<span></span>
</td>
<td class="nump">536,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">13,912<span></span>
</td>
<td class="nump">14,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 4,034<span></span>
</td>
<td class="nump">$ 8,318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Interest Accretion Related to Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_AmortizationAndInterestAccretionRelatedToOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ChangeInFairValueOfLiabilityObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of liability obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ChangeInFairValueOfLiabilityObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense On Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NonCashInterestExpenseOnSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773126110160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF BUSINESS</a></td>
<td class="text">NATURE OF BUSINESS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June&#160;14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on ribonucleic acid interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top-tier biotech company by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, while delivering exceptional financial performance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, we have five marketed products, including one partnered product, and multiple late-stage investigational programs advancing towards potential commercialization. We currently generate worldwide product revenues from four commercialized products, ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO, primarily in the United States, or U.S., Europe and Japan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773125432720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</a></td>
<td class="text">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements of Alnylam are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2022, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 23, 2023. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of March&#160;31, 2023, together with the cash we expect to generate from product sales and under our current alliances, will be sufficient to enable us to advance our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773126273616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET PRODUCT REVENUES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">NET PRODUCT REVENUES</a></td>
<td class="text">NET PRODUCT REVENUES<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net product revenues consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.362%"><tr><td style="width:1.0%"/><td style="width:60.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.558%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ONPATTRO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMVUTTRA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GIVLAARI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OXLUMO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,328&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the balance of our receivables related to our net product revenues: </span></div><div style="margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"><tr><td style="width:1.0%"/><td style="width:57.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773127312752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">NET REVENUES FROM COLLABORATIONS</a></td>
<td class="text">NET REVENUES FROM COLLABORATIONS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net revenues from collaborations consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"><tr><td style="width:1.0%"/><td style="width:62.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.649%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,462&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,945&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.502%"><tr><td style="width:1.0%"/><td style="width:56.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.662%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities included in &#8220;Deferred revenue&#8221;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized revenue of $15.4 million and $9.5 million in the three months ended March&#160;31, 2023 and 2022, respectively, that was included in the contract liability balance at the beginning of the period. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to determine revenue recognized in the period from contract liabilities, we first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability as opposed to a portion applying to the new consideration for the period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides research and development expenses incurred by type, for which we recognize net revenue, that are directly attributable to our collaboration agreements, by collaboration partner:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:24.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Trial and Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">External Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Trial and Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">External Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,828&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The research and development expenses incurred for the agreements included in the table above consist of costs incurred for (i) clinical expenses, including manufacturing of clinical product, (ii) external services including consulting services and lab supplies and services, and (iii) other expenses, including professional services, facilities and overhead allocations, and a reasonable estimate of compensation and related costs as billed to our counterparties, for which we recognize net revenues from collaborations. For the three months ended March&#160;31, 2023 and 2022, we did not incur material selling, general and administrative expenses related to our collaboration agreements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we recognized a reduction to our research and development expenses of $5.7&#160;million and $3.9&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, from cost reimbursement due under certain of our collaboration agreements with Regeneron Pharmaceuticals, Inc., or Regeneron, accounted for under Accounting Standards Codification, or ASC, Topic 808, Collaborative Arrangements, or ASC 808. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product Alliances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Regeneron Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April&#160;2019, we entered into a global, strategic collaboration with Regeneron to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the eye and central nervous system, or CNS, in addition to a select number of targets expressed in the liver, which we refer to as the Regeneron Collaboration. The Regeneron Collaboration is governed by a Master Agreement, referred to as the Regeneron Master Agreement, which became effective on May 21, 2019. In connection with the Regeneron Master Agreement, we and Regeneron entered into (i) a binding co-co collaboration term sheet covering the continued development of cemdisiran, our C5 small </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">interfering RNA, or siRNA, currently in Phase 2 development for C5 complement-mediated diseases, as a monotherapy and (ii) a binding license term sheet to evaluate anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases including evaluating the combination of Regeneron&#8217;s pozelimab (REGN3918), currently in Phase 3 development, and cemdisiran. The C5 co-co collaboration and license agreements were executed in August 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the Regeneron Collaboration, we are working exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases for an initial research period of approximately five years, which we refer to as the Initial Research Term. Regeneron has an option to extend the Initial Research Term (referred to as the Research Term Extension Period, and together with the Initial Research Term, the Research Term) for up to an additional five years, for a research term extension fee of $300.0 million. The Regeneron Collaboration also covers a select number of RNAi therapeutic programs designed to target genes expressed in the liver, including our previously announced collaboration with Regeneron to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis. We retain broad global rights to all of our other unpartnered liver-directed clinical and pre-clinical pipeline programs. The Regeneron Collaboration is governed by a joint steering committee that is comprised of an equal number of representatives from each party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regeneron leads development and commercialization for all programs targeting eye diseases (subject to limited exceptions), entitling us to certain potential milestone and royalty payments pursuant to the terms of a license agreement, the form of which has been agreed upon by the parties. We and Regeneron are alternating leadership on CNS and liver programs covered by the Regeneron Collaboration, with the lead party retaining global development and commercial responsibility. For such CNS and liver programs, both we and Regeneron have the option at lead candidate selection to enter into a&#160;co-co&#160;collaboration agreement, the form of which has been agreed upon by the parties, whereby both companies will share equally all costs of, and profits from, all development and commercialization activities under the program. If the&#160;non-lead&#160;party elects to not enter into a&#160;co-co&#160;collaboration agreement with respect to a given CNS or liver program, we and Regeneron will enter into a license agreement with respect to such program and the lead party will be the &#8220;Licensee&#8221; for the purposes of the license agreement. If the lead party for a CNS or liver program elects to not enter into the&#160;co-co&#160;collaboration agreement, then we and Regeneron will enter into a license agreement with respect to such program and leadership of the program will transfer to the other party and the former&#160;non-lead&#160;party will be the &#8220;Licensee&#8221; for the purposes of the license agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to the programs directed to C5 complement-mediated diseases, we retain control of cemdisiran monotherapy development, and Regeneron is leading combination product development. Pursuant to the C5 co-co collaboration agreement, Regeneron notified us in November 2022 of its decision to exercise its right to opt-out of the further development and commercialization of cemdisiran monotherapy. As a result, Regeneron no longer shares costs and potential future profits on any monotherapy program with us. We continue to perform our obligations under the agreement and we are solely responsible for all development and commercialization costs. Regeneron will be eligible to receive tiered double-digit royalties on net sales. Under the C5 license agreement, for cemdisiran to be used as part of a combination product, Regeneron is solely responsible for all development and commercialization costs and we will receive low double-digit royalties and commercial milestones of up to $325.0 million on any potential combination product sales. The C5 co-co collaboration agreement, the C5 license agreement, and the Master Agreement have been combined for accounting purposes and treated as a single agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Regeneron Master Agreement, Regeneron made an upfront payment of $400.0 million. We are also eligible to receive up to an additional $200.0 million in milestone payments upon achievement of certain criteria during early clinical development for eye and CNS programs. We and Regeneron plan to advance programs directed to up to 30 targets in the first five years under the Regeneron Collaboration during the Initial Research Term. For each program, Regeneron will provide us with $2.5 million in funding at program initiation and an additional $2.5 million at lead candidate identification, with the potential for approximately $30.0 million in annual discovery funding to us as the Regeneron Collaboration reaches steady state.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regeneron has the right to terminate the Regeneron Master Agreement for convenience upon ninety days&#8217; notice. The termination of the Regeneron Master Agreement does not affect the term of any license agreement or&#160;co-co&#160;collaboration agreement then in effect. In addition, either party may terminate the Regeneron Master Agreement for a material breach by, or insolvency of, the other party. Unless earlier terminated pursuant to its terms, the Regeneron Master Agreement will remain in effect with respect to each program until (a)&#160;such program becomes a terminated program or (b)&#160;the parties enter into a license agreement or&#160;co-co&#160;collaboration agreement with respect to such program.&#160;The Regeneron Master Agreement includes various representations, warranties, covenants, dispute escalation and resolution mechanisms, indemnities and other provisions customary for transactions of this nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For any license agreement subsequently entered into, the licensee will generally be responsible for its own costs and expenses incurred in connection with the development and commercialization of the collaboration products. The licensee will pay to the licensor certain development and/or commercialization milestone payments totaling up to $150.0 million for each collaboration product. In addition, following the first commercial sale of the applicable collaboration product under a license </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">agreement, the licensee is required to make certain tiered royalty payments, ranging from low double-digits up to 20%, to the licensor based on the aggregate annual net sales of the collaboration product, subject to customary reductions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For any co-co&#160;collaboration agreement subsequently entered into, we and Regeneron will share equally all costs of, and profits from, development and commercialization activities. Reimbursement of our share of costs will be recognized as a reduction to research and development expense in the condensed consolidated statements of operations and comprehensive loss. In the event that a party exercises its&#160;opt-out&#160;right, the lead party will be responsible for all costs and expenses incurred in connection with the development and commercialization of the collaboration products under the applicable&#160;co-co&#160;collaboration agreement, subject to continued sharing of costs through defined points. If a party exercises its&#160;opt-out&#160;right, following the first commercial sale of the applicable collaboration product under a&#160;co-co&#160;collaboration agreement, the lead party is required to make certain tiered royalty payments, ranging from low double-digits up to 20%, to the other party based on the aggregate annual net sales of the collaboration product and the timing of the exercise of the&#160;opt-out&#160;right, subject to customary reductions and a reduction for&#160;opt-out&#160;transition costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any milestone or royalty payments from Regeneron under the Regeneron Master Agreement, the C5 license agreement, or any future license agreement, or under any co-co collaboration agreement in the event we exercise our opt-out right.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our obligations under the Regeneron Collaboration include: (i) a research license and research services, collectively referred to as the Research Services Obligation; (ii) a worldwide license to cemdisiran for combination therapies, and manufacturing and supply, and development service obligations, collectively referred to as the C5 License Obligation; and (iii) development, manufacturing and commercialization activities for cemdisiran monotherapies, referred to as the C5 Co-Co Obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The research license is not distinct from the research services primarily as a result of Regeneron being unable to benefit on its own or with other resources reasonably available, as the license is providing access to specialized expertise, particularly as it relates to RNAi technology that is not available in the marketplace.&#160;Similarly, the worldwide license to cemdisiran for combination therapies is not distinct from the manufacturing and supply, and development service obligations, as Regeneron cannot benefit on its own from the value of the license without receipt of supply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separately, prior to Regeneron&#8217;s decision in November 2022 to exercise its right to opt-out of the further development and commercialization of cemdisiran monotherapy, the cemdisiran monotherapy co-co collaboration agreement was under the scope of ASC 808 as we and Regeneron were both active participants in the development and manufacturing activities and were exposed to significant risks and rewards that were dependent on commercial success of the activities of the arrangement. Regeneron&#8217;s decision to exercise its right to opt-out of the arrangement caused a change in the role of Regeneron and its exposure to significant risks and rewards under the arrangement. As a result, we determined that the arrangement no longer represents a collaborative arrangement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The arrangement now represents a vendor-customer relationship under ASC 606 as we perform our obligation to provide development and manufacturing activities under the arrangement. The transaction price allocated to the C5 Co-Co obligation unit of account will be recognized over time using an input method based on cost incurred relative to the total estimated costs for the identified performance obligation by determining the proportion of effort incurred as a percentage of total effort we expect to expend.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total transaction price is comprised of the&#160;$400.0 million&#160;upfront payment and&#160;additional variable consideration related to research, development, manufacturing and supply activities related to the Research Services Obligation and the C5 License Obligation. We utilized the expected value method to determine the amount of reimbursement for these activities. We determined that any variable consideration related to sales-based royalties and milestones related to the worldwide license to cemdisiran for combination therapies is deemed to be constrained and therefore has been excluded from the transaction price. In addition, we are eligible to receive future milestones upon the achievement of certain criteria during early clinical development for the eye and CNS programs.&#160;We are also eligible to receive royalties on future commercial sales for certain eye, CNS or liver targets, if any; however, these amounts are excluded from variable consideration under the Regeneron Collaboration as we are only eligible to receive such amounts if, after a drug candidate is identified, the form of license agreement is subsequently executed resulting in a license that is granted to Regeneron. Any such subsequently granted license would represent a separate transaction under ASC 606. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.713%"><tr><td style="width:1.0%"/><td style="width:38.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.689%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Performance Obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Standalone Selling Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Transaction Price Allocated</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">130,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">183,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">97,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">92,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">364,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">246,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">521,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transaction price was allocated to the obligations based on the relative estimated standalone selling prices of each obligation, over which management has applied significant judgment. We developed the estimated standalone selling price for the licenses included in the Research Services Obligation and the C5 License Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we applied judgment in the determination of the forecasted revenues, taking into consideration the applicable market conditions and relevant entity-specific factors, the expected number of targets or indications expected to be pursued under each license, the probability of success, the time needed to develop a product candidate pursuant to the associated license and the discount rate. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the obligations, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs. The estimated standalone selling price of the C5 Co-Co Obligation was developed by estimating the present value of expected future cash flows that Regeneron is entitled to receive. In developing such estimate, we applied judgment in determining the indications that will be pursued, the forecasted revenues for such indications, the probability of success and the discount rate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the Research Services Obligation, the C5 License Obligation, and the C5 Co-Co Obligation accounted for under ASC 606, we measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for each of the identified obligations, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&#160;This ratio is applied to the transaction price allocated to each obligation. Management has applied significant judgment in the process of developing our estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. We re-evaluate the transaction price as of the end of each reporting period and as of March&#160;31, 2023, the total transaction price was determined to be $559.6 million. Revenue recognized under this agreement is accounted for as collaboration revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables provide a summary of the transaction price allocated to each unit of account based on the applicable accounting guidance, in addition to revenue activity during the period, in thousands:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.561%"><tr><td style="width:1.0%"/><td style="width:31.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.668%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Transaction Price Allocated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">215,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">246,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">191,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">193,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">559,580&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">220,100&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">226,800&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.994%"><tr><td style="width:1.0%"/><td style="width:41.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.317%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue Recognized During</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15,400&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,800&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of&#160;March&#160;31, 2023, the aggregate amount of the transaction price allocated to the remaining Research Services Obligation, C5 License Obligation and C5 Co-Co Obligation that was unsatisfied was&#160;$274.4&#160;million, which&#160;is expected to be recognized through the term of the Regeneron Collaboration as the services are performed. Deferred revenue related to the Regeneron Collaboration is classified as either current or non-current in the condensed consolidated balance sheets based on the period the revenue is expected to be recognized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Novartis AG</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">2013 Collaboration with The Medicines Company</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2013, we and The Medicines Company, or MDCO, entered into a license and collaboration agreement pursuant to which we granted to MDCO an exclusive, worldwide license to develop, manufacture and commercialize RNAi therapeutics targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of hypercholesterolemia and other human diseases, including inclisiran. We refer to this agreement, as amended through the date hereof, as the MDCO License Agreement. In 2020, Novartis AG, or Novartis, completed its acquisition of MDCO and assumed all rights and obligations under the MDCO License Agreement. Additional details regarding the terms, milestones earned upon the achievement of certain events and additional milestones we are entitled to receive upon the achievement of future events under the MDCO License Agreement are described in Note 4 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on February 23, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Novartis License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, we and Novartis entered into a collaboration and license agreement, or the Novartis License Agreement, pursuant to which we granted to Novartis an exclusive, worldwide license to develop, manufacture and commercialize siRNAs targeting end-stage liver disease, or ESLD, potentially leading to the development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure. Additional details regarding the terms and transaction price under the Novartis License Agreement are described in Note 4 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on February 23, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the collaboration agreements discussed above, we have various other collaboration agreements that are not individually significant to our operating results or financial condition at this time. Pursuant to the terms of those agreements, we may be required to pay, or we may receive, additional amounts contingent upon the occurrence of various future events (e.g., upon the achievement of various development and commercial milestones) which in the aggregate could be significant. We may also incur, or be reimbursed for, significant research and development costs. In addition, if any products related to these collaborations are approved for sale, we may be required to pay, or we may receive, royalties on future sales. The payment or receipt of these amounts, however, is contingent upon the occurrence of various future events.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773127352336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock', window );">LIABILITY RELATED TO SALE OF FUTURE ROYALTIES</a></td>
<td class="text">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we entered into a purchase and sale agreement, or Purchase Agreement, with BX Bodyguard Royalties L.P. (an affiliate of The Blackstone Group Inc.), or Blackstone Royalties, under which Blackstone Royalties acquired 50% of royalties payable, or Royalty Interest, with respect to net sales by MDCO, its affiliates or sublicensees of inclisiran (or the branded drug product, Leqvio) and any other licensed products under the MDCO License Agreement, and 75% of the commercial milestone payments payable under the MDCO License Agreement, together with the Royalty Interest, the Purchased Interest. If Blackstone Royalties does not receive payments in respect of the Royalty Interest by December 31, 2029, equaling at least $1.00&#160;billion, Blackstone Royalties will receive 55% of the Royalty Interest beginning on January 1, 2030. In consideration for the sale of the Purchased Interest, Blackstone Royalties paid us $1.00&#160;billion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continue to own or control all inclisiran intellectual property rights and are responsible for certain ongoing manufacturing and supply obligations related to the generation of the Purchased Interest. Due to our continuing involvement, we will continue to account for any royalties and commercial milestones due to us under the MDCO License Agreement as revenue on our condensed consolidated statement of operations and comprehensive loss and record the proceeds from this transaction as a liability, net of closing costs, on our condensed consolidated balance sheet. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to determine the amortization of the liability related to the sale of future royalties, we are required to estimate the total amount of future payments to Blackstone Royalties over the life of the Purchase Agreement. The $1.00&#160;billion liability, recorded at execution of the agreement, will be accreted to the total of these royalty and commercial milestone payments as interest expense over the life of the Purchase Agreement. As of March&#160;31, 2023, our estimate of this total interest expense resulted in an effective annual interest rate of 8%. These estimates contain assumptions that impact both the amount recorded at execution and the interest expense that will be recognized in future periods. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As payments are made to Blackstone Royalties, the balance of the liability will be effectively repaid over the life of the Purchase Agreement. The exact timing and amount of repayment is likely to change each reporting period. A significant increase or decrease in Leqvio global net revenue will materially impact the liability related to the sale of future royalties, interest expense and the time period for repayment. We will periodically assess the expected payments to Blackstone Royalties </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and to the extent the amount or timing of such payments is materially different than our initial estimates, we will prospectively adjust the amortization of the liability related to the sale of future royalties and the related interest expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the carrying value of the liability related to the sale of future royalties was $1.31&#160;billion, net of closing costs of $10.6&#160;million. The carrying value of the liability related to the sale of future royalties approximates fair value as of March&#160;31, 2023 and is based on our current estimates of future royalties and commercial milestones expected to be paid to Blackstone Royalties over the life of the arrangement, which are considered Level 3 inputs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the activity with respect to the liability related to the sale of future royalties, in thousands:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.134%"><tr><td style="width:1.0%"/><td style="width:81.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,673)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,308,906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773127107824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables present information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:48.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618,075&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,762&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:48.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The carrying amounts reflected on our condensed consolidated balance sheets for cash, accounts receivable, net, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term maturities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773126247088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE DEBT SECURITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock', window );">MARKETABLE DEBT SECURITIES</a></td>
<td class="text">MARKETABLE DEBT SECURITIES<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We invest our excess cash balances in marketable debt securities and at each balance sheet date presented, we classify all of our investments in debt securities as available-for-sale and as current assets as they represent the investment of funds available for current operations. We did not record any impairment charges related to our marketable debt securities during the three months ended March&#160;31, 2023 or 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize our marketable debt securities:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,391)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382,107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,966)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,762&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,382)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420,603&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,589)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411,133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments in marketable debt securities disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773127107824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER BALANCE SHEET DETAILS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">OTHER BALANCE SHEET DETAILS</a></td>
<td class="text">OTHER BALANCE SHEET DETAILS<div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inventory</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of inventory are summarized as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,385&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023 and December&#160;31, 2022, we had $31.5 million and $32.7 million of long-term inventory, respectively, included within other assets in our condensed consolidated balance sheet as we anticipate it being consumed beyond our normal operating cycle.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674,411&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accumulated Other Comprehensive (Loss) Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the changes in accumulated other comprehensive (loss) income, by component:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss on Investment in Joint Venture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized (Losses) Gains from Debt</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other<br/>Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,092)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,654)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,097)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,345)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,124)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss on Investment in Joint Venture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized (Losses) Gains from Debt</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other<br/>Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,811)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,259)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,217)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,806)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,776)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,847)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,065)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts reclassified out of accumulated other comprehensive loss relate to settlements of marketable equity securities and amortization of our pension obligation which are recorded as other income in the condensed consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773122526064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE DEBT</a></td>
<td class="text">CONVERTIBLE DEBT<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Convertible Senior Notes Due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September&#160;12, 2022, we commenced a private offering of $900.0&#160;million in aggregate principal amount of 1% Convertible Senior Notes due 2027, or the Initial Notes. On September&#160;13, 2022, the initial purchasers in such offering exercised their option to purchase an additional $135.0&#160;million in aggregate principal amount of our 1% Convertible Senior Notes due 2027, or the Additional Notes, and together with the Initial Notes collectively referred to as the Notes, bringing the total aggregate principal amount of the Notes to $1.04&#160;billion. The Notes were issued pursuant to an indenture, dated September&#160;15, 2022, or the Indenture. The Indenture includes customary covenants and sets forth certain events of default after which the Notes may be declared immediately due and payable and sets forth certain types of bankruptcy or insolvency events of default involving the Company after which the Notes become automatically due and payable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Notes will mature on September&#160;15, 2027, unless earlier converted, redeemed or repurchased. The Notes will bear interest from September&#160;15, 2022 at a rate of 1% per year payable semiannually in arrears on March 15 and September 15 of each year, beginning on March&#160;15, 2023. The Notes are convertible at the option of the noteholder on or after June 15, 2027. Prior to June 15, 2027, the Notes are convertible only under the following circumstances: (1) During any calendar quarter commencing after the calendar quarter ending on December 31, 2022 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) During the five business day period after any ten consecutive trading day period in which the trading price per $1,000 principal amount of the Notes for each trading day of that ten consecutive trading day period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate of the Notes on such trading day; (3) If we call any or all of the Notes for redemption; or (4) Upon the occurrence of specific corporate events as set forth in the Indenture governing the Notes. We will settle any conversions of Notes by paying or delivering, as applicable, cash, shares of our common stock, or a combination of cash and shares of common stock, at our election.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The conversion rate for the Notes will initially be 3.4941 shares of common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $286.20 per share of common stock. The initial conversion price of the Notes represents a premium of approximately 35% over the $212.00 per share last reported sale price of common stock on September 12, 2022. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the Indenture.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may not redeem the Notes prior to September&#160;20, 2025. We may redeem for cash equal to 100% of the principal amount of the Notes being redeemed plus accrued and unpaid interest of all or any portion of the Notes, at our option, on or after September 20, 2025, if the last reported sales price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period. No sinking fund is provided for the Notes and therefore we are not required to redeem or retire the Notes periodically.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we undergo a fundamental change, as defined in the indenture agreement, then subject to certain conditions, holders may require us to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased plus accrued and unpaid interest. In addition, if specific corporate events occur prior to the maturity date or if we issue a notice of redemption, we will increase the conversion rate by pre-defined amounts for holders who elect to convert their notes in connection with such corporate event. The conditions allowing holders of the Notes to convert were not met this quarter. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the Notes are classified as a long-term liability, net of issuance costs of $19.2 million, on the condensed consolidated balance sheets. As of March&#160;31, 2023, the estimated fair value of the Notes was approximately $1.03&#160;billion. The fair value was determined based on the last actively traded price per $100 of the Notes for the three months ended March 31, 2023 (Level 2). The Notes were issued at par and costs associated with the issuance of the Notes are amortized to&#160;interest expense over the contractual term of the Notes. As of March&#160;31, 2023, the effective interest rate of the Notes is&#160;1%.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Capped Call Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2022, in connection with the pricing of the Initial Notes and the initial purchasers&#8217; exercise of their option to purchase the Additional Notes, we entered into privately negotiated capped call transactions, or Capped Call Transactions. The Capped Call Transactions initially cover, subject to customary anti-dilution adjustments, the number of shares of common stock that underlie the Notes. The cap price of the Capped Call Transactions is initially $424.00 per share, which represents a premium of 100% over the last reported sale price of common stock of $212.00 per share on September 12, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. We used approximately $118.6&#160;million of the proceeds from the offering of Notes to pay the cost of the Capped Call Transactions.</span></div>We evaluated the Capped Call Transactions and determined that they should be accounted for separately from the Notes. The cost of $118.6&#160;million to purchase the Capped Call Transactions was recorded as a reduction to additional paid-in capital in the condensed consolidated balance sheet as of March&#160;31, 2023 as the Capped Call Transactions are indexed to our own stock and met the criteria to be classified in stockholders' equity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773126161888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT DERIVATIVE LIABILITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DEVELOPMENT DERIVATIVE LIABILITY</a></td>
<td class="text">DEVELOPMENT DERIVATIVE LIABILITY<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, we entered into a co-development agreement, referred to as the Funding Agreement, with BXLS V Bodyguard &#8211; PCP L.P. and BXLS Family Investment Partnership V &#8211; ESC L.P., collectively referred to as Blackstone Life Sciences, pursuant to which Blackstone Life Sciences will provide up to $150.0&#160;million in funding for the clinical development of vutrisiran and zilebesiran, two of our cardiometabolic programs. With respect to vutrisiran, Blackstone Life Sciences has committed to provide up to $70.0&#160;million to fund development costs related to the HELIOS-B Phase 3 clinical trial. In November 2021, Blackstone Life Sciences opted in to Phase 2 clinical trial funding of zilebesiran, committing to fund, upon meeting certain patient enrollment thresholds, up to $26.0&#160;million. Furthermore, Blackstone Life Sciences has the right, but is not obligated, to fund up to $54.0&#160;million for development costs related to a Phase 3 clinical trial of zilebesiran. The amount of funding ultimately provided by Blackstone Life Sciences is dependent on us achieving specified development milestones with respect to each clinical trial. We retain sole responsibility for the development and commercialization of both vutrisiran and zilebesiran.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As consideration for Blackstone Life Sciences&#8217; funding for vutrisiran clinical development costs, we have agreed to pay Blackstone Life Sciences a 1% royalty on net sales of AMVUTTRA (vutrisiran) for a 10-year term beginning upon the first commercial sale following regulatory approval of vutrisiran for ATTR-cardiomyopathy, as well as fixed payments of up to 2.5 times their investment over a two-year period upon regulatory approval of vutrisiran for ATTR-cardiomyopathy in specified countries, unless it is later withdrawn from the market following a mandatory recall. As consideration for Blackstone Life Sciences&#8217; funding for Phase 2 clinical development costs of zilebesiran, we have agreed to pay Blackstone Life Sciences fixed payments of up to 3.25 times their Phase 2 investment over a four-year period upon the successful completion of the zilebesiran Phase 2 clinical trial, unless certain regulatory events affecting the continued development of zilebesiran occur. As </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">consideration for Blackstone Life Sciences&#8217; funding for Phase 3 clinical development costs of zilebesiran, we have agreed to pay Blackstone Life Sciences fixed payments of up to 4.5 times their Phase 3 investment over a four-year period upon regulatory approval of zilebesiran in specified countries, unless it is later withdrawn from the market following a mandatory recall.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our payment obligations under the Funding Agreement will be secured, subject to certain exceptions, by security interests in intellectual property owned by us relating to vutrisiran and zilebesiran, as well as in our bank account in which the funding deposits will be made.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and Blackstone Life Sciences each have the right to terminate the Funding Agreement in its entirety in the event of the other party&#8217;s bankruptcy or similar proceedings. We and Blackstone Life Sciences may each terminate the Funding Agreement in its entirety or with respect to either product in the event of an uncured material breach by the other party, or with respect to a product for certain patient health and safety reasons, or if regulatory approval in specified major market countries is not obtained for the product following the completion of clinical trials for the product. In addition, Blackstone Life Sciences has the right to terminate the Funding Agreement in its entirety upon the occurrence of certain events affecting our ability to make payments under the agreement or to develop or commercialize the products, or upon a change of control of us. Blackstone Life Sciences may also terminate the Funding Agreement with respect to a product if the joint steering committee elects to terminate the development program for that product in its entirety, if certain clinical endpoints are not achieved for that product or, with respect to vutrisiran only, if our right to develop or commercialize vutrisiran is enjoined in a specified major market as a result of an alleged patent infringement. In certain termination circumstances, we will be obligated to pay Blackstone Life Sciences an amount that is equal to, or a multiplier of, the development funding received from Blackstone Life Sciences, and we may remain obligated under certain circumstances to make the payments to Blackstone Life Sciences described above, or the royalty described above in the case of AMVUTTRA, should we obtain regulatory approval for zilebesiran or vutrisiran for ATTR-cardiomyopathy following termination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We account for the Funding Agreement under ASC Topic 815, Derivatives and Hedging, as a derivative liability, measured at fair value, within other liabilities on our condensed consolidated balance sheets. The change in fair value due to the remeasurement of the development derivative liability is recorded as other expense on our condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the derivative liability is classified as a Level 3 financial liability in the fair value hierarchy. The valuation method incorporates certain unobservable Level 3 key inputs including (i) the probability and timing of achieving stated development milestones to receive payments from Blackstone Life Sciences, (ii) the probability and timing of achieving regulatory approval and payments to Blackstone Life Sciences, (iii) an estimate of the amount and timing of the royalty payable on net sales of AMVUTTRA, assuming regulatory approval for ATTR-cardiomyopathy, (iv) our cost of borrowing (12%), and (v) Blackstone Life Sciences' cost of borrowing (4%).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the activity with respect to the development derivative liability, in thousands:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"/><td style="width:81.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount received under the Funding Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recorded from remeasurement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">219,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773124225888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes stock-based compensation expenses included in operating costs and expenses:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"/><td style="width:60.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.395%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.398%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,947&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773124252688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER COMMON SHARE</a></td>
<td class="text">NET LOSS PER COMMON SHAREWe compute basic net loss per common share by dividing net loss by the weighted-average number of common shares outstanding. We compute diluted net loss per common share by dividing net loss by the weighted-average number of common <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">shares and dilutive potential common share equivalents then outstanding during the period. In the diluted net loss per share calculation, net loss would be adjusted for the elimination of interest expense on the Convertible debt. Potential common shares consist of shares issuable upon the vesting of restricted stock units, the exercise of stock options (the proceeds of which are then assumed to have been used to repurchase outstanding shares using the treasury stock method) and upon conversion of the convertible debt outstanding during the period (calculated using the if-converted method assuming the conversion of the convertible debt as of the earliest period reported or at the date of issuance, if later). Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the potential common shares (prior to consideration of the treasury stock or if-converted methods) excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock, inclusive of performance-based stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units, inclusive of performance-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,591&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,703&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773124271056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Technology License and Other Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have licensed from third parties the rights to use certain technologies and information in our research processes as well as in any other products we may develop. In accordance with the related license or technology agreements, we are required to make certain fixed payments to the licensor or a designee of the licensor over various agreement terms. Many of these agreement terms are consistent with the remaining lives of the underlying intellectual property that we have licensed. As of March 31, 2023, our commitments over the next five years to make fixed and cancellable payments under existing license agreements were not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may be a party to litigation, arbitration or other legal proceedings in the course of our business, including the matters described below. The claims and legal proceedings in which we could be involved include challenges to the scope, validity or enforceability of patents relating to our products or product candidates, and challenges by us to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents or breach our license or other agreements with such third parties. The outcome of any such legal proceedings, regardless of the merits, is inherently uncertain. In addition, litigation and related matters are costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. If we were unable to prevail in any such legal proceedings, our business, results of operations, liquidity and financial condition could be adversely affected. Our accounting policy for accrual of legal costs is to recognize such expenses as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Government Investigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have previously disclosed that, on or about April 9, 2021, we received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of Massachusetts, requiring production of documents pertaining to our marketing and promotion of ONPATTRO (patisiran) in the U.S. We are cooperating with the U.S. Attorney&#8217;s Office and producing documents in response to the subpoena. Current and former officers and employees also have received subpoenas in connection with the preservation and production of related materials. Given the ongoing nature of the investigation, it is possible that the U.S. Attorney&#8217;s Office for the District of Massachusetts or other government entities may request other information from, or issue other subpoenas, findings or similar documents to, us, our related entities and their respective directors, officers and employees. In light of the ongoing nature of the investigation, no determination has been made that a loss, if any, arising from this matter is probable or that the amount of any such loss, or range of loss, is reasonably estimable. We also previously disclosed that since learning of this federal government investigation, our nominating and corporate governance committee is directing our review of and response to the matter.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Patent Infringement Lawsuits</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022, we filed separate lawsuits in the U.S. District Court for the District of Delaware against (1) Pfizer, Inc. and its subsidiary Pharmacia &amp; Upjohn Co. LLC, collectively referred to as Pfizer, and (2) Moderna, Inc., and its subsidiaries </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ModernaTX, Inc., and Moderna US, Inc., collectively referred to as Moderna. The lawsuits seek damages for infringement of U.S. Patent No. 11,246,933, or &#8216;933 Patent, in Pfizer&#8217;s and Moderna&#8217;s manufacture and sale of their messenger RNA, or mRNA, COVID-19 vaccines. The patent relates to the Company&#8217;s biodegradable cationic lipids that are foundational to the success of the mRNA COVID-19 vaccines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are seeking judgment that each of Pfizer and Moderna is infringing the &#8216;933 Patent, as well as damages adequate to compensate for the infringement, but in no event less than a reasonable royalty for the unlicensed uses made of our patented lipids by Pfizer and Moderna, together with interest and costs as may be awarded by the court. As stated in the filed complaints, we are not seeking injunctive relief in these lawsuits.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 23, 2022, Moderna filed a partial motion to dismiss, asserting an affirmative defense under Section 1498(a). We responded on May 27, 2022, opposing their motion arguing Moderna had significant non-government sales and the government contract ended in April 2022. Moderna responded on June 13, 2022, requesting a partial motion to dismiss those claims for sales under 1498(a).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 27, 2022, Pfizer filed an answer to our complaint, denying the allegations, and asserting invalidity and non-infringement defenses. In addition, Pfizer added BioNTech SE to the suit and added counter-claims seeking a declaratory judgment that our patent is invalid and a second claim alleging that our patent is invalid due to patent misuse. We believe their defenses and counter-claims have no merit and responded on June 10, 2022, with substantive arguments as to the validity of our claims and the lack of merit of their patent misuse claim.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 12, 2022, we filed a new lawsuit against each of Pfizer and Moderna seeking damages for infringing our newly granted U.S. Patent No. 11,382,979 in Pfizer&#8217;s and Moderna&#8217;s manufacture and sale of their mRNA COVID-19 vaccines. The parties agreed to combine the two patents in one lawsuit, separately against each of Moderna and Pfizer/BioNTech.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 8, 2023, we received notification from the U.S. Patent Office that a third patent would issue on February 28, 2023, as U.S. Patent No. 11,590,229, which we also believe Pfizer and Moderna&#8217;s COVID-19 vaccines infringe upon. On February 15, 2023, we filed a motion with the court to add this patent to the existing cases against Pfizer and Moderna.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 26, 2023, the court held a hearing and denied Moderna&#8217;s partial motion to dismiss those claims for sales under 1498(2), our motion to add the 11,590,229 patent to the current lawsuits as well as a motion filed by Moderna to add certain invalidity arguments made by Pfizer in our case to supplement Moderna&#8217;s invalidity arguments previously made.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The court has set a trial date of November 12, 2024, for Alnylam v. Moderna and November 18, 2024, for Alnylam v. Pfizer/BioNTech.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Indemnifications</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with license agreements we may enter with companies to obtain rights to intellectual property, we may be required to indemnify such companies for certain damages arising in connection with the intellectual property rights licensed under the agreements. Under such agreements, we may be responsible for paying the costs of any litigation relating to the license agreements or the underlying intellectual property rights, including the costs associated with certain litigation regarding the licensed intellectual property. We are also a party to a number of agreements entered into in the ordinary course of business, which contain typical provisions that obligate us to indemnify the other parties to such agreements upon the occurrence of certain events, including litigation or other legal proceedings. In addition, we have agreed to indemnify our officers and directors for expenses, judgments, fines, penalties, excise taxes, and settlement amounts paid in connection with any threatened, pending or completed litigation proceedings, including, for example, the current government investigation, in which an officer or director was, is or will be involved as a party, on account of such person&#8217;s status as an officer or director, or by reason of any action taken by the officer or director while acting in such capacity, subject to certain limitations. These indemnification costs are charged to selling, general and administrative expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our maximum potential future liability under any such indemnification provisions is uncertain. We have determined that the estimated aggregate fair value of our potential liabilities under all such indemnification provisions is minimal and had not recorded any liability related to such indemnification provisions as of March 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773119330032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements of Alnylam are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2022, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 23, 2023. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_LiquidityPolicyPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of March&#160;31, 2023, together with the cash we expect to generate from product sales and under our current alliances, will be sufficient to enable us to advance our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LiquidityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LiquidityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773124281312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET PRODUCT REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Net Product Revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net product revenues consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.362%"><tr><td style="width:1.0%"/><td style="width:60.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.558%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ONPATTRO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMVUTTRA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GIVLAARI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OXLUMO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,328&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Receivables Related to Net Product Revenues</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the balance of our receivables related to our net product revenues: </span></div><div style="margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"><tr><td style="width:1.0%"/><td style="width:57.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773120745264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Revenue from Collaborators</a></td>
<td class="text">Net revenues from collaborations consist of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"><tr><td style="width:1.0%"/><td style="width:62.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.649%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,462&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,945&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Balance and Change in Receivables and Contract Liabilities Related to Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.502%"><tr><td style="width:1.0%"/><td style="width:56.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.662%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities included in &#8220;Deferred revenue&#8221;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock', window );">Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides research and development expenses incurred by type, for which we recognize net revenue, that are directly attributable to our collaboration agreements, by collaboration partner:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:24.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Trial and Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">External Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Trial and Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">External Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,828&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock', window );">Schedule of Allocated Transaction Price Based on Accounting Guidance</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.713%"><tr><td style="width:1.0%"/><td style="width:38.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.689%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Performance Obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Standalone Selling Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Transaction Price Allocated</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">130,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">183,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">97,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">92,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">364,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">246,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">521,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables provide a summary of the transaction price allocated to each unit of account based on the applicable accounting guidance, in addition to revenue activity during the period, in thousands:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.561%"><tr><td style="width:1.0%"/><td style="width:31.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.668%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Transaction Price Allocated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">215,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">246,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">191,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">193,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">559,580&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">220,100&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">226,800&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock', window );">Schedule of Revenue Recognized Based on Accounting Guidance</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.994%"><tr><td style="width:1.0%"/><td style="width:41.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.317%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue Recognized During</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15,400&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,800&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Allocated Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfAllocatedTransactionPriceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of research and development expenses incurred for collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Revenue Recognized Based on Accounting Guidance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773124316960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_ScheduleOfRoyaltyLiabilityTableTextBlock', window );">Schedule of Royalty Liability</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the activity with respect to the liability related to the sale of future royalties, in thousands:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.134%"><tr><td style="width:1.0%"/><td style="width:81.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,673)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,308,906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfRoyaltyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Royalty Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfRoyaltyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773126092272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables present information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:48.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618,075&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,762&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:48.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773124203632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE DEBT SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Marketable Debt Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize our marketable debt securities:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,391)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382,107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,966)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,762&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,382)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420,603&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,589)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411,133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of Fair Value of Marketable Debt Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773298707648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER BALANCE SHEET DETAILS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of inventory are summarized as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,385&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents And Restricted Cash</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674,411&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of Changes in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the changes in accumulated other comprehensive (loss) income, by component:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss on Investment in Joint Venture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized (Losses) Gains from Debt</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other<br/>Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,092)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,654)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,097)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,345)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,124)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss on Investment in Joint Venture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized (Losses) Gains from Debt</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other<br/>Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,811)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,259)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,217)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,806)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,776)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,847)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,065)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statement of reconciliation of cash, cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773126092272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT DERIVATIVE LIABILITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Development Derivative Liability Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the activity with respect to the development derivative liability, in thousands:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"/><td style="width:81.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount received under the Funding Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recorded from remeasurement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">219,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773124271056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock Based Compensation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes stock-based compensation expenses included in operating costs and expenses:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"/><td style="width:60.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.395%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.398%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,947&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773124184256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Share Equivalents Excluded from the Calculation of Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the potential common shares (prior to consideration of the treasury stock or if-converted methods) excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock, inclusive of performance-based stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units, inclusive of performance-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,591&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,703&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773126415888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF BUSINESS (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_NumberOfMarketedProducts', window );">Number of marketed products</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_NumberOfPartneredProducts', window );">Number of partnered products</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_NumberOfCommercializedProducts', window );">Number of commercialized products</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NumberOfCommercializedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Commercialized Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NumberOfCommercializedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NumberOfMarketedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Marketed Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NumberOfMarketedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NumberOfPartneredProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Partnered Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NumberOfPartneredProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773121835776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET PRODUCT REVENUES - Summary of Net Product Revenues (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 319,290<span></span>
</td>
<td class="nump">$ 213,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">276,328<span></span>
</td>
<td class="nump">186,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_ONPATTROMember', window );">ONPATTRO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">102,493<span></span>
</td>
<td class="nump">137,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_AmvuttraMember', window );">AMVUTTRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">101,768<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_GIVLAARIMember', window );">GIVLAARI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">47,906<span></span>
</td>
<td class="nump">35,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_OXLUMOMember', window );">OXLUMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">24,161<span></span>
</td>
<td class="nump">14,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ONPATTRO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">29,817<span></span>
</td>
<td class="nump">62,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | AMVUTTRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">79,013<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | GIVLAARI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">30,291<span></span>
</td>
<td class="nump">23,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OXLUMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">9,057<span></span>
</td>
<td class="nump">5,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe | ONPATTRO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">59,678<span></span>
</td>
<td class="nump">53,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe | AMVUTTRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,768<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe | GIVLAARI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14,471<span></span>
</td>
<td class="nump">9,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe | OXLUMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13,309<span></span>
</td>
<td class="nump">8,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alny_NonUSOrEuropeMember', window );">Rest of World | ONPATTRO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12,998<span></span>
</td>
<td class="nump">21,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alny_NonUSOrEuropeMember', window );">Rest of World | AMVUTTRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15,987<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alny_NonUSOrEuropeMember', window );">Rest of World | GIVLAARI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,144<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alny_NonUSOrEuropeMember', window );">Rest of World | OXLUMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,795<span></span>
</td>
<td class="nump">$ 1,016<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ONPATTROMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ONPATTROMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_AmvuttraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_AmvuttraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_GIVLAARIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_GIVLAARIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_OXLUMOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_OXLUMOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alny_NonUSOrEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alny_NonUSOrEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773122542800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NET PRODUCT REVENUES - Receivables (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables included in &#8220;Accounts receivable, net&#8221;</a></td>
<td class="nump">$ 219,434<span></span>
</td>
<td class="nump">$ 237,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables included in &#8220;Accounts receivable, net&#8221;</a></td>
<td class="nump">$ 190,931<span></span>
</td>
<td class="nump">$ 203,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773120561248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Revenue from Collaborators (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 319,290<span></span>
</td>
<td class="nump">$ 213,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36,462<span></span>
</td>
<td class="nump">25,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">19,990<span></span>
</td>
<td class="nump">12,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations | Novartis AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14,933<span></span>
</td>
<td class="nump">13,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,539<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_OtherCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_OtherCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773120532240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables included in &#8220;Accounts receivable, net&#8221;</a></td>
<td class="nump">$ 219,434<span></span>
</td>
<td class="nump">$ 237,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities included in &#8220;Deferred revenue&#8221;</a></td>
<td class="nump">35,794<span></span>
</td>
<td class="nump">42,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables included in &#8220;Accounts receivable, net&#8221;</a></td>
<td class="nump">22,572<span></span>
</td>
<td class="nump">32,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities included in &#8220;Deferred revenue&#8221;</a></td>
<td class="nump">$ 226,789<span></span>
</td>
<td class="nump">$ 235,528<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773121023440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer liability revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Decrease in research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_DiscoveryPeriodOfProgramsDevelopment', window );">Discovery period of programs development</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment', window );">Extended additional discovery period of programs development</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale', window );">Maximum royalties and commercial milestone payments upon potential product sale</a></td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_UpfrontFeeReceived', window );">Upfront fee received</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria', window );">Maximum additional milestone payments to be receive upon achievement of certain criteria</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_NumberOfTargetedPrograms', window );">Number of targeted programs | target</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeAgreementPeriodOfProgramDevelopment', window );">Direction period of programs development</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeAgreementTerminationPeriod', window );">Agreement termination period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_PercentageOfMaximumRoyaltyPayments', window );">Maximum percentage of royalty payments</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 521,600<span></span>
</td>
<td class="nump">559,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transactional price remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_ResearchTermExtensionFee', window );">Research term extension fee</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementMilestonePayments', window );">Collaborative arrangement milestone payments</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Funding At Program Initiation | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_PotentialProceedsFromCollaborationArrangement', window );">Potential proceeds from collaboration arrangement</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Funding At Lead Candidate Identification | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_PotentialProceedsFromCollaborationArrangement', window );">Potential proceeds from collaboration arrangement</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Funding At Steady State | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_PotentialProceedsFromCollaborationArrangement', window );">Potential proceeds from collaboration arrangement</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeAgreementPeriodOfProgramDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period Of Program Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeAgreementPeriodOfProgramDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeAgreementTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement termination period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeAgreementTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DiscoveryPeriodOfProgramsDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discovery period of programs development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_DiscoveryPeriodOfProgramsDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended additional discovery period of programs development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_IncreaseDecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_IncreaseDecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum additional milestone payments to be receive upon achievement of certain criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum royalties and commercial milestone payments upon potential product sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NumberOfTargetedPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of targeted programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NumberOfTargetedPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PercentageOfMaximumRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PercentageOfMaximumRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PotentialProceedsFromCollaborationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential proceeds from collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PotentialProceedsFromCollaborationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ResearchTermExtensionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research term extension fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ResearchTermExtensionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential maximum royalty percentage that will received for sales completed by collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_UpfrontFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of upfront fees received under the terms of collaborative and licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_UpfrontFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAtProgramInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAtProgramInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAtLeadCandidateIdentificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAtLeadCandidateIdentificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAnAnnualDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAnAnnualDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773120668272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">$ 230,569<span></span>
</td>
<td class="nump">$ 169,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember', window );">Clinical Trial and Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">8,828<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember', window );">Clinical Trial and Manufacturing | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">8,516<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember', window );">Clinical Trial and Manufacturing | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember', window );">External Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember', window );">External Services | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">1,240<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember', window );">External Services | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">9,723<span></span>
</td>
<td class="nump">9,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember', window );">Other | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">9,363<span></span>
</td>
<td class="nump">9,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember', window );">Other | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_OtherCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_OtherCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773120610320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details) - Global Strategic Collaboration - Regeneron Pharmaceuticals - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">$ 521,600<span></span>
</td>
<td class="nump">$ 559,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember', window );">Research Services Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_StandaloneSellingPrice', window );">Standalone Selling Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">183,100<span></span>
</td>
<td class="nump">215,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember', window );">C5 License Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_StandaloneSellingPrice', window );">Standalone Selling Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">92,500<span></span>
</td>
<td class="nump">97,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember', window );">C5 Co-Co Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_StandaloneSellingPrice', window );">Standalone Selling Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">$ 246,000<span></span>
</td>
<td class="nump">$ 246,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_StandaloneSellingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standalone Selling Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_StandaloneSellingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5LicenseObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5CoCoObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773120553664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,794<span></span>
</td>
<td class="nump">$ 42,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">$ 521,600<span></span>
</td>
<td class="nump">559,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,100<span></span>
</td>
<td class="nump">226,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember', window );">Research Services Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">183,100<span></span>
</td>
<td class="nump">215,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">26,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember', window );">C5 License Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">92,500<span></span>
</td>
<td class="nump">97,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember', window );">C5 Co-Co Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">$ 246,000<span></span>
</td>
<td class="nump">246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,100<span></span>
</td>
<td class="nump">$ 193,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5LicenseObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5CoCoObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773119371008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized under ASC 606</a></td>
<td class="nump">$ 319,290<span></span>
</td>
<td class="nump">$ 213,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals | Global Strategic Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized under ASC 606</a></td>
<td class="nump">15,400<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals | Research Services Obligation | Global Strategic Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized under ASC 606</a></td>
<td class="nump">10,700<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals | C5 License Obligation | Global Strategic Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized under ASC 606</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals | C5 Co-Co Obligation | Global Strategic Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized under ASC 606</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5LicenseObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5CoCoObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773120455504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jan. 01, 2030</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems', window );"><strong>Liability Related To The Sale Of Future Royalties Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyLiabilityNoncurrent', window );">Liability related to the sale of future royalties, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,285,200<span></span>
</td>
<td class="nump">$ 1,252,015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_BlackstoneGroupIncMember', window );">Blackstone Group Inc. | Net revenues from collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems', window );"><strong>Liability Related To The Sale Of Future Royalties Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent', window );">Collaborative arrangement, royalties and commercial milestones acquired by collaborator, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent', window );">Commercial milestones acquired by collaborator, percent</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_ExpectedRoyaltyInterestPayments', window );">Expected royalty interest payments</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementConsiderationReceived', window );">Consideration received</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyLiabilityNoncurrent', window );">Liability related to the sale of future royalties, net of current portion</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,308,906<span></span>
</td>
<td class="nump">$ 1,292,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyLiabilityInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyLiabilityClosingCosts', window );">Closing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Blackstone Group Inc. | Net revenues from collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems', window );"><strong>Liability Related To The Sale Of Future Royalties Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent', window );">Collaborative arrangement, royalties and commercial milestones acquired by collaborator, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Consideration Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalties Acquired By Collaborator, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ExpectedRoyaltyInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Royalty Interest Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ExpectedRoyaltyInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityClosingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Closing Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityClosingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_BlackstoneGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_BlackstoneGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773122861568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES - Future Royalties (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward', window );"><strong>Liability Related To Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="nump">$ 1,252,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="nump">1,285,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_BlackstoneGroupIncMember', window );">Blackstone Group Inc. | Net revenues from collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward', window );"><strong>Liability Related To Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="nump">1,292,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts', window );">Interest expense recognized</a></td>
<td class="nump">25,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyLiabilityPayments', window );">Payments</a></td>
<td class="num">(8,673)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_RoyaltyLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="nump">$ 1,308,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Interest Expense Including Amortization Of Closing Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_BlackstoneGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_BlackstoneGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773116596896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Fair Value of Assets Measured on a Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 4,188<span></span>
</td>
<td class="nump">$ 113,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,376,762<span></span>
</td>
<td class="nump">1,411,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">25,856<span></span>
</td>
<td class="nump">28,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">25,856<span></span>
</td>
<td class="nump">28,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">1,618,075<span></span>
</td>
<td class="nump">1,710,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Development derivative liability</a></td>
<td class="nump">219,748<span></span>
</td>
<td class="nump">209,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">25,856<span></span>
</td>
<td class="nump">28,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">241,313<span></span>
</td>
<td class="nump">299,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">1,376,762<span></span>
</td>
<td class="nump">1,411,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Development derivative liability</a></td>
<td class="nump">219,748<span></span>
</td>
<td class="nump">209,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">214,257<span></span>
</td>
<td class="nump">270,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">214,257<span></span>
</td>
<td class="nump">270,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,494<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">190,651<span></span>
</td>
<td class="nump">208,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate notes | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate notes | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,494<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">190,651<span></span>
</td>
<td class="nump">208,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate notes | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,694<span></span>
</td>
<td class="nump">22,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">90,556<span></span>
</td>
<td class="nump">36,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,694<span></span>
</td>
<td class="nump">22,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">90,556<span></span>
</td>
<td class="nump">36,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">742,312<span></span>
</td>
<td class="nump">820,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">742,312<span></span>
</td>
<td class="nump">820,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">335,557<span></span>
</td>
<td class="nump">230,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">335,557<span></span>
</td>
<td class="nump">230,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">13,498<span></span>
</td>
<td class="nump">1,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Certificates of deposit | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">13,498<span></span>
</td>
<td class="nump">1,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Certificates of deposit | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773122504496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE DEBT SECURITIES - Summary of Marketable Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,382,107<span></span>
</td>
<td class="nump">$ 1,420,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5,966)<span></span>
</td>
<td class="num">(9,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,376,762<span></span>
</td>
<td class="nump">1,411,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">744,326<span></span>
</td>
<td class="nump">870,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">377<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,391)<span></span>
</td>
<td class="num">(4,382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">742,312<span></span>
</td>
<td class="nump">865,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">337,614<span></span>
</td>
<td class="nump">275,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,251)<span></span>
</td>
<td class="num">(3,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">335,557<span></span>
</td>
<td class="nump">272,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">194,419<span></span>
</td>
<td class="nump">211,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,324)<span></span>
</td>
<td class="num">(2,106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">193,145<span></span>
</td>
<td class="nump">209,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">92,250<span></span>
</td>
<td class="nump">59,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">92,250<span></span>
</td>
<td class="nump">59,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13,498<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 13,498<span></span>
</td>
<td class="nump">$ 4,419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773122546688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE DEBT SECURITIES - Summary of Fair Value of Marketable Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable debt securities</a></td>
<td class="nump">$ 1,372,574<span></span>
</td>
<td class="nump">$ 1,297,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">4,188<span></span>
</td>
<td class="nump">113,243<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 1,376,762<span></span>
</td>
<td class="nump">$ 1,411,133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773120533040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER BALANCE SHEET DETAILS - Schedule of Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 22,875<span></span>
</td>
<td class="nump">$ 22,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="nump">110,976<span></span>
</td>
<td class="nump">113,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">29,534<span></span>
</td>
<td class="nump">25,606<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_InventoryCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">163,385<span></span>
</td>
<td class="nump">161,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Long-term inventory</a></td>
<td class="nump">$ 31,500<span></span>
</td>
<td class="nump">$ 32,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_InventoryCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Current And Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_InventoryCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773123683984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER BALANCE SHEET DETAILS - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 672,245<span></span>
</td>
<td class="nump">$ 866,394<span></span>
</td>
<td class="nump">$ 534,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Total restricted cash included in other assets</a></td>
<td class="nump">2,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,178<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</a></td>
<td class="nump">$ 674,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 536,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773119476048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER BALANCE SHEET DETAILS - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">$ (158,223)<span></span>
</td>
<td class="nump">$ 588,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="nump">1,401<span></span>
</td>
<td class="nump">2,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income (loss)</a></td>
<td class="nump">4,129<span></span>
</td>
<td class="num">(7,183)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">5,530<span></span>
</td>
<td class="num">(4,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(259,240)<span></span>
</td>
<td class="nump">401,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alny_AccumulatedLossOnInvestmentInJointVentureMember', window );">Loss on Investment in Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(32,792)<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(32,792)<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(1,092)<span></span>
</td>
<td class="num">(2,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income (loss)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(1,097)<span></span>
</td>
<td class="num">(2,776)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized (Losses) Gains from Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(9,470)<span></span>
</td>
<td class="num">(1,630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income (loss)</a></td>
<td class="nump">4,134<span></span>
</td>
<td class="num">(7,218)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">4,125<span></span>
</td>
<td class="num">(7,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(5,345)<span></span>
</td>
<td class="num">(8,847)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(1,300)<span></span>
</td>
<td class="nump">3,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="nump">1,410<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">1,410<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">6,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(44,654)<span></span>
</td>
<td class="num">(33,259)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">5,530<span></span>
</td>
<td class="num">(4,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">$ (39,124)<span></span>
</td>
<td class="num">$ (38,065)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alny_AccumulatedLossOnInvestmentInJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alny_AccumulatedLossOnInvestmentInJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773119436240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE DEBT (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>day</div>
</th>
<th class="th">
<div>Sep. 13, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 12, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>$ / Unit</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, previously reported value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,040.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0034941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_ConvertibleDebtPremiumRecognizedFromConversionRate', window );">Premium from conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, previously reported value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of long-term debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,030.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2027 | Debt Conversion Terms One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading days threshold | day</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days threshold | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2027 | Debt Conversion Terms Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading days threshold | day</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days threshold | day</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of stock price trigger</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2027, Initial Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2027, Additional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading days threshold | day</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days threshold | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Capped Call Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, previously reported value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCapPrice', window );">Cap price (in usd per share) | $ / Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_PremiumRecognizedOnCappedCallTransactions', window );">Premium on capped call transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes', window );">Purchases of capped calls related to convertible debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ConvertibleDebtPremiumRecognizedFromConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt, Premium Recognized From Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ConvertibleDebtPremiumRecognizedFromConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PremiumRecognizedOnCappedCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Premium Recognized On Capped Call Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PremiumRecognizedOnCappedCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases Of Capped Calls Related To Convertible Senior Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCapPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCapPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alny_ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alny_ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DebtInstrumentConvertibleTermsOfConversionAxis=alny_DebtConversionTermsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_DebtInstrumentConvertibleTermsOfConversionAxis=alny_DebtConversionTermsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DebtInstrumentConvertibleTermsOfConversionAxis=alny_DebtConversionTermsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_DebtInstrumentConvertibleTermsOfConversionAxis=alny_DebtConversionTermsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alny_ConvertibleSeniorNotesDue2027InitialAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alny_ConvertibleSeniorNotesDue2027InitialAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alny_ConvertibleSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alny_ConvertibleSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773119055024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT DERIVATIVE LIABILITY - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Cost of borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=alny_BlackstoneLifeSciencesMember', window );">Blackstone Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Cost of borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations | Blackstone Life Sciences | Vutrisiran and ALN-AGT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementMaximumFunding', window );">Maximum funding</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations | Blackstone Life Sciences | HELIOS-B Phase 3 Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementMaximumFunding', window );">Maximum funding</a></td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations | Blackstone Life Sciences | ALN-AGT Phase 2 Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementMaximumFunding', window );">Maximum funding</a></td>
<td class="nump">$ 26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementFixedPaymentMultiplier', window );">Fixed payment multiplier</a></td>
<td class="nump">3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementFixedPaymentTerm', window );">Fixed payment, term (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations | Blackstone Life Sciences | ALN-AGT Phase 3 Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementMaximumFunding', window );">Maximum funding</a></td>
<td class="nump">$ 54.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementFixedPaymentMultiplier', window );">Fixed payment multiplier</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementFixedPaymentTerm', window );">Fixed payment, term (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations | Blackstone Life Sciences | Vutrisiran</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementRoyaltiesPayablePercent', window );">Royalties payable, percent</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementRoyaltiesPayableTerm', window );">Royalties payable, term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementFixedPaymentMultiplier', window );">Fixed payment multiplier</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alny_CollaborativeArrangementFixedPaymentTerm', window );">Fixed payment, term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementFixedPaymentMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed Payment Multiplier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementFixedPaymentMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementFixedPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed Payment, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementFixedPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementMaximumFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementMaximumFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementRoyaltiesPayablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalties Payable, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementRoyaltiesPayablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementRoyaltiesPayableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalties Payable, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementRoyaltiesPayableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alny_BlackstoneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alny_BlackstoneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_BlackstoneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_BlackstoneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_VutrisiranAndZilebesiranMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_VutrisiranAndZilebesiranMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_HELIOSBPhase3ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_HELIOSBPhase3ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ALNAGTPhase2ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ALNAGTPhase2ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ALNAGTPhase3ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ALNAGTPhase3ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_VutrisiranMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_VutrisiranMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773122446240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT DERIVATIVE LIABILITY - Development Derivative Liability Activity (Details) - Derivative<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Carrying value, beginning balance</a></td>
<td class="nump">$ 209,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Amount received under the Funding Agreement</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss recorded from remeasurement</a></td>
<td class="nump">6,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Carrying value, ending balance</a></td>
<td class="nump">$ 219,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773125037968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 39,947<span></span>
</td>
<td class="nump">$ 29,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">16,232<span></span>
</td>
<td class="nump">11,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 23,715<span></span>
</td>
<td class="nump">$ 17,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139773118876912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">14,591<span></span>
</td>
<td class="nump">14,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock, inclusive of performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">8,428<span></span>
</td>
<td class="nump">12,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock units, inclusive of performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">2,547<span></span>
</td>
<td class="nump">1,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">3,616<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>alny-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:alny="http://www.alnylam.com/20230331"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="alny-20230331.xsd" xlink:type="simple"/>
    <context id="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i90f0cfa35fa842e5b3d727a974388008_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="idf7880a1438e4b1d8934bf896e4c4569_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6860c8b46ed14ad2aa0cd94577b727da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8195be6db017423781aa99e5f6eccbdd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i32b8d81e96cb44258ca45844632dfcd5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i84733ccbf66149c5b5b450843cfb6b1a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:CollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic1217f0f803147f79e8c9536b829300b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:CollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9bc45426006b4d8da84244a71315226f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i614f8658aaee4615b1db837d518ecf21_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i165ab1c7d45f4b59b55f6202bd02b29d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i627afa621d0246df9877bb6114adff8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib10c6162d7ee41d8b5073719840fa8ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1effbb5b358434886d5497a4dd79337_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ad08d083b134bc08112b596229b2ed4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0285951fb32549e2b7c666db15c9daf2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i76a77c376b2b4ba987e016002cfe1389_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4c7db22afb9642d498a5f30d7ec9da76_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic503ee23109c47a485d4c943dc01c684_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if50048ec3817431baf2df96733ffaa31_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id68ac710f233437aa4518ad8eb0adb93_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic8d35477623a4ca9b7fc82fa82a051b8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib8b5cdd9d6524a48a7c0e217c8746b86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i349f62fd0c1c46b6a699a43b81912de5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie72229676bde424e88e71e576e78694f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id64ff2050fde4c88a7a11680cbda5964_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1fa61d04167f4839b28e5e693a40c913_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32343cbd739e429184dd13d72f726915_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3a826bcf6ea5466cbbdc81d17d06dfc3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i10b28d8521f2456da2d0123114d04efc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idd6e196fd8bc401390b246f2c1842f21_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iea3984c5c8334ea2b81d6e311a263566_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2d7c4b1ef5dd4faabe5879a7cb1a13b4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia2d23f30f53a4a3b8caa38a11b48d302_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i74133721fcc744889831c3b5bbd754b4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i129714144f56409c862078cd74c09670_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i469113cbfff1448ca7ace21682306c28_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1b92d59400ad435ab232b2e3fc6af18d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5d2c45ddfe4b4783b61d0c2532b261c6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id3e2090af379423a830396d670dd46ed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i879c1a7e15df42b1a622d6d158eedebc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id72a32ea5faa4d2aa4490f6f4d5cd32c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibd786b1197ef4a61a89be31d546d3ce9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5e76d8ae0a064b248bb6fc792baf7c14_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i840efee846e14303b149ccdfdf3a36a8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibd036604ac7d4a5da0d65fbf272d8217_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief1d9b2c9e9b4acd9209bc90e66a8411_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i71831b87aef84d13af0dc46e7eb3368e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifb5e5a391b254ff999e9906a4a44fecb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia2417f18ab724e43af379c82cd5c9c40_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i73ca8156836b4f2da4a82227758bd9b0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i039c753c58d949c39d6d04e4fb10c8d3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:AmvuttraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i463e7ef6195945beb17fb66c0a944c2e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i933f756eaa1d499da77f10cf4ef3a9fc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0754e7eb06254fb4b0be930af30fd4e8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia4a7d3d13d3a4e91a7ac66295559e8bc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0e770d161620415d9b7f5ffaecfd1b16_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2d3be339f54740539cf50f08dd95e8e2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i61661522e28049569e22780fccab15ec_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idfde9e56f64e49eb860585920e3307de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifbc72492b6ac4d9ab9d17a76e1b3f401_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i84b7e1d6726c409abc1a24d2d0d4cd0b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4e09c2afc4be4d46b953611b6eedc4cd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i294c21243c484600ae87664735590a24_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4a9a9fb2de3341c4965ed9d0dcd38e2f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iefe2b83e5c274d98a554d85575908847_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i50560d538c374d999be9a5694bed79c4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0cd6dd169a314d9e8b10044417187c7c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i33c0592038dc4276b0af9495329ef056_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8ea9f42cbd234c25a0f60837c51cbcbb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb64947f4c824451ac2a67d55f9eec37_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i22f96c66a004453596d01941e4ce155f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7d5ea14b863b4413b7307cdb670fe0ab_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i625a2ec4ecfa4a25a2186cc5eb8e048f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i700ea43392914b5bb710a1f264221b6c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic369c5ac0ae741b69d6c684ad3edcfc1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i119bb76ddc4f49b89a1e68acefe7a579_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4a0b91c625484c1db6cf8d6e8200ae4b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i312ec99fcc6c43a5a131ac1f6eb87263_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8140860172b844839f38d726caf34dee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i31d11f918c134929a249af868dc0a880_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8f793b67069946539339f57991faca6f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6ad2eeaaba1140c1b13fa6e42dba1bd4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6fadae33c506406b84c2961fea62350a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iba3a79574455472d858759fccd74a1f2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i505a333c3b1b497290cc1a035457ef65_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0c5e76a3a4cf45db98aa355177c9a5d3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i366eacf4f5df477589f244ba31e7710b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i330d2d52ecae4487a330a3ffa3b3df3e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i568cba070fdc4faab4ba5d1d1b7b45af_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4f5ad1d8efc44580ac18facfdada39c1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i122a5b203d314116a7be9b37a61d8bf1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3594c34bba4944ca91cc9765440d129b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4a4ded065a9d42fca7d0593ecfb28c99_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4ec14d6c93f549abad409a4ee60dc447_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iea75117bc59d46cca891d43505fb5e06_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i989eed19cb3f4fa18bc8d14e53d5af1e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5f79bfbe7bce408cafa73cf4b18f1764_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i9b17e6f85a474102b37c2eb6225b0f06_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ia2262debc8564e2ea595ab280c42f0db_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAtProgramInitiationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i8a62ef305c0f40a79899683564ff0247_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAtLeadCandidateIdentificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="if6a70a035a37440e909aac14f9fda6d9_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAnAnnualDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="ib324fbd9af6f4a3d8ef929b6d99bf163_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i7e7e8c4e7d644c158639d2fb41e9a319_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie79a8fa8f1ce43deb7597002a348c3be_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i537f32b4a16b4543a24f40ddc6741cee_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic42228c3d8ac46a8ac291f126f2d30b6_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i24ae91e0688d4ae4984f1d8103dc8422_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i46343ad3a9fd4ec3a826cb38ab1b6530_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i10bce677b77f433a9d7d79a79b60f6a2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i84c437734fd146c39d505bac418fecf2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie8a02cffca2849af8489d49e9b80b1b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i03b27765edaa4e13a504fbffd73baf35_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i638ed215bf2a42199fc06a55c0357371_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i053739f07c5a48d4bd9b455419e9a9f3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3ae2f34bc0ed44efa8a7bcadc7f60158_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if5ea36d76387472e84cfa6df1370b518_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ida6db6b0c1dc4a37b006d8d1871fd207_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34678b9d3faf4e679a9657d9146fcacf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i567601c061914fc8a2d7fd810936ef74_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i04b45c879ba940b99dd9a474d8b07978_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4d582c41d901411287404a782ac66586_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9f304a30d62e48ae884ec8acc207b442_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i951d48bc07e44f98a13abbaa555cc949_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i78bb229c8dc8423eb6def37c2540a28f_I20300101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2030-01-01</instant>
        </period>
    </context>
    <context id="i5af69bac6577471ab296af25cf52d953_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i49f2778a30db447199954b7fd02c7ed1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie90a9b7be5ab448e86528f65d657a9ac_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i874d4cbd4e084481a20e05ffedf030e1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib9816969b7f844c7b918013a5fb04632_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iffe7a27d97064ac7829a670edeb037a6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie4497af286544b5588685567ad285511_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iacfa0b420e244ddd8c424584e49e0bbe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieaa8b9115a694d4dbacbb16955919e67_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i50b2a82f08e14704917d51373b47b145_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iec58dda78b5f41ec9f8115e957615766_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8e6a406720844217993d4483fc6e7b60_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i07544a270c1b4f91be2befe47f417d06_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6fbdfa377b4c45188b32b4aca0c5858c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifc8655a9bfff4eb6a24a91ec23da2454_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id91db2e74566480db7790bba12bacab3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie0fbbf8a866f4b1ea616c10badae83d3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib4272629d98c4add80b6c45b82c2e95a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i386e3c5b4ba843509503532a3da11306_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4e2b832d64eb4f1a8fdbaef5ca07646d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id76f744f31aa458e96f4d8ebe97eb886_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3272a7ba8f424ca9a1480c9d363ebc10_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7cb86d593e5944cca0236d7b8f81bbf2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iac8bf485b57442459c1b93f20ebfa42b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ica1ebebb32214b719ee306ffc8f6cf89_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0f5ba0082a2340e79246846a43e0e92b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i53c118ebc744410fbbc7719c7a876694_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie823bc3a3540443788e7ed44be452ee5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i210817a6ab294c9d9aff77d7f7d56bcd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i70b5152586914421b5f5705f8c583545_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia372b23a3466460c91b1628f67e16648_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9b1bd941ecd44d1ca58586c4a9d77e7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i40eb73f6cf7b4d478059864b5fa2f8d9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b408457ee5148e38192a975210e857c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i43176b0239cb476c8cf009256b574721_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i076d11b5a6224da98d27eefe80d7e72a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69e9dba36ddb43e3a7cdf9a5872fb683_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if6f8dc928bd848488160e1bd4f401ea3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19e64ae5cf7f45f6b977f634f04d74e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5723f8adf2d1441d932c0847136e9459_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e6ceebd68e64bf0a73073a721e7d630_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i910dcea4abe947e4ab7bab94efb0b6bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i048b6a7660eb403b9a37898a77b5f141_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i65b952c5bedd40b798d1a1561e6546c6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2ccbffe10394a7e94b51ab21066da05_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9706a586a2e648478e8a3e8e5b2af11f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i530c28e6901b4e84a1c2d02163b01915_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iabd32b8fc73844de94f0169aa6a02549_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13efc9571bfe41aa8a26035bcd11ba88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icbf68c6050a641f08b05c2eb2be55064_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7cd53d3ef7cf44699a9bed9051e463e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id76df98dcf234a879e9afbd45704aa86_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8e8b9f7927aa4adf8ad7beaa81618725_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78e4f2d83b724aec84eb152ce5a9a38a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2d9d2300f444085a25bd1044ef04459_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0cb6ddc861e4bccabf7921700859d41_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i08de5c309e4b47ce9d7bc420003d6031_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7888ab348e6b46759e5fa89592e4892c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1532ad29f7b41dfa9abd7737236a3cf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37c9e096a9ca46f28fce0d2487efa7e0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id9ce486293d84aeeb0b9ecdc107a663f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if50ea362dec14ed1a971c9d68f405fc1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icf96df66413c488d9bfbd03f94ea7f4e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifb230ab030c84a949a4708ce9359662e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9e45c4599a0542b69eeec71ff8b3bf49_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie42a905d31064b9fa9efdd8b7ef9b37e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i811b7526e6a94efba6244d85ce23698b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic92f68826e624d329fcbd32713162d25_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94483e1405f840b791882d67766c7723_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b2839973ded4bb9a04db596d1cd0ee7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3ed1c026dd674f1d819dbc53395da662_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibebf4053fbf44fb9b675c41a096d60a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i50c869678d1046f6b8952f17b26368ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i714ef67f5dd5449c8ce319985ec64bf3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0c21a9a0d854336ae2513275c632fb3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a5bbae1628a449d818c46f986a09d4c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if3080c044b38407fba1e7d8658782768_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9ef9a4ac510541efaaf7b5313dd58cf6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if11c68a061924916b804149e7efa13f8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i348f9d6750ba4e6d84377accaa5b9319_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1ed6da55201a4d6098f35926e23ad0c5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id5423daa9097405baa2e53113e5a2af9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaf2fec59aefb4d9abff4b8a755874542_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia64c74b9951e43a2a4ca3afc638421c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i400fd731ed28427a98cf559b0d69a616_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5246d2e962624dce926b3bfedeadb7d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0764c7d8cbc0465a9c4b5bec84310735_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i597049e81b154f63b39f155a686eca36_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id931cec3813c4a8abbaa146d0ecf379e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i32207f7e2b874ffe9f5bb035ed9216a6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i058fa58cb9ad4be2929911d5459f7ee5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if78966f3bc7e4a2c88588d499eac7518_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i58d05b72c281482194642f22d74ecfe5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifca2d339be1249478491d26c1d76e094_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i70f8e370f342484989f74b6dadda0a7e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8575ee7bf1c64fce99658a0882ae7ee3_I20220912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027InitialAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="i8081d56e8ab34c85add2a725bbed1844_D20220912-20220912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-12</startDate>
            <endDate>2022-09-12</endDate>
        </period>
    </context>
    <context id="i72548dd619ad4fc59ff47eaf2277707e_I20220913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027AdditionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-13</instant>
        </period>
    </context>
    <context id="ifbfa928ba64c483796841306c426679d_D20220913-20220913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-13</startDate>
            <endDate>2022-09-13</endDate>
        </period>
    </context>
    <context id="i36aa61efaa244add8aac63cdcac4dac0_I20220913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-13</instant>
        </period>
    </context>
    <context id="ie5b391a1819e41adbce308c1b9dab192_D20220915-20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="ia716907dc7734c6ba46bc53ee763d5d5_D20220915-20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alny:DebtInstrumentConvertibleTermsOfConversionAxis">alny:DebtConversionTermsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="i9e464817379546f69d2a4d409bf930d6_D20220915-20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alny:DebtInstrumentConvertibleTermsOfConversionAxis">alny:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="icebb5707b4014e189d610163d749eb88_I20220912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="idf3afa8e81834164a6949f9f03a9f2b4_D20220915-20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="ia532de6f95c948d98aa0f343c124b06f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icf9b6feac91a4baaa879c5cc27f3adcf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9534211a39af4f07af0f48f741ec3cfc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i303c720c21554eb3a5e123dcdd48b762_I20220912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="i8025ac0fe3c444bd93fb4dffe9e6a50f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icdd6f7a85c0649c687a28ff5014a352d_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:VutrisiranAndZilebesiranMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i0540d1bfbba64fa980c847a4a95c9ac6_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:HELIOSBPhase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i788b9050885e4755ab989256b9364634_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ALNAGTPhase2ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i3d2567c90e8a458eae5bef50162e1ca4_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ALNAGTPhase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ifde09daab1ea4a168820da3d556f2e1f_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:VutrisiranMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="if60b93a866a243d08fc76127d6370bdd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib8b29740f2a6476a91d8e8b96400f6d4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i707ab3ce2b764f02a7efa7c0a56fcdd2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i728568c4126e4020bdaab60c7fd837da_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i770db94c29944af19b3195793999b048_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i920b6c081b7047af9c3d22ecd0aac5fc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i39c75d8b324e44f0a7e6fb8cd3fed694_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i19ba4c67d69f48759c03fa13464eae2a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i16fefe33d0a84bbcb3bcfe4546c9b4d3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3a1e6837336341aebaca13a642e99570_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7e25f80d14ab4e29946dc7feeb321f9e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id9057d82ed2a40ea940df490edf962c1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i402e0e52c29f460db9f6c550106e1cf2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6d2e5ef24f8743d687104b5084f27971_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>alny:product</measure>
    </unit>
    <unit id="target">
        <measure>alny:target</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="day">
        <measure>alny:day</measure>
    </unit>
    <unit id="usdPerUnit">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>alny:Unit</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80L2ZyYWc6YmE5YmQ3NTEzNWE2NDZlMDkzOWEzM2Q5ZGNhYzczOTcvdGFibGU6YzJmMDhhOGZjNTJmNGQ0Yjg0OTdlNjA0YjRkMTJhNTUvdGFibGVyYW5nZTpjMmYwOGE4ZmM1MmY0ZDRiODQ5N2U2MDRiNGQxMmE1NV8xLTEtMS0xLTExMTM2OA_ac0483f4-efa4-4e8c-8629-e8bdad4ca508">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80L2ZyYWc6YmE5YmQ3NTEzNWE2NDZlMDkzOWEzM2Q5ZGNhYzczOTcvdGFibGU6YzJmMDhhOGZjNTJmNGQ0Yjg0OTdlNjA0YjRkMTJhNTUvdGFibGVyYW5nZTpjMmYwOGE4ZmM1MmY0ZDRiODQ5N2U2MDRiNGQxMmE1NV8yLTEtMS0xLTExMTM2OA_6748eeb2-026a-4328-acf3-3cf0f00e512f">2023</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80L2ZyYWc6YmE5YmQ3NTEzNWE2NDZlMDkzOWEzM2Q5ZGNhYzczOTcvdGFibGU6YzJmMDhhOGZjNTJmNGQ0Yjg0OTdlNjA0YjRkMTJhNTUvdGFibGVyYW5nZTpjMmYwOGE4ZmM1MmY0ZDRiODQ5N2U2MDRiNGQxMmE1NV8zLTEtMS0xLTExMTM2OA_d5cbc29d-21fe-461e-a4f6-9a9e2707464d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80L2ZyYWc6YmE5YmQ3NTEzNWE2NDZlMDkzOWEzM2Q5ZGNhYzczOTcvdGFibGU6YzJmMDhhOGZjNTJmNGQ0Yjg0OTdlNjA0YjRkMTJhNTUvdGFibGVyYW5nZTpjMmYwOGE4ZmM1MmY0ZDRiODQ5N2U2MDRiNGQxMmE1NV80LTEtMS0xLTExMTM2OA_ffb82ac0-a35e-4bdd-ab87-71a09bf2cf4f">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80L2ZyYWc6YmE5YmQ3NTEzNWE2NDZlMDkzOWEzM2Q5ZGNhYzczOTcvdGFibGU6YzJmMDhhOGZjNTJmNGQ0Yjg0OTdlNjA0YjRkMTJhNTUvdGFibGVyYW5nZTpjMmYwOGE4ZmM1MmY0ZDRiODQ5N2U2MDRiNGQxMmE1NV81LTEtMS0xLTExMTM2OA_d4ee3200-f610-4177-a8fe-83a8ab16678e">0001178670</dei:EntityCentralIndexKey>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i8081d56e8ab34c85add2a725bbed1844_D20220912-20220912"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82Ny9mcmFnOjA5Njk2YWNkYzU2MjRjY2Y4ZWFjOWYwNzMyMzQxNmM5L3RleHRyZWdpb246MDk2OTZhY2RjNTYyNGNjZjhlYWM5ZjA3MzIzNDE2YzlfNDE_fc402a97-56f4-496a-b650-57c85420fcfc"
      unitRef="number">0.0034941</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8xMjk_ea33a2d3-902e-40c3-a420-da5939516e05">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6YTk3MWQ3M2NmYzgzNDkxNTgwZTQ4MTkzMGYzOTEyMjAvdGFibGVyYW5nZTphOTcxZDczY2ZjODM0OTE1ODBlNDgxOTMwZjM5MTIyMF8wLTAtMS0xLTExMTM2OA_ad0da8ff-8969-4444-b6c6-db965077b9ef">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8yMDk_95432380-3284-4890-ada9-07503785f747">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZTg5MmQzOTZiMmMzNGM0MGFkMDE1ZWJjMDBhMzc1MmIvdGFibGVyYW5nZTplODkyZDM5NmIyYzM0YzQwYWQwMTVlYmMwMGEzNzUyYl8wLTAtMS0xLTExMTM2OA_0d3c5e37-fcf2-450f-bbcb-2efdeb48bf58">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8yMTYz_e0f301d7-0b1c-4fdd-a97f-6785332d1554">001-36407</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8yMTY0_740a106e-0591-4960-8234-98a4d733d66a">ALNYLAM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6N2RlODU0OGE4MDg4NDYzYmE1ZDljZWNhNWRlNzY0MTEvdGFibGVyYW5nZTo3ZGU4NTQ4YTgwODg0NjNiYTVkOWNlY2E1ZGU3NjQxMV8wLTAtMS0xLTExMTM2OC90ZXh0cmVnaW9uOmRmZWI4MDkyOGM5ZDRkN2JiYzJkNDc5YjY3YjI4YmIxXzU_9feae289-0c9f-4227-b54b-4ad176dd21c9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6N2RlODU0OGE4MDg4NDYzYmE1ZDljZWNhNWRlNzY0MTEvdGFibGVyYW5nZTo3ZGU4NTQ4YTgwODg0NjNiYTVkOWNlY2E1ZGU3NjQxMV8wLTEtMS0xLTExMTM2OC90ZXh0cmVnaW9uOmJmMTVjNjlkMmIxZTQ0MDNiNDRiY2EzNGI3NGY5NzY2XzU_23f07758-50d7-452c-9301-e8aea3d00485">77-0602661</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6YzEzYjQyMmJkOWVlNDI2N2E3MDEwMjVkYmM0YjU3MjUvdGFibGVyYW5nZTpjMTNiNDIyYmQ5ZWU0MjY3YTcwMTAyNWRiYzRiNTcyNV8wLTAtMS0xLTExMTM2OC90ZXh0cmVnaW9uOmIzZTNkOGNlYTA1NTRlYTNiZTUyNGQ4MDRjM2ZjMzdhXzU_282fd248-1e5c-4cff-b8fd-5aade8695473">675 West Kendall Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6YzEzYjQyMmJkOWVlNDI2N2E3MDEwMjVkYmM0YjU3MjUvdGFibGVyYW5nZTpjMTNiNDIyYmQ5ZWU0MjY3YTcwMTAyNWRiYzRiNTcyNV8wLTAtMS0xLTExMTM2OC90ZXh0cmVnaW9uOmIzZTNkOGNlYTA1NTRlYTNiZTUyNGQ4MDRjM2ZjMzdhXzg_a46cac8d-d915-4fa2-bb82-4daf157252f9">Henri A. Termeer Square</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6YzEzYjQyMmJkOWVlNDI2N2E3MDEwMjVkYmM0YjU3MjUvdGFibGVyYW5nZTpjMTNiNDIyYmQ5ZWU0MjY3YTcwMTAyNWRiYzRiNTcyNV8wLTAtMS0xLTExMTM2OC90ZXh0cmVnaW9uOmIzZTNkOGNlYTA1NTRlYTNiZTUyNGQ4MDRjM2ZjMzdhXzEx_79145578-6cff-4a4e-9f9f-b4de57a913d3">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6YzEzYjQyMmJkOWVlNDI2N2E3MDEwMjVkYmM0YjU3MjUvdGFibGVyYW5nZTpjMTNiNDIyYmQ5ZWU0MjY3YTcwMTAyNWRiYzRiNTcyNV8wLTAtMS0xLTExMTM2OC90ZXh0cmVnaW9uOmIzZTNkOGNlYTA1NTRlYTNiZTUyNGQ4MDRjM2ZjMzdhXzE1_39eb6863-024c-4fbc-87ca-f1de943a6f70">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6YzEzYjQyMmJkOWVlNDI2N2E3MDEwMjVkYmM0YjU3MjUvdGFibGVyYW5nZTpjMTNiNDIyYmQ5ZWU0MjY3YTcwMTAyNWRiYzRiNTcyNV8wLTEtMS0xLTExMTM2OC90ZXh0cmVnaW9uOjY0MGVjOTJkY2QyYTRhYjJiOTRiMjYwNWU1ZGJiYzQ0XzU_02addd40-bc7a-422f-b31a-33dedfb42701">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF80ODM_60cb1c6c-9194-4780-82be-3a114b52ed41">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF80ODc_cd2eb3fe-916f-474e-a358-f92e6af16af0">551-8200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZmNkODhlZjgwM2E0NGE1M2JlNzBmYzU4YzUzMTE1OGIvdGFibGVyYW5nZTpmY2Q4OGVmODAzYTQ0YTUzYmU3MGZjNThjNTMxMTU4Yl8xLTEtMS0xLTExMTM2OA_203e5e87-74df-47d0-83fd-3ac0b34468fb">Common Stock, $0.01&#160;par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZmNkODhlZjgwM2E0NGE1M2JlNzBmYzU4YzUzMTE1OGIvdGFibGVyYW5nZTpmY2Q4OGVmODAzYTQ0YTUzYmU3MGZjNThjNTMxMTU4Yl8xLTMtMS0xLTExMTM2OA_fd2f0092-6f8d-4c3f-bed5-227dfe8222a1">ALNY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZmNkODhlZjgwM2E0NGE1M2JlNzBmYzU4YzUzMTE1OGIvdGFibGVyYW5nZTpmY2Q4OGVmODAzYTQ0YTUzYmU3MGZjNThjNTMxMTU4Yl8xLTUtMS0xLTExMTM2OA_0eec06d1-89ce-4e26-86c4-d616bccf97df">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF85OTU_bcbeb61a-01e3-495a-9c06-257e081587f2">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8xMzIw_a666fc38-913b-4e6e-b536-3f96cec3607e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZGMxNzVmMjIzYjg5NDZhZDhlYWY0ODVkZWMyNzI4YmUvdGFibGVyYW5nZTpkYzE3NWYyMjNiODk0NmFkOGVhZjQ4NWRlYzI3MjhiZV8wLTAtMS0xLTExMTM2OA_f71a6260-a942-4c2d-ad32-65d191e3514c">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZGMxNzVmMjIzYjg5NDZhZDhlYWY0ODVkZWMyNzI4YmUvdGFibGVyYW5nZTpkYzE3NWYyMjNiODk0NmFkOGVhZjQ4NWRlYzI3MjhiZV8xLTMtMS0xLTExMTM2OA_9507b2d9-49c5-489b-bba6-10cc05009ae0">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGFibGU6ZGMxNzVmMjIzYjg5NDZhZDhlYWY0ODVkZWMyNzI4YmUvdGFibGVyYW5nZTpkYzE3NWYyMjNiODk0NmFkOGVhZjQ4NWRlYzI3MjhiZV8yLTEtMS0xLTExMTM2OA_d1f9d502-cb9a-4227-a755-f127678ada45">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8yMTY1_29d4c6ae-154e-4885-a231-bb58ccc45f95">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i90f0cfa35fa842e5b3d727a974388008_I20230428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xL2ZyYWc6YjJlMDBiZGQ3OGFmNGVlZGI0NGUyNDRlNzQ3MzQ2OGQvdGV4dHJlZ2lvbjpiMmUwMGJkZDc4YWY0ZWVkYjQ0ZTI0NGU3NDczNDY4ZF8yMDk1_5a584891-2601-438d-a00e-304b69fdffff"
      unitRef="shares">124525737</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMy0xLTEtMS0xMTEzNjg_ace2d9aa-3747-44b8-b0b9-9cf4d36288eb"
      unitRef="usd">672245000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMy0zLTEtMS0xMTEzNjg_6aa62e5e-b00a-46bb-9735-58ea3fa6c381"
      unitRef="usd">866394000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNC0xLTEtMS0xMTEzNjg_87f6206f-a724-43f0-b33c-6630716afa84"
      unitRef="usd">1372574000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNC0zLTEtMS0xMTEzNjg_c5e4013c-8d7b-4938-a5c4-4f9f38e81448"
      unitRef="usd">1297890000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNS0xLTEtMS0xMTEzNjg_41472ae2-a22d-4521-af44-f7210f3ea244"
      unitRef="usd">25856000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNS0zLTEtMS0xMTEzNjg_fe457055-15e6-4f03-9177-831844cc98c0"
      unitRef="usd">28122000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNi0xLTEtMS0xMTEzNjg_ad18f2aa-3e9a-4f54-a317-cf92ae7b4367"
      unitRef="usd">219434000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNi0zLTEtMS0xMTEzNjg_d9eac035-11ca-408d-a5f8-329c0a808a00"
      unitRef="usd">237963000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNy0xLTEtMS0xMTEzNjg_153ce335-87c8-4bca-9f56-4f3cd5bf358b"
      unitRef="usd">131879000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfNy0zLTEtMS0xMTEzNjg_033bf655-edc4-4694-b551-ab364a001b2c"
      unitRef="usd">128962000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfOC0xLTEtMS0xMTEzNjg_c44fba7e-8872-4bf9-b9e7-05d703ee889b"
      unitRef="usd">119030000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfOC0zLTEtMS0xMTEzNjg_131289ba-6386-497b-ab45-4b17e9876fa1"
      unitRef="usd">132916000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTAtMS0xLTEtMTExMzY4_6d9acb01-df72-4d61-a6b2-85ec121434ce"
      unitRef="usd">2541018000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTAtMy0xLTEtMTExMzY4_3a9b4a60-9429-4f48-9522-4d947f36e402"
      unitRef="usd">2692247000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTEtMS0xLTEtMTExMzY4_0dbbcf0a-961f-4c13-a57f-46dcd663b31f"
      unitRef="usd">523032000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTEtMy0xLTEtMTExMzY4_08f6cb27-ce5e-4d2d-b738-745502fa238f"
      unitRef="usd">523494000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTItMS0xLTEtMTExMzY4_9a9eade8-ebf9-426c-8f05-88bb2ff131f4"
      unitRef="usd">215049000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTItMy0xLTEtMTExMzY4_913d8c99-6d83-4707-a64e-0f74ff1d66f3"
      unitRef="usd">215136000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTMtMS0xLTEtMTExMzY4_ac196097-71a9-4340-990c-2e07313be025"
      unitRef="usd">49388000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTMtMy0xLTEtMTExMzY4_6dc10544-70e5-4cb2-82a1-5c8bc4e03150"
      unitRef="usd">49390000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTQtMS0xLTEtMTExMzY4_65edb7dd-a6dd-429c-b04e-3f3aafa674d6"
      unitRef="usd">63453000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTQtMy0xLTEtMTExMzY4_d66d9d30-f07b-48c2-b47b-f39a63c69d61"
      unitRef="usd">66092000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTUtMS0xLTEtMTExMzY4_d793990a-182b-439f-b8d4-47012a679471"
      unitRef="usd">3391940000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTUtMy0xLTEtMTExMzY4_9af67621-5054-4d73-9575-fbd5a4cb2f87"
      unitRef="usd">3546359000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTgtMS0xLTEtMTExMzY4_50a7291e-e8f3-4c26-8341-f642f18fbfd0"
      unitRef="usd">62237000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTgtMy0xLTEtMTExMzY4_9ca6ffbc-8d13-4017-bc1d-faec520e4ed0"
      unitRef="usd">98094000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTktMS0xLTEtMTExMzY4_91a244cd-4019-4cce-8333-bdc9b511e98f"
      unitRef="usd">508599000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMTktMy0xLTEtMTExMzY4_5d805816-572c-462c-962b-a56a605c61db"
      unitRef="usd">545460000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjAtMS0xLTEtMTExMzY4_131f61df-ca90-4fe1-863e-5f7f85155b3f"
      unitRef="usd">43055000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjAtMy0xLTEtMTExMzY4_3b4ae8a1-122f-4df5-be8f-527962df969b"
      unitRef="usd">41967000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjEtMS0xLTEtMTExMzY4_589ed23a-d39a-4ce6-a756-e7264c6dd258"
      unitRef="usd">35794000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjEtMy0xLTEtMTExMzY4_21af395c-476d-4fe4-9444-b399468486d4"
      unitRef="usd">42105000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:RoyaltyLiabilityCurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjItMS0xLTEtMTExMzY4_7141a046-f9a8-485a-8f18-3f51f7366fa4"
      unitRef="usd">23706000</alny:RoyaltyLiabilityCurrent>
    <alny:RoyaltyLiabilityCurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjItMy0xLTEtMTExMzY4_b83057e9-ffe0-41cf-8d41-fbfe411268ff"
      unitRef="usd">40289000</alny:RoyaltyLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjMtMS0xLTEtMTExMzY4_57e924bb-7152-4a79-be34-40a9ee769fae"
      unitRef="usd">673391000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjMtMy0xLTEtMTExMzY4_8ae0b9ba-6680-401b-b4a3-65d3ee636109"
      unitRef="usd">767915000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjQtMS0xLTEtMTExMzY4_9866a7b6-04a9-43dd-825e-d4d582acf289"
      unitRef="usd">259399000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjQtMy0xLTEtMTExMzY4_0942c417-10b8-472c-89b0-048b00893ec6"
      unitRef="usd">261339000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjUtMS0xLTEtMTExMzY4_0c2a4f82-98de-47d2-b5ee-049d281feba5"
      unitRef="usd">191257000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjUtMy0xLTEtMTExMzY4_76469ce9-771a-450a-ba05-21bf1b7450bd"
      unitRef="usd">193791000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjYtMS0xLTEtMTExMzY4_e1ddf58f-7a94-4dd3-af55-01d5e1655750"
      unitRef="usd">1017887000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjYtMy0xLTEtMTExMzY4_ca63470d-cd5e-4cf1-97a7-f1fd43aa4117"
      unitRef="usd">1016942000</us-gaap:ConvertibleDebtNoncurrent>
    <alny:RoyaltyLiabilityNoncurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjgtMS0xLTEtMTExMzY4_34b02876-ac97-401f-98ab-032698dbec8e"
      unitRef="usd">1285200000</alny:RoyaltyLiabilityNoncurrent>
    <alny:RoyaltyLiabilityNoncurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjgtMy0xLTEtMTExMzY4_62acd470-adb1-4527-8615-60e99c8d7d0d"
      unitRef="usd">1252015000</alny:RoyaltyLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjktMS0xLTEtMTExMzY4_20ae9f8d-782a-40fb-8b11-19e8cf515a6e"
      unitRef="usd">224046000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMjktMy0xLTEtMTExMzY4_810c35c2-9b2e-4ea4-80ed-88ffd4028bb3"
      unitRef="usd">212580000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzAtMS0xLTEtMTExMzY4_5410f92b-f1cc-4ef3-a01e-d3842df9c5a9"
      unitRef="usd">3651180000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzAtMy0xLTEtMTExMzY4_717af1a0-b096-46d2-b173-2a526733b3a1"
      unitRef="usd">3704582000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzEtMS0xLTEtMTExMzY4_e648215e-5227-44dd-a473-a8414d578b27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzEtMy0xLTEtMTExMzY4_06136521-a925-4aef-8313-791317130a76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfMjI_3ce0e910-4aaf-44d7-ad09-7b2a46501565"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfMjI_eccc08c9-b987-4122-b1b0-41b819d51e66"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfNDY_79a5ca29-d290-4b03-9b1e-6ceacc57a1b3"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfNDY_9b68ffc0-5b94-4dba-9034-42dddcea7580"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfNzE_3a6455ea-b51c-4216-93c5-0e13e72b33f7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfNzE_aa72d455-ff67-406e-b78c-14ee7652a2cc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfNzE_e034ea67-4fe8-466e-9cf3-c67732bc9c9f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMC0xLTEtMTExMzY4L3RleHRyZWdpb246N2M0ZmIwYzI1YmU2NGUwMzgwYjM2MDEzMDdhOWQ3NDlfNzE_eae96671-acea-4347-8a40-f42ff6401ac3"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMS0xLTEtMTExMzY4_b35f09cc-38d2-4a53-9ac3-118b5955e633"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzMtMy0xLTEtMTExMzY4_b153c680-652e-4110-80a4-2a9e57d34bd1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfMTg_7f69c27a-bb06-414b-a634-4305ffb6727a"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfMTg_d83dbb4e-a631-4e3a-a611-27e86e2aaebd"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfNDI_7888f226-cbd5-4a9e-a764-d3a421d0b6d5"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfNDI_e277731f-f584-4f9f-83f1-da3f1ae3eb25"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfNjQ_2fb7db02-9194-44ff-9114-a6ae505585f1"
      unitRef="shares">124241000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfNjQ_e22eeb6e-90f9-419b-826a-bb8b166dc07b"
      unitRef="shares">124241000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfMTA3_dad9b9b3-d785-4e72-98c1-656b1c7ad12a"
      unitRef="shares">123925000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMC0xLTEtMTExMzY4L3RleHRyZWdpb246ZjU5NmNkZWEyN2I3NDQ2ZmI5MWIwZGYzMmZmMTI2YmRfMTA3_e06769a9-8bc9-47b1-94dd-648f8cb26eba"
      unitRef="shares">123925000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMS0xLTEtMTExMzY4_f484f8c3-7a71-4b2b-a057-cd8e2c6c21fa"
      unitRef="usd">1243000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzQtMy0xLTEtMTExMzY4_993ccc43-0a68-4d71-af02-24507319b848"
      unitRef="usd">1240000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzUtMS0xLTEtMTExMzY4_684da35b-f9d9-46be-94c0-6d19979cd0f2"
      unitRef="usd">6522091000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzUtMy0xLTEtMTExMzY4_9aefbe47-6282-4856-b0e1-6dcf369a3277"
      unitRef="usd">6454540000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzYtMS0xLTEtMTExMzY4_e27a8dfd-aea2-4b5c-b1b7-48529499eced"
      unitRef="usd">-39124000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzYtMy0xLTEtMTExMzY4_049b013b-8f30-4013-8c83-1f71ebef071a"
      unitRef="usd">-44654000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzctMS0xLTEtMTExMzY4_73a266da-3683-4af8-839f-3e34e9b59130"
      unitRef="usd">-6743450000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzctMy0xLTEtMTExMzY4_7f665b5e-6b99-49de-9cef-4e4f2884247f"
      unitRef="usd">-6569349000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzgtMS0xLTEtMTExMzY4_87ad614e-9043-4688-8714-03d1fdae2107"
      unitRef="usd">-259240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzgtMy0xLTEtMTExMzY4_d6a44096-3027-4b88-9e5b-5af85c843c56"
      unitRef="usd">-158223000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzktMS0xLTEtMTExMzY4_ab3954ea-0c49-4d73-ac4a-d9b8a6f17e1e"
      unitRef="usd">3391940000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8xOS9mcmFnOjI5MWY3Mjk5Y2E2ODQ3MDRiMTQ2ZmJhMTVhYTE1NzI4L3RhYmxlOjUyYjNiNmY2MTA5ZTRiZmQ5YzgyNTI3ZWJhNzllNmRlL3RhYmxlcmFuZ2U6NTJiM2I2ZjYxMDllNGJmZDljODI1MjdlYmE3OWU2ZGVfMzktMy0xLTEtMTExMzY4_f5dc414a-5ef0-4380-afa2-20dceebe76df"
      unitRef="usd">3546359000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8195be6db017423781aa99e5f6eccbdd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNC0xLTEtMS0xMTEzNjg_13cc2184-2b2e-49b5-9b54-7e957acd068d"
      unitRef="usd">276328000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32b8d81e96cb44258ca45844632dfcd5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNC0zLTEtMS0xMTEzNjg_80e1a205-9148-4905-bda5-010990b61c05"
      unitRef="usd">186872000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84733ccbf66149c5b5b450843cfb6b1a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNS0xLTEtMS0xMTEzNjg_ed477fd9-8696-4c4f-bada-809035633f41"
      unitRef="usd">36462000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1217f0f803147f79e8c9536b829300b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNS0zLTEtMS0xMTEzNjg_645e79ae-6395-47be-bd1e-6326d179f09e"
      unitRef="usd">25945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bc45426006b4d8da84244a71315226f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNi0xLTEtMS0xMTEzNjg_34214a21-5ba4-4912-9376-ac18c8027c81"
      unitRef="usd">6500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i614f8658aaee4615b1db837d518ecf21_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNi0zLTEtMS0xMTEzNjg_f0e657f7-6ba0-4b6b-9033-e45ac876ac33"
      unitRef="usd">442000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNy0xLTEtMS0xMTEzNjg_63943137-3e70-44ca-8d0b-3edcb73360ee"
      unitRef="usd">319290000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfNy0zLTEtMS0xMTEzNjg_e5d9cc0c-2a20-4bdf-8c30-5442ee5fa021"
      unitRef="usd">213259000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfOS0xLTEtMS0xMTEzNjg_51d15c0b-cc05-4c1d-ab7e-0fb11f62a82c"
      unitRef="usd">41432000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfOS0zLTEtMS0xMTEzNjg_caffe389-9628-4cba-8f21-21c1470aab4e"
      unitRef="usd">23457000</us-gaap:CostOfGoodsAndServicesSold>
    <alny:CostOfCollaborationManufacturingAndRoyalties
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTAtMS0xLTEtMTExMzY4_2f563a1c-3218-4701-8aa5-02690d415926"
      unitRef="usd">13437000</alny:CostOfCollaborationManufacturingAndRoyalties>
    <alny:CostOfCollaborationManufacturingAndRoyalties
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTAtMy0xLTEtMTExMzY4_bb989807-e24f-4b2f-8931-e8002b2e1983"
      unitRef="usd">12170000</alny:CostOfCollaborationManufacturingAndRoyalties>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTEtMS0xLTEtMTExMzY4_f9ca65c7-2eaf-46b3-8912-d19e596d307e"
      unitRef="usd">230569000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTEtMy0xLTEtMTExMzY4_b9e24f68-4baa-4614-8207-bf6a82cf7f32"
      unitRef="usd">169893000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTItMS0xLTEtMTExMzY4_b9d0a522-2874-4ecf-b0de-50a328908774"
      unitRef="usd">183659000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTItMy0xLTEtMTExMzY4_08530d73-e690-4cf4-99a4-0f7d9a696520"
      unitRef="usd">154471000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTMtMS0xLTEtMTExMzY4_511de319-594a-4fa5-98b9-e1752c2730ca"
      unitRef="usd">469097000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTMtMy0xLTEtMTExMzY4_0677c596-3da9-4ffc-934f-f75345f8638f"
      unitRef="usd">359991000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTQtMS0xLTEtMTExMzY4_85462302-1bdf-441b-abf4-cdbfc072b04c"
      unitRef="usd">-149807000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTQtMy0xLTEtMTExMzY4_9f81a563-a4ef-4887-9996-ba4f751a397c"
      unitRef="usd">-146732000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTYtMS0xLTEtMTExMzY4_ac2acfa5-c8ce-40f1-9d26-70672bac52e0"
      unitRef="usd">28955000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTYtMy0xLTEtMTExMzY4_effdea72-241e-4d12-aa7d-5fcaabe188f0"
      unitRef="usd">42362000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTctMS0xLTEtMTIxMzQy_912a270f-fe53-4c17-8e94-bd17cdd9a820"
      unitRef="usd">18655000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTctMy0xLTEtMTIxMzQy_a2d5e173-71f0-48c2-a5f5-f41fd97d9914"
      unitRef="usd">1012000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTctMS0xLTEtMTExMzY4_0f7aa063-05bb-46e0-a21c-eb72af5e1784"
      unitRef="usd">-12255000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTctMy0xLTEtMTExMzY4_0b0f26da-513e-46b3-b86a-425cc4aed2ce"
      unitRef="usd">-51274000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTktMS0xLTEtMTExMzY4_c5c1debc-4df6-4e86-89df-69d4c3e59991"
      unitRef="usd">-22555000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMTktMy0xLTEtMTExMzY4_829db578-df05-4769-81c5-ae756613a3a0"
      unitRef="usd">-92624000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjAtMS0xLTEtMTExMzY4_7e015151-9abf-4fa4-917e-f7a763d183e5"
      unitRef="usd">-172362000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjAtMy0xLTEtMTExMzY4_3ce5d2fd-2926-458c-beda-8b5df49bbe87"
      unitRef="usd">-239356000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjEtMS0xLTEtMTExMzY4_b29d7c75-a838-48f9-a845-6db5ebae5c4a"
      unitRef="usd">1739000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjEtMy0xLTEtMTExMzY4_e8690424-ecb6-40ca-b9ad-62dbb72965b7"
      unitRef="usd">985000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjItMS0xLTEtMTExMzY4_0beda309-8cf7-4674-a044-c31fb32a4d2e"
      unitRef="usd">-174101000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjItMy0xLTEtMTExMzY4_fbba0d65-47af-4ada-8004-ede17b3f28b3"
      unitRef="usd">-240341000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjMtMS0xLTEtMTExMzY4_b1e2a57c-249c-4aa8-b8ee-4d7ed6e0f9c5"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjMtMS0xLTEtMTExMzY4_de4630a1-4f98-4ac3-af62-a5eb070f50f3"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjMtMy0xLTEtMTExMzY4_5013b99e-fef2-462a-b335-83ed97ae7924"
      unitRef="usdPerShare">-2.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjMtMy0xLTEtMTExMzY4_99d450c6-166f-498a-83ea-1756748782cb"
      unitRef="usdPerShare">-2.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjQtMS0xLTEtMTExMzY4_70670447-bc71-4e6b-851d-06d0a3899a4c"
      unitRef="shares">124111000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjQtMS0xLTEtMTExMzY4_c9d9a66f-97a0-413a-92f5-a54d7f49c7ad"
      unitRef="shares">124111000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjQtMy0xLTEtMTExMzY4_5bc268ea-934f-412d-bbf3-eda3938e0520"
      unitRef="shares">120393000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjQtMy0xLTEtMTExMzY4_ac6085fe-e58f-4017-b2a9-0f91c0842660"
      unitRef="shares">120393000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjctMS0xLTEtMTExMzY4_7737cc15-bc4d-46ef-9622-a533a5c5d3c7"
      unitRef="usd">-174101000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjctMy0xLTEtMTExMzY4_f1505d54-e9ee-4147-a5ff-4cae2f9e3efd"
      unitRef="usd">-240341000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjktMS0xLTEtMTExMzY4_500f404a-5d68-4990-9244-a5817515e6bd"
      unitRef="usd">4125000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMjktMy0xLTEtMTExMzY4_4e2e3292-f1a9-4342-ba74-36b510cc7e02"
      unitRef="usd">-7217000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzAtMS0xLTEtMTExMzY4_031e4d83-af4a-4cdd-ac89-003844dfd6bf"
      unitRef="usd">1410000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzAtMy0xLTEtMTExMzY4_a6beae6f-872d-48b4-844c-f4c26cc9276c"
      unitRef="usd">2376000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzEtMS0xLTEtMTExMzY4_028278f2-59a4-4946-a1df-74720269ce97"
      unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzEtMy0xLTEtMTExMzY4_2f412236-93f9-4845-8a3e-5defb46d8ffc"
      unitRef="usd">-35000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzItMS0xLTEtMTExMzY4_2815cb0e-2d5d-4ad2-9ffb-ce6edf54a56a"
      unitRef="usd">5530000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzItMy0xLTEtMTExMzY4_aaf36ab4-47df-4bab-9054-453404525e86"
      unitRef="usd">-4806000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzMtMS0xLTEtMTExMzY4_36375944-0b32-4270-8b60-7db752d303bc"
      unitRef="usd">-168571000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yNS9mcmFnOjA5NGRkZTcxNWYyZjQ5M2ViZWIwYmUyNmNjNTBjMDk0L3RhYmxlOjJmNjJmMjViNmVhYzQyYTM4Mjg1ZGNjMWI2YzRjMzcwL3RhYmxlcmFuZ2U6MmY2MmYyNWI2ZWFjNDJhMzgyODVkY2MxYjZjNGMzNzBfMzMtMy0xLTEtMTExMzY4_20603784-17c5-4d10-bf86-41ef3bcddb5b"
      unitRef="usd">-245147000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i165ab1c7d45f4b59b55f6202bd02b29d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMi0xLTEtMS0xMTEzNjg_edffa630-ad3c-4aa2-881e-020754ba39e8"
      unitRef="shares">123925000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i165ab1c7d45f4b59b55f6202bd02b29d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMi0zLTEtMS0xMTEzNjg_52ac93b4-b507-468c-8a47-f109041e7eba"
      unitRef="usd">1240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i627afa621d0246df9877bb6114adff8c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMi01LTEtMS0xMTEzNjg_74eda663-b58f-47be-b05a-ebdf322388a5"
      unitRef="usd">6454540000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib10c6162d7ee41d8b5073719840fa8ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMi03LTEtMS0xMTEzNjg_d44403d9-2fea-45da-8409-45c5f9d98e96"
      unitRef="usd">-44654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1effbb5b358434886d5497a4dd79337_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMi05LTEtMS0xMTEzNjg_a3e796fe-2a1b-4816-86c4-13492456cd7b"
      unitRef="usd">-6569349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMi0xMS0xLTEtMTExMzY4_05370b5a-1e25-4310-ba52-c5454d7522cd"
      unitRef="usd">-158223000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6ad08d083b134bc08112b596229b2ed4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMy0xLTEtMS0xMTEzNjg_a85ddf7c-265f-4dfd-807d-f86118ff4bb2"
      unitRef="shares">269000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6ad08d083b134bc08112b596229b2ed4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMy0zLTEtMS0xMTEzNjg_8e623618-851b-4923-b549-92ff13fd04aa"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0285951fb32549e2b7c666db15c9daf2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMy01LTEtMS0xMTEzNjg_e743e17c-538b-43e6-af4d-60e5ecc4dc5a"
      unitRef="usd">26415000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfMy0xMS0xLTEtMTExMzY4_2ebb2970-cbd3-4609-ad36-b7f71338ffb3"
      unitRef="usd">26418000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="i6ad08d083b134bc08112b596229b2ed4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNC0xLTEtMS0xMTEzNjg_a860c60d-84cf-4341-91c5-828ca496cc12"
      unitRef="shares">47000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNC0xMS0xLTEtMTExMzY4_7f13b28e-e342-4a8f-b617-bc05a7b6a2ae"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0285951fb32549e2b7c666db15c9daf2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNS01LTEtMS0xMTEzNjg_ef99b8e3-e63e-4292-8677-b20a02795f6e"
      unitRef="usd">41136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNS0xMS0xLTEtMTExMzY4_df45c831-5e58-440f-a653-aae0c1bec02c"
      unitRef="usd">41136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i76a77c376b2b4ba987e016002cfe1389_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNi03LTEtMS0xMTEzNjg_b3bba7fe-74ab-4607-b047-2a7d49a8638a"
      unitRef="usd">5530000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNi0xMS0xLTEtMTExMzY4_cf95556b-7c1c-4f2e-bf4f-764b10e17d5b"
      unitRef="usd">5530000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i4c7db22afb9642d498a5f30d7ec9da76_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNy05LTEtMS0xMTEzNjg_56b85d75-823c-4c25-a180-a93b77a7e239"
      unitRef="usd">-174101000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfNy0xMS0xLTEtMTExMzY4_6732c01d-e6bd-41b3-a6cb-80c530035ab3"
      unitRef="usd">-174101000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic503ee23109c47a485d4c943dc01c684_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfOC0xLTEtMS0xMTEzNjg_282b6c7b-748b-4d26-bbc9-702cf5dda3e0"
      unitRef="shares">124241000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic503ee23109c47a485d4c943dc01c684_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfOC0zLTEtMS0xMTEzNjg_23f9ef1f-cbd8-4af5-b1dc-0002906e6ce0"
      unitRef="usd">1243000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if50048ec3817431baf2df96733ffaa31_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfOC01LTEtMS0xMTEzNjg_cadbd142-88ed-4733-8484-e245deb3a565"
      unitRef="usd">6522091000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id68ac710f233437aa4518ad8eb0adb93_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfOC03LTEtMS0xMTEzNjg_b2ef6cb8-4156-4cc9-810c-7636a2c7f304"
      unitRef="usd">-39124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8d35477623a4ca9b7fc82fa82a051b8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfOC05LTEtMS0xMTEzNjg_0fb31267-3dfa-4a2f-b9a3-2175b073fa06"
      unitRef="usd">-6743450000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjEwNzA3YjA2YTVmMDQ2NjJhMzg1NTUxNjZkNmE4MzY3L3RhYmxlcmFuZ2U6MTA3MDdiMDZhNWYwNDY2MmEzODU1NTE2NmQ2YTgzNjdfOC0xMS0xLTEtMTExMzY4_0bbaa988-1129-46a5-a83c-721a7b51eca1"
      unitRef="usd">-259240000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib8b5cdd9d6524a48a7c0e217c8746b86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMi0xLTEtMS0xMTEzNjg_23957b6c-6ba5-446a-ae75-3c353c82631b"
      unitRef="shares">120182000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib8b5cdd9d6524a48a7c0e217c8746b86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMi0zLTEtMS0xMTEzNjg_d09deee1-d66e-4193-b2d7-94b1d4c0de6b"
      unitRef="usd">1202000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i349f62fd0c1c46b6a699a43b81912de5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMi01LTEtMS0xMTEzNjg_879c2305-94ea-470e-a299-5498f28e8c2f"
      unitRef="usd">6058453000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie72229676bde424e88e71e576e78694f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMi03LTEtMS0xMTEzNjg_05be4f1a-4cfc-456e-a294-46a985eb48e4"
      unitRef="usd">-33259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id64ff2050fde4c88a7a11680cbda5964_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMi05LTEtMS0xMTEzNjg_6af42491-6889-4d10-a1b3-ca70c2fc4612"
      unitRef="usd">-5438193000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1fa61d04167f4839b28e5e693a40c913_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMi0xMS0xLTEtMTExMzY4_fe2ed124-c1e7-4f93-9bfe-e826732225cb"
      unitRef="usd">588203000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i32343cbd739e429184dd13d72f726915_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMy0xLTEtMS0xMTEzNjg_acc52b76-e630-4d37-8d4f-8c0b0a67c47e"
      unitRef="shares">524000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i32343cbd739e429184dd13d72f726915_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMy0zLTEtMS0xMTEzNjg_cbf87762-eb77-40a2-b607-4c07683b4f09"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3a826bcf6ea5466cbbdc81d17d06dfc3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMy01LTEtMS0xMTEzNjg_ec1dcdd3-cc9e-4b6a-9001-5ddb8ecf6751"
      unitRef="usd">28054000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfMy0xMS0xLTEtMTExMzY4_23ee702b-7861-4f1d-bfe6-b8b0eee138d9"
      unitRef="usd">28059000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="i32343cbd739e429184dd13d72f726915_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNC0xLTEtMS0xMTEzNjg_a9e1fb84-59ac-4492-98f0-e174e4e6beb5"
      unitRef="shares">23000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3a826bcf6ea5466cbbdc81d17d06dfc3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNS01LTEtMS0xMTEzNjg_e6c4bb32-d76a-4816-aec0-5d94ce79881a"
      unitRef="usd">30051000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNS0xMS0xLTEtMTExMzY4_cd106d7e-f01f-40a4-874b-db58b3274bfb"
      unitRef="usd">30051000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i10b28d8521f2456da2d0123114d04efc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNi03LTEtMS0xMTEzNjg_774fe636-2e36-459b-8817-33e88317cac5"
      unitRef="usd">-4806000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNi0xMS0xLTEtMTExMzY4_fd4b0af9-b93b-42f1-bef7-e88cb78cf7c4"
      unitRef="usd">-4806000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="idd6e196fd8bc401390b246f2c1842f21_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNy05LTEtMS0xMTEzNjg_e2505704-a46a-4091-ba3f-63ee6525cd53"
      unitRef="usd">-240341000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfNy0xMS0xLTEtMTExMzY4_a61c2570-8941-4013-9b05-61ac09f8e55e"
      unitRef="usd">-240341000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iea3984c5c8334ea2b81d6e311a263566_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfOC0xLTEtMS0xMTEzNjg_3e2697a9-df39-432c-8fc7-d9a70c93374d"
      unitRef="shares">120729000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iea3984c5c8334ea2b81d6e311a263566_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfOC0zLTEtMS0xMTEzNjg_9dcb68f6-d61c-41e1-b323-6354ddd26881"
      unitRef="usd">1207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d7c4b1ef5dd4faabe5879a7cb1a13b4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfOC01LTEtMS0xMTEzNjg_c4a2ee19-c27b-49a1-a27b-3274c201a20b"
      unitRef="usd">6116558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2d23f30f53a4a3b8caa38a11b48d302_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfOC03LTEtMS0xMTEzNjg_95d1f324-1724-4043-a3a5-a637d7f0a6f6"
      unitRef="usd">-38065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74133721fcc744889831c3b5bbd754b4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfOC05LTEtMS0xMTEzNjg_2ba62973-f7d4-49ea-a32a-50370c1f07e3"
      unitRef="usd">-5678534000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i129714144f56409c862078cd74c09670_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8yOC9mcmFnOjU5Y2E5MDhjN2FjNTQwMDJiZWZkNTEzMjQyMTU2ZWQ1L3RhYmxlOjYzMTJmODdlYTNhODQ0MmViM2ZlZjhiNGVmMzU3YzY4L3RhYmxlcmFuZ2U6NjMxMmY4N2VhM2E4NDQyZWIzZmVmOGI0ZWYzNTdjNjhfOC0xMS0xLTEtMTExMzY4_423a0838-e987-4e23-9cb8-279e93f1575a"
      unitRef="usd">401166000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMy0xLTEtMS0xMTEzNjg_0b991dc1-0dea-4060-b179-1bb744034281"
      unitRef="usd">-174101000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMy0zLTEtMS0xMTEzNjg_ed666ef8-3aad-4fba-b48c-1f43b0744ff9"
      unitRef="usd">-240341000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNS0xLTEtMS0xMTEzNjg_6e2cbbff-cb75-40ef-8de7-60fe80b03b91"
      unitRef="usd">14065000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNS0zLTEtMS0xMTEzNjg_fea8d7f2-d0e5-415e-b50b-3464bcc15eb0"
      unitRef="usd">9460000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <alny:AmortizationAndInterestAccretionRelatedToOperatingLeases
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNi0xLTEtMS0xMTEzNjg_a6c3ea51-5413-4c54-b0e6-622945135a10"
      unitRef="usd">12014000</alny:AmortizationAndInterestAccretionRelatedToOperatingLeases>
    <alny:AmortizationAndInterestAccretionRelatedToOperatingLeases
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNi0zLTEtMS0xMTEzNjg_adf1521a-e271-4f0c-a77f-e449df5ff172"
      unitRef="usd">10318000</alny:AmortizationAndInterestAccretionRelatedToOperatingLeases>
    <alny:NonCashInterestExpenseOnSaleOfFutureRoyalties
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNy0xLTEtMS0xMTEzNjg_0794d85b-0ec2-4c47-a84d-641bdf30d1c4"
      unitRef="usd">25275000</alny:NonCashInterestExpenseOnSaleOfFutureRoyalties>
    <alny:NonCashInterestExpenseOnSaleOfFutureRoyalties
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNy0zLTEtMS0xMTEzNjg_69d0b405-e4a4-4d6e-90b7-39e8be6e5b88"
      unitRef="usd">27702000</alny:NonCashInterestExpenseOnSaleOfFutureRoyalties>
    <us-gaap:ShareBasedCompensation
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfOC0xLTEtMS0xMTEzNjg_e4619d3b-eba6-4914-9f81-c660e5953297"
      unitRef="usd">39947000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfOC0zLTEtMS0xMTEzNjg_27ea9954-89c6-45d0-9680-6e0401944337"
      unitRef="usd">29293000</us-gaap:ShareBasedCompensation>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfOS0xLTEtMS0xMTEzNjg_1ed846d4-1737-4fc7-93fb-37c8b24241e2"
      unitRef="usd">-2267000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfOS0zLTEtMS0xMTEzNjg_c2f614c9-2bdd-4e4d-a212-2ff4fceec132"
      unitRef="usd">-31161000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <alny:ChangeInFairValueOfLiabilityObligation
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTEtMS0xLTEtMTExMzY4_4df95813-6111-430a-867f-328c1e85511d"
      unitRef="usd">-6471000</alny:ChangeInFairValueOfLiabilityObligation>
    <alny:ChangeInFairValueOfLiabilityObligation
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTEtMy0xLTEtMTExMzY4_2bc8f62f-7ab8-4174-a417-4788e519e5a1"
      unitRef="usd">-13782000</alny:ChangeInFairValueOfLiabilityObligation>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTItMS0xLTEtMTExMzY4_390a8800-f018-411e-93ef-83b44a61e3b3"
      unitRef="usd">-6276000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTItMy0xLTEtMTExMzY4_57ca7968-8666-49cd-af9e-e350c512c96e"
      unitRef="usd">7395000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTQtMS0xLTEtMTExMzY4_7df78614-0c1e-4626-931e-dd0d3a8d3042"
      unitRef="usd">-19153000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTQtMy0xLTEtMTExMzY4_ea8545d0-94d5-4752-8993-16f30726d69e"
      unitRef="usd">-39696000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTUtMS0xLTEtMTExMzY4_d0d37871-874b-4aa3-adc8-6089f4b9a7aa"
      unitRef="usd">403000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTUtMy0xLTEtMTExMzY4_c3145fe4-4835-4b86-b06d-48cfef93f457"
      unitRef="usd">-1926000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTYtMS0xLTEtMTExMzY4_0d5c9874-a242-4d9a-ab0b-bdd7e277aded"
      unitRef="usd">1235000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTYtMy0xLTEtMTExMzY4_52f73976-b29c-485b-9d31-29db9979cea3"
      unitRef="usd">29852000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTctMS0xLTEtMTExMzY4_cc9cc45c-bcc9-4eca-9315-c727a0dcd3e5"
      unitRef="usd">-81975000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTctMy0xLTEtMTExMzY4_272ce412-ba8a-4f12-b3b9-9a39dfce7174"
      unitRef="usd">-48736000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTgtMS0xLTEtMTExMzY4_ec1827a3-903f-494e-8541-0da198f9b49d"
      unitRef="usd">-12827000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTgtMy0xLTEtMTExMzY4_0be8883e-a6fe-4091-86e6-1f645ad07f23"
      unitRef="usd">-10672000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTktMS0xLTEtMTExMzY4_9262922a-1707-4c9c-9c78-426a078aaf96"
      unitRef="usd">-8850000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMTktMy0xLTEtMTExMzY4_c6543485-1926-443f-a76b-b800064b05a4"
      unitRef="usd">-12325000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjAtMS0xLTEtMTExMzY4_94cb2d40-97df-4530-8b34-9e328dece414"
      unitRef="usd">-166475000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjAtMy0xLTEtMTExMzY4_68fdd754-9f34-4310-aa0d-0e1767d02fe9"
      unitRef="usd">-171193000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjItMS0xLTEtMTExMzY4_35140922-0f26-45d7-a447-bf2931f24def"
      unitRef="usd">13891000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjItMy0xLTEtMTExMzY4_6f6dc058-15c7-442d-9316-69e8a3754625"
      unitRef="usd">17859000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjMtMS0xLTEtMTExMzY4_8a96a9b5-0719-4213-a43a-42b8408fc7a7"
      unitRef="usd">435746000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjMtMy0xLTEtMTExMzY4_e3a60a0a-e69b-40cb-8094-1f04c0b61261"
      unitRef="usd">634705000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjQtMS0xLTEtMTExMzY4_5c6335fc-93f5-44b4-ab93-bd1ba12d931b"
      unitRef="usd">373420000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjQtMy0xLTEtMTExMzY4_1cda66a1-2c18-4a1c-a73e-800ff2780563"
      unitRef="usd">505220000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjUtMS0xLTEtMTExMzY4_de2c0963-7a92-4d85-a754-dacf4f149c23"
      unitRef="usd">49225000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjUtMy0xLTEtMTExMzY4_d6f90a62-7cc5-4755-920a-ee955d6c7180"
      unitRef="usd">9400000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjYtMS0xLTEtMTExMzY4_fc26b5e5-c05b-49f2-ad8e-5314a72e7eda"
      unitRef="usd">49225000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjYtMy0xLTEtMTExMzY4_1c61150a-62db-4cec-883a-85295a1d3b9e"
      unitRef="usd">9400000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjctMS0xLTEtMTExMzY4_66fadf89-29ca-4e91-9605-2d2af838b4c8"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjctMy0xLTEtMTExMzY4_4b02d7be-8c38-42d3-9073-c4a4c1ff0b4c"
      unitRef="usd">75000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjgtMS0xLTEtMTExMzY4_a25b3eaf-9891-4350-853e-a39dc10fb594"
      unitRef="usd">-76217000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMjgtMy0xLTEtMTExMzY4_30b0c9f2-f703-4d00-bf82-5a6221ab56ba"
      unitRef="usd">-147419000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzAtMS0xLTEtMTExMzY4_0b4e2ad0-d9e8-4598-a86a-4cd39989ce78"
      unitRef="usd">42371000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzAtMy0xLTEtMTExMzY4_b077d299-72e9-46cf-9f7f-a83275131511"
      unitRef="usd">27123000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzUtMS0xLTEtMTExMzY4_deae82a9-7181-4f84-ad55-e53499f3c87b"
      unitRef="usd">4000000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzUtMy0xLTEtMTExMzY4_4ab3ffde-5a20-41f7-b861-97900910ede6"
      unitRef="usd">7833000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzgtMS0xLTEtMTExMzY4_778c2a20-523b-4d76-9d16-618f6c4e1fb4"
      unitRef="usd">46371000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzgtMy0xLTEtMTExMzY4_db33a862-b3fc-4b52-b514-796f7e762d14"
      unitRef="usd">34956000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzktMS0xLTEtMTExMzY4_795d4846-2bc7-449f-86ce-c65387084db2"
      unitRef="usd">2176000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfMzktMy0xLTEtMTExMzY4_076b9001-7406-4fa9-a5be-492212729f40"
      unitRef="usd">-2238000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDAtMS0xLTEtMTExMzY4_e16f3677-383a-44f4-bde0-8c03f19aff73"
      unitRef="usd">-194145000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDAtMy0xLTEtMTExMzY4_34136376-5243-40b5-8cd7-48bdaa89a758"
      unitRef="usd">-285894000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDEtMS0xLTEtMTExMzY4_e2866084-3b27-43e9-88e4-dd32df3f419b"
      unitRef="usd">868556000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1fa61d04167f4839b28e5e693a40c913_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDEtMy0xLTEtMTExMzY4_1c12ff6c-eed2-435b-8ac9-a86d01d4f6ea"
      unitRef="usd">822153000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDItMS0xLTEtMTExMzY4_ce1dc7e7-443d-4ced-93c9-1254114241d0"
      unitRef="usd">674411000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i129714144f56409c862078cd74c09670_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDItMy0xLTEtMTExMzY4_4f99b3ca-4e87-4b34-acbb-7d56c9cf7549"
      unitRef="usd">536259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDQtMS0xLTEtMTExMzY4_f15e9b5e-472d-452d-8bff-97423567f483"
      unitRef="usd">13912000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDQtMy0xLTEtMTExMzY4_50839b40-2b18-4f7f-83b0-0de4f818a6e3"
      unitRef="usd">14120000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDctMS0xLTEtMTExMzY4_7fcca15d-d0da-4ef0-9650-329dcb1dabf3"
      unitRef="usd">4034000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zMS9mcmFnOjkxOTliOTE3MzE5YzQzMTFiOTg5MDIwMjEzODAzODA5L3RhYmxlOjk0MTY3M2Q1NWI3YjRmOWQ4NGMxZGQ5YzM4MWNlNzAzL3RhYmxlcmFuZ2U6OTQxNjczZDU1YjdiNGY5ZDg0YzFkZDljMzgxY2U3MDNfNDctMy0xLTEtMTExMzY4_8a49b9c3-52f1-4015-9d23-85aae76645a9"
      unitRef="usd">8318000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zNy9mcmFnOjRmNjA2ZTM5NzIxOTQ0Y2I4ZGY0M2QxODQxNDg4Njc5L3RleHRyZWdpb246NGY2MDZlMzk3MjE5NDRjYjhkZjQzZDE4NDE0ODg2NzlfMjA1OA_0e87c99b-330a-4105-ae59-deb9e57d82dd">NATURE OF BUSINESS&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June&#160;14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on ribonucleic acid interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In early 2021, we launched our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Alnylam P&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;x25 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;strategy, which focuses on our planned transition to a top-tier biotech company by the end of 2025. With &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Alnylam P&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;x25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, while delivering exceptional financial performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, we have five marketed products, including one partnered product, and multiple late-stage investigational programs advancing towards potential commercialization. We currently generate worldwide product revenues from four commercialized products, ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO, primarily in the United States, or U.S., Europe and Japan.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <alny:NumberOfMarketedProducts
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zNy9mcmFnOjRmNjA2ZTM5NzIxOTQ0Y2I4ZGY0M2QxODQxNDg4Njc5L3RleHRyZWdpb246NGY2MDZlMzk3MjE5NDRjYjhkZjQzZDE4NDE0ODg2NzlfNTQ5NzU1ODE0MTc3MQ_060d0558-2c89-40b6-a0d3-b28289abbbfa"
      unitRef="product">5</alny:NumberOfMarketedProducts>
    <alny:NumberOfPartneredProducts
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zNy9mcmFnOjRmNjA2ZTM5NzIxOTQ0Y2I4ZGY0M2QxODQxNDg4Njc5L3RleHRyZWdpb246NGY2MDZlMzk3MjE5NDRjYjhkZjQzZDE4NDE0ODg2NzlfNTQ5NzU1ODE0MTc3OA_715ca6d1-1a71-4086-87b9-0d7f39b1b6cf"
      unitRef="product">1</alny:NumberOfPartneredProducts>
    <alny:NumberOfCommercializedProducts
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF8zNy9mcmFnOjRmNjA2ZTM5NzIxOTQ0Y2I4ZGY0M2QxODQxNDg4Njc5L3RleHRyZWdpb246NGY2MDZlMzk3MjE5NDRjYjhkZjQzZDE4NDE0ODg2NzlfMjA2MQ_a58e107c-5c54-407a-ada6-cab2a9c9c7c2"
      unitRef="product">4</alny:NumberOfCommercializedProducts>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80MC9mcmFnOjdmZDZiMmNiY2RlZTQxMDhiYjZjYzcwNTAwYjUwZTA1L3RleHRyZWdpb246N2ZkNmIyY2JjZGVlNDEwOGJiNmNjNzA1MDBiNTBlMDVfNTIwMA_38370623-486e-4112-bde0-d11dc739c2a9">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying condensed consolidated financial statements of Alnylam are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2022, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 23, 2023. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of March&#160;31, 2023, together with the cash we expect to generate from product sales and under our current alliances, will be sufficient to enable us to advance our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Alnylam P&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;x25 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80MC9mcmFnOjdmZDZiMmNiY2RlZTQxMDhiYjZjYzcwNTAwYjUwZTA1L3RleHRyZWdpb246N2ZkNmIyY2JjZGVlNDEwOGJiNmNjNzA1MDBiNTBlMDVfNTE5NA_6afc1c14-e519-421a-8f75-36b87a8286a8">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying condensed consolidated financial statements of Alnylam are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2022, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 23, 2023. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80MC9mcmFnOjdmZDZiMmNiY2RlZTQxMDhiYjZjYzcwNTAwYjUwZTA1L3RleHRyZWdpb246N2ZkNmIyY2JjZGVlNDEwOGJiNmNjNzA1MDBiNTBlMDVfNTE5NQ_10f5b457-9dd1-4244-9c4f-a49545ca3ea4">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <alny:LiquidityPolicyPolicyTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80MC9mcmFnOjdmZDZiMmNiY2RlZTQxMDhiYjZjYzcwNTAwYjUwZTA1L3RleHRyZWdpb246N2ZkNmIyY2JjZGVlNDEwOGJiNmNjNzA1MDBiNTBlMDVfNTE5Ng_50007446-9b41-4882-a226-799cf7a99fa3">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of March&#160;31, 2023, together with the cash we expect to generate from product sales and under our current alliances, will be sufficient to enable us to advance our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Alnylam P&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;x25 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;</alny:LiquidityPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RleHRyZWdpb246MmI4NmQ2ZjRjZDBmNGQ3YWI2YTFlNGE0ZDcyZDFmNjVfMTc4_03ea8f08-03d1-437e-b1ce-95c402792f30">NET PRODUCT REVENUES&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net product revenues consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.362%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ONPATTRO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AMVUTTRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;GIVLAARI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OXLUMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the balance of our receivables related to our net product revenues: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.942%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables included in &#x201c;Accounts receivable, net&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RleHRyZWdpb246MmI4NmQ2ZjRjZDBmNGQ3YWI2YTFlNGE0ZDcyZDFmNjVfMTgx_026be934-dc93-4224-99b5-a94c0a0d1d4d">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net product revenues consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.362%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ONPATTRO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AMVUTTRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;GIVLAARI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OXLUMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i469113cbfff1448ca7ace21682306c28_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMy0xLTEtMS0xMTEzNjg_ae42f319-411a-480c-9535-959e4441cf7b"
      unitRef="usd">29817000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b92d59400ad435ab232b2e3fc6af18d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMy0zLTEtMS0xMTEzNjg_4f5978ba-9f6d-435c-bc34-71c6e742d201"
      unitRef="usd">62307000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d2c45ddfe4b4783b61d0c2532b261c6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfNC0xLTEtMS0xMTEzNjg_c2d98e43-3de1-47e3-a871-65a7f7972afe"
      unitRef="usd">59678000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3e2090af379423a830396d670dd46ed_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfNC0zLTEtMS0xMTEzNjg_437f9439-d50b-4d73-8a2c-1e02ea15651c"
      unitRef="usd">53181000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i879c1a7e15df42b1a622d6d158eedebc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfNS0xLTEtMS0xMTEzNjg_5bf975ff-d2fb-471e-be15-ba04668d06f7"
      unitRef="usd">12998000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id72a32ea5faa4d2aa4490f6f4d5cd32c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfNS0zLTEtMS0xMTEzNjg_11383619-4c31-4d75-a492-38eaff51b2b9"
      unitRef="usd">21521000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd786b1197ef4a61a89be31d546d3ce9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfNi0xLTEtMS0xMTEzNjg_c537aba9-03a5-45f3-8a7e-9c70cf93fb91"
      unitRef="usd">102493000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e76d8ae0a064b248bb6fc792baf7c14_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfNi0zLTEtMS0xMTEzNjg_1bfab180-8622-4678-9db2-ee4870779bcd"
      unitRef="usd">137009000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i840efee846e14303b149ccdfdf3a36a8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfOS0xLTEtMS0xMTEzNjg_c2f103a7-2128-4322-9785-cb953a958908"
      unitRef="usd">79013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd036604ac7d4a5da0d65fbf272d8217_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfOS0zLTEtMS0xMTEzNjg_b4402514-ca6e-46d1-a184-ded53d1013d0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief1d9b2c9e9b4acd9209bc90e66a8411_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTAtMS0xLTEtMTExMzY4_4649abd2-80c8-4320-8f0e-7f02acc615d9"
      unitRef="usd">6768000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71831b87aef84d13af0dc46e7eb3368e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTAtMy0xLTEtMTExMzY4_f262402a-5d3d-4caa-baca-ae032235d434"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb5e5a391b254ff999e9906a4a44fecb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTEtMS0xLTEtMTE4MDIy_c6f7d768-ccd4-4a5e-8603-864e3fc4395d"
      unitRef="usd">15987000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2417f18ab724e43af379c82cd5c9c40_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTEtMy0xLTEtMTE4MDIy_c2974e06-1f11-446f-b435-8aad71b7af64"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73ca8156836b4f2da4a82227758bd9b0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTEtMS0xLTEtMTExMzY4_c4513951-b15d-428d-9c69-2a46429ce74e"
      unitRef="usd">101768000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i039c753c58d949c39d6d04e4fb10c8d3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTEtMy0xLTEtMTExMzY4_b14fad40-70c3-4314-8a01-e1abf5a0cdd7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i463e7ef6195945beb17fb66c0a944c2e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTQtMS0xLTEtMTExMzY4_3fd71ce0-a26e-499a-8555-fea9392ebae0"
      unitRef="usd">30291000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i933f756eaa1d499da77f10cf4ef3a9fc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTQtMy0xLTEtMTExMzY4_df9dee3f-9029-420f-8f6b-c1c40a168fa6"
      unitRef="usd">23675000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0754e7eb06254fb4b0be930af30fd4e8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTUtMS0xLTEtMTExMzY4_1e55d31c-2cb9-4dc6-a56f-b877a18ba056"
      unitRef="usd">14471000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4a7d3d13d3a4e91a7ac66295559e8bc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTUtMy0xLTEtMTExMzY4_2a46f423-84c5-4f2c-9de9-8c0113f88de6"
      unitRef="usd">9688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e770d161620415d9b7f5ffaecfd1b16_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTYtMS0xLTEtMTExMzY4_1b76529f-7500-46a4-b44c-902686716ad7"
      unitRef="usd">3144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d3be339f54740539cf50f08dd95e8e2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTYtMy0xLTEtMTExMzY4_8bf25597-7981-48dd-8e31-5bb5aca4006d"
      unitRef="usd">1914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61661522e28049569e22780fccab15ec_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTctMS0xLTEtMTExMzY4_c9e22ee0-2685-40d3-a86e-e2d439cc76c5"
      unitRef="usd">47906000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfde9e56f64e49eb860585920e3307de_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMTctMy0xLTEtMTExMzY4_335a6ba1-df59-455a-924a-7166b9cf0ab2"
      unitRef="usd">35277000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbc72492b6ac4d9ab9d17a76e1b3f401_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjAtMS0xLTEtMTExMzY4_753fec94-4440-4922-a323-afb64fe24918"
      unitRef="usd">9057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84b7e1d6726c409abc1a24d2d0d4cd0b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjAtMy0xLTEtMTExMzY4_a00624cf-7a76-4d8e-9189-d3880f0532eb"
      unitRef="usd">5412000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e09c2afc4be4d46b953611b6eedc4cd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjEtMS0xLTEtMTExMzY4_5445561a-5a44-4369-8148-fcf27f9eeca8"
      unitRef="usd">13309000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i294c21243c484600ae87664735590a24_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjEtMy0xLTEtMTExMzY4_7088d776-da29-41ef-9980-77a42230607c"
      unitRef="usd">8158000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a9a9fb2de3341c4965ed9d0dcd38e2f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjItMS0xLTEtMTExMzY4_29c823a9-c051-4a80-b22a-57932265e9c1"
      unitRef="usd">1795000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefe2b83e5c274d98a554d85575908847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjItMy0xLTEtMTExMzY4_7f555630-e503-483a-a07a-dc525d61b3a6"
      unitRef="usd">1016000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50560d538c374d999be9a5694bed79c4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjMtMS0xLTEtMTExMzY4_02a35be0-1b33-4172-971d-bf00e7e0c50a"
      unitRef="usd">24161000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cd6dd169a314d9e8b10044417187c7c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjMtMy0xLTEtMTExMzY4_48c6b44f-195a-4e6e-9364-c2e7d1491ee9"
      unitRef="usd">14586000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8195be6db017423781aa99e5f6eccbdd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjUtMS0xLTEtMTExMzY4_6f944276-df70-422f-af0e-dbda61d4fb83"
      unitRef="usd">276328000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32b8d81e96cb44258ca45844632dfcd5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjdlYWFmNzZiMDgwMjQ4ZjVhNjQ3MTljOTg1ZmYxNGFkL3RhYmxlcmFuZ2U6N2VhYWY3NmIwODAyNDhmNWE2NDcxOWM5ODVmZjE0YWRfMjUtMy0xLTEtMTExMzY4_1b495304-0810-4387-8565-ce03c5383fea"
      unitRef="usd">186872000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RleHRyZWdpb246MmI4NmQ2ZjRjZDBmNGQ3YWI2YTFlNGE0ZDcyZDFmNjVfMTgz_7e2f6817-15f8-446b-9bf7-d9d04202f5d9">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the balance of our receivables related to our net product revenues: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.942%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables included in &#x201c;Accounts receivable, net&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i33c0592038dc4276b0af9495329ef056_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjBiYzU2MjY5NTIxODRkYzZiOWUzNjVlNjg5MjVhMTdmL3RhYmxlcmFuZ2U6MGJjNTYyNjk1MjE4NGRjNmI5ZTM2NWU2ODkyNWExN2ZfMS0xLTEtMS0xMTEzNjg_c65affb8-6507-4e4b-81f2-9f4c53be011d"
      unitRef="usd">190931000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8ea9f42cbd234c25a0f60837c51cbcbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80My9mcmFnOjJiODZkNmY0Y2QwZjRkN2FiNmExZTRhNGQ3MmQxZjY1L3RhYmxlOjBiYzU2MjY5NTIxODRkYzZiOWUzNjVlNjg5MjVhMTdmL3RhYmxlcmFuZ2U6MGJjNTYyNjk1MjE4NGRjNmI5ZTM2NWU2ODkyNWExN2ZfMS0zLTEtMS0xMTEzNjg_d1d1321d-e233-4a84-a186-ae4f29f808f6"
      unitRef="usd">203844000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzNDA_03a6be83-fdc5-4266-b221-75455a52b162">NET REVENUES FROM COLLABORATIONS&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net revenues from collaborations consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis AG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.502%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables included in &#x201c;Accounts receivable, net&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities included in &#x201c;Deferred revenue&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We recognized revenue of $15.4 million and $9.5 million in the three months ended March&#160;31, 2023 and 2022, respectively, that was included in the contract liability balance at the beginning of the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In order to determine revenue recognized in the period from contract liabilities, we first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability as opposed to a portion applying to the new consideration for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides research and development expenses incurred by type, for which we recognize net revenue, that are directly attributable to our collaboration agreements, by collaboration partner:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Clinical Trial and Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;External Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Clinical Trial and Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;External Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The research and development expenses incurred for the agreements included in the table above consist of costs incurred for (i) clinical expenses, including manufacturing of clinical product, (ii) external services including consulting services and lab supplies and services, and (iii) other expenses, including professional services, facilities and overhead allocations, and a reasonable estimate of compensation and related costs as billed to our counterparties, for which we recognize net revenues from collaborations. For the three months ended March&#160;31, 2023 and 2022, we did not incur material selling, general and administrative expenses related to our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, we recognized a reduction to our research and development expenses of $5.7&#160;million and $3.9&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, from cost reimbursement due under certain of our collaboration agreements with Regeneron Pharmaceuticals, Inc., or Regeneron, accounted for under Accounting Standards Codification, or ASC, Topic 808, Collaborative Arrangements, or ASC 808. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Product Alliances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Regeneron Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April&#160;2019, we entered into a global, strategic collaboration with Regeneron to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the eye and central nervous system, or CNS, in addition to a select number of targets expressed in the liver, which we refer to as the Regeneron Collaboration. The Regeneron Collaboration is governed by a Master Agreement, referred to as the Regeneron Master Agreement, which became effective on May 21, 2019. In connection with the Regeneron Master Agreement, we and Regeneron entered into (i) a binding co-co collaboration term sheet covering the continued development of cemdisiran, our C5 small &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;interfering RNA, or siRNA, currently in Phase 2 development for C5 complement-mediated diseases, as a monotherapy and (ii) a binding license term sheet to evaluate anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases including evaluating the combination of Regeneron&#x2019;s pozelimab (REGN3918), currently in Phase 3 development, and cemdisiran. The C5 co-co collaboration and license agreements were executed in August 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the terms of the Regeneron Collaboration, we are working exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases for an initial research period of approximately five years, which we refer to as the Initial Research Term. Regeneron has an option to extend the Initial Research Term (referred to as the Research Term Extension Period, and together with the Initial Research Term, the Research Term) for up to an additional five years, for a research term extension fee of $300.0 million. The Regeneron Collaboration also covers a select number of RNAi therapeutic programs designed to target genes expressed in the liver, including our previously announced collaboration with Regeneron to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis. We retain broad global rights to all of our other unpartnered liver-directed clinical and pre-clinical pipeline programs. The Regeneron Collaboration is governed by a joint steering committee that is comprised of an equal number of representatives from each party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Regeneron leads development and commercialization for all programs targeting eye diseases (subject to limited exceptions), entitling us to certain potential milestone and royalty payments pursuant to the terms of a license agreement, the form of which has been agreed upon by the parties. We and Regeneron are alternating leadership on CNS and liver programs covered by the Regeneron Collaboration, with the lead party retaining global development and commercial responsibility. For such CNS and liver programs, both we and Regeneron have the option at lead candidate selection to enter into a&#160;co-co&#160;collaboration agreement, the form of which has been agreed upon by the parties, whereby both companies will share equally all costs of, and profits from, all development and commercialization activities under the program. If the&#160;non-lead&#160;party elects to not enter into a&#160;co-co&#160;collaboration agreement with respect to a given CNS or liver program, we and Regeneron will enter into a license agreement with respect to such program and the lead party will be the &#x201c;Licensee&#x201d; for the purposes of the license agreement. If the lead party for a CNS or liver program elects to not enter into the&#160;co-co&#160;collaboration agreement, then we and Regeneron will enter into a license agreement with respect to such program and leadership of the program will transfer to the other party and the former&#160;non-lead&#160;party will be the &#x201c;Licensee&#x201d; for the purposes of the license agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;With respect to the programs directed to C5 complement-mediated diseases, we retain control of cemdisiran monotherapy development, and Regeneron is leading combination product development. Pursuant to the C5 co-co collaboration agreement, Regeneron notified us in November 2022 of its decision to exercise its right to opt-out of the further development and commercialization of cemdisiran monotherapy. As a result, Regeneron no longer shares costs and potential future profits on any monotherapy program with us. We continue to perform our obligations under the agreement and we are solely responsible for all development and commercialization costs. Regeneron will be eligible to receive tiered double-digit royalties on net sales. Under the C5 license agreement, for cemdisiran to be used as part of a combination product, Regeneron is solely responsible for all development and commercialization costs and we will receive low double-digit royalties and commercial milestones of up to $325.0 million on any potential combination product sales. The C5 co-co collaboration agreement, the C5 license agreement, and the Master Agreement have been combined for accounting purposes and treated as a single agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Regeneron Master Agreement, Regeneron made an upfront payment of $400.0 million. We are also eligible to receive up to an additional $200.0 million in milestone payments upon achievement of certain criteria during early clinical development for eye and CNS programs. We and Regeneron plan to advance programs directed to up to 30 targets in the first five years under the Regeneron Collaboration during the Initial Research Term. For each program, Regeneron will provide us with $2.5 million in funding at program initiation and an additional $2.5 million at lead candidate identification, with the potential for approximately $30.0 million in annual discovery funding to us as the Regeneron Collaboration reaches steady state.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Regeneron has the right to terminate the Regeneron Master Agreement for convenience upon ninety days&#x2019; notice. The termination of the Regeneron Master Agreement does not affect the term of any license agreement or&#160;co-co&#160;collaboration agreement then in effect. In addition, either party may terminate the Regeneron Master Agreement for a material breach by, or insolvency of, the other party. Unless earlier terminated pursuant to its terms, the Regeneron Master Agreement will remain in effect with respect to each program until (a)&#160;such program becomes a terminated program or (b)&#160;the parties enter into a license agreement or&#160;co-co&#160;collaboration agreement with respect to such program.&#160;The Regeneron Master Agreement includes various representations, warranties, covenants, dispute escalation and resolution mechanisms, indemnities and other provisions customary for transactions of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For any license agreement subsequently entered into, the licensee will generally be responsible for its own costs and expenses incurred in connection with the development and commercialization of the collaboration products. The licensee will pay to the licensor certain development and/or commercialization milestone payments totaling up to $150.0 million for each collaboration product. In addition, following the first commercial sale of the applicable collaboration product under a license &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;agreement, the licensee is required to make certain tiered royalty payments, ranging from low double-digits up to 20%, to the licensor based on the aggregate annual net sales of the collaboration product, subject to customary reductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For any co-co&#160;collaboration agreement subsequently entered into, we and Regeneron will share equally all costs of, and profits from, development and commercialization activities. Reimbursement of our share of costs will be recognized as a reduction to research and development expense in the condensed consolidated statements of operations and comprehensive loss. In the event that a party exercises its&#160;opt-out&#160;right, the lead party will be responsible for all costs and expenses incurred in connection with the development and commercialization of the collaboration products under the applicable&#160;co-co&#160;collaboration agreement, subject to continued sharing of costs through defined points. If a party exercises its&#160;opt-out&#160;right, following the first commercial sale of the applicable collaboration product under a&#160;co-co&#160;collaboration agreement, the lead party is required to make certain tiered royalty payments, ranging from low double-digits up to 20%, to the other party based on the aggregate annual net sales of the collaboration product and the timing of the exercise of the&#160;opt-out&#160;right, subject to customary reductions and a reduction for&#160;opt-out&#160;transition costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any milestone or royalty payments from Regeneron under the Regeneron Master Agreement, the C5 license agreement, or any future license agreement, or under any co-co collaboration agreement in the event we exercise our opt-out right.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our obligations under the Regeneron Collaboration include: (i) a research license and research services, collectively referred to as the Research Services Obligation; (ii) a worldwide license to cemdisiran for combination therapies, and manufacturing and supply, and development service obligations, collectively referred to as the C5 License Obligation; and (iii) development, manufacturing and commercialization activities for cemdisiran monotherapies, referred to as the C5 Co-Co Obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The research license is not distinct from the research services primarily as a result of Regeneron being unable to benefit on its own or with other resources reasonably available, as the license is providing access to specialized expertise, particularly as it relates to RNAi technology that is not available in the marketplace.&#160;Similarly, the worldwide license to cemdisiran for combination therapies is not distinct from the manufacturing and supply, and development service obligations, as Regeneron cannot benefit on its own from the value of the license without receipt of supply.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Separately, prior to Regeneron&#x2019;s decision in November 2022 to exercise its right to opt-out of the further development and commercialization of cemdisiran monotherapy, the cemdisiran monotherapy co-co collaboration agreement was under the scope of ASC 808 as we and Regeneron were both active participants in the development and manufacturing activities and were exposed to significant risks and rewards that were dependent on commercial success of the activities of the arrangement. Regeneron&#x2019;s decision to exercise its right to opt-out of the arrangement caused a change in the role of Regeneron and its exposure to significant risks and rewards under the arrangement. As a result, we determined that the arrangement no longer represents a collaborative arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The arrangement now represents a vendor-customer relationship under ASC 606 as we perform our obligation to provide development and manufacturing activities under the arrangement. The transaction price allocated to the C5 Co-Co obligation unit of account will be recognized over time using an input method based on cost incurred relative to the total estimated costs for the identified performance obligation by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The total transaction price is comprised of the&#160;$400.0 million&#160;upfront payment and&#160;additional variable consideration related to research, development, manufacturing and supply activities related to the Research Services Obligation and the C5 License Obligation. We utilized the expected value method to determine the amount of reimbursement for these activities. We determined that any variable consideration related to sales-based royalties and milestones related to the worldwide license to cemdisiran for combination therapies is deemed to be constrained and therefore has been excluded from the transaction price. In addition, we are eligible to receive future milestones upon the achievement of certain criteria during early clinical development for the eye and CNS programs.&#160;We are also eligible to receive royalties on future commercial sales for certain eye, CNS or liver targets, if any; however, these amounts are excluded from variable consideration under the Regeneron Collaboration as we are only eligible to receive such amounts if, after a drug candidate is identified, the form of license agreement is subsequently executed resulting in a license that is granted to Regeneron. Any such subsequently granted license would represent a separate transaction under ASC 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Standalone Selling Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Transaction Price Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;130,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;183,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;97,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;92,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;364,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;246,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;521,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The transaction price was allocated to the obligations based on the relative estimated standalone selling prices of each obligation, over which management has applied significant judgment. We developed the estimated standalone selling price for the licenses included in the Research Services Obligation and the C5 License Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we applied judgment in the determination of the forecasted revenues, taking into consideration the applicable market conditions and relevant entity-specific factors, the expected number of targets or indications expected to be pursued under each license, the probability of success, the time needed to develop a product candidate pursuant to the associated license and the discount rate. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the obligations, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs. The estimated standalone selling price of the C5 Co-Co Obligation was developed by estimating the present value of expected future cash flows that Regeneron is entitled to receive. In developing such estimate, we applied judgment in determining the indications that will be pursued, the forecasted revenues for such indications, the probability of success and the discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the Research Services Obligation, the C5 License Obligation, and the C5 Co-Co Obligation accounted for under ASC 606, we measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for each of the identified obligations, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&#160;This ratio is applied to the transaction price allocated to each obligation. Management has applied significant judgment in the process of developing our estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. We re-evaluate the transaction price as of the end of each reporting period and as of March&#160;31, 2023, the total transaction price was determined to be $559.6 million. Revenue recognized under this agreement is accounted for as collaboration revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables provide a summary of the transaction price allocated to each unit of account based on the applicable accounting guidance, in addition to revenue activity during the period, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Transaction Price Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;215,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;23,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;97,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;246,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;191,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;193,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;559,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;220,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;226,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.994%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.317%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue Recognized During&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of&#160;March&#160;31, 2023, the aggregate amount of the transaction price allocated to the remaining Research Services Obligation, C5 License Obligation and C5 Co-Co Obligation that was unsatisfied was&#160;$274.4&#160;million, which&#160;is expected to be recognized through the term of the Regeneron Collaboration as the services are performed. Deferred revenue related to the Regeneron Collaboration is classified as either current or non-current in the condensed consolidated balance sheets based on the period the revenue is expected to be recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Novartis AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;2013 Collaboration with The Medicines Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2013, we and The Medicines Company, or MDCO, entered into a license and collaboration agreement pursuant to which we granted to MDCO an exclusive, worldwide license to develop, manufacture and commercialize RNAi therapeutics targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of hypercholesterolemia and other human diseases, including inclisiran. We refer to this agreement, as amended through the date hereof, as the MDCO License Agreement. In 2020, Novartis AG, or Novartis, completed its acquisition of MDCO and assumed all rights and obligations under the MDCO License Agreement. Additional details regarding the terms, milestones earned upon the achievement of certain events and additional milestones we are entitled to receive upon the achievement of future events under the MDCO License Agreement are described in Note 4 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on February 23, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;Novartis License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2021, we and Novartis entered into a collaboration and license agreement, or the Novartis License Agreement, pursuant to which we granted to Novartis an exclusive, worldwide license to develop, manufacture and commercialize siRNAs targeting end-stage liver disease, or ESLD, potentially leading to the development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure. Additional details regarding the terms and transaction price under the Novartis License Agreement are described in Note 4 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on February 23, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition to the collaboration agreements discussed above, we have various other collaboration agreements that are not individually significant to our operating results or financial condition at this time. Pursuant to the terms of those agreements, we may be required to pay, or we may receive, additional amounts contingent upon the occurrence of various future events (e.g., upon the achievement of various development and commercial milestones) which in the aggregate could be significant. We may also incur, or be reimbursed for, significant research and development costs. In addition, if any products related to these collaborations are approved for sale, we may be required to pay, or we may receive, royalties on future sales. The payment or receipt of these amounts, however, is contingent upon the occurrence of various future events.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzNDE_ea7bdb04-1d42-44b4-900c-613353834ef7">Net revenues from collaborations consist of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis AG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb64947f4c824451ac2a67d55f9eec37_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfMi0xLTEtMS0xMTEzNjg_66483df5-e1b5-4d85-91eb-1f1f5db983fb"
      unitRef="usd">19990000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22f96c66a004453596d01941e4ce155f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfMi0zLTEtMS0xMTEzNjg_eaea1978-2cbc-4d2b-bf59-b3e0ec7c3253"
      unitRef="usd">12412000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d5ea14b863b4413b7307cdb670fe0ab_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfMy0xLTEtMS0xMTEzNjg_915e87d6-d848-44b5-b7f7-246c50b1814a"
      unitRef="usd">14933000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i625a2ec4ecfa4a25a2186cc5eb8e048f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfMy0zLTEtMS0xMTEzNjg_535d8222-4233-4d13-a29e-b77c64ffb864"
      unitRef="usd">13136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i700ea43392914b5bb710a1f264221b6c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfNS0xLTEtMS0xMTEzNjg_efd8b49b-5816-450c-90fd-d51367c9ef9a"
      unitRef="usd">1539000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic369c5ac0ae741b69d6c684ad3edcfc1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfNS0zLTEtMS0xMTEzNjg_d529f50d-33bc-4d61-8b02-555cdbf0c2c0"
      unitRef="usd">397000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i119bb76ddc4f49b89a1e68acefe7a579_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfNi0xLTEtMS0xMTEzNjg_f77e64e9-3157-4de4-a157-f668189bc63b"
      unitRef="usd">36462000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a0b91c625484c1db6cf8d6e8200ae4b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjJmMTdhYWQxZTU2MjQ1MzU4MWQ0MWEyMTA0MDRhNjBiL3RhYmxlcmFuZ2U6MmYxN2FhZDFlNTYyNDUzNTgxZDQxYTIxMDQwNGE2MGJfNi0zLTEtMS0xMTEzNjg_4f9c3a83-c9ca-4e85-9b43-9fa90d0c3e93"
      unitRef="usd">25945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzMjk_cd92509e-04bf-440a-b0e8-28f432e56e52">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.502%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables included in &#x201c;Accounts receivable, net&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities included in &#x201c;Deferred revenue&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i312ec99fcc6c43a5a131ac1f6eb87263_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjdkNzVmODNlOGEzYjRlOWQ4ZmNkY2ZlZDRkYjJjM2Y3L3RhYmxlcmFuZ2U6N2Q3NWY4M2U4YTNiNGU5ZDhmY2RjZmVkNGRiMmMzZjdfMS0xLTEtMS0xMTEzNjg_5926a305-d5d4-4172-9419-ed03bcd419ac"
      unitRef="usd">22572000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8140860172b844839f38d726caf34dee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjdkNzVmODNlOGEzYjRlOWQ4ZmNkY2ZlZDRkYjJjM2Y3L3RhYmxlcmFuZ2U6N2Q3NWY4M2U4YTNiNGU5ZDhmY2RjZmVkNGRiMmMzZjdfMS0zLTEtMS0xMTEzNjg_27b7dbef-3206-4682-ab46-bae603372d23"
      unitRef="usd">32342000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i312ec99fcc6c43a5a131ac1f6eb87263_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjdkNzVmODNlOGEzYjRlOWQ4ZmNkY2ZlZDRkYjJjM2Y3L3RhYmxlcmFuZ2U6N2Q3NWY4M2U4YTNiNGU5ZDhmY2RjZmVkNGRiMmMzZjdfMi0xLTEtMS0xMTEzNjg_3e2b8781-ae22-4fa6-b3eb-8fe77bfafd5d"
      unitRef="usd">226789000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8140860172b844839f38d726caf34dee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjdkNzVmODNlOGEzYjRlOWQ4ZmNkY2ZlZDRkYjJjM2Y3L3RhYmxlcmFuZ2U6N2Q3NWY4M2U4YTNiNGU5ZDhmY2RjZmVkNGRiMmMzZjdfMi0zLTEtMS0xMTEzNjg_2b267670-8efd-4bd4-a158-4302ae4bfb3b"
      unitRef="usd">235528000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMjU3_40b3713f-4cc5-4e43-b6da-df51f4c54105"
      unitRef="usd">15400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMTA5OTUxMTY3MjkyOQ_b9360484-d053-431f-8ee7-858e3de7e554"
      unitRef="usd">9500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <alny:ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzMjI_45e0f104-4c4d-4ece-8222-e57556e94ac7">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides research and development expenses incurred by type, for which we recognize net revenue, that are directly attributable to our collaboration agreements, by collaboration partner:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Clinical Trial and Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;External Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Clinical Trial and Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;External Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i31d11f918c134929a249af868dc0a880_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfMy0xLTEtMS0xMTEzNjg_0e1d514b-ec1f-4565-be08-64049747c19f"
      unitRef="usd">8516000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8f793b67069946539339f57991faca6f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfMy0zLTEtMS0xMTEzNjg_e0f18fe7-7034-4e67-bb35-08f8793fa5ba"
      unitRef="usd">1240000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6ad2eeaaba1140c1b13fa6e42dba1bd4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfMy01LTEtMS0xMTEzNjg_4207f430-22a9-4753-9238-4f0c0e046a26"
      unitRef="usd">9363000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6fadae33c506406b84c2961fea62350a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfMy03LTEtMS0xMTEzNjg_ec371b55-565d-441e-9efd-b62a76c9c45e"
      unitRef="usd">1437000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iba3a79574455472d858759fccd74a1f2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfMy05LTEtMS0xMTEzNjg_f9c59cce-23f0-49e7-bbac-db7060407cc0"
      unitRef="usd">622000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i505a333c3b1b497290cc1a035457ef65_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfMy0xMS0xLTEtMTExMzY4_e4fd0a2c-f420-4b2f-8973-5960c30cfa54"
      unitRef="usd">9308000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0c5e76a3a4cf45db98aa355177c9a5d3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNS0xLTEtMS0xMTEzNjg_2cfe3f76-8c6b-47eb-97e3-955869bcba0b"
      unitRef="usd">312000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i366eacf4f5df477589f244ba31e7710b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNS0zLTEtMS0xMTEzNjg_b843b6bb-44ae-43a6-8f49-8cd95a78bb0b"
      unitRef="usd">126000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i330d2d52ecae4487a330a3ffa3b3df3e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNS01LTEtMS0xMTEzNjg_d18ca241-ab4c-4b57-9eaa-0ac131081091"
      unitRef="usd">360000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i568cba070fdc4faab4ba5d1d1b7b45af_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNS03LTEtMS0xMTEzNjg_b7fb6026-b53f-45ac-a75b-ab8cfb8a7703"
      unitRef="usd">156000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4f5ad1d8efc44580ac18facfdada39c1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNS05LTEtMS0xMTEzNjg_b2e90f39-addc-49f8-ab74-4a38e227fd7a"
      unitRef="usd">42000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i122a5b203d314116a7be9b37a61d8bf1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNS0xMS0xLTEtMTExMzY4_eb2d79ff-d1f7-4d6a-b613-9b39a014cad8"
      unitRef="usd">160000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3594c34bba4944ca91cc9765440d129b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNi0xLTEtMS0xMTEzNjg_434a62f9-4c0e-4863-985f-2c630067cbf4"
      unitRef="usd">8828000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4a4ded065a9d42fca7d0593ecfb28c99_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNi0zLTEtMS0xMTEzNjg_4160448f-2fcc-4982-83a3-38c51bbbce3c"
      unitRef="usd">1366000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4ec14d6c93f549abad409a4ee60dc447_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNi01LTEtMS0xMTEzNjg_a8d2106b-04c3-4788-8d28-dc3ac7869981"
      unitRef="usd">9723000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iea75117bc59d46cca891d43505fb5e06_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNi03LTEtMS0xMTEzNjg_8bf65790-5638-48b8-a151-dac3d9513bab"
      unitRef="usd">1593000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i989eed19cb3f4fa18bc8d14e53d5af1e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNi05LTEtMS0xMTEzNjg_706db4dd-320e-4259-b750-b476a0d98494"
      unitRef="usd">664000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5f79bfbe7bce408cafa73cf4b18f1764_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOmM2NTBmMDQ5YjQ0NDRlNTI5NGE5ZTg1OWI5ZGRiZjJhL3RhYmxlcmFuZ2U6YzY1MGYwNDliNDQ0NGU1Mjk0YTllODU5YjlkZGJmMmFfNi0xMS0xLTEtMTExMzY4_25432578-e3c2-4fa7-a705-636651106fc4"
      unitRef="usd">9468000</us-gaap:ResearchAndDevelopmentExpense>
    <alny:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMTkyMg_15af0c24-2827-4b70-ae28-94bf479f0909"
      unitRef="usd">-5700000</alny:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <alny:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNTQ5NzU1ODU5MDkx_b0bb51cb-b10c-43c9-8ec2-8fdaef49348a"
      unitRef="usd">-3900000</alny:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <alny:DiscoveryPeriodOfProgramsDevelopment
      contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzMjY_f614b5fd-6fbd-4277-9ab7-2a5f6fde0c4d">P5Y</alny:DiscoveryPeriodOfProgramsDevelopment>
    <alny:ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment
      contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzkyOA_a107450c-618f-4a01-83c7-e23e1cd4b205">P5Y</alny:ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment>
    <alny:ResearchTermExtensionFee
      contextRef="i9b17e6f85a474102b37c2eb6225b0f06_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzk3NQ_c9269504-43e3-468d-acef-567593cfa453"
      unitRef="usd">300000000</alny:ResearchTermExtensionFee>
    <alny:MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale
      contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNjU3OA_1128205a-8881-4847-8b2a-de4c8a6090e6"
      unitRef="usd">325000000</alny:MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale>
    <alny:UpfrontFeeReceived
      contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNjg4MA_db6030b1-764e-485f-a7ee-7feadf5ced94"
      unitRef="usd">400000000</alny:UpfrontFeeReceived>
    <alny:MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria
      contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNjkzNg_ecf64e01-edf5-401f-8fad-d665305801e8"
      unitRef="usd">200000000</alny:MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria>
    <alny:NumberOfTargetedPrograms
      contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNzExOA_c4fe1766-dd8d-42ff-a4ba-59750d752333"
      unitRef="target">30</alny:NumberOfTargetedPrograms>
    <alny:CollaborativeAgreementPeriodOfProgramDevelopment
      contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNzE0Mg_a45bdbe4-ab6c-4b2e-8525-3a941072c90c">P5Y</alny:CollaborativeAgreementPeriodOfProgramDevelopment>
    <alny:PotentialProceedsFromCollaborationArrangement
      contextRef="ia2262debc8564e2ea595ab280c42f0db_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNzI2Mg_3f3a2e45-c8b5-4c31-ac1f-247e90147094"
      unitRef="usd">2500000</alny:PotentialProceedsFromCollaborationArrangement>
    <alny:PotentialProceedsFromCollaborationArrangement
      contextRef="i8a62ef305c0f40a79899683564ff0247_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNzMxNg_18109218-ab44-44df-acad-7c8425817ee8"
      unitRef="usd">2500000</alny:PotentialProceedsFromCollaborationArrangement>
    <alny:PotentialProceedsFromCollaborationArrangement
      contextRef="if6a70a035a37440e909aac14f9fda6d9_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNzM5MA_f7afe988-ea92-4a15-94dd-18f27df0f85d"
      unitRef="usd">30000000</alny:PotentialProceedsFromCollaborationArrangement>
    <alny:CollaborativeAgreementTerminationPeriod
      contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfNzU2OQ_d88d47c4-2cf8-4c09-9697-bde599bde4ff">P90D</alny:CollaborativeAgreementTerminationPeriod>
    <alny:CollaborativeArrangementMilestonePayments
      contextRef="i9b17e6f85a474102b37c2eb6225b0f06_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfODcwOQ_a0a177be-21c0-44f3-8442-020ca6754eda"
      unitRef="usd">150000000</alny:CollaborativeArrangementMilestonePayments>
    <alny:RoyaltyRate
      contextRef="ib324fbd9af6f4a3d8ef929b6d99bf163_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfODk2Mw_9026cfa9-93b0-4c9b-8922-54387e1b0844"
      unitRef="number">0.20</alny:RoyaltyRate>
    <alny:PercentageOfMaximumRoyaltyPayments
      contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMTAwMzc_e1b258ac-f58d-4fb6-be2c-f4c58d9e68e3"
      unitRef="number">0.20</alny:PercentageOfMaximumRoyaltyPayments>
    <alny:UpfrontFeeReceived
      contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMTIzMDI_25d2afdb-c224-4af8-adfd-f112bfc1da72"
      unitRef="usd">400000000</alny:UpfrontFeeReceived>
    <alny:ScheduleOfAllocatedTransactionPriceTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzMzc_9bad50d9-1574-4eae-9db7-5d3a6a279d77">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Standalone Selling Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Transaction Price Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;130,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;183,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;97,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;92,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;364,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;246,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;521,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables provide a summary of the transaction price allocated to each unit of account based on the applicable accounting guidance, in addition to revenue activity during the period, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Transaction Price Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;215,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;23,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;97,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;246,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;191,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;193,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;559,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;220,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;226,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfAllocatedTransactionPriceTableTextBlock>
    <alny:StandaloneSellingPrice
      contextRef="i7e7e8c4e7d644c158639d2fb41e9a319_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfMS0yLTEtMS0xMTEzNjg_33dd892d-8759-46ea-96fe-317b522f63aa"
      unitRef="usd">130700000</alny:StandaloneSellingPrice>
    <alny:TransactionPrice
      contextRef="ie79a8fa8f1ce43deb7597002a348c3be_D20190401-20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfMS00LTEtMS0xMTEzNjg_3dc7f537-74b4-46e9-89aa-466da45ce912"
      unitRef="usd">183100000</alny:TransactionPrice>
    <alny:StandaloneSellingPrice
      contextRef="i537f32b4a16b4543a24f40ddc6741cee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfMi0yLTEtMS0xMTEzNjg_d16469f6-1181-4c6c-b00b-be8b4703c763"
      unitRef="usd">97600000</alny:StandaloneSellingPrice>
    <alny:TransactionPrice
      contextRef="ic42228c3d8ac46a8ac291f126f2d30b6_D20190401-20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfMi00LTEtMS0xMTEzNjg_94858bca-bfe3-44f8-9795-f19483e2813b"
      unitRef="usd">92500000</alny:TransactionPrice>
    <alny:StandaloneSellingPrice
      contextRef="i24ae91e0688d4ae4984f1d8103dc8422_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfMy0yLTEtMS0xMTEzNjg_c96fafbd-f500-45cd-b214-3f1c08271c75"
      unitRef="usd">364600000</alny:StandaloneSellingPrice>
    <alny:TransactionPrice
      contextRef="i46343ad3a9fd4ec3a826cb38ab1b6530_D20190401-20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfMy00LTEtMS0xMTEzNjg_b046bfdb-bc33-4029-ad46-710fa0a75ccb"
      unitRef="usd">246000000</alny:TransactionPrice>
    <alny:TransactionPrice
      contextRef="ic72bd345a96d42859814302ad7ff2730_D20190401-20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjMyMWJkMWUyN2M4ZDQwOTk5ZjQwZjBlNGVjYmQ0ODVlL3RhYmxlcmFuZ2U6MzIxYmQxZTI3YzhkNDA5OTlmNDBmMGU0ZWNiZDQ4NWVfNC00LTEtMS0xMTEzNjg_afd465e8-d227-4f8c-b17d-6c99a31744d7"
      unitRef="usd">521600000</alny:TransactionPrice>
    <alny:TransactionPrice
      contextRef="i10bce677b77f433a9d7d79a79b60f6a2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMTYwMzg_2d718b32-8f54-4514-a319-f5aeae7cf81a"
      unitRef="usd">559600000</alny:TransactionPrice>
    <alny:TransactionPrice
      contextRef="i84c437734fd146c39d505bac418fecf2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfMi0yLTEtMS0xMTEzNjg_f60ec18f-18a7-4369-b0ed-b8fd8e1c3d3b"
      unitRef="usd">215680000</alny:TransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7e7e8c4e7d644c158639d2fb41e9a319_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfMi00LTEtMS0xMTEzNjg_f075e86d-a3b6-4092-bc26-5f184ce28dcb"
      unitRef="usd">23000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie8a02cffca2849af8489d49e9b80b1b2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfMi02LTEtMS0xMTEzNjg_3d0c8803-223a-4ad7-81e7-a610b4da5000"
      unitRef="usd">26200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:TransactionPrice
      contextRef="i03b27765edaa4e13a504fbffd73baf35_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfMy0yLTEtMS0xMTEzNjg_a574efc4-35d5-46f1-8c28-924051e74a69"
      unitRef="usd">97900000</alny:TransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i537f32b4a16b4543a24f40ddc6741cee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfMy00LTEtMS0xMTEzNjg_26e480f2-01c7-4b1e-ad05-d7e4657c872f"
      unitRef="usd">6000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i638ed215bf2a42199fc06a55c0357371_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfMy02LTEtMS0xMTEzNjg_4a0566c1-2217-4225-a704-47659d24e5e3"
      unitRef="usd">7000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:TransactionPrice
      contextRef="i053739f07c5a48d4bd9b455419e9a9f3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfNC0yLTEtMS0xMTEzNjg_6887b043-ff7a-44e0-8f59-44055760ea2e"
      unitRef="usd">246000000</alny:TransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i24ae91e0688d4ae4984f1d8103dc8422_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfNC00LTEtMS0xMTEzNjg_b398f34b-f8ed-49aa-8b7b-3922ec74acae"
      unitRef="usd">191100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3ae2f34bc0ed44efa8a7bcadc7f60158_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfNC02LTEtMS0xMTEzNjg_608b9848-c81e-4ed9-9f98-235bfa86c5d8"
      unitRef="usd">193600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:TransactionPrice
      contextRef="i10bce677b77f433a9d7d79a79b60f6a2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfNS0yLTEtMS0xMTEzNjg_c57d630e-ef96-4a27-a8bc-da585ac17d7d"
      unitRef="usd">559580000</alny:TransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if5ea36d76387472e84cfa6df1370b518_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfNS00LTEtMS0xMTEzNjg_e41d2943-8cc0-4923-8168-0e0e0c9f92fe"
      unitRef="usd">220100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ida6db6b0c1dc4a37b006d8d1871fd207_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjE2MjUyYzQzOGU1MjQwZTI4Mjg4ZDkxOWMzZWNhZDdhL3RhYmxlcmFuZ2U6MTYyNTJjNDM4ZTUyNDBlMjgyODhkOTE5YzNlY2FkN2FfNS02LTEtMS0xMTEzNjg_74252827-9ee6-4c4c-bfb1-47c82169d2a1"
      unitRef="usd">226800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMzYzMzg_71bcce13-d5b0-482a-b3f4-3db471726825">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.994%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.317%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue Recognized During&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</alny:ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84c437734fd146c39d505bac418fecf2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfMi0yLTEtMS0xMTEzNjg_fc8ffcf9-29de-4d3f-b866-4bc920c62041"
      unitRef="usd">10700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34678b9d3faf4e679a9657d9146fcacf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfMi00LTEtMS0xMTEzNjg_711d7b78-b886-4284-8301-90a336b37a55"
      unitRef="usd">7200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03b27765edaa4e13a504fbffd73baf35_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfMy0yLTEtMS0xMTEzNjg_56841068-115c-4ef9-9f1b-c6d9611b796d"
      unitRef="usd">2200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i567601c061914fc8a2d7fd810936ef74_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfMy00LTEtMS0xMTEzNjg_da8dc312-0acf-412b-b23b-6e7f44c40403"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i053739f07c5a48d4bd9b455419e9a9f3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfNC0yLTEtMS0xMTEzNjg_f9eacdea-1e07-49f7-a8e0-d3fda195993b"
      unitRef="usd">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04b45c879ba940b99dd9a474d8b07978_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfNC00LTEtMS0xMTEzNjg_0f1d7af4-3f35-4060-b01e-49efe3cc063a"
      unitRef="usd">2300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10bce677b77f433a9d7d79a79b60f6a2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfNS0yLTEtMS0xMTEzNjg_bee4775a-4490-4312-ac0a-3a8fa48530ba"
      unitRef="usd">15400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d582c41d901411287404a782ac66586_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RhYmxlOjM0NzkzODU3M2Q0MTQ0Mjc5NjUyOTRlMDI4ZWFlNTk1L3RhYmxlcmFuZ2U6MzQ3OTM4NTczZDQxNDQyNzk2NTI5NGUwMjhlYWU1OTVfNS00LTEtMS0xMTEzNjg_6e5544ec-e7e2-40ec-8351-9ffcf9e3e1a6"
      unitRef="usd">10800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="if5ea36d76387472e84cfa6df1370b518_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80Ni9mcmFnOjczYmE2NzI1Nzk0ODQwN2I4YWMwYmM4OGQ3NmRiMTQ4L3RleHRyZWdpb246NzNiYTY3MjU3OTQ4NDA3YjhhYzBiYzg4ZDc2ZGIxNDhfMTY5MjM_a5eeebc0-6ce7-42a9-af56-e358ef70635b"
      unitRef="usd">274400000</us-gaap:RevenueRemainingPerformanceObligation>
    <alny:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMzU3Mg_f9898ce5-57e2-4305-848f-39beaba6db81">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2020, we entered into a purchase and sale agreement, or Purchase Agreement, with BX Bodyguard Royalties L.P. (an affiliate of The Blackstone Group Inc.), or Blackstone Royalties, under which Blackstone Royalties acquired 50% of royalties payable, or Royalty Interest, with respect to net sales by MDCO, its affiliates or sublicensees of inclisiran (or the branded drug product, Leqvio) and any other licensed products under the MDCO License Agreement, and 75% of the commercial milestone payments payable under the MDCO License Agreement, together with the Royalty Interest, the Purchased Interest. If Blackstone Royalties does not receive payments in respect of the Royalty Interest by December 31, 2029, equaling at least $1.00&#160;billion, Blackstone Royalties will receive 55% of the Royalty Interest beginning on January 1, 2030. In consideration for the sale of the Purchased Interest, Blackstone Royalties paid us $1.00&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We continue to own or control all inclisiran intellectual property rights and are responsible for certain ongoing manufacturing and supply obligations related to the generation of the Purchased Interest. Due to our continuing involvement, we will continue to account for any royalties and commercial milestones due to us under the MDCO License Agreement as revenue on our condensed consolidated statement of operations and comprehensive loss and record the proceeds from this transaction as a liability, net of closing costs, on our condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In order to determine the amortization of the liability related to the sale of future royalties, we are required to estimate the total amount of future payments to Blackstone Royalties over the life of the Purchase Agreement. The $1.00&#160;billion liability, recorded at execution of the agreement, will be accreted to the total of these royalty and commercial milestone payments as interest expense over the life of the Purchase Agreement. As of March&#160;31, 2023, our estimate of this total interest expense resulted in an effective annual interest rate of 8%. These estimates contain assumptions that impact both the amount recorded at execution and the interest expense that will be recognized in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As payments are made to Blackstone Royalties, the balance of the liability will be effectively repaid over the life of the Purchase Agreement. The exact timing and amount of repayment is likely to change each reporting period. A significant increase or decrease in Leqvio global net revenue will materially impact the liability related to the sale of future royalties, interest expense and the time period for repayment. We will periodically assess the expected payments to Blackstone Royalties &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and to the extent the amount or timing of such payments is materially different than our initial estimates, we will prospectively adjust the amortization of the liability related to the sale of future royalties and the related interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the carrying value of the liability related to the sale of future royalties was $1.31&#160;billion, net of closing costs of $10.6&#160;million. The carrying value of the liability related to the sale of future royalties approximates fair value as of March&#160;31, 2023 and is based on our current estimates of future royalties and commercial milestones expected to be paid to Blackstone Royalties over the life of the arrangement, which are considered Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table shows the activity with respect to the liability related to the sale of future royalties, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.134%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,308,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock>
    <alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent
      contextRef="i9f304a30d62e48ae884ec8acc207b442_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMjg5_a5646656-1cbb-4702-b538-ff119070f7e3"
      unitRef="number">0.50</alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent>
    <alny:CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent
      contextRef="i9f304a30d62e48ae884ec8acc207b442_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfNDg1_f58ce404-52da-4a17-874f-873e7e511723"
      unitRef="number">0.75</alny:CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent>
    <alny:ExpectedRoyaltyInterestPayments
      contextRef="i951d48bc07e44f98a13abbaa555cc949_D20200401-20200430"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfNzUy_23e69e93-837e-4902-be12-3649feb95147"
      unitRef="usd">1000000000</alny:ExpectedRoyaltyInterestPayments>
    <alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent
      contextRef="i78bb229c8dc8423eb6def37c2540a28f_I20300101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfNzkw_84b4549d-abf4-44ac-a3b6-44e2eb25c867"
      unitRef="number">0.55</alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent>
    <alny:CollaborativeArrangementConsiderationReceived
      contextRef="i951d48bc07e44f98a13abbaa555cc949_D20200401-20200430"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMjE5OTAyMzI1OTI4Ng_bbed4910-fccb-405f-b11a-45d4f045ef98"
      unitRef="usd">1000000000</alny:CollaborativeArrangementConsiderationReceived>
    <alny:RoyaltyLiabilityNoncurrent
      contextRef="i9f304a30d62e48ae884ec8acc207b442_I20200430"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMTc3OA_b55772a0-80fa-4bf7-a71f-7cfe5cee94cc"
      unitRef="usd">1000000000</alny:RoyaltyLiabilityNoncurrent>
    <alny:RoyaltyLiabilityInterestRate
      contextRef="i5af69bac6577471ab296af25cf52d953_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMjEwMQ_cd22d76f-8304-4701-a211-4c4c25da6156"
      unitRef="number">0.08</alny:RoyaltyLiabilityInterestRate>
    <alny:RoyaltyLiabilityNoncurrent
      contextRef="i5af69bac6577471ab296af25cf52d953_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMzEwNA_414549a6-82dd-4d22-a8f1-5e972b6c3082"
      unitRef="usd">1310000000</alny:RoyaltyLiabilityNoncurrent>
    <alny:RoyaltyLiabilityClosingCosts
      contextRef="i5af69bac6577471ab296af25cf52d953_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMzEzMg_cd2b3dd2-1908-4ee4-8f9a-b127a785d6d8"
      unitRef="usd">10600000</alny:RoyaltyLiabilityClosingCosts>
    <alny:ScheduleOfRoyaltyLiabilityTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RleHRyZWdpb246YjBlZjgzNjMyMjM5NGM0ZWE3NjI2NTgyNWE1MmY3MWRfMzU3MQ_d7146c7a-fd26-4279-b541-21fdfcffd1ef">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table shows the activity with respect to the liability related to the sale of future royalties, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.134%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,308,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfRoyaltyLiabilityTableTextBlock>
    <alny:RoyaltyLiabilityNoncurrent
      contextRef="i49f2778a30db447199954b7fd02c7ed1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RhYmxlOmVhOWM1OTcxYTdhYzQ3MGE5ZjAzNWY2MDdkYzE1MDk5L3RhYmxlcmFuZ2U6ZWE5YzU5NzFhN2FjNDcwYTlmMDM1ZjYwN2RjMTUwOTlfMC0yLTEtMS0xMTEzNjg_b65f24f2-cb80-4e4d-ac3a-72f481ec8a42"
      unitRef="usd">1292304000</alny:RoyaltyLiabilityNoncurrent>
    <alny:RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts
      contextRef="ie90a9b7be5ab448e86528f65d657a9ac_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RhYmxlOmVhOWM1OTcxYTdhYzQ3MGE5ZjAzNWY2MDdkYzE1MDk5L3RhYmxlcmFuZ2U6ZWE5YzU5NzFhN2FjNDcwYTlmMDM1ZjYwN2RjMTUwOTlfMS0yLTEtMS0xMTEzNjg_39f891e6-31f1-47d2-af64-111bc3688362"
      unitRef="usd">25275000</alny:RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts>
    <alny:RoyaltyLiabilityPayments
      contextRef="ie90a9b7be5ab448e86528f65d657a9ac_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RhYmxlOmVhOWM1OTcxYTdhYzQ3MGE5ZjAzNWY2MDdkYzE1MDk5L3RhYmxlcmFuZ2U6ZWE5YzU5NzFhN2FjNDcwYTlmMDM1ZjYwN2RjMTUwOTlfMi0yLTEtMS0xMTEzNjg_3a735681-0ca7-4507-a6aa-c792a712071d"
      unitRef="usd">8673000</alny:RoyaltyLiabilityPayments>
    <alny:RoyaltyLiabilityNoncurrent
      contextRef="i5af69bac6577471ab296af25cf52d953_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF80OS9mcmFnOmIwZWY4MzYzMjIzOTRjNGVhNzYyNjU4MjVhNTJmNzFkL3RhYmxlOmVhOWM1OTcxYTdhYzQ3MGE5ZjAzNWY2MDdkYzE1MDk5L3RhYmxlcmFuZ2U6ZWE5YzU5NzFhN2FjNDcwYTlmMDM1ZjYwN2RjMTUwOTlfMy0yLTEtMS0xMTEzNjg_4cb9f2da-0488-4a08-8a97-b1efb5ed992e"
      unitRef="usd">1308906000</alny:RoyaltyLiabilityNoncurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RleHRyZWdpb246MWUxMTAyOTkyZmE0NDE2NzhlYzMxM2E2MzNiMjE5YzNfNTE4_61fda7a6-c616-4935-844f-f7f777c6173d">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables present information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The carrying amounts reflected on our condensed consolidated balance sheets for cash, accounts receivable, net, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term maturities.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RleHRyZWdpb246MWUxMTAyOTkyZmE0NDE2NzhlYzMxM2E2MzNiMjE5YzNfNTE1_40a4cff9-bd8a-496e-82f0-aaf1a7da20d3">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables present information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i874d4cbd4e084481a20e05ffedf030e1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMy0yLTEtMS0xMTEzNjg_69906b35-5f1b-4c7b-a3ce-885a3fd3d116"
      unitRef="usd">214257000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib9816969b7f844c7b918013a5fb04632_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMy00LTEtMS0xMTEzNjg_de931cde-50f8-4f35-a765-4a0d08028ded"
      unitRef="usd">214257000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iffe7a27d97064ac7829a670edeb037a6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMy02LTEtMS0xMTEzNjg_61f2bfb1-bcbb-4ad9-a3d4-403ebd5b3c4b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie4497af286544b5588685567ad285511_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMy04LTEtMS0xMTEzNjg_adb4325c-2501-4f8f-b78e-d3f597766cd4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iacfa0b420e244ddd8c424584e49e0bbe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS0yLTEtMS0xMTk2OTA_36f554da-284c-4a18-9d20-53d9153c61ba"
      unitRef="usd">2494000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieaa8b9115a694d4dbacbb16955919e67_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS00LTEtMS0xMTk2OTA_9d2ac17f-d295-4323-b157-1c064157ae2d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i50b2a82f08e14704917d51373b47b145_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS02LTEtMS0xMTk2OTA_d1ec5851-d746-40e2-b5a3-1b759236b443"
      unitRef="usd">2494000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iec58dda78b5f41ec9f8115e957615766_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS04LTEtMS0xMTk2OTA_97658913-b9bf-4c2e-b831-3ece8009b641"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8e6a406720844217993d4483fc6e7b60_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS0yLTEtMS0xMTEzNjg_cb4d6400-75bc-4751-ae89-0878d67cf96b"
      unitRef="usd">1694000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i07544a270c1b4f91be2befe47f417d06_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS00LTEtMS0xMTEzNjg_f8627b09-3743-4617-a51d-0e036f76f2e8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6fbdfa377b4c45188b32b4aca0c5858c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS02LTEtMS0xMTEzNjg_90a7e698-1e1f-4079-91b3-6cfa0c711bc6"
      unitRef="usd">1694000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifc8655a9bfff4eb6a24a91ec23da2454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfNS04LTEtMS0xMTEzNjg_7f82dd12-4e5b-43ab-8816-c476529fbb63"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id91db2e74566480db7790bba12bacab3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOC0yLTEtMS0xMTEzNjg_120b2cba-6cde-44d5-828f-d8412c2ee752"
      unitRef="usd">742312000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie0fbbf8a866f4b1ea616c10badae83d3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOC00LTEtMS0xMTEzNjg_5ca24d26-9d54-48e9-badf-99792b30ad4a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib4272629d98c4add80b6c45b82c2e95a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOC02LTEtMS0xMTEzNjg_f5934356-3b10-4e1b-9a84-c2f844eace17"
      unitRef="usd">742312000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i386e3c5b4ba843509503532a3da11306_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOC04LTEtMS0xMTEzNjg_16970bc1-16ab-4bc7-8eb9-5a350d6e5904"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e2b832d64eb4f1a8fdbaef5ca07646d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS0yLTEtMS0xMTk3MDI_29d1e031-f98e-4894-8b0c-593375e5b132"
      unitRef="usd">335557000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id76f744f31aa458e96f4d8ebe97eb886_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS00LTEtMS0xMTk3MDI_f2e07b12-748b-492f-ab05-f29ca2b82198"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3272a7ba8f424ca9a1480c9d363ebc10_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS02LTEtMS0xMTk3MDI_048e570a-74bd-4da5-a688-5e2fcbc1a429"
      unitRef="usd">335557000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7cb86d593e5944cca0236d7b8f81bbf2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS04LTEtMS0xMTk3MDI_d27f05ad-6165-4fb0-a6df-6c02c3f3c011"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iacfa0b420e244ddd8c424584e49e0bbe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS0yLTEtMS0xMTEzNjg_fcd6514f-d8a0-4ef0-8d4c-9097698223e3"
      unitRef="usd">190651000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieaa8b9115a694d4dbacbb16955919e67_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS00LTEtMS0xMTEzNjg_efb4eeb7-75e0-4647-af33-b54df2686748"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i50b2a82f08e14704917d51373b47b145_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS02LTEtMS0xMTEzNjg_4d4d6179-4925-439d-9399-07a15ae66925"
      unitRef="usd">190651000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec58dda78b5f41ec9f8115e957615766_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfOS04LTEtMS0xMTEzNjg_a4e22e10-d572-4f5c-80c0-cd8949aa81ea"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8e6a406720844217993d4483fc6e7b60_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTEtMi0xLTEtMTExMzY4_c63f9603-4ae8-42f3-8f1d-4f11454d051c"
      unitRef="usd">90556000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07544a270c1b4f91be2befe47f417d06_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTEtNC0xLTEtMTExMzY4_9b54e7e5-a558-4298-9725-f7ec05b56c49"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6fbdfa377b4c45188b32b4aca0c5858c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTEtNi0xLTEtMTExMzY4_f7874581-3390-45b9-9fa7-d07d7f4aa582"
      unitRef="usd">90556000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc8655a9bfff4eb6a24a91ec23da2454_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTEtOC0xLTEtMTExMzY4_9071b672-8ca1-48bc-b050-b6da5f09c841"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac8bf485b57442459c1b93f20ebfa42b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTItMi0xLTEtMTExMzY4_7000bfb2-f9db-4558-988b-4a88e0ab708d"
      unitRef="usd">13498000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica1ebebb32214b719ee306ffc8f6cf89_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTItNC0xLTEtMTExMzY4_41d7b48e-ae06-4a2d-b2fa-73cd07f9d29a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0f5ba0082a2340e79246846a43e0e92b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTItNi0xLTEtMTExMzY4_d998460c-c26c-49a8-8c1b-83b54dc5d967"
      unitRef="usd">13498000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i53c118ebc744410fbbc7719c7a876694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTItOC0xLTEtMTExMzY4_dd9321f8-e309-4802-b1d4-fc36f2fb4338"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie823bc3a3540443788e7ed44be452ee5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTQtMi0xLTEtMTExMzY4_a292671e-a8d1-48e1-b983-62b87fa92722"
      unitRef="usd">25856000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i210817a6ab294c9d9aff77d7f7d56bcd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTQtNC0xLTEtMTExMzY4_643885e6-bf8c-405b-bf12-bd1d9b32afe7"
      unitRef="usd">25856000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i70b5152586914421b5f5705f8c583545_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTQtNi0xLTEtMTExMzY4_a375c1e8-1124-483d-994e-782d82e9468e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia372b23a3466460c91b1628f67e16648_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTQtOC0xLTEtMTExMzY4_17c28e43-fa3f-4009-b65a-30343859def3"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i874d4cbd4e084481a20e05ffedf030e1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTUtMi0xLTEtMTExMzY4_223326bc-5838-4ce6-899d-0677272e7703"
      unitRef="usd">1200000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ib9816969b7f844c7b918013a5fb04632_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTUtNC0xLTEtMTExMzY4_dc326f9b-48b5-47df-a818-86ada9b2f428"
      unitRef="usd">1200000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="iffe7a27d97064ac7829a670edeb037a6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTUtNi0xLTEtMTExMzY4_9ebebb7d-862e-49b2-afd1-116ae7757655"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ie4497af286544b5588685567ad285511_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTUtOC0xLTEtMTExMzY4_25bfb93a-1dc4-46ef-aba7-6c9bc0cd17e6"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie823bc3a3540443788e7ed44be452ee5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTYtMi0xLTEtMTExMzY4_e0169ca0-a5fd-46dd-9766-4f37db2dc589"
      unitRef="usd">1618075000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i210817a6ab294c9d9aff77d7f7d56bcd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTYtNC0xLTEtMTExMzY4_3c23beb1-131b-4dd1-9b09-053e364d0ebd"
      unitRef="usd">241313000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i70b5152586914421b5f5705f8c583545_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTYtNi0xLTEtMTExMzY4_837993ec-507e-44de-9484-d6b8ca91224c"
      unitRef="usd">1376762000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia372b23a3466460c91b1628f67e16648_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTYtOC0xLTEtMTExMzY4_bf6ee394-23b1-43bb-b89b-182cd486dca9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ie823bc3a3540443788e7ed44be452ee5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTgtMi0xLTEtMTExMzY4_76c3afef-57a8-492f-9be6-ccccbd3cb8b5"
      unitRef="usd">219748000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i210817a6ab294c9d9aff77d7f7d56bcd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTgtNC0xLTEtMTExMzY4_f0aadf8a-3c59-46c9-8133-b4ebb7886470"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i70b5152586914421b5f5705f8c583545_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTgtNi0xLTEtMTExMzY4_a4fc22c1-09f3-4214-a470-1b5357fb8977"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia372b23a3466460c91b1628f67e16648_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjU5NjdiYzMyMDc2OTQ5ODViNjJhYjgxMWEzYjcxZGZjL3RhYmxlcmFuZ2U6NTk2N2JjMzIwNzY5NDk4NWI2MmFiODExYTNiNzFkZmNfMTgtOC0xLTEtMTExMzY4_c488f8f3-65ef-4276-9f15-59850af29908"
      unitRef="usd">219748000</us-gaap:DerivativeLiabilities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9b1bd941ecd44d1ca58586c4a9d77e7a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMy0yLTEtMS0xMTEzNjg_7f59d875-ed00-40f0-968d-fc69317fded6"
      unitRef="usd">270394000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i40eb73f6cf7b4d478059864b5fa2f8d9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMy00LTEtMS0xMTEzNjg_80404871-8060-406d-9209-72ea9cc724e8"
      unitRef="usd">270394000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4b408457ee5148e38192a975210e857c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMy02LTEtMS0xMTEzNjg_79792c0c-070b-47d7-9463-cc9824c88f26"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i43176b0239cb476c8cf009256b574721_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMy04LTEtMS0xMTEzNjg_f9f6285a-237e-47fd-bbb8-c441b54c2ac6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i076d11b5a6224da98d27eefe80d7e72a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNC0yLTEtMS0xMTEzNjg_13bd3263-cc0e-4c31-a4fb-6519e2b3d050"
      unitRef="usd">44817000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i69e9dba36ddb43e3a7cdf9a5872fb683_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNC00LTEtMS0xMTEzNjg_592e3291-f774-4d26-b908-72d6bcc481d1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if6f8dc928bd848488160e1bd4f401ea3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNC02LTEtMS0xMTEzNjg_19bfd4dd-3422-4878-a967-8d5b11cbf3e7"
      unitRef="usd">44817000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i19e64ae5cf7f45f6b977f634f04d74e5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNC04LTEtMS0xMTEzNjg_fd811f07-a40e-4554-b681-7ad74c1cd57e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5723f8adf2d1441d932c0847136e9459_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNS0yLTEtMS0xMTU3NDA_ba05fe36-1245-4bbb-ade6-7218729a481f"
      unitRef="usd">41763000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5e6ceebd68e64bf0a73073a721e7d630_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNS00LTEtMS0xMTU3NDA_cea3f861-e599-4d1c-a556-1ecb64319efb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i910dcea4abe947e4ab7bab94efb0b6bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNS02LTEtMS0xMTU3NDA_1e7fe170-5e06-48e8-8660-ff15f7fe1698"
      unitRef="usd">41763000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i048b6a7660eb403b9a37898a77b5f141_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNS04LTEtMS0xMTU3NDA_7401bfa7-0f45-413e-b6bc-5f35fe66f096"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i65b952c5bedd40b798d1a1561e6546c6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi0yLTEtMS0xMTU3NDg_3134adf5-76d5-4054-84aa-a5b23f8fdfc0"
      unitRef="usd">22350000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie2ccbffe10394a7e94b51ab21066da05_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi00LTEtMS0xMTU3NDg_47cfd5d6-ce6e-40a3-b9c9-562a6a923f12"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9706a586a2e648478e8a3e8e5b2af11f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi02LTEtMS0xMTU3NDg_89f29829-5cdd-4677-ad11-0ee66c9a6541"
      unitRef="usd">22350000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i530c28e6901b4e84a1c2d02163b01915_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi04LTEtMS0xMTU3NDg_8e1ba77b-feec-4109-83f4-75e651eb136b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iabd32b8fc73844de94f0169aa6a02549_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy0yLTEtMS0xMTU3NTY_5dc5a209-ec54-49b9-8fac-4b5eeeddf950"
      unitRef="usd">3289000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i13efc9571bfe41aa8a26035bcd11ba88_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy00LTEtMS0xMTU3NTY_1f39d5ad-d9e2-49cb-b6bf-f0123f6cc803"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icbf68c6050a641f08b05c2eb2be55064_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy02LTEtMS0xMTU3NTY_53fe046a-8fa3-4355-a4c4-dde60413dc19"
      unitRef="usd">3289000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7cd53d3ef7cf44699a9bed9051e463e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy04LTEtMS0xMTU3NTY_85332341-be71-4e99-bc6f-8cae51007362"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id76df98dcf234a879e9afbd45704aa86_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC0yLTEtMS0xMTU3NjU_b4830969-c074-44ab-b84c-9d3b44b7f57c"
      unitRef="usd">1024000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8e8b9f7927aa4adf8ad7beaa81618725_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC00LTEtMS0xMTU3NjU_12fd603c-c0df-4e2d-a96c-c830bac08f9d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i78e4f2d83b724aec84eb152ce5a9a38a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC02LTEtMS0xMTU3NjU_641301be-d070-4811-beec-7b0eeafae4ba"
      unitRef="usd">1024000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if2d9d2300f444085a25bd1044ef04459_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC04LTEtMS0xMTU3NjU_5b7f9e24-ac80-46c8-ac2c-4151cb43e236"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i076d11b5a6224da98d27eefe80d7e72a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi0yLTEtMS0xMTEzNjg_05849b0b-eb66-454d-9967-c81bca4b1486"
      unitRef="usd">820913000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69e9dba36ddb43e3a7cdf9a5872fb683_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi00LTEtMS0xMTEzNjg_7b3db193-94fc-4863-83c0-50e3c43c7542"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6f8dc928bd848488160e1bd4f401ea3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi02LTEtMS0xMTEzNjg_0ee4eda4-252d-4361-9360-b5d969a8024b"
      unitRef="usd">820913000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19e64ae5cf7f45f6b977f634f04d74e5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNi04LTEtMS0xMTEzNjg_778f0148-fe4e-4cfb-b209-0c259476421b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id76df98dcf234a879e9afbd45704aa86_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy0yLTEtMS0xMTEzNjg_de15ba9a-e25b-463b-8513-27000d93bdc5"
      unitRef="usd">208284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8e8b9f7927aa4adf8ad7beaa81618725_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy00LTEtMS0xMTEzNjg_941708b7-2ac1-48a7-98c4-75f4c726af77"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78e4f2d83b724aec84eb152ce5a9a38a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy02LTEtMS0xMTEzNjg_bd656cb9-0958-4d5a-9ad2-f95c5302e8c6"
      unitRef="usd">208284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2d9d2300f444085a25bd1044ef04459_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfNy04LTEtMS0xMTEzNjg_8482a990-25e8-46b6-acd2-71309e1d99c8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5723f8adf2d1441d932c0847136e9459_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC0yLTEtMS0xMTEzNjg_64f3dd81-ccfc-4b1c-af8b-56db4c29a931"
      unitRef="usd">230770000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e6ceebd68e64bf0a73073a721e7d630_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC00LTEtMS0xMTEzNjg_3859a0c2-b686-491d-a707-6da25cac9778"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i910dcea4abe947e4ab7bab94efb0b6bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC02LTEtMS0xMTEzNjg_2e410499-7383-4458-93c8-4b8ed6f268e7"
      unitRef="usd">230770000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i048b6a7660eb403b9a37898a77b5f141_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOC04LTEtMS0xMTEzNjg_7607eff5-851c-4269-beb0-b9e068fd09be"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65b952c5bedd40b798d1a1561e6546c6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOS0yLTEtMS0xMTEzNjg_aee78fa5-6d69-4245-8732-34b42aba0af7"
      unitRef="usd">36793000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie2ccbffe10394a7e94b51ab21066da05_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOS00LTEtMS0xMTEzNjg_aa0dd644-d880-4674-9727-079e9b641e11"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9706a586a2e648478e8a3e8e5b2af11f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOS02LTEtMS0xMTEzNjg_87bd07b2-83a6-47a6-a5a3-7f4c6d8deb09"
      unitRef="usd">36793000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i530c28e6901b4e84a1c2d02163b01915_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfOS04LTEtMS0xMTEzNjg_5c722e35-faf8-40a1-bc17-f2318ada2ad9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iabd32b8fc73844de94f0169aa6a02549_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTAtMi0xLTEtMTExMzY4_96c30dc8-6579-4553-81ad-9e0df37e36ac"
      unitRef="usd">1130000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i13efc9571bfe41aa8a26035bcd11ba88_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTAtNC0xLTEtMTExMzY4_ae8c2c14-c88f-4604-97cd-9797e7ff18bf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icbf68c6050a641f08b05c2eb2be55064_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTAtNi0xLTEtMTExMzY4_a956eac4-af5e-4632-9240-53dc02e20ef5"
      unitRef="usd">1130000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7cd53d3ef7cf44699a9bed9051e463e3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTAtOC0xLTEtMTExMzY4_5ae67c82-9834-4cd9-96d9-3185c8a64de5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie0cb6ddc861e4bccabf7921700859d41_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTItMi0xLTEtMTExMzY4_d44ae324-e0a5-4b5c-9f29-fa2052398f7a"
      unitRef="usd">28122000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i08de5c309e4b47ce9d7bc420003d6031_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTItNC0xLTEtMTExMzY4_bb6f9034-eb56-4ff2-8ea3-6ed5802fb189"
      unitRef="usd">28122000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7888ab348e6b46759e5fa89592e4892c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTItNi0xLTEtMTExMzY4_0c8c2ed5-1932-444f-967b-421313cd4d00"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia1532ad29f7b41dfa9abd7737236a3cf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTItOC0xLTEtMTExMzY4_77ef2abf-811f-4276-bc48-1b31178da22f"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i9b1bd941ecd44d1ca58586c4a9d77e7a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTMtMi0xLTEtMTExMzY4_4cf99c28-1523-47a1-9590-2700e09dcf50"
      unitRef="usd">1197000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i40eb73f6cf7b4d478059864b5fa2f8d9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTMtNC0xLTEtMTExMzY4_ef160bb2-4645-4340-800f-8ba70e5ab543"
      unitRef="usd">1197000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i4b408457ee5148e38192a975210e857c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTMtNi0xLTEtMTExMzY4_6e294688-eae9-4788-b6c1-74cd87f2c337"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i43176b0239cb476c8cf009256b574721_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTMtOC0xLTEtMTExMzY4_115569b6-8942-4a6e-a9d9-1fc4051e686d"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie0cb6ddc861e4bccabf7921700859d41_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTQtMi0xLTEtMTExMzY4_a2dc8b88-63df-4c29-b7ac-4026f0850256"
      unitRef="usd">1710846000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i08de5c309e4b47ce9d7bc420003d6031_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTQtNC0xLTEtMTExMzY4_d62cf7c6-9ca3-4417-a025-0d7cf041e374"
      unitRef="usd">299713000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7888ab348e6b46759e5fa89592e4892c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTQtNi0xLTEtMTExMzY4_d7b9d4ac-b271-4108-b19a-8f1698b11eb3"
      unitRef="usd">1411133000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia1532ad29f7b41dfa9abd7737236a3cf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTQtOC0xLTEtMTExMzY4_fe4db176-662b-4a4b-9415-fb2fca0383c6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ie0cb6ddc861e4bccabf7921700859d41_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTYtMi0xLTEtMTExMzY4_c289107d-e02c-4226-a768-b5b2519d97eb"
      unitRef="usd">209277000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i08de5c309e4b47ce9d7bc420003d6031_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTYtNC0xLTEtMTExMzY4_8c22ad79-82c5-4f1d-a7e0-9fd9080246d6"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7888ab348e6b46759e5fa89592e4892c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTYtNi0xLTEtMTExMzY4_16d791c4-805e-4d04-8c71-a6cfc4c1f27a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia1532ad29f7b41dfa9abd7737236a3cf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81Mi9mcmFnOjFlMTEwMjk5MmZhNDQxNjc4ZWMzMTNhNjMzYjIxOWMzL3RhYmxlOjdhZjQ3M2Q0MTI3YjRiZmZhNGJlMmU5ZTkyZDc2MjE5L3RhYmxlcmFuZ2U6N2FmNDczZDQxMjdiNGJmZmE0YmUyZTllOTJkNzYyMTlfMTYtOC0xLTEtMTExMzY4_432eda4f-b8ba-4cdd-a8d0-84c8d00e7bb0"
      unitRef="usd">209277000</us-gaap:DerivativeLiabilities>
    <alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RleHRyZWdpb246MWU3ZGZjMGE4ZGU3NDBiMzliZDk4YzIwZjQ3MTJjOGNfNjQw_e1345cc3-c4b5-4d72-b838-dc8ebb02b8ac">MARKETABLE DEBT SECURITIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We invest our excess cash balances in marketable debt securities and at each balance sheet date presented, we classify all of our investments in debt securities as available-for-sale and as current assets as they represent the investment of funds available for current operations. We did not record any impairment charges related to our marketable debt securities during the three months ended March&#160;31, 2023 or 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize our marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,382,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RleHRyZWdpb246MWU3ZGZjMGE4ZGU3NDBiMzliZDk4YzIwZjQ3MTJjOGNfNjQx_1d16d58e-c87f-48f9-858a-596be48a6349">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize our marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,382,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i37c9e096a9ca46f28fce0d2487efa7e0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMi0xLTEtMS0xMTEzNjg_21ea1bbf-1bef-4374-a558-d95252fd99b3"
      unitRef="usd">744326000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i37c9e096a9ca46f28fce0d2487efa7e0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMi0zLTEtMS0xMTEzNjg_6cfa58f2-2f92-40f9-b108-9404b473bf06"
      unitRef="usd">377000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i37c9e096a9ca46f28fce0d2487efa7e0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMi01LTEtMS0xMTEzNjg_43756c60-827c-4e70-a8a3-0cc7e808899e"
      unitRef="usd">2391000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37c9e096a9ca46f28fce0d2487efa7e0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMi03LTEtMS0xMTEzNjg_47fba290-b75e-4dd5-9f9b-331cf5fff95a"
      unitRef="usd">742312000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id9ce486293d84aeeb0b9ecdc107a663f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy0xLTEtMS0xMTk3MTk_3f0e1ca3-668b-4cde-9d43-c1cd6233445c"
      unitRef="usd">337614000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id9ce486293d84aeeb0b9ecdc107a663f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy0zLTEtMS0xMTk3MTk_a37be167-14a1-4dbb-abd1-3b8937295a51"
      unitRef="usd">194000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id9ce486293d84aeeb0b9ecdc107a663f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy01LTEtMS0xMTk3MTk_47b496be-7b18-4158-bb7b-2a52af4ed2de"
      unitRef="usd">2251000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id9ce486293d84aeeb0b9ecdc107a663f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy03LTEtMS0xMTk3MTk_5149ca34-10aa-467b-8bee-e9dda9ba7afa"
      unitRef="usd">335557000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if50ea362dec14ed1a971c9d68f405fc1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy0xLTEtMS0xMTEzNjg_d7e714e5-ca06-4fc9-939e-6e4b7b3a4ffa"
      unitRef="usd">194419000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if50ea362dec14ed1a971c9d68f405fc1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy0zLTEtMS0xMTEzNjg_4d85bccc-17eb-4a87-8e74-cd7cde9d572d"
      unitRef="usd">50000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if50ea362dec14ed1a971c9d68f405fc1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy01LTEtMS0xMTEzNjg_7d70d861-a3c2-440b-939d-ae8b87f86316"
      unitRef="usd">1324000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if50ea362dec14ed1a971c9d68f405fc1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfMy03LTEtMS0xMTEzNjg_fba99d99-aba1-43e5-8fc8-ad8b83c04034"
      unitRef="usd">193145000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icf96df66413c488d9bfbd03f94ea7f4e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNS0xLTEtMS0xMTEzNjg_77c6d151-090b-41f1-b915-7cb846ae87fe"
      unitRef="usd">92250000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icf96df66413c488d9bfbd03f94ea7f4e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNS0zLTEtMS0xMTEzNjg_ca226f8b-6568-4030-85a0-bcdbdea65dd7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icf96df66413c488d9bfbd03f94ea7f4e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNS01LTEtMS0xMTEzNjg_380db0d3-bcfd-4890-8197-f4d5a008ca6d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf96df66413c488d9bfbd03f94ea7f4e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNS03LTEtMS0xMTEzNjg_b6f6eda9-62ff-4866-ab3d-4925e83ef4f9"
      unitRef="usd">92250000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifb230ab030c84a949a4708ce9359662e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNi0xLTEtMS0xMTEzNjg_592e1b1b-be50-4cee-a3b3-1dcfcc0c1515"
      unitRef="usd">13498000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifb230ab030c84a949a4708ce9359662e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNi0zLTEtMS0xMTEzNjg_75e8310b-3af4-4636-9a79-de2df9df1e27"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifb230ab030c84a949a4708ce9359662e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNi01LTEtMS0xMTEzNjg_590b50ff-7c33-495e-b861-1d27d011fdde"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifb230ab030c84a949a4708ce9359662e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfNi03LTEtMS0xMTEzNjg_bb51d0b5-9592-4707-bcc9-cd61f1311196"
      unitRef="usd">13498000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfOC0xLTEtMS0xMTEzNjg_a58e156d-071b-4a5f-aff7-7c4939ee3fc3"
      unitRef="usd">1382107000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfOC0zLTEtMS0xMTEzNjg_41243e2e-6953-4c8f-a789-1b530588975e"
      unitRef="usd">621000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfOC01LTEtMS0xMTEzNjg_5193225d-a9d1-4353-8e75-f78cab65cb57"
      unitRef="usd">5966000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjQzMDQ2NGRkYzA4YTQ2YThiZWVmY2I0ZTRhYjUwMzgwL3RhYmxlcmFuZ2U6NDMwNDY0ZGRjMDhhNDZhOGJlZWZjYjRlNGFiNTAzODBfOC03LTEtMS0xMTEzNjg_ef30e750-3e29-474b-a7ab-d2f98e15d5c2"
      unitRef="usd">1376762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9e45c4599a0542b69eeec71ff8b3bf49_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMi0xLTEtMS0xMTEzNjg_352057d5-f882-443c-bb73-b5b4ee829099"
      unitRef="usd">870033000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9e45c4599a0542b69eeec71ff8b3bf49_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMi0zLTEtMS0xMTEzNjg_96cd58b3-2a72-41c2-a2c2-aa2d29d326e1"
      unitRef="usd">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9e45c4599a0542b69eeec71ff8b3bf49_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMi01LTEtMS0xMTEzNjg_caf8a406-6507-413d-ba72-9474ed08ca04"
      unitRef="usd">4382000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e45c4599a0542b69eeec71ff8b3bf49_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMi03LTEtMS0xMTEzNjg_5889755e-2f63-4ce8-9cc7-661767483ead"
      unitRef="usd">865730000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie42a905d31064b9fa9efdd8b7ef9b37e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNC0xLTEtMS0xMTEzNjg_78bac39a-5f5f-43f6-a349-8c55a78caf27"
      unitRef="usd">275610000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie42a905d31064b9fa9efdd8b7ef9b37e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNC0zLTEtMS0xMTEzNjg_9434b537-9cad-4baf-a807-3f24f460942c"
      unitRef="usd">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie42a905d31064b9fa9efdd8b7ef9b37e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNC01LTEtMS0xMTEzNjg_60c6b4a4-cd7f-4909-85a9-43277526ae80"
      unitRef="usd">3101000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie42a905d31064b9fa9efdd8b7ef9b37e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNC03LTEtMS0xMTEzNjg_eaf57e9d-f8a5-4fa2-96c7-1d50075991bd"
      unitRef="usd">272533000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i811b7526e6a94efba6244d85ce23698b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMy0xLTEtMS0xMTEzNjg_f6f81262-5f53-4fd8-b391-8501436ec581"
      unitRef="usd">211398000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i811b7526e6a94efba6244d85ce23698b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMy0zLTEtMS0xMTEzNjg_45ada38e-fdbd-44da-a0f1-dc7ce88dd934"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i811b7526e6a94efba6244d85ce23698b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMy01LTEtMS0xMTEzNjg_0f9cc90f-8016-46c0-b4d9-dfd7aaac93ef"
      unitRef="usd">2106000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i811b7526e6a94efba6244d85ce23698b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfMy03LTEtMS0xMTEzNjg_cf76173e-744c-4924-92cf-fa815b0b263b"
      unitRef="usd">209308000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic92f68826e624d329fcbd32713162d25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNS0xLTEtMS0xMTEzNjg_2948ff39-622d-4c45-9c01-3602cd57361f"
      unitRef="usd">59143000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic92f68826e624d329fcbd32713162d25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNS0zLTEtMS0xMTEzNjg_5cfb9850-e0e6-4345-b9ac-9703173d859d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic92f68826e624d329fcbd32713162d25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNS01LTEtMS0xMTEzNjg_bdd72d2e-d35d-48f8-a6b2-c124664be934"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic92f68826e624d329fcbd32713162d25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNS03LTEtMS0xMTEzNjg_4335f113-b0cc-46b2-92d7-d3661f7f847f"
      unitRef="usd">59143000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i94483e1405f840b791882d67766c7723_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNi0xLTEtMS0xMTEzNjg_ad691625-19dc-47fa-a17d-a8899bc58a86"
      unitRef="usd">4419000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i94483e1405f840b791882d67766c7723_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNi0zLTEtMS0xMTEzNjg_aba2b225-4e5c-4816-a209-4716747e3e87"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i94483e1405f840b791882d67766c7723_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNi01LTEtMS0xMTEzNjg_2a6a6c0c-9388-4a76-b8c0-8a2249f4ce26"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i94483e1405f840b791882d67766c7723_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfNi03LTEtMS0xMTEzNjg_a581f361-5aa3-4fd7-9231-01ac235de5c5"
      unitRef="usd">4419000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfOC0xLTEtMS0xMTEzNjg_991fe332-ffd3-4557-8826-0bf85263af76"
      unitRef="usd">1420603000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfOC0zLTEtMS0xMTEzNjg_b08b920f-38be-42b5-bc6c-0abb9f03323f"
      unitRef="usd">119000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfOC01LTEtMS0xMTEzNjg_b9214f6d-2606-4f9d-9731-107da26c60a8"
      unitRef="usd">9589000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOjc5YTFhNTg2Y2NiMTQwNTU4Mzk3MGU0ZGRjZDczODAwL3RhYmxlcmFuZ2U6NzlhMWE1ODZjY2IxNDA1NTgzOTcwZTRkZGNkNzM4MDBfOC03LTEtMS0xMTEzNjg_2a890ab6-90b5-48b3-bfe2-12c95e877c34"
      unitRef="usd">1411133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RleHRyZWdpb246MWU3ZGZjMGE4ZGU3NDBiMzliZDk4YzIwZjQ3MTJjOGNfNjQz_3c124884-3ced-4dc4-9ae9-78e95f22a601">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOmFiOGEwZWMyYTZmZDQwZmJhMzdlZGIzYWQyODU2ZDU5L3RhYmxlcmFuZ2U6YWI4YTBlYzJhNmZkNDBmYmEzN2VkYjNhZDI4NTZkNTlfMS0xLTEtMS0xMTEzNjg_042b4396-4e3d-4e3a-814b-5ed9e74afef9"
      unitRef="usd">1372574000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOmFiOGEwZWMyYTZmZDQwZmJhMzdlZGIzYWQyODU2ZDU5L3RhYmxlcmFuZ2U6YWI4YTBlYzJhNmZkNDBmYmEzN2VkYjNhZDI4NTZkNTlfMS0zLTEtMS0xMTEzNjg_319c6632-5ae0-49ea-a2fb-bf04042359e8"
      unitRef="usd">1297890000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOmFiOGEwZWMyYTZmZDQwZmJhMzdlZGIzYWQyODU2ZDU5L3RhYmxlcmFuZ2U6YWI4YTBlYzJhNmZkNDBmYmEzN2VkYjNhZDI4NTZkNTlfMi0xLTEtMS0xMTEzNjg_1a11ca26-ca56-40f5-afcb-7e6ab9f2a81b"
      unitRef="usd">4188000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOmFiOGEwZWMyYTZmZDQwZmJhMzdlZGIzYWQyODU2ZDU5L3RhYmxlcmFuZ2U6YWI4YTBlYzJhNmZkNDBmYmEzN2VkYjNhZDI4NTZkNTlfMi0zLTEtMS0xMTEzNjg_d3210be7-5967-4758-a6b1-7286f555b55f"
      unitRef="usd">113243000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOmFiOGEwZWMyYTZmZDQwZmJhMzdlZGIzYWQyODU2ZDU5L3RhYmxlcmFuZ2U6YWI4YTBlYzJhNmZkNDBmYmEzN2VkYjNhZDI4NTZkNTlfMy0xLTEtMS0xMTEzNjg_0e2ef010-24ec-4e4e-bef8-329e99fac661"
      unitRef="usd">1376762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81NS9mcmFnOjFlN2RmYzBhOGRlNzQwYjM5YmQ5OGMyMGY0NzEyYzhjL3RhYmxlOmFiOGEwZWMyYTZmZDQwZmJhMzdlZGIzYWQyODU2ZDU5L3RhYmxlcmFuZ2U6YWI4YTBlYzJhNmZkNDBmYmEzN2VkYjNhZDI4NTZkNTlfMy0zLTEtMS0xMTEzNjg_7acc960d-32f2-4771-9a85-da43d023eab9"
      unitRef="usd">1411133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTA1MA_73ace469-2837-4b6e-8f7f-d29864ecb1ed">OTHER BALANCE SHEET DETAILS&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, we had $31.5 million and $32.7 million of long-term inventory, respectively, included within other assets in our condensed consolidated balance sheet as we anticipate it being consumed beyond our normal operating cycle.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accumulated Other Comprehensive (Loss) Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize the changes in accumulated other comprehensive (loss) income, by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loss on Investment in Joint Venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized (Losses) Gains from Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other&lt;br/&gt;Comprehensive (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loss on Investment in Joint Venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized (Losses) Gains from Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other&lt;br/&gt;Comprehensive (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts reclassified out of accumulated other comprehensive loss relate to settlements of marketable equity securities and amortization of our pension obligation which are recorded as other income in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTA0NQ_ef9cbdfa-511f-459c-82e2-5d4b7eab9b0c">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfMS0xLTEtMS0xMTEzNjg_d5b05838-10dc-4469-b171-8c22b416fbe9"
      unitRef="usd">22875000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfMS0zLTEtMS0xMTEzNjg_d8717f00-29c7-4b69-b5ce-1cf2cd1afdac"
      unitRef="usd">22315000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfMi0xLTEtMS0xMTEzNjg_c4864454-4720-4ff9-b16d-8d6f16480a9a"
      unitRef="usd">110976000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfMi0zLTEtMS0xMTEzNjg_663317e7-70cf-4b56-9133-044abbc04dd3"
      unitRef="usd">113783000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfMy0xLTEtMS0xMTEzNjg_2009704a-0d86-46c6-8424-44895b40c587"
      unitRef="usd">29534000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfMy0zLTEtMS0xMTEzNjg_21b6eea2-0b05-4e8d-99e8-c09160b48187"
      unitRef="usd">25606000</us-gaap:InventoryFinishedGoods>
    <alny:InventoryCurrentAndNoncurrent
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfNC0xLTEtMS0xMTEzNjg_b2517cb4-625d-412b-9d77-d77f0bf4767f"
      unitRef="usd">163385000</alny:InventoryCurrentAndNoncurrent>
    <alny:InventoryCurrentAndNoncurrent
      contextRef="i6860c8b46ed14ad2aa0cd94577b727da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjA0NGFiZWIxYmJkZjQwMDc5ZTU4NWFjMGU3YmU5OTE5L3RhYmxlcmFuZ2U6MDQ0YWJlYjFiYmRmNDAwNzllNTg1YWMwZTdiZTk5MTlfNC0zLTEtMS0xMTEzNjg_ba18bec8-80a0-4805-8815-a35707e48274"
      unitRef="usd">161704000</alny:InventoryCurrentAndNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i1b2839973ded4bb9a04db596d1cd0ee7_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTI3_2fe9a084-1b65-482a-ba1f-91111d5f7fdb"
      unitRef="usd">31500000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i3ed1c026dd674f1d819dbc53395da662_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTM0_d7fa2f5c-372b-4972-b2e1-1d5732f5dbc2"
      unitRef="usd">32700000</us-gaap:InventoryNoncurrent>
    <alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTA0Ng_edd56854-ba30-4cc4-9027-0d9f06ec9442">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock>
    <alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTA0Nw_78fbe82d-31b2-4843-b2d4-d37cd294658a">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmQ3NDQ4ZGE4MGY2MjQ5MjE5YWNkYThkOGNiOGE2ODJhL3RhYmxlcmFuZ2U6ZDc0NDhkYTgwZjYyNDkyMTlhY2RhOGQ4Y2I4YTY4MmFfMi0xLTEtMS0xMTEzNjg_a7357b36-29d8-4d7c-942e-acf34451b602"
      unitRef="usd">672245000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i129714144f56409c862078cd74c09670_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmQ3NDQ4ZGE4MGY2MjQ5MjE5YWNkYThkOGNiOGE2ODJhL3RhYmxlcmFuZ2U6ZDc0NDhkYTgwZjYyNDkyMTlhY2RhOGQ4Y2I4YTY4MmFfMi0zLTEtMS0xMTEzNjg_a60605db-91ec-4e69-b485-9897c08003ec"
      unitRef="usd">534081000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmQ3NDQ4ZGE4MGY2MjQ5MjE5YWNkYThkOGNiOGE2ODJhL3RhYmxlcmFuZ2U6ZDc0NDhkYTgwZjYyNDkyMTlhY2RhOGQ4Y2I4YTY4MmFfMy0xLTEtMS0xMTEzNjg_50f30b27-c736-465f-86e6-3837515043d2"
      unitRef="usd">2166000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i129714144f56409c862078cd74c09670_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmQ3NDQ4ZGE4MGY2MjQ5MjE5YWNkYThkOGNiOGE2ODJhL3RhYmxlcmFuZ2U6ZDc0NDhkYTgwZjYyNDkyMTlhY2RhOGQ4Y2I4YTY4MmFfMy0zLTEtMS0xMTEzNjg_516000b3-f775-47ed-947a-53868371efe6"
      unitRef="usd">2178000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmQ3NDQ4ZGE4MGY2MjQ5MjE5YWNkYThkOGNiOGE2ODJhL3RhYmxlcmFuZ2U6ZDc0NDhkYTgwZjYyNDkyMTlhY2RhOGQ4Y2I4YTY4MmFfNC0xLTEtMS0xMTEzNjg_0567c82f-a2d6-4015-a6da-7fe2f8c6d223"
      unitRef="usd">674411000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i129714144f56409c862078cd74c09670_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmQ3NDQ4ZGE4MGY2MjQ5MjE5YWNkYThkOGNiOGE2ODJhL3RhYmxlcmFuZ2U6ZDc0NDhkYTgwZjYyNDkyMTlhY2RhOGQ4Y2I4YTY4MmFfNC0zLTEtMS0xMTEzNjg_4fc584ba-aefe-41c0-b3f2-dd9d2e736269"
      unitRef="usd">536259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RleHRyZWdpb246Njk0ODEzOGJlNjI2NDVmMzkxNTc2YmQ4MGMyMWE5MjBfMTA0OA_25a70027-4eca-4a7d-a32b-c57974b5f13f">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize the changes in accumulated other comprehensive (loss) income, by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loss on Investment in Joint Venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized (Losses) Gains from Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other&lt;br/&gt;Comprehensive (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loss on Investment in Joint Venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized (Losses) Gains from Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other&lt;br/&gt;Comprehensive (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="ibebf4053fbf44fb9b675c41a096d60a7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMS0xLTEtMS0xMTEzNjg_5d7ab65e-5af6-406e-834c-933310fd6446"
      unitRef="usd">-32792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50c869678d1046f6b8952f17b26368ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMS0zLTEtMS0xMTEzNjg_0fa57883-de50-43ca-8e9c-7de017ea1bc4"
      unitRef="usd">-1092000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i714ef67f5dd5449c8ce319985ec64bf3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMS01LTEtMS0xMTEzNjg_e562914e-ac7c-4cc6-93cd-5dfc4f788cf3"
      unitRef="usd">-9470000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id0c21a9a0d854336ae2513275c632fb3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMS03LTEtMS0xMTEzNjg_bc2c6ea7-ee43-4fc9-91e0-0884ce4bed93"
      unitRef="usd">-1300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib10c6162d7ee41d8b5073719840fa8ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMS05LTEtMS0xMTEzNjg_f01118d0-790a-48ef-82e0-cafe085617a2"
      unitRef="usd">-44654000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3a5bbae1628a449d818c46f986a09d4c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMi0xLTEtMS0xMTEzNjg_fb47afbe-4243-4ffe-a51e-799dceb2e05d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if3080c044b38407fba1e7d8658782768_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMi0zLTEtMS0xMTEzNjg_8372461c-d7eb-461c-9639-4f13ae19173c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9ef9a4ac510541efaaf7b5313dd58cf6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMi01LTEtMS0xMTEzNjg_4e47d765-d1ca-49de-89ac-323a4f79ccb0"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if11c68a061924916b804149e7efa13f8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMi03LTEtMS0xMTEzNjg_3033bc2e-5e8f-4030-a0e6-3372290701cc"
      unitRef="usd">1410000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMi05LTEtMS0xMTEzNjg_5ea7a9a9-bb2b-4e37-9784-b35db7568525"
      unitRef="usd">1401000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3a5bbae1628a449d818c46f986a09d4c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMy0xLTEtMS0xMTEzNjg_f70d0fc6-869a-44aa-af4e-038a26b3c88e"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if3080c044b38407fba1e7d8658782768_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMy0zLTEtMS0xMTEzNjg_f3cf9154-0f03-4d70-8e18-bca01fb3f44a"
      unitRef="usd">5000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9ef9a4ac510541efaaf7b5313dd58cf6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMy01LTEtMS0xMTEzNjg_9e6746cd-e04c-4424-b407-2c0ec706ad15"
      unitRef="usd">-4134000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if11c68a061924916b804149e7efa13f8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMy03LTEtMS0xMTEzNjg_01759530-8b81-4be9-821e-3d63f3b56d27"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfMy05LTEtMS0xMTEzNjg_8bd396d0-0dc7-4f91-9c77-bfa49279b249"
      unitRef="usd">-4129000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3a5bbae1628a449d818c46f986a09d4c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNC0xLTEtMS0xMTEzNjg_81affeef-8470-4fba-9ea4-c0467c4bd579"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if3080c044b38407fba1e7d8658782768_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNC0zLTEtMS0xMTEzNjg_ef229c47-5f22-4832-97e7-e421da52621c"
      unitRef="usd">-5000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9ef9a4ac510541efaaf7b5313dd58cf6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNC01LTEtMS0xMTEzNjg_9f1c93cf-67f2-48f9-b09f-9c7af7b737dc"
      unitRef="usd">4125000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if11c68a061924916b804149e7efa13f8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNC03LTEtMS0xMTEzNjg_436a2d84-9d98-4157-8e1e-11635e542916"
      unitRef="usd">1410000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNC05LTEtMS0xMTEzNjg_704ef917-761f-46fa-99d4-88a5f7e83139"
      unitRef="usd">5530000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i348f9d6750ba4e6d84377accaa5b9319_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNS0xLTEtMS0xMTEzNjg_02cfd7b0-4f99-45dd-b6c3-3b0f3aa96f22"
      unitRef="usd">-32792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ed6da55201a4d6098f35926e23ad0c5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNS0zLTEtMS0xMTEzNjg_33d8e065-7e62-4d49-9e3b-40b774cdf4d9"
      unitRef="usd">-1097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5423daa9097405baa2e53113e5a2af9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNS01LTEtMS0xMTEzNjg_0919eb93-d1bc-4473-ae77-107910830516"
      unitRef="usd">-5345000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaf2fec59aefb4d9abff4b8a755874542_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNS03LTEtMS0xMTEzNjg_d9b35303-d816-46c3-99d4-4eeab5d561a5"
      unitRef="usd">110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id68ac710f233437aa4518ad8eb0adb93_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOmJkY2U5OTYwODRkMTQ4ZDU5OGY3YTdjNjg2OTExYTA1L3RhYmxlcmFuZ2U6YmRjZTk5NjA4NGQxNDhkNTk4ZjdhN2M2ODY5MTFhMDVfNS05LTEtMS0xMTEzNjg_28b884d9-2046-4eb1-91ea-6d8d1e22f5c1"
      unitRef="usd">-39124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia64c74b9951e43a2a4ca3afc638421c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMS0xLTEtMS0xMTEzNjg_20ac04aa-eb7d-4c3f-9376-d72769b878ab"
      unitRef="usd">-32792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i400fd731ed28427a98cf559b0d69a616_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMS0zLTEtMS0xMTEzNjg_d27be04f-e645-4ec2-a921-d02d4133e2fc"
      unitRef="usd">-2811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5246d2e962624dce926b3bfedeadb7d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMS01LTEtMS0xMTEzNjg_ae0ad926-8177-4dfa-a962-471c25a2d491"
      unitRef="usd">-1630000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0764c7d8cbc0465a9c4b5bec84310735_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMS03LTEtMS0xMTEzNjg_5ad84eb1-2b81-4425-9e45-da5ba1284799"
      unitRef="usd">3974000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie72229676bde424e88e71e576e78694f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMS05LTEtMS0xMTEzNjg_ca5eddd2-bd1f-4889-be3c-6148fbc60fa6"
      unitRef="usd">-33259000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i597049e81b154f63b39f155a686eca36_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMi0xLTEtMS0xMTEzNjg_0ace3b30-d688-4eb2-806c-f1040cf1303f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="id931cec3813c4a8abbaa146d0ecf379e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMi0zLTEtMS0xMTEzNjg_6397706a-d4a3-4cd7-854a-e3c1367c63c0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i32207f7e2b874ffe9f5bb035ed9216a6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMi01LTEtMS0xMTEzNjg_8551a7d0-4e12-4066-b851-1dcc732ce527"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i058fa58cb9ad4be2929911d5459f7ee5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMi03LTEtMS0xMTEzNjg_2138439f-53ba-4a44-9534-cf0eb5f9a11a"
      unitRef="usd">2376000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMi05LTEtMS0xMTEzNjg_927fe95c-9fd4-4898-a217-c20d51bfe36d"
      unitRef="usd">2377000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i597049e81b154f63b39f155a686eca36_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMy0xLTEtMS0xMTEzNjg_100a12ff-54c3-4814-9170-7317752ec112"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="id931cec3813c4a8abbaa146d0ecf379e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMy0zLTEtMS0xMTEzNjg_ccf1aacb-27b6-4f6c-8b87-b5113ebca296"
      unitRef="usd">-35000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i32207f7e2b874ffe9f5bb035ed9216a6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMy01LTEtMS0xMTEzNjg_da4d4bbe-84d8-46d5-9775-aed02986e8f4"
      unitRef="usd">7218000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i058fa58cb9ad4be2929911d5459f7ee5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMy03LTEtMS0xMTEzNjg_325f7182-2de5-4989-adf3-299066223efc"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfMy05LTEtMS0xMTEzNjg_3db7717d-910f-40c7-a94a-5a422da51d1c"
      unitRef="usd">7183000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i597049e81b154f63b39f155a686eca36_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNC0xLTEtMS0xMTEzNjg_45c33093-6e4c-43f4-b1e4-1bbd838e8301"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id931cec3813c4a8abbaa146d0ecf379e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNC0zLTEtMS0xMTEzNjg_611cb9df-78d2-4b40-a957-cae9d489568f"
      unitRef="usd">35000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i32207f7e2b874ffe9f5bb035ed9216a6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNC01LTEtMS0xMTEzNjg_66c0fd85-aaca-4a30-83b7-fe08f358dd3e"
      unitRef="usd">-7217000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i058fa58cb9ad4be2929911d5459f7ee5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNC03LTEtMS0xMTEzNjg_6b9d4955-a61e-4a1b-8032-1ea49d7652c8"
      unitRef="usd">2376000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNC05LTEtMS0xMTEzNjg_7d0e23e2-6d9a-4dd1-b7b6-4bc605ddcd40"
      unitRef="usd">-4806000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="if78966f3bc7e4a2c88588d499eac7518_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNS0xLTEtMS0xMTEzNjg_f519e5d0-1c30-4ec7-aaff-bd6d1751628c"
      unitRef="usd">-32792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58d05b72c281482194642f22d74ecfe5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNS0zLTEtMS0xMTEzNjg_d021f1b7-972f-4dd8-82bc-e90308f7ee8d"
      unitRef="usd">-2776000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifca2d339be1249478491d26c1d76e094_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNS01LTEtMS0xMTEzNjg_9d067bad-8594-4844-b8f0-d2fe7f9b96d9"
      unitRef="usd">-8847000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70f8e370f342484989f74b6dadda0a7e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNS03LTEtMS0xMTEzNjg_0c88b1aa-9f32-454e-8838-e2e76723254b"
      unitRef="usd">6350000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2d23f30f53a4a3b8caa38a11b48d302_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF81OC9mcmFnOjY5NDgxMzhiZTYyNjQ1ZjM5MTU3NmJkODBjMjFhOTIwL3RhYmxlOjlmMDRkOWU3NTMyMDQ2ZmU5OWRhODE5NDEwNGMyNDcxL3RhYmxlcmFuZ2U6OWYwNGQ5ZTc1MzIwNDZmZTk5ZGE4MTk0MTA0YzI0NzFfNS05LTEtMS0xMTEzNjg_0cadbd12-1efe-4b98-a43d-10a7d07f78ee"
      unitRef="usd">-38065000</us-gaap:StockholdersEquity>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNjA3NQ_f4d2fc3e-33b9-47c5-9ed7-d96c522fbabe">CONVERTIBLE DEBT&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Convertible Senior Notes Due 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September&#160;12, 2022, we commenced a private offering of $900.0&#160;million in aggregate principal amount of 1% Convertible Senior Notes due 2027, or the Initial Notes. On September&#160;13, 2022, the initial purchasers in such offering exercised their option to purchase an additional $135.0&#160;million in aggregate principal amount of our 1% Convertible Senior Notes due 2027, or the Additional Notes, and together with the Initial Notes collectively referred to as the Notes, bringing the total aggregate principal amount of the Notes to $1.04&#160;billion. The Notes were issued pursuant to an indenture, dated September&#160;15, 2022, or the Indenture. The Indenture includes customary covenants and sets forth certain events of default after which the Notes may be declared immediately due and payable and sets forth certain types of bankruptcy or insolvency events of default involving the Company after which the Notes become automatically due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Notes will mature on September&#160;15, 2027, unless earlier converted, redeemed or repurchased. The Notes will bear interest from September&#160;15, 2022 at a rate of 1% per year payable semiannually in arrears on March 15 and September 15 of each year, beginning on March&#160;15, 2023. The Notes are convertible at the option of the noteholder on or after June 15, 2027. Prior to June 15, 2027, the Notes are convertible only under the following circumstances: (1) During any calendar quarter commencing after the calendar quarter ending on December 31, 2022 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) During the five business day period after any ten consecutive trading day period in which the trading price per $1,000 principal amount of the Notes for each trading day of that ten consecutive trading day period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate of the Notes on such trading day; (3) If we call any or all of the Notes for redemption; or (4) Upon the occurrence of specific corporate events as set forth in the Indenture governing the Notes. We will settle any conversions of Notes by paying or delivering, as applicable, cash, shares of our common stock, or a combination of cash and shares of common stock, at our election.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The conversion rate for the Notes will initially be 3.4941 shares of common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $286.20 per share of common stock. The initial conversion price of the Notes represents a premium of approximately 35% over the $212.00 per share last reported sale price of common stock on September 12, 2022. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We may not redeem the Notes prior to September&#160;20, 2025. We may redeem for cash equal to 100% of the principal amount of the Notes being redeemed plus accrued and unpaid interest of all or any portion of the Notes, at our option, on or after September 20, 2025, if the last reported sales price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period. No sinking fund is provided for the Notes and therefore we are not required to redeem or retire the Notes periodically.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;If we undergo a fundamental change, as defined in the indenture agreement, then subject to certain conditions, holders may require us to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased plus accrued and unpaid interest. In addition, if specific corporate events occur prior to the maturity date or if we issue a notice of redemption, we will increase the conversion rate by pre-defined amounts for holders who elect to convert their notes in connection with such corporate event. The conditions allowing holders of the Notes to convert were not met this quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the Notes are classified as a long-term liability, net of issuance costs of $19.2 million, on the condensed consolidated balance sheets. As of March&#160;31, 2023, the estimated fair value of the Notes was approximately $1.03&#160;billion. The fair value was determined based on the last actively traded price per $100 of the Notes for the three months ended March 31, 2023 (Level 2). The Notes were issued at par and costs associated with the issuance of the Notes are amortized to&#160;interest expense over the contractual term of the Notes. As of March&#160;31, 2023, the effective interest rate of the Notes is&#160;1%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Capped Call Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2022, in connection with the pricing of the Initial Notes and the initial purchasers&#x2019; exercise of their option to purchase the Additional Notes, we entered into privately negotiated capped call transactions, or Capped Call Transactions. The Capped Call Transactions initially cover, subject to customary anti-dilution adjustments, the number of shares of common stock that underlie the Notes. The cap price of the Capped Call Transactions is initially $424.00 per share, which represents a premium of 100% over the last reported sale price of common stock of $212.00 per share on September 12, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. We used approximately $118.6&#160;million of the proceeds from the offering of Notes to pay the cost of the Capped Call Transactions.&lt;/span&gt;&lt;/div&gt;We evaluated the Capped Call Transactions and determined that they should be accounted for separately from the Notes. The cost of $118.6&#160;million to purchase the Capped Call Transactions was recorded as a reduction to additional paid-in capital in the condensed consolidated balance sheet as of March&#160;31, 2023 as the Capped Call Transactions are indexed to our own stock and met the criteria to be classified in stockholders' equity.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8575ee7bf1c64fce99658a0882ae7ee3_I20220912"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTAy_f5dcf393-f0fa-4b3a-9f7d-efeff387ed63"
      unitRef="usd">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i8081d56e8ab34c85add2a725bbed1844_D20220912-20220912"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTM4_2d0f9cc1-61ed-4ecd-b264-a4b8eb71d3d3"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i72548dd619ad4fc59ff47eaf2277707e_I20220913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjk0_0af393f9-604a-4ee4-accc-1030134468bc"
      unitRef="usd">135000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="ifbfa928ba64c483796841306c426679d_D20220913-20220913"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMzM0_1bda0c57-bb80-44cb-a7f9-8dae29594a5a"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i36aa61efaa244add8aac63cdcac4dac0_I20220913"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTM0_bbf26035-c254-42aa-ad91-1cec31d00eeb"
      unitRef="usd">1040000000.00</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="ie5b391a1819e41adbce308c1b9dab192_D20220915-20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTA1MQ_8e5484c1-e1c9-49a2-8098-8fa70ed94ca3"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ia716907dc7734c6ba46bc53ee763d5d5_D20220915-20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTUxOA_11ef9bff-f612-41b6-a011-1c944f96a0c2"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ia716907dc7734c6ba46bc53ee763d5d5_D20220915-20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTU4Mg_dbd8007b-df58-40e5-a2bd-af9d5975198b"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ia716907dc7734c6ba46bc53ee763d5d5_D20220915-20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTczMQ_fd6a7043-1fa6-4e40-af57-2b53094fd36c"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i9e464817379546f69d2a4d409bf930d6_D20220915-20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTgwNQ_80d95f3d-9d3b-4561-afba-8524657ebb86"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i9e464817379546f69d2a4d409bf930d6_D20220915-20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTgzOA_11efa706-390f-4673-813b-fca9a2a44277"
      unitRef="day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i9e464817379546f69d2a4d409bf930d6_D20220915-20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMTk2OQ_9ad83127-73db-46a8-833d-18e8c0f5a0ce"
      unitRef="day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i9e464817379546f69d2a4d409bf930d6_D20220915-20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjAxNw_bded3c61-11a6-47cb-9bdf-91d4813d2cce"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="icebb5707b4014e189d610163d749eb88_I20220912"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjY3NQ_3cf1572e-3f10-42c7-a6c0-bad1c83b9c07"
      unitRef="usdPerShare">286.20</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <alny:ConvertibleDebtPremiumRecognizedFromConversionRate
      contextRef="icebb5707b4014e189d610163d749eb88_I20220912"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjc4NQ_d3a252d7-cf0a-4971-a917-25798f521090"
      unitRef="number">0.35</alny:ConvertibleDebtPremiumRecognizedFromConversionRate>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="icebb5707b4014e189d610163d749eb88_I20220912"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjc5Nw_f03d701d-2ca1-486e-b2e4-c466a77a69a0"
      unitRef="usdPerShare">212.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="idf3afa8e81834164a6949f9f03a9f2b4_D20220915-20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjE5OTAyMzI2MTkzMA_1c767079-8056-4c01-96b8-7592517f83e6"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="idf3afa8e81834164a6949f9f03a9f2b4_D20220915-20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjE5OTAyMzI2MTkzNg_ff7bb6a8-a359-483d-ab5f-3b788fafa9af"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="idf3afa8e81834164a6949f9f03a9f2b4_D20220915-20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfMjE5OTAyMzI2MTk0MA_fe3baeef-373b-49ac-b83c-b439ff6a1b45"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ia532de6f95c948d98aa0f343c124b06f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNDM0NA_d24e304e-d664-49f6-8519-1dd5981207e2"
      unitRef="usd">19200000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebtFairValue
      contextRef="ia532de6f95c948d98aa0f343c124b06f_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTQ5NzU1ODIwMjU5_8ce8683e-a816-4313-99d3-7cbaba6d8f00"
      unitRef="usd">1030000000.00</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="icf9b6feac91a4baaa879c5cc27f3adcf_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNDgzMw_10152ba4-b46a-4297-9854-75aff674552d"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DerivativeCapPrice
      contextRef="i9534211a39af4f07af0f48f741ec3cfc_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTMyNw_07b3069a-f1cd-4030-b2ba-277407f9f697"
      unitRef="usdPerUnit">424.00</us-gaap:DerivativeCapPrice>
    <alny:PremiumRecognizedOnCappedCallTransactions
      contextRef="i303c720c21554eb3a5e123dcdd48b762_I20220912"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTM3MQ_1b7e0994-fa9f-45ce-aa66-6f0bee8b47ae"
      unitRef="number">1</alny:PremiumRecognizedOnCappedCallTransactions>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i303c720c21554eb3a5e123dcdd48b762_I20220912"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTQyNw_5298c9d6-c7ee-4a92-9e6b-332c022a96d8"
      unitRef="usdPerShare">212.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <alny:PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes
      contextRef="i8025ac0fe3c444bd93fb4dffe9e6a50f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTU3Mg_cba88f0c-5e46-443f-8cbb-459c815386eb"
      unitRef="usd">118600000</alny:PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes>
    <alny:PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes
      contextRef="i8025ac0fe3c444bd93fb4dffe9e6a50f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF82NC9mcmFnOmM1Y2UxMDFhZDliNDRlOTQ4YzI3ZTU0NTVmYzMwZjRkL3RleHRyZWdpb246YzVjZTEwMWFkOWI0NGU5NDhjMjdlNTQ1NWZjMzBmNGRfNTc5Nw_cba88f0c-5e46-443f-8cbb-459c815386eb"
      unitRef="usd">118600000</alny:PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTg2Mw_8a5e81d7-2676-4285-90f4-2cc1163d9d04">DEVELOPMENT DERIVATIVE LIABILITY&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, we entered into a co-development agreement, referred to as the Funding Agreement, with BXLS V Bodyguard &#x2013; PCP L.P. and BXLS Family Investment Partnership V &#x2013; ESC L.P., collectively referred to as Blackstone Life Sciences, pursuant to which Blackstone Life Sciences will provide up to $150.0&#160;million in funding for the clinical development of vutrisiran and zilebesiran, two of our cardiometabolic programs. With respect to vutrisiran, Blackstone Life Sciences has committed to provide up to $70.0&#160;million to fund development costs related to the HELIOS-B Phase 3 clinical trial. In November 2021, Blackstone Life Sciences opted in to Phase 2 clinical trial funding of zilebesiran, committing to fund, upon meeting certain patient enrollment thresholds, up to $26.0&#160;million. Furthermore, Blackstone Life Sciences has the right, but is not obligated, to fund up to $54.0&#160;million for development costs related to a Phase 3 clinical trial of zilebesiran. The amount of funding ultimately provided by Blackstone Life Sciences is dependent on us achieving specified development milestones with respect to each clinical trial. We retain sole responsibility for the development and commercialization of both vutrisiran and zilebesiran.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As consideration for Blackstone Life Sciences&#x2019; funding for vutrisiran clinical development costs, we have agreed to pay Blackstone Life Sciences a 1% royalty on net sales of AMVUTTRA (vutrisiran) for a 10-year term beginning upon the first commercial sale following regulatory approval of vutrisiran for ATTR-cardiomyopathy, as well as fixed payments of up to 2.5 times their investment over a two-year period upon regulatory approval of vutrisiran for ATTR-cardiomyopathy in specified countries, unless it is later withdrawn from the market following a mandatory recall. As consideration for Blackstone Life Sciences&#x2019; funding for Phase 2 clinical development costs of zilebesiran, we have agreed to pay Blackstone Life Sciences fixed payments of up to 3.25 times their Phase 2 investment over a four-year period upon the successful completion of the zilebesiran Phase 2 clinical trial, unless certain regulatory events affecting the continued development of zilebesiran occur. As &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;consideration for Blackstone Life Sciences&#x2019; funding for Phase 3 clinical development costs of zilebesiran, we have agreed to pay Blackstone Life Sciences fixed payments of up to 4.5 times their Phase 3 investment over a four-year period upon regulatory approval of zilebesiran in specified countries, unless it is later withdrawn from the market following a mandatory recall.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our payment obligations under the Funding Agreement will be secured, subject to certain exceptions, by security interests in intellectual property owned by us relating to vutrisiran and zilebesiran, as well as in our bank account in which the funding deposits will be made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We and Blackstone Life Sciences each have the right to terminate the Funding Agreement in its entirety in the event of the other party&#x2019;s bankruptcy or similar proceedings. We and Blackstone Life Sciences may each terminate the Funding Agreement in its entirety or with respect to either product in the event of an uncured material breach by the other party, or with respect to a product for certain patient health and safety reasons, or if regulatory approval in specified major market countries is not obtained for the product following the completion of clinical trials for the product. In addition, Blackstone Life Sciences has the right to terminate the Funding Agreement in its entirety upon the occurrence of certain events affecting our ability to make payments under the agreement or to develop or commercialize the products, or upon a change of control of us. Blackstone Life Sciences may also terminate the Funding Agreement with respect to a product if the joint steering committee elects to terminate the development program for that product in its entirety, if certain clinical endpoints are not achieved for that product or, with respect to vutrisiran only, if our right to develop or commercialize vutrisiran is enjoined in a specified major market as a result of an alleged patent infringement. In certain termination circumstances, we will be obligated to pay Blackstone Life Sciences an amount that is equal to, or a multiplier of, the development funding received from Blackstone Life Sciences, and we may remain obligated under certain circumstances to make the payments to Blackstone Life Sciences described above, or the royalty described above in the case of AMVUTTRA, should we obtain regulatory approval for zilebesiran or vutrisiran for ATTR-cardiomyopathy following termination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We account for the Funding Agreement under ASC Topic 815, Derivatives and Hedging, as a derivative liability, measured at fair value, within other liabilities on our condensed consolidated balance sheets. The change in fair value due to the remeasurement of the development derivative liability is recorded as other expense on our condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the derivative liability is classified as a Level 3 financial liability in the fair value hierarchy. The valuation method incorporates certain unobservable Level 3 key inputs including (i) the probability and timing of achieving stated development milestones to receive payments from Blackstone Life Sciences, (ii) the probability and timing of achieving regulatory approval and payments to Blackstone Life Sciences, (iii) an estimate of the amount and timing of the royalty payable on net sales of AMVUTTRA, assuming regulatory approval for ATTR-cardiomyopathy, (iv) our cost of borrowing (12%), and (v) Blackstone Life Sciences' cost of borrowing (4%).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the activity with respect to the development derivative liability, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount received under the Funding Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss recorded from remeasurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;219,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <alny:CollaborativeArrangementMaximumFunding
      contextRef="icdd6f7a85c0649c687a28ff5014a352d_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfMzQy_6a5997fb-7a81-42b8-a11b-3d0b0c4480c3"
      unitRef="usd">150000000</alny:CollaborativeArrangementMaximumFunding>
    <alny:CollaborativeArrangementMaximumFunding
      contextRef="i0540d1bfbba64fa980c847a4a95c9ac6_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTU2_90467aac-6f87-46c7-8273-cc575820af03"
      unitRef="usd">70000000</alny:CollaborativeArrangementMaximumFunding>
    <alny:CollaborativeArrangementMaximumFunding
      contextRef="i788b9050885e4755ab989256b9364634_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfODEz_1b7a810e-d582-482a-95b4-50d3fc6b79cf"
      unitRef="usd">26000000</alny:CollaborativeArrangementMaximumFunding>
    <alny:CollaborativeArrangementMaximumFunding
      contextRef="i3d2567c90e8a458eae5bef50162e1ca4_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfOTA2_235ad026-e305-4b3c-97a9-ede7e964f7a6"
      unitRef="usd">54000000</alny:CollaborativeArrangementMaximumFunding>
    <alny:CollaborativeArrangementRoyaltiesPayablePercent
      contextRef="ifde09daab1ea4a168820da3d556f2e1f_D20200801-20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfMTQwNw_08e8525c-5d91-4349-9e5b-55881b3f24c8"
      unitRef="number">0.01</alny:CollaborativeArrangementRoyaltiesPayablePercent>
    <alny:CollaborativeArrangementRoyaltiesPayableTerm
      contextRef="ifde09daab1ea4a168820da3d556f2e1f_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfMTQ2Mg_8c332dc2-9163-41b7-b5de-b91ff0f647c6">P10Y</alny:CollaborativeArrangementRoyaltiesPayableTerm>
    <alny:CollaborativeArrangementFixedPaymentMultiplier
      contextRef="ifde09daab1ea4a168820da3d556f2e1f_D20200801-20200831"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfMTYyMA_30cf6009-cf48-4a38-a0c2-9483c41c0ba8"
      unitRef="number">2.5</alny:CollaborativeArrangementFixedPaymentMultiplier>
    <alny:CollaborativeArrangementFixedPaymentTerm
      contextRef="ifde09daab1ea4a168820da3d556f2e1f_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTg2NA_1ba288ee-f6cf-4001-bc61-642e2e4c1a69">P2Y</alny:CollaborativeArrangementFixedPaymentTerm>
    <alny:CollaborativeArrangementFixedPaymentMultiplier
      contextRef="i788b9050885e4755ab989256b9364634_D20200801-20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfMjAxMQ_61e605cc-8d65-4b65-a1ce-8d4eba141f3a"
      unitRef="number">3.25</alny:CollaborativeArrangementFixedPaymentMultiplier>
    <alny:CollaborativeArrangementFixedPaymentTerm
      contextRef="i788b9050885e4755ab989256b9364634_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTg2NQ_33cf8b4d-a344-4817-b83c-6f31b57993a0">P4Y</alny:CollaborativeArrangementFixedPaymentTerm>
    <alny:CollaborativeArrangementFixedPaymentMultiplier
      contextRef="i3d2567c90e8a458eae5bef50162e1ca4_D20200801-20200831"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfMjQxMw_0b572531-a9f8-4e59-962a-f1c8b2da5098"
      unitRef="number">4.5</alny:CollaborativeArrangementFixedPaymentMultiplier>
    <alny:CollaborativeArrangementFixedPaymentTerm
      contextRef="i3d2567c90e8a458eae5bef50162e1ca4_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTg2Ng_b51e99eb-ebc0-4343-96a6-dc12de2fed85">P4Y</alny:CollaborativeArrangementFixedPaymentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf7880a1438e4b1d8934bf896e4c4569_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTY5MA_8848fa33-bbe9-4eb7-b520-0f8927736277"
      unitRef="number">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if60b93a866a243d08fc76127d6370bdd_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTc0OA_f5d8ac3b-87b1-4978-86f1-55b2f4f0af45"
      unitRef="number">0.04</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RleHRyZWdpb246NjRiNDY2ZTFmYTgwNGM1MTk3MDhiYjAyYTU3NmQ3YmZfNTg2Nw_eade0fdf-7f57-43f8-96af-ad7d4962b7dd">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the activity with respect to the development derivative liability, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount received under the Funding Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss recorded from remeasurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;219,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib8b29740f2a6476a91d8e8b96400f6d4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RhYmxlOjVhNzhhYmI3MjBhZTQ2MzQ4Y2ZjZGRiNzFhOGU3YzcwL3RhYmxlcmFuZ2U6NWE3OGFiYjcyMGFlNDYzNDhjZmNkZGI3MWE4ZTdjNzBfMC0yLTEtMS0xMTEzNjg_624b28e8-1762-4da5-b309-b2a09e489bc6"
      unitRef="usd">209277000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i707ab3ce2b764f02a7efa7c0a56fcdd2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RhYmxlOjVhNzhhYmI3MjBhZTQ2MzQ4Y2ZjZGRiNzFhOGU3YzcwL3RhYmxlcmFuZ2U6NWE3OGFiYjcyMGFlNDYzNDhjZmNkZGI3MWE4ZTdjNzBfMS0yLTEtMS0xMTEzNjg_ef769e29-9bef-4cbc-99ac-44188a5db2ee"
      unitRef="usd">4000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i707ab3ce2b764f02a7efa7c0a56fcdd2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RhYmxlOjVhNzhhYmI3MjBhZTQ2MzQ4Y2ZjZGRiNzFhOGU3YzcwL3RhYmxlcmFuZ2U6NWE3OGFiYjcyMGFlNDYzNDhjZmNkZGI3MWE4ZTdjNzBfMi0yLTEtMS0xMTEzNjg_59cc8d2f-4c1a-47d4-82b8-5f4b6aea80bb"
      unitRef="usd">-6471000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i728568c4126e4020bdaab60c7fd837da_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83MC9mcmFnOjY0YjQ2NmUxZmE4MDRjNTE5NzA4YmIwMmE1NzZkN2JmL3RhYmxlOjVhNzhhYmI3MjBhZTQ2MzQ4Y2ZjZGRiNzFhOGU3YzcwL3RhYmxlcmFuZ2U6NWE3OGFiYjcyMGFlNDYzNDhjZmNkZGI3MWE4ZTdjNzBfMy0yLTEtMS0xMTEzNjg_f5482b19-c0a3-4ad9-a6ac-78a01f9da39f"
      unitRef="usd">219748000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RleHRyZWdpb246Yzk1ZDZhYTU5M2EwNGYyYzkzN2Y0ZjYxYTU3ZWNlMjlfMTQ0_f820df3f-189e-444b-a9da-5f9f38964fb7">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes stock-based compensation expenses included in operating costs and expenses:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RleHRyZWdpb246Yzk1ZDZhYTU5M2EwNGYyYzkzN2Y0ZjYxYTU3ZWNlMjlfMTQy_872863d4-701e-4c24-a2ea-fdd54be3655f">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes stock-based compensation expenses included in operating costs and expenses:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i770db94c29944af19b3195793999b048_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RhYmxlOjBmOTZkYjg4NTk0NTQ0YTA5ODhjZWMxZmQ5NWNhNjVjL3RhYmxlcmFuZ2U6MGY5NmRiODg1OTQ1NDRhMDk4OGNlYzFmZDk1Y2E2NWNfMi0xLTEtMS0xMTEzNjg_2e18e848-1f39-4828-8072-a3073db40233"
      unitRef="usd">16232000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i920b6c081b7047af9c3d22ecd0aac5fc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RhYmxlOjBmOTZkYjg4NTk0NTQ0YTA5ODhjZWMxZmQ5NWNhNjVjL3RhYmxlcmFuZ2U6MGY5NmRiODg1OTQ1NDRhMDk4OGNlYzFmZDk1Y2E2NWNfMi0zLTEtMS0xMTEzNjg_97174269-4f15-4bd6-90b2-f4b14cdfa938"
      unitRef="usd">11617000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i39c75d8b324e44f0a7e6fb8cd3fed694_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RhYmxlOjBmOTZkYjg4NTk0NTQ0YTA5ODhjZWMxZmQ5NWNhNjVjL3RhYmxlcmFuZ2U6MGY5NmRiODg1OTQ1NDRhMDk4OGNlYzFmZDk1Y2E2NWNfMy0xLTEtMS0xMTEzNjg_bbb5a9a4-17ac-4dcd-b2c4-6626e8ee2ba5"
      unitRef="usd">23715000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i19ba4c67d69f48759c03fa13464eae2a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RhYmxlOjBmOTZkYjg4NTk0NTQ0YTA5ODhjZWMxZmQ5NWNhNjVjL3RhYmxlcmFuZ2U6MGY5NmRiODg1OTQ1NDRhMDk4OGNlYzFmZDk1Y2E2NWNfMy0zLTEtMS0xMTEzNjg_9b55faad-bac3-4756-9c38-751f54271269"
      unitRef="usd">17676000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RhYmxlOjBmOTZkYjg4NTk0NTQ0YTA5ODhjZWMxZmQ5NWNhNjVjL3RhYmxlcmFuZ2U6MGY5NmRiODg1OTQ1NDRhMDk4OGNlYzFmZDk1Y2E2NWNfNC0xLTEtMS0xMTEzNjg_6f10852d-27da-4f8b-ac8c-d5222f83985b"
      unitRef="usd">39947000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83My9mcmFnOmM5NWQ2YWE1OTNhMDRmMmM5MzdmNGY2MWE1N2VjZTI5L3RhYmxlOjBmOTZkYjg4NTk0NTQ0YTA5ODhjZWMxZmQ5NWNhNjVjL3RhYmxlcmFuZ2U6MGY5NmRiODg1OTQ1NDRhMDk4OGNlYzFmZDk1Y2E2NWNfNC0zLTEtMS0xMTEzNjg_55e3ff67-5d05-4f73-8db3-ab6c4a9a5722"
      unitRef="usd">29293000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RleHRyZWdpb246ZjdkMWY0ODJhZDAxNDAwODg5YTk0NTYyYTZmYWFmNmVfMTI5MQ_c466dd98-eaa3-409d-a508-eff8da5f09a8">NET LOSS PER COMMON SHAREWe compute basic net loss per common share by dividing net loss by the weighted-average number of common shares outstanding. We compute diluted net loss per common share by dividing net loss by the weighted-average number of common &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;shares and dilutive potential common share equivalents then outstanding during the period. In the diluted net loss per share calculation, net loss would be adjusted for the elimination of interest expense on the Convertible debt. Potential common shares consist of shares issuable upon the vesting of restricted stock units, the exercise of stock options (the proceeds of which are then assumed to have been used to repurchase outstanding shares using the treasury stock method) and upon conversion of the convertible debt outstanding during the period (calculated using the if-converted method assuming the conversion of the convertible debt as of the earliest period reported or at the date of issuance, if later). Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the potential common shares (prior to consideration of the treasury stock or if-converted methods) excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock, inclusive of performance-based stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units, inclusive of performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RleHRyZWdpb246ZjdkMWY0ODJhZDAxNDAwODg5YTk0NTYyYTZmYWFmNmVfMTI5Mg_f1e20df9-b9c3-4ffb-8309-8d5912f4fcf9">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the potential common shares (prior to consideration of the treasury stock or if-converted methods) excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock, inclusive of performance-based stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units, inclusive of performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i16fefe33d0a84bbcb3bcfe4546c9b4d3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfMi0xLTEtMS0xMTEzNjg_bed5260c-bbeb-49a8-bde7-b57b2e939b1f"
      unitRef="shares">8428000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3a1e6837336341aebaca13a642e99570_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfMi0zLTEtMS0xMTEzNjg_c3bcf4c4-3dbd-41e8-bf4d-dc7feb493ec6"
      unitRef="shares">12785000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7e25f80d14ab4e29946dc7feeb321f9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfMy0xLTEtMS0xMTEzNjg_614f42e1-2592-48be-8d13-ada656b2778f"
      unitRef="shares">2547000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id9057d82ed2a40ea940df490edf962c1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfMy0zLTEtMS0xMTEzNjg_d57a090e-0d11-4745-a89e-0cd5e331d94e"
      unitRef="shares">1918000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i402e0e52c29f460db9f6c550106e1cf2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfNC0xLTEtMS0xMTEzNjg_8ca0a2c8-7242-4de3-8156-21d5231bc420"
      unitRef="shares">3616000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6d2e5ef24f8743d687104b5084f27971_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfNC0zLTEtMS0xMTEzNjg_4c0db331-560d-4b2c-b704-1a46ae590747"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfNS0xLTEtMS0xMTEzNjg_8f994c00-b1ba-45c2-8089-c78ba4709679"
      unitRef="shares">14591000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide5b2100b1f342cfa07dabe861ec60e7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83Ni9mcmFnOmY3ZDFmNDgyYWQwMTQwMDg4OWE5NDU2MmE2ZmFhZjZlL3RhYmxlOjJmNTg4ODAxNzY4OTQ5MzNiNGY5ZDFmY2I4MjgxNzVjL3RhYmxlcmFuZ2U6MmY1ODg4MDE3Njg5NDkzM2I0ZjlkMWZjYjgyODE3NWNfNS0zLTEtMS0xMTEzNjg_3767e0ec-1528-4755-beaf-ad314153d860"
      unitRef="shares">14703000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZTM0MDU4OWY5NzQwOGVhMjM2NWQ4OTQ4ZGY0YzM4L3NlYzo5MGUzNDA1ODlmOTc0MDhlYTIzNjVkODk0OGRmNGMzOF83OS9mcmFnOmI3OWIyNzBhZDYxYTQ0OWI5MTdkNDE0Mjk0NDg2MGU5L3RleHRyZWdpb246Yjc5YjI3MGFkNjFhNDQ5YjkxN2Q0MTQyOTQ0ODYwZTlfNzUyOA_bdc450b5-460b-4651-b6f9-97b2ecb3d0bd">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Technology License and Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We have licensed from third parties the rights to use certain technologies and information in our research processes as well as in any other products we may develop. In accordance with the related license or technology agreements, we are required to make certain fixed payments to the licensor or a designee of the licensor over various agreement terms. Many of these agreement terms are consistent with the remaining lives of the underlying intellectual property that we have licensed. As of March 31, 2023, our commitments over the next five years to make fixed and cancellable payments under existing license agreements were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, we may be a party to litigation, arbitration or other legal proceedings in the course of our business, including the matters described below. The claims and legal proceedings in which we could be involved include challenges to the scope, validity or enforceability of patents relating to our products or product candidates, and challenges by us to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents or breach our license or other agreements with such third parties. The outcome of any such legal proceedings, regardless of the merits, is inherently uncertain. In addition, litigation and related matters are costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. If we were unable to prevail in any such legal proceedings, our business, results of operations, liquidity and financial condition could be adversely affected. Our accounting policy for accrual of legal costs is to recognize such expenses as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We have previously disclosed that, on or about April 9, 2021, we received a subpoena from the U.S. Department of Justice, U.S. Attorney&#x2019;s Office for the District of Massachusetts, requiring production of documents pertaining to our marketing and promotion of ONPATTRO (patisiran) in the U.S. We are cooperating with the U.S. Attorney&#x2019;s Office and producing documents in response to the subpoena. Current and former officers and employees also have received subpoenas in connection with the preservation and production of related materials. Given the ongoing nature of the investigation, it is possible that the U.S. Attorney&#x2019;s Office for the District of Massachusetts or other government entities may request other information from, or issue other subpoenas, findings or similar documents to, us, our related entities and their respective directors, officers and employees. In light of the ongoing nature of the investigation, no determination has been made that a loss, if any, arising from this matter is probable or that the amount of any such loss, or range of loss, is reasonably estimable. We also previously disclosed that since learning of this federal government investigation, our nominating and corporate governance committee is directing our review of and response to the matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Patent Infringement Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2022, we filed separate lawsuits in the U.S. District Court for the District of Delaware against (1) Pfizer, Inc. and its subsidiary Pharmacia &amp;amp; Upjohn Co. LLC, collectively referred to as Pfizer, and (2) Moderna, Inc., and its subsidiaries &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ModernaTX, Inc., and Moderna US, Inc., collectively referred to as Moderna. The lawsuits seek damages for infringement of U.S. Patent No. 11,246,933, or &#x2018;933 Patent, in Pfizer&#x2019;s and Moderna&#x2019;s manufacture and sale of their messenger RNA, or mRNA, COVID-19 vaccines. The patent relates to the Company&#x2019;s biodegradable cationic lipids that are foundational to the success of the mRNA COVID-19 vaccines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We are seeking judgment that each of Pfizer and Moderna is infringing the &#x2018;933 Patent, as well as damages adequate to compensate for the infringement, but in no event less than a reasonable royalty for the unlicensed uses made of our patented lipids by Pfizer and Moderna, together with interest and costs as may be awarded by the court. As stated in the filed complaints, we are not seeking injunctive relief in these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 23, 2022, Moderna filed a partial motion to dismiss, asserting an affirmative defense under Section 1498(a). We responded on May 27, 2022, opposing their motion arguing Moderna had significant non-government sales and the government contract ended in April 2022. Moderna responded on June 13, 2022, requesting a partial motion to dismiss those claims for sales under 1498(a).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 27, 2022, Pfizer filed an answer to our complaint, denying the allegations, and asserting invalidity and non-infringement defenses. In addition, Pfizer added BioNTech SE to the suit and added counter-claims seeking a declaratory judgment that our patent is invalid and a second claim alleging that our patent is invalid due to patent misuse. We believe their defenses and counter-claims have no merit and responded on June 10, 2022, with substantive arguments as to the validity of our claims and the lack of merit of their patent misuse claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 12, 2022, we filed a new lawsuit against each of Pfizer and Moderna seeking damages for infringing our newly granted U.S. Patent No. 11,382,979 in Pfizer&#x2019;s and Moderna&#x2019;s manufacture and sale of their mRNA COVID-19 vaccines. The parties agreed to combine the two patents in one lawsuit, separately against each of Moderna and Pfizer/BioNTech.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On February 8, 2023, we received notification from the U.S. Patent Office that a third patent would issue on February 28, 2023, as U.S. Patent No. 11,590,229, which we also believe Pfizer and Moderna&#x2019;s COVID-19 vaccines infringe upon. On February 15, 2023, we filed a motion with the court to add this patent to the existing cases against Pfizer and Moderna.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 26, 2023, the court held a hearing and denied Moderna&#x2019;s partial motion to dismiss those claims for sales under 1498(2), our motion to add the 11,590,229 patent to the current lawsuits as well as a motion filed by Moderna to add certain invalidity arguments made by Pfizer in our case to supplement Moderna&#x2019;s invalidity arguments previously made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The court has set a trial date of November 12, 2024, for Alnylam v. Moderna and November 18, 2024, for Alnylam v. Pfizer/BioNTech.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with license agreements we may enter with companies to obtain rights to intellectual property, we may be required to indemnify such companies for certain damages arising in connection with the intellectual property rights licensed under the agreements. Under such agreements, we may be responsible for paying the costs of any litigation relating to the license agreements or the underlying intellectual property rights, including the costs associated with certain litigation regarding the licensed intellectual property. We are also a party to a number of agreements entered into in the ordinary course of business, which contain typical provisions that obligate us to indemnify the other parties to such agreements upon the occurrence of certain events, including litigation or other legal proceedings. In addition, we have agreed to indemnify our officers and directors for expenses, judgments, fines, penalties, excise taxes, and settlement amounts paid in connection with any threatened, pending or completed litigation proceedings, including, for example, the current government investigation, in which an officer or director was, is or will be involved as a party, on account of such person&#x2019;s status as an officer or director, or by reason of any action taken by the officer or director while acting in such capacity, subject to certain limitations. These indemnification costs are charged to selling, general and administrative expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our maximum potential future liability under any such indemnification provisions is uncertain. We have determined that the estimated aggregate fair value of our potential liabilities under all such indemnification provisions is minimal and had not recorded any liability related to such indemnification provisions as of March 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@GF0K\2^S\^MC#_-\2\9>>(G,5N*DN"KJCS<&E6%H W;M1!P:R?$R)&6F\F
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M6H* VA[WM%BC)LAI2R(0>TA^BITJ#"'?465^G'9-.YC_L^2:;AOV'<>5&YA
M9>=B=V0[HR,U77?M$/^/H@TTVJP;19L91?.-H@6FT)I%4+?V\"?U]J>Z3'W<
MSO6@:/?=UF%O,J1O%"TPA=:DN58/H%X^,"KA0$73[SK0DW?,86O'E*6!(TA8
MWBR-=OVFT)I4U'T_U#?^!I4<?:3.:ZS=ZSNM9S:3$7VC:($IM":OM7( ]=)!
M!UZ57+:[<$M>4$8E!*-HOE&TP!1:\W?;6FQ >K'A.=H<:G?<#H2VW!KI(W?E
M\+R@OM&@@2FT)CFU ('T L2S)#K4U@LPMN4%IH_<F1RCVL-9,PA,Q6QR<_#&
M@UY3T*ETJ"T*].'0@9:LTNEC=&;![*L-9M]M4 @64DJ:1-1Z!7J67G&H\-A*
MDE0ZA(-:2NJ9=C/],#MGWZA>80JM25&M5R"]7J'7W]3L*,0*A$<M&6*J,.3T
MR$_?"BL7(V2-Y)]W5''M$91_/@]4=N[0L1UL204].'BY3KQLR:?^$/,'WH0N
MN*OU9L@KJ]B^O[B]8?FJ>M_N2\Y8GE:72TKX@Y4PX-\O\IS]N!&O\.W?(IW\
M!U!+ P04    " #(0J16Q %/&.8'  !3(@  &    'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;*U:;7/C*!+^*Y1OZ^JN*AX+T&LN<57&R=1.U4Z2&L_>?B82
MCKF1A1>0D^RO7Y 4RQ:()'7^DDART^JGN^FG 5T\<?%3KBE5X'E35O)RLE9J
M>SZ;R7Q--T1^XEM:Z5]67&R(TK?B<2:W@I*B&;0I9R@(XMF&L&HROVB>W8OY
M!:]5R2IZ+X"L-QLB7C[3DC]=3N#D]<%W]KA6YL%L?K$ECW1)U>_;>Z'O9GLM
M!=O02C)> 4%7EY,K>+X( S.@D?@OHT_RX!H8* ^<_S0W7XO+26 LHB7-E5%!
M]+\=7="R-)JT'7]V2B?[=YJ!A]>OVK\TX#68!R+I@I=_L$*M+R?I!!1T1>I2
M?>=/O](.4&3TY;R4S5_PU,D&$Y#74O%--UA;L&%5^Y\\=XXX&*#UN >@;@ :
M#@A'!N!N &Z MI8UL*Z)(O,+P9^ ,-):F[EH?-.,UFA89<*X5$+_RO0X-5_<
MW5[?W"YOKH&^6M[]]O7ZZH>^6?[0_[[=W/Y8@KLO8'&U_!5\^>WNCR68@M^7
MU^!?O_P;_ )8!7ZL>2U)5<B+F=+6&)VSO'OSY_;-:.3-&'SCE5I+<%,5M#@>
M/],H]E#0*Y3/R*OP&Q&? (9G  4(.^Q9O'\X\IB#]Y[%C3X\YEDBUV"EIXD$
M*\$W0,\\012K'MO498I1>>YR6ZLV=*LUT_I<;DE.+R=ZWDHJ=G0R_^<_8!S\
MQX7Y1,J./!#N/1#ZM,]O=14JN73F1CLR;D::4K.;3V$2P@!>S':']COD4!C@
ML)<[,BW:FQ9Y@W/+JVEN D2*_^E)INN2DD!Q79AR7N6LI*#JC#=/S74C74M:
MF+1_=RRC4\;R1,J.'!;O'19[8WE-M=*<D;;V5@4@&RX4^ZMYX$+>JHL. @?#
M((X&X;6ELC .W+%-]J8F7E.O#BQK3&65HMHC2@<K%U2U!%02I6.I@]O'LJ2:
M#YS9FMA@4 ## 1B'5(!AZD:3[M&D_DGTFJE[%/19<[BD0,,H&7E@)5,OAX#4
MF@))= KS%5C5JA84"/Y"2I.D+G"I93:*4#*,E$,J20+D!I?MP65><$O%\Y]3
M0\,%R/G&X!I-J,PR &=9F S,M*50AC+L-A,&/4L&7D._4U*RO[25)I_J2KS>
M-A5"!T*W0#^I(@_:Z_3/V@1$TKP6;,SGW>N.[$3Q$(Q#"D,8C]0^>,#YT(MF
ML2;5(S6%;$68 #M2UDVV%'2G^[JMJ8;Z6K =,3U6GV5.)-"R,0Z381EW2$&<
MI"/I U&/!'F1W.ED%TZSD/7":8R2>&B7+9;@+!HQJZ=^^ ;W-PZ6 ZJ0DFJ6
M,1GTZM$QVH G[0%.I>W8&7T7 /UMP%6>\]KPJR80JG-*3Y(S0ZE.X*&=)QF,
M\#!LMAC.XBP>B5O?%4 OA\Z_5CN=^URX,SVR4TJW(D/3;"F8H3'+>OJ%?OZ]
M%W1+6/%:_-LTXB;[N[QR6FS3ZQ0B/"SM+C&4I='8[.R)&+[!Q*^1WY*7-NR&
M@6OJA'$P)YQ8;':=IC"S>,HE%Z8)'HM S\/03\1WQWW"&U71IDOM^119%=XE
M%\3)F.M[8H5^9KVF*RJ$]K30-;VJJ=-(FRRG:1H%0QL=8CJ+T$B51#VI(C^I
MWKZGK789CFQ>G,)8T\XP&9R""81C#0'J*13!#ZWNF*X<\CTK N2EYH^6]E-I
M._9"3[_(3[_WM<C7IFDVW<-6F/BIES.P+8GN(,S4-LU0TT\X7>'@:(C3;-@\
M..62-,I&@MC3-/(RW['Y!RV<OW?KE!Y7&!PEX;"Y< G&.$R"L9G34RKR4^I2
MM_=M[=P0U9GZ,0P. DUPB(9SWR$7!1%"(TLTU#,M\C/MO> YI44W>SH4+P:#
M6>,(EJNF))A)U2S.G2!LJ@TSA*PB8(ME83"&H&=D] 8C'R;/!XQVD*W3:H><
MQ^R>DY&?DYN.V5FNG-;:;&JEB(-PD[$,[]D6O;'L'7+#NRUV,&H2(SAD7I<<
M#),0CE65GGI1]B%J6+&*5/E[J,%+Z1^FAA-I.][\[,D=^\G]>(+39RIR)IM5
MIC2+?LWU9J%_V "JEVT[F=H5].@: =ND'B)L+3D=8BB!:(3Y<<_\V+]X/@;F
M7C([S;:7P'HZ#V>30RI)\9C1/5%C/U'OIY,FZ1TK])1Z>'$FIM-RFW_#V.%P
M6PR'6332>..#?70_2]^L5C1736(\Y^W.A>X2*<B[13:O&FAG+4"3/#M-CU6W
MU#ZHS.9W)SZ;IW6]&+*Y0VJ*$![9WL,]E^.W=\D+FHMF4<'^;RPV84]A%L)P
MR"\N091&:1:. .JI'?NI??%N &?@@3ZRJC(I:!I(/7]XX41E4W@:IU%DQ<@A
MA]#A_L$QII[LL9_L/X*)FHKF16-3>YR$(;0FE"T7X1B-];VX[P%PXF6H9;W=
MEM34+%*"@LF\Y-)L$VNK\SUYN<^FO,W%AP^G3J3MV U]CX']/49#U,VNRHJ+
M_?ZZ$[;=+$"<030,F$,LA&/-,NX["NSO*#SQJGC5G0Z\<_V)3]IDG$K;\?EB
MWV2$_B9C0;;,^*393BJ8.>LPFZYY61=MUT@&.U#MT=5@$\IY/AE8!X_FV'%X
M.FE+I?:)S^S@>'Y#Q6/SU8($C67M\?;^Z?[+B*OF>X#!\\_P?-%^W]"K:3^W
M^$:$+J02E'2E50:?$IV#HOV"H;U1?-M\!/# E>*;YG)-B>Y8C(#^?<6Y>KTQ
M+]A_1S+_&U!+ P04    " #(0J16/?MI$,,%  "Q#   &    'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;)57[V_;-A#]5PX>,&R :SM.T@U=$L#IVBU%\P-Q
MTPX8]H&63A(1BE1)*H[[U^\=)2M.EP;K%T<2R<=W]^X>F:.U\[>A8HYT7QL;
MCD=5C,VKZ31D%=<J3%S#%B.%\[6*>/7E-#2>59X6U68ZG\U>3FNE[>CD*'V[
M\B='KHU&6[[R%-JZ5GYSRL:MCT=[H^V':UU643Y,3XX:5?*2XTUSY?$V'5!R
M7;,-VEGR7!R/%GNO3@]D?IKP4?,Z[#R31+)R[E9>SO+CT4P(L>$L"H+"GSM^
MS<8($&A\[C%'PY:R</=YB_XVQ8Y85BKP:V<^Z3Q6QZ-?1Y1SH5H3K]WZ3^[C
M.12\S)F0?FG=SYV-*&M#='6_& QJ;;N_ZK[/P_]9,.\7S!/O;J/$\G<5U<F1
M=VOR,AMH\I!"3:M!3EL191D]1C76Q9.+Q8>;ZS=T^99.;Y9G%V^6RZ-I!*Z,
M3K,>X[3#F'\#8Y_.G8U5H#<VY_SQ^BGX#*3F6U*G\V<!SY6?T/[>F.:S^?XS
M>/M#D/L);_\;>)>^5%9_45('8WKM;'!&YZHK"YO3E>? -G8?7$%OM54VT\K0
M$A\9-1@#_;U8A>A11?\\E:&.P,'3!*2S7H5&97P\:F0O?\>CDQ]_V'LY^^V9
M\ Z&\ Z>0_^?&GXO!BV,W1A5TU6E4/X9MU%GRH0QG=EL0C_AT4E;LO><4W2D
MPG;)F-8\)M=Z<I[:\#-EKD82,\R#F_B4YT#(];O6,NT=B-"SN0 H6FG7/-I0
M%C?*;B@PWVI;RE8YW\%.FB1>PO:BEO["9!U&*%;8I4D (35M+KMYO7*VS0SK
M#&Z@<](VLD< 0FTL7*\O%GI"GYB4YP2L8^R" R*I_ YED<I!JD3B&[BA,B*7
M&_F^:K7)A:BB&MZ@7S3>Y6T6QU0:MU)FO$/YF7#7.E: R)F[. /, ":K5@;4
M(%^:W.B&14K95\@_CAR>344;6P13HJ8$#T"*O%L!3"*6OD!YH"25SRIB6PJ8
MK-O=3END]:%=2KA_I,9%)$)BD.D-AB4O&N2S.*&E1J9(?IJNZ]9,E;H3;+A:
MIT>N0P:Y/'(UWDJ:\O:5JO+MO\&M-L2@N#(Z5-M5<@H)ZR[[$,7A050V<@JT
MDC O%1@WH!]TBDC;)&[:H-!L\O%CW%Y:J1ECM!1 Z+0Q. -EPE?Z"0^C"Z:0
M:4ZS.T4UHW5*MJG^L<PC8-MB.%;>M27P=":'G5!'ACO7&2<XJ2(<0&PVWY^F
MKN;,!E%I&4"\.>-(SP$//$B7@I%B?HBT43Z":$B]D&3#ODY:(;1P095TQVK\
M;#N!"Y0!;!*]@N)"%85 C5'6)G6W%3;H+-&-H9=M"]1+Z[<!819P=QJDQT4B
MLL^M[FJET&:8?X_4)AF>EMG+J1R$0.9;G1*/37'=2%TL")&SJFLF!%847<:]
MTDF)3#4Z*C.!Y_74<"3MI6HVJK6X(N4I^L$KZ9#NYX>#'V!FI=%87=4GSY/I
M*3%B+%[9O@S%0/'3O$ ?>;$%X368 8I=BA2R2;[!X1#2B&Y?;YRH*5UW+FEP
MX_'=+MW]#>^(#7X@0>(HNE-&\H!.9+@DU9SK3+3;[6FX,@I4,@4&N&.9?"C9
MITTB!6UXN[_DD>][(Q"[&$Y72)1HH4LFM @2VGGRH>W9OV,;PAS7QEN6*NP=
M%;K"84R;]'<PKKYN'V9T:B8;;HQH%OD%*)="]PYMKDO5L\*"TJLZ]"[?'31K
MY?.PXW2[[986I@;)6AR!J9OZ]N[3A)L<;XD\M'OA78WT=H?'P\FU&]3EQ=7B
MPX?KRS$MSC_>X&DQIC_./KY?+*[/4D"7?[V_.<=PX^$+7F/GWL5NK);\I&M+
M2$?:S60Y&=.;5AHBK7VG4%&3IZX=TYUK)(B5Z;(L]M7:V-THAZ_#?7S174,?
MIG>7><B(DR3 (PLLG4U^.1QUK;A]0:6G2^G*15QQTV,%/V4O$S!>."2]?Y$-
MAO]23OX%4$L#!!0    ( ,A"I%:RD=%)HP8  )(0   8    >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&ULM5A-<]LV$/TK&'6F)T6R93O-I+9GY(^TGB:V8B7-
MH=,#1((B8A!@ 5"R_GW?+DA:=FRWGC871R2 W;=O=]\2.5P[?Q-*I:*XK8P-
M1X,RQOKM>!RR4E4RC%RM+%8*YRL9\>B7XU![)7,^5)GQ9&?G];B2V@Z.#_G=
MS!\?NB8:;=7,B]!4E?2;$V7<^FBP.^A>7.ME&>G%^/BPEDLU5_%S/?-X&O=6
M<ETI&[2SPJOB:##=?7NR3_MYP^]:K</6;T&1+)R[H8>+_&BP0X"445DD"Q+_
MK-2I,H8, <9?K<U![Y(.;O_NK+_CV!'+0@9UZLP7G<?R:/!F(')5R,;$:[?^
M5;7Q')"]S)G ?\4Z[3W8'XBL"=%5[6$@J+1-_\K;EH>M V]VGC@P:0],&'=R
MQ"C/9)3'A]ZMA:?=L$8_.%0^#7#:4E+FT6-5XUP\/IG.+^;BZIV879_/SR\_
M33]=7%V*Z>497EQ<GE[,WI_S\NG5Y?SJ_<49KQ^.(UR3@7'6NCE);B9/N-D3
M'YR-91#G-E?Y_?-C0.YQ3SK<)Y-G#7Z0?B3V=H=BLC/9>\;>7L_#'MO;>\+>
M-,M<8Z.V2S%S1F=:!?''=!&B1]W\^5C R=[^X_:HE]Z&6F;J:(!F"<JOU.#X
MQQ]V7^_\_ S:_1[M_G/6_[^L?0<WXE.IT&R9JVII-T1HYI!T&U1.OP+8S67$
M0Z&MM)F61H2(%^CT&(0KQ-38C9&5D%Z)QLHFU[1;VER4<J7$0BDKP&F-]5QH
MR[Y\#E,*O1-+?FY367L-#[5!,I?**B^-V="ZJF,Z&X'ULV4'<P*1 %3*ZTP.
MA?/BE^ET-A2RKE$3<F&4B [G(C94HL9?EP>"-NR,N5I;4AN8J:2%K%%8M)J9
M)@<OQ@A+:F(X(*^RQGM"*O.O:/;$02QEY.BMRE0(T$KRRB2)0FJ/&,@5R@K2
MPXBAT5Z2R@4!G6Y7:^<IKA;E2%PU_D6I8+:E">X!Y:2EI(0Z0,K1(1)<,[%D
M4H>(PYR((8<82M>8'"8$S0RB"=N^-C:)<MKG@*S+\S_CZB+<*.F%(CT19R"J
M6BC?*<)D*-:ESDJQ5J"Q)9^=DZNIM0U,7C-#% [IN]C=>?5;HGXMX40;'.!Z
M(E]S2I2.I H4U/EM5DJ[5.+4594./*'(CEKXAM(UV4O"-.)F(*"O /0I]A?2
M</6F*8QWDB'D2-R*2/"NND?1HZPL&AQUP&==O%=NN0Z9<:%!N2 %?S6:<KC8
M<&4G?-N%!#</B@E-_*#B4VW"35>?VM"6'!U"(Y;L/*S/Q\TZ;/,/C6.-UT71
M 'T!] B4*!S]-V7!M*=/@;9+>RS;@H,4$=)UZ5#.K]S:PA:5N,XU@E3HH2D@
M,=X61"<VJ2PP+&R063)\)U;*:$QN0I::,.BEU0780J-LBU4W=XC>7(7,ZT4J
MVDN'SI]TO-)3($4XW8[Y71_S_"[F%U3^O^FJD?@<.+WG(>J*Y9)2DI2!^:3%
M1]E/?4\?D3INOI-.=^4=MJ27>*KDC1*JATR9D@%?H75*5)+;HNB*HU=.6:74
MPA7VJS;)1LN%-G=:0$?N>HPV(U"*BKP_=2YYHLQU67U)*7=N'T/JU4K9IL6F
M;FNR"2UI>,K<'6+6N>%&XB(5QPL00%XQF\-SK'IE^#CX)^/: E9TT,:5-$VJ
ME30!T[;V&PF6.YXVVR8(>)"&V2J:2$1[MY&&V!RB65:X7=2<;U;-I$.])9Z_
MKL+PEK>TO^6(QJ]#*Q*8(2.0'C.#8&U;[$ALYUETV<TKN@@03Q4M<30C\47Q
M_8##O>,%<988BHXJU; M* FI/:N-!1U(0A-:+?RF+M>D(48##M&0IFAPECY%
MH$99I';NA#;C29MKE+)/4R.6;CM)(W'*8XO;<2MUQ&92Q]1M?5UUEML.;!4:
M3VFZXMT&F)C:&PN]'(GW&BV84_9.F"+7UA8^<XC+5GBI^##SAO?"HW!YKPSX
M)J"_@OH9]=(7/>Z--RKR=UC8FLA<^!\X>=V58 BZEHHY[8<XFX1'2D+&RI#$
MACZKB*W:N[S! A5:\M>@(_R] *!,FH8UM8#&,$!&0E,4)-Q);!3G!LU!#S)?
M\61G[6VGS$P<B-O)@:"K153+39IV41@D-LF"5;=1[$Y$E:Y,;285?9,0<RP8
M^/CZB$\-3"(HY;=Z_G'TV"UCO'5/A'8N^3;,=6-CNC+V;_L+]S3=,^^VI]LZ
MV%YJ%*E1!8[NC'XZ& B?;L#I(;J:;YT+%W&'Y9\E/@"5IPU8+QS&6/M #OK_
MACC^&U!+ P04    " #(0J16[2[YF* #  #F!P  &    'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;(U5VV[C-A#]E8&V6+0 $8G4/;$-.([;!MA<X-C9 D4?
M9)FVA)5$+TG%V[_OD+*UCN$8?9%XF3GGS' X'.R$_*8*SC7\J*M&#9U"Z^VU
MZZJ\X'6FKL26-[BS%K+.-$[EQE5;R;.5=:HKEWE>Y-99V3BC@5U[EJ.!:'55
M-OQ9@FKK.I/_WO)*[(8.=0X+LW)3:+/@C@;;;,-?N%YLGR7.W!YE5=:\4:5H
M0/+UT!G3Z]O V%N#UY+OU-$83"1+(;Z9R?UJZ'A&$*]XK@U"AK\W/N%598!0
MQO<]IM-3&L?C\0']=QL[QK+,%)^(ZFNYTL7021Q8\7765GHF=G_R?3RAP<M%
MI>P7=IUM$#N0MTJ+>N^,"NJRZ?[9CWT>CAP2[P,'MG=@5G='9%7>93H;#:38
M@336B&8&-E3KC>+*QAS*BY:X6Z*?'CU.Y_ \>[I;3.8PF[Y.'Q?3EX&K$=GL
MN_D>Y;9#81^@^/ @&ETHF#8KOGKO[Z*B7A8[R+IE%P$?,GD%/B7 /.9?P//[
M,'V+YW^ -^-OO&DYK*6H88):)98#IEH7,+%)YA+^'B^57?_G7 (Z_. \OKDZ
MUVJ;Y7SHX-U07+YQ9_3Y$XV\FPOJ@UY]< G]?Q_2193S&L]!PR,V@ZT4JQ9S
M)+O,*<@%WD2E0:Q!%YA)4>&%+IO--<P+R?F["H!?[QNT$JW*FI7ZS9ZB^3!X
M>GP>S^>S)U@TI4;#%YUI!/\%6$H2&N,@8L3W8IBV$CL/A"F)X@1"G]"$PHQW
M KX*6:V ,I*F"3!*0D9A+G16 ?48"5(?J!\3STMA_/"Z0+[Q"5^<$H_Z\/E3
MPBB[.9!%)(Z2?O&$+"1I$O>;!S;ZSN6/^]<OX_'L_H3-]PA+*3 ?8PD/9#0@
M04P!XTN2$RX,-@B DI0&>Z(@)JD7@1\2%L?P]->7Q<-I"C&B,(:0!)3U%#ZF
M,H6$T/"4 G6G(7X]&NTI6$!H1(VL,#FL-><* <\JCHC/$AS1)"))S+ $CBH"
M=+:L.-@B:[2RY;+,JJS)N1$@6HE@.2_?C)G"<969.+2P6^<XKT\+:JP,$G:)
MO+!MHIO?(6J]Q*MLEF9'%&635ZVIR[*Q9\6\FW&>B]:H^RF%&&Z[36],;*E'
M4I^:>#V?)'@BYZZR>]1[L8ML[ MC;@N"=VVX7^T?L7'7NW^:=R\@AK,I&P45
M7Z.K=Q6'#LCN5>DF6FQM)U\*C2W+#@M\B+DT!KB_%D(?)H:@?]I'_P%02P,$
M%     @ R$*D5G:=0@,*&P  H%P  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&ULY5Q9<]M&MOXK71K?*;L*HKB(6IS$58KLS$U-8KLLS^3AUGT @2;9
M8Q#-H '1G%]_S](;%I*RG<G+?;%%$NCEK-]9NK_?Z>J364M9B\^;HC0_G*WK
M>OORXL)D:[E)S4AO90F_+'6U26OX6*TNS+:2:4XO;8J+Z7A\=;%)57GVZGOZ
M[GWUZGO=U(4JY?M*F&:S2:O]C[+0NQ_.)F?NBP]JM:[QBXM7WV_3E7R0]3^V
M[ROX=.%'R=5&ED;I4E1R^</9W>3ECY?X/#WP3R5W)OI;X$X66G_"#S_G/YR-
M<4&RD%F-(Z3PWZ.\ET6! \$R?K=CGODI\<7X;S?Z3[1WV,LB-?)>%[^IO%[_
M<'9S)G*Y3)NB_J!W_RWM?N8X7J8+0_^*G7UV?":RQM1Z8U^&%6Q4R?^GGRT=
MGO+"U+XPI77S1+3*UVF=OOJ^TCM1X=,P&OY!6Z6W87&J1*8\U!7\JN"]^M7;
M-Q_%AS?_?//V'V\>Q$\?WOTJ[M_]\LO=C^\^W'W\^=W;A^\O:I@%G[W([(@_
M\HC3 R/.Q*^ZK-=&O"ESF;??OX#5^25.W1)_G!X=\->T&HG9)!'3\71V9+R9
MW_*,QIL=&.]=M4I+]>\4I2(1][HTNE!YRD)2YN)])8TL:_Y"+\5/JDS+3*6%
M>( O)4AD;<3_W"U,78%,_>\0A7@!E\,+0#U[:;9I)G\XV^)<U:,\>_77OTRN
MQM\=V=ZEW][EL=&_BJ/?-J)X"\:CDH^R;*01RTIO!(AED2YT140T\!&TV-1(
MS7HMQ1)^U3M5KEZ*C^M*RI;$".!WMB:&/_^YA.=U8X MY@7Q'_^9B@]R)4M9
M 7_>KU/0S4PVM<K2PHAG8G*;W-Z.\8]I<CF9BK?Z,:UJ9<3=W\3D,KF=S<1D
MEDQF5^(=K*42DV0^NQ6SVVOQ4=? Y&=B=I5<7DWAC^D\N;V<PQJC)8LZ7112
M;%E(#.UGD18@(1*WIYL*2)%)]8B/&1(HV#V)BBA4NE"%JA7\4,D"A"D7M:9W
M6@03Z0JH0H+VLDN$.X/3!!H14?C+US#O9@%;LM\CG<)*5)D5#=)7E>*O?[F9
M3L??W669;G 38<6)*&5-/T^^0PI,D_DUDF(V36:74]26_E8&1GXME[*JX"LK
M%O&(5\GUS2W^-9LG\^F-^$WB_'H%.AE>P/T\F\Q'EV#TBL*IYK/;T=Q_H4HB
M?DT2M&$)DAT)(NK@FTB.! 8W6TE^H-@G\&9:BUW:W@ .V6/8WK,8WB".RY4J
M2Q0'*]);62F=CP0P2U<Y\ #XFLM:5F"SI=]4M$\[%;_GE*9/W$3L0/A4!<J3
M@@1F(#-^-)@"AU!EKAY5WH#L'EDX.&13 R5PS<<W(4 D5$%?N)GDYTS*W##%
M[(BPUZ5(\URAQ/+<1L'.68*5$RK8JB8!-H&N2'&  0LC?V] R.V\O-?4 #Z0
MN-DC5*OD5H-.P\H=_9A"VVV! FD)$_8W0!=@N]YN856D@JF@ 5',8(P]Z3D/
M4@*P:&\-D%"+Y</F00-+2,V-)&E$(<QA0X7>HF(#20%7&=:>AE1EL1?U?@L:
MB!/LU@I>VD6;1\5T)+&RFU92Y J>J O84%U7:M'P_">L2H*3M7_<@I$$DWK"
M(@<3W#%+]^ TT *+CQ5Z2MSMKVG9+('H385T>?,9E 'EY '\G<I@XVQ^O_K%
M8S[@)IE/KM %)--+= 6WR>QJ1I\O9]?P_]5TRM^.;^QH,_ 4D^D5V/ZQF,RO
M!-@Z\,?>)=PD-V"I<(#9U16]>CWE >>W^/_5U25]>WEU0_+P!6QWXA2XT[-'
MS%/@U:.,76FF3=T9Z+EZ(3)'43=78@=$:FY:M,5!W-,@LGF3U>!U%0PB'=6-
MHWH8 Y< H!?_]+_B/D&:0*NM#N(7[M>$/L&X,+ F<@\M#1:PE,:P-0FOPFJ=
MH\%1@ ;5&J(/9PX17_#X*5 ]-? V$DN:6FW06!*=-CA;0'C.]S(!P1* 32AB
M7PP64%:H$62!3^OC(.H9B9\L:[_$1>U0I7-1ZIHY*W 7I!H0R@"O5HD@N;>Z
MDN;@8!1"4?1J0;R>""_(83DCGK3VQP1%D<!7[#BGY1K]]GQTW7;;L]&M_V+Y
M%41I^VU+:X/D5YM%4QG:C,C!5S0E.M],5C4$I Z0'=H]Q%KU^K A28 XV2@!
MAQZ> 5%CT&05CN>S0 JE^ &=;%J!L[S7N5JJS,89\.S=PWT"%F6K,G$SOL'0
MPR\+6'=756FY<O:9'\?G1A"0D&:*.R @>EYS:LG(U+MM!4Y\.@8XC&R5*-%D
M4<C;K0H-;CP1)#C@)K,.C3J$03"C3(:ZESBV6VB[V<@*@R/4B ]O[Q3RMDJW
MM"!#)$K%HM*@L+0]9 D,!8H*VP G!+)7H=*CYPPO@L6K5A(8!&*%/P=3*/>2
M)Y;HT0M0PNH1G) P>P.A&='M_NT#FA4OUNS?.1$@RH80,@*>0U,4BK89:?R2
M\5S*:#^0Y3ZF&0.! S\B'EHA^4IV]"G(.BP8F.R$,>%Y*HM'NE/U'^?U+626
M ER2RR7KAZ!G]V)*2C2Y)5D @UW:+ @Q]N303./P2$MZT,< 3U5IG<%YICO2
M@[!7<$Z)9,9REV"8 G/9-AUHH>4&A$*!A"2DL/=S838( 15.O.010+J(OT;1
M7^3U2D0^BM0 \.6T-2[*'@R$UK^@C9UO9*[(*CH)3)#0*1HAS=*W=YXJWF(!
MC@AL6[PM((-\3(L&/4P*FSJ'B?#_A<[WY[1 G!<&L 'P$]82>4([="";'PF)
MY=F"0=7D^CL#V/7?L@!WMQ#//[SYV]O9[>3FQ2"!9C&!$JM(CO0LP+3*/DO)
MOULZQ 84Q (T2&9-S0ITUZP:,,PL>O\@XTC&'DAG7)AQ0$=8[F \S.,1&3X#
M00P9_2,&Z8#5<88"K$$@,9DCC!S!,*1%\&8VBH#U ?RO]&>"#C#K$C5J#\^8
M(_;@9SO:!S?:1]CL*%KL&H4,6+=UU@C!%2SMX,OB^: MB)] 5,R9T?>T=F9F
MK<&D(;[R:CXX?M(?\ 5[LRU-6,9Q74P#-N>>;*00TJ]D*3ELGXW'H['S]\?-
M(K@LS3;"#-GH+FL1(ZZJ%$0)8BNU*IE ;,D)%ATVYT&[T,# ,X\*_ ;&364)
MOCLC.'C<!4) !RJ^W!^0.%+5-3P+ZZ1)G=P!F -"9GJM08/ Y<JTUFNYA6EJ
M!0B,\A\$5]A/LF\6%>:3*99%0VB1#*/GIK31FLQYIG.. G$/#LZC., NSP.^
M5UN)F3U/PR]T6/_28(QQ]6R-T?.K&CYQ**H,&;=*(>51C\!I_(XIB<!,"-I]
M9O7106:9HOK!;O:QQA187F@9\R[8"*$X4L>+!8L"&8^]#'K_W#2+?Z%H 37!
M4"JD%.8T2",-V$ID+!8L5J(ADCL N=4U_@3[ '&&F$*7;%4JO4^+>@\KW[,A
MW (*;< #N+2!-WAIWVPF-@D*R@,/L%U!&[&0TJ+3'#01MH<9 4PT<"!"DM+V
MRV@M81T8J=&FD6Z@2FNU11R IH_M-@JCIQ&IF\TW'+7&SH;@J,PC*Z@XE972
MPSPBT([!*B=<.!HR#>QU>%V)6(!T][''.GV4M QK/T'8:$$9)K-R=,"AQH.V
M%1&#@[F#GNP;V8"> .@'7])Z4>K3$J/3'1@\@ ?($Q)]M"U%88-,O4RL2NJE
MJEGX$_K]M)13Y8HCX,9[5$LVRL)1GDJ7YQ&CB"0DRAA)/ITHS'4;;S%R7@&;
M6)B @2V>#2!%(D)KNI[X]Z8@H;!#LAMK"QV-N6 AL/GE7WA0GU?V.;FFPIR>
MAQJ]R3V]HO'9JPUM\# 9&9>=DJ[R/T2@6,^7L3CP\! 9E<:"%-(<\AJ\64=?
ME'OXLB,V?RRI?^OL(UJH$=YEP0\G8?K.^TA*Y>JB'36T$'P/X@;B@Y?"S5K_
MY4&U37W%;T+4W;'HAX!Q8'B8!Q8#H3_:#TIUOP6+2UZ0,J>P<K0 N<R4\8 0
M-1Z(AS^0XZ>$R[8^UTVHFC45\?&TP3A(FQ%6B@C -45GP:+0$)Y7;,",2XVA
MQ?(N<-G4326]":.H8-\B?9!"8'S#'LL%?;@CP-EL;Q'*+ JULN%1,&M!"7!N
M&Q 872 :]PZED-[SGR8&[634U4"0<4!#*V63Y;96(<#(HFO,=0,_ *I:J=KZ
M>K2^2"@ FB8MT!N'Z 9$8\#)XQ(C-L L,&F#^ B<#*H;PX,!04S:(OOMVW?$
MI*V[O19Z=VBC'4_NL0\I.P<)SV;3>4#Y3AB"L SIER7<L3"S[9R'">M,6#=Q
MP5"!W#?/;G-T:<C.>:-%8U22S SE # %5;0=Q9<G3L)O&S#0"(*;+7AZ+'$Q
M4*3XZ+(='_TF+8Z#4&A()H>"LF?3> RT,0&?>DQ*X 7PM0(A"9D6!K99I2BM
M+'*N!$! !R+F@X5N'B6.ID/\T,.CVX(%/<T?J>@X:.QY/[.QS\#90(UK>"'<
MC*S"H2#%+OY(%(Z@DV,,!UDZAL!6ZM!2$XN?3=LEYF7C:Z;.NG'ZP*=%NIR)
MWN]C51M#^K2P%ZO(S*+(MM(0$%&WF0TQ*\96+@6R]ZM$\IH3B4HLDV1KT &,
M1/,]_ >S=/,55&5UCHC+V+C\XPK )D^7@!>51/Z3!$*X( %:Y.G>V(P5^4>L
M('^TD5*4W3HQ0ZYAX8C%4LIX^EB+8\[] )BB)1U#O(33@*B<0^U41*2*L-,F
MW7\9+=)0O5D0U2&6H!RFPJ8C(%.VI\B@ ]+0MX V&])*A3K@)LU;@29Z80HT
MDU.+L88?N_3"5GLX,U84VP7P/'W1AI\+";85#6AK4?9'K$ N7L31TBFH>Y([
MQ[!P-X/1V[8MI!KQF%:8[FGE(*APN$NQ[,)Q'>I2F5+Y!31KV]181@1K&!<.
M@6T-?=S(; UQG]E0#3.7FS*J43(KT;(8[G^B1KZTXEB#X'F:,?0AD0<G#X0$
M<,4&:UB00\,$F(0X(Y_$^-LZ>5LCA"<7LH<<"+WM8FS0+TNK8>_W)/#)P5&K
MNX 1@'7^[:5N4:MTM <="GB=Z2Y(7+HS#KB^&NOVE,YAL#*9QQ9TZ9S"X"([
M%B!J[?!.*L)&B&G<GJG_)*/Z\^#(UJ,=3 EYNE#WS.^-LAG@3?I)>I)8B-K-
M0"547\-E4EZM"^Z,I<1T_%])C]K8UFK;='!-L*@5%S;(RWC(>Y2UB8AR;$'>
M?079!-$^KO!'Q'PXF/ZRE,N7I%O0*<8%9IN$Y0E] X:+)^+*N>D6ST\5SJ/6
MLQP_4]>@;4R%#R9TGN(BMM)U5MHM@%5;8Q:>8+WALCZ52Q_9PV&SD,L,V5C3
ML!FP,2;Y^N10YF4H]/CSC4<<)L::=C2,B*72EQ^1@Z[_A;91KRO=K-;8STUA
MPQ:3W89;W)Y"M_^$D7A"?!2QZL\Q&7$FZ8^P&CZ6J]4F:D3T^1#[N4/M$Y;&
M=P,Y_4.1=4.0\U5Q9N!U:*7$.A"1K$9<)K:MYHJ>^.(;:U@1_ .+J.B99:H*
M3))@6X6)O'!JC,XXJT7JD%?-JIVI N.&^!*QK8O\*+WBG1MLHE=V(,8%>S@4
M,?6CU,.1M370-M$S_( 5SY-V7,46:!?SM*G:#!V)=P?S00?+4XSL7MIN!&]>
M_9H9K?&7H9D,%^L:B88;+NPKH=G0+^L[UQ>PTU61[S!H])T!.L[T<!04TA^<
M'5.N#Z[=@D=]<M@TMT]ZOL&N.R;-Z2T 9VW*MK7VT('7DKK^8H[6'SHYK9#[
MH]T-K^9>G]_K:"VC=H>DHZ'BN Z&!B,-RDVB7<=/^F;#;061<:5(K7PZL]4:
M 4Z+T%_INF$7\#V@ #17#OUJ6R9GFX;0OJDR:IVS780P_".H,[?%V_U$J^7,
M 9$MRS!:P^@$PA1NAF*WB </X&4*AK*FH"0+-IS7MD&/7N)R,L03I2[T:N\+
MJA3FNA4X?8*-?Y+UMD@Q?GX JTF#LE)_M6 >)OXW"FL:]ZIE6&JOAUCAI\/&
M%]FM*""7R%B@6=P2HWD10  )I*4D28)2H:GDT6^0\;GV7C+^3TR^,X\.%"U.
M!,%I;!--!@ 0Y[$=@DCE/C3&SARJ4/+!-RN#:IN6(>76W4V'VT'O.7],O3Z^
M9QX;,"B35:(=-Y^,-;H[ZG[DPQ7X2BZWV-Y9$L=C4-2PVCA<%&9SWX2.R-$Q
MICZ5A]%X((N<B1<8Q:^\=E6:@5I48H<]*6X3U :]XLF=1R@UWD"K\H)=ONYT
M2,ZTZJXPE&1\TL(0*HR;1ELS?.R-L&N_"ZXXU]4Y8R8:F',;5$BTG:P@4E?C
M*RM2P_4:JN38M.F3)>@ 52@#&/(AJ,29]$==\JCXQFXD6D53*BZA<'I_* ZC
M_C" EIC>9?L%C-Z"1&PDF)0\0%CJ)O;A"]/ET<-"RB;XEG+7-^X*H2ZEBV$#
MTXL/W(25+O:>VRY$ /JY$R>P!;F$UZ(%D%N#P;#+->6F6;L&?G#'G=XV:X?A
MESV'PD_U"=IMS\$EM.L0O4H%=Y?[O#9FT&S0$A^&B?K,G9].3B$,-MZQ<$2C
MG$)A'GD/XARJ20!<9P_,H<26*P_L6BSC6Z>S2"@W)$/4IA2'_);)1K;2 K_U
MU1<!\6D:441TSF+7+K=%-;8.-;[)J^?H07);?,1E@6S0HBT9 ;)I,&J^[X5Z
M+K$7W[ODGC#USPQ0_F6@<F7CB&AK5!!@:_]'E*6(P0=+4\>*:JVBKEUG)V!W
M:)=7!M,D[1X16[Y*A*+2PW=BK7>2>@VMP&SX<"51IT76 W)R.NJQCAZS3R5F
MQP8V1OEQ-[7"%-BRIG0"19Q1(<I$AJO="M5//6,1NI66<QV_[,^04UB5"@)J
M$>P*<^LL?GY+X E!56B9K3'=LQ[UZ:;(@_^B]E &>RV1;+DMYGMP'FB=;5VP
M;Q-=P:/K1]IYC9"MB<K(JP:(2,=!C4W]4!5 ^ -Q+[$MU[N"=U%HR^=#"@SH
M'_A CWA/R_D8+9"_N?,;.6H0GXG);)Q<C^G,\\TLF<!?@\91W%XG5_#C[329
M\S/=T$S,KB[ID>GE53*F$>?3"7TS[*@1F/:<=1S)MXCI_6IPI2:0PYYOXI$)
M!!)[PF@)^W/NU /*IBM7]C?VZ&?>@F;_:O*5;43R0,5YA9,+\/;%RF/_5-[7
M>ZDH@&W1!\S7PIY//=_1?1)46V/Y]Z&1]VC.;*5F+98H@[TL$Q'0*53D5NA[
MBE67H:F:[+HE$YWM0Q5UA&([;XGL"!O"B($B+OJ5#'-/_DPWEBG33VPL.!T;
M&;^.LG&82^EP%9)ZL 7YB*RE?MW]N=\" @Q=V3JH)U#_L ^57G-;?3?A2?:/
M5%O%KBVR*3'QDBY_. BE "9Q"4P\$BAS:=&%/23E,YW!]'9[A2.NQ>DKHBQ6
M^-$H552C_Q8YCH]J8AWM("Z+Y9PU<-E5:SXWX[F5'!)H+FJZ ?P*++790C(6
MP16MM,[=CV%U%JNXG8;H,%#-)G(_/HT@]OTA\X?F+! 88+L=+J#VI^LB^<!6
M'Q<WF3NP3.[ZZW2N&TS$(LUQMPV%K$ GAQ22A(/FC(8X)NN'!-.==#UF$Y/#
M!C&)[66/*X,G+MGA<]I<IL8V)MJ8"H\[Q*'8?SH,C-4D"@=;&H,;$;\W:06\
M8SU1? [_3PD-L3R$*T$Y="+EMG4\_.XXX1$>SW^JY_6W7%3:I7HB8<>L@E=K
MAH6<C7$W.!@9J?U >-^^0P,^,32 []Q(3*ZLV326E; MA'Q;>^SFW)_B.T )
M;V[PP):#)+WK)RA6'KB8)8GD9A@\Q6$D&;YG\_GMZ"IT!W[H7X+AX@1D90S1
MVWJ2FDXZT2K]X(45QB=T4G<_E]OX4\3C&R!T[ZBNN_7#QMO[N,EO:\^ZM:'V
M,>3L+Z)Q=#R$R[OWZ@Q_;EVQ<P*53R?SY.IF3#?=6# ]O4JFQ]#Y+?S(P/N:
M_AVRA@Z:3VXG!/4GMS,"Z #5Y[?)G"><CNDWOF[G!OYRV_\0Q.@UT_4000;N
M 1GXZE1DX@*3ZR,;G])ODV1V:,<4KDSI=QARGESR'V/:V="%2$FW)NVS.T^0
M:(Y4-O:<TW&/-KPA2D<,;,1?.-30;12&G 1^?C:]O@Q7';FSIJH'4",CX#H6
MZJ@!\D3JH(T"JPB!C43WPJ9^2N[@,<&L "C&#@\FL0V3]O Q FX\8N(^'N]R
M<7<5T1GK3NQH+2TSAY=XC#ZCUKU?T_%DUEDXQ4=H"7^5@'P4)J?NZ2C7'B'9
M3W)1-6@$\4W?>#3X.!7%?WU]_R[I7K(0@_E#E9TX%O GC*.T"0Y,ARG=6>AD
M.!]HW6J<;I6] M70#0WAQ"3BCDK7DIMW'C'O93"?M,!T*N"FBT_R,_)OOY7B
MEG;]_O[A[[=)N-$#^^E=1F^]1Y"RUICZDUA6V:@T:HY<-[#0Z(!/.)Z+?[D#
MZ;]%IZW;_HXCD W?&Q+K D58F->D]B\6>B*BT].[5H<_6(MQ$LL*;<Q]3NRQ
M)#K<CJF\[/=&V>X1-#K,G-Q>6I7SK55\;I>V.MC2<&@U=R'9GN-9IP(SP:NT
MRIWWLZV^43H5+%/I3BD>R:I2#X;I9O2C<5P.MQ^@'!S;!CQVZ%.[XZNJI,DJ
MM6#@]A8D35PZJX6?"/7=Q_9@\.;%.#Q%!'G'_48?").AM<#;.L$YG/_="R8>
M)[!7S/3NR",A6:K"I4SP^0<)]BH4/M]\MF#R'L\\TPU%-(^W$3/V.I'-Z1,
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M"R+PD;FMN:A1H"6O>#%"3FGCXF,DF4$K9.L(1R)EZBBS)L<3Y<AW4XU1"#0
M@< KO^F'_@,S"50Q28EQ'NWO>8 +H461(/]X\PCY">/LO,%.A"!@59$!B\B-
M]>J/!P%K;3^.;9/-6864D!W[(5@QH>J6"P'PKW)N\"SIC4=48*R*G-4:VK+'
M^9VE8.[JB&F5/2FD+G*#,$(>U,LV@Y%[P$)OD/<RJ;:]%=N3"_FVD)QF5F[Y
M'=''\Z[Q>[,WYSJWA N%&#J(O"]#NGVS2],P2+!-8< UZU0_!+VE-DAS^@2
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MND2YX9)NK:CL!GH_EW02NXEUL+T'C_\%4$L#!!0    ( ,A"I%8@Y_J0UP4
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M2CR?,A*G+8]&),B06%N-QF>5 _]1K7,:HZ!;X XY/ JL6!=IK)^?67L8NR/
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MFG0T >,S"[/2 VW0?I*[_2]02P,$%     @ R$*D5M*^H4SF"0  TAP  !D
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MGPEKEC*%Q[ JQU#G9$KI,!7C#[=_W-Q\&HN=E?+G; RV#5XLE01"8*:8*/3
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M+5J^0.=S0UG8+%C!9F(>_P-02P,$%     @ R$*D5I[3;"@5#@  "R4  !D
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M-X5;-O:_1I0W-RW%29!24O3>D^R?B<@:QO.T 7MF7Z5J1S@06U?D%^X=J"8
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MH7LP]*GHSZ1A]*;6BG>23<B1N#L*@G?E@Q!MC<JLQE$'^ZR+#^"6ZY 9%VK
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MQ;S5*&(TV]4V=OK.H^*<\^,:8&/.HT0VG8>0CZ;??Q!;BC7OE0%#$7T*(A.
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MA YDM=*B;(U109E7S6_ZJXW#D4'L?F# 6@-F=3=$5N5]JM-A7XH]2',:T<S
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MZ&'1-#?TDD-E%]#\2M(VZCK60?\VG/P-4$L#!!0    ( ,A"I%8WY=">704
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M]_H4^E<"3"%KC>[5 YBZE1C6K.CBV@Y>L(Q52Z8>Q@.XH5ODO&$* Z#A!(*
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M(N C4U?0:C8@#,+6!;Q6K;WE\%KO:4?%M\Q6!<QR;51)Q68TL#R&!XPW/-_
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M#4NVPZ#O^AY26]*OI^=KIW=W>W_V^#BY4TU,.[+O&A@2DY(,ZB0#2S8,3);
MD)A4 NB(\[!SI!$K <EB#B(!;CA1%8<]Q^GX=H1[J "U4SR[>9KF9CQ33DX[
MM.]2F%*3$T4B463)D)6PJ3(84I/+(( %:F'@$$MBA26AYS:_'!5Q3H<;!4M
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M"^<L+0+RUY^3A+\=%&]0W^$Q_A]02P,$%     @ R$*D5LO"I@*F @  !@@
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M89P99C=&R*G!*1AI]SFG$ZEH]LBZ<X5H*\!H.!Z@H8R?6/K'\0".#T_@$)B
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M,'(Q30+$YQM"^,=)\@7%'Q8F_P%02P,$%     @ R$*D5L7V'[K? P  @1$
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M#=W,QYX)YQ))^EW.ML#3ULB67F3J9VC4*XC3#V4B.;X-$"?[H^'@=C@:3K_
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MXK0!OE\P)O<W:8#RT*O_/U!+ P04    " #(0J16/, 2-RT#  #T"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6R]5FUOVS80_BL'M1A:8(W>XK?,
M%F WSFK 70+;V5 4_4!+9YL(17HD92=#?WQ/DJ,ZC:P"+=8O-DGQGA?JCJ?^
M7ND[LT&T<)\*:0;.QMKMA>N:>(,I,V=JBY*>K)1.F:6I7KMFJY$E15 JW,#S
MVF[*N'2B?K%VHZ.^RJS@$F\TF"Q-F7X8H5#[@>,[CPLSOM[8?,&-^ENVQCG:
MV^V-IIE;H20\16FXDJ!Q-7"&_L7(+P**'7]SW)NC,>16EDK=Y9-),G"\7!$*
MC&T.P>AOAV]1B!R)=/Q[ '4JSCSP>/R(?E68)S-+9O"M$O_PQ&X&3M>!!%<L
M$W:F]N_P8*B5X\5*F.(7]H>]G@-Q9JQ*#\&D(.6R_&?WAX,X"@B"$P'!(2 H
M=)=$A<I+9EG4UVH/.M]-:/F@L%I$DS@N\[<RMYJ><HJST70R'$VFD\4'F(VG
MP\7X$A;7L'@WAOEP.H;K*[BZ7=S.QC"[_C"<+B;C.;R!J\QF&F&F'IBP' V\
MND3+N#"OX25P"8N-R@R3B>F[EB3F1&Y\D#,JY00GY(3P7DF[,3"6"29/XUVR
M5OD+'OV-@D; ]TR?0>C_#H$7A' [OX17+U\WX(;5N84%;GCJW#A;<L'M \Q0
M,(L)+!3,F4"X7CT_H(\S)010&NV93C[5'4O)=E[/EI?FA=FR& <.U9Y!O4,G
M^NV%W_;^:/!R7GDY;T*/1KCF4G*YIOP63,98)["$:!<0>:GO(C]H!9[?ZKN[
M&NY6Q=UJY*;W_!WB,K[UA+A+S%X]<;LB;C>;%BR^H_*2"']JE6UA(N,S^ Q_
MT4VH<8<RH_>VTBH%*C'!EDJS_!JIS>E&IA]\>9W*1^>7)F+G?_#2K;QT?SX1
MNS7YT M"[[P^'WH5=Z^1>R(MDB,+>$\=SR E0:S6DO_W[354JN@]4T'5T#E1
M#+[W]3;V&E7<L =J>;;^YO2><;[IMCOA"<ZC#N#_9 D> )X4?^AU>U[[&V[W
MJ!&EJ-=%NS5409FT94^J5JN6/BP;V=?MY?< 7=R4# 8$KBC4.^N0;UVVV')B
MU;9H:TMEJ4D6PPU]EJ#.-]#SE5+V<9(35!\ZT1=02P,$%     @ R$*D5I:0
M!$BM"P  GVT  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULM5UM;]LX
M$OXK@F]QZ *WM4B]]Y( :=IB"VSO>DG3^ZPX3"+4EKR2G&R!^_$G*8Y)FM2(
M#$=?VC@9/9JA.)Q'CZCQR5-5_V@>&&N]OS;KLCE=/+3M]MURV:P>V"9OWE9;
M5G9_N:OJ3=YV'^O[9;.M67X['+19+ZGOQ\M-7I2+LY/A=U_KLY-JUZZ+DGVM
MO6:WV>3US_=L73V=+LCBY1>7Q?U#V_]B>7:RS>_9%6NOMU_K[M/R@');;%C9
M%%7IU>SN='%.WET0&O5'#";?"_;4"#][?2PW5?6C__#Y]G3A]RZQ-5NU/4;>
M_??(+MAZW4-UCORY1UT<3MH?*/[\@OYIB+Z+YB9OV$6U_F]QVSZ<+M*%=\ON
M\MVZO:R>?F?[B 8'5]6Z&?[UGO:V_L);[9JVVNP/[CS8%.7S__E?^Y$0#B#A
MR %T?P U/2#8'Q ,@3Y[-H3U(6_SLY.Z>O+JWKI#ZW\8QF8XNHNF*/OK>-76
MW5^+[KCV[-/YYTOO^_D?UQ^]+Q_/KZXO/W[Y^*]O5]YOWJ>\J+WO^7K'O.K.
M.V\:UC;>%Y8WNYK=>OT5\"[9:E?717GOO<^;HO'>?&!M7JQ_[8Z^OOK@O?GE
M5^\7KRB];P_5KLG+V^9DV78^]V=>KO;^O7_VCX[X]R6OWWH!^8='?1IH#K^
M#__ 5H?#J7SXLANIPW#1PW#1 2\8&ZZBS,M5D:^]?!@074#/"*$>H<_+=\TV
M7['319=X#:L?V>+L[W\CL?]/77A(8%*PP2'8 $(_N\B;!X_]N2L>\S4K]<$^
M(\0#0K]F/)Z%)$U/EH]B$*H1(0$-@X.9Y%YX<"\$W>NFQH]NOMVL69>W-ZW7
M]+.Q: NF=?09*Q)]")(XB>F1KQJ[D'3NCC@;'9R-3)WM1[3].>%NI+A!HS2*
MCYS56*6$4KVK\<'5&'3UD-4ZO\!#;2<W$I@497*(,G'.Y 0S6"0P*=CT$&R*
M.OM2H]FGL1J??=G!U0QT]5O5=M?DSN#J9&JFQB3UD^C(38U=0OPTC/6.$I^7
M3M]P"JV+_*98CP[G'@=I(F&AR5$+A(& %^@#>^S8W[;C<FVW[M9=<>B)V&$(
M?FH'@*A3A61)>%PH='9^1I-DY%+QLDW 0LG7-.]_WG]V5=LQF*]UL6)-3T_.
M!RKI/2=)QV+^Z"/TR*_:2%"K.Q::/"J\OI/ >0TD($>P#A@)30Z8,P9B3!F,
MUD&BL@'=0J@S&U\)"><,!"8-YFLAT3"!D 0D./948Y=E"1EA-X1S!A(CK86H
M# (+38Z:<P@"5NW7K86)<@G\XZL$F<BN<@9 8 H@KH!7Q7U9W!6KO'/[WS?]
ML PI\;G<[OCZ1_7K'W@6Z\N'A":/":<:)'-?_T"Z8ATP$II\\\H9"P6Y@?7Z
MMX>#YBIH(KO)*0:%*8;YND=5PJ"_K=,90O=U5% $3"6!B96/X@H#<U 'RJD#
MA;6!UZQ\>TAP-D$FLJN\Z%.XZ(^M?-=E-;;V!=JU#SZ/]05$0I-'A7,+&KDK
M62 ]L0X8"4T.F#,4"LL:UFM?/#U;(1/934XI*$PI+-:^:2(!FL@.<B)!4Z3U
M#I4J8*')47.J0&%9XE7KG:H\:.]Z=7; 76_ RWT EWMQY?M2E>RGMQF2P+O;
MC8CQ,*#M-<-"D\/G-"(@SDM< #(1ZX"1T.2 .14)8)7#2+"GFDD9TB@YUNPU
M=HD?9.'(I!0>*L#,X9(U;5VL>@EFU?O[9J/,3&WU#51J0*A_O.+IK+J<&W&:
M<XC G$.HF>0J*L$GMYZ$<Q"+@!.+P)U8!*C$ @M-#I@3BP F%D99IS(%?=9I
M[*"LX[0B@&G%J[-.91"ZK--8C6<=IQJ!N6:AS3H'(0,^M?44G(.=!)R=!.Y"
M1H J9&"AR4]^.;,)869CDG/AM'@!FLBN<=81PN+%:S,M5!4*Q5W(1':7<X;0
M_,G(9(Y9WS+#)[>==%AH\E!QYA*Z/RX)41^78*') 0L;+&#68Y1EZK,/9=I"
M)K)KG&6$\*.15V>9^@!$<1<RD=WE'"$TW%/1)=1%56^K.F^95W:<43^HJ ])
ML-#DV#GU"-UW6H2H6RVPT.2 .6T)8=IBE#::S1.A0//V@:A6Q*<C9##D="&$
MQ0S+G5.:#129'T?DV%F=C)'2=,3=B!?[R%S&.$H>USLO^,RV\PX+31XGSCPB
M=[TC0M4[L-#D@#EWB=SUCDC5,8X7?-!$=HUSA0A6.>Q2+)I^,@*:R$[R^AZ9
MJQIJ8CG<7,'GM9YE<P@:D;!STUW0B% %#2PT.6!.5B)W02/2"!5J_=)8C=>O
MB#.*"!8S+)-+(T[HZI?&#JQ?G ]$YC(&G&;6]U?PF:WGW1PJ1L1I2>2N8D2H
M*@86FKS/FA.;V%W%B*=5#-!$=HUSB1A6,>Q2+)[6+D 3V4E>_V-S[>*BVFQ8
M/<R>;;YEM=9-5#4""TT.GC.,V%V-B%'5""PT.6#.5F)W-2+6O+X1*V5)8T5I
M$(W-1\X48N.7/$R21M49,C]2-I=JS((XR4;V+<7"6QXVDH2</*ZW5?"IK>?=
M'/I%S-E&[*Y?Q*CZ!1::'##G*[&[?A&KRH2RXD,FLFN<(L28RD6L*A**DY")
M_&(1+^N)C5ZA9);#?15\8NLWDN:0*Q).,1)WN2)!E2NPT.2 .5U)W.6*1-4B
M- 5,8P44L(1SB@13M4A424)7P#1F0 %+.!](;-0+,,VL[ZO@4UO/NSD$C(33
MDL1=P$A0!0PL-#E@3FT2=P$CF=[>"9K(K@EOG6)*%\GT%D_01':2$X#$7+"X
M?GOUUFOKX;W_J2VS,*SU))I#C4@XU4C<U8@$58W 0I-?$>:T)757(V (VX!3
M5;@(PY2,[!M*.;-(,<6+5%4FDI &Y/@5$HU=2OUL[-VYE/."U%S&&$LWUSLR
MV 7K"S>'])%RFI*Z2Q\IJO2!A28'S*E.ZBY]P!#6 1OOV4@Y#TDQY9%T>J<&
M:"([R;E#:BZ+ ,GH<!,'.V!]H>801U+.9U)W<21%%4>PT.2 A4X:[N((#&$=
ML*JC0%62$YP44TM)5:%$7R55.ZA*9IR>9.:JBF%B6M_VP2[87C@L-'G . O*
MW/65#%5?P4*3 ^8\*G/75V (ZX"-=XYDG-QDF!I,-KUS!#21G>2$)#/77H9D
MO*\>65WVK\?]UFRKLJGZ)G'=)U9OZZ)A4U&@<A<L-'EL.,W)W.66#%5NP4*3
M ^:4*7.76V (ZX!5928D23Q68SB;R3#5F4R57H(@BI27>C1V-/"39"P+.1?)
M+'4:\RQTO9^$/;.^GG-(/9G0<LQ=ZLE0I1XLM*/.96+K,G>Q9P+#OF^9\3X5
MX@OMR'Q,L><%#6R_ ]H<.4H%1RUE'JML=>G9 SMF?QUGZ5KF"VW+?(2^93YN
MXS(LN*.@A=9EOKL&-(%A'[2J @%UEOA"9S,?4PMZ09LLM3I#J-827^APYELJ
M0Z_.7^O[T@G7[*_K+&W3?*%OFN\N&[U@H 4]AW!$?*$#F^\N'4U@V =MO F'
M^$+?-!]3.GI!@VNN\48<(G9HA9NARGL$6-T.&=CONZ[N.L^W55.T6H^1.[;.
MU+)5[-GJK@41N/&K?=!SJ$%$[/DZT?35*-^0&[H251$*:)J-S62!\\"M46U3
MCFCZH 1AIC;<U?5+"48S3Z K$ZU6#3+/N1<O[(+]M9M#-R)BNU?BKAP1N&>L
M?=!S:$=$;!P+]V@US%)<_D.,=_80L1GL1#=8VQ0U: 1KT0E6; 5KT0MV/#==
M[CB1V\3.TR=6;!2+T2D6N57L++UBB= LEDQTBS7*3!C#OB&ZJA$!]5-H*4LF
M>LI:)J>VL:RF?NKLQNNGT%66P U<7Y&C]G>5N!UIT>".QDS@2!1!%X(;V]H'
M/8LN)'2W)1/M;<VR%)<I4>/=043H2$O@#K#6*?J,%D/U$[1Y=G0I?'E6_]5E
MG1?W1=EX:W;7'>._[?<RU\]?!O;\H:VVP_=IW51M6VV&'Q]8?LOJWJ#[^UW5
M<=K]A_XKN@[?R7;V?U!+ P04    " #(0J165S4E#'H%   B'@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,RYX;6R]6=MNXS80_17"712[0!.+I"Y6ZAA(
MG.QNT 0(XF3[4/2!L>E86$E42=K9]NM+R5I=3(J)$"$OMBXSHS-#S3DD-7UF
M_+O84"K!CR1.Q>EH(V5V,AZ+Y88F1!RSC*;JSIKQA$AURI_&(N.4K JG)!XC
MQ_''"8G2T6Q:7+OELRG;RCA*Z2T'8ILDA/][3F/V?#J"HY\7[J*GC<POC&?3
MC#S1!94/V2U79^,JRBI*:"HBE@).UZ>C,W@RQW[N4%A\B^BS:!R#/)5'QK[G
M)U>KTY&3(Z(Q7<H\!%%_.SJG<9Q'4CC^*8..JF?FCLWCG]$_%\FK9!Z)H',6
M_QFMY.9T-!F!%5V3;2SOV/-76B;DY?&6+!;%+W@N;9T16&Z%9$GIK! D4;K_
M)S_*0C0<H-OA@$H']%H'7#K@(M$]LB*M"R+);,K9,^"YM8J6'Q2U*;Q5-E&:
M#^-"<G4W4GYR=G-V]\?E_=GY]26XN#R_!XO+^</=U?W5Y0(<@<5^; %;@QO"
MOU-)'F,*+NBC! NZW/)(1E2 CQ?J1A1_4@X/BPOP\<,G\ %$*;C?L*T@Z4I,
MQU(AS9\W7I:HSO>H4!<JPH\!AK\!Y"!L<)_;W2_HLG)';?>QJD]5)%05"17Q
M<$>\A6J>U5:EK@IQME.YYG4X4CUT)(BZVJC%7]?*%5Q)FHB_36GOG^.:GY.W
M[(G(R)*>CE1/"LIW=#3[]1?H.[^;BC!0L%9)<%42;(L^.TL8E]%_= 7F3$A3
MJGM_O_#/R60W@WB"H!-,Q[MF%@8[%SF^@RN[%D"W NA: 7[A3 CPD"INBPN<
M7Q2G&5_%?1RO <!'\ "D;@-A: ;H50"]?@"OU3DU(O2TIQ]YH>\?8#18A=ZD
M Z5?H?2M*#^3B(-O)-Y2$S!?+PL._,!'!] ,=BZ$$'>,<5"!"ZS@'HX7QT"J
M HJM8BE1M:$)JC52W\X;*%@KZ4F5].2=R&@R9$D&"M8J25B5)'PC&87:"QBX
M+D:'+:2;30+'Z7I-H5.+K#,0&96!FA!P<$B9!J.@H\]A8R( A^*C,E*+:A .
M#TG39.8J#>A 6JLQM"K;"YQ4.K?'&F%XR$D&NXGO!=CI@%<K([1+8\%*3VQ'
M>:KFN_)(9"P5C*N*JC/*,QX)^@)9V9_0MS6'BM:N1RW$T'TGPH)6R>]=EH&B
MM<M2RS^TZ__+I 5U1<=*7J%[^";K=BCP?-CU)M?:#^WBWX.V# H?:CAU(^1V
M8*RG - ^!^A#6X&!MI"GT9;!#$,'=B"M=1M:-? EVIH8!MOS/(W[=3L4(*]3
MHVH-A781G3.>,4XD!2F3'06T1NC=?P-%:R_I:DU&SGLMZJSBWWM5-U"T=EGJ
M:0"R3P->IB6DR[KJ=;>Q'BH3T>V0FO.'$_.;BAJK<;O^OYZ6D*[QGG,(4[>!
M?@?$>@Z ['. 'JQ41FK1#<3HD#Q-9FHUW86T5F=D7R?;60D9%KXAAJYWB$ZW
M0TZ(G:ZQKE42V55RSI*$\F5$8I"1C'(C2&N(WOTW4+1VPK7F(O^]:,DJ[KW+
M,E"T=EEJF4=VF7\%+>FR'2IUU]I=-_-"Z';()ZK5'=G5O0<IZ0JN@;29M '6
M^H[L^MZ'DO1UL(;09M+>4:P5&=M7R78JPOJBUS2^!C/+^.):%[%=%^=4O7_K
M:*DF2"+OS17-F(C,.Y_62'T;;ZAH[;QKL<7OM?>-!]W\'BI:NRR-[>\W[W_K
M@@VQVYC]E'GH9JVY5!M?+>MXJ.UOK$NWUE,VDS; 6MCQ8-O?6%_?:@AM)FV$
MM1+CMVQ]E\[^2\.KFQF&=]SX@)=_/;TA_$D-%XCI6KDYQX%*C.\_2.Y/),N*
M;WJ/3$J6%(<;2E:4YP;J_IJI-5QYDG\FK#X+S_X'4$L#!!0    ( ,A"I%:$
MXM@QIP(  )L&   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;*U576^;
M,!3]*Q:KIE;JRF<^VA&D?%6+MDI52+N':0\.W 2K!J>V2=I_/]L01#L:[6$O
MX&O?<WS.M;F$!\:?1 8@T4M."S&R,BEW-[8MD@QR+*[8#@JULF$\QU*%?&N+
M'0><&E!.;<]Q^G:.26%%H9F[YU'(2DE) ?<<B3+/,7^= &6'D>5:QXDEV692
M3]A1N,-;B$$^[.ZYBNR&)24Y%(*P G'8C*RQ>S/MZ7R3\$C@(%ICI)VL&7O2
MP2(=68X6!!02J1FP>NUA"I1J(B7CN>:TFBTUL#T^LM\:[\K+&@N8,OJ3I#(;
M64,+I;#!)95+=O@&M1\C,&%4F"<ZU+F.A9)22);78*4@)T7UQB]U'5H -_@
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MCVI:9F,8N7)-Y$8:;$EN6.%7!BCK@.L+*<VM8?M2]]V2_0502P,$%     @
MR$*D5E0ZBZ=9!@  IR,  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
MO5I=<Z,V%/TK&G>GDYW9K)$$!J>)9VPG;=+9CTSLW3YT^B!CV:8+R!4BWNVO
MK_B(94#(<</D)0%\=77NY>J<B^!RQ_BW9$.I -^C,$ZN>ALAMA?]?N)O:$22
M]VQ+8_G+BO&("'G*U_UDRRE9YH.BL(\L:]"/2!#W1I?YM7L^NF2I"(.8WG.0
MI%%$^(\)#=GNJ@=[3Q<>@O5&9!?ZH\LM6=,9%5^V]UR>]?=>ED%$XR1@,>!T
M==4;PXNIG0_(+;X&=)<<'(,LE 5CW[*3N^55S\H0T9#Z(G-!Y+]'.J5AF'F2
M./XIG?;V<V8##X^?O/^:!R^#69"$3EGX1[ 4FZN>UP-+NB)I*![8[I:6 3F9
M/Y^%2?X7[$I;JP?\-!$L*@=+!%$0%__)]S(1!P.D'_T 5 Y ]0%VRP!<#L!Y
MH 6R/*QK(LCHDK,=X)FU])8=Y+G)1\MH@CB[C3/!Y:^!'"=&G^>W-P]@,OXP
M_C2] ;/;FYLYN+Z9C^\^S, YF!4W%[ 5F&Y(O*8)"&(P]OTT2D,BZ!)\%AO*
MP91%LH@VV=U]I. N]EE$P=D'EB1OP=DU%20(Y=$Y^#*[!F=OWH(WF9OYAJ4)
MB9?)95_(2#(\?;]$/2E0HQ;4&'QDL=@DX"9>TF5U?%]F8)\&])2&"3(Z_$CX
M>X#A.X LA#5XIL\?C@QP\/ZNX-P?;O$W_CR] V,A>+!(!5F$% @&[@FGL7@'
M/LG%+6_(G'P'?SZP, 2RGG>$+__2Y;&8Q];/DW'$1;(E/KWJR?N74/Y(>Z.?
M?X(#ZQ==$CIR5DF)O4^);?(^FM!U$,=!O):K-B2Q3W71%BX&N8N,P!Y'Y]#Q
M4'9+'P\#:=HYGH<L95:!Z.PA.D:(Q5KP*VOA+,P705 LB065Q$LE_?DA29)@
M%?@D(S/M"BCF<@XP0MN"M4":1@B[KCZ,P3Z,@3&,<<326"0'*.4Z7W$6 :8)
ML(RLB%,7QZ !T89H6(NC:73N0J_E?KC[0%QC(',F2/C_0+L-/(Z#K1KHIM&Y
M[5D#/6AO#]HS@I:,=J3(O>:TR!DBNPZO:2?K!PY:\ WW^(9&?!FI ZF_=_$C
M3804=)%Q^>\LD =?Y5G*M:"-3D_EH8Z<5>*'EE),ZY7(N9RHHZQTY:V:EH-&
M KZ<H$L?E>+%R!VB6NT>MZNB1 HE>D6.+B<[A%E?A4:3:A"J.X!&I>V:H<O9
MC%&83*I1*$&'9D5_ 3V7GHV(3295Q$K?H5G@CW,S; JROKZ/VE4A*NV&9O&^
MIBMY90DF-)9' MR73USW$K*^A(W^3N:@CKQ5HU>"#]W7HF9C:W%R6CKR5DV+
M:BF@N:=X'C5K^@IH-2M7UWYX$+84KFHKH+FOZ)B8A\<)PF12?8A4K0$R:FS7
MQ%S.5LFU4PM#8X.=ECB4EB.SEK^ FI%&N1N8FS:MF)6R([.R'R=GU)3BK,+=
M.CJ-&7+=EKX9*=5&9M7^$G-*PN!?61+YU@B5I?T;">*DJ)!KNA!@1OV4!R*@
MVJHV3W J*77EK9H.)?_(?B6N1L8^X^2T=.2MFA;58R!SC_$LKD::]F%HNW6*
MTYG! 6ZC.=5D('.3T2U7(\W#?WU_0&/3HCA(-0O(O#W0-5DWMP-LB.UZ()I-
M Q=!KR48)?'(+/$O86S-1@%$#<[6Z+X$WK+7A)3N([/N/X.VFT)][F"[ 5!C
MYGEV"T"L-!V;-5TR#PW6,9BF7'*3_P/,N6REP[R>P7CY=UKL@F@W7SM]ON_*
M6S4/JB? \+7VI(W-Q\EIZ<A;-2VJ[<#FMN-9?(UUG0>VZGRM,<-#UVZIX(.7
M">;&HUNZQLVM &C#1BA-*X3;>BBLF@9LWC/HF+/Q\7T$HTDU"J7QV*SQ+R!K
MK'LMT,R^]KU 6_:5[F.S[A_G:JS1Z2:ZIM$ .VU957J.C^CYD=>26<^MQ=SI
MHWY7WJI)4'T ]EZ+I8T-Q\EIZ<A;-2VJR\#F+N-Y+*WI(&Q[X-1[.)T=QL@9
MZBO85JV&;6XU7L +=G,;0//&2F-E>&5EJ][ -N\7'">&TD'EU2P>0E3/K=9.
M(JQO#_0//GF(*%_G7X(D,FM2'HK7_ONK^Z]-QODW%K7K$W@Q+;X946Z*3U@^
M$K[.GLY#NI(NK?>N3!LOO@HI3@3;YA]6+)@0+,H/-Y0L*<\,Y.\KQL3323;!
M_MN<T7]02P,$%     @ R$*D5I?[9/ N"   5TT  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#@N>&ULQ9Q;;]LX&H;_"N$M%BV0B76P';N;&$@L$1M@.A,T
M:>=BL!>*Q-A"=?"2=#(%]L</=:@E*C(3I:^Q-XDEB\]'\Y4^4J]$GC_E_)O8
M,";)7VF2B8O11LKMQ_%8A!N6!N(TW[),??.0\S20:I.OQV++61"5A=)D[%C6
M;)P&<39:GI?[;OCR/-_)),[8#2=BEZ8!_W[%DOSI8F2/?NSX'*\WLM@Q7IYO
M@S6[9?++]H:KK?&>$L4IRT2<9X2SAXO1I?V13LH"Y1%?8_8D6I])\5/N\_Q;
ML7$=78RLHD8L8:$L$('Z]\A6+$D*DJK'?VOH:!^S*-C^_(-.RQ^O?LQ](-@J
M3_Z(([FY&,U')&(/P2Z1G_.G?[/Z!TT+7I@GHOQ+GNICK1$)=T+F:5U8U2"-
ML^I_\%?=$*T"]OQ  :<NX'0*.,Z! FY=P.T4<-T#!29U@4FGP.10A&E=8-JM
MTO1 @5E=8%:V?=5894M[@0R6YSQ_(KPX6M&*#Z5<96G5P'%6G%FWDJMO8U5.
M+E>___;5_WQW??6K3SS_ZHZ\]Y@,XD1\(._(F(A-P)D@<4:^9+$4)VJG^OPI
M3A)U6HCSL515*$#CL [G5^&< ^%<\BG/Y$80/XM8I)<?JZKOZ^_\J/^58P3>
MLNTIL:<GQ+$<AT3!]YXZK5Z#<&O$EUN/O'_WH0?CO0;CZ)A6(_8UEIGX*>"G
MQ+5+HMM#+#\6NO2@J1GML7"/=@Y64E/$W9]1;HEV#Z!_5=LD?R KSJ)8$AJ$
M<1++[^3/\HMKR5+QGYX*7U7423^U2+ ?Q38(V<5(95#!^",;+?_Y#WMF_:M/
M<23,0\)\)(R"8)K.D[W.$Q-]N<K35'4-*D.%WTZ("O 8YSN1?%?]S3;GDD7D
M,4AVC+Q7"6,G(K)EO#K)/I#_F2^+*V/@H:<"$N8A87X%.RMAQ0C@<6F=6O;Y
M^+$M\0L':=)-]])-7Y N>V1<QO<)(QZ[ETJ0]JY;EL4Y)[_E4N483TFHDL19
MGT[&*$-U0L(\),Q'PB@(IND^V^L^.TIJGB%U1L(\),Q'PB@(INE\MM?YS'A]
M7Z[7G*T#R51:CK,PW@8)"=)\EQ57^KL^A8V\H0I7L%DK9=G6Q-+SFH>,Z"-A
M% 33E)OOE9L;E;O.)%-42;A2KT^HJOC<V&>L7G.0]YJ#_-<<1(T_Z8T-MM@W
MV,+88&7W%6="\IVZWY4D+/NQZKXW4/>N?6UH) X]V9$PKX(M].:VW,EBTA4&
M&9:"8)J MM7<@5I#)#QI:ZCR5_BF(:0YYE"1H32OIK7'=,Y\=NIT)(8&I2B:
M+G++9K"-(M]PEL:[E#SP/&T)W"N=D318.B3-JVE%8[8N47?:E0X9E*)HNG1.
M(YWS_[K1,T<>+#62YM6T]C#&L9]=H\B0%$73A6Z,&]OH%]2)6(A=D*FD&^9"
MBD/C13-IL'!0NP9*\VN:;;>'LXMNLJ:HH+ITC1=CF\T8&L2\O@S5_5V29^M?
MU$ R)5%U=]^O(=1F@=(\*,VO:?H=B6MU)03%U"5L/!D;;\JH8\I#5\V(Z4[)
M+LCO6>_=@[D*@R6'6C90F@^E411-/S4:V\8^CF]C0XT;*,V#TGPHC:)HNMR-
M>V.;[9L['D1QMBZ>9@DB-RK$)D\B=:WW/]ZZJG'3]DBED]Q6YI"#Q8.Z-U :
M1=%T\1H#QS8[."H5"Q;NBN?E1 X5<OY,R&XOM3*''RPDDN9#:11%TX5LC"7;
M["S=,!ZR3 ;K,O66=S^U'2%YO%XSWJO@XIEA9I^Z70FAGA&4YD-I%$737PUH
MG"7'["Q!AU1W3[UFHKD*0_M8*,V#TGPHC:)H^JG1^%&.?90AE0,UIZ T#TKS
MH32*HNER-QZ68_:PA@ZI:ER[)^YX?"MSQ,':(6D^E$91-%V[QI9RS+;4SXRH
M:G1;1[L[HC*''RPDU'V"TBB*I@O9F%2.V:1ZTXBJ9NJ/(!?SKH90]PE*\Z$T
MBJ+I&C8NE8-WJ4[(=1;+.$C(9?D20J_,4&<*2O.@-!]*HRB:?CHTSI1S'&?*
M@3I34)H'I?E0&D71=+D;9\I!OUAD!@X6&NIB.<]?5%I8G=&!#PU)431=O\:<
M<EXTI]Z0O2\C=6VK&V%S D=Z/RLHS8/2?"B-HFCZ&=&X7,[B. D<^A(5E.9!
M:3Z41E$T?6I&XXBY9D=L> (W P?/R[">/XGMOCWC04/Z4!I%T73]&MO*-;]&
M]88$/NU5%6IC06D>E.9#:11%T^5O;"S7.4JV=J'O64%I'I3F0VD41=/E;LVD
M,SM?0UU+][G;]>Q!L#GD8/&P<^.PD^..X7:YC=OEFMVNG[$M:[3Q0; Y_& A
MH987E$91-%W(QO)RS9;7FVS+FFE^$&P./%A"J$T%I5$439>PL:E<HR_2.VP*
MMEL6J7])0E2>S410+G70^YJRF3ZX^X2Z55":#Z51%$U7O7&KW+/CC):@GA64
MYD%I/I1&431=[L;<<E\RMXXV3\$<>? 9 36W:IIYG@(T)$71=*$;S\HUOYFE
M4O=+$\,.K(IQ928/%A)J6T%I?DUK#R$GSJ3SRCLJI+Z 1.-&3<QNU$T]*4Q=
MM6'5'8=%=RQ?Z([-U*$B0FE>3=->..A<B]" %$73)6P,J<D+\_IV/-P$@HFB
MHVV)*%3638(BZ<J\GN]7#;],,U+,L08+"W6EH#2_INFSBNSYZ:R[^@?4;QJW
MUHE*&5^7*WH))<\ND]624?N]^U7#+LNULL;-X=628Y\"OHXS01+VH(I:IV?J
MC.?5*E[5ALRWY:I3][F4>5I^W+ @8KPX0'W_D.?RQT818+^6VO)O4$L#!!0
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MU,Z!GB^5LB^&.Z#YSL6_ 5!+ P04    " #(0J16BU'^;E #  #G"P  &0
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MF&(G#D(;X/Z2<[6;Z .:WC[\'U!+ P04    " #(0J16?\BO%, #   &$
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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MFT%?5 1ENNV^Y>B^0_GR-U!+ P04    " #(0J16BC%V7\\!   S'P  &@
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MA4\_ 5!+ 0(4 Q0    ( ,A"I%8'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ R$*D5O'BIB'O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ R$*D5IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #(0J16E_BM6@,&  #>'P  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ R$*D5K\*4H4'!P  OQT  !@              ("!1PX  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,A"I%:5/:PI#0,  %L*
M   8              " @805  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " #(0J169B8$;@,'  "((0  &               @(''&
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ R$*D5AMM]!AW
M!@  42H  !@              ("! "   'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( ,A"I%;$ 4\8Y@<  %,B   8              "
M@:TF  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #(0J16
M/?MI$,,%  "Q#   &               @(')+@  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ R$*D5K*1T4FC!@  DA   !@
M     ("!PC0  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M ,A"I%;M+OF8H ,  .8'   8              " @9L[  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " #(0J16=IU" PH;  "@7   &0
M            @(%Q/P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( ,A"I%;PT5L720<  )D3   9              " @;):  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ R$*D5E)VCM6B!
M'PT  !D              ("!,F(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " #(0J16FH[W-,0$   3"P  &0              @($+
M9P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,A"I%8@
MY_J0UP4  &8/   9              " @09L  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ R$*D5B0JF93@"0  GAL  !D
M     ("!%'(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,A"I%:SM)*DV@8  &@1   9              "
M@3B<  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ R$*D
M5A0V*"S, P  I@@  !D              ("!2:,  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " #(0J160EM\XA8&  #T$   &0
M        @(%,IP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( ,A"I%8C[;C$V@(  /(%   9              " @9FM  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ R$*D5O-L8VO !   -PT
M !D              ("!JK   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " #(0J16H@.#]CH$   G"@  &0              @(&AM0
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,A"I%8WY=">
M704  &T.   9              " @1*Z  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ R$*D5CD:BP/; @  '@8  !D
M ("!IK\  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #(
M0J16,7F"J-$"  #H!0  &0              @(&XP@  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,A"I%;24(U*2P,   D'   9
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M970S,RYX;6Q02P$"% ,4    " #(0J16/D&9RS(#  !B"@  &0
M    @(%0V0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M ,A"I%9\SVPEY08   LL   9              " @;G<  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ R$*D5MZ6^^0>!0  O"   !D
M             ("!U>,  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " #(0J16Q?8?NM\#  "!$0  &0              @($JZ0  >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ,A"I%84UCRVGP0
M . :   9              " @4#M  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ R$*D5@UXZ'?K P  >1(  !D              ("!
M%O(  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #(0J16
MNT2]VM($    &P  &0              @($X]@  >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( ,A"I%8\P!(W+0,  /0(   9
M      " @4'[  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ R$*D5I:0!$BM"P  GVT  !D              ("!I?X  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #(0J165S4E#'H%   B'@
M&0              @(&)"@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( ,A"I%:$XM@QIP(  )L&   9              " @3H0 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ R$*D5H.W+6OQ
M @  8PD  !D              ("!&!,! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " #(0J16A)U,1QD#  ##"   &0
M@(% %@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,A"
MI%94.HNG608  *<C   9              " @9 9 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ R$*D5I?[9/ N"   5TT  !D
M         ("!(" ! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
M    " #(0J16+..=-.0$  !H'0  &0              @(&%* $ >&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ,A"I%9MXK=?!P,  /,&
M   9              " @: M 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL
M4$L! A0#%     @ R$*D5HM1_FY0 P  YPL  !D              ("!WC !
M 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #(0J16?\BO
M%, #   &$   &0              @(%E- $ >&PO=V]R:W-H965T<R]S:&5E
M=#4R+GAM;%!+ 0(4 Q0    ( ,A"I%:9W5,'.P,  - 3   -
M  "  5PX 0!X;"]S='EL97,N>&UL4$L! A0#%     @ R$*D5I>*NQS
M$P(   L              ( !PCL! %]R96QS+RYR96QS4$L! A0#%     @
MR$*D5F7DGP5?!   "R,   \              ( !JSP! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( ,A"I%:*,79?SP$  #,?   :              "
M 3=! 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,A"
MI%8RX8'AQP$  !(?   3              "  3Y# 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     \ #P 6Q   #9% 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>256</ContextCount>
  <ElementCount>230</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - NATURE OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NATUREOFBUSINESS</Role>
      <ShortName>NATURE OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION</Role>
      <ShortName>BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - NET PRODUCT REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETPRODUCTREVENUES</Role>
      <ShortName>NET PRODUCT REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - NET REVENUES FROM COLLABORATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES</Role>
      <ShortName>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - MARKETABLE DEBT SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES</Role>
      <ShortName>MARKETABLE DEBT SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - OTHER BALANCE SHEET DETAILS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS</Role>
      <ShortName>OTHER BALANCE SHEET DETAILS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - CONVERTIBLE DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONVERTIBLEDEBT</Role>
      <ShortName>CONVERTIBLE DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY</Role>
      <ShortName>DEVELOPMENT DERIVATIVE LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - NET LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE</Role>
      <ShortName>NET LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - NET PRODUCT REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETPRODUCTREVENUESTables</Role>
      <ShortName>NET PRODUCT REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/NETPRODUCTREVENUES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - NET REVENUES FROM COLLABORATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables</Role>
      <ShortName>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - MARKETABLE DEBT SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables</Role>
      <ShortName>MARKETABLE DEBT SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - OTHER BALANCE SHEET DETAILS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables</Role>
      <ShortName>OTHER BALANCE SHEET DETAILS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables</Role>
      <ShortName>DEVELOPMENT DERIVATIVE LIABILITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - NATURE OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NATUREOFBUSINESSDetails</Role>
      <ShortName>NATURE OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/NATUREOFBUSINESS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - NET PRODUCT REVENUES - Summary of Net Product Revenues (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail</Role>
      <ShortName>NET PRODUCT REVENUES - Summary of Net Product Revenues (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - NET PRODUCT REVENUES - Receivables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail</Role>
      <ShortName>NET PRODUCT REVENUES - Receivables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - NET REVENUES FROM COLLABORATIONS - Revenue from Collaborators (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Revenue from Collaborators (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - NET REVENUES FROM COLLABORATIONS - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails</Role>
      <ShortName>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES - Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails</Role>
      <ShortName>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES - Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Assets Measured on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Fair Value of Assets Measured on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - MARKETABLE DEBT SECURITIES - Summary of Marketable Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail</Role>
      <ShortName>MARKETABLE DEBT SECURITIES - Summary of Marketable Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - MARKETABLE DEBT SECURITIES - Summary of Fair Value of Marketable Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail</Role>
      <ShortName>MARKETABLE DEBT SECURITIES - Summary of Fair Value of Marketable Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail</Role>
      <ShortName>OTHER BALANCE SHEET DETAILS - Schedule of Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail</Role>
      <ShortName>OTHER BALANCE SHEET DETAILS - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - OTHER BALANCE SHEET DETAILS - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>OTHER BALANCE SHEET DETAILS - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - CONVERTIBLE DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONVERTIBLEDEBTDetails</Role>
      <ShortName>CONVERTIBLE DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/CONVERTIBLEDEBT</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails</Role>
      <ShortName>DEVELOPMENT DERIVATIVE LIABILITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY - Development Derivative Liability Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails</Role>
      <ShortName>DEVELOPMENT DERIVATIVE LIABILITY - Development Derivative Liability Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - STOCK-BASED COMPENSATION - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail</Role>
      <ShortName>STOCK-BASED COMPENSATION - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="alny-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - NET LOSS PER COMMON SHARE - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail</Role>
      <ShortName>NET LOSS PER COMMON SHARE - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentConvertibleConversionRatio1 -  alny-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="alny-20230331.htm">alny-20230331.htm</File>
    <File>alny-20230331.xsd</File>
    <File>alny-20230331_cal.xml</File>
    <File>alny-20230331_def.xml</File>
    <File>alny-20230331_lab.xml</File>
    <File>alny-20230331_pre.xml</File>
    <File>alny2023q110-qex311.htm</File>
    <File>alny2023q110-qex312.htm</File>
    <File>alny2023q110-qex321.htm</File>
    <File>alny2023q110-qex322.htm</File>
    <File>alny2023q1exhibit101.htm</File>
    <File>alny2023q1exhibit102.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>alny-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="611">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "alny-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 611,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 256,
   "dts": {
    "calculationLink": {
     "local": [
      "alny-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "alny-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "alny-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "alny-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "alny-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "alny-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 397,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 50,
   "keyStandard": 180,
   "memberCustom": 33,
   "memberStandard": 32,
   "nsprefix": "alny",
   "nsuri": "http://www.alnylam.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.alnylam.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - NET REVENUES FROM COLLABORATIONS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS",
     "shortName": "NET REVENUES FROM COLLABORATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES",
     "shortName": "LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - FAIR VALUE MEASUREMENTS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - MARKETABLE DEBT SECURITIES",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES",
     "shortName": "MARKETABLE DEBT SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - OTHER BALANCE SHEET DETAILS",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS",
     "shortName": "OTHER BALANCE SHEET DETAILS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - CONVERTIBLE DEBT",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.alnylam.com/role/CONVERTIBLEDEBT",
     "shortName": "CONVERTIBLE DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY",
     "shortName": "DEVELOPMENT DERIVATIVE LIABILITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - STOCK-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.alnylam.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - NET LOSS PER COMMON SHARE",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE",
     "shortName": "NET LOSS PER COMMON SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies",
     "shortName": "BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - NET PRODUCT REVENUES (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.alnylam.com/role/NETPRODUCTREVENUESTables",
     "shortName": "NET PRODUCT REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - NET REVENUES FROM COLLABORATIONS (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables",
     "shortName": "NET REVENUES FROM COLLABORATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:ScheduleOfRoyaltyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables",
     "shortName": "LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:ScheduleOfRoyaltyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - MARKETABLE DEBT SECURITIES (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables",
     "shortName": "MARKETABLE DEBT SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - OTHER BALANCE SHEET DETAILS (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables",
     "shortName": "OTHER BALANCE SHEET DETAILS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables",
     "shortName": "DEVELOPMENT DERIVATIVE LIABILITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - NET LOSS PER COMMON SHARE (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables",
     "shortName": "NET LOSS PER COMMON SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "alny:NumberOfMarketedProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - NATURE OF BUSINESS (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.alnylam.com/role/NATUREOFBUSINESSDetails",
     "shortName": "NATURE OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "alny:NumberOfMarketedProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - NET PRODUCT REVENUES - Summary of Net Product Revenues (Detail)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail",
     "shortName": "NET PRODUCT REVENUES - Summary of Net Product Revenues (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "ibd786b1197ef4a61a89be31d546d3ce9_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - NET PRODUCT REVENUES - Receivables (Detail)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
     "shortName": "NET PRODUCT REVENUES - Receivables (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i33c0592038dc4276b0af9495329ef056_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - NET REVENUES FROM COLLABORATIONS - Revenue from Collaborators (Detail)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Revenue from Collaborators (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i119bb76ddc4f49b89a1e68acefe7a579_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - NET REVENUES FROM COLLABORATIONS - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i312ec99fcc6c43a5a131ac1f6eb87263_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alny:ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i3594c34bba4944ca91cc9765440d129b_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alny:ScheduleOfAllocatedTransactionPriceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "ic72bd345a96d42859814302ad7ff2730_D20190401-20190430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "alny:TransactionPrice",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alny:ScheduleOfAllocatedTransactionPriceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i7e7e8c4e7d644c158639d2fb41e9a319_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "alny:StandaloneSellingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "if5ea36d76387472e84cfa6df1370b518_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "alny:ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i10bce677b77f433a9d7d79a79b60f6a2_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "alny:RoyaltyLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
     "shortName": "LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i9f304a30d62e48ae884ec8acc207b442_I20200430",
      "decimals": "INF",
      "lang": "en-US",
      "name": "alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i6860c8b46ed14ad2aa0cd94577b727da_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "alny:RoyaltyLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES - Future Royalties (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails",
     "shortName": "LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES - Future Royalties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alny:ScheduleOfRoyaltyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "ie90a9b7be5ab448e86528f65d657a9ac_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "alny:RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Assets Measured on a Recurring Basis (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
     "shortName": "FAIR VALUE MEASUREMENTS - Fair Value of Assets Measured on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "ie823bc3a3540443788e7ed44be452ee5_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - MARKETABLE DEBT SECURITIES - Summary of Marketable Debt Securities (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail",
     "shortName": "MARKETABLE DEBT SECURITIES - Summary of Marketable Debt Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - MARKETABLE DEBT SECURITIES - Summary of Fair Value of Marketable Debt Securities (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail",
     "shortName": "MARKETABLE DEBT SECURITIES - Summary of Fair Value of Marketable Debt Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Inventory (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail",
     "shortName": "OTHER BALANCE SHEET DETAILS - Schedule of Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail",
     "shortName": "OTHER BALANCE SHEET DETAILS - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock",
       "alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i129714144f56409c862078cd74c09670_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i6860c8b46ed14ad2aa0cd94577b727da_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - OTHER BALANCE SHEET DETAILS - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "OTHER BALANCE SHEET DETAILS - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - CONVERTIBLE DEBT (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails",
     "shortName": "CONVERTIBLE DEBT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i36aa61efaa244add8aac63cdcac4dac0_I20220913",
      "decimals": "-7",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY - Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
     "shortName": "DEVELOPMENT DERIVATIVE LIABILITY - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "idf7880a1438e4b1d8934bf896e4c4569_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "ib8b5cdd9d6524a48a7c0e217c8746b86_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "ib8b5cdd9d6524a48a7c0e217c8746b86_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "ib8b29740f2a6476a91d8e8b96400f6d4_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY - Development Derivative Liability Activity (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails",
     "shortName": "DEVELOPMENT DERIVATIVE LIABILITY - Development Derivative Liability Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "ib8b29740f2a6476a91d8e8b96400f6d4_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - STOCK-BASED COMPENSATION - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail",
     "shortName": "STOCK-BASED COMPENSATION - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - NET LOSS PER COMMON SHARE - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail",
     "shortName": "NET LOSS PER COMMON SHARE - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAmortizationAndAccretionNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - NATURE OF BUSINESS",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.alnylam.com/role/NATUREOFBUSINESS",
     "shortName": "NATURE OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION",
     "shortName": "BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - NET PRODUCT REVENUES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.alnylam.com/role/NETPRODUCTREVENUES",
     "shortName": "NET PRODUCT REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20230331.htm",
      "contextRef": "i17472e54a53140dfbc1afb7ec5216597_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 72,
   "tag": {
    "alny_ALNAGTPhase2ClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ALN-AGT Phase 2 Clinical Trial",
        "label": "ALN-AGT Phase 2 Clinical Trial [Member]",
        "terseLabel": "ALN-AGT Phase 2 Clinical Trial"
       }
      }
     },
     "localname": "ALNAGTPhase2ClinicalTrialMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ALNAGTPhase3ClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ALN-AGT Phase 3 Clinical Trial",
        "label": "ALN-AGT Phase 3 Clinical Trial [Member]",
        "terseLabel": "ALN-AGT Phase 3 Clinical Trial"
       }
      }
     },
     "localname": "ALNAGTPhase3ClinicalTrialMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_AccumulatedLossOnInvestmentInJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated loss on investment in joint venture.",
        "label": "Accumulated Loss On Investment In Joint Venture [Member]",
        "terseLabel": "Loss on Investment in Joint Venture"
       }
      }
     },
     "localname": "AccumulatedLossOnInvestmentInJointVentureMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_AmortizationAndInterestAccretionRelatedToOperatingLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Interest Accretion Related to Operating Leases",
        "label": "Amortization and Interest Accretion Related to Operating Leases",
        "terseLabel": "Amortization and interest accretion related to operating leases"
       }
      }
     },
     "localname": "AmortizationAndInterestAccretionRelatedToOperatingLeases",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_AmvuttraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amvuttra",
        "label": "Amvuttra [Member]",
        "terseLabel": "AMVUTTRA"
       }
      }
     },
     "localname": "AmvuttraMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_BlackstoneGroupIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blackstone Group Inc.",
        "label": "Blackstone Group Inc. [Member]",
        "terseLabel": "Blackstone Group Inc."
       }
      }
     },
     "localname": "BlackstoneGroupIncMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_BlackstoneLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blackstone Life Sciences",
        "label": "Blackstone Life Sciences [Member]",
        "terseLabel": "Blackstone Life Sciences"
       }
      }
     },
     "localname": "BlackstoneLifeSciencesMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_C5CoCoObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C5 Co-Co obligation.",
        "label": "C5 Co Co Obligation [Member]",
        "terseLabel": "C5 Co-Co Obligation"
       }
      }
     },
     "localname": "C5CoCoObligationMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_C5LicenseObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C5 license obligation.",
        "label": "C5 License Obligation [Member]",
        "terseLabel": "C5 License Obligation"
       }
      }
     },
     "localname": "C5LicenseObligationMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ChangeInFairValueOfLiabilityObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of liability obligation.",
        "label": "Change In Fair Value Of Liability Obligation",
        "negatedTerseLabel": "Change in fair value of development derivative liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfLiabilityObligation",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_ClinicalTrialAndManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial and manufacturing.",
        "label": "Clinical Trial And Manufacturing [Member]",
        "terseLabel": "Clinical Trial and Manufacturing"
       }
      }
     },
     "localname": "ClinicalTrialAndManufacturingMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_CollaborationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborations",
        "label": "Collaborations [Member]",
        "terseLabel": "Net revenues from collaborations"
       }
      }
     },
     "localname": "CollaborationsMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_CollaborativeAgreementPeriodOfProgramDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period Of Program Development",
        "label": "Collaborative Agreement, Period Of Program Development",
        "terseLabel": "Direction period of programs development"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodOfProgramDevelopment",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_CollaborativeAgreementTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative agreement termination period.",
        "label": "Collaborative Agreement Termination Period",
        "terseLabel": "Agreement termination period"
       }
      }
     },
     "localname": "CollaborativeAgreementTerminationPeriod",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent",
        "label": "Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent",
        "terseLabel": "Commercial milestones acquired by collaborator, percent"
       }
      }
     },
     "localname": "CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_CollaborativeArrangementConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Consideration Received",
        "label": "Collaborative Arrangement, Consideration Received",
        "terseLabel": "Consideration received"
       }
      }
     },
     "localname": "CollaborativeArrangementConsiderationReceived",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_CollaborativeArrangementFixedPaymentMultiplier": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed Payment Multiplier",
        "label": "Collaborative Arrangement, Fixed Payment Multiplier",
        "terseLabel": "Fixed payment multiplier"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPaymentMultiplier",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "alny_CollaborativeArrangementFixedPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed Payment, Term",
        "label": "Collaborative Arrangement, Fixed Payment, Term",
        "terseLabel": "Fixed payment, term (in years)"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPaymentTerm",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_CollaborativeArrangementMaximumFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Funding",
        "label": "Collaborative Arrangement, Maximum Funding",
        "terseLabel": "Maximum funding"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumFunding",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_CollaborativeArrangementMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement milestone payments.",
        "label": "Collaborative Arrangement Milestone Payments",
        "terseLabel": "Collaborative arrangement milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePayments",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalties Acquired By Collaborator, Percent",
        "label": "Collaborative Arrangement, Royalties And Commercial Milestones Acquired By Collaborator, Percent",
        "terseLabel": "Collaborative arrangement, royalties and commercial milestones acquired by collaborator, percent"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_CollaborativeArrangementRoyaltiesPayablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalties Payable, Percent",
        "label": "Collaborative Arrangement, Royalties Payable, Percent",
        "terseLabel": "Royalties payable, percent"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltiesPayablePercent",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_CollaborativeArrangementRoyaltiesPayableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalties Payable, Term",
        "label": "Collaborative Arrangement, Royalties Payable, Term",
        "terseLabel": "Royalties payable, term (in years)"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltiesPayableTerm",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_ConvertibleDebtPremiumRecognizedFromConversionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt, Premium Recognized From Conversion Rate",
        "label": "Convertible Debt, Premium Recognized From Conversion Rate",
        "terseLabel": "Premium from conversion"
       }
      }
     },
     "localname": "ConvertibleDebtPremiumRecognizedFromConversionRate",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "alny_ConvertibleSeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2025",
        "label": "Convertible Senior Notes Due 2025 [Member]",
        "terseLabel": "Convertible Senior Notes Due 2025"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2025Member",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ConvertibleSeniorNotesDue2027AdditionalAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2027, Additional Amount",
        "label": "Convertible Senior Notes Due 2027, Additional Amount [Member]",
        "terseLabel": "Convertible Senior Notes Due 2027, Additional Amount"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2027AdditionalAmountMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ConvertibleSeniorNotesDue2027InitialAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2027, Initial Amount",
        "label": "Convertible Senior Notes Due 2027, Initial Amount [Member]",
        "terseLabel": "Convertible Senior Notes Due 2027, Initial Amount"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2027InitialAmountMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ConvertibleSeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2027",
        "label": "Convertible Senior Notes Due 2027 [Member]",
        "terseLabel": "Convertible Senior Notes Due 2027"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2027Member",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_CostOfCollaborationManufacturingAndRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Collaboration Manufacturing And Royalties",
        "label": "Cost Of Collaboration Manufacturing And Royalties",
        "terseLabel": "Cost of collaborations and royalties"
       }
      }
     },
     "localname": "CostOfCollaborationManufacturingAndRoyalties",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_DebtConversionTermsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion Terms One",
        "label": "Debt Conversion Terms One [Member]",
        "terseLabel": "Debt Conversion Terms One"
       }
      }
     },
     "localname": "DebtConversionTermsOneMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_DebtConversionTermsTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion Terms Two",
        "label": "Debt Conversion Terms Two [Member]",
        "terseLabel": "Debt Conversion Terms Two"
       }
      }
     },
     "localname": "DebtConversionTermsTwoMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_DebtInstrumentConvertibleTermsOfConversionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Terms of Conversion",
        "label": "Debt Instrument, Convertible Terms of Conversion [Axis]",
        "terseLabel": "Debt Instrument, Convertible Terms of Conversion [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleTermsOfConversionAxis",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_DebtInstrumentConvertibleTermsOfConversionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Terms of Conversion",
        "label": "Debt Instrument, Convertible Terms of Conversion [Domain]",
        "terseLabel": "Debt Instrument, Convertible Terms of Conversion [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleTermsOfConversionDomain",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_DiscoveryPeriodOfProgramsDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discovery period of programs development.",
        "label": "Discovery Period Of Programs Development",
        "terseLabel": "Discovery period of programs development"
       }
      }
     },
     "localname": "DiscoveryPeriodOfProgramsDevelopment",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_ExpectedRoyaltyInterestPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Royalty Interest Payments",
        "label": "Expected Royalty Interest Payments",
        "terseLabel": "Expected royalty interest payments"
       }
      }
     },
     "localname": "ExpectedRoyaltyInterestPayments",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended additional discovery period of programs development.",
        "label": "Extended Additional Discovery Period Of Programs Development",
        "terseLabel": "Extended additional discovery period of programs development"
       }
      }
     },
     "localname": "ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_ExternalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "External services.",
        "label": "External Services [Member]",
        "terseLabel": "External Services"
       }
      }
     },
     "localname": "ExternalServicesMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_FundingAnAnnualDiscoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding an annual discovery.",
        "label": "Funding An Annual Discovery [Member]",
        "terseLabel": "Funding At Steady State"
       }
      }
     },
     "localname": "FundingAnAnnualDiscoveryMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_FundingAtLeadCandidateIdentificationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding at lead candidate identification.",
        "label": "Funding At Lead Candidate Identification [Member]",
        "terseLabel": "Funding At Lead Candidate Identification"
       }
      }
     },
     "localname": "FundingAtLeadCandidateIdentificationMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_FundingAtProgramInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding at program initiation.",
        "label": "Funding At Program Initiation [Member]",
        "terseLabel": "Funding At Program Initiation"
       }
      }
     },
     "localname": "FundingAtProgramInitiationMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_GIVLAARIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GIVLAARI",
        "label": "GIVLAARI [Member]",
        "terseLabel": "GIVLAARI"
       }
      }
     },
     "localname": "GIVLAARIMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_GlobalStrategicCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global strategic collaboration.",
        "label": "Global Strategic Collaboration [Member]",
        "terseLabel": "Global Strategic Collaboration"
       }
      }
     },
     "localname": "GlobalStrategicCollaborationMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_HELIOSBPhase3ClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HELIOS-B Phase 3 Clinical Trial",
        "label": "HELIOS-B Phase 3 Clinical Trial [Member]",
        "terseLabel": "HELIOS-B Phase 3 Clinical Trial"
       }
      }
     },
     "localname": "HELIOSBPhase3ClinicalTrialMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_IncreaseDecreaseInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Research And Development Expense",
        "label": "Increase (Decrease) In Research And Development Expense",
        "negatedLabel": "Decrease in research and development expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentExpense",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_InventoryCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, Current And Noncurrent",
        "label": "Inventory, Current And Noncurrent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryCurrentAndNoncurrent",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in marketable debt securities disclosure.",
        "label": "Investments In Marketable Debt Securities Disclosure [Text Block]",
        "terseLabel": "MARKETABLE DEBT SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To Sale Of Future Royalties",
        "label": "Liability Related To Sale Of Future Royalties [Roll Forward]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesRollForward",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties [Line Items]",
        "label": "Liability Related To The Sale Of Future Royalties [Line Items]",
        "terseLabel": "Liability Related To The Sale Of Future Royalties [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItems",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties Line Items",
        "label": "Liability Related To The Sale Of Future Royalties Line Items [Line Items]",
        "terseLabel": "Liability Related To The Sale Of Future Royalties Line Items [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties Table",
        "label": "Liability Related To The Sale Of Future Royalties [Table]",
        "terseLabel": "Liability Related To The Sale Of Future Royalties [Table]"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesTable",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties",
        "label": "Liability Related To The Sale Of Future Royalties [Text Block]",
        "terseLabel": "LIABILITY RELATED TO SALE OF FUTURE ROYALTIES"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_LiquidityPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity Policy [Policy Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyPolicyTextBlock",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum additional milestone payments to be receive upon achievement of certain criteria.",
        "label": "Maximum Additional Milestone Payments To Be Receive Upon Achievement Of Certain Criteria",
        "terseLabel": "Maximum additional milestone payments to be receive upon achievement of certain criteria"
       }
      }
     },
     "localname": "MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum royalties and commercial milestone payments upon potential product sale.",
        "label": "Maximum Royalties And Commercial Milestone Payments Upon Potential Product Sale",
        "terseLabel": "Maximum royalties and commercial milestone payments upon potential product sale"
       }
      }
     },
     "localname": "MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_NonCashInterestExpenseOnSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Interest Expense On Sale Of Future Royalties",
        "label": "Non-Cash Interest Expense On Sale Of Future Royalties",
        "terseLabel": "Non-cash interest expense on liability related to the sale of future royalties"
       }
      }
     },
     "localname": "NonCashInterestExpenseOnSaleOfFutureRoyalties",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_NonUSOrEuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-US Or Europe",
        "label": "Non-US Or Europe [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUSOrEuropeMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Medicines Company.",
        "label": "Novartis [Member]",
        "verboseLabel": "Novartis AG"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_NumberOfCommercializedProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Commercialized Products",
        "label": "Number Of Commercialized Products",
        "terseLabel": "Number of commercialized products"
       }
      }
     },
     "localname": "NumberOfCommercializedProducts",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NATUREOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "alny_NumberOfMarketedProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Marketed Products",
        "label": "Number Of Marketed Products",
        "terseLabel": "Number of marketed products"
       }
      }
     },
     "localname": "NumberOfMarketedProducts",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NATUREOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "alny_NumberOfPartneredProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Partnered Products",
        "label": "Number Of Partnered Products",
        "terseLabel": "Number of partnered products"
       }
      }
     },
     "localname": "NumberOfPartneredProducts",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NATUREOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "alny_NumberOfTargetedPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of targeted programs.",
        "label": "Number Of Targeted Programs",
        "terseLabel": "Number of targeted programs"
       }
      }
     },
     "localname": "NumberOfTargetedPrograms",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "alny_ONPATTROMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ONPATTRO",
        "label": "ONPATTRO [Member]",
        "terseLabel": "ONPATTRO"
       }
      }
     },
     "localname": "ONPATTROMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_OXLUMOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OXLUMO",
        "label": "OXLUMO [Member]",
        "terseLabel": "OXLUMO"
       }
      }
     },
     "localname": "OXLUMOMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_OtherCollaborationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other collaboration.",
        "label": "Other Collaborations [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCollaborationsMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other.",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_PercentageOfMaximumRoyaltyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of maximum royalty payments.",
        "label": "Percentage Of Maximum Royalty Payments",
        "terseLabel": "Maximum percentage of royalty payments"
       }
      }
     },
     "localname": "PercentageOfMaximumRoyaltyPayments",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_PotentialProceedsFromCollaborationArrangement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential proceeds from collaboration arrangement.",
        "label": "Potential Proceeds From Collaboration Arrangement",
        "terseLabel": "Potential proceeds from collaboration arrangement"
       }
      }
     },
     "localname": "PotentialProceedsFromCollaborationArrangement",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_PremiumRecognizedOnCappedCallTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium Recognized On Capped Call Transactions",
        "label": "Premium Recognized On Capped Call Transactions",
        "terseLabel": "Premium on capped call transactions"
       }
      }
     },
     "localname": "PremiumRecognizedOnCappedCallTransactions",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "alny_PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases Of Capped Calls Related To Convertible Senior Notes",
        "label": "Purchases Of Capped Calls Related To Convertible Senior Notes",
        "terseLabel": "Purchases of capped calls related to convertible debt"
       }
      }
     },
     "localname": "PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RegeneronPharmaceuticalsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron Pharmaceuticals, Incorporation.",
        "label": "Regeneron Pharmaceuticals Incorporation [Member]",
        "terseLabel": "Regeneron Pharmaceuticals"
       }
      }
     },
     "localname": "RegeneronPharmaceuticalsIncorporationMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ResearchServicesObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services obligation.",
        "label": "Research Services Obligation [Member]",
        "terseLabel": "Research Services Obligation"
       }
      }
     },
     "localname": "ResearchServicesObligationMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ResearchTermExtensionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research term extension fee.",
        "label": "Research Term Extension Fee",
        "terseLabel": "Research term extension fee"
       }
      }
     },
     "localname": "ResearchTermExtensionFee",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltyLiabilityClosingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Liability, Closing Costs",
        "label": "Royalty Liability, Closing Costs",
        "terseLabel": "Closing costs"
       }
      }
     },
     "localname": "RoyaltyLiabilityClosingCosts",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltyLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Liability, Current",
        "label": "Royalty Liability, Current",
        "terseLabel": "Liability related to the sale of future royalties"
       }
      }
     },
     "localname": "RoyaltyLiabilityCurrent",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Liability, Interest Expense Including Amortization Of Closing Costs",
        "label": "Royalty Liability, Interest Expense Including Amortization Of Closing Costs",
        "terseLabel": "Interest expense recognized"
       }
      }
     },
     "localname": "RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltyLiabilityInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Liability, Interest Rate",
        "label": "Royalty Liability, Interest Rate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "RoyaltyLiabilityInterestRate",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_RoyaltyLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Liability, Noncurrent",
        "label": "Royalty Liability, Noncurrent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Liability related to the sale of future royalties, net of current portion"
       }
      }
     },
     "localname": "RoyaltyLiabilityNoncurrent",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltyLiabilityPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Liability, Payments",
        "label": "Royalty Liability, Payments",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "RoyaltyLiabilityPayments",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential maximum royalty percentage that will received for sales completed by collaboration partner.",
        "label": "Royalty Rate",
        "terseLabel": "Royalty rate"
       }
      }
     },
     "localname": "RoyaltyRate",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_ScheduleOfAllocatedTransactionPriceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Allocated Transaction Price",
        "label": "Schedule of Allocated Transaction Price [Table Text Block]",
        "terseLabel": "Schedule of Allocated Transaction Price Based on Accounting Guidance"
       }
      }
     },
     "localname": "ScheduleOfAllocatedTransactionPriceTableTextBlock",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement of reconciliation of cash, cash equivalents and restricted cash.",
        "label": "Schedule Of Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents And Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of research and development expenses incurred for collaboration agreements.",
        "label": "Schedule Of Research And Development Expenses Incurred For Collaboration Agreements Table [Table Text Block]",
        "terseLabel": "Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Revenue Recognized Based on Accounting Guidance",
        "label": "Schedule of Revenue Recognized Based on Accounting Guidance [Table Text Block]",
        "terseLabel": "Schedule of Revenue Recognized Based on Accounting Guidance"
       }
      }
     },
     "localname": "ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_ScheduleOfRoyaltyLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Royalty Liability",
        "label": "Schedule Of Royalty Liability [Table Text Block]",
        "terseLabel": "Schedule of Royalty Liability"
       }
      }
     },
     "localname": "ScheduleOfRoyaltyLiabilityTableTextBlock",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_StandaloneSellingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standalone Selling Price",
        "label": "Standalone Selling Price",
        "terseLabel": "Standalone Selling Price"
       }
      }
     },
     "localname": "StandaloneSellingPrice",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_TransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.",
        "label": "Transaction Price",
        "terseLabel": "Transaction Price Allocated",
        "verboseLabel": "Transaction price"
       }
      }
     },
     "localname": "TransactionPrice",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_UpfrontFeeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of upfront fees received under the terms of collaborative and licensing agreement.",
        "label": "Upfront Fee Received",
        "terseLabel": "Upfront fee received"
       }
      }
     },
     "localname": "UpfrontFeeReceived",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_VutrisiranAndZilebesiranMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vutrisiran and Zilebesiran",
        "label": "Vutrisiran and Zilebesiran [Member]",
        "terseLabel": "Vutrisiran and ALN-AGT"
       }
      }
     },
     "localname": "VutrisiranAndZilebesiranMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_VutrisiranMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vutrisiran",
        "label": "Vutrisiran [Member]",
        "terseLabel": "Vutrisiran"
       }
      }
     },
     "localname": "VutrisiranMember",
     "nsuri": "http://www.alnylam.com/20230331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "verboseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r276",
      "r301",
      "r487",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r328",
      "r442",
      "r456",
      "r482",
      "r483",
      "r502",
      "r513",
      "r518",
      "r558",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r235",
      "r444",
      "r503",
      "r516",
      "r553",
      "r554",
      "r560",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r235",
      "r444",
      "r503",
      "r516",
      "r553",
      "r554",
      "r560",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r321",
      "r328",
      "r356",
      "r357",
      "r358",
      "r418",
      "r442",
      "r456",
      "r482",
      "r483",
      "r502",
      "r513",
      "r518",
      "r552",
      "r558",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r321",
      "r328",
      "r356",
      "r357",
      "r358",
      "r418",
      "r442",
      "r456",
      "r482",
      "r483",
      "r502",
      "r513",
      "r518",
      "r552",
      "r558",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r276",
      "r301",
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r329",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r201",
      "r329",
      "r525",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r236",
      "r237",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r504",
      "r517",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r469",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r504",
      "r517",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r201",
      "r329",
      "r525",
      "r526",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r515"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "verboseLabel": "Receivables included in \u201cAccounts receivable, net\u201d"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r29",
      "r34",
      "r98",
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Defined Benefit Pension Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r163",
      "r170",
      "r171",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Unrealized (Losses) Gains from Debt Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r154",
      "r451",
      "r461",
      "r462"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r169",
      "r170",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r31",
      "r34",
      "r98",
      "r411",
      "r457",
      "r458",
      "r534",
      "r535",
      "r536",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r27",
      "r34",
      "r98",
      "r170",
      "r171",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r543",
      "r544",
      "r545",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r92",
      "r93",
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Non-cash adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r125",
      "r137",
      "r152",
      "r183",
      "r226",
      "r229",
      "r233",
      "r245",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r377",
      "r379",
      "r395",
      "r515",
      "r556",
      "r557",
      "r569"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r148",
      "r156",
      "r183",
      "r245",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r377",
      "r379",
      "r395",
      "r515",
      "r556",
      "r557",
      "r569"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r242",
      "r252"
     ],
     "calculation": {
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r69",
      "r241",
      "r252",
      "r445"
     ],
     "calculation": {
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable debt securities",
        "totalLabel": "Total",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r68",
      "r252"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable debt securities",
        "verboseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r60",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CallOptionMember": {
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option.",
        "label": "Call Option [Member]",
        "terseLabel": "Capped Call Transactions"
       }
      }
     },
     "localname": "CallOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r55",
      "r150",
      "r484"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r50",
      "r55",
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r50",
      "r55",
      "r59"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r50",
      "r119"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r373",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "NET REVENUES FROM COLLABORATIONS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Net revenues from collaborations",
        "verboseLabel": "Net revenues from collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r24",
      "r129",
      "r142"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r258",
      "r259",
      "r472",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r543",
      "r544",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Common stock, previously reported value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r515"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value per share, 250,000 shares authorized; 124,241 shares issued and outstanding as of March\u00a031, 2023; 123,925 shares issued and outstanding as of December\u00a031, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r35",
      "r166",
      "r168",
      "r174",
      "r447",
      "r453"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Statements of Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Balance and Change in Receivables and Contract Liabilities Related to Collaboration Agreements"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r304",
      "r305",
      "r317"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Contract liabilities included in \u201cDeferred revenue\u201d"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r304",
      "r305",
      "r317"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract with customer liability revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r82",
      "r273",
      "r274",
      "r285",
      "r286",
      "r287",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails",
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r510",
      "r512",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r40",
      "r444"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r182",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r289",
      "r296",
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "CONVERTIBLE DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r126",
      "r127",
      "r136",
      "r187",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r408",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r83",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, conversion price (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r21",
      "r86",
      "r87",
      "r88",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Consecutive trading days threshold"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Trading days threshold"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r120",
      "r122",
      "r273",
      "r408",
      "r498",
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r20",
      "r120",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r20",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Cost of borrowing"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r22",
      "r187",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r408",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Depreciation, Amortization and Accretion, Net",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAmortizationAndAccretionNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCapPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract.",
        "label": "Derivative, Cap Price",
        "terseLabel": "Cap price (in usd per share)"
       }
      }
     },
     "localname": "DerivativeCapPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r113",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "DEVELOPMENT DERIVATIVE LIABILITY"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r157",
      "r158",
      "r394",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Development derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails",
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).",
        "label": "Derivative [Member]",
        "terseLabel": "Derivative"
       }
      }
     },
     "localname": "DerivativeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r107",
      "r108",
      "r109",
      "r110",
      "r112",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails",
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r316",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Net Product Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r333",
      "r361",
      "r362",
      "r363",
      "r367",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r175",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r202",
      "r204",
      "r206",
      "r207",
      "r208",
      "r212",
      "r383",
      "r384",
      "r448",
      "r454",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r175",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r204",
      "r206",
      "r207",
      "r208",
      "r212",
      "r383",
      "r384",
      "r448",
      "r454",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock, inclusive of performance-based stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r85",
      "r146",
      "r169",
      "r170",
      "r171",
      "r188",
      "r189",
      "r190",
      "r192",
      "r198",
      "r200",
      "r214",
      "r246",
      "r303",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r382",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r411",
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r153",
      "r393",
      "r486"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Marketable equity securities",
        "verboseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r550"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Realized and unrealized loss on marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r385",
      "r386",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r114",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r114",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Marketable Debt Securities"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r287",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r386",
      "r415",
      "r416",
      "r417",
      "r498",
      "r499",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r287",
      "r322",
      "r327",
      "r386",
      "r415",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r287",
      "r322",
      "r327",
      "r386",
      "r416",
      "r498",
      "r499",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r287",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r386",
      "r417",
      "r498",
      "r499",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Loss recorded from remeasurement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Amount received under the Funding Agreement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Carrying value, ending balance",
        "periodStartLabel": "Carrying value, beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r287",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r415",
      "r416",
      "r417",
      "r498",
      "r499",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r390",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r298",
      "r302",
      "r381",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r496",
      "r547",
      "r548",
      "r549",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r37",
      "r123",
      "r130",
      "r144",
      "r226",
      "r228",
      "r232",
      "r234",
      "r449",
      "r495"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r184",
      "r199",
      "r200",
      "r225",
      "r368",
      "r371",
      "r372",
      "r455"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r443",
      "r539"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r539",
      "r568"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r121",
      "r132",
      "r172",
      "r224",
      "r407"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r178",
      "r180",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r529"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail": {
       "order": 3.0,
       "parentTag": "alny_InventoryCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r155",
      "r485",
      "r515"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Long-term inventory"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail": {
       "order": 1.0,
       "parentTag": "alny_InventoryCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail": {
       "order": 2.0,
       "parentTag": "alny_InventoryCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r42",
      "r223"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r183",
      "r245",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r378",
      "r379",
      "r380",
      "r395",
      "r494",
      "r556",
      "r569",
      "r570"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r128",
      "r140",
      "r515",
      "r542",
      "r551",
      "r565"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r149",
      "r183",
      "r245",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r378",
      "r379",
      "r380",
      "r395",
      "r515",
      "r556",
      "r569",
      "r570"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r16",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Fair value of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r22",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONVERTIBLEDEBTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r215",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "NATURE OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NATUREOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r50",
      "r51",
      "r54"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r38",
      "r54",
      "r131",
      "r143",
      "r147",
      "r164",
      "r167",
      "r171",
      "r183",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r205",
      "r226",
      "r228",
      "r232",
      "r234",
      "r245",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r384",
      "r395",
      "r495",
      "r556"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r226",
      "r228",
      "r232",
      "r234",
      "r495"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r105",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r28",
      "r32",
      "r396",
      "r397",
      "r399"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r34",
      "r36",
      "r170",
      "r400",
      "r402",
      "r406",
      "r534"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive (loss) income before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r36",
      "r85",
      "r165",
      "r168",
      "r173",
      "r400",
      "r405",
      "r406",
      "r446",
      "r452",
      "r534",
      "r535"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Total other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r30",
      "r32"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax",
        "negatedLabel": "Defined benefit pension plans, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r159",
      "r162"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r537",
      "r538"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other investing activities"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r46",
      "r67",
      "r176"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.",
        "label": "Payments to Acquire Restricted Investments",
        "negatedTerseLabel": "Purchases of restricted investments"
       }
      }
     },
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5",
      "r515"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r532"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r177",
      "r490"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Proceeds from Derivative Instrument, Financing Activities",
        "terseLabel": "Proceeds from development derivative"
       }
      }
     },
     "localname": "ProceedsFromDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r49",
      "r91"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options and other types of equity, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from maturity of restricted investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r78",
      "r141",
      "r450",
      "r515"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r34",
      "r36",
      "r170",
      "r400",
      "r404",
      "r406",
      "r534"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedLabel": "Amounts reclassified from other comprehensive income (loss)"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r94",
      "r145",
      "r577"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Total research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r527",
      "r540",
      "r578",
      "r580"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Total restricted cash included in other assets"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r55",
      "r59",
      "r124",
      "r138",
      "r150"
     ],
     "calculation": {
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash (money market funds)"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsNoncurrent": {
     "auth_ref": [
      "r470",
      "r471"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments, Noncurrent",
        "terseLabel": "Restricted investments"
       }
      }
     },
     "localname": "RestrictedInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock units, inclusive of performance-based restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r89",
      "r139",
      "r460",
      "r462",
      "r515"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r146",
      "r188",
      "r189",
      "r190",
      "r192",
      "r198",
      "r200",
      "r246",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r382",
      "r457",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r221",
      "r222",
      "r227",
      "r230",
      "r231",
      "r235",
      "r236",
      "r238",
      "r315",
      "r316",
      "r444"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue recognized under ASC 606"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "NET PRODUCT REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transactional price remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Receivables Related to Net Product Revenues"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r34",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of Changes in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Common Share Equivalents Excluded from the Calculation of Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Marketable Debt Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Collaborators"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Development Derivative Liability Activity"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Assets Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r12",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r330",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r25",
      "r85",
      "r146",
      "r169",
      "r170",
      "r171",
      "r188",
      "r189",
      "r190",
      "r192",
      "r198",
      "r200",
      "r214",
      "r246",
      "r303",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r382",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r411",
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r214",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Issuance of common stock under equity plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r85",
      "r89",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of common stock options, net of tax withholdings (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Issuance of common stock under equity plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r85",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options, net of tax withholdings"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r66",
      "r515",
      "r542",
      "r551",
      "r565"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "OTHER BALANCE SHEET DETAILS"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flows:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r298",
      "r302",
      "r381",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r547",
      "r548",
      "r549",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESFutureRoyaltiesDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r562",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government-sponsored enterprise securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r492",
      "r510",
      "r512",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r216",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r203",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares used to compute diluted net loss per common share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r202",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares used to compute basic net loss per common share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3505-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r521": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r522": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r523": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r524": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "83",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001178670-23-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178670-23-000011-xbrl.zip
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MJ#@W* JDJ'0<.^NL7=S]FA9#$K/;F2E:P323D3E%&./80/ LI.<\ZA# /U7
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M!H:-488(1+EUJ>S#*%4IS*Q(YM,#,(1(0CF!.#*"X8B41=R18(D-G"/!G@:
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M<_:V]@]V/\_(K Q'-0Q'@@-A*\NQLAS?A(J6$\M!U[,W!_5F>P=H0DJU)B,
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MY,^S:-R7+W8O1_OU?EH'CI -^EWH=>"+ )2+_@@^]L"-I+VWXL4_]7$24"C
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MI23W. "_V2]%ULG/('X]Z??]9[UT17A7H'UDT*:1I-$5H;R5I;B1R9BXG0M
M6L=<E*P#H'QE@%*FQ>2=4=K[<3K"?76G,<><)#SNFX:=!"R39DVYB4O[1/HT
MJ)?]<C7*-HUFLOZ=)]I0FLLQ.9Z,P]R,J<<CUC>#H%_7IK^, 9P7I1(ES;WY
M6D7Y1#AS-![RNW&'%8H?>\!@:M!N# &DJH11WAE+O /R+PPPZ73V)&5XC0(
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M!,TMD6AM0W)>)XI6"*!*XO4+P0<;5P7SMZKD[Z3[^'$K,15[%QFARJ)0F^.
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M.\\.BADSBLN5CO"3<:<TW)F268(8L9Y$W)'"2D!-!!\56+)PB'7,!,*D6=M
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M_(WC(JEKS9E.=.]KJU/\;GX3Q*R/"M K6S41_)5N(I;H])&O:9O2HW3G/%6
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MH76$)OWN)8U.K(Y-/)NL_U4\:$I/0\NX\9*X,6%/&HNYC%9#,?>+(NR ,8&
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M ]I*!2 DDE(7'#<AM6RC:#(?_VE9$ N:4+?<R%!Z\E-&AD5#AHF4*6Z\]CP
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M;7%,*.@)A4RJH 2%TFM,.'-24>D"M43^B^7:^$-'E]U]3O57#TS/ZV] A_B
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MBAF6";VJX(5+?_ZE(VRE6DS?Z>MTBV][W7X_0]4CH*HY97ZT5AX%(RE@2EM
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MS1CEZI(5W>Z<O[H%8+LC&5T"V<>AA ZZ>V/YO"O$D]&M-'1K35(7S2WQFB'
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MVY!UR2;GOV3'R3)H^CPY2=;T^6GZ1+8*9Y10R0"*.@\HC3:(%MP (^-6Y-1
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MPZ8,X)>\R[U>].-)7K!A)L/Q>6NJ%61+?-[<\H+4C;W0OOS<>FLSS?1ZW4P
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MF^*;QK7$^I#W';'RO*MF*CAV*O54K-;:?J'BL7?[QO=/STJ@P>,N'#K5B5!
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M:QT9RU54V.U,]+/]7G_VSR*XPC.5S@2S6RIM*[22K4W=\?DCH<OI>3R:CP$
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M8LD=Y=HYF;PRU-FD/.$-"ELS\;"(PERRCFB,-*C2B$NED0F.HABY5E@IXWP
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MPKCVTG&>$#'"(AYE1(9)CCR-*A!N2(RFU!T0>IWCO%<6H#6!G$T@YZ_C'RY
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M\&-JMN&)#V >)>6O,_*/)W]'.R%?3L9QB#^*33CS'I^,"ZV:&=IFT2@7[E:
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M+C//W,6SNY>K&Z\[_[?ZZNUZ9W-]]<W;U[-8M!M7K_GQG2]4K_&21:Z2,E0
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M>)VE#DLKK$OY3Y?QJX<B[46U2<;;K"W7SD'3$3UJGQ#/3)4LF7HHTE9 TXN
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MJIY @)L3^GL<#IP;*J;CU$A0,M^^:>]^WOB^ ]?L'KP_WESS8G?[$V]]?G,
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MVQQ1G3VANO\*SL_(2+WUZCP9\7&7SKMS]NM9B3(7;#!SY491V&%QU]J#H][
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M"6(TZ+QL ;',T,-9PIGB566!5<HI?-,\1:"9ZR=8/:M7'O4!Z,H%<V#8'C3
M[+(56-H"ZA%^ZV3\OI[2\2N($-0.#S_9O;B52FC#WQE\M_OMO;T\ON>KC?@?
MH(VD($'MX R19"7B,1?O24(AZ@3#AJ? 9/$<S1/C?TVHJ)+2Y;QY+->ZE89A
MCXXZ8!EDZ3U#?'\V?J-3$9WOOP:(@:HJN2:**2.X3-($FDLG8X!>PW"0]R[E
M9NQX,"E\MN6/>_TPB-UG#&I[QRU0:W$P(K& 3& .<2$)$)*S2 MXGE#1.2U?
MO$R 7/.PYD8#L+S :LK8-)9NE7*65;@EIX\+A5Q-*XMHY<=86P+4D8B97/)4
M*H8T :I)WH(Y9#FG2KUX.8S=*TO "=6TNS.>BLGO%2IEZ^D_21-C?(GS,*O@
M!;_F)*:]EDI>$^.R$^-7NO7^B[%!,T(54BP <$D+ICC+X7<Z:H^3 -4]WHP8
MC^V@49Q!16NZGJ;T*XBGUI0N.&%;_=XZ_N)"#,R#6",D:TK*.V1<2,B0 !O%
M O693LQ\AX:IHG34[X61GZ+-M?P"Y5SEK+(U\?N=(E=O?-Y[5MMBOS<V4HE%
ML9U.D:C9QP!_SJ%>]E >%F_.G_F:W_COC4]'O2HJL.=]J0U>C6]P!*262K1;
M'R:01S+V)P/-#^)P[(T>1Q2>>LWW>C#Z[D3S&Y]L?XZ5X[.*?*S<-M-I%@_U
MV.=\DCU?Q<[I ZUW@.WZQ<:!=Y[JFDV8YV"_V1CLVW[E C^_F,6Y;_-7KMV=
MQDWFNRIO^O3&LS<!^N<GQ7)VU>M>*<!Q[*X>^Y0Y75&YVO51;U".S?XH49\P
MC3^/VV&X/\F=F;EQ'*:+3V^Q;M#KC(87WS+C3,_<#)S[X*YSFL=$S+D%FOEW
MOS\9S1&@#7)@77Y%1>/[PW:.LZ;]K[/G!>WNY.&*PMO/S_W"&:9T;S.LCBA"
M#J8M&_Y'<4[FJV!,=FG&T@!T!X'R'Y>'V8+*M5V,-:#\UUD6 3O_][_LRPM/
M<1Z>TN:B# NEK;YK[;Q;W6S\_>_5#YNKK]<_;6^\7GWWL=G8:+V^^ QJ64;?
MVMI>_]C8WFJ\WFJMK;<^KJ_EOSYNO=M86]V&#V\V6JNMUQNK[QH?M^&+S?76
M]L>EG]1OG[IV%-H@V'Y?A (+@V8O#8(]'S2;J\;SD(*)^<JD#=$">Y^LUA(L
MB6L&S2[3D>-Y*9_&I]$SIX3C<*]..2EF*]QP<H'DNLSR&8=;5'93>U#2#+YE
M'^#IH7D5O3'OZ$E9[O9[WT'K+$[$GP9=@'KY,0_PG*;KHW-"8>4X)CP2;8(D
MF$@6%#?1:;TXJI5>6;U]/1UU46>?L??Y8">'T#.?B% T(I8(1ISFTDO28P3\
M1KQFSG@,DH!JN;+HN"+34B&S\U16'13^C%1."1B47J#32EW,CN?#]NAPGIBN
M9S#=DHQLIWORQPS59'+ZNQK9!Q"K>UW@X)";Z)R24S[9?LY6D>= 38%9*FA0
MR"=L$3>*(&N(0E0HHY.@!!N\L/@[6$7?QJ>OOQ U7A<*KHQ=V]_J?\Q)3N$?
MVQG%TQ<_6[SP NS>A&%1,0F(>DL0UQ+T=1HY\EQ*JY25QL(.4T)7\$_QXF?F
M[AEQ-1M=TY@D4U3P<EXN@K0:C-P!&&1%5(4LRC/\CP,%)L%09T($2J"$SREP
MI7SE-$81E*7#P02G3L.^'G\,$YC7.: LGR=7(4@S2'PTB<,X%V%$<5EV48SS
M?/?XSJR(%$-Y>@"8C;!3!\?/_*HN9M-]&@5UU!D-\D;T<YA>MKM'W2/;#J>1
M3UD@9"]%=0J0Z68FS&02;EK9Y%4(2O-,Q,DI#4TF\Y.(C,%/7"_[-H\]=J\0
ME[%0,H7$+.BD41/-.)$<.(:#$09\94VBCM>NO >$M'6QM;UZLOEC@VYN?_VQ
MN?J%>"5!CABDL9"(>TR0D4XC)0P51"7-HKSN 2A\62+IP7C)T'33F)Y?03AU
M3,\\E;3VOJ2DG,M' Y8) T*0!62=2(@YI76"73(VW55\S_6./'\%D=1Q/3\E
M& RPDB)S-D:@$)6/PXWUR&D&_W!F4I*6."ZN%>,S/E1: <G7&+2[7_/7:91C
M?;+LZGUKYXS^LWZ"\9E!/\+7,1\ 9#6L4@/ Q!_G7(P%>_'^#^'+6>6@O+&*
M[7X">E!U"%(TPSU0%LOJV4SBV5[=M]V]6$X20DQP:YB<74PS!AIVKQ]+ 81F
M!? SFN=4T>QUJX084$W&%53&VE-9\,9H4"WY--MNJD]=J.FT)\DW)=9[?LRS
M3ZNDSPU4,[C8S3[I<NUL!53D::)@4:PN/A(J1T>GJF9^;0FDS\4L0CG$ZN<'
M'(^3-F":0*1C;>ST2*JD4X]=7[X?\WP7'8BY$LJ&)KMHQX4Y\D)/=N1XOU>=
MXI2MJ_!MO-3=LAS53G:K<Y[*0JAB?,_.;&J3C/<\;V(5DSQYT_E%GKRL9*AD
M3CR,^<W PN-8NY7&X^>SU=.& )4Q,8Z<9G/AW:>E4O()7J/3Z^ZA;(8U.FWK
MVAV@CV:C&PNM9LHH]IKO#:JLE>LD>%G!:(@R&>'S>8?1UN9Z<\P3RAV6J7@+
MV%R-I 6IJ56RVIMV-P_F=1[+VWYO,*AS4Q=F>*UMXM;JET!Y9)@#4TK)018F
MB;0@!I$0A-&$8A5I/B]<F2_UWACGI1;3[B?%:=RX&<5@/\;A8*5Q"0T"@!4O
M(TA,"US_+?M[SC+K<76F?%7?]MW0VUQ"X3O@B&U@B*R2O8&1%L=4G4VX.)OP
M/<SA$XQMXWCSX)/XHGW4$JPW9#4!PXX1AHP)#"GOK+,RZ(1QR2R<;ZN](+-P
MADZ.BY*0<:I(&%?DY9@\BV?!3G);L_J69>E,_!G&\V$7Q?L$NC6(12"B_1+-
M#;>=::G"&K^] Z'3:=#?+TIU! 7AR/;'Y9@&)11CT//M0N93+]<41\^,(J/Q
MN(Y4T0JK!9AZ8N+W7% JGGIL,['GQ2J*1@;LV:==SGW%+*ZZ:(_?,!_+TAZ,
MBT1>[Q0@&2=3M-X0RYVU5BOCA?=4@9D4?%I8;ZG.:KL5QN_!4[[ B@KJ+ <#
M1UK$J5'(:,&1$A;,'<6%H&%A5MLM#(OE*7,$D@+XYG56XL$@[@ZJR0T>ORZW
MT3WC1\V)T0N4X[&!X<<UC>8S_B?1:_,U2DH_</7GM#+)J=6SH#;)XI(#8!:4
M4(=BL^7+JS)+@+_=N >&1 % 7VU1"8$;SFQ1B06[:/\JI+WHUYDC^)SYW6^>
ML0BG6>&V.VRCT.Z,RG1.SR@&%1A6,%9BZA:?WI>PXW$\3YQ%V6)\V*.S!ZP7
M#W9VO)>=N'V"C^<#4@7CE!#+C$T\86433EPGQ4GTS">_6*59<$Q?=@? 'T9:
MG-+/UFN4ZXRVCK]@Y1B6QJ)$?$ <,XP<("FB2G&L$FC+1KUXR2G_^?G:)(#C
MHK/UZ\E1V$BO*/:4",&C8U9$0EGP(7#ME*17.4V?.S[?ZE;4F8ESEC:?L?#<
MWF2;[[\0IR(VA@.&FX2X\*"T6BF13-C%J!U7-H+P7+#_,Z?H5S]?O<1VON#$
M_98D49^X7\F&R8@@J-'>!(F\BKE-KJ'(1.D08]3#$EL#QLM53MP7'J2/$T0'
MB]R7,\)I)M7^S,'XQ:+R<W9O9C/DQE:SQE18CU-DGG/N@F')\9!;PD=I!;Y,
M>3]UUU3P,]8:!EOI%'8&'TJ=W;#=FSG7J&H<%:E:^W$6T^4GMKGW!0QG#5:S
M1R)RL*@Y2TA[EY/]C-=$,"U+K1ZB5RYJWSRI,G::$.%C#(.JR$G),I@IC3GU
MFA[9D['5.1A>2H?7B,I_-%KX!?&RE\:_?LZ.:D#6H@'_5#O,F##CTR@Z)]QP
M DC2&W5"/AW(,3.C[G!\RC2(1[9?L?AT\V;UTO%6U>S_)-B_!(+='?N?M^DN
M),OL:ILM5V[S>=#(3PS#F4*5^7 *9=/4'F6S_9):YF?<Q;,=C,^ZJR8%Z2YF
MFWYU0/B].DLMH4C'LRE;U?D.C*/?!N9JV_%)V\S)1WM\^?C(Z'^/J[ROS$/7
M@J.AJ]5/5WAYZZ<3_  %U"<FYZD?;[#:#?^.(9<77,VNR%).?^FJK+/-TY86
M>.?@/6T=?OJ^>[C.-]<^'+2VU^%]JWSG<.-X\W"=M'[L?FW1OP[/<WKKX ,@
MPP[=W7YSN)-S]=]NDLWMKPS>V]XY6#W9*6TQWK.=PUW@]#VZ>?Q%@VZO25"(
M2@6<3K5 !JQ]1+TG.<;6!,S/9V.01+@, @P"HL$@H%HY)W0P4CK/<RN@<U76
MU];_67^W]7=.9VFLK7_8^&=U>^.?]<:[C=57&^\VMG=N4'7]\B&<';)F08(I
M ^RB%<^)M5&H)*D+EB<JL[_R46H+&]W&ZF@/QI0Q#,_[QW+F(\BT;['3.RK!
MLC.!#0NJ<;X95;5E5D^O*DZ_5__OW<?&/XU7O7"R-[+]T"BN//)GX^_7?S?>
MK?R]4@"P7/6F3+.Q 2)W')\+IM^P"W"WWSZ"9TSN7/_XNMS9_&F)T%<=Z[\"
M9G9CXUT[Q<9'W\YIJ8/FF6*/E3?DHFNK0()QW$QC='3=BJ%@]<JDK!8>2VX\
M$)"E.B6!";=,T*JF+<:Z@B7XXZ>ZRFN8K74E=^];7.WW<UQ'7J9-"W;4Z'"\
M X]".7EPR-K\\?[D"^B'QJCD$&P) <!R&N4&2(@%[#!HDQK[7%-/7*D\>QH3
M_.1HS@.+Y2"HQBS/@,+P;33LMP?M?JZ8#93^H]V)+I;/S<;PN#>-)0;>:/<.
M<P\7T#]\)KJ]OCW,%G-FHW[,@3.%9$\?V+R8<',T<G;GM(?#BB-N3L18@$0E
M+KE<FCE9 ZNDN;+<YF-KZV5-Q \G=S_1+P9SJ:SU2":M$)=>(4T50]X+)33%
M-F$@8G4Y#0,9E,C 67JM3H2K+D-A$H7U[_5W&UL?T:O&WT459Z>D#H1H.R7&
MJ]7[-CW](3^AR][1<!PTUQL_CIY[W)2Q@#'.,,N8G$M5@&KH3:!FF,@A:.>E
M(MG8/W4$M)4G$[M](+8RK^$D)G70O $'**V=P0)K#3:-$L(ZHPT5TADFN62\
MYH"'XH"MM?4?V0\.^(TC"D#OB&MJD1&.(X$#2UXZ97R.LI:7<< **"W]'/EZ
MV,L'(S_%TLP'I6]9L^%&P^P8S7%YX\99N6SOA)NN3UTL "DI#_:9MER 81:%
MBUE'D#02;VOJ>CCJVEZE7R@3-F J4618Y!XN'AEE#8HAJFA  BHK7[P4_%)\
M3:7\R$^PU5X J.>0KW*5G<;C3O!QU!E.W.?3R&YW<C$9MW,\TE$LAD=V^I?(
MW?UV+*6\QV&Y\:PX@*G$\JA!I<S/:"&E]-5Y0? Y1P<7#![T.K%<WNL.VE60
MYE13.F-45%WA#O.Q/IA)I_WI7 _>=['N] 0"S5<'Q=L$^U95XRCK<]'N30(@
M9K7.F=59J'P6@BN&W;[]-@Y,#Q-/^85D8J_;MR-$;(*UCD30"8G4H(,$RX(0
M,@& I4O@ZWQJ]6+T^M [L9WL?/F[JFD]3EQ;FB/AA[=GMM\?YZ@ ';6@PB.1
MNR%PQ@TR(#Z0$%H3QQ+E7B^N$MXO*WJ2@2#'3E?9C<!WJYO_?-K>_K#:^.V4
MO'ZO<M-^ZH&[$1G<8.=SG.M\G;HPZN="Y<^/".CFWA?M&:/!4V2(9+FJM$).
MA(B<(2GA)+GR.3<1G_>5H5(EO@1FGM9W'TTJ>:5V?S"<P>8J5N"TH'H_[N5N
MI;T<NY3/<K]5@FL&E#+1K (MH;%M>](#S7S_I*3/',=<9&P ;\E.<0"D:<O0
M2H%Z4 RZ&B6^R4/]NQKI9A:^1[EUP[)$(?P"XMLYV5S]PK!/$F.#?.(:<<LT
MRE7,D>&:>4X\=C9'(:S,EW9H#(LTK<+XVJ=.OQ*J\FO 9G:++P2::4',9[7=
MV>??6@7;RU*M8T1)^H1 L2'(Y6J'DM-((_?$2O/BY?"X5\#E/.),2EX6D+DQ
M@)3#L*F^6HZ;^^WLV!TW56D7^ZQ3*I%GM37T[7'W]/RY:I4\@V06ONJ&:B3]
MF&,_2VSZ[92S.>?&O"EPWL%Q347M;J#SEKZ-JZEO-72>A<Z#U>^;[[]($B46
MWB,=9+8TX1]+?(2//#I+.$G,OGC)5N@EV#DAM>MAZ(TVOL;06V/H^R^,^:0=
M#\@RSE$NWULE?<O$B!/*&)9+Y:3>J'\YB&9 &XP\X,$@C3JEP7HGSE9 F4&8
M"QRN4]R<^$]G@'E2K;5*Q1G78YT>CYX_ZIA]5\GF+3A:%T#]:0'47 VB+H#Z
MR\=2%T!=\M'7!5#'\2MW'(_RB[R?=Z%=LZ77KF]YME,[)FZD7;__OGG\!8,J
M107+A2:31CP*@XRD)7]*.QJLP$:_>,DO<TQ,*.UZRO6-]KU6KF^M7.]]<8)$
M8Z)#T7F</>(,MMU*%#RA(=(4@Q975:XO\%#,JKGW[XIX_ ==6Z/^!$@G)^8E
M+/HT=V@N>'#2XK:1:USU\_GZ@CRD^-W'HW%ZKCNI+LWGC)-R :5"3_Y0@@1S
M$0+80]C??.IQW*U.2T?C$]EQ5,G/@K5FO-;PW!RSE9LF3Q(>SO84FLBJ$(M!
M,FW9"]L;GDBQT!*V>9'T+*?#1=Q. R=*-%')',E%'!;O>MZO82YLD4N,E9VL
M*D%\BZ>EJ'JE,MZ1A6T<:P:#<]VK!VV8<>Y_6^4-P2NJO+.?CCC7WZK:.5US
MC+W^_-EXNQKCN)'+^5G8K#44LLX%KF(Y\L^F';S<G9R?8W/1"^STV:4RV+FX
MI_UH.\-QDQ*;\AAS':Q)%GL[+<2U,T!V: _@RC$Z35'M-.HEOVZFCMSI8"8X
M5KD)9GT19WT.@_/WGBL4=K58G)N0U&AQIYISO==/'1Z9S\=5IO+K#NW7>*H5
MGB+8-#BZ454O&^NC^=-L>$.<G7.U'V5 =E*FK63APG+WBJ09 >'^E&)A)2]?
M@HNI9USH]J '* D0$JNDNDG<:*S*GPWFEWE6VQX'JHXWU YGR7YVY4OUMVD%
MO DUQ&XXRF\?3*L.5C$I4^J:>6"OWYR;RPQ@YU[+Y25YRZ;T<>%&S-R9NQET
M\R)4H8GV(DX8IQ8-0,<>\S$(Z+A7[(1A16PIKV!9]D+1D_E.EB\SPYDRTZ?E
MZD X3,/)+@_2Z$X"@LH*5>T82CF_<=>BPZD= "-MSFW:1#[E;J[MLMA9);DX
M9#YCR?&DQ/-AGM'I6']61'O",87J)UP#7UXXL1 'OM]V.8_+@9Y=9E/X?1RN
M<.[W:0*7K6J"3*(7FI.,Q.,XAJN%H)=)[(S3LG^5XZ<9F#O=UB<BU,?*S 2=
MY\&DVNW5CZ\;V[TC,'MT[LI^FCM5Y8B.<Z:JEENP9Y-?9ROV'8),*C(0Z/>T
M;%;%X9F^B@B<7-^NVI951;>O5-JMI)=6F)J#]4_K<@7X_SBP&4BY&L3AC'XQ
MRR:+1IZ9;3;9L!KHM/;53P<YR%4,I@Z%K(O:T\3:+"_[<1]N*^_K#<YG*3]&
MFKJDQM=%"WR^YF-5U(PU4JFHF!6FF<O'\2JG6PP"I)_?>%*1097;W"Z1XL/]
MTOYS6J+S]-1CU.TYF.2WXMJ=O.]KS,\_&A5;8MPLN_%;^_>)&'>309321:!W
M5G'K,W&5I6[%14&5I<IK0>!3=+P$B7]K7^/MBS O7WL5*"ZO@G<!S4SJ($Y8
M9"QZSKYU%J6/JEBM"X/+,C ,1H<7#?'"P*'?VM]^'_-7E3CN>OU^!<6_7;?:
MOM(:6\*9CMR1H TKN?$R<L^%-(OK%%VK\%M5LN2TQ/[S#59L;>^(S=4O6G.=
M+&/(N6@0CR5.C6*$8=VI4DR6?KYDOKSG?_U>:2"_P>Y?1*[_^_8TD21VAEDM
MI:6<!:R35Y)0%213V(50T\2=TH3'6ZM?D@C:>N:05H[DQD ::9D($L+17$#,
MIEP G2\@B96Y5-][3 [_Z/=C&'7B5CI5==Z=ZB:KIV57MZL@U>>;&-XZ_A)M
MB#B%A%02"G&6=/;!)F2#"MQ(ZE0(YQ.]'Z5V4TJ^GEH#1>9-ZZH525E5#3B9
MLUNOHFDV*]6F-X(AAL$?-U &IV>;U="FP1*@N_913IZV1X/XQ^2//T-[<-2Q
M)W^TNV6JY:8_QT\?1UCDL(Q2$05@:_R2\K[JYW' @98K@IL<<S#LP__#Y,7C
M<(25$H[PKV&8_TV3%2+9A3_C%7+#WR3G-[KS9X,E8D69JPWV7V4AJL6 Y<X;
M^7]>L!?3'0&9MM<'I2J@,>EZ'V-*?QYEEUAW[P]Z]+U!SNYM)Z:YK:AVX9)8
MC_OBB!)E\MKV^Z7W<J6)5S53UD#'/6T:-;8 Z+D#[_$2WF1U<%Z;^6VXTJKB
MQG77]E<LZW].%^LF4YR=6G&,+=7<KI$JZ;2C.2HG42NYDM: XAZU,Q*>G&3@
M57%!0L]E2++SXGPJK3=/[?^<9O]IQ@;<*&9?+DL)!B=@<C'4/^0SINSB>V4'
M[<%$ SBY1L%U]CA5@OV=P^^=K8-_]EL_]N'O#;9Y\&I_-^>?_'C/03DXV'T+
M:L*/-_M;;S^QG1_^>'(/O&NT2S_)UN=UMO7V#:@,_F3S[9L.J!0_<B6IW</6
MU]VW\+S/ZWQW.QRT?KQ*FZ_QR;OM]>'F1_Q]<WL=YK'W15+N*&PV(DI2Q(,5
MR#%LD*,6F\BU<3G)A6+3!"OB@LS,VS 1($3CFLQT,^1/Y7\W1OY?P<&KE3]@
MZDS^R<'N^2VXR9*<A_OI,^CUEG4A]#]J?%186<=\! U;@O%$K8K)*H^MD,F'
M0"^KC7=G0'D!3F[D%@17+)]7 ^45@/+C/%#&I*2)U"#C8D+<.X],[BO&.=':
MBN!H!'.+YS[?MX7)Q5#U,#!Y2P7Y5S#RN]Y@YNB@^'G/G$#<"!LO486OA(U7
M58N?.S8.8+[PUSV#Y%O;[F92V2@'#C%L=-=M/^?FUL!Y=\#9G@=.8;S7@6;,
M)!9Q%3C2N4282-Q)&ZW&SKUX*9M<S>?3/Q_]<KD\"PL.%F_A5KA$S[SLOK%?
M;>PI8["AH3?*?K>\.)-?2R%5^*D<"E>_W,@= <_Y14[/J_LB[G)=+F6+7[<@
MUQ%"5 NI/2=41HXI=CF)76*O4M!,!7M!Q[?:@?'(Q,O)O'A)@H,X(0:!RL$0
MM\$@*T$O5]IBDDRPS.2J9<0T%==WI)G?!>==73!5''@JE?Y5#A!F$S_/%.I=
MF AZQ5+5[ JEJG]%KM,%U:O)_5>OGA:EWDJO>X<Y&&FL8Y9R8Z4%:>F:\BKW
M(1QGD R6YISR9%JJ7L#SZ,[G=;*UW=H'GC[<A.\V?P2X=H<"CY$6S27I-\1\
MJ?JO9'=M=W]G^Y/8I.O'</T)?/>C17?P[L'.]WQ.N?NYU=D\Z.3".?A+RD5#
M$DN(:!-1[B6 ++ AZ'LF,9TKO3EUOA8TCIPZ%XDG 4"<,:V=C<)*%HA)Q-'S
MIYH?M[=>_U_T:K7*5MS\>[WU<75[8ZMU@[+5E[[ZX<[ 9PDL4]:;7G^.MF:2
ME@:K':"Q<O56.KWP_%,&KT[^[MCN<AV@/SQAGGS1H"7 MG*D, '"])0C2Z-%
M*03!700L%.G)'I\/1H<P?GC(H&IX@*K&J7Z&6";!EI.8O"IJ>QQ-6>+72UO3
M;IA>^(C.SA59,?1&9^<2KVASL_/QGYYRJQ5FQ#T<R6LB[V>P^JJ/76 43K81
M<#0NQY67&/B/R0&Z6(F=3LI<95(56S[,M/1EVEV9U7;IR;S9*SV9U\_V9+Z"
M2_?I4\?5EO&WC9E@I]^OX@N_R'Q98,$L-P6=<5O=<L(7'@ \T86C]\YBOX!M
MG\1QUX<XB 4'[=DF ]?UDE^97)]H*-?5Y_]TSNH4#LZ Y6,,YS81XQ@Q0AEF
MC'&8ZVO',8PMT!@6FY_KE9WP2!R@-[-)QP[05_#\W:\[!WN\M?T5M[;?XYWM
M5;&5'9F?-[_O'KZ'9[;VX;T'YQV@FV]A+H<?VEMK>_"^]Z2U]@'>^95OO<US
M>'.XN_:5[-!UF&,KGZ]]/^\ I9'HJ+E&)#&3VS9HI+&BR#*L6' <-C)WWY%-
MRN930&YVP'8=27>CT[<'"EBM(?#90:"AV$F/-7$*<V63\2Q0&GW UGJ1?(%
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MQ[DOU59^UMH.S*.36C\^G6RM?G'!<X&=0%QB!_\(@IQ,!ID<$N,="]B%\TG
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M5QHY&<QW;/NPPJ"%KZE26X_+NZHDJW;W6Z_SK?1++)9.P^];X"?0:Z;\/_#
M5<W<9!T,))@DS"1F@/-QW"JZ!#S9DN%?@5$9:Z],8PIFO>G?F6M".V>*PN0*
M%YV^TIT LE[KQ27);?SR_9@G-<;105F203R=6;4XI2+'66"OP )0.V?53C+2
M)@^%M^:*$K!N>3XS(%MMYRQ;9]@:C/S^V1=46],;#0%DRO9F*"R7S>U1$]9O
MS_9#!S9^,KFLQI3XLKR#\$9X50=6J3L&[4HL@*E1D=PI^96EG<B&"=540#O(
M3\@_%_'2SB9(>56^J#O)W,NS!:ZQ5<?6<GDU8Q!E\)N?KEPAI?+3<4ZP!J*"
MO83;JAZ<U2*!#?:M72W&1LJ+72!PU"W(F7,7^O&;;7<F@O"BU3G+&#"046=8
M%FK<ZA-$2%X"$&^%8/*84[L+(%TE0':K53JE?AMR]G/,JY%2S,%Y*XVM4;^(
MV5%1[QM'8-'YDRKGV/M^%C/POFIL55O1]J#*!/>]O2X 2C7X:4/2(MUSAW5X
M]J-&^<6P^#9+RVZAD(T2(3FFOL</^!.=,)-FUFDZF56*E9<U)Z#\9J."=>N
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MOT@FCB7']O^;E1WC+QN?/DZ^_9DP&E]=N7BF(G00X]=&L(<VN[2RT&S/*A7
MLT6XCA6.%@@]0IJ4RZ9AK"B21?V7?\+'\479"3@6?%/38&:PT^]@24;)^J(D
MY]\'MC/1ED$'/\SG#C"*?N-#:[6\Z+#\\7KKGXTU1$SCF_4^^U:JZ50.L+%2
M/W7*Y2@(4'VGKW1M&,->WX:"1[X02=N#^G[4#F,/4=8.4CY<+S^"_CJUZ;R?
M=73!8!:,Y?'K7F/[.%-%5K(/1F&O.OO(BU-Y%M-X=\^08/'X%<*9.'\7$,;,
M*=*$XL#:^9]1UNE*=:__S]Z7-[>-)/E^%41/[SYW!,3F3='>V0BVCV[-V)97
MDGO>^VL#)(LDQB# QB$U^]._/*H*!1"42%D'2-5$3-LFP4)59596GK^4W0ER
M(])D1M<99VA$H/$DKG%2Y'J$F8'UFYLO8$%':R](UWJ0+-2QLBPA$W.J7=?,
M.!21(B88KRM6Y\+LYH)L33*^-5HDVRSH6/,2[5\'#1-1QB2:,GK*4PKG)"D9
MG%)G9946EQR +FI$O##6HK;?#_^=A6R) FO[8B9_G>0'^ AX[ASU_;6#\2W6
M^!53\1YQP *]HM+/ ZP"-NC21\/5 S$12_L1':,^>0K0<@?AA[8@1[@NI>^D
MU1V>OO)^(KN6S44D520G,% 3B%:H&#,CHS#B]\)^9OBAFM[" ZD%^^G/_(D'
M[!A&X8EA[J) TVX%TP[&.PI3?1Q!;P>2LD,.W]W0HQ>F]X\L%$Y+;Y!TD-"R
MM^\.0E(E.I: IX&GQ%NBMN)X^$>33YY@R3[H&TMN1*S<A_K,N< DX5K)*XSK
MS)5?GCK/:M;R0QW7P2^0SH5;4O):4HIO*$$R12+^XD>?,4G!N7R?WRE^*GO<
M3DD69"A73B2]E S ,#9\!!IX!-9H42#G$HP%,$V3AX3?8Q"!J<^+XY5N_=DT
MX_ &?P$,!,*2#LH81<^UBC6IQ4KA5Y@S.3!!/%,<R/#)%+BXJ<@D8U!CA(JE
M,XL'C#UUGK[#\X@:"VPC;$@A?0\1H6;RC5I]*"R"?W,<C/Z/#!2[5MLM^T8\
M)X1WR$M!^S=NN; 5>U6H?LJ[!B/"RT!?H@NR0@_LG+;=X6#X, I?M48EM3N.
M?E+\<BI5A3%\S_B?-Y$.@&(4+]27HZM=1A@U*^V)V@B<"L_^9W5&CX-5/HAQ
MG*$'ZU1ECYB!'E SZ-[2;O7<DR:)+/WYTA>MPL2<]$)!2>F#-][4UJ^" US!
M,+UATVVWAVX>W"?GLA(PFVRJF6>#,_(0.()2-QQSP:V>L6)U/N3UJ*,GI)B1
M:32=LLM:+DX*'IT4,_%(VDGVV9QCPW&.@E^D$M)7>Y=O$N4J@+XCO%AYZF&^
MOM@DT_?H(NV?.":0_Y8I(PS.*=%H(N-KVIHU+ Q-<68 4,?5B9<CJTPR\W;7
M%Q#9"+DQ(#/CD!7PYTFV6@5\]Y=WH'(T(WJ" Q^!?+G*F<-#785$!$89-:SZ
M9U!XJ6^,O*VZ+I%]%(3KP%LZUXV"!,Z?/MWR]"/)Z#J%=<Y@2LM0B^7C".64
M(]>5.89D/)-GD1^:D.?&9U=.-*9SFB>T5B92FCEN9M:H+S=51D#SD9&_E S0
M[@@98]T2<:_.X)03RYT,)-/(IM!K;#A?Z5.:0RG/54^:PI<4:L>YK3QMF["/
M009RC;0I,X,M3W M[*WV@=R1ALJ+*&?P*>=&$DU\\EXP=>2N%6:"N6#J9WHK
M*M^ELS#H\C?R$3VCU92Q!.(+'BQ2[I,(7X9W?9Z)F"=;L7:!9C:E/*]76+2"
MK[_V$T:@)2MH'.#LA<SBR_F$QN?T9I5V%Y4)ES?UB"9\"TUH$FIKR$%5V$YC
ML[;G5Y8L2)46G"N^^2SQ/BKD).A<!>(>E=3E:I.1TR/P$_C&"W!A+H+B8R)<
MZOVI,APQ1T/>;9Q @+>Z/ZTZ$LB-Z2(6>"=C1PL8EY8:22-;L&--K[N0'Z=W
MQI7S]? 7;N%>WYX\H!-$O5#M KY6[8%SXW%6 _[5!X7 3!\EY8"8CM*B9 (=
M=5M!(@./)E&H+W1TVV6D652_BIS3X[5T0*I#*@L#4^^;")4KL'*>"]!.Z&F6
M.BRCO)4W\7%Z8!W_&QXDDT<?NJ7/E7U&UFCAWE"G-J8,V7C.G)/ 0:3=G@.Q
M,#.#/0]+/\0(.3O-)-,<@7YR3GEB?_K+;&GTE9AE9'T&ODK*95&MTV/*&VF(
M##\Q\UA5PIU*XE'),&0X4/8,LKXWGZ-<1'^VYV/!09#ECF<]*34;7ZO#V#!F
MA_D@Z9:2D.B+1,\QIG:2^YEO"K5.E>VD!-DM WL5A0<-FY1P>U)"9WM2PNY5
MC*?M'QX@DZ';LYD,CY_)0!D,![J([5D8AU-">W;U_I.#T9+1Y]&OE+T@+^Q+
MY]W9Y=NOEY=GYY^IXA(>^/C_+L\NG?,/1M(#9D6<7:EG+MY??OUX18^<?WE_
M,<(O*K(A=CS&O3N*D9\IL:!Z(\]!P\(DRL._\I51X<R#:"R;2&$C/2\ .QS[
MV([]:,7)?"*C.G9I#.JR14K;!94SP'L\]E;T&/5=X_A%[(^C,)L$PI^ RN:S
M>1//!&G_I =>?![Y#?HO7M >)P'#=;Z69@*^ ::!]9=DDGCI J0Y:=.H7X.*
M)IUC&.!#0&;,1,9KVDE 3PPGROT&:H71N HU.M3=P(+$.[SA_+(&A2!&8TA9
M9#0E^;K<KI#KUO&#2>!QCH,?PCZP3K@$A7W"=L.W,+K!)H,\FKE'C<V/9)[]
M<@4F-6X?:-=+5&S4GN',5&Y'XM/?*$V> MZ(J;%*L+/7DOL.A]=<[8.^134A
MU*M9C8+]S?=G6^H(IS"$DV@J[>L8?NNC*@6&!RI">7">NWV1#<X$PHH$6 8P
M HZ3L4=/<-4-_&#)'O2QH/>CAZ\8-_,39@?X$2HTN XP7;T53 &C$7E&OU8*
MT:"/X3!@ZKN<$B>38UU#7L$5>[$J31#<4%/-$XV#B)QQ[%45,VRTEK#S\YH2
MJVE>6Z9$[+'V13 5[(.E;ZZYHHCJ3&=^G."Q/V&F0?I+^'"#8U0]AI(N#RH7
M^HW>#H*A0@-%67;2:51T2,,%L(;RGW]K#;IO'F7>.\HSLX;%=4:??O\*.SFR
M.WF?G;S.TEAOY:]GOW\<C2[.[%;>9ROG_G6D=O+\_W[\^LD>[GOM8Y M/5F@
MA@+\H_CCVH_L5MYG*]&5*$_WD;BN- 0'QUI)2^.D,G35B?E:5O*FZ-Y+20$D
M\H B1.%'4F;P4^GKSKM![Z;L+( Y0Z5*D#(#*D* %<.>\_D$%&C8DKD7>),T
M2CST?SFO?O6"SZ/)3ZBK_3LCIY=6)J*8TRM!'0XC\JF##NV\^OCYRT^X",%I
MFPN!]]T$EHL &C'-@Q1#4&4^H,]4?:Z"OP+3Z )07.-KQ/%(UDDJN#KP[>=+
M5Z<(B36\*\)&K_D8/^ET2UZ72B ,4HQ(DMY;L0YM"& L_$]0\R;KP'GUMM7_
MR5E&OL"0+VIYL%8P-&!83"V>PS1* 0]2O^B-<F 9C,+X.N:L?!.!2%'1S1+<
M)_;3PICHI^><BZHM0K:9P3))U40G,' 6&1E8$BD#BLX-%N63FBY8(UT XSE9
MN 0F"@7Z\+TMS,2<YE)C[37:,%2%*X,-I" B4$RBLL;UVV4Y_9J2A*CE7RO_
M,DFSJ:\"#YCHAA7P#% "RBV./(VSN7D 7&7Z1$I;A2FZ2BM&7S[F!'-JFC+_
M_+]H]4<@&LY"N?^Z<#OPP%Y:(%<"^1]9"N\9S5:Q^R^/?:GM-:][7G.]>NWM
MG^W'GM#M5ZZZAE2LE02/(+E#P8W "RDF@B:LK]-YX#^K$SBH,<H/Q'U2#AC*
M%UM2&V].U>$2?PR$T9;\):-^,I F0O(GP"'H@6A%.[A>U+&<?[2<SWJ#OZ34
M-KZ%<T<-*P[;?3*&ZXH3/*0KQR,X3V+MFR@.\&_PR1R3HQ.,-]*5J%QRE!=
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MCQ+4G_DRXR<GA83&(7\!$"F58'\@/&G'*;_'J)(P&"/DY4F2\RGQX=/?A!<
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MY=1?4A)QC!9#QF5N0*)$/ 1(P3,9"956P#N!7E0JMH2E7RW\>$J>S#T*Q*T
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M3JY84X4%CB L]H4 P6&='V$_0I53?15[4^%<8@,3ZQ9YGA 9WH8E8Y@T!A;
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ML\B,GV[S^]L2$?LXR\%-26&71UI582"K(?>5/T_5Z4_O/ISM4: TZ%ZUB";
MH=R(:$"*F)"+$U6=Q2]6@XD'"8V[M-<)CS1E/)BOF&&AH_Q1,:)M(;3$,3V5
M+S_UY]:'!L/UV%U<CJC'AOSHT[?FBJ( E.:U^QMJ9!/@,$.Y*!4^4)LT"R*W
M2'<7Q"X&L4Q9K]C?LBS[_L HA\F- ?@;'%;-XE4KZZ!B#$_>1.E*0D64<1AE
M%07N[& []#9)%I ,JJBE(:L=Y03\&X7A["GOK4)6Y:[T"!Q],)*#0Y7.,+Y!
MDVP,T"A(&!)"7C1I+QV):S%0&W6!"=X?.@JK"FI!E58\M#U+QY1K2AS2*=\#
M9]GPJ;FNMXE,<R4PBT)NNK54K.442?X=Z#E'D8C"85_>RJF<&'@9/.4(L(LC
MOFBH$__J.N:6,[&OH4KRSS9=A 35U2X1,CG0G=2,#PH."!Y9)X"/)4D"LD&G
M1"^J,BQ7-)HY)E 4 'USL*2OZ&0?Q_<Q]1UX?,+Z.R53']'9253TJRLF:L1H
M+;+;KB%8A.L%71&8YSP8D[!WPF.::H@8;D'UU71K :5&T'!K6U)Q+* M535C
M4)LNPD40^HX#Q^:,U=<P@ET7#%W!@R_R%XM$G[$Y-L;!80/RG(RN%C X<#,N
M=U3NS<-*4OWR>H8F^EME#[<CF+AUCA3/O09Z<<U,)6VX?W[ZIL@RZ+S=^=$8
M"V?]P^]>[>L5*GJ$<0P3ODPEI00'3PJILB)S)6N%NS@U]DGB]1DM0NGHJZF6
MN]&F1F Q^KYB$&+T2ZFBT7;M6=RCY\33/S4D>2DY*&%JTMU*2C!TC E@V 7S
ME.0QZ+"P3TMK!KNQ#7MQ66_S.TJ@9.;_>OO-G%BMU&EM2TI!%; P$SYSB4[%
MF:75<FP1]2EFMD;^DH7RY:*J P]?!2E&L\O5W[A$=(U$K2X!\>9ND^5QJPV:
MSG%(:"2*<0H[B1_\_*7\CS<O6:_L+R6Y'UW_"9ML4UK%3"#D_$X1,R@;A3#\
M:OH<MUTV^$O86,D>*])Q;DG^9H:8K?#BT.W9,H'#U-7C22]U<05XVR0 (RL\
M8C4F/RC5RH2LS&V(_'7\GN"-8.?] 3B.(H)XW '4%8HW8"ELA 26G_/#Y>93
M# !#&/TY%D")AXP!X6[V<@1 5\:[B*MKUV$S(;'Y\WL"GLH]@J%8;[XT+'!7
MS$Z])S+>'6*!2BOC0H!K%6!"21&)CA/YRH)SG.>:=TEP:B"6).^UCJT1V(Q>
ME1#@DVMA517+CDMT6'39]9:V\X419@\#%-8<;[5*"$Y75;G"3307$AF[B_L]
M,J)#RJKD2$6R"E-*Z$XM:0H-+\2EZ);OR<8OJU23B EYD4=V8'#O%C!TG&8]
MKJ.:OQ2F*D[??(U*?OJR@EP'*O)P7X>(UVR7/8O R>\[.*KIA3B;9\#,G CI
M 9B$[]A^BPN(8Y:S!WR2+-ZTTQ(E^8QZ8KUXD<F&TQL]Z_=\.%^\>E8DMP<@
MNB%Z(N;OY-]-Y>?OP=,=@A,B>0&E03*YSB3S8-D&X2:$G8*776_BGS/0[6V6
M&#D61!]-A.!43XV'Z>!S4N=J5XUS)ZD#3TN'8G$89H@EZ2+68+^]FM!8Y-'Q
MVPXN)#'L=0*@XF,HF1\Q2G&*)@#]W24'Y/B@/+*8Q,/;"\[.R11$R#>E>12C
MAJ_TNF$+G8&$A?G8/]1+:S[3EY4?4'](%XN<8VQ9,F:;B([@@#ILJG#N^AJ&
MC33/-K2C::94%O=-U871&&/AVVJ[#Z-8 H8?UJ,L]&I[\_8I6\&GY>8R.- E
MHX]B5P[[W1/CH54W1@RFWJ$+T=U'4/BT;D^^)37]$&GFI6%!L8M]N/9CFB#A
M3@=H7&VR#9R-246_/"S[?=B&&/?$B(,_=@4- $)+TDSI.X<=1G(%N'J:IG+
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M$=UATFH(<6O7IT_)TBC4N&%:$AE)@K80)?#.K'DQO"U*4(5/R$Q((RR:\I:
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M<5#!W0N1&95&])7U&$\M82Q6)W,P3LKEB $NE%@WIJ<UPQ90+IY1ZM,6OIC
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M\FLP >7BB&&=FO)VV-<I!13W0DC12?XJBW@)Z'7P_Z]*JK127O3+#W@N6NL
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MP!WJ-MU.W>X4/S1RZ7'#WY9R\0<WJF$^P'AV'=CB 9BW-Q'S;O<C^95]I>P
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MR5$G ([@(5I8G]ZL"KG<B]\!>RHYV34'6 _@2/PTS5SL?43'7T[_R=<!9I.
M9J:-*656LK+EMMJ#YI;6M5Q>4R#_W]58WENP_/@PBC^TKMLF_(LCA/+@_S';
MD5+N#L0-)'$;.%HAS..4FC@4X*.*:X6KG#96]?CLMGO[ZJ)VRI]H6XMR>G5D
M*2!?E&J6I FZ4W4M;DL-=_N2KV"C$>/@0C@$)MZ'W 09>[OB'KJXGYF[JK.J
M511G3@F'OOQ]R0F M2@,ZW:D$EK8C0QM52>?W"-V[[5-%/.GW,DSYD!8'T[=
M>/?8$[!CWG91J>+PT)BD*:(:5^O$Y!/JPX3"8S^85@$C599!H=R'* ,K9;Y3
MD] ]+_<1WIS)KOS!D^Y/"O#!?QJ$C5DYSX+G2YG"5''6V/5/JWZOC9LJ#17N
MOZH%[Q.OORA'^KBE:^=WPVG5[OFLTJT:_@":M9@0\"Z)9Y4FYX]@]-R/E"]J
MKUT(C.8"^>FD9\C9OHI2NO4@-A[>^&GY[]M4<R^8'4CUNUW.2X/8T]K<\]H(
MPYTT+-!QJ_X!CA&7J)D,*-+ X+1N][QNR@^;]705$@KOFY(JV-Z=(6,[X\RH
MMRMASK;JD?7@.U28Q&LE662"=((,6$^H1E'"[\) ^K1YY=0F?=^-]/G!=FOO
M])U25:^=5_/"JDX$N$Y\JNRK)/_!2E2ZG<QA0Z\0"8RUU;K6OE;HER&+29#5
M.) 'D&-(4+?HP.13NKOM9JHOSH6)*_'+$+6%(^WD*@<.,!*39?"?B4"*J&DF
MG"Q$/MN^.N/D4BSNSE=7+#_64Y&%7HUX&$195;F?&,M,]>6889+F):G\*=_J
M@DD<,KQ+1^U!%208!)ES>5B\Z%I^;? I(1,F,;O+I^L+0L9BV%\N][NRK=##
MRJFODC9"V/KIL]^LPZSU'WLX)1PI;T1XIZQ',6SW/?<ZFD+C(!*-ZJG:N:%W
MO XQZO8Z+%:931MRT3*S*@U^0J1Z1.J3$R+U,QC+"9'Z!2)2":FF=CSB*:G4
M?440FN%\\<9)8JWCM?4+U#FY%B:E:49\AE"]:2JE]!GEW!]"N5(%*!8;$JXZ
M,^\JU@T9TR:)36C%YZRD#+!("OIW@#AE#[G<U\TJ[>\HF 2F\#,_\(9(&!A'
M'?_*Y6B:P;[,7;?KON2.?/2PNX)MPA'##>\I/B7YJ3N7:-WW'Q"KS _E#6,I
MI5^%-??Z(;KH7@#K8G]%S*]/'CW^(Y ( )MX36=,E%](2)1^ZE:@' &6I2EI
M1XJ/=*A*LAEAKPM;37-P6[D7K%>*4"-.]W+?4GW%9%%R[IO)8IM]Z*JB%%)P
MGE3\5HS4^>*'[K8"ML[(?R,=$<WIW<GM,Z9@SVJD+R]C)51/, X$#9VDZHGC
M*Q070CPJ?&B: QO O]N:$-!Z&6ZJ%2!8<4DC&8=!FG_A>8ZZ6H:'U!<81(M+
M!20:D]!D2N+G%)EP2OXOX9DM<ZDPJSXWS4OW@KZE^M#7I6(MR8UV9JHPA.&G
M63MN?$R;(5,1-OR2Z.Q^^I2MI==^AL/BDS84#8MS)'&HN7'4>/L6TMR2:>DK
M['M3%Y-5\BK7BCK6;<JA7$]F97!2*;B%O3:O8^&3V-U>[E37OD^6V7 I*G"=
MEUMI!N1V3;:K?C+#[Z4W,.\)=^1/J=M[7-!K=-\63LP/YDM7;MAO">PZZ"J'
M_QJHQZ@AQ?%F%>+0ZK1<]YQIIT0EV ;$RXVHM8([A.C>EQ7T+I8_E=36!H)%
MX/:+<6Z'UZ-&/ Q=>&H@4C$VE4A5Z#Y24TC#6Z[?2_I16D[:]4T@T9RC)01C
MNO:4C[_GK03)*;0ERE9(Y?]4LMOMB>@!/(#P);9;[EM5!/3QJ%44R I:*!A=
MXE_HUFKWRM)1!- !R1ROJ%DF:Z!#/49GZIMBR.'M]KN,Q<P%.@\AB0%HKS1U
M;+NM]?8->T)D@(J$<,VCVD1PAW]X@ZE_\\-C5O[>H+5--8B-/,-'JEJ,X-92
M-.ZB<,U=4=%GM0Q6/?!SE9SD%I$O5,*Y!QE;,402*%>4U(U:WH;1*#R%8?56
M!N.-55ZU7%YAB@\!^JZT*1D6FG=5Y, ME]< E2JN6R@'A>C#AR:"^)66+,.=
M/@CMP=?[WN;?LP%Q04O[1E0 A4[4QP3G"HF?5"T^CYZDW3W\9"7<D!M@Q4:1
MD/% .\1OA!49(XML-3?$1#@NHK=C/[Z5S3S#U%S+I6\.B!RG/N)U3.>)9B5K
MK0BK[-U:%.?EO"?[I9-2)K\;BT?.O*-V\"8LN/4OK&ERW^YN^B%I8CFR%(2-
M6Z_)D.Q48\]5MR>TRL&.P$1 )BNK2H_XC7))+*FE_N-*5^/BS>L??WQ]]MWB
MS36!(;X!0;VRU0ZB''E=KB!8(VL2)=9=4M/KLJ?SYREUKNMP)6$@MD%M!/S+
M"<<J)0/S^8Q2X>/,_.*V'*2E]Z:*'=DLO)!PY&$Z,2$\6=*G1"$G>%=Y+EWV
MQQ$&W6$E]5QP_ZUZWS)Q^J#?3(G:9XL+QG)QKRC_"(LO^\!9?N$R9Z(UL_<&
M)P]^/IU$_1[MJTJZ(W%EZ2E,4"]D6WC$\70\??W7%\_.'O\IK$*PS9MZF1TR
MH;7% XTQ:BAO8664)X3R/57%+1M5)B0>9Z)FEDGJEEPYV%VYHQ0FW!-TY+97
M/1/VPODZD$"3:,1WR&EFC\3B.1 ?&N!9COH"%R2B)IHD;*\-XJ=^2U>Q7JI%
M>@DGWM7=;N312J%S1F70LM:9KF?9*>%#F;F9S^<+ZE^.;T9T'";@JTXUWW+H
MVG5$)/LV=ODHG"QIS9_5'3=:031F.18#J-%MY(X@2\!5F[ZZ9#%ES6L\H);N
MGZX3RDXVC0R>G.XZ\<KNZ:RN!=S,ZW=3]H2-69$["$O/T),#1T[XG^>+=[2F
ML4G%I-@< SPW2\@:>TVX2Y8.K%&9\+*XL)\;2+9&M(L''0HK/O/]AV^&E1I$
M\BW)>6A2(FQ=HLWU7'G!3%R%ZTE_;:#W4!I?*7D42@W*4,2LIR^.A7ILAQEQ
MZ8AB9;=FUW<-^+QEN.K-3(Y+B[5*4""RS>*\#NFZ@ZS28E+P_)+AG-5U(#7"
MM&1D&LC<SKOA1D)N/0??)LI),(@NQ^_*6SZ#+U&I= ;WOA0G-Y1JRTT^U8A.
MIH+ADBZ+0<F*RZ50%-/N\C.R!J\RP*,R#B@!NT'&0N&&$UZSZO3R5>M6=%(7
M8X&#2?D2^G9,E\D!*H(E@B/3YE(6H[=A!ED("&1%9JE;9D**\%G!:H"](Q.5
MY/,D(:+3:LP<YM?AV&;/K5LCTH U2-KO>75Y(T6K(.($P3A74('1LS-O??]7
M LB^.0'(/H.QG !DOP1 ]KEX1:]3-:AQQG1\*<XD<Y+8 '0XN))6%5'Y(PX"
M7$'NM \@2395BK%_E27>V D32K*(A=<X(N*189-=3PP[O3EP.DGK*/F;?#0X
M*9%6FDUTUU^5K>2BB%#\#E>9^_8TL,'?*'*?3E 5NS(#R*57 $93J>O,F@-B
M7TBYH;LDSJ:I&-$[49!5RZPS+1NS%,#_T?N?!OK5\/7<(M/4&?,8)1 NRQ#2
MD6<8>8>D7WM,;'![W<6AQ=Q&&ID8OUKD?\@ZG'2YL$Y,R]* &X(#&R5.9C^
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M,).$QM^ 6I ,;46,$(^_^>8_U4M0_V!+SPJ#)0+U)M+$I5Q&2O^ .S]N<_/
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M4Z^N*F-><%@@RU24P='<E#L(L.GH@/RZ&77%2IY&X641+">Z(^75%<GH[!+
M?WB6'2DC/8B=R8S=?O*?Z'!;UR2QA5?7'W%/FFH'O0@N5,-P^C!1: (75FE"
MR(59H>\D@#]:'AN$XTPI.-_-M.T$YJ@4W:J33QVGUEU++=-;6\I@!JA+DS#F
MPYYV&"?>J2\,D'CN/+-G,41,^MZ>Z(AAB*9$.#3]A=':XXE7_?%_FL&)JW<9
MUB"9&<+BDQ R/X.'\)=]6VD/[1-&;#V9>AAQ4VZXU @:@<?^&P*Y;Q<_E1]
M\A@.1E-7:W<TGTP?366?F-P:NO?2'D4#Z/A50P\_,;A(!Z1T(.HA<KL79T5X
M0L+_,[T5A2BOKX38\J9*$94 K1-C!6/K51+)R]+&_>KY.":Q:^JKVQ^!SL_;
M< ?5U1767.6FG&4JGE>E3K@2W2,GB.T-7KCN<8J6!][[_/6$,'"2.Q<]*0QW
MON1L/.7J'\#-9ZW-<X!TAR[<'0,?68ELPW1#RZHF35W 1B)QR6ZJFYB.'%/O
MLCQZI9)78[R1WV[E4F0'T:L3^V+1L$."[$E3SAUZ=:R+1MIH,U)KZJ?19I.8
M5CTR(>@G"7Y5M-W@UN;H&ILQ7A"X&_\D:D2/_SCSZUVK6J/5RE!4CI&14>XP
M9MS\10T_*RZ*RLCIOJ52;YAS@=C$_B!!V.BA*@</Y7E7+7O0]MA=2UGF\$]R
MQ6[*]Q5T'NA[5,.J2(L+5J%491 >@A$#^U=T?5BN<QJJ1@P&E_YGF&VY:QZY
MIBQ>7VJ<VFXKRED=7>JG=;_<!Q<&Q9%]W\J"K/2SF+WXHL*XR^T@W;Z-_4!V
M/H"Z/#I=2KAPP'Z-/!&/?^=?9ML0'U*]7@]GP7A535.1I:L;[,DW0A2"EWM;
MA=, 9^AYN_BN;)>+K^KSZKQ0Q1EKM</+?.U:KC!5S+_+>T,)2&B"7R]W'8;U
M7SRL\\6;8T/:^B&5B]N^9I&QBC KP86HM3/RW7Y+:4E=J';Q?779<_L@W]N/
M,2]8WR?:(S_^HF^HT]^6+P87X/'O?;=>^LW@9;;UIML/C3622;B4;1U9,5OV
M@O!G*V,E_^&'=[:F.*MR:/\T2;Y TP(;$;.IV"K F)?](?/;\+!]&VYE$J1=
MO,#-LP\N*:&=KD%>/-T+$?'G;!7<SUUW(ORRW0='C13#@.+)Y1S;E;^LA3J"
M+U:QSLC 1;M[Y.Y.6'>Y=:*]>['P\[TNR;*^,*XFBYNBATA;+\S*"^HJ83,Z
M6P+F^9/ .W)$.88SO?7 S%^=#6&NEU7*Z 1X34)1G[9@*4$&Y&"%GR$26K#_
M'V[[Z_".G@X.=/ TA!!UY1C.L%.9D8HE](*98&01PR0>_UX_QT_B#X4[6?_P
M'<W/Q$?^6,A!.OZQ/TDOQZ%K5]*:X5I"1%MHF'(SR(U ?2PL"///Q5H6-K_3
M20WQ$&BZ2^;(7I=P9H1CBFAN+'+ROWYYX$H^Q\N.F$FD&XD]O4'NG/(+@U"Y
MT5-L^5=Z*V_*#_5FOZ&?EKYSO9VC[T&Y'^DEWY7ON6:;D)/SKU-P!T3_6N_7
M?-JD40=1]S!!]E%.M2'X@$ 6ZA94_OD@QK_OO<ZTI:?<1A"F=.PLZY(:8=0J
M"V Q>#W49K_MEH0-Q7(3K+&%<N%N\1]/BF )E&F:?@9'DOA=J";!#*1>]>IF
M'VY^UO*D_WQ'V8ZR7^W(?X 4)9/*+$NJO;+T1M,)D[N<3U%?K#Z$Z-FN1&TR
MD_#9 D3,D0D]@$XM*MRB\THO8C8J1(;>ML'WH#CS5H=#NVI++?\$UU1AU%0Z
M 2$H!$O=*X;'C]Z0MX4F(]8Z:8KZ3'IBLW9":VH*SV6:]H8I_G%+Q09/5<]-
M8LRQ6"O]G#[R@5P:<,1X;HW>%G[K6-8Q/0^MD'Z^;TFEG?&8>O9)\!>"/8YA
MRU(B"2]9'\G$A'6*DH3AZHF1_+B1V/=?AU5=(M3"RU@Q.0K3W?&%3+>@#6L3
M?O-6HI__O[UW[6[;RK)%_PI'=W57<BZD6'82)Y5[SABR;">NBF-?RTZZSS>(
M!"7$(, &0,FJ7W_WFNNQUP9 24XELJWP0W<Y(HG'?JR]'G/-Z=6&(%,3VUS)
M%#6MQSJPGAP-C-#=9D8304R/+-&HQ!R4_MK&UT;OJ@.3)<UT=.H"DGU.(8/8
MO>@KB0Z%@E?!%6(=B&(J,P?#0>!0%"I3[$?$J& %=*VBP$/0-;MK-0'AZ<'4
MJ6(>R8C@0M>[92Z=;GO88T@[TL'EYLBP9JX7^-/?<HR\IV9/X[0<ISAJ$KP(
M\0 1:= I4V4)(P2Q5!1*99F-* C"2@F1D.9&U%7+*3Z/6QS=K*+Q:*C[0MD'
MH-,0.SKC!>&.C%*[5%5(Y2QBW//01TS8AVGP$Y;BJNPTXG%AM;U\O+^_WPF,
M20\N4LD("6R1%E(XA#4A,6=@R*9BM4@)- 4P@!<4"@:Y\C[E2YI6[Y4\[5\[
M%WL-N6$C:YY-#G/<@&"3)7'1.T'/1:Y<W0;WE%/^DDZEDSA&GU\)E:P:3BG4
MV-\UD2!,VDA(&E?WB!PU8C?E<CJ2C"0/X?U<3]K!XXMR$ L:47Y'EE0BKJJ&
MF!/ (%?@IG_5%Z/[E:UC9E:+B*]M#*D#RZEM>]3R82;!@\I<\((T-\EG\XM;
M+3$*-X%_LFW8 <>BSR$(98A8]H5%[!T<HAZMQ!O%GI=YN5'S"L=>E!4XR=O@
M#K)C&N=A^")7S8@]>FPYGXJT)YJS<9Q9_4T6,R_+ 9>,T6 +X4$TUV0L=*?1
MD%+*@0E0L#9B_9 LA)X!-Q)S_E,B7[[>(5\^@F?9(5_N@ISH86^IR$(;!M3E
M@<43WPF-!Z43C62/DSFWH17:P1=-4@S,JSWMAWN.827?&*'2A3I61)5G3@C+
M\7[9\2+J:I%):%!NB-(#SD_/C*Q?Z9SU$#:]:9PSF9-DXZQ9N$+5@.$.X;&G
M4HJ49"CHER+##J&++#ZX'X/PNV#RX94[NF3X+4/5:63#-M5;3>YB;!(\2QAH
M=C!]/.?(G[D:K=TE'O7;#F9Y@UD]*0%%HB&9%PLE.3/%N=D%F+\G9T_< N1%
MP1>-@UQ]84->L).+O-> 86JZ\CR$<MB8<F;<->IMJA["=N2U<#%GI(P(NACC
M^:$%M&$U!\RN1&/#U?CI1TR_%)IL(%%5JH%A'L?NC[C88:N;^(8"H ;!B63Y
MKJ(H&W-6)96-'(HVU' YC**"6]IP#CH^C6>S0BS "<AD\CRI&<5(0!NQ]L/<
ML4;7EI6*X!SBIP(+-5&CJT8A[\F;* J;1SB!9%"52!K/1(E96?-UK=X0[F#I
M-M=T"B\X;+0I.CON*C&>++TK$Q;:8_X+J_R/6]2XXM_(8)7S9)D_W+;,P7_&
M=0)Z62,_,Z( T3X**XV:'.3@HG_*T41\ 6$(<49DLV(5(I+3ANU[7^X%QZ+=
ML,7B%AT,+GU"=0<BG87'@?.1L#=N_;/FP-.\K#:L'#(H-G38.1R"B]@9+UH*
M$\IV2'?&RA(XD8V!G8U],-5U+FD'(7?;G[$%H'1;0:V-*W#16Z>?L[PT&90V
MH3.4T322'SLO&WD++7[1!>DDN&$$\RE9R\$RDM6BWHM;-5.S/&S<PB)\PI<X
M3"/)5_Y7#'4(8]&LNO1ZYSE/"B4"FI7,=+C&HHB+-<U]>DT]R6/B\J];')^7
MCM7"ZMTO2*8*1NZI[)+#KB-J0$&Q<OY)/SOBK3![J6QD6B<]^/;A0Y C(\F%
M_*W>W5;J"4&M"($HA7$A7N-CYN ;?/MH?_:?_W[P]</OJ/Z>^5<(5KQB7CG\
M\?AP]O+P]:MG+UX+,UU<S#B0Z+]M1V"SZNVOV;VE9KK4'ROK:*2U^X7>_ER@
M2H<3-D(\K3 5X:A"6IE8Z431(ECTL_*D],QR4H&A-$^P#\UE >-SRDD4!A9(
MRMQS+E55?D)!3Z/(0"7Q148]W&95=OBGUC#9^U$YDNUDBY#+68.T4U"(C*%#
MM7M65)PS8\)GQBV6:Z8,4HH\;DUU<END$M.TP18"P1AV+O*$X7\S/?R*^I1S
M.F6[8,Y"XT_ATS75#Z=Z(>7'?*DB,T[(! "88_0Q=E]P@E(.VIB#(O&UD@9;
M6"S"O\@O0)1Q:ELW&?^)4YIM+AP.'DP_L+P>5-P()T #C3CMQ[.I3^EV8X:0
MBC[VYST2RJJXPNQ(NC8U9>@ZK$W_M$U[FJM^3CP:3J@F1-)89:Z=QKSX>9N;
MAT/L!:<@!=-UKV[1;UROX90]I]3O,B6QH4PA,'6RD.&%L0,W[RF6H:)952Q.
M,>W,\9-LQ4MW9.G*F#+7%)P)]#,\TWDQ ,PZ^E*!&,"?T#-T2:<>[V4%'/"F
M*;NFMM($E9/Q$'*2L" >_8LV11E&%"6E(G@;\IO\'<17E;@';+[ SX-5G4>5
M/4>T#A-HYS37F#!$-6KOZ(!.ASZ>ZW?CK!88_+*9;Z+*3>?F&E6SN%I[(OJ6
M^2\X;&=1]9Q1;[0&* =0,GUU/CNMFA,AR.)>:"-C2L+Z%5JJTW(ZV9<U"YL3
MH5Z\@GI]92J.>A>\\.\=.[@:9CN\:6\QBG@F:$S.Y43OFP]8Q#=#N2<:6@W.
M[L#:?>W(A8:,VVF*I8.:*Y60G%.:E([4-1T-^#/=#N;%9'93AU"14R@M1[D\
M$IT0/8& M13%33UT>$?>*"A'K7LNDX_C5@:1RE$<_+@F!KD^>R=2'"C\Z$\M
MKQ9?XL*T<3U7G7EE(Z ,*\%2IS+; .3V]M(VY>WM"+2183^%=+["$+?YNA0=
MM,$[+%.W ]6G^%."B(F6+[W9/-@(N%4K>CUX9N72!J$D$?2><$^;N@N3U3%F
M0EA?**N51H:,T4%GD^0Q&%2'Q*ZR4U6%1)<GA028=Z+CX=EXG<18[#E#LH^Y
MQ"T>P9,W&.^_Y^%I,^MDV:HKB=FX>@]Z72\7.[!%:\+V4/TTK.YPI,<&C"MO
MC;T,/^</WLKOMXV3=#3C'\2=3*YO>;I$F;=+@[6W!8&QT6AGC27LK?G-I>O>
M5;([1 GL&W6]AI,B%\#Y8J]K375H&-8L#:FWI2II[I:2\.1#?*YHWN'@2Z%[
M:EH MFY$DX*'.F$F3]\R0EG82E*GZ2NCX=,;;(1E3S,$:>V :!F"NUXENMA8
M[WD;HD[<6=4:B#X00\Y]KP -RW^[]88DDHR$I-YYGGAU_E8;S1C&*"\=_C/"
M!-AH7V&S\['%OM)@0Y%=425R!E&*5UV^:\\C1QE(^V:/5OIFI5!(>LCJ4@,K
M$P%O!2\L'();%K=AA^;4M*FMLQM.,6]H:,BV@W8QK/A:=*%.C Z29#<-F8;,
MSTB;A:;?V0.:H8KZ>:B-4*;69]75,!6BM#W>BKXUAF<?8*"U>RP?@,CRP+%Y
MPT-.CL3?]9!USJ0(FP(3>')YY6A;1!'QY GCXY4U@G'OH:1)&N^@"?SW!!!B
ME#_,!28C<%A+(,[P$>D#)0L>SL&B5J0XER]5ZT NN"PJ^<4IP#>M5RCF#X!=
M9[0U57"41I,)/_7HBB^E7?$)+>>[-6'-OQOTM4J)60M*$0P4W-JP@K K+!3W
M++_Z#,AF2+NJ[=_YA@O;W%G(V@D[&$T"HWFX@]%\!,^R@]%\G(J2[YG>>(8\
MI9P/@T3FT?,7L//*IN*Z]?.R&A;]7/E]NHR$3B+*M3;A(#W-M<S#=+,@ RC/
M\_EE1H3-N9?^Y4(@5;ZE<ZJ8;Z@Y-9-'1PK,#@5?Z*(?S?EXS;4(*M6^(='Q
MN*:LR!EAE!GEWJU-1&J&,5%Y!T)/=/@D,F<C'3GVB >U10%09%RL4F8U,*I)
M'A[EMFL6"U4M%"Y+%QWP27(PP%H.VFO5TL,CC(IZH=3X]+NN.$7M3#ZS8()V
MVD.W3"N%Q. UY*&\Z;4^V4U3HVC?"83BA*L63B359@0\2,B>$-,PY*6#S]>+
MZ"#IS"=%28;T77(@14GZU0:Y+%I1G[EP/WSV5IXXXUHRAR;4FO/Y]EHF" 'X
MSW/Y-Y;_/._.^+OALC4W'%&+&O4-\9_;@H@$:#-FVBZ 9NL,O$CX&H1X'?]F
MQH\D+$L6G-&SGS9-N(GT6M,CH+<H'AL1#*0D-Q)%K_(%$/S4B\D13LF:;IDT
MCN972$=$(8S^K-C"'1;!=H<RN3:WE[-%4W"K:UVP-=A:C>NO(Z>=,;L5>DM8
ML@VVD MVU-MCEY\+IQ6U\%H];W_V<RSM#>SIS6IT&&/4T^RB83F'"&:V67,V
M#L0ZV(V<VG9+L:S/F^I<.-Q=H0^56XZ#-)IRM=M)3.,P>^9_L&+EY+!..7%
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M.$-\3O]-[E,B9D3D'$#\X)?N8@;][$ @:A2142;84AB9R,[2E^B_P-G-31[
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M8"=U:'->]\VJ(#XX^J]UPWJJG2J6GI7!!9&NC,\S&Q 2=K9[N=*EYECB9\0
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M'_9H$N'W23CN^0+T,.SU<0*T(X#,R.DI:ZA%#<726)B-XZF)#GWGRBT*DH[
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M.SD:=[K6%7T59=?@#--R PTL/L]UDGWQRTIMSOX)*Y?[EH65UKTG;5K2,L;
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M FX7WG ]:Z#X%U710;RM'(60.BX E U!2'@8(-10%"0$YLF6<9F$,S$92OA
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M\<>@:EHD6TS,\35AB'88J!.'68/[++*)&!80+%E>3A9#\:[LQ#TI2O%PM%F
M7K!F3Y!Q<YKX9@DK*7U#DQK 95R1BS2;"E8+$LA4<Q.>PDXEO].89+MN(\4@
M?;DR[C7F7'4B(%-'5G+42BUI7#I+,S2IS-XVSJ.XO-133(K6OM%'H[6XQ/5T
MUA2@2_?H?4TWUN.;J;$6NAN<L-'*$QR,@ABD!<R[0UYYY-67.^351_ L.^35
M)XB\VMKUD!1)8!6[2%- QXWT4O !.B BC'T$29=!L;W)(DU46R\!XTYB1\!O
MZRCXS4T UG_I,%M)>8@+!$42NFL >@?BZM>&W(:'(6?<.#.HM,^LLN*R#^&E
MFGHSKXK@F))(,N5JF,H5%)A)PD;R@RC#J0XZTA>4@/&(#-$?FNZEE+I9>*P]
M)@WWN1W7J7FSSDR?H/IG\/=.B@DQA"3JA3/%7HHV@<96ZCB>J#_[09T82,XN
MT:T)6\+]-\'MTU"0_^C)/(S@""4N#!OI"J'IZJ+LSES3ZBA@*UKK =XZS8/"
MY_4T(CGW!CB'S0!8%T15&MEBN91LS)((,0S,",:CY7B%(%OAD>UQN6R9]692
MOXIA;;^M(7@@BW:#GF KL]ZT.?CUV6:+T$929DM*$X@SF"D@K2NY:K6-8^Z*
MK.W4KP8<2A.S#20/%^+3!PG':=)K0PT9EOQ7->-!76S<UZQ8*5U0(>AP) _#
MQ9 4T:($R-0B'1"@#MLN[4FW]5J/VN8%X>6U'M2 O/CIY>'KUZ]>9+/#YS^_
M"?\ZS&;?/_OYQ\/#5\]HX%_\UX]OGK_(F&RFA9+8-IVZE$;V7/G.C(; [XQ!
M5D5Z@$F%!U=E==OC8-RH^?!UDGA?5W,\CGR:2<P;I;I4XRT)Y8:<K3^$V9@=
M8=Z"V7I2GU8XK\/__<*TX/3/.J>6U$T\<B_".JPN)7- 1?UR45(NXK"J+ZM\
M-7OSC]F/_6*?;.Z\V>.X+<?KZKNH#HRFM_BQTZ<+"T2GQ;IF%LF^TJOYIKA6
M0-JPXAX_I04*Y<$]@3!F'[>V7FV"8TE(HZ:<(PD+8;1-9),G[J)@\!*C9>AI
MCHN^KZ+?(Y0]L\-4Y,BFE*1!N,74*ROI6.6.J.Z\&.1Z(T&3T9A)5![1X*JD
M!X4?082GNGTX;F(%2F>!JW?V1TL9 J<7]N*<D<P-BTK>!4 !]Q] \Z/0;DCK
M>IM@J(G9?+,&?@[:R-^46\;+*I[:A&YL>ML(LCQC6J:57A3<<V8_&Z* FO0Q
M/-VTOWHD*4-[&_>A20NY9P7IPLPE#$E#2LQQ05<:\^^$ SY,I!/N2ACM4IA6
M.8"7#,Q^F+07\[Y1 38S1'#U-K&<_P\VFV/KZ(O!CM$\S.2XVL8D),\?'[W
MR>IP*S>TL4,[QW)QB_C4L'&+Q&2Y)1B-#F7%?=;:])K$Q3;AN?.H<V X8VY&
M@1) B=C4<1LU::M%PMKTZ:^[1+?HNFH.]P<U+913!_VFC4-S3OLCOJ?K($,6
M^$W-VE:<O7[3YV?,G(!_2-V!N\2IOII8F.?YN]E+DBI\._N^(+W=+CSKLI_]
MW_!,3YNB713M)JR5QV%=_1(.GO!@^#RLE6+_9P:RN$L\J^OF7!2W^B8$8Z S
MBE_(B&6C+\X*TE9Y_NRU48.D;Y!0Q&:\]&R#0:YT671=T^K;HD #[$13Q>'-
M1'  D5(E?=#GJ).!W\6^B'-1,N(R'6'1C:?!;J6UE7G3MI&A>CBM=-_7FS!>
M6@8'A8F "TCM3$RXYY>BN"UL06;H$E^1*PHXN]/8L%.J6L7Q]"(4TL?>,,KK
M-)Z(:[6B[4=$(.PPR"5()(4Z \,K6A@I6L+YA3VJ5N8X?-^?/6;?&*E_]/;,
M+TV),U%?B_$^?5> Y=X"+8INWI8GM%)/&IJDBX)/6#K5?/X*AZR=JW!KZ&#E
ME_<7I 6E*J'7Y;IT^$7T3<P<COD8?,? B$6J\ ##H.(.G*&_N$@7U<..N%"I
MGR>.+EH &)9NS5^2!O$6S'?!1:!UY$[(ZT52VYYJQELJ.R"?(),,09[F!R;%
M=]%-QW-XB((ZRHBUO.TY'@DV]2NL/;6:_DJDJA+%]@#@9B$2LZBZL =D1A,H
M (JMF=UG'9;<&?(Z@!\^#Z[9V]GQ6=ZN9_\9'OF[V>/F;%6X'@U\@YLR8I.&
MG?!TARM/>'J,P_ &%1P%N YZGMR_OT5GMB..[1R:5CPP>&OB-DQ()QZ7(N/$
MP:M"U>W/88 ?!R<;!'XZ9"^786ER@^OS9D&ODH5'FN]G9F75^#@7KE  -]"4
M@F#XJ=F?A1/Q_I=?9]\^>*"C+<>PDA\/T8TJ>\@.X8H03.@^#I/$Z'W\X^C%
MS\\>[QU\&Q;K?$Z9[GU];CI)P@ \*IN?7A=A$(^?X&?ZWYE6(WF9( N*C !S
MJQ@HB6 %U66< EU^!-_51?:[#+?&@?SX7]ASN_&_:N 5-AV>BUKXY)29F(4'
MW]S/OGWX+5>I^?F" W*"P:*'["\:7^(FT9OZM))Q0L7]!@_*:8"6>3EH1,(F
MB#\.EXV<F/?N?\G/DE-A?L6G@4LC<_"GC0,G94.]P_F"B=$<=+!<N+Z/):'9
MU*NWB9[/'2L+K9^)Y?/IGQ+/$B6G<9UJD%A$7F<R!%\5.9@[1V''U1&')2<]
M5$ 6>;CN:NPU)V+@9C9]=2I?+(9[<Y"@YP:NL*KVVD+@?NEI$X^$)"KD&@M_
MTA9"\E>H2"&??',MH$5_%]6+30HOY%5/\572%I@ D29?56W*\-!RP>Q5YF4L
MW:!O*)7- B)M#=$92%Z!LWB12OB80J2P5 ]))*2E)SPDN<A#,.E%UR\YH#(-
M9=_[H+L;FRR9UV$*5*,6S;IS>F>Z'\E!VNEO"R;O7Q2KFF@Z]4II[ H= "._
M[&"KQ2>?>!HW"QZG=67]6LZL =V%&,\=:L>C=K[:H78^@F?9H78^0=1.M(+L
M!*IR]Z;C9LSKB@,WMF?9K! $(Y>))$D ?:MS2DE-Z>IP-L,] 6<>.(,Q2%=8
M<D9S]K-C 7WZ_EMM@';-OEV8@-S$9+M>,DK,'*E,?/$1D&8VN4_7F4S\C2?"
M<(_^"^X93YJ(3ZFWQR=4]H-KH>T=Y;0T3!E\CS)&\((1< VSPSEBMDLW1SRT
MBS!3E]>(@FVM@,A$K,I^B&(RS$*JI7(7?(RE\!?QD9_"M:(+CN5%\RK#'_W6
M,:$VB[AQI-XQ7"6!L8@43"=1]]4;BD #VKF.C!,+5%/KOG(QF@I0=>F+U6U!
M:]^^%6',2^Y":GCM$O2#7]<76Q02D&0/!@4CYYZA:EC;,\6G9AHS/'!F< RI
M((+? )1IOVY8?54J>2*.J]4\WA\6@)LR;V2"-N %=[FK/VAU0?;!(T^5I[@'
M"#UAR8_[H[J<@'&$@<P1X P"CX0Y1K@=W@K7U0GA1>J]V$B+'B[ J)8HFDR9
M+_96.9[6\)K:=QP759IJ''+2V>C80'A/F9XP E%2=FO-:DZ#5KQA5(HB9X;=
M\TD/KF!;/"YHTLPPUR\1-RO1 (%XYF<0L*.Z1YF@ZP7==#GJ?)?K\-&%*X79
MH0Z?LF!./ST.!N;,L=!>#)H['&IC1'L@^"FEY\,/F'J:3$%8^DZ681D3Q$;4
M,&T!9-B;Y9+R.D04MJ+0G"Y8FGC(B$4^C6 NSF27R]IB1%VW ;/NMAO'WA4Y
M,"-0$+VFVR37?9T"C!%)"XI-*6;(\)D1SZ99DH',P)U!:NBN]/J)6'\GE<E]
M1T-E:P0\&@(32J/9"4T4=RXX%#,1T45HFOIW'O4&0)M1, %A847X;,0<(;O:
M9[^XJ.\8^@88UY&H"IL@HB%09W.H9S50I4!BV> G>"6-S2-8D4&#D='D+G@H
MA*A'U@$NJJP*")M+UQB-HF!-[7/%>0G**SF,]+<*=$OX#T;.889N?:R#%;&7
M]DU-,#!FUJ<6I#!F# VS8<>737'04%E*CJ1.KI308B&6EX+?#TWMCC6!<27<
M%>[+F?IEV_F!!I4YM("ENAHJ^'&S[<5%5^9<BD<V3":\'[+'@J,JW)<+WM26
M&-2_)B["-BN[43"Z/[MEAR0*O'(RLP)-Y1B-;,<[!*A[#,^TR81Y+%[L>6QI
MJ\&U2+R3B0L,CM0$.S8L:RMJ=U%V[6:M;N6HP6(!?*'A#@;U[-B1Y[M/(@)P
MX*4)YC,9 5+0'6;/I>V5$K+@D9MUA:*3I8LVA6F4W&P+BE13GXBL25)Z)0Z,
MA6#GB7025EYDA@B)GN8R:^>_&3HS9\8;K [)&_X]K )NPSWXAF^A]<(K")L$
MYIG7P<FRM:T'SQ/S6U^_?F404?K6X>L']M^OR3_>E_'!<  )%0?".X:\<);<
M@M'.7A\^)9Y.%((;L^A:88.5\]Z/[=\Q*K;0EZ !92X15AC"8U6(S+46\+A8
MB1 "4?^5JJ]L5WK4D+F3#G?KIV?B_SKYR6'7-7,-X!W R'H44A!K\-* B9U
MIL[>K#D&"4M/USCJ+NYN6BX1_VRJD'__W@#$1W]@&D<T,EV0"!#-C. 69 <D
M=\GKHN+EW#$NV;4X>\P!"Q=*<FE\!;D#Q#6H(UAN7B:@/7H\-G@$UF?Y/<H9
MT=M@ZBSU0P8Y3"UF+:>%@YAMX J@]$TW=[W;$#^:%^5Y[,.>6BJSSTXVY,#^
M*NX-@$SA+KP =2C">.&Q/C<PCCTNK\S@-H!0] 8/G\>358U%?%*N(I6.,GRP
ML%_KNSHV[SC*0"^&9R'(U?9'"0'4'M215@R?)H2XR&'E?4^2TK&]9HDNDY?$
MZ9?7VK+-3_#7Y-ZP^-BN?_GR8/\^O60E1ITW(]E5LU7$*/#I.VOQM!OS,0J5
M%79Z4UU%B$KD%9R>*.JATX+,@;/ZWE=QHN2*R&<4?15K\L!YM&6?F8,]X'"<
MR%7I-M#WB6MHG K"-JX*29;26XCS6ET.0%"RH<2^J5:3=_\N(C'-T VC%%5>
M,3N4VM#I0*-IQYU8);)^F7L,RQ@[MT0,FCTF$ME\J<FG=:RGTJ(V2(5L9:UD
ML39)NJ7]?YP?TKSZ19&F*+=WG[FTRT0*1Y,J\%N%'C1)L-R%N/O((;"1,XKL
ME#CBHUB[11^1UU65=5QZ24C=-R+ ZE%V*=W$),[[TS=NS\A^(6C9KE8X3OXQ
M 5_&QR_2S$8(/+]F@D89KBS.609YKV  <^1#CIZ_0#-O3XI?GO,QS9 A&@H.
M5C!BX%/A&@GXH>,,YHOSL@-GZFNF$HF/I:O#IT"GET<"_Q\B-/4R)N-41R4G
MPF<MC!]:%**7:9AZLUL-[+);X ,Y L%03RSI+8O9G!Y8+%#)Q/ .NX=92H?2
M"D.HDE490J!XQ"W\B#T2=5!?^;("8LQ6>3 NVA['0%OM,IA0U83_/U(9\&8Q
M>7Y'S?E;B8"W&X(_):[CZQVNXR-XEAVNXZ/&=4S[-Z_*[FTW>Q4;-X_4[C3U
M'7#?$-BF:DZ2TY3.YQIVUQE;S12GI4UE7?%G-OM_Q' &J#?17F2 FQLQJY'V
MH=V</DE86*><ZM0!3[&U5!P'N<:@K'$'W,+WGR=.>(I6.F39D,EXCL(7T9@,
MKX<N[FVBL?F<=).#JT<N1=EOI!IP2BY-K2S#5*,HDW:S-<H5XN64Y^QZ"7_"
M@+B[+5C#0./@A%IA&1R><\HT87JU#0&9&N7R34+MR-."'+/QWN'/,@@3@"8J
M+?SMIHME35Y??;I7%<O^;P]NL'SV/N#Z 6?CU]]].)K5=+@.OMS_BL9B1;ZI
M8KE,A2MC.V"K\FQ#D.ZD=ZZ.4..>_/?@;3*WD&0Z_B7J<0WKO]LMA5M<"H #
ML@S8.0-#0APAQ!R4.YV'ZV!)]$772\V\!@("Y!CZ(?7J4)2*((/1*<:'P8DK
M?"ZQ55P/7'V%3=7Z.Y7T].C:+8H/L2BV01; U:2%+,H-4)&=*N]A:7"#*!6_
MT##B78K=W-W^W(TYGS1[3+/$LJIHC(/]1J[966PPZ.]F[?9FS96NZ7!MVUQZ
M80UDQDZ4J8IP7TZ1"T!:I7>DW,ZNGG<:[X S_HN43,+!4:CS'5UO+=:Z4(0=
ME8K47B\'FP#E/[554B!>%0N<9>2<;&JGB.$B)_%S3*^4O>*$2$[K%GB0(=QB
M&1]![OKT\2%@1*4P*$;(F2/N0]$U.N:HZA->(5]=5DVY:+H2G/5ES"_/B6"J
M65TVX<]GI'J"E)[&BPP#R&F:%F6G!S _%/?E:LF:\ Y6Y+)G)Z>>QH0)(206
MB'*"T?7'7(WFB&).-T\,Y\(4X#D2>DB'3N6?Q,=AT$GB:/)#<_@*]J@$\1RQ
MT(E$838]T5=-<L_9V<%<<TZ='U-"Z+3=(@O!TY(&%U5+)I/"GST=(WP@HAX<
MMFID[((#[*U6/H;;XT+98/'%KX:;&)O1Y*N?#5<7\NVQ^?2;3-=N7!-V1313
M6P=*6?\Z$+@;[:9U4UW6!<D6T%J=O#\ ;8M-I7EM^MF3(T/1. =2*@FYW?(]
MWS3>B7<)QS<' !?CG_<'S\O+GI8J^O&5UF*B7+OIMFV=A(HO;DOVEIN>TO!U
MYF:/"RUQSSYC 5"'3)UPX9R^13STS8-/ME%\FF)=43:1'R"O4YQ,RGX%?STA
M\30L!-5!2-:6"'0PJH<$!?N_15W,<]NT!8'E]M9M"2(;C@1H#])_%?5B3=0^
MBFP$CH,H=L.-+VG6J)-H]I+H-F8/PNMM%M%ZWV!YR5"/C8N+8D2?))IM?I-P
MU\=OGAX*T>&,R9V7#O]S/X-J1-B,A!\1!:JX7F !'[7EXK1X5#;T"NW*F#*(
M<$(_RCQ]1[,&@RKC) 1X_I)*CX<@+ I_TK%(0S2,$^67=84!]M9Q:1QFGWJT
MP]_VCIX/84P'.E-A0:$2MBH*UNC0.=-9BHI7- ]$CAO6T-GLX/Z^>U/I"RL(
M+=L&]T?P.?P:C][G->R97_X43T&U\-26<S8&D#&Z6(4QNM&(4I!:+O9XYGY1
MV ?X=\]ETA)"."4R%:<#"D55E3#B"N-VHKDLNQ3XA*J8-E'IP3XV6/ASNLBG
M27+] Q,:U9Y9:[;J'@#OE9]H,IGQR F\?6Q>,D/7=-D$DL>P!X+.<"*%DDWV
M>%HN]C&(HRY.V2L.M\GUT?NSJ4L $",53VF"'(RT\JKK12L6#I7B9M<W\[>T
MFN?#LW/P*>"%HVM$ITY7$=&<V*ZTI?_7;<OZ#CCI7*7PRWX2U#.U?I"_EKXN
MR1CIAEAE!I@:>926D!A()U)^";@*.\QV.>9;C&BY4K LI*'-W-A:\'I>H]5T
M38'?BHQ^$@.5A>':=JFD6YY"\DY5;(_._F3:N&7<J)'1<:'>.7+*?:19MU.,
MP^ZAE&W;0.V'SG5'M-S4NPF_Y0EWPE.&,)K*Y:MI=I[!;JYN>:XDGQ';AD%_
M$2;LZOH*P,7S?,V_W"7H;W_BV(F\Z2D8TVYZ'.XF[!8GK"W*U<FF[;B#!/7M
M_+38E4ANN[ EK;;78DT_F5AIF#?\5W)VTZF#ES\<:-YZG/\WE96IBH/9G*&Z
M_9,WVQ*YT^G,%^_RDW 2_>>_'SS\\CM*.-%_D>38'@=NPRPB/\3EL.01 NL7
M[Z@LD,\.'U'O3]6\"Y.:=\*SDEZDJ/]YN2K\M33@'@Z9IJX:H>4N7-+Q[')=
MM'2;<(SF] 2'Q/6>2XY.$5R=)NL834<Y&9;"&C_6=76=< OC=)S,!,G#)@_F
M268/OLUV_'HC'/;#'0[[(WB6'0[[H\9A;Y&_>'P86]5GCVA[*)G-:S&NCT&O
M9.SQ9@%ODLR>-&B&$K-Z(Y4>U#"V!4G_%8N8(YXLAJ!V\,-_O_BO^[-U>=X0
M4'9<0KCN6:?-[2--. XRO?Q[ "E_:LZ;\/_:<!Z^I=;55=ES97?V4QA0Z2NF
ML2V]%#V1A&\_QU%&TQS**<03WHF$!#*G55BC7*85BEWTG:<4NSJ5W%;*9<H!
M?=>\;;I.-3*4I4)$K.GS+9QN$:E?;5:Y'8%V:^NKC6,^<G=88G7(%:8I8_07
M3[6!2IW6<6[D"^)T8G?I7.G1)BKFECJ.Q"N:-IY596?,Q2AMJ"2$?&'8@7;%
MDT?:B[P*+DL]+[0)L-5F>&6BX<4+H'@[1(HW[7:@.'?;"8A[)97).@X$C\.F
MFQYB8VLSQ$*J!3YD2>)>:X\TJZ6HF5*[7-M!ILX$H^"-]?IHJG!##[K*WQ9;
M9[,AAX2\6RH:-772J<9O)RR78<RY)_"L,$$O!X#3/,GPK;WT5G31]V?':!1T
M0RHO3TB8<*MV(VQPKK_3#])T*:JB9T$'."%R^U)(29BFW%CEBG?$.E2,U'K7
M55[OSQ+MH@O!YDPC<JQ?Q%I"1LTBS/U&Y&<8X8)H[HS]QW1JI=\$W8\B"B.$
MDEB+5+Q6G%48[G)>"+?&L.\@/,+@>Y'>:_QL:C2M*V'4D,!CC?4S/8^#)9,E
MRVE34U#0K.AY[D+[^"_%EG7  QSQA ;[O6C:MT*3J_O-]X9@;4;+%-9?3QVU
MA'G!K^)'75@VP;[)R:)RJ85 ^?BN":R*#9*VU*BM633",%ZV@_:E&'HNPAI%
MCT+Z!:@X#V!9UTA;NU,G07<-#5RQN -IB0'YJ93:;9U<R-K!>HGDBSPNX;!@
MALKJ.HLS7&G7++#1.F)Y:,YGR!I9E"3:E1 07M1C>);*;[W/6A]%[I'*0FF:
MAXLX1RX!@BN"S.(#TFLCDPKX'-#$[K*F"Z %'L+-$.,27.$+;F]GAMNJ:BY@
MJ3'2EN- PB8G4F3C>#IMV,V%O2Q9O)K]1T)BL->$V](+R4V)("C]) N'0Q-N
M!:A_6)X]WCP\)LMN,[NJL)?P1WRM/:+E"Q,3?$5H%--5R9<@*3H^XM.)I[[S
M*\>#-W8807I&U2D&V2KNGLU>!^N^&*9GY$Z7T,AE0BY\C=3KVG" D:)/#T$?
MSN(<MFUS03IVPS0/?>YP6?:];/;_;?+V[;:L4/@J/L^BT.QA&]Z *+2.P[ZN
M>\)A'>\?[K]AA6'[FSKMB(: 7$GH(GXY_/G)[,=R6<R.Y^C8Z>05#ULJ_&RZ
M1,+8Y:B^#_,&SE/]718<SDT=!A_X%7DZ?/554R;?'-+A%!91>%+/9AU1LYX0
M5E"*CPI2(YG3P+.'&Z=&/LK\Z-IHZ3#* 'EF$P;KL5<UW(<3I!!;-G4D;\AM
M747T,?L2'?,P0[-SO.>]UT]3-N .38\R@#@GV=COGL3)@,O/T8XD,D"%$W"V
M_4R4429#.@Q73:\=(+RX:L3WS#M8)TQ6",J)(BZLI.2*HMLXGXTNRBOXP3TQ
MM#S_0BXEQLC11"I/6XY0V3 NGC!2\?%)&O[*(Y @BJ3-64BV7 Z$'\FTCI9O
M%K^N\'II&A'[&3ENNLV:M(IDD(QV?!E' ]8]+/:W\R(?B*&3*9E]EL^%MLH#
M?3TIW^<\T$;WYJK0'MX%1+M_["QBGF5UY-T$KG@+:O]:O+8!O*\#5H:C73R%
MX;!.@)PG&JV4B3QBBA6RS:M5?QC,!FDFK(F)U&XT70L:]%LJ]2,90R;#<P%L
M^LCL/Q&C5[T@_IE?-Z=(V'R?5S\=SB>)UX7[T #W=JWXKMT9,;\IMC7L">*4
M1VZNAV1HF+S@K5"31M,-WH!1I*Z_E,#")9,?A0U!"TNR&(,E32LB>/]T^%-D
MZ5E/)UYG,KH<7E/!P/PW;Z]C(PF7[4D;K$WY/BWJY4=+MASM-!5J3C?6G;+O
MD8JBC"RCDC.DSU@8LUZ,/K!!22C=$#"D^NOQVF0<E=2)29$DR98OBQ1IR )T
M;$T1"*HC*4&-<;_/T3,!<B8(-_27:^1U?N<K:M"86(]!WE!0L#>.1J?AY!=*
M)341GPZ5'>(HQTY_]/F"B1GIL84"FSW_OI)X05]EZZSDV^<%"3>,(MW(?/P;
M#66( 9H>0I#&D&&NL;9!FB1.NVZ@O- 5E+C=KJMS$[T;EW^0,L7X.@@VA3>E
M+DX;=#DX[\(S2Q/7NZ4I4$^%YYPLD63<I^E9KE@A6[*6O\'^W%(1]X:$0)3'
M#J'=*IB$8P+FWX&LW+/EJ,]@61$;+N/C54^X[=SJI??G'R0$Y&Y;5TUW-]0"
M7EN#:(J?2T:!W"D;M$1@7",N$B!U[0GVY<%W2U"?$)]B(8VLK$-B/ C%92.F
M6FAOV=7@QU"6($N'\8-!$ZM<X8KXW\BWL2#$-!$DRLO1LYX'@["*BX#)?[0,
MD-:"V+AIKUTYWU".E>[YWG?@U_ #W7'6+"PLH$51&KTQB9%75^?;A\$]!_5N
M)6$;AW[N.?WC\(@WR^!0NDMM:JTX,JL^%2*AJ5J+V"],_Q1.*GSSM)5>(=''
MH<Q8T8(!LIY/Q?4^J3R,9/F$36X!8LLN5JI/+H>YQBP&_Q0>\>)T%][A=SQ^
MYYL=?N<C>)8=?N<3Q.^0DVV:(Q:G ,QYDM?(-G6775^L9A!^M 9&UT5Y'.*0
M<,+-?B9%D<O9H_"S07,DYV"8BD3<EJ8='\UZ<"5_M';Y$\T&VZ'B$F/!-IZ%
MMW(GQVS!B@:]*4Q6#B%+?S5M]G 1A C*SW#2-KEFH[3-G,[.Y-3!4</66%(Y
MZE\YX@BG7:-':W(1^?)6;R4% K#TYC5>'F1*?W<7[Z-Q@7\I)%\_+:/#-<<J
M)[T<[K>/!,IWP,-],?#^:2BB?[H$24BMPHU7>25& ,F$ 2OQ1T@O03=-](-X
ME=U<2E6Q%C?_P5">1^C*OV@&N0\DHS6G!*4V<F;%#M$EW@8#%%RUCJ1Q*I;Y
MBEN-OB!]_L%01-].(7IX2&+DY.R%&(#SO-+M^EY^+;$"%+5CK8G;/'>Q"+Q5
M,UHB&>?G6+^4S<X X1/[1<HT<A'"G\WG>0<,>46*3ZS3XCSR+5O"ZEE:PP=I
M.<H7+%S3:\!R!S9/VJ_O<94'H.!0;/S1&;'54?)@4_>7LR>FE/ JK,.6FWR>
M;HC (+Q3>5XN-LP=Q-(7)\597BTQRU6EY4?!M%#9NN3 ,S,AIF#/)0S8-E]@
MRB%*=M;LHB4KVB3,B[DL%H@@W>^K_*)+Q)BT^*1;343U1 )J11EX@"-4*(!U
MGUH73L)'N@C7=R?/3\VYC."7&,&':ECT[%X6K2CBX1K'FS4.P2-HX<HY?-P+
M)0K-\W\W5,+5?\D<3!)L%#P:Z4EJ/^2+'L<1^=&);%,7!V6:FTVO@C!#-#$L
MH&0R(53%Z-RH&0;VRV!?49;I&U7]EOW>]X2U/:1"\5F1MP)?8. MKS:B?;GY
MD%@9732&M#ZFVKA%WU=XKOW92]/%ME%Y6K;AQ1[#6++@&=BS%K^&>];0" [&
M)\*"PY.M14AN<#N1XXZWX^5A [IH\XMZ>-8,KV'C\ V/ ^$01<%QH'7@]%63
M9+\(YEVCDTZ34!MXU#*T4SX5611JH2+C/A3>R[:<%$:+&WG 4, U\82JU!2]
MZ4%^%VSX10$&$Z8KD)<1-F36Y1,Y-:UON5$IWM',BFZN7-+Z#7WB-ZIEGX35
M)PK%+5NDF+S08;1;*SXJ':)4LGZ,\. #R(D!P04-'G7PS2:* D/9.K5,\3UY
M4:%NYR^KB!XGW6BC<!=<6]D%)NW4A=583#KYWK&3$I%WA?$=<18RTLV28&N;
MA?<[X<IPA M;E#7[5P;\8_$'#F?=BG9$JF[M!R\L_;H@Z6P<\%3)SA-+E,IC
M^9$*MA\S]QP\FP\.F.)+:(+*=PS@[_JK[\;-E;3IV0O_ZMY_Z+U([*?/V4;'
M=9(^@58+MJX,%A66Q:'+00RKK)2,]5/'+ST=?&H\RTX N[V9Q -$*4L'0S"F
MQ.^!4BV\6-KGO.BA%#</1W8VZ39OJ6AL*6,>ZSY*?G+-=IFM:($P#+SL%35*
M0T,'T1(JNSCM<P+<4T]&1Y=41FH2:NM9.1;_VM,DM'/-T@0!]-61Z1<R_GDQ
MBS()Q8K/S36%,7?"R+TJ4.]H:CNF::$S\=_V*5Z$8<2PJMY4+H$:'RA:P-4Z
MRQVP36(]+F?W#WQL0LI7 %.+?VCQF:6%MBG#TC5F-OHNUL:!&S\X*Z@UA1;=
MNW+%&G!?3IJ=4>KN3"!UIO^L<!\@'>,T;];TX8-[_T'Y-J)4;&HJ'[06S\2O
M\NRS5W83@Y#NK9/+':'7+?(O8),BVEL !24R'[)E&9'N=RU+@3J<Q8Z^ZW8G
MK%RM"TX.4A1\2E$)"<\U%4% 8!;Z< X"LF.M5=9!%B;LI)2NWK(^#[&OML#I
M5(8?[6;S%K<?P:M"-'3*,PJ$)3MLC,-M.3D>7!O^0E^P)#OE:%+A6PJ<5^M>
MD,;"N#B]7^^"2W(8AFG/5CH:93N?,@XV"]2PBV:^X40YG7;<4? XV#RT#87_
M\2V$E"JB89?N52ACI^3CSMO7C$/JG0]\3X6FF ?$D]291^N]6.2CUE7.G9AM
ML4*/LLO[Q73)'7"67HZGC#IBR;UG+RDX(N(C:C8("9Y+9$FY)6/H7T[,'S(H
M[@1+TTZ#O(@1W^F3H533;KC5.[W5Y>\VF?1[V>#3T<NV"Z^0QK6@[J0A_734
MAB40W)\]*CA#,/TYQ78"AP*?,(#[:Y ]:T%I< _WU'V1KR:&+!94-VVM'>)N
MN*X;+1N?*V^L5=]DXZ-W8^<]WN+QE7/-(^Q:2NV-UM?.,;S5N0B;X:P\$>-7
M2R%JVCR%OU%5B.!WY#V2.-!NKFYOKM"'J/5II9Q9:;4F[I\=&^$M[R%FLZ"*
M!64KV@)../N/2]!C2(9&RTWC(U6*LR#1X;0/%Q8%\JKDRN"5WZQIFR;)3,@O
M4!EPI[J=H$6_W:%%/X)GV:%%_Q6TZ,<2>B4QSXE$",*M$Z,N+F1IK&SZ-JQ2
M'#&ES@,G6*G8Q_OW'FBFVZ+M[Z5GXLB%=3_F%QIAJ_<BY::.\N!G#>65N[2B
M%MYA*K5]WB!HX9PR9TV*]E3RF9SXHO] ;GW#YAPW*IL%/VI;%,J\ME3I,I^R
M#T%@W0FZIZPC+X$^K;5.O^_39K--76G;-B?UXC-+LJY+N%O)URNZ>5N>H .[
MK@FX,HJ(N&$P_*ZZ1/<"P1=DRL() ,XFO9>/FZU 1YYAN>"R?<Q[4.6,H G>
MG_SMC6>WOR?>JQ.M)JP*8N.?FK[H[D#B[+AHS\-$2MIW49STR'*(JT.U<D^Y
M9[7R>=Z="5*&)7^DKY+R%"48M,,79LNJN1 B($]<1B0R^:5 8.B6Q0*4<)]^
M%NO%&)%(2*P+T3%"WU-N<NT*K:,!_<NW]^[MWYN%9ZK$H.2GIP3F[0O%J"5@
M!=JXSP02C[6X/TMO_L #U!0\[W#G &01.D<?HGA'P-Z. :.E$KQ@LK0LF4K#
M_>7@P5?O^\B'\>=XZG#@T,TUO=0W+'9_W67P6WJTOQSLW_MR=L*/P$UM4(TC
M7$:K>.KXBV WE^4[FH1^%GYY[S_(6!.">K-2<;BP,N&H=,6JW*-/@.2@EVM;
MG ;A5:FF>_ 5?N%&_"LP^1'I)AT;=)2&]ZH%-L@@DH.O5"?N1=K]C81S1PC%
M#2%*PT-PE-&HB=9Q:):9[A][4<91(VG&@+9BM+<2[4$=CDQ^AIMCP]I])PK0
MC'0C"VC'NUR%:7<Z)2B4RJWKMG,ZH]WFY%?A!5"VO<RKT_M.=^/^L<;,J7[,
M%]ZTJ#GBALR^&-DAA@$ZM*D\K3-=U&H-JUA$F\B9^[?$@4@G.1'&SO,U65GI
MGB_I*DQT)YY1;-RVA\&&LR?R8#^QMSAJ\D78>DP^U'+^U^E$.-I%!:SD70?*
M&EH+[4;T0/BQJ21D8NUNZ^)#&77VB 3UHB]%&[\@:C]$J?*0#:$+.(<NC3J+
MDIK9SXO1>HXKD9:-C+%?D*SSQ2M'<QYZ<Y4_UB3_!$ISIJ C@MTD!]%)[,LO
MZM.<T_R1^K4S)IR2>:SBE\:?UB ^:_EZ-!PIJ#)"6W,JE^? RM9QT3C@XZ"R
M(,_C=@NOLLB8I!W,.;<H]VW)M H$G RCT;N944\9;BPM<BP@YH?QK^T6$<^7
M]G\)L4>J!!AO-'K9FIM?F=R!7QO# D LT)V;EIMV+W(B!<I&EV!"HGE1%0XQ
M(L-V%\J10\=HP.C*R#.V/F0XHU&![2%@-@XNF(J!S8V'F=I\.Y[C1_9C3BGA
M-CDM+-I#*'Y%#A*_ /VJ&R0E!W0E= #%.\1GO.DC[F]O?_YDO+T??"^/OK+-
MMT&HU)?>=./!*%OY&8:1?@;L9%O4VF4TGKK99Z#*6I9U5.[@P=A80)Z<\Y\S
M0M'=F=%7X;FX<$W)KK&KL<7EPFFE5PI[>UUMH/?6;J2'<E.O\W)A[HG"Y/=G
M;ZY8*A;TAC,1:=6$@*>I",.V'4SM]@V?L?$FGPF=,%&ZK(%MXG6+%5YL!@PU
M.*U:CNJI&X?N^'G4I1R<U-..DU(?)0/'3#O\7("V#DT$<6^>GCGU<ER7Z,#C
M@28PCGAPY]SU!>RIN!VCYXN3%7VV,$JTQCB8;]HMS_C'I./OWVAOS3Y<+6"0
M$6N&GLV$O64[M\TF#BR$>%-*/GER2<"3C/[72_"QQ#D#D<-'SC6(.]R9[R20
M'I[N[IGY$2)B^4+[&]UW  .(O'_;[ MV6CUX?T0)LB,XX5OK(VX=D#R]'ZX;
M;ZBB1G6P_3WQH$=GB_$[Z??W9X>#SZ^UC]KL.F%JRSYXV4M/]EX1:RQYZ8.[
MO-\$,1\V#3H;#AT0Q9JGKG+!TWCBG":RM4A+ DNQ7@>_!,,MI:KP1J<MX2<X
MHQD9I:9R->R$\#K)XWS;_;GU:GK93YC X>J_ WF=D4%(8VM.S6JS%W*['+9:
MX)+T0*&/FL#2K*]!!UF)GC[KX^%V+%RC7%%G*7?'UUW8)L+1FW3"ECW_<(=V
MN<7J,);^1FC)SS<5!?ER4"MAD.M$5XHHTUB[:-IJ<5$N"I<("8--Z#+5^8RI
M$ M\A<=RXOHP.K E<HSLA'4_ (J#37Y5O"NM;Q1"'3@.0EB6,?Z//$Q <S,_
MATF67.,S71.[N;Q-'4J #S?B*2W*+HKL&'.M@#X\*R15*&&[$<K0$;&;M0^R
M YW#?M(08;C/?FKW(S'^;<B:QFJG$$XK2;=F)!7%PT>RFO+8M ;^AQ!@[1!:
M'^(,'@.]77<#;\6\A[M5GL>DNH&J[X!_>N@3O5HL<8UW*1>"D[-S]9"M? B)
M\UNBOL'436Y+I?XPI[^H@NXDXR8/-T^ K#675N*0H9\MD:!V)%Z10?PS0N(>
MWMM!XCZ"9]E!XCY. L7W+."\/G,Q%YM#32@OBUS9RESVFK!4;7EZ2AG5#)F6
M25W$R5(FV<(A/<T=.)2>"7D\:H7]^PTHY2#=>)Y-55HT(T\MDGW%AXPDKWUR
MD=N-D.P4.DD1)""<!6?')(]NH!?FW7 %>+V_52;<?;2$,UG!Z,*D=DM5 (B5
M#TL'4<+3,^1?6^GXW>H9"NOS!0.IH5#G::O\?$(XM/T-5"N8Z;8LG4E/=0.E
MT*H,MP_+XG+@:"A"48=>U$"NG@$ K8;O)?G9F"/-YW,* +#;H%J&U*>T+EWR
M"[=^$'C5>;RF!^2DF>S<6M:,.RHC*))-6M4$)Y;0!/X+/$P7(U@!L3>TK-M
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MW8^.D]]A=V1"LPX8JE[]JWOTU:.S?-T7+?_Q:RB,O*9.X%EPUR1!1<X>/#\
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MDM-U\;PL)CBZ;4:_P,1?,EZA+[W $2N"'^G41[]"""R?9G*Z.DR[HBVQ9ST
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MEPSS%R)+%7F)TE1/%=):Y &^].\&FC;IET_B_59UF)_I,KB]9YN(RMJ1DWW
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MRY87=/NI;?VV;;?8&@ ;GZHWQL22J&/I#L3H4Z.%[XCP3TVHIRAN=3Y6ZX,
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M;&:>YYSIKT!=C:0/JP"/18>'J^!IHXO#DG DAJ/E^>])75$R%ZX7R749B&R
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M1U,.$'O;/KRL?K'^P2A^AV50-NW1+<L&/L!@]K>]ZPGYY/V7WL44S\]RE*+
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M\ ,_(Z:W>*0-1E_*7CB71<_)9+SQ#A>N$I$J)!(BGE@\)-P6O7')V.JFQ".
MGCD[Z@O](2/$MHRX@ '^Z-.O,(2Q'R#$HW2%8B[+GO:_P@*EMHF"L9QP2+(8
M3XQ8'BU)$?T_KYB@C-;VH1HA>R$<Z4 -#\DB:]N4O2B,<28A>7$_(Q($GF[2
M:/Q#2"MP0XMZ1?BGJBWY0@BPE6@?JEIMJ^JS+U"H-_QT.HSHXKP?32:]D+F,
MBB;",IY@Y<0B5J%#%4+(AE*;K-"5M;T"QK-W&K85;0=VP8?1</0]JCD/[[SG
M*$,J.X]6*B,=8R8^^42T3,)2;2A/L;+NGP3U[)E05^P=6 >GPRF,87)KK*!1
M(FC@B@ >0$0&IM&OD66/RBI$Z3@#49D%2Q!VK_/*2AK5DW '@8/3X5<$4QA^
ML]0%O)Y%TX/[I(G77*,?ZP1N4-Z2Z+(+7'JN0JBN^=587AX%*LB\@T/A;/H9
MQFN7WC,A65P7)32+0*3FF5CJ*<DY2?1CK?'5;;_'$;TT7E24?P='PWI@4B=G
M.6YA+ 8$9C7:,C(:HM"Y%5DD,*EVA/'5<**.U#MP#>]LV<4E27]XC2#GQNYH
M.'D#>32&F]^[]'_"Y.1/E <^OS_TXV\S8PI7%\OURFCF#-_N@T(DJJ1G) B7
M2IJ2)!YM+(*^L&4F^*!<[:O.#I?S[*W60U%U9RQ&R/.WZ@T,43_3GF;2@5*.
M4(U@I. )#;+HB<)7F4H#Z)#7MWY60GDA[-E.Q!W$.S[ ])X[S@S764H@0 -N
MT8$JXDN>),=#U>MH& 53^PB[#^#9:WES<3[4K=Y6MR=^/,1-9O(1QA>?_1C>
M^$D_]F1 N@EO2HZLP:T&D=G"/ZT *&Y"PE-96<<K@3Q[76\OWH<Z-[5U_K8_
MN)Y"ZB6EDW=&$#3!"A4+0*\L$8(;ESB56=3V6M9 >7%ZWT3$#S5OM]7\/Z D
MQD,Z^HKFR"?X<%V$<I9G$"=GU].2-5YR=6YHFHT.'J(CX$$A38TA3O) M-;>
M61 J\MH[?2N SYXEW:GC(7=<1]R9,_L!YA[C 8\V6>P5AU0WV1/'#"4N,4$-
M0W-5U#Y#6D)\J?RIHI(5 =2M<SB/1U=?QO"Y9-E_G;M : R=9;1X;R, BB9-
MLY)$H$M#I)::>*H,H0QLRE0&&6O?IC> ]>RI4EOT*^BQ=8#]>\-8X")3$I[P
MK'"U0J%AG!5ZO\HG$6S0FM?>/Q[Q,S8,$:\0>_GLA>C1/.B/$O[]&/P$WL+-
M/V\58GB4@)(GWG!)9$Z>>*X]6@O:JJQRANJ9)=NCWD?2065NKPHV[TZ375U7
MK%C![T.$.>C_#Z2_C0;EB/@5Y5V6=3:\@'@][I?$O*-Q?X(_>CO+V+M9YV+5
M/2:$%X8R8J.D1$9.B85HB::0'.@H.:]=/]+56G;/VUWSJB&M=TJ*#NYIUZWK
MW6B,]M+P^'H\AF'\=CGVPPG*L*AXF&;?#68AVL5R'UNBE<9%X1U)0N,2-6AB
MO0"2,WIS)N5 ,]\1[RLNZ\<KL&>J['#K+[ _WM2[XIIFO_5QA"*%:7\\LSOG
MP>>/ USM4?H_US?7\#?7%^<0!WXRZ>?^3:'XW<]OM=;C#E3VX$@$]#,DNJK$
MQ62)R8QJX57,K'8^S+[6^N.].412=7"QWT3LO9A4B>3A\9? $ EX_ 49$HF!
M:1TYFJ&Q=M5A$UP_2+JMLCK)&E_KNO3 "&>Y$80E65*F52CYSH9$D9SQ7*9H
M:F^@C\!Y>6Y=+=EW47FR"/Y<^C" 7DI<LI@541J!2.8CL=Q+PE4H">\J:5X[
MN?Q[!!65?Z]Q2^=!KRW$N,HO^>FF#<>_QL%H NFO/T_'UW#WEZ/A%/Z<G@QF
M#_SKSQ/X5+[8E F3\;3W<3Q*UW%Z-IY731[]V9_TDA<Z">:(PZT/%V$DNEDL
M$9LM54Z[H&TCCQL?<(\'^-T=!]8]NR(+'FF5\P@K-E#CJ*(X*_JJ]_#<+XM]
M.]L9&X'J+?7KV5[7#X'4W//7]1FZ4W<='3U4>"4![TS[D*+RR42B@]9$QLB(
MLRP0%J,-Z#\R1ALU(3@LK7_7K6DO2F\CUP["4G-@O\VLGIY5 GP,CC"K\5BC
M-)!0DE,M9RE2!93)VJ'][P#LSIRKJ)11+8E6[$\SKW._5^$^F0/*6=,0$B6&
M&H6N12&OP</*&<5=RIXGLZ3BM5T#'G[Z<]9?'9%U\(K>]"+X-@?CN3?9,?0X
M6?$!G  2N. D,RM%#E(I7KL9S'< GK.*MY?HVE#HO_VR) _T%?[950>\B\NS
MX__XV]G[MR?G%R?_[^^GE__U/;Y*7>]6/&8'G>Z>6MQ2=SN#FZBDPK,,3@9(
M 0+'7=6Q[%%U/CS=W6[% ZMWM M<AJS*GN%*WU:9@2!"6WSXJ)!@*NO:Q;CU
M.]HMQ\-.AQ?34?SGY]$ WX3)R7]?]Z??SG$#?3<:_^''J>>S85)$3:)U):'4
M6>(=!*("ZL4K$XRJG:G7$N)!)-"TX<:*W/S.5-)!N[SCT=75Z ;BPSPP2Y,
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M902!!VL96K"$YU+SY TC(5E/&)JP!B10$VLD&3R;N&DKI3X5-VTCW)U%SIJ
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MLX)P$2A:K!HM"L%H*8V:95 SK\-+)-1F:0X[Y%,;Q>P^S4$SEFEBBC!1?)S
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MEWRM8]0R6>(H^N=2R$Q\*)GI1IG$DC/!U9@:_\(GE&SB/%912<72RG8-N9N
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M'8DL1*5CUBPNA:@VRG):^?!=W[-VK^9137%7SG1;X/A].$&GJ9_[D!9)P U
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MI F]EL^JE<?\_C;Y2F5O!?#22@$X$JI$*'#?(,YRG4S(UHK:C417P-@RVC'
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M=53I<6N#9;A;6<X2D5:B/1,2)]JC$1]95+F#XKZFZ)XO73K61"?=2!8KO[E
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M/P,D>FJ4X9I3DUN9?Q3(B3&@O;'W'L/=([9O_IS>G)W']^_^ %!+ P04
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MME=&+UC8)=1A"G".JY7EJ8KRAQO88/\5U(%(6JN4Z7W#\N$M<D %%E]4*Y(
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MEM@P2^GJ6IT.-/.B0NKA1"LG#$4"VX&E<O_A/.3U("A2KC#3;]<2 @[CPAB
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M9!R$TR((<^_(EULJM%/YVL'PR0:J'<:Z,(#;R0<%H&HP_TO4T;C9CQC.$/D
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MI_R.H:)LA1/^Q]K5NRTC^7_<.7")GI@W&*)+:G./LCD)W=XG;&?;\JS(K?+
M*\'MZ5J-@6A&L40Z\V%EA# #J)8E[[7/L _0Q2B:9D3Z=Z<3N9_7_!/'\#:W
ME<_]Y+ZHKT>6,:!Y["^ \!%&C8[ B7J8R1:"2S,\[FW/'!N46TO0?#-+Z[;C
MH**GO0Y"[OU9ZI4\S03I8T!_U4GKR%7\!JC$CW=3F*E*J%Z0%U^'*).,&U$:
M)!_K3I&P+$JP==7PE^HZ9U'%*]=[16.M(AXGN3:_51ICGB&X^V!?FW]MZ^6)
M"7Q2G!F]$E2+RSC(U#_5/78_67!@,>^LMD>MK1W=V'@?HH/J@9<$-&/&U@SJ
M2BD.LXH<% 5Y0T?;CL&BFWU!HL?TEXU\Q-,#5-5*%M__<801'D&WJY+08R/H
MW4[X)PCQ^A9%F@&T<U(N<C;BN)%AA(!7N]=4.Z[7OH$-ANCDBJ=T8HTK8KH>
M.C:>Z4A-U6.]_9Z5-8VV%TFWV$90!?OH'V1*ZZX%7:U;(9Q;R(/9XE%Z%;M*
M/POZBY+U?/FR-L1RBDK3."D*?;1"-2*"O@@_O-H)UP?Y:1:Z_1C-AE[WA1[H
M/(.KHYO\T8L.N##T'E@ 5WJ-#J!TSK^55YD"8M[IT]_*&_T:73,+75O [5:G
MP0Z7A>@GP2.YM7T.,=#9: 90SDSC\R%S$2/C:&ZDSG)YP3Z=B-'&&?:49MMT
M)A<7KJJJP",]POY;4BFP]R5=BP^41?Q/@>7][F%I@RBHE(5IH42UMAIR23$2
MK?MKTGQ@XP];2C6]-66"(.1V(?QCBM4'9_AT6,GM0(#?$7T;-_O6@(?.XDD\
M+\T*G6,;[#M*?Q]-BP,K)5A0%B]CSN+6[<$0;[G9QX_DV/+%-ILH&+1[RLH+
MVXY0*Z?3$?D[+JPM>ID\+-%O0C;-!@."#=V+2HT?I9IL:M+9RL!:P4$#6>N[
M)0.XXVW9#R5Z8VB\6P2!)H0 $DI&4_3SX;]1XJ2*?'OW@X@,,9VO@?=O/ZRL
M>&E^OOV1G_?/ZB=/@.>V4,W_'-54^JE 8F8%D9G.^H*8-"^7HF3GJN1V$)+2
MR_QC3\-OOEM<_.UU"?&8F.4+\9^*0S@$S?,6APIH"GY>F;T3:SN6^^?.U%2X
MP2#W(EL_W9FQ$X)+'JH-C%ZD/07]=M.^1O^)/IY-:9K%O[&I>J-]R2HPH&H"
M&EE8/#<$%@JY]I%#%^4'!K6=$I]C2B.T._Z$T5G>S*,G9-LPWTH[2&7-63<I
M]9^+>L(_3M2WRO)7<T'[BUVHR@9.W><2S[V(:YXS<'C N0$'4VJ%(D#,)4L-
M-XA1V CZST/L"),9EYV)#" "5V[AL>^U".BEJKJN/>.^<#4)>?-(PEN#8B@Y
M&,SB=MJMPVS<;"+\#-052K'P1W$/T<YZA&1";M4EDO'F2(=[HYJ"5[3-[FF?
M.AMV)EO84V5YOF"^8$ZF\-:UL6L;7?.EY?Z' ;7C*N-A66$Y49]_PV8R=FO=
M[1#R#(#-TVGA')S.,7/X!>>%>=T@1[+<4"-U=;28.*E-7*&^FR:P&1[]ZA;R
M_C9YQ>7(<=WV$_Z'4T '2!&ST6@1[0NH%CS1ZCW4Y0Q*0C%.6WC:W9(.R92U
M':D9D' M6LJ433>36SN6Z?A\[I12;Z&MJY@4G:7DGQ NT*L/*_8*I*J-3U0C
MCVUDI,[PA+$B!S*LW=1-58!_ZT0()>5^2DM9?IN[T_CBU_,%X<7@F8EX=LF_
M75V("(ZE:+&2 A=X_><D3;VT4[.L,<VO*VOS0TRVYLN6P-XS1YAO[%K9^#E9
M(&7(S\P6]IW8;FC*JLCO5_A;5&R566@],%NYD]AN2OD^G+VPWS \*C,P:G1
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M:(7O[^\(4C'D:V 6@%39=.WQ86&=DK8P?0#,"*GX.C&"D$>/L@F"QRWV5$[
MDT[O*"[^DPI9FGHF=:^$+[&?O:.=RK7N:HET@X]M3R;<7!VQWT[9@VT&>16'
M;$C9U"L6R@9[(:)Z>Z[@:^8KB@;S)TTXKX*7VJ5 S,"-%WC%AZ@S]($9@9=(
M7P; \\!V-2#BDFIW@%LEVP^-AX$C,<^7$^WZ!C>Q%,6MC5$'H@>=Y6J>>Z;
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M*OG2MI_-ZMUK #PZ- 6S"=0R+]7H(--41M)X6G1)HZVX2"@Q$9F_934D[]Q
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M(XIS)N'=RZ:A1PJS>$WZ,)1X VR \40CZ L!3+G <[JFO;OV1>)H<BA!NKS
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MQ#>W'V_9-%U>M53R39BJ?FJ.S=%C/D.HL9&-YXHN>OTRU^:.H:\7 Q@M7K:
M<!J%PSST9)0V4__L/0G!@FW- $A]MT)4__6PO]D!;([V'I#:2\ ^M&I<>QK<
M<"P6=22#+:A+\H)M2\S^5L9D67C[U3Y-4@O]9" 1,[^U0<JA]]MTO$:)VB(G
M#8?*>^X)R6I2KPRDV7)*WQ14K7#SKTJL??Z.)^EEG=-ZOBQL@QTVHEW1N[_A
M\:>TE):H''?JY6?BJFS"9@T"_9.(H4C#:3SS36#SBGWA#_)PG5\>)<NPW]//
MRL\O_<;WEVQ9<H:B,BEI9RT=N"OUIA9.Z:-2R4:'"31%JC#]ISV$8CRW4F'B
MU$P_5YDV(#"2*?LF_?UBBN$#(Z<X]3$>6?9C1\\P:R6M7K&$5F)*?!4WU?QK
MU#S@F[\FS#[)E!2/UO-U8<S2ZQL.8;VP.#S1 [%>2\IMWQ.<?J6M14&3<P,?
M?R.V%QWSO[WN;=3AAX"F,/5R*WUE:KP+'%U!CQG36?R(+G26[BR\#K&[A<,E
M;[4_VR:B#.T]FI:\77RI2/9I5$)UMOMKVXSOV$_2Q9'O'>T4'9?V@^'$W<L'
M*9")8"_=GIGIX(/]?[NM:4"-0,KTPJB.]%ZZ#,6%X%%OTW&#Y/=/61W&.$6]
MF'!]=3\VV_"T\%?JCY:SA'KNZ.5DMZZ/;H;4DOI4CU4&P.-Z/T9&H\1^IP(?
M[+DG<A3$R-_G,=X4,3I+,M'V/E'J^1\8G_N!=D%!9Y&) LX'\>QIF9;I+7.;
M,PYVZ0[WF.YYPZX!^UC"%DV(A7J99D?!^\T_CN_(%*&&SC74_MH-M9?V+8BR
MT1&CE5[?T2N\P]HF<_P,*S_NUM?BUTMGDN%K,@B,QY^!$5I"_-#O8$C!=K')
MQG(Q[@WUQQ.YP3LE$3/79NSJ/ 0WKZH?/2I9AR7C#V/K+E-#Z#T3R\U;9^ >
M$XC(/ROR"]75_5^BA5HOW4Z2;$^Y>M?Y[=%W6BZ?ENK=HQ>70KKL[L.6,@:I
MO>_;I+>+BA#)1?LBRM03J!84#^AK +V/'\U.X_N*?&/VZPE"0=$)8YMYMKC[
M)W6,/T(ZR?7:I>?4-+*[='Z1C=_C5;, 1!ZO:_,[WHL%XB%K_U93&1A/X_69
MU8ZG*H)EATU;/$23>-B>$_B9HM9HDCT.^VJ0:&?,>X//1N^6KMSUA?RO9#YR
MFS<#$*2S45S(493[6"2DW09![@BGF;B/V"2G3DA446_+QV _\,B]&<S_IKUK
M5*&O^PLV7;^Q#$)=YLIL@<Q&<*<-W;*^88?$0S_)!DYR"T7G[W_?@K8_H4P:
M4Y(_/3 .S:&L+KBES:1#Q_U,U%"8QT+=J>R%]62#X@_ Q@_L )8BM47C$IN%
MTG@B6Q.1D4U!>B7%R.^?D3RM(F*UQMUK2+QFR@7A9VW\9AMR"05\LR7'EL?0
MCQ3' N80ZT*S\CHM$!8:Z/+)XLA\?,:=U4FJT2:UI_IRMO/>5+=8?.*5,\=.
M*<<DP@HM2SXL\Q39>[=TF;Y*'/3\G#1>OWX8E&E_5#9<YE(L,L](;1155#0*
M:UH/A&_X4?EH5PYK&OBKPNC22,?1UC2-+@7Y;LT6'Z=+9[A;KCS2\@P+*Y^+
M9#\I;MFJ_??&YUVH,YX#^=,]-17/6W?#\1R&*L( [%_(O98*GT9X\E+LP_:^
M_Y'$W?Z*5>.,P=Y0T?-2V]@_V-\,<+Q4[C$YT:;IB5Y#R,?!FJ''M!2):[/K
MVDS$W@2WN3[6\96-+S9C*_VOLRK"W^6-7=+;>O_Q8Z*AE'C:/I[.4@2&W8OB
M!*[+1NNLO]*T1T,""TWFV8*#/89)'!LYS:W?KL1$0$4GN%F45 /X?VL$' Q$
MOR;D=V3D0=&$G>FUG2=Y#BN&-]0+=.:V)Q'?P;X?Q-^Q>Q0+'-&TC I#(VC7
M&< KRBID OZ0ZI=+AGX@PTOGNZEJ&54NZCMEM1_GHZ$>$(IH:C-N4HC<1>SK
M@/!X,(#3<B'6<_!U!E!JXQ8PDN V$!KMHV7O:.@I'BG7JBI^]IQJIL<ZJ\S*
M?$'3X-,D^QX;;:.1TGVN^\QZ[NZFL(P9>Z^]T:5 _(8#]8HKM%)Q?8N C4!)
MU@X7^D($;-@T.W>_.T5OBI_"OI^XE<#4%5\7<SE3-OS?%OT6OFM#KR3NG.JR
MJ-GR-"U<N>D=LU 1N['HY[*7-0^=+*.?5*%>H^/IZM])\*A=.T2+]J6&<7(/
MHD6MV\4GM HXZY1X]:%_8Y,/__8EM:>78611$!)HG ML['['B+W\+U_/X+9,
MN8$%MR<J"%YXSD(E^[.(..FL:&"-IN"H\%W= ?[$U&:@@^ V2+ZR- 0RN5UJ
M0NR#<ZP5UXH,I!3(-"JM.5JZ6.?K_^Z;J?_EFZ^<!$1KAL#L<DN/1QM*O)[>
M\TM+TT7ATU>[0"43,E+L7B]5S,*_\=B<6=*8X!26 YS - ;0I46_P@#&,O+0
M*YHCZM%Q&1=-O)+0WBJ?3.YD/SPHCT/,5M'XF<F^AY_HTFXB[$1T*VPCGGMM
MH%Q5%3VFD8'+G#O[ R]?^IF6W['D,-"0@HU'SZ9[4HUS6Q 1&_,.Q$LT.1&^
M<M4P'?HP".WG;>1;?\6-YB'$7W7__7SQS/!V;RXIF* ?#19)12'Z<"QIOAT%
M(>6&T_3]/%UF?8?$1 0KHH7P%ZZ,K[/2MP-B%JY>B%N\IC<W;G,YUW0P5#%@
MW$>Z2*U^IHL!A"8MM7PW?YFV.F!<^\P;7Y%"MMGW/.C713U;G5B.90!>\$D>
M CFV(,2=5-58KS@'B=R-U3<H^_7GS/KY.-OTRSXJ,_]@X\N;>&:5E$4W&J?J
MDE;LN2G=15 :+V:6'B[5VD:*C/P#>[5G63:]4H72BR5H_M@T"_TN/Y\\I]!5
MW%B@VE]]](7UU]HV8[U-^H/2Y-WM,.JHBX>WA7>\,4J!%;^O0<4DTP<^XRYN
M-"B%6%&:J"=7X<1(VNTAR9$_\3$'Q1G<:K&S RH]P8;6=R8Y) _62SO.L\=$
M9_#=^>53\NU/WV0\0:I1<:R%,!I>CCD;<K>:M!Q!NY_M)CK9X3A(#6ZN3'LA
M[C5\K%3GV=*Q"X\3Q"Y]X.PNOU@X+R6](U'T>6!U_QU4P3=]&V49^H1\Q[!A
MJMAH:S1Y<CAP\L] =5\4I!SR2IN+,M]$%R+Q8P\Q1<@#L@GT1A55;C"TQO?Z
M>GJ6GA4Q6_B'&<2&-DQ1(U')L8<IVL(A(16DHQ[=G.$TU@ERDB>A+TH0&NNW
MP4\I#?\P,2:.=T$N*$FG0.0"SY_0_ 9*=];TNT3(!@^5=VTBOGWK3,C]:E)[
M\<$4.8V>=6[;MD<^\4J2];G/!D7;DUJ??_[S(N9<<T5,8/Y-M?YJ*0: N"H;
M1"VE*>9L<&=\NNAGY(F>++F'RZV'M/=YT-_3$)2=.>AX1R,#("8B!\WI[?VH
M480#.;ZTYQEU98&KM=91'_%AC'W^Z%7Q4QY8; IZ]AON-*CT(^ E/X:UU(H]
M1"!#N#GI?GGZZ!=[0S=HJL2NL2@B)F*BRT!,_?Q;)#:#?IF"('!VP"8*R+BJ
M"LHXR;9)0[&% V(\7!ZJW'+06?7""U<Z\RRC*4W=6*]M_E7'DD WMYF%=K_T
M'>\)!<O=Z# T%+UM89O6GIY\1W<"&I(CC>U$!:WCC O"2;@-V5ET)/1,G021
M 5B/?BHC1<:]VOCL]IDE)Y'T\.;VY4<W$Y[_,_NCZ\S+$P:BU?BQLGG_3_.P
M,<XY!A!/@P=+;'YZ-B>M8F>QKJ?6VWUB7WRB[O]@[SVCFNK"[\%8$5!1D*Z@
MTD2:A0Z25Q$1$4)':EY%2@@A(AU"HB @74% :I0J)42ZU$B7)M*%T)( @K0$
M)%P@"1/_4];\ULR7F<_OAYNULN[*S=WGG&<_>]][SG,\M0R^'DGZ8;T@&(I!
M*D6*\X/G"J <:/6 F,Y$U?*BE: JS:87GYO<4#(%&=Z(O(F7"XC$>TH2WWZD
M.FQ=ESR4OFR!'=<IWE/%DI.;;/>35IRD3+5OMB/RQZ=#T%"MZJ$U]#CC+A#S
M$25%-<XG0_C<QS3%PO+NN#8V-[[3/U5_^D9?B 'H=-Z;XP;XZ\SWF+]SYXYC
M/'"V!R (@*0T@=MMX].S$1UI-5\JZAX!Q_6BR>K3/W@/.1^[?9'/WI7!O](V
M<XR&7U4B.W"0!6,+J*<C<5.3=K=Q9=A;?_QJGS@G\JBJ6V;TN/Y3:CP*8LYY
M0:\'*&YUBAUE*PK! 'U*2N3<+6C'S$UJTP$H$B5,$R3-5/H[?;*UX7:56JR1
MO^11DAA_B2NNQW/2R'LX*2EQV\#?7=&J>9PX[><WJE:>;WA/%F\]7Y:\UH0+
ML=RV@A?M7:<.DPD1[&$09&376M\?WY3?X:ORMJ$RJ2^\(*KG?C$E8O)KJ+7$
MQ2V'8^AK#"EJ88S.47:BE"FKWCC., :2\X"8=NPYA3\7<67@M[GOMVU(3B?=
M!9V,&I5_MY?F*=Y3Q^<0$$9'VL4Y7 %7JFX;00#CEB 8D&#+&AI75*BZY3A$
M;$_O><H?6)TVH[ZZ]CAD[M[G+\[?M.XL9N;56:0F;J/>9M0FFC&T''(>C$IQ
ML VC5/^5DJ:R*<1O)M]^+UFF W\*)1UFD-2>/AH17[^>?SRAD#M-M7I[OK_F
MBH1CZ:KWU_,@@Z]'XZ,)Y[9%"<+H<?%RP=7EHH"5KAF=2(LAE@H^S(A94!_G
M=9Y'FG=YG?]$XN:I\"=U&OO?T8C1<=8X5!#CQB. 'B6<0]V<"_$F"]*5OF:!
M(345335 6C[@.#.@^OJ7R6CB)AAX7YJP=5U)Y.29^[-60P\V&HB[%H_EZ(3F
M>J+#'P^[R>GZ Y":=JXG?0=JN%P]J;^R]EQ<&*T-0.CH0>4FPXY)/%TON[J8
MZ);R/"0=GJ"Y2:II$[A\3ZXN0NT:E]9;*%<_Y0 4!:WA68-3L:3QJ.8K 3$D
MO48H-P+E'802++7MW*,7#^TB:Q;!JIQKR?IIGY%Q[\1.[*;VZ5Q #XJ?F6>^
MOC12 'PD$\ZXQ^S?N_V!G4.Z2K[C,(7,')5K1=:["/NGKRUV SP.17\:1@^:
MAZS];BJ%:?F-UN"'O@]8&*;/+VX2<NF>.=N#<KO3#I[H*FL9V@ %&XYQ&0A/
MQ\>AX,68)X#K78M@XD"ED==\Y%LGZ'1K@H3SM'Y/85G0T_$6OXJ  7HC0-N_
M'1!CQ<QMM*$^$ ]E2;-Y34%^8Z[V1]7*HQ%,_F_5(7Z[O'>A^FF77_A[QUYA
MGJ'&Y]5WA2OW5H^4^H;75T6;8EQ -4U3+W8'7_2IZO@K"D><F-\NS0TT,[=5
M3=K(2QXG#1-"C"[D6K;:YDV&J,140M$#4)W4W:2_3&J'G(@D@V/_8'G<"'SH
MB5)X[9ME.CN+4^-_#^YN]9 DC ;<^9_W'7_TXF;WX::-N:XN+"?K1_KQ_.(
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M8=2#E=XTW31B<^V. U8AB^@G;2GQK;B+-#N0BDT.@M&K[2>5:V]!6>+#^^R
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M+SD_)"?4>^^WT$G>V)MOW'.%#2:OSO<\N+KI=TLDFFW_@$#"*O$ I,])!1^
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MM^2'(->?;,;LZI[Z/O>RP?6\-4S/^N8LCDBP^_*I"47&+:-7LQ_1EU*[U:2
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MUP4EVJC&"DC;Y#WY/GNC;!2:B?A;*%[$1TP@[._DH\GEO$A2# H\0'?=N^G
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M0&H N@NY;\"<)%5660C%,H; $&?W$'(MI1Q#I)T>\<KG6BWZM]X2LM@QM[F
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M!MTB(D$16X-T*)<[^CQ;^)9C2[A%0+#E#54F$1>W)/WO#V<NXEJ]SZKAGB$
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M6XI0GT"SH.03Q^9$7]$1//(QH022@N%7PTLMK*X^R5=D+C![/?T!"7DA!O9
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MJN95K1@9]M:6+TUO-U-_,6)/+_/5O!?_,ZCA=-:V8]#[(23_,:AAGOYACQE
M81<8DLH;O:0\?P:WI7X,*M*^T["K\-<(1TC[/=B".UK/!=*6$]9?15^M[!T:
MO?-_3IG8?D"!&Y.+RZUDZGX(F>>52F9,O[9F3T;<#/[+N^PR']:,=LO9H;\V
M6US[?W?"OJ(OP@[_,;E"=!M8#KV0!ZZQR^&./IPWI*@E/%?5/D/W=SIO]1_?
M?3/204LI5W05*$43PEKOSJ $#/Q\S*#1?V.?#:,)YAL\(U&V&EOE\N6%-1].
MOB BKHN6?A<+?AS_\>(MJF "WQT-M*MDWF@@-FT7?(>0U<%R7JKZ_?MGF:UX
MJ]W)?M/$/2F:P'^4#?M1.AB8)Y29^OH06A_?05\4/QUCX!IXBGS'WBKO($J'
M-[Y(H\<+? N]\$E$I,68JH,T(^?4$ZB]:FNH<Y2(6KSGKO%1;HF=K:UM/Q->
MU !Z79:[YW+<P"OE# )N@:$^C6#S@-10N&HE>U ?L7N7*!63;QQ,K$$KL0H/
M"WC7VUQ7;Z[CUQ>1?\3UG,<WS)X2NH\@0WO2"<E=&0K[96U%T-55U*26 %PA
M_]Y6_M%TY?S=1\W;\DJ%#TR06SZ67%5*V4)?QFD'MKBYR5G?Y1I/2^&*)^MM
M#CQ6NY@*I"OU$>KGO(#6[8(U[&DL1>0U[498Y2P -KN9%OG%7^"&:.VXOQ0F
M]7NOT*')^Z#WZ7E)W$EJSBSL5[HGWS 4;1%6:?A/Z!"["8'5V);\("=C#.I2
M0P[ UKB_6_LYP^NU,N%J5=UH,S?I)..8[SZJ9&0Q$&9"S)TR_J:C2CF=6EJZ
M"O; CBZ.BM:GD2:EERJRGT^J.;%<9NI/3V]D"O">CN32[]B7!]R+@R96'$Q9
M:].L'MO;91KNR3;6-K@TZAM'Y7T--OFBU%=Y.5@LROYU0E)@75#14>]5M^G,
M U6NTSLUV'VOP[HA9FZSF)S2JT?[R&-0:(V#$5Z.C9VRG:"C;>\&/8?80W @
M-4<<*0:Q?@&&*MHWCT%_]R>Y:XSELBB87^=+^I@^5">JW5;4JV&+) _M_P02
M&?0Z$H\']*?;]I.06N3?<U<GT/6#GY#X]E9Z7B*^324-LG T&Y.L%7>S[&;)
M6YF%4&PD%824)B]'3ZBAA,?RH)@IAY[G2-U2[;VRJ2VJC*[?Y)D@Q[>:KR/4
MK=_?6Y#G>XG"44_0I"CRF<53LT$N!+@?-=BST_)PX*AZ#F*L::>-^1GO3+4[
M8Q6PXZ7UG1X@X'VOM'0_15M!<A(B;UVXX5+IBMT.B"K*2/)7K35#P4T:0QSD
M\?"1"8,/2+4C'-*8PD/0R22Z_8%SXTU@1'O<Z_)K2_%ZOHY*!J(<][-F/-%8
MG0?*-5PXJ@!J/$<%:*4(F)'G.P7L13IR+B?<YT\" DS9/&[J%!8_1<CKV;@&
MPS&R?C/A),O!<!^^*-WR0/[(365R_6,@4B1:DOPC%^^][KVAV"5<%BKT"JK'
M&R6OE_%#[C76]K6\6/]5?&>\[&,"TV;V OBE\.5D<_)@0K![T$11^TG?,@=H
M3[%MV@5XN5A#ZEU,N/?CI5MBIHDH:(J/WXSEQAZ5'1J;G+Q1D3I!Z==$5.1
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MP)KP95,AR*\YMVJHR>G6R,C:9CF=8 7SPIDT[H?3<IC^'P61P8N)F8T5[DO
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MTI1J"?TZ9T2!3-_Y>?MB_3,S^P\G-O<.9,HQU9J^T%OT7VCRPVUNU$1&?*-
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M]?'169N2@KS$+)_W[]V[B@[,FR2V-9Y74OU5N>L"ES/AO86''5+MX*FT_4)
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M%D[P&Q4!;>[^CC)?HK6JX9YYW![<^&%#A+(V9D)8&78I[5P4^WF?TQ)8-4;
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MA/OT) 65F0ZV("EQ1\OI"VYJ;V@$$ NXZG24NZ</)J2[!;XG3>JHL@_MU](
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ME)O E<>+&7;86/D_O@T+UZ+7W!9&%K8V9D39>7;UHOGWM8#*_DZ1*=V88B6
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MMOC^A/C>$PTVXZ2_?MSTWUV"'8\'O6M-D X\GLI9D=[+HU<6(E+-I6:>HKW
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MYK[M2P85T_(.6TS$G_LB(3X-09X'.,5&Y<_2;WSHPD<6#U73]>8%6')X/Z
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MD]/GC<+JMTZ^;L@TQURG!/F2<M2FPH#C*B=BF.[TK5KS1Y; G(DSR1=B(U#
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M+=$UC^S8 22^L2;;3%J$N?L4K4M*J1Q&EJKOQU]FC=;*$7H!)-!G)<7G2=$
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M,GX.>:#=,G*8H!< CE?QR:'<()J6XJ0ON7 </(C(QG0'!?DKN\5AN(:K&H(
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MKO&NOU16@;C$NYHITG2/PW)VTN72]EO@E>2!>PQ#QBY@*++A8.UR]UKOP#]
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M4+ONE+&Q RI"32M1@QQYZ&A)T2,M(@Y!Y(UV4R#;-ME[]I1+"F8WN@ 94:W
MYR[A&,Z;_FU1-U(J&7+YJU5E&_V/EQEZ]/B->!K *3YVMLH]'BX<.Q<?QT\W
M#-/(AE:.F:,?E$"<?=.40%GSEM/JS<KON9_%#KUX6=?Z(@+T-#^=]%;OS.'
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M('7RK:X!OH4^'[!L9//-1PVIFZL#UE%.6?[V5CO-<AVYYL]"Z3DO6=PA?>3
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M/2D:7?0-:*'?HRI;LZ]KD@4J#1#XG[:G:N(8G,*F.YYU=GT)Y"#9(G44YO-
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MJI6U$H\ Y[!EQ3F0 /):IM\LFXM/6_S>K!X(Q!1OY"S]PK9AVEE_LMXJZE)
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M.%DBQ#[S904YDY'-K&E&G=AIH+4?W$;@OWO1Y%IUSJ-06U-BMT?D/50&#/X
M,4;<7SKY?E>1:IQ3NO^P9^-NI)_HE?U8DJ+&RY1/RIWS^VI>E2&56T]_;97A
M/?G4-#DZ)F 5!5,UT?MR N/1SO/8WFCN_RT[C"B0A)OP:@%RZ$#ZSR,4VP^O
M4X!AWHW N]]PT<;.EJ\[EM>623;O?F2Y?16X<--!BNU3]ZU%.3:B&IV'$X0_
M5I[+AU?*ZT$_O'\TZ#J(9KHUV:,< K_862^5VZQ]^*C@>+Z-!19M[]@,>->4
M4!3$4C<@1(H;KHX4U+(AJ31GL55"$O/>ED</B+/A=E^QZS\L3KXL[*.MYGP
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M+E>_/R4<_63>X);I;5ZA6T9' *]>=$SZU/_!WGN'-?FL[:)1!%2:]"9$I:F
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M#]5,VFW//K]_(_:5SOG+7Y]6BK&_]CO54/+?N.T WXV_J5+X2/_=A26=1.P
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MN>$,5.*71#7+*%<^O+ _YSL#Z>DB^,HG4'NJN^[LL=!+')16R9<*>Z4A1V%
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MV0#R_%ZG+^L+(!LN/AQA6L@..BCG3MXD&&X\<L#T=_A7JM]1/RE[,# WZK/
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M?KTNE0YFO2,89:55@36=0"]EK^S$:3#:MU">U$5]U!;2%^R9T;1Q)P&S,L*
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MN+W:MH>/9<MAUO>LH_L -R#GMZ40(*T@C.Y@;I%TK2IZ94<R*":]QH5+H&,
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M<AXTY=&+@ >[I[%QR]2P%V,,[:G#7\5P3-EONN=&834/?ZJT >MV[<91VSG
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MP,B!<Y3'2-3:?.)QB$71[_3Z,/34B]-J;DY@3TAKF-CQKJRYB:--$U<,?=F
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M6G<1(FUC;.=^D%69[Z'42JPNX8FOX%@&"%Q0\[HZP]S1$K_:HP:%YZJS1MD
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M<E.+HIA!^T+H[D@U,F+'-UZ+J[JFZEOCUY'R]-_-181.C/SN(X/J*L%[HNN
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MG&?."U8D"L*MP\//65\YHCYYV(I]^E_-]2]PX%SUB@F2@FM"O4&>!>0SVG,
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MM;1%JF>1V3A;TR7Z[K.\0G'CZQ\'C"W .[&*1ZC2+4:O6M&9XQH>^9_5\A]
MOXR/C,Q?"W 47RR3RN+TD^PXTJ@N1Z^[64#<IW6QE/:$1_1R3_,NZ.<P:;B5
ME:WKBU,B[^38N$E;KD5A9+%O+F3.LSA&GSD/.ATI^F'8#10K6G0^_&FT>4($
MEA/N19;WDT"(%MG3;D<%.9,@WF("41L*G$<.OH[(ULS7K[SVY/1=T/#Q?2B]
M.A:OAY/0ZPRMI9L]4;L@BNX8<XME*2Q*47CBB_$G*F>$>"%4>%!1I<#2\7'/
M.>G, OTQ,YD-/OV\EWG''T'\I+2]N#D73"@$%0HZ6 8%J$UCRZF&J3(IVN7B
MAJN/*A._'^08$:J,FPH]TBYZX47>FZD[B@/[##KV6MT%!6(^09W<AV=R</["
MNC]QI%+[1$::&VES_29"[T@R=W)B_!<?E(N[6 ,'>D9;]%O)@^2"T(8&T-*W
MPW)$VC7 B?6MAS:?^=$Y!HOK7-^J7M6 ;-C\XKTM+1-#)YC<BD,B:4C^D8'I
MO4_65H<#./>C1X/M?-9W0>(XP8T3':-UI\@$DF& '55GM;7W)Y0J2_O($:4T
MDW:)Z'0NZIK:U-)**Y^:@G_@K08!$%,PG(=Q?/G3&,(&2"&C>4P:"M#AM=I\
MA39.L"]$P0):,9[0=L%H*+0=]E+?.,O#1-_ ?/,PVYW%7=#^+B\3I!:&L_&Q
M&#L/%*YR:ED4/+LU(H->\=RNX6!<0;;N81HI"A2MF@XK*LL,)V:Y-.6WP3Y;
MF.#G;[0U._C 3N:SX//.'W1_R<1[\S-#9"<$S 4T-6,24S:"BI3)#@)2<QP<
M6W6+17'YM7<-Y:J^AMJ45SX]<]0F).38IU\B3?MZX1%50PD8=BNBH!J468!#
M;:F7J4)1=AY6G^&?[R<].9YG)EOX/2_D?,)"J\I!C>(S#X-#OY\[J'.M.XB2
M>X=";(;ZM%08\ND&*VH?*2S*]IKY1G2(_*E^T?QMJ 11=M/@\-+,S?/[>OLI
MLE#CL'**8>=2B+CV _& RJ]"]9@*2B'SLQ#&3!TP2$08S;X(@;OE>?08H39K
MZGTT)MQZYNW +N@9.O!V7+,7<_J<J>^O5V\9.9AJ6US>[+"_TPR;>11XW/U=
MFZB?Z>5QBSN-X2>\]D-._!04I]=&G>4';Y0Y3OQ$HN7"(4I:TSA?:;],&@O1
M_J4#9L,TXCU>IRYO=L/SL=GB]IU \O$^^\E8QZ60"ZJ>4?%H"T8SZF11K=*G
MV1^ YZ06'Y<#4;NNK]QG3%Z_PJ%=.JV"\#U!S.:YZ;T^_NLKA"B9?=Y_W(9L
M_5!&XU"UL^[+(S,-6Y(--3T@X]^[H*>4G'284F%7=N$ 14.JI_)[U^V;']HO
MV8H+[2P8QS0G#S$UZOXDU.^"#@GUH4B<,!X'6O4%I$%DFF2D;$V=W&'\$^$1
MH1H?UT]\YUKOW+QX\,#I_3Q+>CSMY3JWQ\,'=TC]";F;RQNI^WU@?/$_)REK
M2,N;)_?(YN NZ(<V_*_/=*K_**R["VI.,6K%6H;O<4E?IH?&O!F5O;4F'E]T
M5EW>V&?W%\8]RG<U4U>_ENDPJNGW:OV<WITC>^U"V[^K1:Q9! 0Q5,ZBZE%K
M9RSW>AHL<+:X XP?^*BW=&7.-Y>IRJW$\ZKN,!:=K;>C-^P]U1DVW>F*+IK%
MFX^"!#@-1Y?" B\\::_)9O<<PZ&'%@6*""77KLJ,IA2@=T&LNZ #<F,QIFDN
MO9:L/Q&L?:CGDE'*)<N-Q!.0V3X'%@>R(;:VME^\2+)HZ4BH0G?LMPCQ*B_A
MEV]_L..#KGTRZL0QXU[@0H@GE&UZ_)5/(;G1X67;$;KJ0[+S-<O,@!0_A^/C
M-X/.E]4YAARNW ]^^E'@\-?1#[QN655&C<N%":FE-9LB\F-%"3^N<+FZ:6FG
M$3'=-//R\8Z9!7;VS1#^<+ XLB^M MWH>X]HK.O/SU;>\V;8*5^K .[6D]I+
M'C!3OUQ2Z8&W7@F(DO;\.1)YZL!G/LD]M&<C;*F8AJBWW.! V7G=\_"X\O>#
MY;BC\-N29RTL479FW@<*"VQC;M(T-K)\B9(4OYOYCGB/FOYV33TH>'QQ"QPB
MA=AR0-N)Y L,^T*SAQ*@_/E/C&9Z(G'V,'P26;X>%XB]W+_6PXV0Q<1T4^#5
M\]H4WHK"@A:WDPPSG2WS7[W5D/9C4M/\-YH0GZZ+)F&%=CZOLYZA&U"60^CR
M9!8F"VD$R[#L/.RT"BG,1RL$?3'N3O3A3@'*Q6B=>;>KX24KA7[V>9MG8;GR
M#"TN34;$73P-N\VN(P%]X+RX4:4JMWE+%#]#E#&JQ[$BQ>G60SAK=! ^OFK[
MGDHNL#TI/R)1J\"2T-2I,)]W1<M*;(C2-JUVMO2DAD _**PCHVA*MA$X2QL#
M=J@^3<3#M0K90+]NKZ(>&74>"&I,Q*(]/OT<%5PS5'\K87%L+-/D-*?"TSB]
M%#6QY*2X6]<B$_ ZQ)A7BYD.RCCHPTF!B<_N#K@8?51H&":[S&XVFYTJN;"<
M">^GK0+,Y&4F8!?4)B_<G,;,N&3^.P8(>%C"86?$(7GNASJMM[J1-67J1H<<
M^S']2$0O#1F0C7IF[^EY3R-G6^ JZT>QDH?+90?BO;E20MJ,;*U&8[LD(*(;
MI18.6?UT3]$G"T/Y9?1$J"S \3LC]-W?5C<4G>%UFMP(J97?-D:HQ+<U\MVB
MYKZE2V;,5KNU9!)G7X[,;KRUJZGT9EO9(FX$<A4BK0TWC0Y''EA%!1 K+",4
MKY)\6>_4:ID_;E$^@U"P(>N>4,G7D!EF]<XGCBM&/WR8ZU&84O6Z0ZTL2^\F
M4QQ>;;P<@T)+6[X*<_KTJ\IYO*.;8;%(;&\7WDASTK/DF4O#;$1A.0!A-6I;
MZ!YO.39OP4X5Q]:YY3I4B\=]YXYI>%ZJ[?"R3W%%M(#:QBT5'-CV\9@MTU-W
M?@QGRQM*3O9I2GG*$ XE%P%+'QT'Y,TIM"3VP<450J>-"/:X8),*UZHBH!G(
M)21("'0)<]6#U(AZ5_19!OU>=SA[52 YM6,7Y%I.G-PP7TBRM-*S9,8SAHCL
M6+X]"2=P.[4P&QXSTSPNGM1DJC6+91Z2+%@SEB'<]^EL^5I>69EJ(ZTUY>W8
MH>6_>"WO6%)BT"*1>F^[X?;4#C:,1&31G;!D(L)CF\71O[G#V<QJO6*;;"^6
MQ1L+O94@EZ74?XB/^AZU/!&H-W1-RS9V\^8JTE)NS>@59\=RYPPL35Z2$9=K
M4U/BN NRU;.4&&>,@*7+@%XKW@$D<Q^"V4/ L[C]9:Q9W6*S9XPVREER(HZ,
MJ:V 3UF6]#ACGX8$?SA;#D<Q,PC\9\21!^;!TOU[J#V!G^4[\/7K@.)=J\]U
M.^M+Q=ZH"_)])GA=P6[HFY=CS7G6JPV>Q_*Y+WX.AT EXG%Q-%AG?[\;&,J9
M6+VG5OI7T\#X#*P5X+ -@:^VHL[2+PYS6'#NB1VU-KYK0VM*<GWC?2[YA7'^
M9G&X&-ODU@,QQ&?A]UV%5$_E3BGKZ)>6P-#K.[Z$443'HN2\(4YWV-8_5"3K
M^I_YI/[3[3-8D"J1-D%D'7?$EZ_G?,R>_5K>,C@V\.6<'#6O4Z'F-/L=+H'!
M.4"><>H8E5%(BAJ1;]I2>ML<3P-?H1Y4R5O8!<53VT[&%*CMQ%[.]+7B+375
MS^V1/353WE2ETB5][=:K!,FR./2(,[$P/M5F%\2S)W!0X!, I(7->'8+%E'[
MP(X9>OMMQ)L;3<**[TVR(WKHQPVQZ3M)RHZPP\BAU -[F FKWVITC-=K_S7:
M_/MY54EL4;N5\Y,-ILQ3=Z\D,EXZ+:" 2U[-VI:-EIB<V$SCG0QM^193Z&).
M-G>IMV;TG8TS'9W]E]7C#MQL2[RC+,>:&UQ_3V8TO5K9C4P\[EHKI&?$Z?<^
M3E//%=$E*\CNY<N>$A]?46V\4Y41*OI-.=G__P?%-O]UHU@2<!8#0J6 P\2\
M^;UMM7[L97CW\/W!Y1=+W.,NMI=2R>H<]R^]Z_IU+.SJ8=$*EI?$TW06RB3-
M IB:<%BS?(N4H)P8A?OWJP8T(]FT^7JTAJ>J51]4X(+-=G+@ =(<WN(;7W*F
MD*X=>R8LP'EMO0P%MJY9SAD67LJ=XH/%X7=!!,N$5-I6=RB@2SL%#$Z*:Y'L
M_)"<P)%:Z9RY (U!NM9GQZW%\ T*!+(+>C$&:3KI2>DZI!BC?B%>RB\TS2/L
M@%Y4!-_MG2R4(S%@./$P^!QE%Q2NJ*AH1UJT=?II-^!.L"M+[>:R#12(YQ(T
M:F17N<R^>LIX8;-0=47/W!O[>TQ^]GL5BA<CF+W<F[WZ*GMN\O,V!DS)P.KU
M[X*@4>Q.^).OH$-U%$P#6*@/H9(/.!FEZ6'J!EK6N]ZILN;.]FJ<*U&E5M?$
M5QZ]\+:YJNLE[@3*@>4Q+0.8W;X-!)B6E)8.RNR"3@.X!U5R%?WX)M>A"BAG
M\E<SY!;+Q*$I=:WT;P+1]Z]\WQDK1,6:*J<,1?9 \(VQ4Q8;GEC'#<M-T4%S
M[S1WO0?L5_ZE#/EO-#[]+UB^/UX_*E,D=P[_8-+]ET\D$3O;JJ@&6>P)QE J
M.&K/AC]=RRL<7%Y9J-\NP6,Z(!Y_\U'Q$V-2RFG7[W"S&.\N+R('5@:(;;0\
M[<&BK NH45E;..(9E@GYLPF)YSPQ"IFJ"APS>H'/RF)R$4X=R38OVY+W+-]P
M:M#.:>4P9> ZI6W/XIR]F?N%.];T<E"C,B",:=@%O9:&.^N> -2VQ6LON?AZ
M9:4M0D88[>*_-%@ZD2NV1.S-'\\VCK0:'8XU84CO<3QK.C/P=L^V8!P; O./
M6,+=&M$RB0_%49ZE(UQ94IH<))NSBW;/6[3BA"^\O(';!;%P3;)N741QH"C/
M2%$,2.]?>@8U=2";2![?8<]SOL2@+4818_70'V]'A"=T6T7-+[/N"=1^2>@:
MRR5W<3F1I2)H9G&IB6)]=(%^GN%8[#1K\M*SFL,!^511QG$JQ8Z\W"A^J'Y/
ML?9S]\&= )Y ^\3(WH407?Z6J:ZS!9DN7+"T&<4*;<A?\?+[7Z!*R2#-A[XT
MMN-,P'DVV/>;LV,-R^O$8C#63Q$/]U#QG,X$X";0+("/!>"2.>H /N-'<+A!
MT'6Q$<RZ'W]UNN&R^IS)QV#/IR9A?!JR _(+5I2V[R7V]*M.CM5>@46*EZ"\
MY<TTJDJV;H!XY?V7N!M<Q(B)M6>Q!CA2IN*S/>.3E=S#.*EX8Q?4^4KYKUV"
MA?WSGG2"MG*=7)H[\65DO%-VX91M(B93 RU3<QIQ?^<UXPS"!% @18& L(;X
MQ-RWBMS%.6%VXF/??-@C/$5,XN]>Y;ES6/I=/<M(+ER8Q@)H48@&E,7I@ E
MIDI1\/.XD^EM"-%<C-MC</2Y0F"DI'3GB8Y/QV@+EB0#64FZC%VX\N_7=),]
M&1 4J+P)4_M+C\'WS>1JC.=VG>QZK^\W0T.]WW$).9_'XZ$(HEL!8$"1;L0=
MSJ9>2#W?MPLJY6E);-YB?$;VRQ =ZY)@'R67>2N<\> G^,P+!\RA>T;:W\_W
M> K?^:M,ZU>9RMC8^O#TQK^9;/8]YU&]AX#275  ZTG4RGC47WK\_AGX_\Y
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MWUZL*RT;=M\.4\4F#BV1BFPQ'VTK8L;5Z4.C54&N[$>,+\1>^"-F@O_$3W,
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MD+;0^K).;V:$?!3KOYT!XG]9X(0D1:C6G1R[!Y:2F)8VF.&3]QWLP5%<8:)
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M@1_258/LUR\=;*YRD!^L90,8"-13U*JU#C^*#,EC ^C$OQM;3^-,-D"3^7-
M+G/V@Z(Z%9%8O*$)0:DT+@+'HW5X:*IC%\L9#D4FORPYU!'D<7=RH*6ABYN:
MRYA/8 ^$2ZYZ3.R<T4;@ 3D.D,RV,0V_,PE,><2+=$D:9EAG>/MY]O LRG6Y
M#@]L#W8@E<NY>4^+7OQZP9\@N&-X+]&469&&GQ%,^54V@*5IR-3 ?\)O*DIR
MX6F8OIW^4X\.'N9USFN[I,8&Y!@O5;99/2YQ"\)/9:)9\;A%ZB@;4 I<:&8#
MN'VV+KG@>7=(/) LS6I-F8-4;<<N!/F@W648R^MMT;@'I#J/*/I;R\)?'K$
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MB\ASX7 MOZV3C/)FH1KL=!/B1:%VD?I:"W&X]:7U=[M6!!L@,>L.%6P?'E&
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M?^Z"=U0^L=PU@!/2])/0JS[W9N4HNA%,3&U!'<==]D4T"!,B$>I/)T33-]D
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M#^\..UU3F3^N">08<[E\/#G$.S</X:'X%?/>M?>)PH3O#_T7!W(KW<^ U).
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M7Z+JHA5("P7W+?)$<GR@3PH]ME%+"NJD@01[V_:V6'UEO!%)O@]2 !%ISBW
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MNXOI<QCS*-G#T+=L3*&DX*N2V)5)Q\D!*G\3J4PX%+&PJ,"212J_^-Z:TRH
MI)6:%K,!%)O8#^57W3K=Z' 1;[/6O>ZN)SKR@.N(6:C!S5$B-*<LJ5[M<4+M
MHQ48(>4"1%$LZ&:3,*JR-9QUR)6@;J]:37M%% [6<D*0BQ'6SP:G#DQ4I1K
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M'J. 7NMCN.*$O_V$08[8NO;XQG:+>>4F9-O/62>V/:W\JM.,.#22'QYFM==
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M)T\9FZD76+V'![+=>L/RO0"(59&@2<C__TW"(H[V7!'8D8 8@N0/E 653,J
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MB1&#J9CE2N+;B!6J>:S\]K2PV5A#C2)?<<!$/EH @I*1YB-GX_3*3TQU316
MO<<.GA%Z$WBZ).S*^Y%& T*/<]@B^Q?66>T&],KWS'&+0NUB'TPWBK2"&")(
M8AIE,+?!\1B1^C-4.H2B,B87$/.[*\)^R  GX=ME>-]*[NOCIHF3SW<W'SHA
M^\O*Z=<?<S.H*GJ H);9#-O&WS=7R#D_"KCW4Z )5 4[OIB/1A!5H\,SX4C,
MU<4+>+R59O)7X>![^5OK8)%D<:@^UYCWFG\"&6*.Y[VK>&VX12$J!B54C#+J
MR^VMY%T[/W%WP_-;[TL%$C[Y6MK=VK%]"X\T"L4/F.29^QRH"2"=O!\P?8?;
MQ[B]_NO,E7V$LN0DLG(&9RF%CNX8'87](XUXM8!))9A$^$'HO@Z*J+-]9!,)
M%NE/T$#&:D'G+UNLEN*7BS2GE[].X$YUSNA]51V[=Q\N!02R<4 -RZM1'&73
M/\R>J@->?FS:>)Z">(N$GB$<?%.NHT<=.*$O#1S>,[OV%/7SZ];20;,V)Z>U
M=7TP[]A)N,:J0Y_>J^LY0T-SM5;3.7$"*YSN%9!_^'_6E,KY?6O@W<.3_()-
MD+ H,4JRA7X/9?R)%S]ZKLOYJ2B;SK^SJB:O1P/*6T,P_REI%/3;.8P]Z)\;
M:RUTYPL-_;KG8.P'42TA&;K?('O8Y2I3_0UU.71/SYO7GC<>F*E1,*6 V\3$
MT*TP9K^10-HGW6=)P$3S$U1_W*Z.!LY,GA!)*Y4+_J:^3 R9B1K'9C[Q(3XX
M.*AC33PU#D'GVH_."84'SY,NR'_/UX0.0XX)'N1H![FJ'(ZY/;(@D,#_[^%Z
M_PN3Y#W#)Q(#P*.!\%XZ01-E#" FG05-!55@*7S'4K*NCTXH#Q]QL,._CE0A
MPA84)%&/I<RVZ2Z!F98]\D"=Y3!!@WN4E1ZK*W;0C:LR_/9S/_<"1A$"6=3V
M4ZI^['_POG+O<T^O^3')H0+;D/MI":ZCW%-3F 2"";I/ZZCI=?HF*,4T"PU.
M(+@,_\'"#S'_L<8!AV>GKKM2X")<I[^_2VK*LJ5I$A7YZG.U^<VN(2TAV7)]
M197PW\)*Y;6I]76L(X;IEX/WW^B*IAE?DTDK<KV4.3.BILI1[D/79;;MM3</
M'G HM,!]W3#_9]M];K@"&T/>68_AG.,ZU@&MM(!]OF!I0XL/OR:4F(,MO[)E
MGI/X)+,JQY^?^%.MI1>_?E\^>+NT0^@1#\=7]PDCMI"C9?;Q>^$5^&B4)Z6N
MKJ*_PNI9F&YKU>-W'1)"B6W3'HF72W*OBNE.W,?^=3SII8/#6L@,1]ML_?0R
MWG_##%$UOU9)36=HTLJM?=;-.E0Y")G9JLS17^!_<\TA:27H%6=V0S4O_JX?
M016):PR!2QA"BLVIF;R]TS>35_VH<0_?GS3$GJG**O& 6J>^/M_Z4&ZFE$8>
ML821XBB7X/NA1Y"DKF;R'ACE./-[*<[WSJQ+G\K#VD1C&6\)D\.]CI?;QG,.
MS&K7LJ^XC)^ASWZ=QE@<(1$1P37&G^KKB8B4Z9[;A!#?A:K\XC\WCU18(NPM
MO#B4&.>:#TSX+AJ$.L\*B<'9DUQ-:,UKM:TS6$JU_\$B6_CW@%<7HQ!ZY]VE
MS-H/@2_S/J A0$XSD7FYYQE4N9QETN!!M;!&*6KK7@XZZDZH.]7M,\OXZWC(
M20TH-Z5:^OL#Q&M G'-"+W(3M",<&"^!M(K%O, __UVL[R).1A#\L0_]:74P
MK_HXW_6JX)%O)_SAFF+U88,#4>5%E',Y1_-G.Z0@J0Q MBG_G")RB28+T?9Y
MP)?FHI+^7++Y+X:2VD,ZQ4[#1&'VKEK%*&[AO?][_33&#=J;GSB-*W[H0T<K
MCCT^VWI4KW@7/G%LZ[7CR>=="G;$=$?<HA5B9=%D;%5Z#%3.F7N%-=Q$WH$Z
MRR2D?W+;!#7)HVJ#"PI]9>8];?RKZC3%V][>!?DKSPY<<B=9&HSG+SL0,W[5
M_^X/-'/2)PSQKONM=: (5&(+$5"66;1EQMDQ&Q(;F+.+(=DG!W-^_$::1@?5
MR"W3>]^H=3V\^"AZT?%SCL*#\^?@?TKD%08]G*.$ND)@"2V2WW.M 3QUH<&;
M>S&]N4JN_=EJ6EF:Z[EWV<[AZ_N_O->RMD-]>!F2D/6SU'?#@7V2E1Y="1Y=
M86<QEPIP0.3UWOI3^E$>?7ZZ(G->SUMO]X_DGE!2*)@Y/M8*&AO+]NF+?7.;
M\2E@Z0J6QACGC0L7J,DZ=T0LV<!#ZO+)@[+8?X8YU& )*A!X384](@C'F0"I
MU&Z( TN&KO 1N.';56!^7]E>PCQ0PBC*O<Q8[D6'9.0!=:SVCH?D*J\DE!5'
M!W6!"5E<RP$*V1]8P5&J42'4B  79JPVD99UZ5Q'K+IQ__9]SFTAGKWF8N.J
M9[HON5)D,;J"2G]DDO.[PG,%860*#L5--_#V3XNU67.#SA'_$7"* @"5@#9X
M]-GA%C%9Y"FW7HRW-%,[TS, 0QE'4'NBNA,KE#5MJ'WFJ8JN7\%*.1+*TXT'
M0,.W!*5]AC633BE6:SKK5L/*:<.(/&SP1;R*.-4HYY(.56>=RKV5JN65<#MY
M7&DZZ^DEA4Z1?-F@B):,!?SJ?'$>MZ12%4L@T8GCF*ZE^=O_B;__9=UR1:R1
M00ILS1!Z"O.%"WFCSP"40B2B&2::V8*6'80>6J\B*)=5>\^(:MI*)7J(N^\^
M(Q()[MQY,JPXI!$K!;N#&TFBR-"WA+)&J?G1]6:8($K+</VYC[XGNBF<.HVY
MFPF3YJYOKA2J[PP.#CZ<>:C*N.E@GWG./8>5-WE2^2EQQ#2"2>#']YGS-=C.
M$_%8BLI*_[<UJS^[KX?H!094]!<].59(6Z<A';'(C<JLDB@<'!D6-&!H_,E4
M:<SIBOO+5RHKD;*W4I6?F-HI:!0D?2&<YC5@?#9!L4M0"-<8\*(0G]8N*H*9
M_$R*1FZIC(./GU3+L/[$[0#VQY'I:T=.7RQ<,AL1B A-9U][>#DX_O"0]EO"
M( 6(H^XGU#R!'-.(:1V1.(MC%NI=5GC<:@P.=Q@ZV-5;[<CK&^T.)16&IYFO
MU\ [3]6NGR;QK?(R_WR0/]']LV%0#M#,YO.JH4>YL"AJ>@ODV80P8.#SX<)!
MMST#,A;$P4J1KVZ!.L/RCO'J;]7C'ED9*B+TVT]R@^N'^*+\[X1CP%\Z&'%D
M:5 F8Q]RM&D35#N ^YVI1;AXJ4<B+KQF^T?EA[85'^PRE27TDQ/P:04A]OYK
MFZ#=,U7L$?V')?9Q/HOXY3#'"+HIU\FOX.>_6E+/UAJH#^?LY5YDX9MP@"/_
M+/"8DB2)TAXVM'H[CU89@/;C #2_>Q?*[4C.UX09#>U[UJ\\#G2L_.2>8V$I
M28LQ3'U:$*X=!_9UTV%=GP#W+ND4VT^Y HC%C,>7Q;-[MLQ46YU0F TUKQ,Z
M(WO@WAJ]J_R^^9#-*XE-T)>WW.*/N6]L9\8#8:\\9,F;H"W)*X1LKQ_$?T:1
M6TBEQFP]7C(QP$*CZ23*!8AA239O@L0-98L0^C^ 3SSMC#9^W^7[*F\3Q/UR
MCKAO]]9[O/"L_;O;_VKA>-]:<O*H54.G-9?*=V*\171_Q3<D,Y;:S/O-(*9K
M6+M_T9U=\VY2P&..(I^$V14DTA,/WF<8<8MU8WZ(K]875/<TY>ISYXAS)3D1
M9X=T1+S?O4AX6ZH$2IO"OJJ D1:H47112@%!W1G3_,"49LZNJ6'RB$_JU:3:
M'VFEW@YZ(OVHE'/[IBA.@Q+3(VM]98'+K?2=""E'='WOJ'-U#:JL[R<0["NQ
M71_(OO^F)J;=5%DR+3VCDNQVP(XB:MJ&E>"+C@#M%(F%";6^"H.:AW4<\Y8Z
M^3[=UU8CTRMZ!2_:9T)];0^=*(FT $)H :-8=@J0-PGP3Z%L@/!)01-JY2-#
M+L-%YPM]/LZOM?TPTUIZ!VWJ+U 6@QR3QW4^L#A=F4.>&*VX/4GF;T]V9?2J
M=LS -ZS(Z@4J:WIDQ+GQEUZM B?9,P)K@DMRU2A)?T]J!@0V[YB,*<>IV7Y(
MM>\WYLCQ3=!<2D1%*/1.<'OCV)=$C:(_.W2X!7P *H\>@)?!GZ*/()L4C-P(
MD:W[D+$6NY>1%>1]T5I2Q1^R%4H++^\OW&?K^_4&;B?!FU<(/=U\*P=8:)U0
MX.42?9(44)>8(_75%9N@ITK&V3U?JAX8*7U^<MGPPV/*8V2:?=;RIQMI2GX6
M9B;"!N/AWQ?*4ARJ!,'-KI4S>9/WH<>"4[<ZFH\-RNNYSQ+C2F#9NDP&?9L?
M<Y OBG" 'JIC#O;$NH=C]OGB_-G,JR\J;O*JS_Q5$5=YT4\)=MS0GM&X"0*.
M,!:QK'!*=A(5#EBC59A$=HLBANT0K9OEWFY;-I60TLQN^\GUDC44MT/)L" V
M0";'#76"%3&5;8G#H;^O.54PA#K*0KW*7\;2\K^9'9ASV5&1814K<.IIF%U\
M+4'>UEDKC2%RZ$<_B-PC:$BX.7F_:\>IOVA!#U\N^>_]\<G\7HWRL^VQ;UQ/
M0R.HBP)[XWFC, 208$3@3\:GFK6G^&C@N%O?5-)95>$A_\)-G$6:.P!TSC;T
M%[?3 DF0)(VR'*PW8X&O]^L0=_]R.S*0QX(64S1\9KR'[!UWFZHL*.<]O>!A
M,R>!5_Y$9/L!-)8&!4<'3P8SE^(X@<@4<Y9>N514W%N@D!*@;XJORCSF3\^-
M"W3\*]<SXE&HY[:MYZTS$J"^V=T!#QN4^X+1Z0[A:#V;K'<]\SR;VMK5\K+Q
MT6[X3[Z@I!IEB(*3/@6+ZF($D-44RX+$PLH.KQ#+ZF%%"S*D+,:WG5\/<]P9
M_H'QB5N*>3#^+B..VKST/A=,4VZ&&%0WI2N]):.I0]$D^#,'ON>L^(*; 'UV
MV+(^E#)7^,(LEKD3DU]<X!W6ALV-T0KXS<FOK*T*.'NB1OFBK*6P[/8@W [@
M)04"YO>1F3;R\*@AC#1!"1!K3&!FMSL..C1GX$:6\M^,=QPXH?-X2/; "Z?;
M%M,>HR]$O40Z7>+"-T'TLO1I23/2<=MPQ"8H[Z(&Z_7$GROY03W 8?ABZEMO
M?'H_2NWEN[+'L_>R58=$I.PT[V=^/O5XP>U".,>>>X7WBG@'FT00CFK+:(]'
MV4Z"Y7T(XDQ\3/V%JOGE"04++6Z!-AA,2-ZWK/!MK[/L#K0U'7J EP#5Y'=/
M0%P]+( 1*B.:+SKX,.*"H=<'Y*RMOHWRS'C\J;E;AUM 9B]N:19^7G7?>:I8
MPSKUQKDS_@*+G6$1=D5_+KC6]5-NRL=W6DO];E<LM;BDX(6<A=O<% J1*^G,
M/@.43O8\(QSZL0GR(BO"?<!2.3[%VN\'5AV/_,@1UWFW*F3.OB%5M6@C\F1*
M+&R5^*<DZ<!X@141!!G E .:RW K_S2W$5R??L\W.&WX@='./#F?Y%KEK[F:
ML47;0%\>F9CJ3CMM@MIP![@G@,%/9)0_0.28HB18W#!N5[XO)%\[GTDPM[V'
M[I%P-@&]=E(4.754*.UFY_U!FQ,WHLS\NI4)%AJA#1$ARR;[I]5,=!673@3,
M=N.2UR)T77O>Z0B:^^]EW(\HKX%Z>0&WR[3^O1?B<V\>.UHV3VKZA7>['8_U
MBJ71B;I-]+&.BEN.EI:(PC^OU"$D/"TJ5H>12*ZX&P:)#_KZL$%C\I+3Q M-
MW3,Y515U7K6MT[6%],2+6ZF7UC_+S$S:X4  P@6PXFS!-/UD)=$A-*+H/'F?
MCJC<FLV0[B/=.(4M"M;Q9UT?7;,)M6YQW@2A%IO10W>'3A#53LVMUWP_BIE*
MXH.-+*8[:^G+\<J"LQ#G?(/_<RCSWPS!-$>/&UX'P#DHK@IS[0E:"=WOIL.,
M:A%>E1<-@AZ[8.!8U^R[W,H^JO9<U5'J\_>/Q(<?K$X7PG= 15#VO/<8SYX8
ML@0#XQT0[[0W?Y*X#TC@:MWZL!"N*75W-G4PP$C#+%#VH;J2U^[HMSL:#WV;
M>B?F WEFW+&N7I&=%6(18FRB;7OM[T7,&1M\?E,_-/+/'='Z((%B,.6]0"L
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ML.?XD&&()]OJ%.>:J^.Y JM38>O.(4O?A[^?:'=:_R# YUUTFCGVF5Q^4UT
MR;Q-+J0QE)*M &MB$Q3*$N=[E=VI1X- J!'*6'?MR4\*EL(*5N.O[!_$AEB5
M\#',<0.$7U=\1F6MW[3 LF<W;"PF9?)W\;](HHX HTQR6[KB25>G@"@!3GL
M:+_G+]GW/]Y]>=!U:26SBP):9N-=&'3[8D&XLC,4<2Q)&CN?:F$=1!>C?=/3
M6PNS+MV7I>57[+2G*&_TVX/++YW=]WLJ7.Z.$#7VL;',6]\H4)L[&FC.2",X
M:QRYM>2<G@_A7TE.&DN&OUX>COG[4Z5G-T&Q4''NZ2B^] S^ _<&8+=GJ%8F
MJ:CB(W?=;\HUVV(\M^QR^BZ/&Y%/:.&F==-CQD&P[40/HC0RX"(+SM5DQ&=K
M \7% -X\0B[T=E6<:5^1WU\G4P+RSU\]>D)TY4K(&=+.\U^AZVXJS![V I/1
M!B8YN %^E!X1@8"S%<@R=Y_%5=C^]AR/9GO\O4>W*_0]E[UV//JY;SF,IOH!
M7O\@<OBU6>447VTZ?'ZPA!PLOB:1W&N<VX#N7,%?8N-?SA"W8R8S%)4 +Z'&
MNHAP:C.R:G@RNS0DY'TAX*XA@Q"^:YQKK]G;'=^Z GO3^'KMYN-'B $!^6^"
M1M3XLBN4M18M(;Z$&!T#6 FL'Q#7PQ$;X3>SV3TI^&\!I[KX;(>0-?N&Y-AC
MT""5<Z$I5MU09R[Y6-W$_-K@6%)=5T!9OYO]#'Z\6TMON,-Y)8G]$3A%L?JI
M,:G_I0%B#SRC,;8BXR@-6=//4UC.QLR_!BH:#"\[?*L:T'R:7)H8T5&ZZZ;3
MJ97$"X(C/3$'3*\#CSDWN!9 ->$TRZM5;.]"-KA?D(E;Q;^$C))<ZQU"53BB
M!7;+=/<+<H_Q\N.?K52)%]4_)9A\F#>W7R<N(\A6!@U%N,(ZU>O4R8+V2W]_
MEJAB> I/3$T2XI42/2R<V?$LTTB4ZR0YVBFJ&1SMM@V1VQ=4_?"CKO<EF2LQ
M]_>GE>]+JK&^]T#OS>J<FPBU!U!3BR;L(''=@$:JP(YO@EJ2)!!PD=4($0>Y
M#RFB%0_PR9ZF5>*GG;T=NDX_U=A3I]#\AF?%<>4/*BKRX@A;%\#BAG9>17#O
M,*4O*<UYS0?Q5^^\/NQ:J/RRH/FTFN9I(5E#^^FD=K#8 GQK>XO?R>E*^)Z.
M]UEAPL7GO:JK]KTF7+LL'QM_\V5D8VO@0"Q;5R[8S$R?"-%QY6EG!ML3<!&6
M&2=]*PT*ZSZD#4\G(Y:"R7Y54&7>2\QDEML18)JC@E*N9*FUX63@7'D"<^EE
MH0L FAOZXG)5*39PVSQX@?2M>A.4].#X3M#-K93V2;5XOM;_K"86H!6X-H,$
M262<61_WA(3;J(_]1F76-PDG,\*98K66NR:MZI//C>J$]ES@!$XZM&F=8D<"
MNA3L0>_/<*<YJ$;_NP'ZD89+YM'45"/UE]:OC4"A6Z+7=(<<_(]8C794^GGF
M7Q_'A=3U.KL.97H_N%:6TUE9&TNTD O32J7WE]3ES,A; :K^J>^Y$LS99YHH
MQT_=GWSXAF7 XQ+$1EYU?0-+@:N_U<=PO.BQ8?>G1_%/[>"IB8&!+6"F!5&,
M>SZ2UIT4JUN88'49H'QT\H6(5N)'O'[D5N$33V><":E^.70Y[7SK]:W'[9X'
M_DZ5BC*IVP2QXRR'IIX5(Q[,^5E()YA_&IYEG M?../&(;M%"3RV*&8R4U&E
M'HC+6< >(.@BXVA2N*>W:B*;G>YNZ%8E[<R:;1IBZ,Q(.,W?EY22J-DNT2YK
M&#I!%%"Q/XL<0]@U@5*OY7U W20*OZU 6,@WL_FRI4\0.D+'\[I)XBICZC^U
M9)>;'^UT  U/I'X=0]UG=A/;4H%PWMO;K'#O)"KXL[+VE1'-)O!Q@E[@89+,
M&0.SMIV^GC[>&\5UI"5ZD(\K.:BPFH:<KT7+^#@&6XPX>H]7&,*=>$_J+V*E
M"'N1_0)1)0EOWEAK/K<3O <AQ!?_Y?^69?*F6,1"ND.YN_"R.^RLC*=HX^F.
MKU: 2G;F?:;&-6;1A-[0W=5?]4$1--ZVEEJ+S^7U/R#^JJ%2=HY3CE)V(P=.
M;#56>W:Z_0=F!U2@^IKF )]\9 I?G"B%M.*8?ML$Q3C$Z&R"/OL&CRI[;X+"
M]\Z,UOE/3TT[6H7-%UY)=$"-CA,SDS/+G<,[S)R]PIV66 =:E=,ZNY;BGA Q
M094E"^$CX!-<,0$TH)%Q%P$<N$4L#BY=B8F'ZO4]7$C0N%";>:FJ]ZZ.NK_,
MW1Z%W.T%K]L[_P]GWQ[-]!__OZX^*H3<4E1NE9#<<LDJ(4F2D.LJ=YHE83);
M-_?+0E'$RB6YC%QFN6VY)R37L9G9W'*9;62F77S7[_S.^9WS^_/[CS]VO,_K
MO=?K^;B];AN2[?'2_6;P44A"PB^)Y*C/$58VA4+ICV*G[EV_(J (>DE8NH1*
M%-YO'4E>U\7V+QRU"O[]X[1_X*7A: ._^M5M@+$-CDY^HQP15$ VK6KG9>4&
MW..9,>\P-=H])=K1CP@65L/'AE/;2F,_K17<V7PJJIG7\$U#87D*Y\!RX4GO
MIQDAST":%:L$PUXF!)S8TBV9)N;/CP6NY"""X=QF;N38D=PXS\D0S3R\3DNT
MT'(1&;8<^T+8K5&#*E'.*L&&XUC26>JY)%9<X!9<W:SN=QA6=:*"+J\(4MO9
ML.N",$B_W 8$V4MP>F?R\.U<]POW+_@MMT4(SKD6)^D&G9E_VU:=)26[_N)
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M"1%6K#U$RA/VD-#LPAR>,4H4R 3"S=YIFWD7C"\Z8UE!0R_O]+&'[#)]3;L
M@0YW,@Y-2PY\@+<#:QZ#JJU7-KR9 K%']I(6)10O<G>T6C4VPCTY4?V_'SZO
M,CZRL[2RNA[J)6W\/1G?H'2''@S+ZAU\[*Z=)1K]D]$BB @25*XRJCS3MU#<
M8)@+$[G"Y_I!N\!&,RX= Q-X$ LR(>V:V"ST@Z+BV3/H5V5:73D_:A+\;_LF
M%AV_<U99^Y$]F L0M![N:N J\?0\O6\1FH$:\3CU 9;LD%9(>]^HP?Y+JLN[
M(VU;8*7%J6-6D+>E#\#&,XRRDX7<.G0C!A7B7-2T0JO#ZUS)N.>^F38 AJPG
M)W-'4+;TRG^S$ >%Z'D//U?#0=%B@JG*W1!IF.HO7C3L+RJQ[KR^J:>S8F[I
MSHIAHHVNF/^9)%%_N^X(>6^ $T(1T:KVQY6GQX1<9=JGF5V:-D6\R @RBHBL
M_X+^68R(C%02Z^WKDT;DO3OJ9F2SZYR,D\%OE"(^:!MPB+>/U9D;A!>G*>UJ
M)OQAB%M6*!_L"C?M81Q5L4'_X=!"5455GI(6TCS.I)PX_0';Z/ ?,2=TPE1[
M^8VFYFI%444CZ'*QQL\M;.!?\^!/7,.5X>@6^VQSX0L9%#76L\:*6=$TJP96
M6)>7&?,/3KIAK&CXP^#,\.,&HY#G0\2C/:)^=_LF3-\=F@Y#G>;\NT(HE(-D
M94\3H;LZ\1B1I'#(?[^3=W(BK\>W13@_G/COOS5+:F([9;?3S5WG[F5'>NSX
ML]!N3W)O!<H(\YC$$9CJD,^(?1)LSVX7N2';?5IYWQ_&CHF(V]99W<FZZ!3Q
M[M"!];3GRD0Y2Q0[^RO'N;ZQA*=J*#AB+XUI337O N?/H=OV4O!]4T4S?I,(
M66A9<N3+PE$-Q0=;444Y[H$,4T9T$[G&M\1 T$MHG)]SCGG 'P6C?8-5%*F0
ME4&-=A31OALOZ4MPN9G9;>*57G(AH7K-\F.US>N>^:A4?-]Z&#:(3DJIAZ)9
M%+;C-B!V@GN9=YRUP-YD^_-.YW*YE"_\Y)^"$:X=/AW;MR[W@[19BUD?WH5^
MLG&H<K68='O_E:&E"KY6[U:@L*.8RBFHFO X-&L;T(F0#7?&L=2SHYC$A=9L
MN%3-\.AJ^,D4QL/Y4VZ^MU:+NJI?%:H>G2F&^W!HP0@BA)J5RW2A,KH'DKW.
MKT'^+(/EJ''%T[)?FIE]H9-7%+GN#FO?,O8';(;B@VJZ4^C]\&:>+?^C/B@6
M(0-7Y@!O8D;51W J4YZN@36DKM3=$I '!'&_,TL_B@\]P]S)3'EJ7+F:9#X[
M8YZ(-AMYSQL>LUNJK-QR.UWQ/A,4B.;EW.059*5J0*+T>G!'X+T49I5P\"C*
M,'O!)!?$TSA\([M8&!UBD+U<N?&L2_C^J4C&NLD#SZ]+8=UOH"B!*#Q?E9\/
M/\U1%DB7)YOB$_)-<[NS3"K<KF5^G,1T2'<JQ!9K/OS\*R7#$>K=1A@=N44*
M&=L&]+S&_RG*V_R5G[580I7;LPW(J$?7+I>N2W38C[?/W&@FBE=3D<2P#H$L
M*QR7+IY=.8F/ QMH*;L%;"ICK#]=$]@5K=X)"<C=?5*>X97)/0'_40^LB6PG
MV]HBW4::'2JAF<Y?"1O\$+Z4\4;P%GLK8ROT:7JES.6"E),./<8:HP%EMX+8
MRXA.<O$$R%U+WRW@Y2@=GL63R8PAUS41X L#VP!)X'W3;8 L?$+HD&3T\4<,
M,XN#\I65%%C^<7Z#]UM>=&1=\_.Y9'H^^O[A^S87;<&[GKV"?0)R5!&)/LPA
MGG$#_T-S:!A3W/ V:+=A=A V;N+.V5KP;3B/%(KM)9K;9U]8I@>=OO_ZEBV$
MH[4\U5]?A2&C(V[G0G(K\]U5ZU96,L!!0RXMZ2XV@V!]+5G2C5ILTE37SSWU
MSW=[J#J4Q=[>]>OD+AE653)P.@-^K(&)3383H:+2IC29^%:4M,6308[V!24B
M]?'BJFW#'<;^,[2^JZ34FC>31J=@N@8;1MU5*8V@%0;3NT-@,H9FK-:A1!>'
M@R(?CA=<Z$CO*GYK5?FC..'(SF_1242F=;(6+WJZ7\6C-BV ;E!^$O+!YJFK
MC-K%)?F=%^_*^^].V30XE_1Y=J[*>AW'9T>LC/ZR\NJWTATNVP9@P=A@3U@>
M,H<7+$3)Q(ABV[]?6V@685DX<R*%P7 @[ACSO=>IFJ%CS2^<:U)5_F\PG-5.
M LWZFV%E%K<!-8R599K]\R<AU>$SH"2ETYQ2FC!\@*-C2D^[CE^4O%;F=N<*
M+-G76*U^[OW,F8< EA#,>])_;6@A/&I_F>^&#RN=Q3 %Y>&%]J501*O#DJS4
MI/N/P:M2MQM:VW4L7CP_)W*-39FP9W<R4?08:K_0F8\)C@UB[,7)6FF8#\M_
MPP+_UJ>:'@M/@\KG-3BV[GD]_?21N+[C&\M3C/[R/YE-@8_MFII</;=>S<B[
M*;K;-[BJ_ZW+RFY!?^J6XXK]4_,_.N/YH 0_@DMFAP-GP2EJ.HU&^.&I8K?7
M*M[N^G=N84J_[O=Q1<3D4<X%18%HO-!NQ@=,23-UZ&HS57MARAF!GC"MP$+7
MGL^+K*LK]#WY910\-D5VQ]GBU[MZ- S8!C(7'%<RMK0J&WF,T=4)NRD!&)]+
M+AF>"R%+SD10JN>2!$,N7B:-8QHC=:2!'=;3-G7)XU,T5YI[_)N2K,59'163
M:N<##1IG/#*3F/].6Z<+U#+;;9GS"^SGK,Z!;^<G'& 'B9YE4XJ^=]OZ,0[<
M=7 712=@R]QCLPKS^6, 8QMP8./1Z(.-S*!-#/G%<.^HZ\G??P,/U6'HI5N;
M-,3$3 ?J(&*Z%"15(5"$71D12"[G*S+%GXFC8GP_M9828][W/$S=/18F6'4B
M)M?-GI/9K?2!*\-8^4A#3;BSS[/H5>V(P]#,6YP&FFTFF@RM7+!Y<7O$(,\N
M7_=%R$S/U8E#ES_P7AW7^3ED/W+;0;'+#(>-86CH9+14UH,]G]>@+KQY4]$8
M*',T^G=>54V$98RZ9D)=[NVF5W:/OY3U'[O91-D5^FW:9Y8%,N?HL85,]-*:
MK<6)9;X02 W4(=JB#!MTV%BVU[_IQD ;S9F>=>2[N:VWW&4\A+F +/A<?+YT
M'4171Q4&8CC'/DT:/Q#(YFS8% F) UK5,2#L3H&LSG.<>( P9:7'( 4RVBW%
MR_#(<;,!.JC:O=G<F7(VRGUSE9Q-2KG72$A90C"O(0^[V="0!SC>[ 16_$NX
M)+11L.G0PL3$O? A#%X@U646N>7Z^:3F(7N_\(J>W["IJCM9XDAY](AKAUWH
M[XVN,K^S6(,9^[CG>Z$\_W7&FL,\!I6MCZ$XSJ$FN )1M,XWOOWTA3[<^</=
MO%-B&BY#-Q'W^2CN/9TODHGKI![=DP F]R\/0X+FLM6&F\%<*\XVH.LO[LNF
MFTN'\F[+Z=Q^!2U#_9OE?0-G45$]OF\K*6>\%7H6O:B6)DAB\ 6X#B\W-Y<Q
MCX#G[;EQ^K"%??PV0"VP>W4.%,K$?11R0 PK/@E^:-%+A*5,%Z,A#W)<6O_&
MQA)B]4E("7<+V3=B%=^7LL4.):K-;%V[[Y(^ZAAZ3^'X92Y-T%EO$M^-3_8Z
M.VKP3J>.DFQ^I(8Y-_7F*#:#'7KIT*!IXF9>YYAW5R<I#4TBG2P&QAAH0:*W
MUM7DX/2B+/S;F=6F;CN<1\V\,]V_$I7.!*8"IU.!!\U5>:+9U) 6[@UHS3H5
MEQN4U;@W622V @SO>+4-Z&[T[%<4U?%&!L%>=F<\?5XBOU&5*K3,*"EH23=1
M&6FNR',?$<C"KM;\.L:<0I>3 IS_%F<U!<KNVZIWK/^VQ$WZ<O^VH?$W@S\;
MAR9SR1LM?[%^E5.KBW6,QL%)?9Y62*+G!=G>VSDKHX-"YY"(F,Z<UWF>?W0(
MILDR]?@E.!%@KHLXVC,#MK!]X?1U)-S582;'%?V^R/+:>2</ZDZ=J053E!1^
M.E^@/;H-"#!E)'CMX9!H.G&;N+/5M=6L8DQ:K#\T9W.B<&THX,"$;-B#,T;/
MCBO(=XG#BPJ2!9%K$U9CQ#&;1_2"X8O; ,TH1C]N<QY<T@B>6(*%3P]P5//P
MSP0*'(EV69S9UPS"-_PA19J^GGVQ?@WYTZ9OM5_P<]+3AP=FJ^^?<\S94"8.
ML,\*1<_,G4I1X%ATNW4+J3[12SHNVLZHPU#V(46%9/="K:6_ J_*DG6Z6Y1R
M]F<P63.6X\B]]!LO;X:888@'UC<6R5'$P^_4I=JL%EHF1?E@TZ;UU3R3U7MN
M2[7>N#1SY$WYM?V?<$$_SK9L3ECIX/LG)]8CA\=6';%3L\+8E]XGZ 76(I-Q
M^PW19=!UVD 23A-:Z";9;3"ZHKO8Z%L4NDK4JN/89^X_PEL]-_#L^Q$7(-=3
MT-FXV8U*F))A+3S%J2TI[Q,<X]P86["K'RT81&_D1JVL[E.XGS'VZ.#[@E??
M4L):9Y0O.EQIF4>!T26VCU=S[5O(F__]SF&T;/"XKNZ8-_7FFDP"3PKH43V&
MTPPB;G:AH[L.4SH9NWNIGEY<Y\'[6I"'/*V^_4<^5[<EMY%V/,N _6PGF!L*
M.E#,K]L ;\9^GH:0A'*Y1@+)^D%[=@D[,H^-7%D\ELFWSVF"#6@HP^ADWIV%
M8;@:#\PDM&FYM+%-V!_9I@,*08._GYB=T$BOTB8KM,$^Q.Z0'*^]>R"\!U#R
M5'!Z&] 6.0.2#< S4SFU5L(6;JQJVF.7<A 3*QC4N>,:N;[J,PM6#>/]S^)W
M>[?<5OTSQ]4"6HOTX19,2;6>6@'O'>%L.C GPP'Q)+9JEHX>D.:T<W=PLETY
MC'+H,C6R2T<2IO*5]>HY4.[.Q*)L8S&N_CA(RR_!(S0X;(Z7_RB.>IO^W7@%
M?P\YL5-Y/'N:_7&:BSA(AN;L;WG"=4U;G=]UY#OV'$2RX9QQ^NN'/JIRQJ96
MH5[]EM<O= :PL3\628/Z%8V/R=G J"E/QGJMRT;MDXTEV##74M!JKL;"=VM6
M)8)$!5I!%!&8/WK<LGAYO?TC*=CYR6BS\5HRZ:>3L\_/P9.JL3-'E^4<M@'/
M'7XW@EH']B_"I5F4))X>2[KU+YJ1<,8L0E83?3G&:A,8G#6OOM.X,'=.3)*X
MKR"5'+81>Z@ K>2T#1")GK@PA*MW WV8T_QW3]8W4K93;<00PST 5C6MS%$?
M^YPE,"'@3O!NC0K48==9);&K,!7EA-4_4'VNIVR7;V@-L4WVOW=^!Q;@'E5.
M/0-V-)UQ1RZ"?97CS:P52*$T!#+]4R_"^27\W":N!5?[*@J2.8_4Z5^KSJ/7
M1K*\41_*3$GC=<O&E1KI]^/(!S),'UON4A5^RGZ?SQX+C<F8#;%A#]93(LBK
MVBXZD=%DQ+2-)7]1M4FM&*G%2>;J"DLA1LAW+C0@>V$"2%5@LDL_; /\8Y!]
M7'O2=9'^]<C4)C-4TY=5\FCHP'L2HM787.B'=X^_8$<)ZZ8W,C,HBT+:!DQ<
MB)A*KN#G_F1/((THQ!;2-*5+0H(7P_$M@K:W8=&ET&BOA 'OQ_>@,$[[N=7Q
MZ;.[2[NFQ4U=[.PT]O1@4+3B4_!'F5LDG^?GFM]8XC:WU+8L8[JS>'?Y.2*=
MR%3E?68>Q(%Q%VHJG4ZM-81#V"CB@RE""'^FEX2/B,"%IHACJ$Q$ZSFS*.::
M@'N)X\^UA'93"6TM-Y:B2V&:P1]=/2?O1*T.G(DP>8EJP=CU78MU/OGHD4W5
ME_+7(SA#*,2&TUO, ^;>[$XV2#T7<Y_8<87>."1W=?85SK!JX,13T9X%P--0
M3=IP9(SI1J1G! Z+R5U5M"++X-SJ,(L5.;B_X^MH1;8V\B*_4DC8EY4/!;DX
M0$&M8M,=PQM[HGN;OOF[PD>U5C*RH\P]SOJH)9YQQSP"'D5,H_)/LN2ZP<$T
MC390BANAE1S=)<MFYY],$Q,GN=:-.>\Y=:C@U/>#/S]';"79[_J@FKD*^@_^
M#\#D7QN*#(X5SY6*7.'?6K;EFN-+^$G1J./LF *UR?]W@W=CZ;PLTRPUK[I4
MJ%RWLAN+M3(@<^JS#+(A*5"0$+09&%Z#8-,+<*M.9?2P>> .H4O5?:P<IZ3)
MT8LJY"!O!NO$:E;:1&0S8SZM=V /5[C[?\V9-MF"-->^5_$_;C7IU]SUOUF1
M&$/4^G?SE=E%'(V/T/5V=F->/I+VWVS&U-'+^FES.Z^QCBZE+9G[J-Y#RO]U
M"7.ZI855V/K4&#)%"B!A@Q?OIN34@A @?,R3S>6P!9TXT)<S4P"6R[.-8*1\
M9;'1"[@"L#VC\.J:Y:J;E Z08-CWW\4UW(/5GZP4E]A@$--268XXR5-N8N*[
MTS\$*8L\EEA)U5UMEMR+#B'L#2R*[L!^;0@H2,^ZXD'W4[KV:FL7Y+?,H3GC
M:Q[TY6@>PVCK)P*14==U2ML)@UZK<\+]MEY=C]Q"V/%?F,6P+*C**3PY5N],
M^$)GC'+'%U*JH2U0= (:LMQ../O=Q_VS#]:/<BQ449L:J_OG>$*Y\E[\?532
MU&$.LF@)=1 8J*,(W0:T"Q11 T-UMIXG2.W+IP!ER5OTW#[<S6(;%V)%;]9N
M*<W%I';.NQD2,!8A'KX-D%Z2G.POX43>^#JRZHUU"LP_[QTH?^S^A^I]#T5W
M7>AV>W?[-L-A$0RK6P97+>#S8T^'E*R.88<9B[^YX,W:=/X7O#^*$RPQ4=))
M$=\&U ._ *FG:[D:[/@)\U$V* \4^:;%*&;2^^'R6'6S(E<=T:;&];!E.0JD
M).JB\D4QS$@V:#S"^_O70-SP0E0\PQ^279O6A+S&@.^'.0\+3'@GF .I^@D0
M\!^\3&#67W212T)IZ!%'JYJ3KS3/Q>V(NWA?;W+$2YE3RL>S(!U*TD)B@71&
M@)A((I&,>$!>%'BEET9Q\9%@\YEY&R7*E/8@]M%&OXMJZ4APH*;@A@X3C&BM
M%K]6;,ZB,$(1[[TW(QIFE(X)B1W,0=!V*RL]@#F@/8*>6'>+71YV@(+1N%[S
M6#5,<VC'8&]+1UK-E9J]IS](/J_0RT=0"3SIL,YAWL6A<$82Y8B9!>LNQV1J
M7EET8C+ N=$3E['^[9=B8L<9M]7PU 0I8\>,[M*9Y=.:YDZ]O4,]L(PYD'X=
M3N#WOM]T"[L>PIB=6H:HS"-V"2%EBJ >8&ZN+-_;!HC&$Q'42PH#[_AO:KF1
M?771\/Q0KKG1ZK)Z:)H)06-F@*..[!@X:HV&.B.(8=V9L.,LZ9^-\7$8,:D!
MAU%5[+MW1?5V7O>'*V!TCW*92]A\S)_N3D3JE )'0_RY0'4$WBILPZHVF,K7
MO6*OXCDUJ7NG8,>EKH<=U=]VV*@C_X.Y"/NWB09)-M/;!OQ'2=;'<Z[T?Q:,
MCNAO S2NCYEQ^E"_'4/,([-3:QX:5N_*&<0:&[>$@]G@M:EE_^;',>R1M]QT
M!S=7S4@;H^ +FX\(!$\)"4[L/U&H9ODGPH^3 ^'J@LYA&)@YI!S'SE*Q$[;C
M8RF7(S43]>[Z5U? VG=0T^;6C#>M9$4"P@*RC9GV_R;Y;0W$E.]PHI3>F,?3
MW$WU=<"? UEE%H_!>>]<;7:_?8<42YT $'Z]OO4([,9W7&]\792W*?PC@%_[
MH>L0:5OHY1R:XE8_%IKBU-Q,%AC]VV\BT4W,ILLPEVG(#AVBM!<GE@:)QP[U
M[I;F!!%N#*MBLC32KA;6/_L6YSS9D*M]]>*^_/\V$,^ U=F\4_83F9W; '$$
M554P+.RNLDVW)L$OP< :O)=?J%J%_;'N'ID][VW:16^1,XM.E9%*>GW4J-;.
M8':%,C4$;]R(_-Q36HH>MH-509J$KL!&^3Q'<QJ!% JK.W""] TNPPJ?6XCE
MJ00;9M(P]A+ML\&R7R8D#ZU=7Z$'7>F5OS-S?V!!Z5K7Z#*HSNA;G@3[+4>O
MBJ/< 0KRU.R0%5S/(/;,3;HU?H'.)WZYW',D*:WH^:Z3WU62Z*<KFRK=./Y7
MFD>J%M+&NNV?K8:HA\4FZ=_JZQX'V#D]>=_SHWR)% TICUR<(Q4_?QWEX610
M8Z-C2QI=AIBJS(/B\5]$TC 2R@%/XCL9:<3-SBIQCH4#TNF7O@+,V+NP76S$
M_:6>9\]>+_K,=U]R'<2S0^EY52>%HP%*W;!/]CI#$,CQH"RYME0YFLRW)I95
M,O@#<<F!/#"GJG.AHJ8&4U1U6.SGL[05H[N:PT ?99+%57YMG9V+"W,;\$)P
M HJX7!V0FE9*LY/CFA,Z)&V:*]AV+2G5]RZ=N3SSA)5Q\3>&00QN,Y%+@@5_
MW#_!,!B(_WL"^L*U!OLLY97[U9IFJ!\Q9?4X[&3(^9\[]B:-/>?/9]GA]8<@
M[\('-:>XFBL5I4';@,C*TB?!OB'$)DUW9WJ3-DR2<[Q8\).RZ['R3NAM3#V*
MVG+AP8.YKTIA>H P_:<R4WVS37=3LBYH]F\ QR^W._/?Z3-VV='V9[%D417M
MM&J:=P#ZS-^52%"P4<W%/@L5NU?W*8**%?&S\D_BOU6EN/G319C![>;G!^_B
M,$,PEQ*+4J+EDX1LR<[3<0XG"L_% =9V2:X&5Z!/KY=EA'&JJJ)+$%F-BZ/:
MWW-"S!(MJ/5Y%:.X)X%55MS:/J _:&(,],($GP*S0 ?+"E18V<@-^8VCP;?J
MAW^B'DS=%MU]L'5'EG/:R9D;NVQ59/W5&K[- X-!XXWK_]8MS4QG0'LY7#>.
M.TNS[:&=?PGG>=M/34XQYFVY#20L6%L*VGOR7Q8;N*!)+L]4EEEG-7,T!))X
MV=!"Q(-M $18O=N CA0!]P=7AQB)Z":PMJ+A"\9T5WQ49[B[NZV;X2)_A) S
M7.JPZ1AC0O$D,A8@]NE4^)Y_3-Q3##/D?,:=YB160)=I_IW]^SQ%G%EQ'TLL
M]Q&_W8,6IA%_J-^AQN[/7AL5^"VUIT17?4/% 9G%YJ(<ZU9*R/]!H8M5W9 Y
M878+&+1V_&IS?VYN"+V!]'7F?,^RIZ>,Q\]^[?IM0 \$8I](;]F0J<?;"@SQ
M56W8"2V)U[A_>VMU$=3 1>!A-()JQ)7@:4M(!0B.D_FI\T)VXK]8V08T=.>;
M,?2^<RGJ9++BD;]5=$7N643[12B)ZE7-;_AWDFG?0,<B#:BQ@@@0#)%V?]DR
M;>Y<6Y_WARNOSD",E:HMK\>,RE?5#'M5.]BN.B#)E2NWDF $KDW)HB9V<QV(
MMYC520 QKRM+V\P,*-@P*3/92>;R'&6:TQ]B=E*S@7\!D1)31@O?'ZI6W%?2
M5QMX42UI[^SL0\!1>+*077\/-LO-["^O$E^V*PY ,,N[VTVU#"J:YS&)/NF=
M)-MY"5T<W#&@9S=C8=?OI?7@ 2*J/5))D9,8\\$]>.IL$\<[5"VKJOCWD[!)
M4&_$JZ(NXI0A43W[01+ N6LF9?:(WXR2M=U*)I[S@+KL\XG6J T^LQ+<KV$>
M@J["+7EEAYS"51+)'JSE*HX&'FFFPHRGUB<R%V86DG#*R]L B>8+<O&J3<E7
MXQT&-][>U&'X#JVJZIZ94#[SK/>DJF^<;F[TOTMT31:^#4@'/.GN2+7U8!'2
MFFV+H;D=^5K-0R= V/Y[9^R/.! OL[H/N-\G?M#5;'Y?#Z@JYQFA$6TV5#+P
M)E>-'D^B%W[E&LQZ.77B-L1JKO00E]^?[6G=[43\_?I3F3$^:7-K_53@1)CJ
M2AWXP=U"44<'D!AZ;2YT&S#D6;EA%CV=_>^\_KY(=C8'SSJX3"&"F)A/P[Z"
M :Y$)C^;;>J]UXRBVTS>(N>58DLN!'_3QD^G>YW#,N-:F)M6_ +>/:JPEAM'
ML(\T7J[4[5=KKG?/#E2+YUZ=]T]HPMW\/(FNR^P!/G3)]8*/"!2_,BD=MO2=
M)"]6+*5=,?$,)D;'8CB?)G"OBU4W'&/5#^HW^=S<66]TQ/_8C.A)C']-*IH_
MZENV#):AN)#S)%]G-I)[@-QH=_=:#'L1'O\.MN/?5E$[IGT71013RO-K[$")
M\N3"IZF'?V\#_ 0CKEXG:A=^(C2#.O;VF:\L/%ST>C8M,8$4'(00"32)3AWZ
M  ;1%EF\F -A^X^S8^)7[CO@^Z=@_0)_NV0LQ#'_@D;[$P)/-?_H\(9$C==X
M#(YHBJSULISS<&?<)*E>SZML:#_P_J"E)WKIFL=FUF+O-D =W,L \_\^-E[\
MO.9F:J#<:%;/;7 A5]TL2-+4NUCP%7A$\*M1YZFY,4>.RI^K+%6O9>W4N@PV
M"?"VPKQTM<JPG:]^^./:=T.Z<X^(Z1-"E+7M-L#-%!Y@]CSIY(>=_T#[/,YF
M1D=1,(D'P(]P(FERR;Q=A9RU]HZ#P7J_Y;JFJ-2D_]3(2A8G^G;6%%6D#&ZE
MN(CD<*\U(VB$E<)MP'Y;=BW'D67-C5X!,BONCMX3]'$E<OG%[''9,UNXNVOU
MX(')F(GNWK&$HB7+7E]AB4Z?LR4XXSU%^D;4>EOJ-AK-@Y@EK2 YP1CE:',4
M<Q1W'N;#1#Z#[^[^Q($/Q4AXND,.0I/^VEXRPV(WIUP#H0^; (#TIGW6YYU!
M1P0G.:94EV0=#$H^V.O$*-"W*F'0?=DMM2$ 0=5BSJ9;^7,]FZ%I-O>P7\^%
MG'XX1HWOLU6.YG\ WJTZ!"V?\2MF*5*5N\3\IRG)9C;@/:@$MPM2)(_AC<_3
MM[XTN=]P<G[L6'=5GE<HKZ ZV,*,;T-PU!@KZ33)F?XP-X(^12%(&IN 2;7Z
M";[,[?C[9NG<E_2[J?5;23BWE-T.3]TUU&-J7QZU;K2U9I?TRR%LW*Z1B-=.
MN6H"_8H-Q+/)@0&/>@R6*O/8S5&YUZTX566\>_RO,%_#Y!E1?> NG@K3I&)3
MS+3^C3KZ<Q51BD:3/*&Z" Z6,E>(,UN/\YC'27/(7/M>)J(M"R]EKL2#\S_C
M-*!MW;>JHTDD\HEH4/S?E_;GK/5B<JY*R1^'K=A5;@-,M<DD++(./YU'^;(4
MH,R\H5BU%[ITU$W+D5:<VMF=D$7S +EWA@&P<5+CWZ%HJ=T+YWT?I!5\1210
MF-;*"=L !;A8R5,S=^Y-:(DS,RWABT[\X^\P#5]_L5=/D:I>\N\O,"V= 'KJ
M"I'AWQ2[3F>=T(VVSA(:3^G7!*_*7EN;@*F$?ENB(Y@TA2/!3NL&^Z,;\L@T
M\A"X]CT?;28F+"<]F@:]%LS'T,1$A'HAH7_4]N<@P[Q7?\JRF#=E42_^VX=4
M<T6@[Z>@T/] ,&"R%\,]PMO/S^)!Y-)@4950';=ZS"#,,1"]- 1R=^TN=[_\
M8/8J4^HDNG+LY"OZ9/JDS!G+&)D8KH0[YT4W2GX#[-)Q:Y+(N\=L0<:%T#_4
MK'FU@NFKQZ*R+%3VZBQD[;L-_K=FS<03#7]TLS6%8'EHR_2FN:092"1.J;.<
M\T*IC)UJR-C\'_-K 1]3'X =P+P.U^.OKK0%'K7U-GMC\,:8J^WWAM+@@QM]
M/U+0/)MCRR18%Q72/0XUZ5/6N*_J4*\]?"B]G\K'_UU<H[@,.H((LD^%ZX"]
M;V>W-NXM%GFN+P:DWXIYV>L3RUC-.K-RSJ!CRN7MWM"]>DGK.J2X[BZ0#&*Z
M +\/KO ;)67V;S]+._P,,ZM:NT9P9,0.W9=\(-VD3C7NZOR/LL0(V=O^^ZR6
M_DJPU3A[-%;ZN3I0ZS:Y6P9=U?Z!;/1]ZKB>9Y!T=?[296N/?M6WYF_+<.?Y
M;Q!4/7ZMV7Y6F!#A%&;L[YRX5'XF6\@;#[@.CO-14W<G:B'D\8D!!Z?300;W
M]JX6/J98;:E6+9YJ(@U4OPXR'GH_4_@FQ_/60EJ^W24W/B'LWW%_T,Q X@:#
M".J@B))N\JLQ$B*\XS7#^N71^)?UFN'E2UA(4,V%J=+/NN*>+P J^V1^U#*A
ME0.MB#JC+A7N<2+O(DL-WYDJ;O\\WSR.MMCL6&SS8<E+DUD;:Y//GK@:YY]T
MBIRL36T<,9I2Q\7_@SM#&EHUX_7Q']P[^]VG*2EF%L%[LO"J;D<K&TJ6';[)
M7UES]Y!Q.%>Z3U5LTTIWA!##K&5[" V1[;1APW25+*>]$RCEQ[H=:8L.>L(?
MR-D$!B![TX^_A*]. 9K/Z#XM[YG-N#Y<>GXX[$F/ZP2_]-0IT)!SX-28?=88
M!O/Z[GQA743CHIR<;(L3HWB58"@,)J'\SP9H/78:IYK&E[LYHF.FS#7G&6>L
M>AI.K3I5CQF4C_?WW?>QJ+\D4Z>;_NI:S(?T),YF.[".T*5I)W*-DT[E DE-
MG<I2D%NDFSG"<->:J-'.OV5T<NV26)%ORDW]J-OY9KBSX[U'X"\%G7BF/5J"
M?9/_!J,39U*)UD"JL YD6WN,0+12),J*OA^7;%10/7Z+[)T 6WCYO>OA>9T]
MB%9]@2I431A8]Y'@PWC)XQR+HK<SM4SRIW?!_N7M$(4]PA*H]^[\GN(-^5$6
M ?N0XE<I>KG,X8F:HM'4VFO&&"'#UAI:;AJ>K7'2R[:\T=.I4)X$F0.3RXUB
MV.L$3OC, $E'L$^%5=)6 [O+J64N?VM42J0N4S]Q(,Z&<@\G)]VR]RM^KP03
M-(^G>SN=,R1WSW4^Q*+JC#K*E2<LVALO,-*:'3XOY^_@?T0W[XFJLHY@$Y[\
MS),9VSG9; G[MGBB//X[3(R$U%C5B4743'-\N8ZP&YPL@RZ<LB1:/]?A$^:C
M10D_3BXY].WW+I >/,J2E(9^3\A>HC!M>Y4/\B0YF51%_.$@YTVX(8NW#3A8
MUP^RKW&/1HI/U57;[BNK_9K=&\!TGYV4?WIP>JA$3=22=*6 N$0L%77W:GZ_
M^+@^]8U#F'I5)6'M<;$LWWC+?3GFECH?C3NUK"0JY)$7\)\FGOF8<K??Q&)L
MXJJ!Y[FQU2LO;AV\H](YWU;RH$E1+7)77?[9X&F^!+N1\Y%K 0V"),E2F)/I
MG"%^90@,")FN$NT,G=[OZWKT;NR',_ )^5W!/SCWP[INNTRBQ/_MI5+2JN47
M"([ '#C/6.4NG'1:U8[N4O=K(77[8\S'5J>6)-14XOY3%874JN5]?U.LNO/V
MR5V&$AQU:Z2Y$H@2 #RP#0BHDN>9<%Q*R?;A.K'@QYJ:3<D2%R;FTKIO9F[6
MES8DWBSK%+]A8[!/RQ7D;FJ>V&!4Y>GH-D'L?] UC[+3;UQ:R>-A?Q,; W^/
M(C^:[^54N0D5RP *<6:IORN' CO,57\59#K6Z-KX1Q5[]!R4*JM(4C*RUL(^
M_/ZMJA>TEZ=# /I!QE^PO[((<8+3,#<PI-W<8 1V(0AKKO:J7<4:<?_&QV.I
M#JE_DE]'O1#[T6>X#JJ<DF".P \P/^466827@BP_N5L'91^.)9')/R4O,[("
M1:-4S_?J2=FHYFSE=@*9UU$<&X0O)14EAJ :KB&HH=":]4YE(G"<BZ\QVYK.
M_K[6S%H KX7BG_A'1*3<)=M&!V7&)7860UBMI&W #F&NB?]R;^OVJ<N5]>_=
M\;X*GEO+0L\F%M9K%C.-2@")PRXQRZE>V:Q:FH_@!/\C),0 ) G-OMF<1/.4
M(O[\;A\*+NK^HO7J3=&.AXIW/194<M<L9I#CINRD:DZP4 RMNRE29HHLE5;B
MZL>2?AKY(BC8;>_'>X#7W[.3$@:DRZ>/[_(^>>PO?S_7'M[EC*^#M _LFR!Q
M"EV9D<D\D="CF_%F=L6G^85V#7=2KE\'O\DX=? 52[==7,_#ODV'HQ&'*8:V
MN[)*.B62B-V=R(1(HMA O#[9;<$:.U3QV-2F52I*]N;1YU8ST:N]>[J/C$&3
M>V[?YMH]*9']D!UL&K#RIJ$J8E >$>X8)J#S4!=F*67#ME@FD8A2^9V#Z$+\
MF^<VQ<D)?BVS9FCBQ3-@XA7)W]A-2@"3W)DW.AO1&H+^L875DWEMVK>VJG'\
M&O7JW_UMYKM8A)7L;< ><8YWP20,Q(EE25MQ,,7!.I43T)Q58SHX9(66Y)/5
M)3\H-2KZ"JGU2+=5JU4I];.P,7,XA;N#XS@-X:F1$%3YPS<%),&/ 2*\,U)F
M@!>]1='>!FA"_K9C(^ /[OX5Z<!/X 6R&G1=Y@!-ATT8WP90/5K+6OFH?T?%
M+>B_NF5AY)G>B;D%1?>(T+49@]%3G<ZO"['Z=('<'@COWPID3-]Q!1,;>_@=
M"L\&/]2+J;-^)7R+H$)7_#0J_X2SDR_8_\J!_[ZK<&^--:^[A?.?AZ,2*"*K
M1%M$'%!:7\S=E1.CF7*I")0;Z-,R^,)_[I8]:M_[ _I)YRQCC+B!@CX$D[ -
M !A([-P&A"#:3-G+),4!; R2'FW>'R[31=%YXA^9C36-,_(7D=<5$/$UVO'<
M!_"??[N?AI?'#WLQ5?]&E!ZZ;%.7_/WG_:\I/E*W9P\JV&J>F_4W:'46HR[\
MQ]!0)4"_ML8LEJ,QSD^,X,1;U^K4M-[D<0W4!<NF0'5ZF74794\X0X[W@&/#
MU8*),BFIS9>8"]8$<P6D- ?I^LOUWNBJUH<[=Y.(8Q%BL[I1^_6?/=I9:?IB
MN']Z()%R 'X:=H6?*Y20I"DSEH_7"4ZX3G*S DW+^S:0^>JWRZ#'EOF5[.J7
M@851AH8WSC9<O_O^;_Z_4Z5]Z0(1F-H0S(BEXL9$=$!>N%T=J@/*+Q)A#]12
M"Z[.VZP4^=G<R[ROFXAZ7CB_G(]E._ 3=<SWPBX1S(]!9[J)V$Y0DM*)6J1M
M(VL/_:7)8\,QA^KP^OJZ^%.[?;_T[3!]ZY\61O*Z5NQ:MY);&DEYUYM>.8E-
M8V,U,:N,?JL_BVU+]).N$<'9.7Q&(#AZ7:W@VI2+$=T2#1\=0]1*Q/,NE 7E
MB)?.) I+YB0KDAW32[(+#"Q6UZ:K^AQ_;@.[M=<K9=>++DLH@HY@6=B."M1Y
M%[_&LY/XQ<T6,SIB9/*GO *8YF"E5IV8^-579A%&FD<>68:?N!M5N9[":WT)
M2_H[P_YWB"#J-[Z&05=CV=+4\C&A948=FE6&W3<R2+W(]FH;S8&P W8MV#-8
M<9_SMW?M.QN:.?\7Q9,J[,K*@!:VF\OS"\SN495?>FGC6T8@,*U['R8,_MA'
MT%4793]-O%/Q]UY; 9XZEID1G(^9KY+Q5SME"E:X-F;#=K#QU"B+J,G$U6W=
MW?(JT]9UF7)PB8PA0?S&LG"E2AK!+!0-0H=HK 0683NJY*#G($E3,F/#G7)_
M]RQ,:.N8)=SW>R<7F*BMV NN>:"NHOFZM?.QDB@_#4$5NJE6'WVN)0?-0KF9
MR+6?#&\-+8>^GQR >[=P@1/")Y1\R^GK;MIZI[32AUJP0AA+'P:]R!E8X4;I
MI'6AA4Y$V7[TSRQHQ;YV&P!66WMSV3Y_RB;QJD@\!4GMC\#+; .\8X([A;;$
M/E9P%NK?O<:YL6 WB*<>)3PN&;P_<H+PAV$V,)MX=!1-BC).WZ4D]V&WX7BB
M-?'4+8;C7#_=V/P:*\(]^-/OKISLZH>E^#/FX/,-,**=YU80,J6.D4@Y; 86
M5F<-1[-R/(@B'TZ777?Y=Z^I^2A,+I*-/VR0X>FIJNR7<?_GQ;L?W]V8N^V5
M_#Y&1/@$BM-/W08HN4+;K_P2Z'/6:5=,KKPR^6UN/MQG?II9>[#M=D,#^-.B
M9_5S:<DWI*_S]68:PJ>H+*-VG0F+;[@=3/\NO S4J(,BL0K1?L"[].F.SOB&
M1)W=F=2C4[FJ2)F.X'G8QTEJ]D,551<0]Q2\,P??"DPT871(*,.L1G"G>3:L
MO2AQI"'&/!-<2"+=Z52Y^LHB&/+Z>JWOVUK98TK&>QL*Z4' &A+O#7HN?%0=
M$]B2-S:J[3G,,\XE_!PH9A0$EV%8>ATY\:T(DF+[X0T!YK/.<S-(@6= I&'M
MU+4QMXCBH,-KHD,G8%_[ZA<CTK[M[#H9;T#-%^/7F86C>;LXZ<%E5\>43%AY
MHWD+[>-/P\[('F:=77PG_W,Y(LT_\\C)E'S-)65B%1LRA ^6>.Y6\CP\N:G?
MG'0KH,BVU_K4A=KN$U]/7Q)YM4_)RFG\L<$;&N/?=<GY6OPBG#+O:OK<\V7J
MU+O(DCOC5O]A7_\H>_7]VUF%V -+'TJW 5XWK*8>EASB_\@-PM/')E'\YKF
M$K9+3/+K'!B38ETY^6,0Q&9HD3Q=68A.NKW78/,>[F..C@/+.K'9L@BJTWI8
M+3\GI[[TPF:&NS7"Q'+=\\M:(R/B2-.1]SELR#/@6J:6AN#[#:%BE>RM;*?)
M\:1[!=+]UNR4K\+P@%_!,_%UY5IZ$+;+._X+=K15/05U/HJ+#>E>9:7X;%3V
M?D/51/*. ^OZ41T0^C8 $Y/]+0LG*AC@BO=/V;7FTLTA;T.;3&$M[\,GGSB_
MGN47^9O_$.!^%($$=JJX2.)\>$%+[DLS(3:>#2)>JPH\B?@4(<Q ?V*\.W2X
M%\8Y"&=/$==F3FF)1>#GNITS*]IC!(M^2>R/OH;O(L\O#LC$2W':!:+M7 >H
MK64#!\7:3\,^-U<+-"'WL>':38>S/GX"+;+QP5+N?>FE=WPN]LSM(9;L]LF_
M,,R>YB<3V+\&81(^4V=&FH]O _[S3_S .D%>_+7:E%Z0=MLIR6YY]NNYO5('
MIP^U7A8+H^P WFV);,,K*-)$.I%).=@NT*% MO3B86FO@#&B75:RO[G9=#W3
M5REJ9VQ4VGX=Q>"3IT[>T(T ]U"*\\YW!E81718Q&S7V-FL-ECV>CSK=_<.-
MC:J"#9;+EHB\O\P%.H@51AMX?H)37%)%[XEDJ3C$;HBI$RXR86$P8V._ '#G
MY_LA6LS+"@.,_[:J7^V!?X6=8&5]9.T7YM&X#;ZC3?.O<#M_&VQ+\W#(1ZC_
M\'R&6F3LX#=?G_NWXP I82"=WQ3F=: RS]2*B7J&"-0Y"M6;YF5>6Z8&VQW^
M:6=MGV3M'W!FPYG/;[[[133VS <E&^.JRL=Y)X 2G ABVZF0DK0N\ET;[4HE
M6M3.SS<'5#)^=BN<Z<AX9*->65&XHEI8XCNJ:;H57.*"^3.V1?0:-*K<C%$J
MHT2TR%2!G\#]!;W 7?"S\$'@EUF4K"J_$*<9J'22R<OI$QRI?>&PKM]23XB4
M][0RMFA9G4_Y/-7JC;P?>_Q&M#(242?(8PU/Q[>VA'52%,U587KVBIQK1_T@
MHC"]H4_F)T9#WEIYS7I:9?2(5?B<%9W[#,,R%&./",FWEWV$54(7X4HMZ@;B
MCS3?F\;'3YT>,7@+LZ5&:YD0J579W,OSZK+8# G#?L]#(K</5-@>V=F/^F1^
M#M%Z?B,1?HP3UHG8 S_I!9,AU"F+M5-%=*%PDF=MX]#T?6;[K,?9_Y:Z&<\?
MB5Q?OQ&*;60W/YX:2ZGDFOO-D!?[?573,58M%42R<94&HUQ;L'3K-Q:S,K&N
MO-+)LJ8AA"3_0KG._R5,<T8GF4",;].RL"7P)"-GI+5*$K5_61'4?S(!2'VC
MG5)E-2DF-XH^4ZV'E)F#M? Q$$;D&]JHU62^Q)L:SIS$2YE=/K-:A.5>E[+2
MJ@!K$*WF]'HTZR"MAKRTTQ+/$+5*2"$58Q')%-GF2)9WA]*909BK3"J[Z7/P
M87</+[=^42CQ_ACWW0S$V,G[3GQ6V=ZK1_P1K:H(_V4QZ5:0I/D):^]2UT#0
M(0-2"9-<O*9_RY43KI%7,7/[[F'],+.U/>?;ON>_\2# 5YNK_X>S<X]G\@__
M_SI*DA"B6.54.:4<DL,^Y8,0BA!BE3/-DM,P6R7DN) 4L4\AY;2PD=.6<Q)R
M7"9F<\IAMI&YM8/?^O[Y^^_[_6./_;/'8[OO^WI?K]=S[_=U7:GHF>MSHQ-1
MVFY:^M>RZRK:KN.A]H%ZI#:&>FE 50"S*&]LS/^K,$GX=Q^YIX=61#2UD_"Y
M#-T9W-/"HX:YLEC6DX#:<4"V_XI/Y"%KD>??3<[J2'T=)CK;2G7 <#8C>CJ'
M!>/4>L,V^;?LN@:68+D+O.._D8U)A_:2XR,4HQ!ZUI5*/]\[(7T:I]=W9I4=
M.2"=.0459A/%YL P5M$-P!7&M4:TVP,Z)N?;2P$O<GO=]4EWE;1;%MK_2>2;
M&+^JMW0V_]"J_&&1  54<Y-/LM7;J9*(J!G[2IJ.#.\"$"?Q6(_OX/#]9$3A
ME0('RKO';EY&)WWVV#7M/$]X\O#]^Z+>PPV$VJUE^V*O_*"?(57,T1:[((.?
M#>$AVZ _GD;:!5(Y!3F-JF]H)'Q5_8Q$ KC6D'&=9=4A.$<V.[%(%&?-YU0"
MZ%MC$_VC%B6SG>Z4I=N@5X,T%:.C+W5_M_5P@P0C4^KL;1##MP*IFXX.$H.+
M !+FPZJ99J*+8FHE4=$1<@7SGI/5DX?/Y#M+'DXZ>=FA-^6/M$ QAH);&6?;
MMOW9[( Y=5 /$<^J*'>8&8SH?=DD9>/-C[F$-JK<MWSSN /7&FG4!9H"MD'<
M/4!\%U3F!!#/JJ?75;.2NFL6K_UJ+-D@IL,J;BZ[#$IYKZ\LG#B0_$+L^+V'
MH7VGX4JPR):F-7QA70O>;I7:\DFMP3TC?^+K:@&'R,G)&E3O?7L./9U#DD<=
MY]D $?0^]>X\G<ZC%Y ZY?OTQ)VZI\ 7S0CE@6N6\F;?_XM^8"N=9'Y2^M,]
MK42U9A+G$[_0ZN^\[VKLG@U+-KDC716.%W=P-*#X$3BQL?"/_(+FI]EW)L2[
M0B_Z;#T\Z$+\R'^%VA,,WMDL%Q%,UP$#Y72KIX3@HMCW2W^^-5W[<D.[-]B'
M/UJQ2U[24C?+6F7]%H:ARP4'0^4%ICQ]()T&!=M-0P_Q(,&IT6%%YF7FY3=O
MZ5G&^KDI(M_2M=XZ]Y[R?O1:,DR@;U1:[S60V9U?A%JW6XRJ*CC@+;?B?Y!O
MTC!2.:HEDVOQKCQLGO1_&W2[X;HBQOUG"4K068F:!BL%R[(FEI6.#YM3-94E
M]=A-%LKO5RH&7^SZ>"\2I\"6XTE1.RGVI71%.1JS>QMTA&<*N-*7>_/[/-I<
M**8EL\\(O>=OJ:;_QK;46OEY$YP_WBP,@U[C*0*V;Y![ 8__ ,-V _2=[TA#
M7\7TY\:IY[KBY?U,:I6LU;.L31>= IT" UHFM"@U2,I&RUA]$X%R=:ARTJ-J
MC=Q#^$JT^7.OSNXGH#[-Y.DE\0Q$&+I"J^L@.(SAZ/#4V.@ =!N<_X&#P\<]
MIBJYCIM!=4+,-HT&@N@"E:EE!<.54*Y/ %1*=A)E<&7L8G<*V-YHL*K25]+J
M-N>8B*3F=9D[I]8-XS^]3HN3H8,!=7077((7#B30J8EH?"E/H\60KE35V#GU
M=^N5T^VZ5G*H6'F3+"T+.7,PI6BB)1 ,J X'D6J%1"6^3)721TLC+P&=,HV(
M^*Z8C%>R,[-[)%4,0L^IW/]/O.XL#P[1!>THD FZ[A"QKY,:6V5;,D3&Q&4M
MUU5G.6\UQEII&=2?IU8-E'I&NB!%&!LSI(/U'7RY=H$*P&5GMUWK?N,QY8$P
MIMF_NAB\[X$S+F1U.L-/U^"RYM7JM(>6,]E>$%8V9PW EJ#:S?0&[R&MZ>,F
MSML@,7<JK30Q@GGDQWNR7KD'3L.G?O!L[RW+0G]ML9 [F5T:2Z0T*,L!HQ!$
M4MS0 2,U@/%RY*D1GE.IVR)1/<'$*+#2JERU["4-0?Q^J>Z9\MF?38WQC_KO
MF\FC6\'A#J+(G< ;UGJ'F1G;,#5\&_2T<06EFNKR*?W.6'CE)=GS'"Q^[TDW
MDU\=#Y][B3H>5<E_-S3_8-24C)ZRP+?<+LZ&P>$1;IIW*X^H-MIZ49N"H:K&
M!EE1-3%-F&&TCT0*M%:[I&KR!\^;[=^!2[I(2MC0I=N"%8,JX]Y3H-$'[F =
M?)-$Y8U<$EXYWYB%7YA81_.D,#.60L5"Q-+ ;4<K/82/!JDQ#17KQG7+--T*
MS*5*JMB^DN'E/S]CD7;@GXCT>AMKD=F]Q+? W_UA*MMS(4.9;=B)38]9Z$R'
M7Q["X;$'Y'^+>:H-FWM\0K[R#[CMS4E-?P75?2DE.G/A9-=? >P3FED/3B2@
M3TL'=W7;LTFMQN]7]> R[S(DL/)^7#M\W=1]-5'ZW;3'(6\\U(^4O=WRCX:M
M(BN6@A=Z^N1"*!KCDHZ&Z44M);BRTK?;(#D-UPV8QO(:DY'.UNGRVL$O,PF-
M9D?111@Z+&P[IY[&DZ!+[/ZGWDL47RU9^N+/D^L?HN?6'W@9RB_([[]1F,])
M JPD&*+<!X(OQ)/Q,W(9^@$\Y[=+FA'8 TO*MK4%%2M#?@V$AR)<HT8_C8LA
ML"\[D4UAT$O(6_PD,RU$+EV[)6X:2_'N\CK PJ54*<PX?=<)U[!#7FJYW*.8
MWMD+KTVKBGR;>,/OBV(96!@$YY2'D(8L^PD:&J-#5%J"[A(,'GR%#BUNK\CG
MQCX7#<^V4C[)S-V]%;^:"RLS\ZQ-V/0^"*.3<>TJLYM+PS#C7I>9\,QWRE//
M&?@BG<%.K2:]["%(7W#]''8O41)I*23]-$18!U56#6"RS6DKJ71Q^_;6/^!$
M'>_:H?#>6..DQ\IQ>[NXP<:=+>UGC]S];WHZ>BR7^P_2A?_)Q)JK_F."]X]0
M:R<&%!8%ZC5L&#5)^]^3OQ=7/C:S.SYWJ(1)'_:SU)5/OMX9)S8C :A%I>%Q
M\L!+GA:P11]($(BRQ]Z8E>* $*H%8>12X?0\;27$]Z2MLII;QN<??E]^[8DL
M%/\[5!,118-WD![GX1(B3NL5B$P3L\L"72@W7A"1>=B)3)EWT9M5Y(,5C#4#
M3MAFP']% >LK6<-Q-U3RXX:S706PV9S'S06SM*:0 ?RMG-PR#[06/F2AGX4,
M89?RI+,[J'BK)W[L@33BF464"$NQ--U$'Y*ZN@W"1XA9SV4%*,F7.KMDG3]N
M^6MGV31L%GN(%<509,>V&BI(9#0;OQ-,%9YE]W5PLI<HZ&2D;.5TI?MD@=GW
M9^YM-RD?,*$95^K/'D<C,O_(TTD_PJR >*XE@MM5>'Q$[L9WP7'$&? >:H!6
MX$?-TYI50UL"/^L[VCN?[+%9"/UELD!C\J2Q]*@G<'R<R#5^*?%D$%0,:<;B
M)[6/47RK\LM>OCGC_1CF):6MDOJX G3YZ^79NX5*=O;G/Q +7S@58L9,"L &
M0X%O@S6ZKF>0)\8.30S=XCOG-YK6<MIR!_@8E'H/(1?]1-^R_8!DOE%,"J#>
M!ME'5!,,0%EVN#VH[^XZ751%ZRJ$;9N"WSNBU(N;W4\6AH8ND+ZGO[RZU:4D
MWOI@;@UUS9(ZR$S#2D!H,.0)MD."V3@?NPT2U<Z,*(DK_[I.[%MH&XS.-]1F
M--6FMU_HLG+?TFG#LJY0)=T1RFTD":0%>[ES2@4X3^/&ZD9-DP<9_RD4C\W=
M+/):#>S,_])$_&:;<.0:()9<%&%$*-G2W+3-Z=_TC/+4;ZF[-V9W\;[CV,]-
M#T.4K=OO%JRGX:3R^^^0@%3,>"\G WA./#M&"&R6H>-$U3NPXE5%H9KM]AX!
M_\84/+<[82R#'IR7/+!G/7^_$>Y?880AW( RAW&==@5R.D'+R9%ME;:;J-HB
M1W:T'SO)L?R4,F8ZNQ7:+MVM\%];U?!#C85M$'#:-/<)^AY6F*'$!3M_/0C*
M1LQ8D$\2V>KCFJ6)ILKM6102I2.[9I^;NL.9LV5]ZXPO>T*A#_1SQ_&X6K>M
M2.(MKULBO3^?3=]!W4I[U"VO>#'E?4^LNAZIL>7DQ'!C5!J<-T*-]*%OS8B:
MWBO1<<F"/G]'#L0IKRUPVO@UQ%T\*SX!90 $TZGI=UES24E(A2D0:VT;Y.>U
M!%Z,,BK\PXHKE-]I\J $[QTJ<C9OF7A<,%(M(*-9EP-XUU5_1N6U%/1CBI;6
M=(XRM0@>%Z:N*EF]W/EU!XA^Z?,B-!#U!5+K3%K!LBYVMUF7&;2\CWNWX#@:
M$57/-5XBD\_K#?_4B\6&S-_;\_,'Z,!KUVS>;>%-#$2W?8$<J0RG'C5(>L/S
M(@WIO_J]7AQ7$MYW^6M 8? 3N)%AW)OCZ6[WF]RB?(F,PS"1([8W&A3'R&E;
M^;5C WEP<NZ_=668/*_!P/)!IK\,V)9REE142Q2X5B!/LZF,P&W0'A5@;KH.
MZ&,[?4;M8O5G_W>K,C<A EO=K^U7ITF\D8&;/:&A?.6D\SFI)HQ,/&L;- /I
MP$F@>BA)J?H2"HC\#G?,RC#;<=.*'$+Q7S=QH'&C78YB"99)]P84FP4!_HZM
ME6L'K=57)!)(-9L\#0=*$3VJ8X Q4+<-:NLF#,'0M:C.N;_U$XGRRI/S6TG?
MJ*0+/YI",?F5T2'5-&;2-HAEAWD$EHEP2"Y4R79AD3HECBRYXZO5DDR>F!6_
M5$!]N5JRINR[?O1NUN=#S?[Z3N.7EXN=:I?U+^AA8ZL"%ALCE])5CXSD- ]%
M+DKXC# 6-2#.?34-\>PDNF4IFRK4'H(2IBH(S'HL3*%W0O?T$2I_)OM_6*(4
M-/57GCP]KI,=J"#S\^!P:.;CX*](ZYD6\+_\!(C?I!P4F&3OHE7EER/4^A+C
M65S;%_##B)1_\8_B.\.D;%4.=>S0>OH0]D/GNVLMNM5@&^3=8D[KYDD3X0>!
MQW;F=FS7CO*C^7WN'G/K516HP1 M1M$S'ZGOE.+]-YY%:1Q(8_\]GS']DJ@R
MB(<G_$EJQZ3E);53P3PC5IK9_EPO!_&)H!>4KL)'HBZU!5^[NOX]N"^R*W1@
M=^#%H-<EMJ4-RQ&,6XWC%"=;KQ>!!FF+(PLV4:Z;=1,"S^*QW%M?M3V91815
M9.FT!"6_J]%AA<'U1$"MV=U=P0SP9Y1\S6BS>CDPW>M++]?!JZ2M^K5=O?Y4
M_*C!</T1D,)O)IAG /2R#&\ <G0/"8S 9 1IS<8XUK&Z2/ RO:@\V;QZ@W,V
MZA]K?KPUNK/63XY\L'*8..WF\5T/#2BOEO@7\>YA;@!].(000FFT7WH%KDYC
M>HCY3W6-R?ER^Y1SY+[N:Y4%'3Y^/4D9%-O=B1XW%L@BP2)% BI7@G<F+F;8
M8^ '<H !/3GF@=;@WUZKC\ZO1P(3:<=F;\#ZY&T%!:6_7C_GPF4)!&KEH'1+
M\1O".S+P^DXOE5$ZUL,LP4CR"TQVT0<>8^M%,$2Q*:0+D#,#%P7B/U\'7E"X
M'3$?F\?T8AM"BO'/)G[NOJXP'>(L1KAY>E<\MDP@@33<!B5<8@U8L08XF\G(
MZWR,2":_G"[&K ^*:LXF1M=5;2[(?Y[>/]WLQ-6;0K?;!6^#9/6V0=+6I=0I
MQ"' GC)F>LI3_W5JJ.K7J9U0J6??1+)K"TBQKUTMN']K5'S0_NA]]1UBRP6V
M78XW-?-*^CK37,[;*DNU?WNL,]E!LTFTH%U1+B0<REDLWO00!HC3'+<(GFWK
M86QD.>KA84IB[0N+6R/U&9:,\I(X) !&9V+^='/$L6VD:B#>>@16PBKM>*EO
MN]=!HGV^765=:D#QM]2SK!./C_AF7/^HE^_V.#:I&Y-*0?\=*V7;Z64PFA^)
MI7F>F7%ZZ1_XW$+^=OSDT_VF7ZH:F^N%&/IJF%,#1)4 ]MR;@F^L/\MU"N]J
M[VDAA4R>[Q'XI&O >+C73>6*,(4:[K><>G#R>@BV)I4PQ<?YS,&U5NHGJHM]
ME5#1&N.P*7(DJ7 RA_F3AP/LA"EI/Z##PK6C=R)#2X$_1YFILDJG6D:043YZ
MJ8#=:%W#:=@ED\43-V].U#_KY;;MJ]^R_C(P096*<--"3[]3NDBL_H28Q4Q;
M%TXA5,Y\M2PRUB@_>.G8(8LX<S:<%IG#+J*Y/D6"*\WG?PE4A_V'M9^A!TY[
MGPK]]8^12/7.9O7I;1!/FGD#B,51EO+('3J M?X^,WGU]JC7OTA^@2^,9C-U
MCFXRUW='7,9V7*MC-^UP:?YO9D]PV!IG\X/]&8V:M 98U3J\:'^,S5H428OO
M[2(-VX2%02V*'9<RV5T)TZ0T)4EA:O="A'%R/_'_(VIY C.7AK0(B/# #=_<
M?YIJI9^LA6A]??$IAW[7/=#S9?6Q P?B'KWC!38#XESO8"KK>7!C/D*"[OI$
M)#7\!JDA*T OML_L!/\-3/3NOT$<QF'NX82O-O_TJ"P%83_*<7)YTGZ0\66!
M5%\A-(G^_7_Z;Z\79%3.\_/[F?5'D5/GQYKA@OW!_C0TQ=@+".4:_MK,:R%W
M,!E'-9IR:ZH+E8L#',VU6O@3_4X]DCWW?%-O1ZI.[CV?,M7<4&YS./)Y'J8X
MVXY8AVDR%,AR7PZFO^]RKK\> N4P-:S#FS;_J^2-K61 :5J;R3PH6X)CQ2Y-
M)8B[K[L Z72F-%!F'+O\05W!LV0LWYCBWG$D\U@@?.Z.W'XQW2[K*J@P@-^4
M+ E7#^KX+7.N!6IHZ@0[-W%U==A^T$SF%UF6LC=)Y8J2\=&<#*.3C9EG3<C1
M7:C;;686<7UL98XS@4WJ1,<+3E:/#%O5 %9A45K$UR]0=Z>Z];/=->]LXIX?
M.GN/@9PYHAC<%@$!5*W2M5385HE(7>Z_B':A<6OV1,>^GP+<VR_5!/\J9%"L
MA[3L:L]9]G?/_4 Y7E)7&;N0[G$#;VV;VTN[3AXTO3?)RR?^GL.7!?V>WYC/
MSVDJ)Y0,U:YFSA#!0 _;E5/;S$^':0E4$9C6>K1DLWIE+SV6H79'FKKOY!.]
M7MD#X !C#V^\S[]#YT]]V=F(>0*IQ71@DL%'43H\,1+_#?'L!*!.PS>&O'D7
MQ*'4Z*0PE?[\^'KRTTB:;YJD7LCE,Z?AY_<\?N_.<?C?U*DO40^@_9B *P1?
MVBGQ%#T!O2=,;YFR.6 .>MR$M,*L_H>U\&T*V<==WW0-T5V/J$KYF>$X.[XN
M.!\""8_P;+EZ:KTLT"&\:+/X.9$/GSP&Y4G-T#$I9MJ"3C.Y41/?LKH&NH9'
M@;E-XXA\9$\LQW:1D66U\:!:VR$L>X3\4##E9<1:;>!>678_V,"]Q$-];!Z^
M0S#P.@A 2FZUAK[=RGRMO]$A:;?0<Q[Y-6TPQ_'3563WLL/X+D[H-BC1$5 ,
MGAY@8!G,FB6%A&W0A%D/QY,:U)RW$-+'3"\,^;FZ$'+__*,9JA1DN@!U,7LF
M*LW$@34P0WY*E L@2585$=D&&!AMV=3&]L.8:D)Q7>/+9"VWHNM?$]L?7  =
MT/"*T)D#%C>U-JP)@\$1>*.[Q46$25)[%+R-8M \]0*M]@N+)W=)9&"K)3Y_
M6D&B9R0D$.U.P#?!P7R/EV*>-A[Z7)OW+8^N9%A+[E]-WCR-2&1TYVVB#URB
MXP!U88ZL?P=XS=!S.P92E ZRZQ]O5*)L(7)+&A\F;U)O1CN&/+9(M['\]>VM
M_JV=,4JZ@\B_Y5G60HEX"X1-.QSH9"MP76I9<AUU0'QP:&QQ8F-S6I'.C_G0
ML^(G_#5#='L@2YVQ\ [TN!?D*96 ?H12ZZO0O \86HSJ1>LEUJS+7?,8/*+I
M.V6P1Y(_F=X4=3TCI(32K%B\5<4/Z-3AO2^<=.;4GLO@9 VZ4X&+=CB>'#R[
M;M.J54C[J/W(J\#?C?UF-KR[,G@F*J/*Q'Q&9^_/I4V!;.",F13&OD",GZ6A
M]2KCQI.'M4F3+=%?U"%OMT&U4;Q\TD/2BN?P-NAWWL4MARX(RVH;)!4,.=!L
MRQJP!OAT!GAZJAQVOQ'ZQ,.R[M/%?VMTP\V%6JR*3^^WJ+MV:&>NLC&Q"X#1
M) !7TL'?BKL8X'N"]N'*W]L@2.\:CWE&'X/Z6= P\=IGQM3.50]FYNSS\UYC
M<<-J_EKC$C-V=?)YD7: 41!9?ZJGOL<OMP!K9S"NO&[%<6)#&7>FX4^@L@1,
M?(Q.JX,DPLGN;T\!;>7A",)(/K2Y '[L:V:%HU7(^$R MNALQ.>J>AJF"^8Q
MC5V19V=S:K([W<$91!7$GZ_#_78:5U],V'WWJS_9+Z:[&]NBM3M;-TQ;ONXA
M8@OS@U0CM]*Y#3KP81HN&4":P$Y0)Z9.C?"L%^(P*T2K"?5S6\911,:K+E[Z
M9&1&3OLBE64?=Y#<"977G!]30"="%8ZO$QSVB>EHA?,M<N^1Z\@[!.:G=KPR
M>8OL=!'OHBS4WFB0%?2?X3O9&*;S&#YC?5KWQIO=.<UK$Q0#LI6<VO!6H(:I
M$BE0!6G%&N8\!'"LB>Y".;9.4CAI8K@S;X-3&E"H4LT>B'=NUH@+5"[[B3_4
MYE:14BYGKK1Z8U>K&O$IR_^Q2;10I4' !-NV\RPO $A@+5P!_.D3V/T(;RM6
M9T?D&%R_.%0^1']?H8%<REH#?^+VGB.[_9J@B9"/(IT0,42^12U;G6',WM4A
M)%9#O7.+?_;4Y<**J5<_9LYU1GWX_.^F9&B2HQQB^G7$%HZ#!VIIX$=0 @E3
M$8Y)WP;)D/P];3LW?U&FXK=!^R0X#%+ZN[-=V. A=8MGEU2>NIQ7%Y_W/K.O
M4OW4I"KE5HM"5 +>,^M%YGQPWJ+9*Z<G>;!M4"0SG-R";OFTK.&I8="X+@NM
M8W8PQ5 =8%'D^= JY#5RLP/[:)>9<O58!%;T9ET]W=O?.T(7$?Z[0.!R[^WC
MFR_?6IXY^%V#R']&-.)=8>5V""/&?<"67UEEIA3D)36"@Q"(9W_9R7"2/K1+
M(O+$+YM5?VGJZMG/\+4KGB4'<I70K1>8)G][7]&!X+?+"J4I B5@N?UB"S,%
M:5A1=F99X>C/6U?9_+>&1V_V[$Y12_XH>O?@/EP08,R5Y_T["/8B J^$H ^5
M)J0[7?DT6#'CJ2TN9O4QP[<UIT(KO[?P?HRULL_.?[K";"7M;?1O$S6L(YMF
M:VP))8/C:@VX#\7J\O;24 E][C:HMXOY:\8W(G+LA9G&]V8Y=GP;A&4[<! U
MM G&RW66DXX%7+2HPQU,-ZNH^247>?=^H5UG@R-9JOFJK9U&K:SRHT<9]1P*
MOZK9C@WGU(\1P>U@AKG_-%/D5R-L-I-W>$C6TWY^;4T'\JVIR;OQ5([!VY,[
MCR6+0K0UEN*<.#L%0\*L=J^;:XIN<ZOM9?'<Y3C;((Y76/5H,[4V>I(S \_O
MBAF%9( _RCTUL64K#'2CQ5":P>!]O%@^!OXF*"^!F XK_[$<^7T;5'Y^O/^R
MO+2F3+NON7<>6?)4X] <8)3OE6X:L1@++X._"O*_I&]I0@5K87M:*YL;QO(\
MK$HPF<TP[@WD/0QG!_M E#3R-BN$0,,]=5?#TK"'@&&+;/.Q#;N+=+II>63R
MT]7]!L LI=/'KJGK9@H'GH(6XP6SF'1X.W2<VKX-4B!J@ &WX: I5;9ZFKZG
MHW%?I)AMP)V]O0ZYO6)!..59&'1R_3%J\3=<:1O4>D$?DTRJ=>6=,#L)--%Q
MTHB4]8XZ);41I'G%!+]$)8MR(_M+7:VU<LK0WO&'F:]/W[5?]]QDQ''!Z@Q3
M&*W%]0K;KUJ(X]U3(@TOF.V%JL-WK6>'IV[R&ARO^&SY)5I\1O0<K<OXY\LY
MBL<R,SBD/$O4%,89SG8/<YMT2SECMUC:R)C=>O<'NH+/)K_8="^:=Y!=\C+E
M)Z%.("9HKCS-;9 B\A]6=S)1+KA0_7L$1&H)'$CF0=!^3\QT)*_/6J[+Y%XX
M]54WS6>K@)I U$3^-;6Q/#-^R2K1#'ES#.GF[?N&ZA5@F)=G2^,NBR5//_W,
MZ13-\CY<%+YF;&S@L/NQV3N6!$\Z^(8M6C&8*HDZ'21T>F9JB.&V33-)3$=4
MC(E"7%6J][E/X[ [8KNOUNX-(VF[ELTN_ >\XNX2"F'GWW^9 M$[T#1-+I@3
MDET2B)X@C1?ZO^*</AZW#?)?MS3<NM#],G)UZ<?\!S.7$O5H=?$8-_NBW$F1
M(TV5$3;S6==SBO >.8+0=[CUK&R7B3AY9AYA,;6=;"@6 ;_K,EDL)R?6J(%^
M7K!JJ.T<D_GI_L4, K#.M40-#;"8M*D/;.7/$#R48<K6Z*;HL7\2-JK237'M
M$\_4;Y:HC;Z194\\M-DK=44LYWBU$8Z,/8J0[::#VQD>[1??]JCE5RZN!];?
M-?C!.%S]DBI23>DN'&6+_-^ZZG09.D>3;3V84= (/*&D-NA+6>1LRH=U:!25
M7)5?O*J>C#2><:"0!?N=Z .[#3LQR5X[69ZX1^$.DK;^-$^?\:MD.Y6'F@_.
M?4HQF)JZ;2&N]J/U@CM;(AE,@*>A TCI K/F3_ )+[(#"YH,UY,XV,J*_R?#
M3DH&'ZK$'9>O]_RVVC2EOE_FYBE:>MP&*Y=CG$\K93A5(*]]8I];"EM6.C3<
MK*7Z>)'XCPO^;M>T]7P]59WO1<WE]MV2P_P=EJ-D,"C00&1W0/<*+@93]X5O
M@XY!"YPZW,\ D0,>^(8F7^>L6#AD+\5ZY]RK*-^G)K?W?U#)NSY!Y?YDRE&G
M71J;7&TF)LX@^[4&T&&KUVQLMT&[F$6U8V.D_X3+S%2@B:#.0%:PM )_ND%"
M%8#NLE&K';D]II<[M+IZX!P^\#YG1>2%;YI*@NL9L4/%#S7H$$HMIX3MVL6D
M,.E6B?Y@P@8N 75LZ="B@@]X-][WQ^9.F2PWW.JK^MKSU@E) 78IE5EVJ R>
M# #=!NT/IKW(H=7B@.Q.J<#JG%QG\H8(<42GX&6M259]N73"$><CSB"01KN9
M@> S47M$H!^,/61VD.<W9B:^/'7VBES'?>U'@;A 2NWE!&7LRN:>?\,8E'<6
M(<[_=%FK"J_HXH1GTZ+_L!U?NP(_]"'0NAN'A84O5TU&U-HMXQ(11SGI0".V
MUNHAZA3B*Y5NE>1!@W;L*@82=:0":WZYFJFP)OLG(HC-M;O_7?M7^\0#UYCR
M5N73RUZE](%4A07APPC$9BB,8CJL379-DYZ82:6VLY>B3E3A\^V\:*CQT#@M
MW,O, 54\Q-_B .+<V=5+'(F#@AZ7[X)>RC:H'2*-J.WT,H'*N$UY!#5V/]41
M'QUMOU6N\=Q+Z@@9HG(]X=_]NOW6ZP.)8-95L 0 $8ARRW@B9!/KLF V\-3!
M $=725TAU]<[7E7U2*\80O;4J.YX]4@2A+CPMIQDVJAE\O-MD39%I40[]_EJ
M)6R_B[W<>!/DU <C[3]U(S'<LGX^2@W+R<JFB70.) A4 3@[GU,")*L_Y7F_
M"[RX0CPWO*K,0KWQCSI^\'9&,.+%9/%LA[3*J7NW#V"O\HM, G%($^ T-SK8
M2WZ4$"?A,<QS+>F!H=]Y6@='P 1)I7M]LL[)HQP_/[/:S<%=82?QI&+IZ"YE
MFC7QA&"X\"0[?&K/6 6A8/\X4M6_=''0M#F%NGC(_+BAU.$#Y<I7]L/5Q;,D
MJI>P'_=BZ SIF;%L7'"N*\6AVW:T\5,&Y8='7U%";>*/W9'^4F<#_GV4\EX$
M]*'+6NN$!CS08^BWNX<&\ORP+RXBID3#I?3TO=<>6[&V1"9BN6FX]H(0?'KI
M7BW35%%!7V4)(MYUR)\M(O15/X+V#OVY G:LSSI]]6,OX5&6P6?-])P+\GN;
ME3G?@$=O@:09;'IE%20 3G%P8ALDA:G$P!/-#OW:E/V#>MBF&K"R2CDU:]O0
M>Z Z.KM\9W7*1CX<4$W*,+G^ 6G<S&8R=M$E%.U8[9VR%^>390:28"L,.J&N
M'S9YXIF\/_KYT5=N7Q..JW_KF&"+\*1W=8UYG67GX!YM@P(<9!$B-!R&8%OI
M[\8:38SWUV=20FI"%*B.:.H_%3\^[[\"2GL]>V9JTU![U2GX*_M=T2*>8(W_
M[6[P<W#36T8+=J1TP=^ 'Y617CSVIQQ\&E$UT &MAW[6^8'K*M0 XMEB5]@B
MR<WV J663]\)SL,<O-^&Y1N%"A^K&)=#Q(!IC;/=1E7=G J S)9H@XBA@W_A
MP<< (M61A4LWT2D-D -/2%?D!=G471I2.V!">%8KYTS!M=0<M(LEX'A2:"?6
MP$H2:X VD"C0\ Q J0)6]-,1VR )1*E \D<(\EVT]A$KK>*LY]FB]WL_?=S]
M'D9J=Z=*DJ9SR6 II ;[<==R][(BN;,%;4%^U^ IEF[ZFPUOV!GW7W1AX,/7
M<P;P7S\6@EO'"O#Q!0+[&U"[BB)(3TA:M-]S)89&W->R,>X4BW]O]7XCLQT-
M1K5C">!617=X.E::>,*-Y\@60X1U_'%XRKS[:3BMQJWWI)W_SJ[RH/*3_D$^
M,[M4?(Y1$Y7V"=4S&##LHA[3$EQ "!-D;EYD=<4X8-7>:+((3F+ -$M>3.[9
M*#]AZ' B^=7+FAKFGBO'O9<P%$/.;2%T/V37M[5X<\.XZ@(9;/)P!\KAAV"0
M7U(G>F<M*CIU;N%;/P\RV37U '(1'2"17'@("&;;TM&/D,;LVAFKUE&VWX?W
M?1^0VM"D!4<2>\_(1'Q?\=3;+UK3C??=;$C&+WGQC[I=[-JN067>%87D7:9H
M;2S8]!!BW0?LRW3QSPNG%@RQW;'$O ?&=4(:-5L5.@!7Q,!-($EHI#F :R4B
MWF6$T.=_;?!)?=2?A.%)SUND_.,_UXPTNT$'LAQDUC&MX(=821(,G(P&BV]V
M,U/-Q >;P6QUQX\L?FX2P4G,PZ:ZX_/5M9! K</G]A N/Y5X&?;BR)]4@6@K
M*]L-D.:*(758I4]AE(%;0^&G7#CCQ T\[M4!F&"(28EKQ65M@_QTQI.ZMT'R
MQ-.HP;RDAT1]1#;-H8 -=1[>R(^U.S/AE'2]3O+SYPZU5L*GHS^BV:]G0BY1
M/JUT6ICX.H/G"@B#J+4\!_9B9/V5A;;)VQ_6X0BAJ( *R+1?G!@)EH.0F6PY
M)!:N%?+$$9AQ9,&?FEPW?%K9[$_OVW^X?D3G]F"I0??*/==#UO<[;WXI,S@4
MN>G^*P*=A#H'*+)SO?C8"(E4ZF$3SVGLT\*=(_J3&NXCA CX843,TM"-=6?X
MD]L]Q\JF[^2>.???CJRX^"X2ZZK.0:'5>@;$TD@[$$4=8 FD ZOD';9=Z33A
MYBKS1&'$R;E5[_M2-'\_K3.*;S#W+U1*C),Y^XA [ PCN!LJ;::\#)8S4PYV
M-T>@N7X+=O'6=</XM<XTV;IG<R<U[WO6V,H,R!LMX)00_1IE!5SK3X2C.C79
MH9&#&@95$\21N:\SVKFIMA6.63##T;5)J,MJ]N MP)\&[70XC!+>9Y8-Z5$,
M^DGS)7:PRPA1/X@6<M2ZWC/6Y7NEHY&"!TQAG*/BVV$>5*M(]*DZ]\^N8<A=
M2#I:TD2>:^$&0.T&2?>T;&G4I_CR]0]4I._W(SUOO;I%LZ:"8W_OKH!7S^CV
M$,S/R:B\=JU%R E$[:+>"GH;T>VF8?2Z^C)TFUQE=P5BE]?P[]BX\XXL= Y6
M^^S7_GI(=+O>0SFILY^W(C?!.R#>?]OX2;+#*9L=3,R4)O F3OSYV,6XYPI7
ME12'M,:<=Q3G]8^F3-H84=:R#DL_/'@D\&FN2;D-)#AO*D/4TNP#+WLSVR^\
MJ'?_?;0?><,1UCM8'DTHN@(DT:(>FIT-!K-LOJ #\G$4Y9G=J/,L8DYL16",
M/Z>QIZ@/#@\]+CG9]FL@<O5]-[(J<O5ZVBF<RPCJH&&7#J"QV8:5-\Q J03"
MZ."D0/K,'=_*+8-G1TKPX#LW.<?<^@J$Z-/28YP0)_J_FDX56*C!?Z+_ 76.
M=Y+=G8!2[J/%>="(R7*)!#W8_J._D-;O]B:4Q$M=$:\U2N7?E?45[[:/F$_I
M#+.B.6XB<0K)1.Z:X>C24,@LT=]R(+) X/ANB/M\B#%:*5'8+,.F.N9S5-DY
MVZ!4HI%P7?T49\/=!NVK92H:QQJB@NHS,@/S[JM.G=X'4E9Y$!U4^6272M@V
MZ*/0,J=;M6'KNS#3.N+  B>1G2N$-3F$ZW7B:YYKHM/9YH<?)/PU!ZV4S[P_
MLW3XE,XH9G(39BX0=0X%M[T,GY2C^[VA,>5_$4U'>+$TII3[KT&;1L_.9;-?
M*H075M;?51*L-9N>BH!\;052Z-;S/%\:E%+>#CEB F.3O8!T>B78KF4([MWR
M76NEHK2^\-S[NH]M-%BD[M0/J>@D;DMPEB3R!;K'?YZ?@L%._+:FV&S>&RKU
M@L[#8F)==;1H2QMSD=:*8)[DC. ZB=4K: DA_:ZC-^>UMTY!A/DOG8<"!O5)
M79"G6+'?$@FH$V:RK+%7--O1:FOX\00OC_(90OHWF'*:1<Y1RPNFJ!)^AA"-
MH( /<YS4#I% UT'JMT&T8RDWB52.0PV_"#EDB]6)973QXF9>^Q,U>E"ZZ%;C
M9N</2#A;/9THC0QBB[1NF<3-8F5O>@2\H!"(9>S2%^I)_<<I_=Y;5Y.SGQT\
M_YKQ-"LGVBXH+Z?1K2X/K9*W-!PX45M:8AS12,H;6YY?^>,U%O)M'2.-20<K
M"O21)OS"9BC[S'JK0EW^=#32>09]"'$073L57%6/]JFW]7AUTJ6^WV1\?X?9
MW1L[/U6)S> Z<$^W0360QY  7/P:TI:-2:WD05CS$'G H8.2LP@]M'AFG=#\
MS#;JD&5._/N(W$10YB(FABW!DZJU8W4_1('-6:7=4RJ ]PP\L>[\XA]X<E%]
MDE/VM42Z@\$<O')V0O%+UKW>>+R(T:XC,@?0+%MK?=+C;9 ,7OA"7ATSN<,^
M3^=D-9I5SIB:VR;+CNW>!KG*$-+L,SOW9WGTNLYE6/_:[;)9I*](*?@39C#7
M$S+6'.N14Q(^.6E\VN)WLQ8Y1]LK>+.EA,",B,N<04$ &#MW.N0#2Z>C#@SF
M1;\'LF>42F"T=!3U1@!33TL_Y)[/<X<[OM7_/FB?*ZA:F?MQ.NYS#8'AW5ZH
MR<\GJ@B^@_?#S501ZW3#)QO@^/I"[;KL+H6G(Q%B8G6&LD,J#Y[\\_%9@V3"
M_@N?CV5ON/YO=E3]>+?XJ6A:("^879H&H:D*/Z]*/>C'$AF'U/*H-='9MNJ4
MS:URDE*(24MY0</4^8?5J87ZRN+Y[W,!3T@H>GH@+Z9E3WS(P=>EC3<FMD%2
M[QLXVZ#2X"&*5KB9+@O3II-,JB7SI(-;H7C95'9]MV-PH10K\=4'W).2%[HT
MH]_X#)W?RG[29J%)\?=O-2"QSR7K/_#+( &0(^8X 3G*W2&EV:G$XQ?IP&]%
MUW\3Q>T1D.K2/*-7<X_,)=0LMZ+.[?%^5)CSR^RP<*58 BG#K4HR0"Q=!^.E
MS59OQ4I,C*>2]A(Q,-"H6OV93H7-,'O-*8M)SMU;I]J2/M^*(ATE3;].92=U
M@(_!LSN72]2[X&*+ H6;B=D+XH?=DT7RL49(QI3_SX[8T,V,X%OA+47O:?C7
MC$DO+0V287#D:(N'K/3/:XZ3IZBU^.G?OVU<![TXKM9*>^@#0L,BO0WRB1.9
MSNWD#F1 I7F>E8C:#O>#Z72<Q!*9W?N? QQ-4/$(MOCG8Z/4I[AOW;M7>XRR
M.5/L[B2>+=<"*+(:A01 *5J$=-6W&>UM$)'P\OSP[U$=^\VC-76_:OOG)$XK
M7?D:GUZV3W_#GR'./8%N^P,83T-%A6IN_K<SSSZ7IJ)@:!!7!,L96-ET6:N+
M3JW]-I$^D1\2HQ\MY/[IO"DC E ^XVE%(S-VT#&)1'$@_8-U!9!TJ?:[)E/;
MISEGIYT6@9?45S<E$TJP=CPH\8^,?]_I4XP^,ZC*J!G4 A5WCQ*GI9%]F?WD
M5OU<"@IF1%T(\?J@3[85^NVAA0YJO=R*'?<T4-NE9 8DE0*/E^E(U.%/V*LC
M<O99_Y"C=$O6+=]?AG8\*RLN6I7-?NRAOPJ6A 3ACJ"^$I7Y'YF:/ L<XA$1
M'#AU>)BGKU0;L_GQQ\])MPJE:$OC'8&>OME!Z2O%S\*\$DK0K<JK)J>Y\@A_
MFE<2VY)K-]HL,B,](W$ >/7[5)7JQY=V*IG%8TR=W/NN??=OYARX'PDR*.2:
M_STG=W/IST!7<G,$W9(=@>N:U+ 9CD#<'4XL_&Y:\*H^>O"%U='BL/GW^]^>
M VU5YWVP,2$<CH0UP6++8M3JHIQ<%R."BZZ,WT@K[%&=ZKF1O54J!VXH]2<E
M\AX UFP=@2B9M6P)]$IT8Y*IAPABGE"[^,Y&B62X=\.@/D*[2OFQ;TV])*;Z
M'+[I6?FQ/:TS\=#/T)W$XR@*A*#../J.BHP 6J8QH@"D\]I$P NS(V2S+E8_
MYWK3WLSX3_77;FQ)KCCV?[./QEFS!GA2W$[*:A-M$D)/ZAZ00SH 8=,3O_3%
MC[:1W?4KD[,\PEZ:4:/DSTV5'2H]>%CVFD-)+'2%^S_=3I.!7+9'!W0"2\&R
M:IO_R6.."[IGT7Z,N@P)C4C..F1T=?+)<EIH7H$B]7E#C/LJ]LR&2[Y'29SB
M.(;XW-6CB]GR?)6[D1)K6.MBU2XX :RSV^F;/.E2&JI&J#W2A& M2(="(88M
MYP)$/L.E:L.TU NGY&&',PS/G<C,/J";W>KM-?=_J+LC\$S_YX2L8?O ^(PY
M"QMO9H H;T6IL>:;/BQ'QLR_NDWR;N#>6[/Y[KDX=(7M:5GH)Q<KA#98C\P/
MU%=HM1^.Y4"W;V+OZJ9*$G122%+(2Z7M17V5#L43 1S.F.Z5(95#E(DY:<UQ
M/\W.IR(9E\H>;+Z;XQ!0=1[AA#]N'B[YXY,!Y:H.18'HI%<4/OSK9A,QN:H\
M@U^[\;<(EU^!W,52;T<9L$7:"\"WON-X#G13_TN^2:Z?ZAY?F?[_BW#I)&D3
MT1F)1*%LE7"-@H6F6AU1U!93VA[("WN#>+SLXLS6?L$9?I[WU:-5R?_QW;U1
MH$C92P_#H#<$9&PU'HO/J*1AI!'PKD9R._3IE.CYOX.T,/;U&2OFQY;*]:0G
MK-=N79ZX]ORNT?6!:]'P>"K+06- U'RF#]T-EMR )T,.F\3]UT-KPAWV6GPV
M;EXZ+G/_XX3;Y<L61_P.?@4OW'E=91?:+Q7N*]-2BF8:E/2$_*SLCD7JQ#;]
MOASJ[*U.H,%7Q[OS^*O/ZYHVLX:^CFR#IC.@^] T%\'GJ1V-VZ G15U*RG_?
MKM2.\BK#'+D^[I9<1/?X/7+ &BQ7_N96JWIA\$(D_S6DFC3]%DQP(0B]Z$)'
M/FX%O5N[G".6#O]6T\*-*-C\H\=>V6(PUKE/UTPJ(H*XO9R[@-8VZ, ,UP30
M^0RE0"<@K*>+LG]<)X@#'#1AZXKTM[5-LV\SQE$&IG;1#AT#/PS=V5"&.1WS
M]*)(1W*S<3&PWJ[>7JC&XN4=<.WY\*3^4^*4SZ= V2O(V@L/WIO%O539U6WI
MSZ405&W]WN46I=JB_N@,E.M^1JT^]W;BIO_Y8$%J$T ?L;%)1##O,C]/>.6O
MH&+H /&_LWI<1IH-WP78$V4RYH\TZZJ]TF2UP=R_6:WWSO5^ZY]+[C?@-<7H
M3!ASRMB0+O"$<K?7'E]^A182S&)HPAAT0+E8X]9/3X<0]6A<5<]4>=+^S#V4
M5C%__0U7H<V;QJ)9PF]K-<*3'H)9N7&Y7$/;X7 J@[G2(O#_,9_H*<35]43#
MK9O=>9&K_?9G;P/KW-U ?@=67@=U$JD,-)4C%=F)+?[P.[@>V83@RL4_(_=/
MWRS.&IM.<,NY<OTXO%$WXUU=I\VY2C4"QB3O=Y!!S._&%W_>;54^.,L.+3K\
M._>,P^Q87C04IMD0*2T0A;.SZ2*=Z,?NDZ0.4VFZ;$$LK2\D6/P,MRMOQV!$
MG+?]&<SNX4Z,YM>F/(. G@/>N]?LHID,#S:TTTR17R]0"[R(3M;G*IYIYZ!'
M(O*#->(N!U0RF"]6G3WPZ3?/]!\&J8 N@ Z0AZ&U4:U:YM,.[9O#^IBC"!S]
M("$V?)/\IZLI8MY:;R"M0E=B<N+S68/V(_N;-U2R6WG>_"0T#8;ZKJ3))O-4
MP>-"KGR.-&@$8CG@%:KARE3X@,Z$R8!^%(R*T0CH/]\<7H7TG.53Y[(V0IZ_
MQ=K-CM6Y+Y?:?7R09@:93]TZDYG-Q#L-U^5A92<!#WIW*QA0)[4S*5[+,PN=
MZ?Z=+PS<%3?FXZ,_%!/!Q(^?"O>E2=R[]DI-U\;00;FVUH=U17DI%9Z1BZT%
M,WS9CP>ZW,=*PZ8GH6T];(GV^3^,>=M]#.4U?8V;4;H_WB0TO]7_O#?R^(/@
M6+K_BL0V2$P(JK02WM])#+4KZ/%&^YR2;5"(\$%'%_K_*'ZTR<?V':'.SBC=
MF6@J]\[FL(4:%[,(J;? /*2/Z"^G[W38N]2V%'V\[EQ=^>TEV:76ZI,PZ[;_
MM-9WU#^_1[8\\<'>)K_F098#WB<'RV]2*8%-YG'=:98&I7).L1I_.J<F<:I]
M1U>JFI1G(:E4_$"G3B*IMOLS533(/:DK>. 0$BX894<E:YM(^E"Z4S0KCU5V
MQ* *:\VT1J7H^IK-'=52Y3U5V1Q]8)A=Y,"&9#3+T;1V<7)'\,98$:\@)841
MHD& F<5<8I,2\KW9SQW6;W(1)WR/?TC=]=@N+HSK+NAVV0;AJPIH^0QP!Z6T
MG7D,(35O2SH 8&P3C8J'%6?69M-IS^[EB7B^H5^8Q#\PZI=HQ?T8Z+ZH6)JL
M;:;*BP8>L:4]V7MSM--E^@N3:?FF)^4&F)656D?O3L:GW=+U/_+YL\HQ7[\R
ME4I42(M"T&DS]G"L1A4L9'A,J\I*PW"UOM0KN(?P#N.)*YHC9)F=XV>@C&RG
MJ12QUAA_C)DA:@@J(5 -EBL/Q"'\Z8FOM9N-Z6ZO0"_$M9YK1J;XW+_[_.S,
M[?VMS_4=$J B!(?QA6D2HX=>*4>'=P87>+35Q]1E!VP23T913U(\OC7&/W?V
M1DI\43^PSUYWBH@=)$WG80^9N-(=),9YCOPW/#OV>=IF0H1QG(<=B]&=N%(1
MHE8XWCYQM GHM0O#/_0X89N996730*<":B\(E4%":=7ZV]S!*5 @!BSZAH>$
MRS<;B[<.$8SH*6HM'IEG>DX^2<.H,*#8*LO &TUI#>$ATBEUR9ZMW2VX0 VU
M(9AQ>=/ABE(9+<?G1XGU]>?@)0Q$$S[?U7U<>:#B+KN4,<RNMP6"2#(F<:S-
M-N(N(.Y-< QA($%?HCK8?;X$??3<*^UQSR=7,GW>@XV-^F/O\DX"Z4) *Y3G
M5^ 'CB'C2(,.CR+Z+G:1N_((R2-[LX/&,H^U^S9;UDMI[.FP37RU^?3',X(Y
M9VV$=YJKC/1D>;*!ZAGFP\*SPTC%0*%S .QIK&MLD42>7;#TH;H''J>?I1;[
M1N^=.^KBT/SS;NF*-7>?'?<J:F ;I% \VNP\TSDL.([H'X"RNE,)Z2;N09NU
MXRHA>9EUF?\<(G2Q,FNJO*^9>>T;<W3*L78"XI:WIBKNC95[>5"T.L<]:*ZZ
MI7)[;/0--\U<BIEQ2AGN=<]?U%/-TP$[-F>&YL\H8"4.?(8>A@3I'$6@NRF_
M&PV?HFF^'@Y\S#D3[2_W*(B3NC9'MAYY0QN+5';$@]MP\932E746E#/+=DEE
M&]()_94TCQ8/:WPL5=*8F0G3FO>\]/5,-5%D5CIQM_H1)M2R76A^FH#,&9TT
M]$%>+%N:DT'F1>-X1N23(RN5U+:QO) 7G.F[-XE]NQ]J,C]S+_D=#_THY LX
M3]K6?8R QLCFH3M/"XEW#R^\IM'PXH$IQ<3I1??7; MIK\HO.3Z9ERVMLB)Q
M V1E_;2W_-=9P.L@"^36,9?>6#OM/DZM0:G.E$4O;?X=M;? D!S<N55"-1\(
MGYG!3.!F0K"L3M1I!)=&?8(48VV#+H\14G%BT%2M,.@(_*UV!;FBJE=*,_KX
M@29C?Q/).1(>UPU/!>]"^^M0Y&@VO'_9:@UTB8087*(*BYPZM3(1+#6^9'@V
MI[[AA5:BE5U%NAH:4145VAEGRX8*1,<K@QJ[$Y#.+#*]B\"JIQLF(8U@-(_*
MH(DK\4XU8Q5O=@7]O-D_(9]3?QBV9;? O.U]U%F8%*]1EJ&U26G-&G'L72YC
M)A%L.;=APH 4,.PT/!2X(5JQD')SQM8',7;J<M=U9=>39Q=>?)895!=Q)M7V
MX;!,)[M(O*F"UY*=\4O'^725O.8&;[C:?]D.+7.H1>HK_&#G,DF<%\<]*!C!
M[HX()!H@[8$$?[9MAQ9M0'I12;DE9<;^7(^_9K+^:S&%RK**Y((/V6D',I\A
MZ__/)R('N9:";V#6=R4#P+4"'8+V$1K[6O9%!*:'"Z9 \'6MFF;V3%UD\]8K
M:A+WTT2_5?S_99I.E?OKH51;RX:&&#=]L9C@ 7^_,8I%_C#>)W_4W7 ]L%_0
M^&#24YU8>0SR62(MALK8P;;BR+.3DK7WS+=4 JX=-=2?N\4XKUR&=@?NNP;2
MJ@\%[<@*A;Z169=8V08)XWDV=QH!B,\#/X+!K*+?#&][<SZ&@V8\(>ZXAJ76
M9]UU!O'Y?)3[GYA&ME1J]BQEC?MZECP].'#Y7)I4(<?Z3XG?X>L6M^_)+&R#
M9$D!DW+3FQT#2872(UH;8NE.=)=2LU?O7DI>O:9GP+S//*VYS_/#([R4[4'=
M+-.=1#%A4+Q!]8 E4!=1/[=!M3<$9X2ARRDFJHSJX#VMB9-A(A28%D.M,5%G
M\DM3Y+?.>NTC"[LS.R7'BD]R'EC_T5WL,1RUM(LIIO+ IHV3<:9<0]0PEO4=
M=0YX4RSTXML@'W1;'?MJH<(Z:IR#82@^Z]0IJ+^[%;VN6ZNU&=;T6L(%UR?\
M#>B/$@_1]]!I:/SO0E.EXR.,<.S37-U%E[/!KBZ1>; OM0_YU=Z)_TI<^/F?
M7O[#?:!C=4B,.\!DZ\P,K&"XIWD0S%\&*Q#)T-(GD,.?FMPJ5&Q@NP=F';G[
M&';YZK-"+Y_,'>)JWPW]WN4_*!'AO XD>06$&;Z;,!BMJ*J<G3MJ'P7<>->B
MI>Y;]2>@X(_QEH!X'9I+W2W8QW,#=DT/I,6@>:?X'M.DUDI;&A%'LF@ 4N'T
M7@_8]1.1UI7;((1?TC?+9Q<??NTXK7+;A?D9\I JAMJ!;M7Z34HI/#XJ.+EH
M=@I(H"EJ.(SI4P\&A=G1Q>U\ A*(^=['$NAI]:O3EZ1.B/*">_?'&M39F-5G
MY]E\Y=^97QG+_9YO*A?)UY+9.SG9:#NTN QS&++16(-\%NRLYK\BA> >_L$(
M,^(CJB1JKQN"U+&V>+&/^M3$A9Q.1Q2*F-VJ2UR*5 DY)W?!&7G0?A\3X@,!
MU*'M Q-REL!$)6*)VY&;F^?0"99L?RMF%Q)["JESKO_89.LQ^[(04=^[:TE'
MTD&@7=DK#;]M[#8W;TG;CMKIQ\914A:M+39";0533KP&10::9/Y[*(47SX9V
M8U(@!'CK-FB\Z;-AH21;I',"+!EPL6^54.0!M.F(D=($K0_&0JU-EZ4&CCR-
MQBE\/*?WJ":2[#G-?$R2(^Y']4/QEDD1+'\7 ,)"7P,"W_>5!D2A#VDU.XLG
M?CCV(,2 .2__UOINI.:3<ZM/%3]_/%Q&O-(?I]P7DCO;PHRKH@\1-FHB%\/I
M<Q>&EWXZ+?MKP&",\*FOE/(-OCWNPB IT$ZG$ZS$@[%F;(<WQ+"2"+"0RD+R
M[#(];L7A^M;N6O48DR+6I?X3G\GN-S/C5^J\$0K%8RV>?(:UC-(OQ,D+CP0&
MTFYU(KP]-P4R4%K22C*+*;S[+&<L1;W#!:6T%I&^J]TE;S*A>V+5XTOS2"5S
MSTK3U02/;SU;-X6?%W.0 ?N>26XYOF1EQ]QW6GTN=HLR"2^^,\>X(_NBYL;<
M'-,A1P!-C=''36)%A-BL(\\[/[CA((N "@Z1)*=:YZ&_L)3K0=#Q(1^,#D,2
ME'5_Q\^B8V1KZ',(2 \"!.">@*M+6R4D@Q1*,.UH6823ZUA$K['&N":)IA+K
MV6:LGF7@NO8Y,M+BWD?3O;LD_(%4[JYEJ!AQ'\\+<&"ITQ^?"T*/YU7ELOXL
MN&49#QQT%Q6A5,XT!TXAWC3?N%TR>.-0>^C/;WH=5EF.C&A5TGAV*I&AZO=[
M/M(K-\VD848QQJ*%.&3GX3-5CG*."LF@Q@Y"7T-8]F+@70+A$B>XY--.HZ20
MM_BO><[TRHM+1TP,H^BB^@/[$"]NDA!KW6$GXC9#NY4N77YX^OB"1M-/TG2E
MV06R'N8)2:)9O7A9(3=Q!:4&;-JPWM56W+QZ^U-U=<'KKU*7!)78VW;CQW2/
M+<B<2]T\K/\@4)O\8&X2:LOCX=Y<S]EJP,_9$3G_C[/O_DOR^]^G:65F[LQ!
MI65F2J5FYJ#ERI=:F9J3RIRD9.9&J,R]4E/+1>7*20XD)[DS4W.BD"*X<J#@
MP%L9?NG]_0\^/_#C_7APGW,]K^=UW>><Z]R=#?88*R<NA-H:H)#(8&XF1YM/
MO)\8%@D-,(9-1V=S6<ADF:$Q9T_(%_U/W*K0 Y;<,F\U;\%HU:&P,T-^RB_]
M-QG@2&B55*?0[L%6?7W AWT1P!L J2JVGNJ!O+FI\((BK:A/OQ!GZZN3!I0?
MYYQ_'>;ZITA@IEF9Y'MW/I_B^B<]/UW%:X(U_V*@:.(BP=%KSD5J$1VDFD&P
MMR6,VJFL%;: *\!A!"\HF<SZ4@U$U8WD?YS?W!:)O84?5CM?9C#H$67P*^=6
ME$ORA6_7VC[/)!S4#>12^#J!M@(HQD'!.(H8T&T'M$X^4$0< 6*F[&J%/[>Z
M%<D\H$9(^$B.Q$"RLQW'LJ.=OXL).4M;F'[1&OEIRH37],!#V/EGUTS3Y/Y8
MK1/SV:IR$_/SKCBH8\G<RB'4F--9((,@KMIPDD'DB0HY4_'QSHS"433U9,P@
MVU#VVNK$5G*')%1-^T,#]CT^_>68MZY]&Q34 .4K+%%N/>\4WQ&TPJ_BPWE2
M[L'B&4=>'2G1QSS=U/K:I4&*EEQ5J'[USC OZ^R]BS"MQ8FC?'NWAV7._;RN
M.8+@7)=/8:X852?PMA'Z"R],L[5M>E)*ZKX<^A7T."_'I#A79O@.YGYIH^=@
M.'D]I6YI\YZ=VSU8K6^B!<]&>PPQYKE=ED'96*B%2@*$]JO0MAW0P7D[F[ =
M4(VN5DDLEMX8P+:602\)JUWXC<[]2O&9TU9>%:F2UMY/T$5[KXQ!VHA07&)L
M@P]3;!(?WW054+ISP8P:[]PBK_JM>KCAH+C_I*[_MN?5K<H/[TR^N9B LE(J
MZ\T$:1:13>=Y_3N@BOTXJE= VX1B_Y,!CJ77D4^T4X4V'SY]-79P3+7:[_?"
MY?E^065M[:X,1,:YT.#RB:6<>AUV8UEH5MJ&Y7A*HJE>J"K>@FCVN 9Z_0OV
M%P8XX_8='*DOP8W41"1,7!C1-<@%8@TBV_Q% M,H]S)[&;U9:MXBR3_W0[S!
M.M/W'OE?,K;0WMU@-*7T:AWV^BKZ%4J)HPG(, NIR]\FE/H;*%$H"--9=1FW
M=^V,->WWN+&+!T/K5,?+(^8"/SU%&A\,A@:AS+V[NXGV$PO*I*4R]K=>V,^Y
MM6D*DQQZGFQ3P38Q0/D"-UEB#"B]A#_7DMRBDT#\D;*RP(#;A-_)%*,PF[H*
M'#Q]\$[F!TD!BXO]]_?^,7;LZ]1<QC",O4+NU7/?^0D)WAG"R3U""M.XB%;K
M@(!-(;U?-37$\J^1_M.I-\2#]^TI%"\J=R_8]+'$I\PLCFM#K,H3K]]/CBO%
M.?PAZ&AMVNIL;=IA[MV%Y>R \ &O><=X_02<?N/'!<IAG@:J_S@QPNM\\MKU
M 1QV:44(N)YG^(34I4G8OE],)H?<]L\IWD_:PK?VT" Q?):B' E4O]] U-53
MBV8;V0'VYO&X1#PLT/N/ON2$3G.2PK6!*[92<5\4XN[E!J>9^D]YC_C&079
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MEZ6$U5L/7[HYPQU3M+JK]/["P%ER7,;"ORLNZ]M@E?^N6;2_SE2*46(:S.R
MHC8<G90?7*\\5HYUS;[P&!^VF5 I\%;BG*+;@5N/[@="Z1<9.GR'49W.D3 &
ME-HE"9[]R.L,Z]6)AU>2)7DC<7D5>,:/!(GA^DMAMS K'S^79Y--RXI^6IMM
MU/5O3BS,)L6\6*BAER?B%LX6>A?W>4\$8PQ0?'52O<)17TE 2;H31M$DOH.I
MY-S)D5EK&F.AE\9_F_(=NG/0^U5FE?)F57T<V)JO/T0XOD1-;"RF"MN"CK*4
M!/(9A;34&DR1V<D=T%ONJZ]U[#-%X,TT]^_"W#&)YHYKY81)FR6720*@C(C2
M5T9> PA*T9I84?<<[6&DSD?[]O+Q,<AK^M+T ZID?^NI<[^>5589%_IZZ02G
MW1U1[;0*TMF,N5_F,K$V1B(5#%JK>Q7EZ\E]+B,TC)LNDGZ/.VUKX&JWA0U0
MGDAA(!/[ "G#ES;=;<>GX#!&&1)6C-1A[J_W5>HK_JNE%=$A4XMY.^' ).EH
M7[GBKY@U!)9'G5J<N,C8 74@8H_+5X1^_)=-,Q+/2#=D[LO*<:@SC$3XUVRF
M/S/IOX6_].?EUC$=XQ.O+-(_Y MYT\D!^\ $TO4F8AJGCMB"T4^CS/3T;#XW
M*V<E_"&A/MA(L(V1_W:4A@*[IJ!R:#<TG#_E"KF.GCN@QVN\/A;AS)F4[K7+
M-3UDGWJXLYX0$L8LY)<T@B.F1+-HID@CY5*<&,M%M#YYCPD)IMR;[?'Q=?GS
M-0UKDK9*"1['I-^&G:H#B:?I!#O/\P=7@/->J@/!%O.SX)Y)_MINTBET]6MP
MN<O:78O9LM/ 7Z_(Q,NGQ&>K4S%=-4T61CR7OE$TJX5?2][@,8H)<S;^*<F!
MJ%.VH7?&I&&L.I;O=FWWU PK21\NM0I04'GHMKMSR8-MM@-J=4"*6DBC'Z-;
MH/560QI]%=PJ>B!;=2B-O;ED09A9[IA0C\MR;;)E(-&,9A;T$$ISM%T1*L0[
M$6AO\)NGT"K-'<GT83UPKAR)F7J9MZ6NM2DGLS>.^)8C,81M"&6?XAP&G(_4
ME@2B6S 2J'.!,:U.0R]*JN":/7E:6GA!URK(.35I*Y-[QXK?7CHH0;;+L)HY
MH-900U<+[ QU+%W&^\.#'&5?*"%U/2W*\E',Z2R,RXLIMYKB;8/<#<\8X,@B
M*^3?-7"1K!' EHIXXU7L[B0,X KA-<$[H/#\86_$TB;)=HL):ZOZL2+[Z6O<
M6/,] 3D>DHO1%YTG["=,)M:A.U4E%VUP0$DY2?B@4HSBT)PSE7YNRM;^LO')
M2P<>/YC:%[;WL-P'_.&,#I4/3OJFO(EW^>*-$ GLK96ZJO%RZW?;G'4<>>5S
M4V9-:G4 C*^-<#;TZSN@P]U*K3A>*X_,9S]VA_^_(_2)?56A870GMVVC;?S:
MY24V1LUW,T*E[%_F@7A@IBWSEOXI1B+G%"O8O'@D0[./56I#(->\$H]M3'KY
ML%L2IKS:ZAHL @.A1M ,"THDH8(0CW;+-OVNOKAM#X=)5E_9B+4O\Y[=5@U&
M3WQM3#J3]/+;L:<-CZZ+?E4H@-@B%9ASG9!PODG2BN#)+.SN;",2) 2C>']&
M5+_8YTE:Z!7_@5SXX'PX<QLYJKC;^#TYS<R3J/49_]51<S"[?JS^<JT]+M/&
MYV]&HG<3<88EBJ._P%RR(?PUBN>8\#L;XO5&J',7VX)E]8Z88\W-0:3%L0,>
M3EWI>.8S[V"Q%,J^B6ZUX?WB"0.QW$0NWZL==(EJY/6Q;4A-W6N5]#7_,SN@
M^BRZ7+#-=W1E:.*K'9 KGT/M5M[D R9,7Y8OTR:F0;FD52!BF7/]3"U56+1;
M7%BA6^Y7^.9XIVS0OD.@O+"L\F4$[V! T032[QL@,RD<9V<VDC2I!VF9LP7\
M\AHJN@H".[9) 6O+WC')=@_V[(\9Z]C]>EHL;OQ*D5D[VH^"9VJ7N9542Z3Q
M8C^4>IJT*T-7/(9W0,+I_4I* ;CZ>J7M6AJ</0YI#0X?R7S$+?EB3S91+4O/
M^1I::77O'N1BT_T_W]6FOO>:W0&<L8LH92#H\X*3(I^+.*?JN!M9OI['H>3<
M)MZO#^^D(OOB]J9[3 7'R3ZQ5J*K=RY1F'MX[8U&.R"3/&S/B@2JFW<9&&/+
MHG[5T3A7ZP *H]60(='85#)I:B%A2IWGC<[+&*$;I9'<J/I;07\.7CGVV/!N
MBK=I5>3/A=QYGCBNKMZNW;$QZT7L2L\:7FD'=!J5 :/YFVZX-C2166_91O04
M/T8*6PHQUG 2',.'+(JXB1]OQ"=-+]'Q_EPN$]\8!.6(QG8T"34!-VG00X U
M.,;N\,31X5]:$^+,Q?0AI-)L!U:B5#%^=M!=59[EWZRM<,)F#_L!TFP8=1CU
MAR+98/^IX_0(4HL--?LRMOO5RPS5&]3^*+UK)T1U7EG9W<ZB35148XKOSV@2
MZ^QU]%D25^K>)MO=9L*T[ET(U=$:M+!<]E1AYE+[EL:9!"<&)+))$1!FP9DO
MT)*:IG S)^'H 8YW==VW$=.G[ZI9YHMBY)\$Y9?A+6]K?\S]A9$M6V!'"!YH
M$M2RGV/ P$X9=:Z( @'F@QV%U$85!WMA(>"<QV.W0UA9QAZ_$\][:O.W+ Y_
MW%=<=/#F.%J"!!\L'N#9Y;L1;IP\V^6K6N:W6;:!MR_10D7^30V"MO>1PG@2
M;G0]1B&5P +S"YSJIE:,KD:19]"NW(AQ/G"M9C#J*#HA]/(45.LV9YJ;W:00
M2&@'5T1&HB06KN*C&A1RX12Y62 T%._ =F3%YA5+][Y/;VYZ[(A,.B5[U%CV
MJ'#% JP"PR\#9PB@3%GJRT/J\88&=+6+KM-L"5^5AM4@9:6S]KN::&!]HQ>7
MO'=]US&)-]_5ZWG1W(.;'A+$F[]/K$FVURH.U3QXNS^9;:*U>?O.8%.%=X^J
M[KK^+*!.HX@'DIM50FG_4Z4M(J69)5$)Z=P2R?RH>]8/"M8^[T('';,AQY73
M"]_"B[$_A ]P-/B4VL[8PWK$Z%ZP*TA"E"*?,,]+:5WU&[0;/R_OQTQU3M5_
M CGVY,\WA8"[(XUYR$O]_P*!8#70V&K$&__@&@PUU(TJB:5U,A8]I:Z&UPZ?
MS[\KUW(P>[2^B!0TC;**_?).>P:'Z4O+^,+;\%OL5W SJRO/TB)\'LDM*&OJ
M@3EEVU/6[6(X'[@?H8]@^T;Y7D!A Y$ 8[P%"A9IF%A=99=2^(1B)NQ;.ALY
MK@$YG?=;(V+/$9CGN8\N9]_(EJ$* B5=\$! ;I?">9^"[#WJ8B\_WJK5Q-U&
M]>6H3QSIPVV,L0;+&E5=F7%#[TX+%?K7SW?7K:P$H.KS<08H3=Z0_BZ&0%M?
MV(0ND#^)>4.0US\%'[D 6[@:T $Y&EC%OJ3B'V%[[(_]J;[CFM57$,JB8Z;A
MHQ_!&8W/(:]94#R:7LBXW$?;-XL-S5^$@>@;CBC2X-V<ML7PN<07EKKG*X^1
M3/941DB?5>\4N.KS;L 410#VSBVRCH\%P2QOI\4B/A.H9XT&Z84$LZ>H+)L4
MWC ,)\!1/X\Y0F0+LQ$\L17IT4 C'E2_AR6,"\+,@Q<HO\A5R\C:OHECV-?(
MF^4+Z*__3KV1NJGHUD:XW>\&"%7/K?4R:>\JI>LY3P(_LO?B^+$GJ=WG/KJZ
MZ%3F+?<^'Q[XOS0;M7?WBRW1KO<*&KAS^X?K/!3+<U;,RC\'Q)W!M.5JS>39
MFW/]&\L&'0?0G] 2* 6/'9  [Q@0VYZ!S>9^H&9?GKI?+Z(V?_A.QX!^_Q^J
MN4!9$'')DFT(=+,^ ZX3*DRC5FU]F?F,MQ&+K3384?N%RD7)2QV*IFD/K)"O
M;T*61]/V8LQ]T)-?, >14&8DZP#PR9FF!V4;$F\SN+-5GCG(MULV_K]-SHNZ
M7K[G7Q=6/6-^X;JL32?E -0-(\@1(!(>^C/2$KFI7C23%5R/#?><+:\?[?OI
MQH IF_BXOH%0]_YZ JCG_-79K"DUAFEW9J83YB?1I6#9)M[:^HV+_+ B9^M4
M-D%B#KOI!1G<5ID4)O%X,AC@K$7[7^<D.WOT6/T]T2\+;\9_&J)R,QCT$!:$
M0?C_RX75@"_[EOMFCA(LS@D\B-0KOHZ]W.C?,VWJXXUY)"*MFUKS(/_BF_NR
M1TRZN@Q\\Y4^>ZOL@'9G&T.XIU9&QC7]3M&VG$M&*&=OP-BA33;^39ARB;6Y
MEAT06:<=?'P=(O4GT(9:R&J<"T,I]$W"ZQ& \6/\#NC6:^,1+PMDTMDMB<W0
M+&_G. %%8IP)^PK@QCNDPO;A/*D"2K<GBO(XRNE&%8RF2$3IGWG&O)?>^]K0
M6X)!=S/<DJ)LO$'_/9Q*S.(H?=0*A[HD'IWW*G%<["G@#:>-4$A:]PZJ0?R=
M[+$?%(Y(DZ6=_TSW1R9J&G>@/0SR9\Z]^YRY \(_6:[7.^ZYX&ERSOS.WXFF
M=PLF>8V/2SDU'HO;= /4,Z3B#NAU*"# (G++T9[:38HWR^ 9^A^FSCX<K/[F
M%UNB8F^:\D@DI/%MG4"FA\$]]LM#AMKE-ZF0:#\"Z28KE)N!$@3JVYI.I[1,
M0)B0Z&J$""Q__>TX7RB:.H1F=-B_O$F[(WXIXD^WI+JE^5J<%]/$T'K>0W&B
MR89$6B=>_]G_'.VJ9M*$3[S<W9>Z88VRPQ0-V7SG2TB7OD.\+C##!GL @#5K
M'<_'1]A3T_)]/3X[+EC"C'+%T*!'@O^MG.L\*5,C>>(R[6*RR@@?FAD3A6@J
M-'QB'V[$#W+D[PY(7#?H$;71]^[7;VS-EC%=W]L,Q8]A,O\]?K )N?)8N_=@
M@\<WA)9+J.;<,V*H&I;WF&1I23JW3)K_45A &B-S$DT //L.NJ6,6\@3YVCQ
M6MD!G//48@P=7!,$&R,\PML2AH/<>BCU"(K9M[Z>@<;'!&V.)1L,0%A\F_<Z
M!=5[&7I$8;B:NW^YKUW*@]KE9[)21E\6,Y<IB*2+ZG2X_(S859,<\^R([QJB
MI2\<)HE^BHC(I7WG9C4X_LO_/A52GZU$,\-VO-<(B3]S72,JUN/A[3R1&]>O
M"[XV%DI9>W+(I%TS(!=AAE)63+>HW(0;E.//W0T8Z8;[+Y!#;4S']/SKAGG#
M=V%B?[=7H@ENPB3P9%\;(;K;@]J]$CTA#-L7^-?$1RK)J\RNC9A6I=[1(T*I
M6;U@%;7U^]!6'ZTO3C>H"-7K),F4C/RTF%%3Q+9!FGT;PE8O"OE#A2<6KMYZ
M5C=/\J08'\#;JM)IC[^[O*M[+3CXSL[?;M%+TZ$766&GQ%3I\<";5CY>QJIJ
M--7I/-?6*JN!IX3 BJ$/U K9FM7)S@%I^16+KYP0;#E>/XPQ JU"1Z!.\#OT
M#N@ANL5(O)(;1D=[LO6[\F+E7=O&LS^P<Z4[GQ+;T5\3ES:9<%80MV"]BKH#
M&B/; &!&X?U!K!?G[B.E-C9"?+0/FMI$6KAB9W%9^4WT3)H9.<W\FF#&-.I0
MLQ\3P;+@)J*$)A8R>F,GT=$V=HM @N-EYM+,$*U*2\RH\(/-X2)UL6\J^UUN
M"'Q!X@>NXKOA\_#:"1;!>-S/<\3&_[3>5HT-JDAEHZ81:N^)*KP+R\DY <A]
M0C?K[8#@0DK\_]32A?."?(>*-1RDJ<3;M PNI$NQ@D/;L[\EJXS>6EZ1J?4W
MW*KYNKE'WH0QQQ)G_.^VVH3?*'W[P-CV-+24KM+D"GU<JJVKO#?R-OMJE4%A
M.\@'A-?YS^60Y.-ED]-17V83%8IYXBFA&^]HZZO/$*&6?]?]<Y4T39!FU?5>
M^\NWD?YDP[I"WXV,&,X4W\6ZJ0JP-OC C *:H%']BZ+N4A1!CF:1)TH>-^0V
M2"5\R^QQ$<,U1"N<OU5[L-[C\<'>?J=0:M]H82N_E* /P7'RBDS#^BG5$ =
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MWA/S.5>+.J@;0%/^\MCMMHIQ.W?ACMG6,O'62HB!5Z<A<LC*5H_$S@@.>K%
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M7[1G\L;'$')L1]!TQ^8E\^7I&@&F\^]# *J;"D[4UT9"N!4-6@S*'4G],XW
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M9Z#/O0'E<([IWBCD_).D+..M8]=?7@/Y@QD&9IK5B#%T.\NKR $N!&>*M5W
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M'N^^#.7R;7V7<O9[?+>\_7C1*J5NYEUZ3[DUO>KW&+<8.IE+ B^ELJV0EX
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M761 %A;1HL6R:J%79$WSQ,%.(4S+C<_9]\V_0MS9A3"6.ION.E00;2_A? ]
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MX_G)KBVG'FR*OA<?^]8EE37>B,I#H2Z%C3NVCQ5AO(*AMH) -T:!H;H&H7P
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M0CP8Q)(%'!'7Z1I)D6%4[I!I6'T#3%B#T%>J:L'__5=5U%/ZRMW>68RT&Z2
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M&&UPC[N6#F X@BR(.QP563)0CK3[#G/\_<U6DT;ZZGNK3S;8Z=:$@,&A@VY
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MD&QX-A%BZ-_]>W/!W0N\OAAZ60X#R>>!>1]P'PCXJ]M.[@-\EXS"C:Y6D)=
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M3 6G8W$<1_Y@?M_R'.>X944$KMMIYA1SH1N8XJ5";+WZWLTM)G/XJ_X$T^+
M89^5]$LC#D>V7_TL_"AE:CB0G\5N*VR#GS(!:5YJ#AFSVA?P")\.\AT?*RTJ
MAV[B XVBN6V@ORUR,Q!WV;I07ALSD>7)%([E"@4.Z&JA+)EIB4GN-^P^18Z2
MR)6?C]VR,DA=$7J'@3,Q*];0OWU(J.#X,XT_L%!0LI/;FPV%5N<6NU&#Z\?S
M;O1]V"ZRU>B8:7F(+KA4DT$B>(XB+G+.<:^V$TL2E%4H7;DK$:.OCV4LKXJ
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MX::>5AM:8)4$7+E9 =/Z'H]D3<C+)RCG?9 '&U0U\- (^<HEPA&$+<<, 6[
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MB&DOWONG=^)YS4NXDKF,B++EP?"@L/Y>O8VB9-Q)RD4*_,5YIXS3D[N -[L
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M8U8J<T]1<I>\^O+IP2H[PA!T:W,5_C@Y]'?/<CYW;7MIZ3WRLR"M6E$2<_D
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MNO=0TA>%3./F&H_()+7,*0]+J:K&!-T#AA]$/@-\B.J,BWP1REO^5R(2"#[
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MP+4#7 K(6,"@3/P@CO5K/3#O:&PY^=0V]$9,\%S)>:7[.G#C8HN]%L#@!G)
M6 =_Z;<D!RW1K\ 6[/L&[/O!P;:XM!P0])%N,=V";W>]V1.]SOM.VS''NP#M
MJ>W.C6C?,7J>Y72IWC13:ZCK^7Z0S\LB6S4W^Y$?LX0AZ"4>@DCZ$<0"!Q S
M9;ZI<UTL$J-VS09S3>T-T!95NVA$):SE6:X#6\/CG!O$AB;W/;!J.0=(,C'
MP]6YKF.F<8]VYU4^.-T9?*2'1;GU075&(A>W"Z[O*L3'9=[BLN7B^ELN956Y
M2_-7]1_Y??5.J?NW6<@8]T6 (1'2ARC$/B3()U $">74(['$@;'].:BH4^.J
MMO_Y2SMYY4@X?P$:E77PP8.2!:P>Z0IHG_.'+)=\-7\]: Z[ PW88F-AGPW[
MW3$PG2?SC1CK,N(N/9O;T?HR*'5/+C,HE:VO)(!6&I1:V\00#KO^%M;\9+X'
M(]G^;7(XE]FF<VSK[T.ZU(D*[>\#W2CN*O)QE*7H/$@,*\%XQXY1D-PYI(PS
M8[\C31,RH<,)21)&B"48^DRJ(PQ6AQD<A E, ATB%1'L2:NZA:VQK<R T4J,
MS[<"VAU6VJB9'4YZ8C&T#]H  .MSQQ%5'9TSVB./>JXXHM+^.>+8(SW#CO35
M\SM:2*$OIQ4S5"2P=6Z\>]T^4M?WO?Z3YN+3IIMYA +I8>%!=3+0U7%B'](T
M9#"0<>(A[ ?,,ZJ.XTZDR9T#M+B0:7E!6Z>VQT];_>WG:L5 J=D%3>L=++ 9
MZ8R[;$,;Z^5*O#-<L7=]5\P^6,@9R*X"A"X7:-R@(&< '@0"N1OY@LY,O\CE
MMYP^/V:<SLM;:R*\0"".H;*O&40!22$F(=8]V82?LCCTD5$GMLY9ID:X;?EZ
MM&<Z +&; 9U!,S"IM44;IE73*>5=M&LZ&'O\EDVGU#O:MNGDPTXSYJJ^"CLY
M+9O -(]Y(O1U;W)!.=1-%R'&.(!>ZH>(>"$)(ZNBS/8B3(T7WF^*,%?AOEDC
M>BN!SC(LL,>ZF-E3PZ(],-6<R:C;*-'*J!LDUK _B,,FV74),(5D.P. #)/N
M3$;J6ZY5&5I/R\77U9+_K32MBKOUJEC1,F]YQOR$2.JGD#(20(0\9?A(X2L>
MC&0:)BS@D6$7$K,);7;?.+U'ZG"_2FA02GU5G5@*T!+<MHAK)^K=W.8>R8%Y
M[%((>Y1U-4'F@N*NG<./7.+51-7#0J]&G[JPW.NODNK&#:4??/./_YK)7#O4
M7^O>S#Z+$!6QA!&GBF$\PB%.TPBB!"FFP9[G(:.+\5ZS3\VT:O6%W$A:7F=]
MOOZ]9Q58HT4P,Z8&@W9@_NE"=8 FVKU@<ET\UFCNMRDG:P/+R0*S5H-<FDQ\
M*F91YYA\5MJ?^/6#^JG09Z+EHMB[TH^HB&A"?!CR4+< 91A2&A(8"\%8B*3O
M8ZNV>@/*.C6.W(T'>I$+M:WKM--&M65N>3LXY%(;.OZGL8 #,_')4.V2CMM_
MK\H8KA[I NQ^R").YX(LXL$6P7E*L7M)WRB_>##(3R<;#S?EL%U9F[(MJ8=9
M&'C*6/9]"5'@AQ#[%$..,9$IX6&2#-0CM$?-EW&.ZV/W:=U4*<))PCQ,H6!"
MKX=ZJY.82O56YS))(RD2:91?-L)"_/^Q7:Y=(:,!P1WX!6K0:W2 $D<]\1JY
M]^B;%$'J"4W?3J1NRB1=<[Y^6L]UYXG/<O7;(I=TGOU7N[_X+^KXI(L"U^D\
MJ1<SJG,68I2F$(4RA0S['J2A1XB'8H*I5722K0!3H[>MQ%51;5G\"+3$]8W8
MWBZUI#S;Q3'DO $A'YCTKN_>WRJFVRI08KTI9V[$B?=4[YL!<K;ZXNJ*'&VG
M'Y<=>X)S0(]]Q^G'C_=J;:2.ZV[YQV^+8BW%3 I)PCCA,(DC#A%'#+) 67P^
M)00)/R Q-RI2?GZJJ7'>1E)05#<X176#DY72@A_4CJS^Q;)?60?89LSF!L*!
M.6R+WN[]5R6H.SHZ#X8CXNF8:%2*.:_P/ID8?,+^+OU#G>^D<PYG?IBFB4[&
M\%&DSN4QCR'UE/7$4$@E8Y'@L5&GY/V!IT8)C6QEIJ7Y#?@.5MU[_!($ACZ*
M&2EO=7=]3-->M]0[ XUV'WU,_/;-\]'?]\C4KDI%O'Y1YL",XYBR!,60A[Z
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M3HW42OE *6#/I&'7*VE&<U-8GZ'MX^W2@#\JZ89(.!X(0-<)RJ[%?)N$YH'
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MNEEL#<LQ ]E^D MCJK<C%]NL 83#-&$X@8*'"4182LAP*B&6F"5QQ"5'::_
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M%FP93?31:[Z,O2C'RL:,+D._5^T'9;6^E$$YMPLE4!F<5:C)_E4*9;)_V\9
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MUGV]+RG+NAEKO+*K^^+OE%4]^&7?R*NF?,_MXD56E9^+EDD;I3'R/$HAXYQ
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M(RO(-\*6-S/6+;Q.P\MD2%"<A#"1$8(H801B+"5,(\)ED,0,^<GL1>9L.3;
M[4F'M)$:*76&LR[ 6YY<@6X#$GC_>&H%RE_[_^AP(<S>!Z[ '=H1WL#VI04;
M35>Z$^-<,8=N8%%VJJX+&'Y:%MO *J>-T<ZBY:X-VNFIQFYZ=E;I(RW.SG_F
MPBR'JD'$^^73\W)1EF#5OEB*>!)(+X0ABR1$,A20"1Y"&L=>$'+L>\0J6;ES
MMJG1>]VP9"MDSQR(H\B:\8DSO 8FE .HG/F]K9!PG3=Q=*ZW2:/H4OMD5D7G
MA^QOL+YRN:!YMOQM43Q+GJ69.OQ6;?AHB F3G$'A4\43"660"IS @''=IH4F
M06CD ^N<96K\T AZOCF?!9+G;[^<X#/T;9@Q-%878&=5O^!"[/38HUV0G56O
M?6%V_N%^!L%'FN6_T_E:MFXQM>&AK UURJS#'P+../.$#TGDJ5,?9C&D3)W_
M DDXCY#P4F95&]UDTJEM_XUX=F:!$;YFUH%KU 8F!2TN*.75+85J*0=(B+:!
MQ9'%8#3EJ(:##0C[]H/59_OG:G[,"D[G_T?2_*/ZEV(FDHA*1&,8L50W? L]
M2-,H4$9$FL:)T*U.I9FOHV.6Z;DX-@F)E:1 BPI*6>T3-O<A[>811S -3!L]
M\.F5L7D"@8LR-O?''#UC\X12QS(V3SW:SXS0#@I:/-[GRY=,2/'N];="W] ?
M<5=OTA")4#N=( E#7ZK]'R$"]:$"AK'Z.PH8\KE1U_3^(DS-Q'B_::D(]/*V
M"SQN9+?, .VQ+F;&R+!H#\PQ2OCJ[JL1'[!7\(/6 &2+'X]>E@V27]H?1$>&
M3 \!1C5K^@.T;^1<,%*/E(.O_%&*]5S>I=K!SG7<0"N7ZC[/N"Q+8&R;P\44
M<Q8I\T?9/KHI!(\AB7T!41+X@J=!BJ212Z7?]%-CPD8!G?2T4:&='@A*)< [
MJO>L^FOM,M=[]I=U)LQ;<O=<KFZ2''X1!G?HF.%?%<@!)BW[7*!ND88Q*/HC
M96H8KH*C1([>B'7F>MB/.EXZ2&^-=S)&^H]RX17>ITT[O4 $A+ P@3+TJ3I*
MXQ!2[ON02$8]*0@.$RO_W.$4DWM!;&MT?>K;HO (D);7=+W@&9JZ[9#I?S-W
MH+SKZ[A/;]-H\+2")R_>#I_L83/^]JQD4>=R*:M[?REF,HZ%C%.L4U4Q1 0'
MD'J)@&D4""_AOMKR1M%6)\:?VJ:N)02IE'6$CQ06]L01  W,M,M@&7@S-X@H
MZ< 7)XA8F%"7(3.2C?1%/JOARAB$U:,$]$D? [3!M-Y^F8K-MPFL%VHWED^J
M+_13L==][D76/32X7!2EW^5;+LL=_I,C(^LTIIU6U)&/C6<FG99YQP[J>*RG
M3W&YV'C ;A=\^21OOC^KA9&SA*41\P($9<(Y1#'FRM0)$0Q\1KADR/<\=5A>
MKNC<T'5X:B8KAMS,-]RW_4'/ 99E2+>L1.P1@GH:6$/?GPNXAG;QM60$E9#@
MAUI,ASDV9Z%PY:@[.<^X_KASZAZXW<Y^X,*PA7>OFQ__-5,3Y?SQ]9-\42C4
MJ??(TY$*84@3B%"((4D##Z8X#1AA-$V$50<&LVFG9E=M;^+!1MCR1??Y^O>>
MT0S=L)O1B'LP!^:4+AR=1T#:H>,ZL*%[TK<);3 "XF1P@]FG>[IDY%S]]MLO
M<J$&GE\OQ+5XRA:9OD?01F7S=N42I]R/)/2X+@0B8P$)QQZ4<>(%@M D1E:I
MPV;33HV-:JFOP+=*[G('T1W)+?TX9N@;^G:<8SJTOZ>!\Y<6G+M"@UIJATX@
M*Y1<.8;,)AW7660%Q($#R>[3/?/Y7F@VUP[HC\O\*YW+W4Z>K<SF7_)E4?RV
MR"6=ZT*0.@OHG4R7N7R@WV=!+!+A)S[D*?,@"GP$F:<3_T@:2Y^$1!V\9@OY
M30]DQEY.Y#+:B*3:B&WIAMN/I;1@*VZ9367;GMC-FIDQWGCK,%( V6YSXBNP
M41 J8:%6\0JT*R\<7;$KP$K=@%+.80J<2ZQ=Y<HYD6G<I#J7,!YDWSD=O!]G
MW^=+L>:K.CQ<QI1&0L;02Y#B7NE+B"./0!Y1[G'DH2 RJGM^=/2IF8<Z-NNY
M$A#DRCY?K&W)<Q<\,Q+L#<G 9%;+-4#8_%&-'5'*[MBC4L-1M?:W^/&'7!2V
M_I)]>US=I;\5LNR3,//C1*21YT-"] V>D G$/"!0ID'H"Q;+-+7J6=(YV]2V
M\GY!ZUR+"Y<I7*N_5 U-+BEAO8^UV4YWAN# ._^@=/67!CTE+"BE':IN]0E0
M!JE9O3_7&]:K/J%V=ZWJ4Q_J77NEL2[*<B\ZES>7C_HV\D56_O/&)D T(H0(
MF)9EH:(DA 2'#,8ICA&.J.2A;2$6LYFG1C)M2[ZJ=;0C>FG,6Q<&,5P$PP/6
M$- .S#[7=^]OP?5JE6=LO2IC/%=+<$^K3DO.;1%KA-R5"3&<=^R:(79P'"D@
M8CE G[Y-4GW7%BOZ3=ZEO]+OV=/ZZ<ORE<Y7K_?TM<PAG%%!4XEE"M/4UT'M
MQ(=4L10,..&QC'F<"J-.R(;S38V::BG!\T9R'6^25T*#YUIJFY9"YR'OIJ0!
M@!SZ +3%[BX%#:*UO.!^$ QM^C$YQ7*L1DP[W\>G&M/][Z6KD"=SB+I;+YT?
M9L2>2\8Z[39;,O]8_SSK,O@\T]^@NHVKEX:A3#F'U!<2(C]0+)RDBH7#D 0B
MCE(<&?4?Z)ID:M2[R2+>"MJ[+>X!H-T<ZPJFH=WD]@CURK,^!<%%B=8'@XZ>
M:7U*K6.IUB>?M=_DGQ3F\_O'Y4)^7I='$!0A%,4T@ RE&"(>($B1VMP<^=AC
MC$32,XIP.C;XU#9U*1\H!025A.:;^0"X\YOX$C@&WKP62%AMVE,J]]JL!X.-
MMDE/J='>G">?N= -7!VOM-=A%E(6,A&D4(12Z$YC(60^]J$,D4 T03[%5F'*
M1^:PVJ(C!"AKF7:*%QCW3.T"TM*SVP^>T?RY332R%M!A*'*'^JX]MZT9WL9?
M>ZCB22_MD4?[[7 U4*X]OA]D]>?M0G<@6:A%R60QX\*749Q*&$JBC&PJ$,01
MBJ",?1\G+$BB$-O%QW3.-[VXET:X5[OMWHVJV<:_'*EQ**"1$_S02/JC+F[=
M$M8=&QAAXH@7NN<:E2&,U-[G"K,/N6*-^UP^TTSW$9%Y+D4=Y'>]J%RUY2U2
M,0N8+UD<>>JX'A.(0DPA([& -&1!Z$D6A0)=2B<F@DR/9VJIF_2GHHQWK3*B
M^EPI]UR?OL3D#/,W9:QF#6KQRR6H[MZNNY?  8W9(#@8OQD)\<;$9P/4>4:T
M&JT?5;Y?/CTM%U]72_ZWKX]4?8WOUJMBI;Y;RHJ;^3X+$2,>9 F/(?*PLJ]8
M[$%,?,1$1(5 5M7BNB:;FM^CDA446M@K4)3B@N567O"#VI/5/Y\^3_2 G$N$
M)6,PBG4SDM"+(>4HAE%(<9(&(6'J^*K,[&PIOJYHOAH7^/V)AX/_'9V7'3*&
M09G+.(QP(*!'='"G3QBD0<!@*@F5C#"4$K]&^69A^*YWBW$S[7]7A,W>U:XP
M&_B-7'/!UXH+*DFO0$M6=^]>$T0<O6$[IQKU/6JB]/[;TN@S/0/"Q'^LZR:G
M#\LO4BN1E>U@MFZ-AZ5MA4^4(,H8(I!KAP5B$8;J%8HA)0$1GI?Z?HRL8L<&
M$')J[^#/RP7DNF0HW2JK8Z+R1EU=A@',M?M3_:O^N7QZ7=44=5'*=9"O@ADW
MOO4"#\RIU[M+NE$0Z%R$'6^M_O44"L<.N2"N8NN&$''<,+P!03Z(V!MRKMZ>
M*S7S _U>G_7>R85,L]6,BT2B-*60A%QG@JH7!\:^A&$:R@3[@3H:4&O7U+&9
MINA[4N 7.E)"=\O+*F98T>^V&4JGH#7V*O6&:S2WD49&B;AQ$?U02^GPPNL,
M#NZ</T=G&=N[TZ7J$?=-Y^,]>H');YJ<?I'+;SE]?LPXG=<=K/R8A0'V(DB(
M8!!)0=1/E,.4(82%'PO!C#*<.F>9FC78EM"B#=A)$+LWOC-H!M[V;>%<MP([
MI_XEK<!.CCU>*[!SZNVT CO[<,\J-IM"QN_;)1&O\UPM<M45Z'HAU$&(G_AU
MJ^QQ498\GDF22$4&*90HI(H<N \9CR/=-S#UD* 1P5:9R^Y%G!JSM&M^[^@(
MVDI65:?TD?34(^TRX45=I]VV/K+[[X.9@?.VJSRX ^_4BI6%>UI_KV[45H]T
ML?=-.+>:]N5\!@/<5>D?]P*.6R9H,( /2@H--U/?4A;UE6'I'[VG^5U>ULT6
M92FV>YF7+M.9%^!4:I]D$H;*C SC$#)/1#"25,8)#1-&C)(4[*:=&OMOI&XN
M^YYI#E[*BH/Z;D3H-<L+G5!6W9-87I,8KH492[M'>&#FW8);WYXHF=57&512
MUX4=E=S5K8K+2ALV0#DKP6$TZ<BU.6R ."S:8?7I2YQ>F\+^&S]Y&*-4Q*$/
M$9.:GF@,:<0"A7L8>#%+(HQC&WHZ,<_4^*AVY+1Z2IQW9EOA:N/QN@BM<3Q>
M5D#U='B=A,&IP^MPEC=P>)U4];C#Z_3C?2]?19FU1>?W-!.WB_?T.5O1>5W\
M@7B,Z7,L# ,N(*(\A"3F" :)$+['/3\TR[PRFFUJQ+ 5%FAIH3).:GEM+S6[
M(#:]G70$W.#7C*<P&Z*DA@DHSJ[ZNN8:^<[.0.W#RS>3#_7CD#JTZ>NCE"N=
M<J;GJ9V^)-'.<2ZA9'&L8[PC2&G,8>S%"*=>1!!/; CD]%138X\FWJL4%32R
MVC%'![!FM.$&KH$YXSA2#IWKYF@X(HN.B49EBO,*[].$P2?Z5VVHVG'?EP&7
M53-WF9(0!W$ 8^%AB% :0QS)%'J)1)B2&/U_W+WK<MPZEB;Z*HCH$WWVCA!J
M"!(D@:Y?LBSO4;2WY+#DKNBH'QFX6CDE9:KRXK+[Z0_ 2R;SQ@28(,4Y,UW>
MMD0":WT@/BP ZR*Q4_*<UE[&Q@S[U=]+4<_4?_< M9T:@D'5,RMT0JE3]H:3
M*%R4ON&PU<'S-YQ4[%@"A],/=XUT6*X>]!_SN;2'L8]J\6,JU/)Q_B)-MRK.
M%8JA1ADSLSY#D"-*(.,DS_,HB=+,,\[A5%=CF_I64GOK]=W*"I9&0E\?\).@
MNAD$8:#J_?JH1*D0L[@RJ@4%CVV0=?#^/H=&,-_ODQT-[/E]3N%#O^^S;W0M
M\3L7_[A;+M=*?EPOIK/O)?44!YW%*6=1]]QF]5.S96&'%+G()VFD,RU$#/,\
MU1#'6$,N<P&E9#981\DL9WYU@#O),39FL1H45G11[7$;2U55@U3_7$]MWC/S
MCJ<?7]=Q<N.C =#OF:S*: A0ZG!5WK!402NP$+Y.X->\]]Y47O@T7V@U7:U#
MWL5<B&FP$L?=I!BX#O)%4!T62[ZLN6Y,^M%T\J.XXOZ\K9:.<L89PQ"GVH:2
M4@9IRC64 E.:T"CAR.O@]D@?8V/ K8@7U$L_AJ4;DUV(4-^[*4]PO$FG1?U
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MA*N=H"\"H?>C:2?]G>?W25V/F*1+)?[R??[C?YEW2FO4_&5KA!ZV-,BT/:E
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M^B2F0@DS$&+^?598C^N9F0S@^O$&9%'6_\"X$GRO8/=._R7*ELY +3_XEU$
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M^7#VY:N?(IQ#<)&B=QP9 +*1.?$F1I*,%MSS!$SOEE]X9O%NN&@^S;B[8)O
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MS08DA><B]6UP]A@=P_1DZ0],.\NZ"<0<Q%@>@R].(0+:8=P;'V!YC7\3(9N
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M.Y\8,YGGFX:-]2.[8<M@]WVYMI&P&XCL2O>R\64U5'F B8X=!A,PC845X:-
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M4LR6L?;(AI6:V$B]I-YP8WN\N-[8U>JMH&__6-I" 2WBZ/:9GGQYEQC+4,J
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MAZO![X\SJ*5%F85,E!*,H(?"RPRZ1 R8X$50RD/M80,;$SELB-D 0BOIKUV
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M*_DX(3UU/D>F6 \MD#I2UV3RM"]<]J2T!CS>HYPAHF-V]'M<O=X[15?M9/6
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M3\&B*Z,MH<[$2'6F^?Y;IPIV\66Z7E&%VC;XZTV%/W;AVO7DO#C[-!W_3YE
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M[@)/V8?I[-]^EJZC$KBEDJAI2@.D8!/:0-X1&JEG45(9H5L%R?9KOPE7PXY
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ML( Z+N.9>*"H10!SF68=>*P^;JXK<<.F?O2*M8I2>1MP*S?VV4,.C8< -LI
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MP6OOB$H!500M4<NETA"#&V*,9PFV^KR5GY/5"7#N[0"N+XDT,6WJ_7KAU8P
MO)?GB_EOL^E\?@W&@X\I+TOIB0PRX8V,VD"@B@5/L^2ZONMO S'=O,GT[6&J
M#OL;N*Y*+=/5NI;I@Q_-5L/7#*4I:;QI+="$-HS$3TXJXM&FP0,A0.GJH:V7
M".F&GS<8CMB?[0U@YSW,1M]\\=P<^Z]+??!:)K1P)1C"O5>X [Q1K:&,!&M8
MP#LV:%M[(N6/5'1#S9L,,NS%\*'U[Q^TO?,)[N-K&3DV'B^[!?NX&B)6.!*E
M1!,V"GR.F=#E$J4D@:(A6.T@ATYJ=^<ENV'F#04'>N3XX#BZG<4O?@XE;^5A
M-_,+6'6=GKZ<RWTM+'B5,R/(,[Q<9:9X2""44@,C8PK!V&Z)ACLMWPU?;\C#
M?R!)-#JA^_W)7R=GYY_^./EX]?[DXO2OHZM3_,+IT;O3L].K?WSTL]GRFMZC
MG\^6*]3H\[//IJKU_[E_X1[=3_.C2?H=TN?1Y/,1WE;?1HL1S%]H$./PCG)2
M1&(47Z;)6N)EU@0$4P*\E!#J^Z=W)K>>\K7*LL+-IQ1+9H$JBD"$3&QI0:#P
M;!OFF U0>^;>,Q*&+H4]#'(VZV3;RZ$!';[TKSC/1WBT)Y_AH<P\IE+I)#/1
M*I0\3<G0$"DI>RI%-&1Q)U"[&=6+A+0"J1U$.ZW-YP; \H3\<K0^3B?^\2M/
MU<G[<DX\-XXI?.BS*4WZ-"J5*0,Q.6>+"D?0KG:[F"U)'!9@%4#QO--[CQ)J
M (#'TS%^=;K20Y[L];Y"TU*IA/1$&VL(JK2*>.Z!V S9ADPSZIK5_>JO431P
M%_@^P?"#D[V:9 ;$V7RVP)W<ENQ-9/'BKM2(+L^D2!P@6+114LS%S<*( T<)
M?A$2\L4*W2D(C0L\017^[1%1F]8>NM1Z_S>P"E<'1L4%?%W;ND>?9P"KL/CW
M6UI7SKBH(K7<HDWK4)G,N!]/8RS=+)CF7HC<K:_>3Z#2F:!A[J Z,I_V+8"A
M75GOQC[^<[Z83N!LE.$RCF 2X?X^ELD!U303KHJ?1(1(G#.&0$ @Q*AY>I[Y
MLL%C]=HJP\&C)XE.^V#OP+?/I]DTW<;%^>P29M]&<762LJ9(LQ?$)5I*]$IO
M;<-4F:[,!,>3]$._CYTNFI?6'KJ/0YTW:6^NMH&*HMNM=S"_;VC!5.+9)1*-
M06A3ZHGS+A+K ]5*.K"B4PY -VC\2,!PE\K^,OT1('LR>.@WYJ_;Q6PT'Z%*
MCOOXOZ,Q/K3+OZVO0<<=#?AB$,MB*.:F(UXE2P1-AAK%@DC=XB*OKS,X)/:5
MXK0?E@Z-CM]/SD[/+]]]*N^P.,8?&44_OIJ-_/B^QC\4PRUGXI!T(O%I)-8X
M_$0E8TP9ZIYW%]^ CY^M-(RATQ-"JK)U:(P<G7T\^NUJN1?^TEY<T:! 24(I
MHX5+BMAH)1$NA<SQEWG9+5S_DX6&43MZ0DA-IC8$D!?!GJ-RVHE$N&'())43
M"925Z6J&&<&<CKQ;&O5/%AJFC*Y_@.S-U*$!\OA@KHEGSFACF"=61C3IBJ?;
M<S3NLHY40C"&2[NEUC'DD.O>]8P=V#:@S!.,KL_@LQ^?3!:CQ=UJIH+!)R\$
M39C5CDB-ZGC010GG'GA(0>GT6C!H#O%_?IY^^U_XJU<F"7YXM$9>6'#8DMH:
M-NJ^7!P8 "NJ[^>\Y^@80Y*S,8)(J0RQ"E\S$"%$9E1D^K6(\L^E_W2U86R-
MO<4UK<"[H2_Z5SUNU+.4M:($==SB^Y6 +U8PA$8(G.,AR+);Y^/V')K[":VS
MSW(;#C80KWV\!<\>D@U5]E8 +SU/@*-Q7#HNBT2)LUPG$[*UHO9LSA?(&+9Z
MO69FR;X\'OK&V!@Y]G^/;FYO/MQ.2E.(:TM3#)Z7X+$O7<2L11TJ,!(R17T7
M%5[N<Z>[H]MZK60>[2C3:;\,;A4S%],[/RY)?I_\73E8ZTX-U]YDF8QTQ%J&
MEW&9SV0-OLK<)B<L,E99OQ=X-BS<2NR^1Q358/E;@5.IV+KV$I)-S! 1<RYA
M0V2>X(Y$)J, J8#Z;O[0;59M)>!V0"!MS>Q64?1A]#<DW-3RSKW%+7X=CTKX
MN3CXK(@D&AIP:Z7DN(R+LS0S%J-3S'=SFFZW;BMF<8](JL#PMX"EY0')P3I\
MMLO$E Q$*FE*-S=)L@6F( 3EG:B&HLXWT0$4YP/A9VLF-V%U;>I%N6I]\-B_
MZII;&RS#6]7RXD.V$O6]D#C17D@;652YAWK=KM0-V]2I%M1ZELJ;+)![#]]@
M//U:&/&4S3XL"Q/7M3IWO57/;;=\_Z5U>["C@;J[DK7IO(K$T&5NMP+BK=6$
M!D!5GTEG77\U_X/7W6D.3G,\JY%K2Z1F>"4$*XC'JZ+T:Z#Z^>2 _ZZ[VP4Y
M/ZN[VT8.#;S1J\8Q(S]^/N#50YGXK E>]>6%\1)9$CQA5"2\WCAN1U6&TP92
M6H'5#N*=UN=U Y!95NS@RH\!9CQ?Y_F%W<U+8=G\Y6^MPQ,LF\QHTH2C542D
M% PUF9*5+R3+/)<<@MJE4C7I'Q:<50#UO$!T*.DV@.S'P[X.<QDI=3!.$(J:
M,#X, D^[,KK,6_1".<<9ZZ^8O872O>'0L/&9W4$T34'KT8J3:,WK;!0)5F<B
MHW;$>Q'PK]9H3UVFM'ZO[=TBD >KZ]OG?=V7QPW Y*$'V[W5-2HA=U^TU70^
MN8!X.RM3/-[Y^6C^YV0:YG@F"]].)U]O%Z6]TJ3TU%E*[]B/X^UX^?%B.AY_
MF,[^[6?IFM.BVD(DFH$D$MR2MYPHQYC,CINH:H.N]TVUHB+N"+OG:F)3&&CI
M4*RY4-Z4_QPMOORP^?GWNY]_SZL'1\:JR6'T)H4R&C>ZD,L,.$8<39D8+450
M)G!/4U\'H>9&!E9!VP+KIJ,T&')V/CY?EX.:+A=^MACT$&W@Q.E\?@OSZR!L
MMAD\$:ANE6[_F7@7++%)6@DES_!Y)MU@A^C5C0RK!/V:AZ@><M[P&[2!";^A
M/70VG<]/)W%\FR"=3D[\;((_-K\N1: 69"0 &1DCJ21.)"!))?QLK5?/(ZFM
M':G-FQLV?>2_U#&KA+#MCYY;';T)?%XVWQS\!+[^EJNDT-Y4CBAPADBK*0G&
M,Y)%5@Q2M$S6[C WG!;86SK-KWFRZB%G3RWP9))Z"Y!?7IT?_\>[H\N3]\?G
M?WPZ^7AY='5Z_O'R]N;&S^ZF>3F6 K</Z7AZ\Q4F\^5Z)W^7C_!PN9PCG?B-
MR>?E  (_2>L?6(6*=PF<'X*L&@'U@[.O5J#](0I:AJX_DK;NF;PD9$E\*,2O
MDY#F#Q%3\%(HERAA@2<B$U/$>N^(<!I$MBFQY\7X^[LN]Z)XW]?G,GZ!=#LN
MD_9>%.G3'G?O[AY_9DW'4;G$UF/('77.RT!TB@H5W^")LR6G*Y@8E0]1IMI^
MAVK$#^QH.QQFGS\APXB_ ;L'KZCIS2HSK&SDK/P'9;\ES)A$$#Y:3[S. M]D
MP]&$,XQXY05(;KFUM:-CKY S+#8' LBT'VFU"[QU*#%+&H J/,O9 9$^EXR=
M$C!RC'KFC*4.#@.]%O( JHF]&YQVD$$#@+I F2 !7XXFZ4F>XUK36@>5;4XI
MX?-!#)=H97C-2&!%L4\\).",IUA;K>E 5I/@V@4$TWXET@#(+F&,W_K\&TQ0
MHQ_CQH[2S6@R*AI("1#>*_[KS?&DP8(0Q+$RHCG&3(*4G@"U63L\K[KZB+RM
M"!S6*]X?\/J34@L0_)G^L4G]>(Q>)QE+5R=4DAE0(@,@;UFF1"B3O,HI,*B.
MR[VI'A:L;>A_!Y9] V@_&B]_!M*KGI9KXYF(960OS;2,%0N2.!D,44FSK%1
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M_.?YU\+-^R[&5*042RJ4-Q'M&&F(%5$0+23N*G/@M'9$82,Q+6)Q5YE/^Q!
M TBZ %2R1K$8KV4KZTTH%R5E)A&-'XA,KCP@WA%M?#26^L!X#P&$'PD9UAG6
M*X+V9WP#Z'DRD;ST8[F?!,6,QT,0"&AOB61E_KFVCD"D5EMN.+6U_:XO$C)L
MFFZOZ-F?\0V@9T]MX=%Y9PW77H= E.$![]QH21!X=**)6N$_@7G3EBG2G+O_
MK=L=NX'A[1^"HYLRX^]:.&NI<(K08(N+)!;O""HAPG+F:&+1V=K5%E4(;U%%
M[!MS=8&_ P#Z#RZLOU'^*$F,__M__']02P,$%     @ R4*D5B#59>[5!P
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M@[;_=THMC81G4LV'WX]E!I:]@QF[U1G/OZ];#$O#@I%)$+3R=PB#^-M9<&&
M>I3,8>%2ITM.7/_[A]&;T9CU.LWN0P]VLSW&R0?SA8R_O+X=C]Z.+B_&H_?O
M=K7^;[>UO]764?W%0>>H??HC)(F!.?NUR6YTJ9S.ZRP&XV0R9R[E[L7!X?'I
M+KX<X; %%P+734-!XH;'G45H9"XP+,-&[^B+N=MYM?#AGQ_]X;1T!\VC <W#
MB*5\"LS 5,(,*<>ETK)?2FX0P&K.;J'0QC&=L[?:9*S3;OS"=,(N5#Y7/&,W
M*3<9CZ%T,N;*UMDHCYL8K)-G$*SN_@7K#;<8(@Q&-F=WN9XI$!.HAYB9$"FA
MT89<8P[!(;C,&<_GK,R=*0%=P*SB$PR&D+,,[XSDBB4\QD>&Z4PZYG20VQ#(
M(09KN9F32,;O ,==TVGQF4!C<$CELQ..00*Q-)B-4"S'[FB) ,-FJ8Q39DOZ
M6?6?@8%*"3F02:LP;5$&G$F7HH.V@-@;2'H+-$T+='.*W02+YNO3\$P@V/N*
M( @LD3D&F?"R"FH=\8?BV&S6VF6>()MP*IKP.E:E0)T(G+4(UA%TDABHP+@3
M9 G*2JTP6<'!/AH:82]\-58G"4PEEH"H$2U^..OMB;E-6:+TS"Y0:F BK<-2
MSC%.#X/=:&5]#6QV8<R&M<\$;_W]P]OX07!>'!QW.X-36R&J*A&((G222+SU
M81LQ;L #! ,N(P442 :(RDA)FY(XB65(CT21="^DC96V)?8CXC1:!:041L<@
M\+%E+Q$8 A!I(?K7]W'*\PFP"^2DVU*!#:5,I\<;G<.7\,KW[QR*<!=N)=6%
M>8 I#<*(O=;0&]!$!GW::,F#T1(<C3Q^#&R4H&3_YXNI3O?H,5K[AU\,K7QO
MT-H;-+M]FH<KL%C_8\A\;OLXJ.J4=F->VMV[4/Z+ +%1C10RJBX-*D":FDKK
MR0^E(/=ZJ'Y>T>8Z]1I0W(.M2JDKK-0K6J9&B12*MEBMI/"[4EM&5@K)C20'
M9$C\/AGDI*FTE(S] K4^<WNJQ&TO&H3[4=^IP/I2QJ7BQ/#HEC=BE=2Q1R@1
MUBL;O(J !)&$L3^(/T^Z^X7C:']P?%2Q[D,<[\Q:&W#>G>]V1C6NA*D4!%9N
M=<Z)W;E%H%-]20CF1BS0A/B6/))*NCGE^6W#TMKRP/.8"LOB@>A:?>J3R'WE
M4%&: C%M?5T2Q]H(;X"O5">08[FA$-K8 @6M&1+!*CS %]>6+#R%/P\ Q_L#
MX 417T^Y*CU;470A2;!4E%.,B]U2\BVKBAW8-]QNKP(]7K$C,J<-M6:D2_>T
M!;OD![Z4!BJDDX_O?5BT*-']$H0P$VB/AQL-\ P@)_8'<DO.#-'<1 7MP*OJ
MS;=LA=XG,"7E<QW'I:'8KR7/+5HS;1T^I_-(U&5C5/1;.-MA+Y_HDB"(D<,>
M25>&X\8)_.$!G2ODY=*N5\&JE-MEI4'LYT$/PJ<%/Q\59<^9DG>@JI.$1_+U
MSYZBSP/Z7NW(#O<&YY^Y(_.GC&*Q1.HKDB+.7(?IBJ\(:)]0>FP4L4O3.!:R
M3AN[S/;^ :K,,ND<P!]DA$AC/4'M0J)]7LE+!#,2L"6"Q[]43B]6(/Q62C3?
MK[8RC_V!PZO_;[?^MBQ_H;! PX)1(M)HATL;YE@"0J/*U,MMSPSX':7>4+#Y
MY.M+37_LN3@<^B3 53N4<-*PA=>XP(X6EK3V)#BK A6[(,*PCJR'_&\Q^=LR
M0WS@+'EGJG2R]1CM.>7V/=P/76 *3PS21AW##I[I$#C^E+I"6#UD0)E/M9H"
MI<&<3ZK#=E.1(V2%TG/ UEFJ R/R!_A%O/TE-4)S1Q1@@)W?056M$<(/3 .G
M6O'"PG!Q<8K$72@^'\K<3YCO=%KIBK1S.AO2B^ IL3^6#=5K4 ^HT%R](SXY
M:0[: WI-[ S^%XN!JS?(3?\&N>7$9EO_N'G2?KJYW>P\V?87J6UYDX/9.#&V
MX/GK6J^VZ% !9]@M[MFR@@CS0%AZ/#=A6O[Y%>:=O:*=D<]+[&<^9_VZ_Y1@
M"9IJ)KYR)U\<]''1^%^V^7[Y@;,[AK9-/M?^<(*J%>1?JQ?H,AV:L86O7]/L
M;9FQR)Q?WT-<TC:6_8JU';O!+:JD?%%GEZF$A+U=<M'[4/UM3G/+D\<6:GKJ
M^XDMWY&L]7KT*4JAP[<XPW"V.86-CU-6D?*TU5YUX1&&JW2;73[R/4OU&[ZN
M\=_YG/\/4$L#!!0    ( ,E"I%;G.GV-'@4  "$0   7    86QN>3(P,C-Q
M,3$P+7%E>#,R,2YH=&W=5^MOVS80_[Z_XNI@:0)8+\M._&H 1W97 TF<Q@K:
M?AIHB;*X2J)*4G&]OWY'2D[S6-ILV%9T04!8O.,]?KP7QR^FBR#\<#F#5.49
M7%Z?GLT#:%F.\\X/'&<:3N%->'X&7=OU(!2DD$PQ7I#,<687+6BE2I5#Q]EL
M-O;&M[E8.^&5HT5UG8QS2>U8Q:V3L=[!E9+XY*?Q"\N"*8^JG!8*(D&)HC%4
MDA5K>!=3^1$LJ^$*>+D5;)TJZ+@=']YQ\9'=D)JNF,KHR4[.V*F_QXY1,E[Q
M>'LRCMD-L/A5B_ED$"=1XO5\?]5-COW!JN_1?I_03K+RCU?QKQX:Z2![?4:J
M;49?M7)66"G5^H?=CGW<*]5HPV*5#CW7_;EE6$_&"2\4ZA-XOOY9BWDLC(@U
MRE.\'!ZA($4_*XMD;%T,C8>M6M*..^(9%\,]U_R--,5*2,ZR[?!ER'(JX8)N
MX(KGI'C9EG@KEJ2")36C9+]3-!&5F,]-[<$QRLE807<>>5X/?9B]?S,_G8?@
M=VSOO@//,CU"Z*GX3K8'LZMP_GH>3,+YX@)#]VIY/;D((5R UX=K>VD'-BQG
M@:%Z?L]MPV0)D^GB,IQ-;]E_-*?1NYU/ _<(%J\A?#.#Y>3J='(Q6UJ+]V>S
M#S )0DWIN&[G;_CW6R452[;U%BMB='?H(\^_[G'W3SV>%Q#QHJ"1+CRP82H%
ME5)X6Q&!UY!MX8J67"A XFLN<O!<ZRWP!"99L<U(#I<I$3F):*581#+9AGD1
MV7"@9>SO]3L==Q3PO"3%UGQYHT-(N# J/M4J@"(&,9P3$:7@>^VZ&!$)"<MP
M_]:B)8TJ@>4172=%#+//44J*-<4JEN=,2FT]_FO.&$L>I%10-/.N(;4G.SO:
MAK="Y4+BO="X#1]N-!)P9L,O@M)"*EQ5&\Y/@_2T#4'*:()ZT0[%;B@LDH1%
M:#]JT9(:-]M&\VH+2,)[1G/;4%9"5@3O5G'MAD9Z?\\[<D<Z;_3Y("6EAN+(
MUU^AKK6896VX+IBNWDN%'DG4$%-M-3&"4B;A8\$W"-*:[N_U^J/G!F-)XAC;
M@971!//@R.[M K2)1JOKZKWO%) 'WF$-SN-5P]R$8U)E&)L18I[IB+B-$D$_
M54Q0W;2DQK*!&RO4 3D$C#RO=Q ?[N[L3DS=QM,D4IKL#?PNHCH8Z6C[GR#;
M^2JRK,#,S(F!"TN"(B@@QEVX"SMANB:4@DJ-<%N3298!'D.;2(;XRQ(AEW5V
M):P@1:3W46!L9AN3O,A59?4%\9(*HU,^2"3[F: CF(JL,&$:ZHH+3&D+0<U(
M*>EP]V,4,UEF9#MDA8'&'!HULE9<*9X/]7W=Z+S%4M:4:W-]-;D93P8#NVOP
M'"L<2U2\4]P,+[897AP5/Z9U^_; ?9KLVMZ3M'](K&-,KLU&8"0"_:KEMW8'
MFO@==LK/X-UO6SJD'V)3P_+?1[-Q=JH'6U/WL'=LH5LWCMN@:9#XP9W<W^L>
MCZ19O]&=SD\G]WQ_YDV[&H+65_%J$DJG&_*"Y!F+8>?ZCP3FMP'$=\837;XN
MDX\1=DP9^8N=X3N.>Q.HAQULA0SMP\ILJB[.$AMLA(H6:! FEGD\-KTT!IQF
M[HTM>C1.<4);(8K8"_@-TQ,<SB1WRK>I\QN&O6&ENW+335#20YZD$@63Z1<!
MSQGT!#!L'VAJDD!5XHZVE4KU=--X\-(L>?W4'@J:$7W1C]Z>7\+?M ;WRQ&R
MPARHU.,CWWBN-FO]>#;/^),_ %!+ P04    " #)0J16WD0R9A\%   B$
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MF2XOPR[;QW5*?XUNH,=I'4*].O\-II8PQ9*XDF$#: LOI HZP!T,I= 4F[)
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MGM?]1C6O=RWGCI;N^8XYB09*..Z?7=:R%M?-M)N@I.OC7 94E+H D^4J36Q
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M_?'US>9F^86_HGVO\B_;<[(K7]6>?[EQ<O^.3+R _TV+6?+R_P!02P,$%
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ML!VS\@.L%>1/*R%O(.)06], 8 2UVL PIZ+&L7^\/SVHMN12AY7/OCIT *_
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M,S,Q7V-A;"YX;6Q02P$"% ,4    " #)0J16?FHJE=11   V?P, %0
M        @ %/'P, 86QN>2TR,#(S,#,S,5]D968N>&UL4$L! A0#%     @
MR4*D5I39<:=*"00 R2@% !0              ( !5G$# &%L;GDM,C R,S S
M,S%?9S$N:G!G4$L! A0#%     @ R4*D5G4;X=5OO0  C*,' !4
M     ( !TGH' &%L;GDM,C R,S S,S%?;&%B+GAM;%!+ 0(4 Q0    ( ,E"
MI%8YOHS_#WH  ,)8!0 5              "  70X" !A;&YY+3(P,C,P,S,Q
M7W!R92YX;6Q02P$"% ,4    " #)0J16(-5E[M4'  !.)   %P
M    @ &VL@@ 86QN>3(P,C-Q,3$P+7%E>#,Q,2YH=&U02P$"% ,4    " #)
M0J16>,4(>-P'  !")   %P              @ ' N@@ 86QN>3(P,C-Q,3$P
M+7%E>#,Q,BYH=&U02P$"% ,4    " #)0J16YSI]C1X%   A$   %P
M        @ '1P@@ 86QN>3(P,C-Q,3$P+7%E>#,R,2YH=&U02P$"% ,4
M" #)0J16WD0R9A\%   B$   %P              @ $DR @ 86QN>3(P,C-Q
M,3$P+7%E>#,R,BYH=&U02P$"% ,4    " #)0J16YBH:S+<7  "#B@  &
M            @ %XS0@ 86QN>3(P,C-Q,65X:&EB:70Q,#$N:'1M4$L! A0#
M%     @ R4*D5NY;(*R;%0  <78  !@              ( !9>4( &%L;GDR
I,#(S<3%E>&AI8FET,3 R+FAT;5!+!08     #0 - &P#   V^P@    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
